PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	LUETTEKE, NC; QIU, TH; PEIFFER, RL; OLIVER, P; SMITHIES, O; LEE, DC				LUETTEKE, NC; QIU, TH; PEIFFER, RL; OLIVER, P; SMITHIES, O; LEE, DC			TGF-ALPHA DEFICIENCY RESULTS IN HAIR FOLLICLE AND EYE ABNORMALITIES IN TARGETED AND WAVED-1 MICE	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MESSENGER-RNA; TRANSGENIC MICE; STEM-CELLS; DEVELOPMENTAL EXPRESSION; FACTOR RECEPTORS; MOUSE EMBRYOS; MAMMARY-GLAND; RAT; PRECURSOR	To explore the physiological roles of transforming growth factor alpha (TGFalpha), we disrupted the mouse gene by homologous recombination in embryonic stem cells. Homozygous mutant mice were viable and fertile, but displayed pronounced waviness of the whiskers and fur, accompanied by abnormal curvature, disorientation, and misalignment of the hair follicles. Homozygous and, to a lesser extent, heterozygous mice displayed eye abnormalities of variable incidence and severity, including open eyelids at birth, reduced eyeball size, and superficial opacity. Histological examination revealed eyelid and anterior segment dysgenesis, corneal inflammation and scarring, and lens and retinal defects. Although TGFalpha deficiency affected skin and eyes, wound healing in these tissues was not impaired. Similar hair and eye defects have been previously associated with the recessive mutation waved-1 (wa-1), and Northern analysis revealed reduced expression of TGFalpha in wa-1 mice. Crosses between wa-1 homozygotes and TGFalpha-targeted mice confirmed that wa-1 and TGFalpha are allelic.	UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT OPHTHALMOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	LUETTEKE, NC (corresponding author), UNIV N CAROLINA, SCH MED, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020069, R37GM020069] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43793] Funding Source: Medline; NIGMS NIH HHS [GM-20069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BENNETT JH, 1956, NATURE, V178, P272, DOI 10.1038/178272b0; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BUTLER L, 1953, J HERED, V44, P13, DOI 10.1093/oxfordjournals.jhered.a106340; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COHEN S, 1962, J BIOL CHEM, V237, P1555; Crew FAE, 1933, J GENET, V27, P95, DOI 10.1007/BF02984383; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DEFEOJONES D, 1989, MOL CELL BIOL, V9, P4083, DOI 10.1128/MCB.9.9.4083; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1987, CANCER RES, V47, P707; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; FINZI E, 1991, J INVEST DERMATOL, V96, P328, DOI 10.1111/1523-1747.ep12465223; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GREEN MR, 1984, J INVEST DERMATOL, V83, P118, DOI 10.1111/1523-1747.ep12263298; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Keeler CE, 1935, J HERED, V26, P189, DOI 10.1093/oxfordjournals.jhered.a104066; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LISCIA DS, 1990, DEV BIOL, V140, P123, DOI 10.1016/0012-1606(90)90059-R; LOBB DK, 1989, BIOL REPROD, V40, P1087, DOI 10.1095/biolreprod40.5.1087; LUETTEKE NC, 1993, CELL GROWTH DIFFER, V4, P203; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; Lyon M., 1989, GENETIC VARIANTS STR; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARQUARDT H, 1982, J BIOL CHEM, V257, P5220; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCLAREN A, 1969, NATURE, V224, P238, DOI 10.1038/224238a0; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MOORE GPM, 1983, ANAT RECORD, V205, P47, DOI 10.1002/ar.1092050107; MYDLO JH, 1989, CANCER RES, V49, P3407; NEWSOME DA, 1983, CURR EYE RES, V2, P553; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAMSOONDAR J, 1986, J BIOL CHEM, V261, P4408; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHULTZ G, 1992, ACTA OPHTHALMOL, V70, P60; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SEROOGY KB, 1991, NEUROSCI LETT, V125, P241, DOI 10.1016/0304-3940(91)90039-V; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SKINNER MK, 1989, ENDOCRINOLOGY, V124, P845, DOI 10.1210/endo-124-2-845; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; STRAILE WE, 1962, J EXP ZOOL, V150, P207, DOI 10.1002/jez.1401500305; TAM JP, 1985, SCIENCE, V229, P673, DOI 10.1126/science.3860952; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TODARO GJ, 1976, NATURE, V264, P26, DOI 10.1038/264026a0; TRIGG MJ, 1972, J ZOOL, V68, P165, DOI 10.1111/j.1469-7998.1972.tb01346.x; TSUTSUMI O, 1988, J CLIN INVEST, V81, P1067, DOI 10.1172/JCI113418; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WEINBERG WC, 1991, ANN NY ACAD SCI, V642, P281; WERB Z, 1983, J BIOL CHEM, V258, P642; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	80	571	590	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					263	278		10.1016/0092-8674(93)90228-I	http://dx.doi.org/10.1016/0092-8674(93)90228-I			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8477445				2022-12-28	WOS:A1993KY50500009
J	STOGER, R; KUBICKA, P; LIU, CG; KAFRI, T; RAZIN, A; CEDAR, H; BARLOW, DP				STOGER, R; KUBICKA, P; LIU, CG; KAFRI, T; RAZIN, A; CEDAR, H; BARLOW, DP			MATERNAL-SPECIFIC METHYLATION OF THE IMPRINTED MOUSE IGF2R LOCUS IDENTIFIES THE EXPRESSED LOCUS AS CARRYING THE IMPRINTING SIGNAL	CELL			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; DNA METHYLATION; SEQUENCE-ANALYSIS; GENE-EXPRESSION; CELLS; INACTIVATION; TRANSGENE; MECHANISM; ISLANDS; CLONING	The mouse insulin-like growth factor type 2 receptor (Igf2r) is imprinted and expressed exclusively from the maternally inherited chromosome. To investigate whether methylation could function as the imprinting signal, we have cloned 130 kb from the Igf2r locus and searched for sequences methylated in a parental-specific manner. Two regions have been identified: region 1 contains the start of transcription and is methylated only on the silent paternal chromosome; region 2 is contained in an intron and is methylated only on the expressed maternal chromosome. Methylation of region 1 is acquired after fertilization, in contrast with the methylation of region 2, which is inherited from the female gamete. Methylation of region 2 may mark the maternal Igf2r locus in a manner that could act as an imprinting signal. These data suggest that the expressed locus carries a potential imprinting signal and imply that methylation is necessary for expression of the Igf2r gene.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	STOGER, R (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Stoger, Reinhard/0000-0002-2301-0805				ARTZT K, 1991, GENOME, V1, pS281; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BUSSLINGER M, 1981, CELL, V27, P289, DOI 10.1016/0092-8674(81)90412-8; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROUSE HV, 1960, GENETICS, V45, P1425; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; JOHNSON DR, 1974, GENETICS, V76, P795; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; Maniatis T., 1982, MOL CLONING; MONK M, 1990, GENOMIC IMPRINTING D; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; SAJANTILA A, 1992, AM J HUM GENET, V50, P816; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Surani MA, 1991, CURR OPIN GENET DEV, V1, P241, DOI 10.1016/S0959-437X(05)80077-2; SURANI MA, 1988, DEVELOPMENT, V103, P171; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8	39	527	539	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					61	71		10.1016/0092-8674(93)90160-R	http://dx.doi.org/10.1016/0092-8674(93)90160-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462104				2022-12-28	WOS:A1993KW75300008
J	FORLONI, G; ANGERETTI, N; CHIESA, R; MONZANI, E; SALMONA, M; BUGIANI, O; TAGLIAVINI, F				FORLONI, G; ANGERETTI, N; CHIESA, R; MONZANI, E; SALMONA, M; BUGIANI, O; TAGLIAVINI, F			NEUROTOXICITY OF A PRION PROTEIN-FRAGMENT	NATURE			English	Article							RAT VENTRAL PROSTATE; SCRAPIE PRION; AMYLOID PROTEIN; MESSENGER-RNA; CELL-DEATH; IDENTIFICATION; BRAIN; APOPTOSIS; PURIFICATION; DISEASE	THE cellular prion protein (PrP(C)) is a sialoglycoprotein of M(r) 33-35K that is expressed predominantly in neurons1-3. In transmissible and genetic neurodegenerative disorders such as scrapie of sheep, spongiform encephalopathy of cattle and Creutzfeldt-Jakob or Gerstmann-Straussler-Scheinker diseases of humans4,5, PrP(C) is converted into an altered form (termed PrP(Sc)) which is distinguishable from its normal homologue by its relative resistance to protease digestion6-8. PrP(Sc) accumulates in the central nervous system of affected individuals8,9 and its protease-resistant core aggregates extracellularly into amyloid fibrils10-12. The process is accompanied by nerve cell loss, whose pathogenesis and molecular basis are not understood. We report here that neuronal death results from chronic exposure of primary rat hippocampal cultures to micromolar concentrations of a peptide corresponding to residues 106-126 of the amino-acid sequence deduced from human PrP complementary DNA. DNA fragmentation of degenerating neurons indicates that cell death occurred by apoptosis. The PrP peptide 106-126 has a high intrinsic ability to polymerize into amyloid-like fibrils in vitro. These findings indicate that cerebral accumulation of PrP(Sc) and its degradation products may play a role in the nerve cell degeneration that occurs in prion-related encephalopathies.	IST NAZL NEUROL CARLO BESTA,I-20133 MILAN,ITALY	IRCCS Istituto Neurologico Besta	FORLONI, G (corresponding author), MARIO NEGRI INST PHARMACOL RES,VIA ERITREA 62,I-20157 MILAN,ITALY.		salmona, mario/AAA-7116-2020; Tagliavini, Fabrizio/AAO-7891-2021; Chiesa, Roberto/G-1561-2017; Forloni, Gianluigi/AAB-2115-2020; salmona, mario/ABI-4066-2020	salmona, mario/0000-0002-9098-9873; Tagliavini, Fabrizio/0000-0003-1039-7315; Chiesa, Roberto/0000-0002-3842-3733; Forloni, Gianluigi/0000-0001-5374-3914; MONZANI, ENRICO/0000-0002-8791-6446				AGGARWAL BB, 1984, J BIOL CHEM, V259, P686; BETTUZZI S, 1989, BIOCHEM J, V257, P293, DOI 10.1042/bj2570293; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; BUTTYAN R, 1991, MOL BASIS CELL DEATH, P157; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; CLEMENS JA, 1992, NEUROBIOL AGING, V13, P581, DOI 10.1016/0197-4580(92)90059-7; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; DUGUID JR, 1989, P NATL ACAD SCI USA, V86, P7260, DOI 10.1073/pnas.86.18.7260; EMRE M, 1992, NEUROBIOL AGING, V13, P553, DOI 10.1016/0197-4580(92)90055-3; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; FORLONI G, 1992, SOC NEUR ABS, V18; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GAJDUSEK DC, 1990, VIROLOGY, P2289; GIACCONE G, 1992, P NATL ACAD SCI USA, V89, P9349, DOI 10.1073/pnas.89.19.9349; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MONTPETIT ML, 1986, PROSTATE, V8, P25, DOI 10.1002/pros.2990080105; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PRICE DL, 1992, NEUROBIOL AGING, V13, P623, DOI 10.1016/0197-4580(92)90069-A; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; SERVER AC, 1991, MOL BASIS CELL DEATH, P263; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; TAGLIAVINI F, 1992, SOC NEUR ABS, V18; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	35	889	913	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					543	546		10.1038/362543a0	http://dx.doi.org/10.1038/362543a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464494				2022-12-28	WOS:A1993KW45300055
J	MACDONALD, ME; AMBROSE, CM; DUYAO, MP; MYERS, RH; LIN, C; SRINIDHI, L; BARNES, G; TAYLOR, SA; JAMES, M; GROOT, N; MACFARLANE, H; JENKINS, B; ANDERSON, MA; WEXLER, NS; GUSELLA, JF; BATES, GP; BAXENDALE, S; HUMMERICH, H; KIRBY, S; NORTH, M; YOUNGMAN, S; MOTT, R; ZEHETNER, G; SEDLACEK, Z; POUSTKA, A; FRISCHAUF, AM; LEHRACH, H; BUCKLER, AJ; CHURCH, D; DOUCETTESTAMM, L; ODONOVAN, MC; RIBARAMIREZ, L; SHAH, M; STANTON, VP; STROBEL, SA; DRATHS, KM; WALES, JL; DERVAN, P; HOUSMAN, DE; ALTHERR, M; SHIANG, R; THOMPSON, L; FIELDER, T; WASMUTH, JJ; TAGLE, D; VALDES, J; ELMER, L; ALLARD, M; CASTILLA, L; SWAROOP, M; BLANCHARD, K; COLLINS, FS; SNELL, R; HOLLOWAY, T; GILLESPIE, K; DATSON, N; SHAW, D; HARPER, PS				MACDONALD, ME; AMBROSE, CM; DUYAO, MP; MYERS, RH; LIN, C; SRINIDHI, L; BARNES, G; TAYLOR, SA; JAMES, M; GROOT, N; MACFARLANE, H; JENKINS, B; ANDERSON, MA; WEXLER, NS; GUSELLA, JF; BATES, GP; BAXENDALE, S; HUMMERICH, H; KIRBY, S; NORTH, M; YOUNGMAN, S; MOTT, R; ZEHETNER, G; SEDLACEK, Z; POUSTKA, A; FRISCHAUF, AM; LEHRACH, H; BUCKLER, AJ; CHURCH, D; DOUCETTESTAMM, L; ODONOVAN, MC; RIBARAMIREZ, L; SHAH, M; STANTON, VP; STROBEL, SA; DRATHS, KM; WALES, JL; DERVAN, P; HOUSMAN, DE; ALTHERR, M; SHIANG, R; THOMPSON, L; FIELDER, T; WASMUTH, JJ; TAGLE, D; VALDES, J; ELMER, L; ALLARD, M; CASTILLA, L; SWAROOP, M; BLANCHARD, K; COLLINS, FS; SNELL, R; HOLLOWAY, T; GILLESPIE, K; DATSON, N; SHAW, D; HARPER, PS			A NOVEL GENE CONTAINING A TRINUCLEOTIDE REPEAT THAT IS EXPANDED AND UNSTABLE ON HUNTINGTONS-DISEASE CHROMOSOMES	CELL			English	Article							POLYMORPHIC DNA MARKER; LINKAGE DISEQUILIBRIUM; FRAGILE-X; REGION; LOCALIZATION; CONSTRUCTION; LOCATION; STRATEGY; COMPLEX; LOCUS	The Huntington's disease (HD) gene has been mapped in 4p16.3 but has eluded identification. We have used haplotype analysis of linkage disequilibrium to spotlight a small segment of 4p16.3 as the likely location of the defect. A new gene, IT15, isolated using cloned trapped exons from the target area contains a polymorphic trinucleotide repeat that is expanded and unstable on HD chromosomes. A (CAG)n repeat longer than the normal range was observed on HD chromosomes from all 75 disease families examined, comprising a variety of ethnic backgrounds and 4p16.3 haplotypes. The (CAG)n repeat appears to be located within the coding sequence of a predicted approximately 348 kd protein that is widely expressed but unrelated to any known gene. Thus, the HD mutation involves an unstable DNA segment, similar to those described in fragile X syndrome, spino-bulbar muscular atrophy, and myotonic dystrophy, acting in the context of a novel 4p16.3 gene to produce a dominant phenotype.	MASSACHUSETTS GEN HOSP, MOLEC NEUROGENET UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; HEREDITARY DIS FDN, SANTA MONICA, CA 90401 USA; IMPERIAL CANC RES FUND, GENOME ANAL LAB, LONDON WC2A 3PX, ENGLAND; MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA; UNIV MICHIGAN, DEPT INTERNAL MED & GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV WALES COLL MED, INST MED GENET, CARDIFF CF4 4XN, S GLAM, WALES	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University; Cancer Research UK; The Genome Analysis Centre (TGAC); Massachusetts Institute of Technology (MIT); California Institute of Technology; University of California System; University of California Irvine; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Cardiff University			O'Donovan, Michael C/P-7005-2018; Datson, Nicole A./O-8797-2014; Bates, Gillian P/E-1146-2012	O'Donovan, Michael C/0000-0001-7073-2379; Bates, Gillian P/0000-0002-4041-6305; Swaroop, Manju/0000-0002-0576-1664; Datson, Nicole/0000-0003-2887-0238; Baxendale, Sarah/0000-0002-6760-9457; Stanton, Vincent/0000-0002-2205-6000; Myers, Richard/0000-0002-8365-2674; Snell, Russell/0000-0002-8166-4014; Mott, Richard/0000-0002-1022-9330	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016367, P01NS016367, R01NS025631, R01NS022031] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22031, NS25631, NS16367] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALLITTO BA, 1991, GENOMICS, V9, P104, DOI 10.1016/0888-7543(91)90226-5; ALTHERR MR, 1992, GENOMICS, V13, P1040, DOI 10.1016/0888-7543(92)90017-M; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBROSE C, 1992, MOL GENET, V1, P697; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; ASHIZAWA T, 1991, LANCET, V338, P642, DOI 10.1016/0140-6736(91)90659-D; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BATES GP, 1990, AM J HUM GENET, V46, P762; BATES GP, 1991, AM J HUM GENET, V49, P7; BATES GP, 1992, NAT GENET, V1, P180, DOI 10.1038/ng0692-180; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; Biancalana V., 1992, Human Molecular Genetics, V1, P255, DOI 10.1093/hmg/1.4.255; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUNNER HG, 1993, NEW ENGL J MED, V328, P476, DOI 10.1056/NEJM199302183280705; BUCAN M, 1990, GENOMICS, V6, P1; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CONNEALLY PM, 1989, GENOMICS, V5, P304, DOI 10.1016/0888-7543(89)90062-1; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DOUCETTESTAMM LA, 1991, CELL MOL GENET, V17, P471; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; Gusella J F, 1991, Adv Hum Genet, V20, P125; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; GUSELLA JF, 1989, FASEB J, V3, P2036, DOI 10.1096/fasebj.3.9.2568302; GUSELLA JF, 1984, SCIENCE, V225, P1320, DOI 10.1126/science.6089346; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARLEY HG, 1992, LANCET, V339, P1125, DOI 10.1016/0140-6736(92)90729-M; Harper PS, 1991, HUNTINGTONS DISEASE; HARPER PS, 1992, J MED GENET, V89, P365; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEHRACH H., 1990, GENOME ANAL, P39; LIN CS, 1991, SOMAT CELL MOLEC GEN, V17, P481, DOI 10.1007/BF01233172; MACDONALD ME, 1989, J CLIN INVEST, V84, P1013, DOI 10.1172/JCI114222; MACDONALD ME, 1992, NAT GENET, V1, P99, DOI 10.1038/ng0592-99; MACDONALD ME, 1991, AM J HUM GENET, V49, P723; MACDONALD ME, 1989, NEURON, V3, P183, DOI 10.1016/0896-6273(89)90031-7; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MERRITT AD, 1969, PROGR NEUROGENETICS, P645; MYERS RH, 1989, AM J HUM GENET, V45, P615; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; OUDET C, 1993, AM J HUM GENET, V52, P297; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; POHL TM, 1988, NUCLEIC ACIDS RES, V16, P9185, DOI 10.1093/nar/16.19.9185; PRITCHARD C, 1992, AM J HUM GENET, V50, P1218; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNELL RG, 1989, J MED GENET, V26, P673, DOI 10.1136/jmg.26.11.673; SNELL RG, 1992, AM J HUM GENET, V51, P357; SUTHERS GK, 1992, J MED GENET, V29, P761, DOI 10.1136/jmg.29.11.761; TAYLOR SAM, 1992, NAT GENET, V2, P223, DOI 10.1038/ng1192-223; THEILMANN J, 1989, J MED GENET, V26, P676, DOI 10.1136/jmg.26.11.676; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WHALEY WL, 1991, SOMAT CELL MOLEC GEN, V17, P83, DOI 10.1007/BF01233207; YOUNGMAN S, 1992, GENOMICS, V14, P350, DOI 10.1016/S0888-7543(05)80225-3; YU S, 1992, AM J HUM GENET, V50, P968	64	5994	6171	13	470	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					971	983		10.1016/0092-8674(93)90585-E	http://dx.doi.org/10.1016/0092-8674(93)90585-E			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458085	Green Published			2022-12-28	WOS:A1993KU17500017
J	DEMENT, WC; MITLER, MM				DEMENT, WC; MITLER, MM			ITS TIME TO WAKE UP TO THE IMPORTANCE OF SLEEP DISORDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SHIFT WORK; ACCIDENTS; INSOMNIA; PERFORMANCE; PHYSICIANS; ALERTNESS; DISEASE; ETHANOL; THERAPY; RISK		SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037	Scripps Research Institute	DEMENT, WC (corresponding author), STANFORD UNIV,CTR SLEEP DISORDERS,701 WELCH RD,SUITE 2226,PALO ALTO,CA 94304, USA.		Winwood, Peter/A-6363-2008					AKERSTEDT T, 1988, SLEEP, V11, P17, DOI 10.1093/sleep/11.1.17; ALDRICH CK, 1986, POSTGRAD MED, V80, P233, DOI 10.1080/00325481.1986.11699572; ALDRICH MS, 1989, SLEEP, V12, P487, DOI 10.1093/sleep/12.6.487; Bartels E C, 1965, Lahey Clin Found Bull, V14, P21; CARSKADON M A, 1990, Pediatrician, V17, P5; COLEMAN RM, 1986, SLEEP RES, V15, P265; DEMENT WC, 1991, 5TH ANN M ASS PROF S; Dement WC, 1978, SLEEP APNEA SYNDROME, P23; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; GILLIN JC, 1990, NEW ENGL J MED, V322, P239; GILLIN JC, 1992, POSTGRAD MED, V92, P157; JACQUES CHM, 1990, J FAM PRACTICE, V30, P223; JOHNSON LC, 1983, MIL MED, V148, P727; Kales A., 1984, EVALUATION TREATMENT; KNUTSSON A, 1986, LANCET, V2, P89; KOLLER M, 1983, INT ARCH OCC ENV HEA, V53, P59, DOI 10.1007/BF00406178; KRYGER MH, 1989, PRINCIPLES PRACTICE; LAUBER JK, 1988, SLEEP, V11, P503; LUMLEY M, 1987, SLEEP, V10, P306; MANHEIMER DI, 1973, AM J PSYCHIAT, V130, P1246, DOI 10.1176/ajp.130.11.1246; MELLINGER GD, 1985, ARCH GEN PSYCHIAT, V42, P225, DOI 10.1001/archpsyc.1985.01790260019002; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; MOOREEDE M, 1988, NOV P FED HIGHW ADM; PALOMAKI H, 1992, NEUROLOGY, V42, P75; Pollak C P, 1991, J Geriatr Psychiatry Neurol, V4, P204, DOI 10.1177/089198879100400405; ROEHRS T, 1989, PHARMACOL BIOCHEM BE, V34, P321, DOI 10.1016/0091-3057(89)90319-5; SCHEMO DJ, 1992, NY TIMES        0413; SEPPALA T, 1991, J INTERN MED, V229, P23, DOI 10.1111/j.1365-2796.1991.tb00301.x; WALSH JK, 1991, POSTGRAD MED, V90, P211; ZANINELLI A, 1991, INT J CARDIOL, V32, P347, DOI 10.1016/0167-5273(91)90297-3; 1992, NY TIMES        0411; 1989, TRANSPORTATION RELAT; 1991, SLEEP AM, P1; 1986, REPORT PRESIDENTIAL, P2; 1988, HEAD END COLLISION C; 1991, ACCIDENT FACTS 1991; 1991, OTABA463 OFF TECHN A; 1990, SAFETY STUDY FATIGUE, P1; 1988, OTASET382 OFF TECHN; 1990, INT CLASSIFICATION S	40	77	81	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1548	1550		10.1001/jama.269.12.1548	http://dx.doi.org/10.1001/jama.269.12.1548			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445820				2022-12-28	WOS:A1993KR80300030
J	GABRIELLI, BG; ROY, LM; MALLER, JL				GABRIELLI, BG; ROY, LM; MALLER, JL			REQUIREMENT FOR CDK2 IN CYTOSTATIC FACTOR MEDIATED METAPHASE-II ARREST	SCIENCE			English	Article							MATURATION-PROMOTING FACTOR; PROTO-ONCOGENE PRODUCT; MEIOTIC MATURATION; XENOPUS EGGS; PROTOONCOGENE PRODUCT; MOSXE PROTOONCOGENE; CYTOPLASMIC FACTOR; CYCLIN-A; M-PHASE; OOCYTES	The unfertilized eggs of vertebrates are arrested in metaphase of meiosis II because of the activity of cytostatic factor (CSF). Xenopus CSF is thought to contain the product of the Mos proto-oncogene, but other proteins synthesized during meiosis II are also required for arrest induced by CSF. In Xenopus oocytes, ablation of synthesis of cyclin-dependent kinase 2 (Cdk2) during meiosis resulted in absence of the metaphase II block, even though the Mos(xe) protein kinase was fully active at metaphase. Introduction of purified Cdk2 restored metaphase II arrest, and increasing the amount of Cdk2 during meiosis I (when Mos(xe) is present) led to metaphase arrest at meiosis I. These data indicate that metaphase arrest is a result of cooperation between a proto-oncogene kinase and a cyclin-dependent kinase and illustrate the interaction of a cell growth regulator with a cell cycle control element.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	GABRIELLI, BG (corresponding author), UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262, USA.		Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651	NCI NIH HHS [F32 CA0981] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GABRIELLI BG, UNPUB; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MALLER JL, 1991, COLD SH Q B, V56, P533; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MASUI Y, 1980, CELL SURFACE MEDIATO, P235; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY L, UNPUB; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SLEIGHT SB, UNPUB; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	40	77	78	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1766	1769		10.1126/science.8456304	http://dx.doi.org/10.1126/science.8456304			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456304				2022-12-28	WOS:A1993KT81000041
J	ANGERT, ER; CLEMENTS, KD; PACE, NR				ANGERT, ER; CLEMENTS, KD; PACE, NR			THE LARGEST BACTERIUM	NATURE			English	Article							RIBOSOMAL-RNA; GUT; SURGEONFISHES; ACANTHURIDAE; REEF; SEA; DNA	THE large, morphologically peculiar microorganism Epulopiscium fishelsoni1,2 inhabits the intestinal tract of Acanthurus nigrofuscus, a brown surgeonfish (family Acanthuridae) from the Red Sea. Similar microorganisms have been found in surgeonfish species from the Great Barrier Reef3. As these microorganisms have only been seen in surgeonfish and no free-living forms have been found, they are considered to be specific symbionts of surgeonfish, although the nature of the symbiosis is unclear1-4 . Initial reports considered them to be eukaryotic protists, based primarily on their size1-4, with individuals being larger than 600 mum by 80 mum. But their cellular morphology in the electron microscope is more like that of bacterial than eukaryotic cells1,2,5. To resolve the nature of these symbionts, we have isolated the genes encoding the small subunit ribosomal RNA from two morphotypes and used them in a phylogenetic analysis. In situ hybridization with oligonucleotide probes based on the cloned rRNA sequences confirmed the source of the rRNA genes. Our results identify the symbionts as members of the low-(G + C) Gram-positive group of bacteria. They are therefore the largest bacteria to be described so far.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; JAMES COOK UNIV N QUEENSLAND, DEPT MARINE BIOL, TOWNSVILLE, QLD 4811, AUSTRALIA	Indiana University System; Indiana University Bloomington; James Cook University				Clements, Kendall/0000-0001-8512-5977				BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLAKEMORE RP, 1973, ARCH MIKROBIOL, V89, P273, DOI 10.1007/BF00408895; CLEMENTS KD, 1989, MAR BIOL, V102, P403, DOI 10.1007/BF00428493; CLEMENTS KD, 1991, J BACTERIOL, V173, P5359, DOI 10.1128/jb.173.17.5359-5362.1991; DELAPORTE B, 1964, ANN I PASTEUR PARIS, V107, P246; DELONG EF, 1989, SCIENCE, V243, P1360, DOI 10.1126/science.2466341; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FISHELSON L, 1985, SCIENCE, V229, P49; JANNASCH HW, 1989, NATURE, V342, P834, DOI 10.1038/342834a0; MONTGOMERY WL, 1988, MAR ECOL PROG SER, V44, P7, DOI 10.3354/meps044007; MONTGOMERY WL, 1988, J PROTOZOOL, V35, P565, DOI 10.1111/j.1550-7408.1988.tb04153.x; OLSEN GJ, 1992, NUCLEIC ACIDS RES, V20, P2199, DOI 10.1093/nar/20.suppl.2199; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; WARD DM, 1992, ADV MICROB ECOL, V12, P219; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; [No title captured]	19	146	151	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	1993	362	6417					239	241		10.1038/362239a0	http://dx.doi.org/10.1038/362239a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8459849				2022-12-28	WOS:A1993KT02600054
J	MCAVOY, BR				MCAVOY, BR			HEARTSINK HOTEL REVISITED	BRITISH MEDICAL JOURNAL			English	Article											MCAVOY, BR (corresponding author), UNIV AUCKLAND,SCH MED,DEPT GEN PRACTICE,AUCKLAND,NEW ZEALAND.							GLENNERSTER H, 1992, 12 KINGS FUND I RES; MCAVOY B, 1989, BRIT MED J, V298, P968; [No title captured]	3	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					694	695		10.1136/bmj.306.6879.694	http://dx.doi.org/10.1136/bmj.306.6879.694			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT216	8471924	Green Published, Bronze			2022-12-28	WOS:A1993KT21600024
J	MCGONIGAL, G; THOMAS, B; MCQUADE, C; STARR, JM; MACLENNAN, WJ; WHALLEY, LJ				MCGONIGAL, G; THOMAS, B; MCQUADE, C; STARR, JM; MACLENNAN, WJ; WHALLEY, LJ			EPIDEMIOLOGY OF ALZHEIMERS PRESENILE-DEMENTIA IN SCOTLAND, 1974-88	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; PREVALENCE; POPULATION; DIAGNOSIS; AGE	Objective-To describe the epidemiology of presenile Alzheimer's disease in Scotland from 1974 to 1988. Design-Retrospective review of hospital records of patients aged less than 73 years admitted to psychiatric hospital with various diagnoses of dementia. Diagnoses were classified by National Institute for Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association Criteria and the Hachinski score. Completeness of the study sample was evaluated by scrutiny of neurology outpatient and general hospital records. Setting-All general psychiatric hospitals in Scotland. Subjects-All patients with onset of dementia aged 40-64. Main outcome measures-Probable and broad Alzheimer's disease, sex of patient, age at onset. Results-5874 psychiatric hospital records, 129 neurology outpatient records, and 89 records from non-psychiatric hospitals were examined. 317 patients met criteria for probable Alzheimer's disease, 569 met criteria for broad Alzheimer's disease, and 267 met those for multi-infarct dementia. Minimal incidences per 100 000 population aged 40-64 years were 22.6 (95% confidence interval, 20.2 to 25.2) and 40.5 (38.9 to 42.3) per 100000 for probable and broad Alzheimer's disease. In the 1981 census year the annual incidence of probable Alzheimer's disease was 1.6 (1.0 to 2.6). Women were at greater risk with incidence rates for probable Alzheimer's disease of 28.2 (24.5 to 32.4) per 100000 compared with 16.5 (13.8 to 19.8) per 100000 for men. The incidence per 100000 for multi-infarct dementia was greater in men (25.1, 23.3 to 27.1) than women (13.4,12.1 to 14.8). Conclusion-Female sex seems to be positively associated with development of Alzheimer's disease before age 65 years.	UNIV ABERDEEN,DEPT MENTAL HLTH,ABERDEEN AB9 2ZD,SCOTLAND; ST THOMAS HOSP,STOCKPORT,ENGLAND; UNIV EDINBURGH,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; HAMMERSMITH HOSP,LONDON W12 0HS,ENGLAND	University of Aberdeen; University of Edinburgh; Imperial College London			Starr, John/C-8951-2011; whalley, lawrence j/E-9019-2011					BUHL L, 1988, DAN MED BULL, V35, P288; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HENDERSON AS, 1988, ACTA PSYCHIAT SCAND, V78, P257, DOI 10.1111/j.1600-0447.1988.tb06336.x; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; KUKULL WA, 1990, NEUROLOGY, V40, P257, DOI 10.1212/WNL.40.2.257; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MARTIN GM, 1990, NATURE, V347, P124, DOI 10.1038/347124a0; MCGONIGAL G, 1992, NEUROEPIDEMIOLOGY, V11, P121, DOI 10.1159/000110921; MCGONIGAL G, 1992, Health Bulletin (Edinburgh), V50, P309; MCGONIGAL G, 1992, INT J GERIATR PSYCH, V7, P751, DOI 10.1002/gps.930071011; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MOLSA PK, 1982, ACTA NEUROL SCAND, V65, P541; Morris JN, 1964, USES OF EPIDEMIOLOGY; NILSSON LV, 1984, ACTA PSYCHIAT SCAND, V70, P478, DOI 10.1111/j.1600-0447.1984.tb01237.x; PFEFFER RI, 1987, AM J EPIDEMIOL, V125, P420, DOI 10.1093/oxfordjournals.aje.a114548; ROCCA WA, 1990, NEUROLOGY, V40, P626, DOI 10.1212/WNL.40.4.626; SCHOENBERG BS, 1987, ANN NEUROL, V22, P724, DOI 10.1002/ana.410220608; TREVES T, 1986, ARCH NEUROL-CHICAGO, V43, P26, DOI 10.1001/archneur.1986.00520010022014; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412; 1977, INT CLASSIFICATION D	21	91	93	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					680	683		10.1136/bmj.306.6879.680	http://dx.doi.org/10.1136/bmj.306.6879.680			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KT216	8471918	Green Published, Bronze			2022-12-28	WOS:A1993KT21600018
J	EHLICH, A; SCHAAL, S; GU, H; KITAMURA, D; MULLER, W; RAJEWSKY, K				EHLICH, A; SCHAAL, S; GU, H; KITAMURA, D; MULLER, W; RAJEWSKY, K			IMMUNOGLOBULIN HEAVY AND LIGHT CHAIN GENES REARRANGE INDEPENDENTLY AT EARLY STAGES OF B-CELL DEVELOPMENT	CELL			English	Article							MOUSE BONE-MARROW; MICE; LINE; EXPRESSION; VH; PROLIFERATION; TRANSCRIPTION; REPERTOIRE; MATURATION; ACTIVATION	The compartment of mouse B cell progenitors can be resolved into five developmentally related fractions by multicolor flow cytometry. Using this system and employing mutant mice in which the membrane exon of the mu chain, the lambda5 gene, or the J(H) locus was inactivated by gene targeting, we found that expression of the pre-B cell receptor complex is necessary for the transition from the large CD43+ to the small CD43- pre-B cell stage. We report the occurrence of immunoglobulin heavy and light chain gene rearrangement at the stage of large B cell precursors. We show that neither the pre-B cell receptor complex nor any gene rearrangement in the heavy chain locus is required for the induction of K light chain gene rearrangement in early B cell progenitors.			EHLICH, A (corresponding author), UNIV COLOGNE,INST GENET,W-5000 COLOGNE 41,GERMANY.		Muller, Werner/B-9044-2008	Muller, Werner/0000-0002-1297-9725				ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BENATAR T, 1992, P NATL ACAD SCI USA, V89, P7615, DOI 10.1073/pnas.89.16.7615; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BURNET FM, 1959, CLONAL SELECTION THE; COFFMAN RL, 1983, J MOL CELL IMMUNOL, V1, P31; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GIGUERE V, 1985, EMBO J, V4, P2017, DOI 10.1002/j.1460-2075.1985.tb03886.x; Grutzmann R., 1981, THESIS U COLOGNE COL; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Hardy R. R., 1986, HDB EXPT IMMUNOLOGY; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; JOHO R, 1980, NATURE, V284, P179, DOI 10.1038/284179a0; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; KOFLER R, 1992, IMMUNOL REV, V128, P5, DOI 10.1111/j.1600-065X.1992.tb00830.x; KRAWINKEL U, 1989, IMMUNOL TODAY, V10, P339, DOI 10.1016/0167-5699(89)90191-6; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; LANDRETH KS, 1981, J IMMUNOL, V127, P2027; LEE G, 1989, J IMMUNOL, V142, P3875; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; MALYNN BA, 1990, J EXP MED, V171, P843, DOI 10.1084/jem.171.3.843; MCCORMACK WT, 1989, GENE DEV, V3, P838, DOI 10.1101/gad.3.6.838; MELCHERS F, 1989, COLD SH Q B, V54, P183; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; OSMOND DG, 1991, CURR OPIN IMMUNOL, V3, P179, DOI 10.1016/0952-7915(91)90047-5; PARK YH, 1987, J EXP MED, V165, P444, DOI 10.1084/jem.165.2.444; PINK JRL, 1990, IMMUNOL REV, V115, P239, DOI 10.1111/j.1600-065X.1990.tb00794.x; RAJEWSKY K, 1992, NATURE, V359, P371, DOI 10.1038/359371b0; RATCLIFFE MJH, 1986, EUR J IMMUNOL, V16, P126; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; RETH M, 1987, MOL GENETICS IMMUNOG, P111; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHAPIRO MA, 1987, J IMMUNOL, V139, P3834; TAKEMORI T, 1981, EUR J IMMUNOL, V11, P618, DOI 10.1002/eji.1830110806; TODA M, 1989, IMMUNOL LETT, V21, P311, DOI 10.1016/0165-2478(89)90025-4; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1991, CURR OPIN IMMUNOL, V3, P186, DOI 10.1016/0952-7915(91)90048-6; TSUBATA T, 1990, INT IMMUNOL, V172, P943; TSUKADA S, 1990, J IMMUNOL, V144, P4053; WALL R, 1986, P NATL ACAD SCI USA, V83, P295, DOI 10.1073/pnas.83.2.295; WEILL JC, 1986, P NATL ACAD SCI USA, V83, P3336, DOI 10.1073/pnas.83.10.3336; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681	58	289	301	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					695	704		10.1016/0092-8674(93)90398-A	http://dx.doi.org/10.1016/0092-8674(93)90398-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453664	Bronze			2022-12-28	WOS:A1993KR43600006
J	FORGE, A; LI, L; CORWIN, JT; NEVILL, G				FORGE, A; LI, L; CORWIN, JT; NEVILL, G			ULTRASTRUCTURAL EVIDENCE FOR HAIR CELL REGENERATION IN THE MAMMALIAN INNER-EAR	SCIENCE			English	Article							CHRONIC GENTAMICIN TREATMENT; ACOUSTIC TRAUMA; CHICK COCHLEA; STEREOCILIARY BUNDLES; ACTIN-FILAMENTS; GROWTH	It has long been thought that hair cell loss from the inner ears of mammals is irreversible. This report presents scanning electron micrographs and thin sections of the utricles from the inner ears of guinea pigs that show that, after hair cell loss caused by treatment with the aminoglycoside gentamicin, hair cells reappeared. Four weeks after the end of treatment, a large number of cells with immature hair bundles in multiple stages of development could be identified in the utricle. Thin sections showed that lost type 1 hair cells were replaced by cells with a morphology similar to that of type 2 hair cells. These results indicate an unexpected capacity for hair cell regeneration in vivo in the mature mammalian inner ear.	UNIV VIRGINIA, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, CHARLOTTESVILLE, VA 22908 USA	University of Virginia	FORGE, A (corresponding author), UCL, INST LARYNGOL & OTOL, 330-332 GRAYS INN RD, LONDON WC1X 8EE, ENGLAND.			Forge, Andrew/0000-0002-0995-0219	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWN AM, 1989, HEARING RES, V42, P143, DOI 10.1016/0378-5955(89)90140-8; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; CORWIN JT, 1981, J COMP NEUROL, V201, P541, DOI 10.1002/cne.902010406; CORWIN JT, 1985, P NATL ACAD SCI USA, V82, P3911, DOI 10.1073/pnas.82.11.3911; CORWIN JT, 1983, J COMP NEUROL, V217, P342; CORWIN JT, 1986, BIOL CHANGE OTOLARYN, P291; COTANCHE DA, 1987, HEARING RES, V30, P181, DOI 10.1016/0378-5955(87)90135-3; COTANCHE DA, 1991, HEARING RES, V52, P379, DOI 10.1016/0378-5955(91)90027-7; CRUZ RM, 1987, ARCH OTOLARYNGOL, V113, P1058; DAVIES S, 1987, J MICROSC-OXFORD, V147, P89, DOI 10.1111/j.1365-2818.1987.tb02821.x; DECHESNE C, 1986, ACTA OTO-LARYNGOL, V101, P11, DOI 10.3109/00016488609108602; DEROSIER DJ, 1980, NATURE, V287, P291, DOI 10.1038/287291a0; FLOCK A, 1977, J CELL BIOL, V75, P339, DOI 10.1083/jcb.75.2.339; FORGE A, 1985, HEARING RES, V19, P171, DOI 10.1016/0378-5955(85)90121-2; FURNESS DN, 1989, HEARING RES, V38, P95, DOI 10.1016/0378-5955(89)90131-7; Manley GA., 1990, PERIPHERAL HEARING M; MICHAELS L, 1987, EAR NOSE THROAT HIST, P89; PICKLES JO, 1988, INTRO PHYSL HEARING, P298; POPPER AN, 1984, HEARING RES, V15, P133, DOI 10.1016/0378-5955(84)90044-3; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; TILNEY LG, 1986, DEV BIOL, V116, P100, DOI 10.1016/0012-1606(86)90047-3; WARCHOL ME, 1993, SCIENCE, V259, P1619, DOI 10.1126/science.8456285; WEISLEDER P, 1992, EXP NEUROL, V115, P2, DOI 10.1016/0014-4886(92)90211-8	23	410	433	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	1993	259	5101					1616	1619		10.1126/science.8456284	http://dx.doi.org/10.1126/science.8456284			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8456284				2022-12-28	WOS:A1993KR54300041
J	FLETCHER, AE; BEEVERS, DG; BULPITT, CJ; COLES, EC; DOLLERY, CT; LEDINGHAM, JG; PALMER, AJ; PETRIE, JC; WEBSTER, J				FLETCHER, AE; BEEVERS, DG; BULPITT, CJ; COLES, EC; DOLLERY, CT; LEDINGHAM, JG; PALMER, AJ; PETRIE, JC; WEBSTER, J			CANCER MORTALITY AND ATENOLOL TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DIV GERIATR MED,LONDON W12 0NN,ENGLAND; DUDLEY RD GEN HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND; UNIV WALES COLL MED,DEPT COMPUTING & MED STAT,CARDIFF CF4 4XN,S GLAM,WALES; JOHN RADCLIFFE HOSP,DEPT MED,OXFORD OX3 9DU,ENGLAND; UNIV ABERDEEN,DEPT MED & THERAPEUT,CLIN PHARMACOL UNIT,ABERDEEN AB9 1FX,SCOTLAND	Imperial College London; Cardiff University; University of Oxford; University of Aberdeen								BEILIN LJ, 1974, BRIT MED J, V2, P212, DOI 10.1136/bmj.2.5912.212; BULPITT CJ, 1976, BMJ-BRIT MED J, V1, P677, DOI 10.1136/bmj.1.6011.677; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; 1992, BMJ, V304, P405	4	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					622	623		10.1136/bmj.306.6878.622	http://dx.doi.org/10.1136/bmj.306.6878.622			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461813	Bronze, Green Published			2022-12-28	WOS:A1993KQ85900021
J	BAHN, PG; EVERETT, K				BAHN, PG; EVERETT, K			ICEMAN IN THE COLD LIGHT OF DAY	NATURE			English	Editorial Material																		BADER JM, 1992, SCI VIE, V901, P178; BARFIELD L, 1992, ZEUGE GLETSCHER; HOPFEL P, 1992, 1992 INT S INNSBR IN, V187; LEHER P, 1991, ANTIQUITY, V65, P269; SEIDLER H, 1992, SCIENCE, V258, P455, DOI 10.1126/science.1411539; Sjovold T., 1992, EVOL ANTHROPOL, V1, P117; WEDIN B, 1979, J FORENSIC SCI, V24, P543; ZISSERNIG E, 1992, MANN EIS, V1, P234	8	19	19	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					11	12		10.1038/362011a0	http://dx.doi.org/10.1038/362011a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8446162				2022-12-28	WOS:A1993KP97600025
J	EADY, EA; JONES, CE; TIPPER, JL; COVE, JH; CUNLIFFE, WJ; LAYTON, AM				EADY, EA; JONES, CE; TIPPER, JL; COVE, JH; CUNLIFFE, WJ; LAYTON, AM			ANTIBIOTIC-RESISTANT PROPIONIBACTERIA IN ACNE - NEED FOR POLICIES TO MODIFY ANTIBIOTIC USAGE	BRITISH MEDICAL JOURNAL			English	Article									GEN INFIRM,DEPT DERMATOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary	EADY, EA (corresponding author), UNIV LEEDS,DEPT MICROBIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.			Tipper, Joanne/0000-0002-8719-0323; Layton, Alison/0000-0003-0473-3319				CRAWFORD WW, 1978, J INVEST DERMATOL, V72, P187; CUNFLIFFE WJ, 1989, ACNE; EADY EA, 1989, BRIT J DERMATOL, V121, P51, DOI 10.1111/j.1365-2133.1989.tb01399.x; Leyden J J, 1976, Cutis, V17, P593; LEYDEN JJ, 1983, J AM ACAD DERMATOL, V8, P41, DOI 10.1016/S0190-9622(83)70005-8	5	113	119	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					555	556		10.1136/bmj.306.6877.555	http://dx.doi.org/10.1136/bmj.306.6877.555			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461769	Bronze, Green Published			2022-12-28	WOS:A1993KP88600021
J	MASON, J; DRUMMOND, M; TORRANCE, G				MASON, J; DRUMMOND, M; TORRANCE, G			SOME GUIDELINES ON THE USE OF COST-EFFECTIVENESS LEAGUE TABLES	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; BENEFIT-ANALYSIS; ECONOMICS; OREGON	Decisions to allocate resources in health care are increasingly influenced by relative cost effectiveness. To warn decision makers of some of the pitfalls currently found in cost effectiveness league tables and to suggest how meaningful comparisons may be made between health care technologies a published league table was scrutinised by examining its sources. This showed some of the methodological problems surrounding such tables and how such difficulties could be reduced in future. The source studies in the table featured different years of origin, discount rates, health state valuations, settings, and types of comparison programmes; all of these differences may raise problems for meaningful comparison. Decision makers need to assess the relative value for money of competing health care interventions. In the absence of systematic comparisons such assessments are likely to take place informally. This will probably have a worse risk-benefit trade off than the formalised use of league tables.	MCMASTER UNIV,CTR HLTH ECON & POLICY ANAL,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University	MASON, J (corresponding author), UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Mason, James M/D-9904-2011	Mason, James M/0000-0001-9210-4082				AKEHURST R, 1992, 92 U YORK CTR HLTH E; BIRCH S, 1987, J HEALTH ECON, V6, P211, DOI 10.1016/0167-6296(87)90009-9; Cairns J, 1992, Health Econ, V1, P76, DOI 10.1002/hec.4730010111; COX DR, 1992, J ROY STAT SOC A STA, V155, P353, DOI 10.2307/2982889; Drummond M F, 1992, Int J Technol Assess Health Care, V8, P671; Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561; DRUMMOND MF, IN PRESS J HUMAN HYP; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2135, DOI 10.1001/jama.266.15.2135; GERARD K, 1992, 0492 U AB DEP PUBL H; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LEESE B, 1990, COST EFFECTIVENESS U; MAYNARD A, 1991, ECON J, V101, P1277, DOI 10.2307/2234443; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; PICKARD JD, 1990, BRIT MED J, V301, P629, DOI 10.1136/bmj.301.6753.629; SMITH GT, 1990, AM HEART J, V119, P725, DOI 10.1016/S0002-8703(05)80052-3; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; Torrance G W, 1972, Health Serv Res, V7, P118; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; TORRANCE GW, 1984, CLIN PERINATOL, V11, P267, DOI 10.1016/S0095-5108(18)30920-5; Torrance GW, 1987, METHODS EC EVALUATIO; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; 1990, BREAST CANCER SCREEN; [No title captured]; [No title captured]; 1990, BLOOD CHOLESTEROL TE	26	158	161	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					570	572		10.1136/bmj.306.6877.570	http://dx.doi.org/10.1136/bmj.306.6877.570			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KP886	8461776	Green Published, Bronze			2022-12-28	WOS:A1993KP88600029
J	BARKER, DJP; OSMOND, C; SIMMONDS, SJ; WIELD, GA				BARKER, DJP; OSMOND, C; SIMMONDS, SJ; WIELD, GA			THE RELATION OF SMALL HEAD CIRCUMFERENCE AND THINNESS AT BIRTH TO DEATH FROM CARDIOVASCULAR-DISEASE IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article							PLACENTAL SIZE; FETAL; WEIGHT	Objective-To determine how fetal growth is related to death from cardiovascular disease in adult life. Design-A follow up study of men born during 1907-24 whose birth weights, head circumferences, and other body measurements were recorded at birth. Setting-Sheffield, England. Subjects-1586 Men born in the Jessop Hospital. Main outcome measure-Death from cardiovascular disease. Results-Standardised mortality ratios for cardiovascular disease fell from 119 in men who weighed 5.5 pounds (2495 g) or less at birth to 74 in men who weighed more than 8.5 pounds (3856 g). The fall was significant for premature cardiovascular deaths up to 65 years of age (chi2=5.0, p=0.02). Standardised mortality ratios also fell with increasing head circumference (chi2=4.6, p=0.03) and increasing ponderal index (weight/length3) (chi2=3.8, p=0.05; for premature deaths chi2=6.0, p=0.01). They were not related to the duration of gestation. Among men for whom the ratio of placental weight to birth weight was in the highest fifths the standardised mortality ratio was 137. Conclusion-These findings show that reduced fetal growth is followed by increased mortality from cardiovascular disease. They suggest that reduction in growth begins early in gestation. They are further evidence that cardiovascular disease originates through programming of the body's structure, physiology, and metabolism by the environment during fetal life. Maternal nutrition may have an important influence on programming.			BARKER, DJP (corresponding author), SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; BEISCHER N A, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P398; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BLACKWELL NM, 1968, J NUTR, V97, P79; BUTLER NR, 1969, 2ND REPORT 1958 BRIT; DUBOS R, 1966, PEDIATRICS, V38, P789; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FARCHNEY GJ, 1987, AUSTR J BIOL SCI, V40, P365; Gardner M, 1984, ATLAS MORTALITY SELE; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; HAHN P, 1984, J NUTR, V114, P1231, DOI 10.1093/jn/114.7.1231; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LUCAS A, 1991, CIBA F SYMP, V156, P38; MCCRABB GJ, 1991, BRIT J NUTR, V65, P157, DOI 10.1079/BJN19910077; PHIPPS K, 1993, IN PRESS DIABETOLOGI; ROBINSON SM, 1991, BRIT J OBSTET GYNAEC, V98, P1223, DOI 10.1111/j.1471-0528.1991.tb15393.x; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300	23	544	557	1	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					422	426		10.1136/bmj.306.6875.422	http://dx.doi.org/10.1136/bmj.306.6875.422			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461722	Bronze, Green Published			2022-12-28	WOS:A1993KM70000019
J	COULTER, A; BRADLOW, J				COULTER, A; BRADLOW, J			EFFECT OF NHS REFORMS ON GENERAL-PRACTITIONERS REFERRAL PATTERNS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare outpatient referral patterns in fundholding and non-fundholding practices before and after the implementation of the NHS reforms in April 1991. Design-Prospective collection of data on general practitioners' referrals to specialist outpatient clinics between June 1990 and March 1992 and detailed comparison of two time periods: October 1990 to March 1991 (phase 1) and October 1991 to March 1992 (phase 2). Setting-10 fundholding practices and six non-fundholding practices in the Oxford region. Subjects-Patients referred to consultant outpatient clinics. Results-After implementation of the NHS reforms there was no change in the proportion of referrals from the two groups of practices which crossed district boundaries. Both groups of practices increased their referral rates in phase 2 of the study, the fundholders from 107.3 per 1000 patients per annum (95% confidence interval 106 to 109) to 111.4 (110 to 113) and the non-fundholders from 95.0 (93 to 97) to 112.0 (110 to 114). In phase 2 there was no difference in overall standardised referral rates between fundholders and non-fundholders. Just over 20% of referrals went to private clinics in phase 1. By phase 2 this proportion had reduced by 2.2% (1.0% to 3.4%) among the fundholders and by 2.7% (1.2% to 4.2%) among the non-fundholders. Conclusions-Referral patterns among fundholders and non-fundholders were strikingly similar after the implementation of the NHS reforms. There was no evidence that fundholding was encouraging a shift from specialist to general practice care or that budgetary pressures were affecting general practitioners' referral behaviour.			COULTER, A (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; BRADLOW J, 1992, PATTERNS REFERRAL; COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; COULTER A, 1992, BRIT MED J, V304, P397, DOI 10.1136/bmj.304.6824.397; GARDNER MJ, 1990, STATISTICS CONFIDENC; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; ROLAND M, 1991, BRIT MED J, V303, P171, DOI 10.1136/bmj.303.6795.171; Roland M, 1992, HOSPITAL REFERRALS; 1989, WORKING PATIENTS; 1989, FUNDING GENERAL PRAC	10	79	80	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					433	437		10.1136/bmj.306.6875.433	http://dx.doi.org/10.1136/bmj.306.6875.433			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461728	Green Published, Bronze			2022-12-28	WOS:A1993KM70000025
J	CUMMINS, RO; GRAVES, JR; LARSEN, MP; HALLSTROM, AP; HEARNE, TR; CILIBERTI, J; NICOLA, RM; HORAN, S				CUMMINS, RO; GRAVES, JR; LARSEN, MP; HALLSTROM, AP; HEARNE, TR; CILIBERTI, J; NICOLA, RM; HORAN, S			OUT-OF-HOSPITAL TRANSCUTANEOUS PACING BY EMERGENCY MEDICAL TECHNICIANS IN PATIENTS WITH ASYSTOLIC CARDIAC-ARREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AUTOMATIC EXTERNAL DEFIBRILLATORS; AMERICAN-HEART-ASSOCIATION; TOTAL CIRCULATORY ARREST; VENTRICULAR-FIBRILLATION; BRADYASYSTOLIC ARREST; IMPROVING SURVIVAL; PACEMAKER; EXPERIENCE; TERMINATION; DEATH	Background. Transcutaneous cardiac pacemakers generate electrical stimuli that pace the heart through external electrodes that adhere to the chest wall. Transcutaneous pacing has been useful in some patients with bradycardia, but its efficacy in patients with asystole and full cardiac arrest has been limited, possibly because of delays in the initiation of pacing. We studied the efficacy of early transcutaneous pacing in patients with out-of-hospital asystolic cardiac arrest. Methods. For three years we provided transcutaneous pacemakers to about half the fire districts in a large emergency-medical-services system (the intervention group). In these districts, we authorized emergency medical technicians (EMTs) to begin transcutaneous pacing in patients with cardiac arrest and primary asystole or post-defibrillation asystole. Pacing was done as early as possible, before endotracheal intubation or intravenous medication. EMTs in the other fire districts (the control group) treated similar patients with basic cardiopulmonary resuscitation but without transcutaneous pacing. Results. The EMTs in the intervention group initiated transcutaneous pacing in 112 of the 278 patients with primary asystole. Of these patients, 22 (8 percent) were admitted to the hospital, and 11 (4 percent) were discharged. Among the 259 patients treated by the EMTs in the control group, 21 (8 percent) were admitted to the hospital, and 5 (2 percent) were discharged. The two groups did not differ significantly with respect to the rate of hospital admission or survival. Survival after early pacing for post-defibrillation asystole was no better than survival after pacing for primary asystole. Conclusions. Transcutaneous pacing appears to offer no benefit in patients with asystolic cardiac arrest, even when it is performed as early as possible by EMTs in the field. Our data suggest that the widespread implementation of early transcutaneous pacing for out-of-hospital asystolic cardiac arrest would be ineffective.	SEATTLE KING CTY DEPT PUBL HLTH,KING CTY EMERGENCY MED SERV DIV,110 PREFONTAINE PL S,SUITE 500,SEATTLE,WA 98104; UNIV WASHINGTON,MED CTR,DEPT MED,CTR EVALUAT EMERGENCY MED SERV,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH,DEPT BIOSTAT,SEATTLE,WA 98195; OVERLAKE MEM HOSP,BELLEVUE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					AHRQ HHS [HS05740-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALTAMURA G, 1989, PACE, V12, P331, DOI 10.1111/j.1540-8159.1989.tb02666.x; ALTAMURA G, 1990, PACE, V13, P2038, DOI 10.1111/j.1540-8159.1990.tb06938.x; ALTAMURA G, 1990, PACE, V13, P2026, DOI 10.1111/j.1540-8159.1990.tb06936.x; ARONSON AL, 1986, MED INSTRUM, V20, P27; BAROLD SS, 1988, AM J MED, V85, P817; BARTHELL E, 1988, ANN EMERG MED, V17, P1221, DOI 10.1016/S0196-0644(88)80074-X; BOCKA JJ, 1989, ANN EMERG MED, V18, P1280, DOI 10.1016/S0196-0644(89)80259-8; CLINTON J E, 1985, Journal of Emergency Medicine, V2, P155, DOI 10.1016/0736-4679(85)90390-7; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; COPASS M, 1989, EMT DEFIBRILLATION; CUMMINS R, 1989, PREHOSP DISASTER MED, V4, P70; CUMMINS R, 1989, PREHOSP DISASTER MED, V4, P196; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1990, ANN EMERG MED, V19, P38, DOI 10.1016/S0196-0644(05)82138-9; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1990, ANN EMERG MED, V19, P1245, DOI 10.1016/S0196-0644(05)82282-6; CUMMINS RO, 1988, J AM COLL CARDIOL, V11, P597, DOI 10.1016/0735-1097(88)91537-9; DALSEY WC, 1985, CRIT CARE MED, V13, P399, DOI 10.1097/00003246-198505000-00006; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1986, SCI AM, V254, P37, DOI 10.1038/scientificamerican0586-37; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1980, LANCET, V1, P812; EISENBERG MS, 1980, JAMA-J AM MED ASSOC, V243, P1049, DOI 10.1001/jama.243.10.1049; EISENBERG MS, 1986, CIRCULATION, V74, P9; EISENBERG MS, 1984, SUDDEN CARDIAC DEATH, P44; EITEL DR, 1987, ANN EMERG MED, V16, P531, DOI 10.1016/S0196-0644(87)80678-9; FALK RH, 1983, NEW ENGL J MED, V309, P1166, DOI 10.1056/NEJM198311103091907; FALK RH, 1983, CRIT CARE MED, V11, P779, DOI 10.1097/00003246-198310000-00004; GRAVES J, 1989, RAPIDZAP AUTOMATED D; GREENE HL, 1990, AM J CARDIOL, V65, pB4; HEDGES JR, 1987, CIRCULATION, V76, P1337, DOI 10.1161/01.CIR.76.6.1337; HEDGES JR, 1984, ANN EMERG MED, V13, P822, DOI 10.1016/S0196-0644(84)80450-3; HELLER MB, 1988, AM J EMERG MED, V6, P78, DOI 10.1016/0735-6757(88)90228-8; JAGGARAO NSV, 1982, LANCET, V2, P73; KENYON CJ, 1988, ANN EMERG MED, V17, P711, DOI 10.1016/S0196-0644(88)80618-8; KERN KB, 1990, RESUSCITATION, V20, P221, DOI 10.1016/0300-9572(90)90005-Y; LUCK JC, 1988, AM J CARDIOL, V61, P574, DOI 10.1016/0002-9149(88)90767-9; MADSEN JK, 1988, AM HEART J, V116, P7, DOI 10.1016/0002-8703(88)90242-6; NEUMAR RW, 1991, ANN EMERG MED, V20, P222, DOI 10.1016/S0196-0644(05)80927-8; NEUMAR RW, 1990, RESUSCITATION, V19, P199, DOI 10.1016/0300-9572(90)90103-L; NIEMANN JT, 1986, ANN EMERG MED, V15, P112, DOI 10.1016/S0196-0644(86)80003-8; NOE R, 1986, PACE, V9, P101, DOI 10.1111/j.1540-8159.1986.tb05365.x; OLSON CM, 1985, AM J EMERG MED, V3, P129, DOI 10.1016/0735-6757(85)90035-X; OLSON DW, 1989, ANN EMERG MED, V18, P806, DOI 10.1016/S0196-0644(89)80200-8; PARIS PM, 1985, ANN EMERG MED, V14, P320, DOI 10.1016/S0196-0644(85)80096-2; PETERSON J, 1987, ANN EMERG MED, V16, P493; ROSENTHAL E, 1988, PACE, V11, P2160, DOI 10.1111/j.1540-8159.1988.tb05982.x; STUEVEN H, 1986, ANN EMERG MED, V15, P707, DOI 10.1016/S0196-0644(86)80430-9; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; Syverud S, 1988, Emerg Med Clin North Am, V6, P197; SYVERUD SA, 1986, ANN EMERG MED, V15, P121, DOI 10.1016/S0196-0644(86)80004-X; TACHAKRA SS, 1988, ARCH EMERG MED, V5, P184; VUKOV LF, 1988, ANN EMERG MED, V17, P554, DOI 10.1016/S0196-0644(88)80282-8; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WHITE JM, 1985, ANN EMERG MED, V14, P298, DOI 10.1016/S0196-0644(85)80090-1; ZOLL PM, 1985, CRIT CARE MED, V13, P925; ZOLL PM, 1957, AM J MED, V23, P832, DOI 10.1016/0002-9343(57)90384-4; ZOLL PM, 1952, NEW ENGL J MED, V247, P768, DOI 10.1056/NEJM195211132472005; ZOLL PM, 1985, CIRCULATION, V71, P937, DOI 10.1161/01.CIR.71.5.937; ZOLL PM, 1954, CIRCULATION, V9, P482, DOI 10.1161/01.CIR.9.4.482; 1989, 1990 HEART STROKE FA	63	76	76	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1993	328	19					1377	1382		10.1056/NEJM199305133281903	http://dx.doi.org/10.1056/NEJM199305133281903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB495	8474514				2022-12-28	WOS:A1993LB49500003
J	STRAUS, SE				STRAUS, SE			SHINGLES - SORROWS, SALVES, AND SOLUTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							VARICELLA-ZOSTER VIRUS; POST-HERPETIC NEURALGIA; ORAL ACYCLOVIR; IMMUNOCOMPROMISED PATIENTS; THERAPY; INFECTION; COMPLICATIONS; VIDARABINE; CHILDREN; IMMUNITY				STRAUS, SE (corresponding author), NIAID,CLIN INVEST LAB,BLDG 10,ROOM 11N-228,BETHESDA,MD 20892, USA.							BERNSTEIN JE, 1989, J AM ACAD DERMATOL, V21, P265, DOI 10.1016/S0190-9622(89)70171-7; BURNETTE T C, 1992, Antiviral Research, V17, P118; COBO LM, 1986, OPHTHALMOLOGY, V93, P763; CROEN KD, 1988, P NATL ACAD SCI USA, V85, P9773, DOI 10.1073/pnas.85.24.9773; DAVISON AJ, 1991, J GEN VIROL, V72, P475, DOI 10.1099/0022-1317-72-3-475; EAGLSTEIN WH, 1970, J AMER MED ASSOC, V211, P1681, DOI 10.1001/jama.211.10.1681; ESMANN V, 1987, LANCET, V2, P126; GARLAND J., 1943, New England Journal of Medicine, V228, P336, DOI 10.1056/NEJM194303182281103; GUESS HA, 1986, PEDIATRICS, V78, P723; HAYWARD A, 1991, J INFECT DIS, V163, P873, DOI 10.1093/infdis/163.4.873; HODGE RAV, 1989, ANTIMICROB AGENTS CH, V33, P1765, DOI 10.1128/AAC.33.10.1765; HUFF JC, 1988, AM J MED, V85, P84; JACOBSON MA, 1990, ANN INTERN MED, V112, P187, DOI 10.7326/0003-4819-112-3-187; KECZKES K, 1980, BRIT J DERMATOL, V102, P551, DOI 10.1111/j.1365-2133.1980.tb07654.x; LJUNGMAN P, 1986, J INFECT DIS, V153, P840, DOI 10.1093/infdis/153.5.840; MACHIDA H, 1990, MICROBIOL IMMUNOL, V34, P959, DOI 10.1111/j.1348-0421.1990.tb01074.x; MCKENDRICK MW, 1984, J ANTIMICROB CHEMOTH, V14, P661, DOI 10.1093/jac/14.6.661; MCKENDRICK MW, 1986, BRIT MED J, V293, P1529, DOI 10.1136/bmj.293.6561.1529; MERIGAN TC, 1978, NEW ENGL J MED, V298, P981, DOI 10.1056/NEJM197805042981801; MORTON P, 1989, NEW ZEAL MED J, V102, P93; PLOTKIN SA, 1988, NEW ENGL J MED, V318, P573, DOI 10.1056/NEJM198803033180909; PREBLUD SR, 1984, PEDIATR INFECT DIS J, V3, P505, DOI 10.1097/00006454-198411000-00004; RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003; SHEPP DH, 1986, NEW ENGL J MED, V314, P208, DOI 10.1056/NEJM198601233140404; STEVENS DA, 1980, ARCH INTERN MED, V140, P52, DOI 10.1001/archinte.140.1.52; TRIEBWASSER JH, 1967, MEDICINE, V46, P409, DOI 10.1097/00005792-196709000-00003; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; WEINBERG A, 1987, J VIROL, V61, P2120, DOI 10.1128/JVI.61.7.2120-2127.1987; WELLER TH, 1958, J EXP MED, V108, P843, DOI 10.1084/jem.108.6.843; WHITLEY RJ, 1982, NEW ENGL J MED, V307, P971, DOI 10.1056/NEJM198210143071602; WHITLEY RJ, 1976, NEW ENGL J MED, V294, P1193, DOI 10.1056/NEJM197605272942201; WRIGHT WE, 1983, ORAL SURG ORAL MED O, V56, P39, DOI 10.1016/0030-4220(83)90053-1	32	26	28	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1836	1839		10.1001/jama.269.14.1836	http://dx.doi.org/10.1001/jama.269.14.1836			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459517				2022-12-28	WOS:A1993KW25000040
J	BURNOL, AF; MARGOTTIN, F; HUET, J; ALMOUZNI, G; PRIOLEAU, MN; MECHALI, M; SENTENAC, A				BURNOL, AF; MARGOTTIN, F; HUET, J; ALMOUZNI, G; PRIOLEAU, MN; MECHALI, M; SENTENAC, A			TFIIIC RELIEVES REPRESSION OF U6 SNRNA TRANSCRIPTION BY CHROMATIN	NATURE			English	Article							RNA POLYMERASE-C; SACCHAROMYCES-CEREVISIAE; YEAST; DNA; GENE; INVITRO	THE U6 small nuclear (sn)RNA gene (SNR6) from the yeast Saccharomyces cerevisiae is transcribed by RNA polymerase III in vivo1. This gene is unusual in having a TATA box at position -30, and an essential B-block element located downstream of the T-rich termination signal2,3. The B block is one of the two intragenic promoter elements of transfer RNA genes that are recognized by transcription factor (TF)IIIC (ref. 4). But accurate in vitro transcription of yeast U6 snRNA gene by PolIII in a purified system requires only TFIIIB components, including the TATA-box binding protein TBP5. Here we report that, after nucleosome reconstitution or chromatin assembly, U6 snRNA synthesis becomes dependent on TFIIIC and on the integrity of the B-block element. This observation resolves an apparent paradox between in vitro and in vivo results concerning the necessity of the downstream B-block element3,5 and sheds light on a new role of TFIIIC in gene activation.	INST JACQUES MONOD,EMBRYOL MOLEC LAB,F-75251 PARIS,FRANCE	UDICE-French Research Universities; Universite Paris Cite	BURNOL, AF (corresponding author), CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE.		Burnol, Anne-Francoise/P-2181-2017; Margottin-Goguet, Florence/F-9272-2013; Almouzni, Genevieve/ABG-1029-2021; , prioleau/S-6007-2019; Prioleau, Marie-Noelle/G-9824-2014	Margottin-Goguet, Florence/0000-0002-3124-6690; Almouzni, Genevieve/0000-0001-5570-0723; , prioleau/0000-0003-2585-4005; 				ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; BORDONNE R, 1992, NUCLEIC ACIDS RES, V20, P479, DOI 10.1093/nar/20.3.479; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; MORSE RH, 1992, MOL CELL BIOL, V12, P4015, DOI 10.1128/MCB.12.9.4015; RIGGS DL, 1990, J BIOL CHEM, V265, P7596; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; WOLFFE AP, 1991, CURR BIOL, V6, P366; ZIVANOVIC Y, 1990, J MOL BIOL, V214, P479, DOI 10.1016/0022-2836(90)90195-R	20	93	94	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					475	477		10.1038/362475a0	http://dx.doi.org/10.1038/362475a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8464480				2022-12-28	WOS:A1993KV42400092
J	LI, XX; FRANCESCHI, VR; OKITA, TW				LI, XX; FRANCESCHI, VR; OKITA, TW			SEGREGATION OF STORAGE PROTEIN MESSENGER-RNAS ON THE ROUGH ENDOPLASMIC-RETICULUM MEMBRANES OF RICE ENDOSPERM CELLS	CELL			English	Article							INSITU HYBRIDIZATION; MAIZE ENDOSPERM; LOCALIZATION; TRANSCRIPTS; EXPRESSION; PROLAMIN; ZEIN	Developing rice endosperm cells display two distinct rough endoplasmic reticula (ER), cisternal ER (C-ER) and protein body ER (PB-ER), the latter delimiting the prolamine protein bodies. These ER membranes are utilized for the simultaneous synthesis of glutelin and prolamine storage proteins, which are subsequently routed into separate protein bodies. We demonstrate by blot hybridization, and by visualization of the spatial distributions and densities of these transcripts in endosperm cells via high resolution in situ hybridization analysis, that prolamine transcripts are associated primarily with the PB-ER, while glutelin mRNAs are enriched on the C-ER. The results suggest that the initial targeting process of these storage proteins into distinct protein bodies is the segregation of their transcripts on the ER membranes.	WASHINGTON STATE UNIV,DEPT BOT,PULLMAN,WA 99164; WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University; Washington State University	LI, XX (corresponding author), WASHINGTON STATE UNIV,DEPT GENET & CELL BIOL,PULLMAN,WA 99164, USA.			Okita, Tom/0000-0002-2246-0599				ABE S, 1991, PROTOPLASMA, V165, P139, DOI 10.1007/BF01322284; BINDER M, 1986, J CELL BIOL, V102, P1646, DOI 10.1083/jcb.102.5.1646; BONNEAU AM, 1985, J CELL BIOL, V100, P1209, DOI 10.1083/jcb.100.4.1209; CAMPOS N, 1989, NUCLEIC ACIDS RES, V17, P1573, DOI 10.1093/nar/17.4.1573; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; Fawcett D.W., 1981, CELL; Juliano B. O., 1972, RICE CHEM TECHNOLOGY, P16; KIM WT, 1988, PLANT PHYSIOL, V88, P649, DOI 10.1104/pp.88.3.649; KRISHNAN HB, 1986, PLANT PHYSIOL, V81, P748, DOI 10.1104/pp.81.3.748; KRISHNAN HB, 1986, PLANTA, V169, P471, DOI 10.1007/BF00392095; LARKINS BA, 1978, PLANT PHYSIOL, V62, P256, DOI 10.1104/pp.62.2.256; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LI XX, 1990, EUR J CELL BIOL, V51, P9; Maniatis T., 1982, MOL CLONING; MASUMURA T, 1990, MOL GEN GENET, V221, P1, DOI 10.1007/BF00280360; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OKITA TW, 1989, J BIOL CHEM, V264, P12573; ORNELLES DA, 1986, MOL CELL BIOL, V6, P1650, DOI 10.1128/MCB.6.5.1650; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SHATTERS RG, 1991, BIOCHIM BIOPHYS ACTA, V1068, P179, DOI 10.1016/0005-2736(91)90208-P; SHORE GC, 1977, J CELL BIOL, V72, P726, DOI 10.1083/jcb.72.3.726; SHORE GC, 1977, BIOCHIM BIOPHYS ACTA, V472, P197, DOI 10.1016/0304-4157(77)90017-X; SINGER RH, 1989, J CELL BIOL, V108, P2343, DOI 10.1083/jcb.108.6.2343; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; YAMAGATA H, 1986, PLANT CELL PHYSIOL, V27, P135; YAMAGATA H, 1986, PLANT CELL PHYSIOL, V27, P1419, DOI 10.1093/oxfordjournals.pcp.a077240; [No title captured]; [No title captured]; [No title captured]	32	122	133	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					869	879		10.1016/0092-8674(93)90576-C	http://dx.doi.org/10.1016/0092-8674(93)90576-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458081				2022-12-28	WOS:A1993KU17500008
J	CAVARELLI, J; REES, B; RUFF, M; THIERRY, JC; MORAS, D				CAVARELLI, J; REES, B; RUFF, M; THIERRY, JC; MORAS, D			YEAST TRANSFER RNA(ASP) RECOGNITION BY ITS COGNATE CLASS-II AMINOACYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							ASPARAGINYL-TRANSFER-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CRYSTALLOGRAPHIC REFINEMENT; 2.8-A RESOLUTION; SEQUENCE; IDENTITY; HOMOLOGIES; ATP	AMINOACYL-RNA synthetases can be divided into two classes according to structural features inferred from sequence alignments1-3. This classification correlates almost perfectly with the attachment of the amino acid to the 2'-OH (class I) or 3'-OH (class II) group of the terminal adenosine4-6. Six subgroups of higher homology can be inferred from sequence analysis7,8. The five aminoacyl-tRNA synthetases whose crystal structures are known (MetRS, TyrRS and GlnRS in class I, SerRS and AspRS in class II)9-13 belong to different subgroups. Two of them, GluRS and AspRS, have been cocrystallized with their cognate tRNA11,13. AspRS, like six other members of class II, is an alpha2 dimer. Yeast tRNA(Asp) exhibits five identity determinants: the three anticodon bases, the discriminator base G73 and the base pair G10-U25(14). We report here that the refined crystal structure of AspRS complexed with TRNA(Asp) at 2.9 angstrom resolution reveals three regions of contact, each involving a domain of AspRS and at least one identity determinant of tRNA(Asp). The mode of binding of the acceptor stem of tRNA(Asp) by AspRS can be generalized to class II aminoacyl-tRNA synthetases, whereas the deciphering of the anticodon, which involves a large conformational change of the loop and the formation of a bulge, is more specific to the aspartic system.	IBMC,BIOL STRUCT LAB,STRASBOURG,FRANCE				ruff, marc/J-3011-2013; Cavarelli, Jean/P-3566-2016	ruff, marc/0000-0001-5451-6377; Cavarelli, Jean/0000-0001-8620-8723				ANSELME J, 1989, GENE, V84, P481, DOI 10.1016/0378-1119(89)90524-6; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, EUR J BIOCHEM, V200, P337, DOI 10.1111/j.1432-1033.1991.tb16190.x; FRASER TH, 1975, P NATL ACAD SCI USA, V72, P3044, DOI 10.1073/pnas.72.8.3044; GARCIA A, 1992, BIOCHEM BIOPH RES CO, V186, P956, DOI 10.1016/0006-291X(92)90839-D; HECHT SM, 1979, TRANSFER RNA STRUCTU, P345; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; MCCLAIN WH, 1988, SCIENCE, V241, P1804, DOI 10.1126/science.2459773; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; von der Haar F, 1976, Biochemistry, V15, P4131, DOI 10.1021/bi00663a034; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8	29	274	276	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					181	184		10.1038/362181a0	http://dx.doi.org/10.1038/362181a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8450889				2022-12-28	WOS:A1993KR02800067
J	SPECTOR, TD; HALL, GM; MCCLOSKEY, EV; KANIS, JA				SPECTOR, TD; HALL, GM; MCCLOSKEY, EV; KANIS, JA			RISK OF VERTEBRAL FRACTURE IN WOMEN WITH RHEUMATOID-ARTHRITIS	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,DEPT RHEUMATOL,LONDON EC1M 6BQ,ENGLAND; UNIV SHEFFIELD,SCH MED,DEPT HUMAN METAB & CLIN BIOCHEM,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND	University of London; Queen Mary University London; University of Sheffield	SPECTOR, TD (corresponding author), ST THOMAS HOSP,DEPT RHEUMATOL,LONDON SE1 7EH,ENGLAND.		Spector, Tim D/F-6533-2012; McCloskey, Eugene/T-5197-2019; McCloskey, Eugene V/D-1065-2011	McCloskey, Eugene V/0000-0003-0177-8140	Arthritis Research UK [17489] Funding Source: Medline	Arthritis Research UK(Versus Arthritis)		COOPER C, 1990, OSTEOPOROSIS 1990, P1578; HOOYMAN JR, 1984, ARTHRITIS RHEUM-US, V27, P1353, DOI 10.1002/art.1780271205; LAAN FJM, 1992, ANN RHEUM DIS, V51, P826; MCCLOSKEY EV, IN PRESS OSTEROPOROS; RALSTON SH, 1990, BMJ-BRIT MED J, V300, P563, DOI 10.1136/bmj.300.6724.563	5	191	198	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					558	558		10.1136/bmj.306.6877.558	http://dx.doi.org/10.1136/bmj.306.6877.558			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461772	Bronze, Green Published			2022-12-28	WOS:A1993KP88600024
J	CARTER, KC; BOWMAN, D; CARRINGTON, W; FOGARTY, K; MCNEIL, JA; FAY, FS; LAWRENCE, JB				CARTER, KC; BOWMAN, D; CARRINGTON, W; FOGARTY, K; MCNEIL, JA; FAY, FS; LAWRENCE, JB			A 3-DIMENSIONAL VIEW OF PRECURSOR MESSENGER-RNA METABOLISM WITHIN THE MAMMALIAN NUCLEUS	SCIENCE			English	Article							INSITU HYBRIDIZATION; INTERPHASE NUCLEI; LOCALIZATION; RIBONUCLEOPROTEINS; ORGANIZATION; COMPONENTS; TRANSCRIPTION; SEQUENCES; ANTIGENS; REGIONS	A quantitative three-dimensional analysis of nuclear components involved in precursor messenger RNA metabolism was performed with a combination of fluorescence hybridization, immunofluorescence, and digital imaging microscopy. Polyadenylate [poly(A)] RNA-rich transcript domains were discrete, internal nuclear regions that formed a ventrally positioned horizontal array in monolayer cells. A dimmer, sometimes strand-like, poly(A) RNA signal was dispersed throughout the nucleoplasm. Spliceosome assembly factor SC-35 localized within the center of individual domains. These data support a nuclear model in which there is a specific topological arrangement of noncontiguous centers involved in precursor messenger RNA metabolism, from which RNA transport toward the nuclear envelope radiates.	UNIV MASSACHUSETTS, MED CTR, DEPT CELL BIOL, 55 LAKE AVE N, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, MED CTR, DEPT PHYSIOL, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, MED CTR, BIOMED IMAGING GRP, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester				Lawrence, Jeanne/0000-0001-6572-3128	NHGRI NIH HHS [2RO1HG00251, 5K04HG00002, 1F32HG00026] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K04HG000002, F32HG000026, R01HG000251] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BERMAN SA, 1990, SCIENCE, V247, P212, DOI 10.1126/science.1688472; Beyer A L, 1991, Semin Cell Biol, V2, P131; BEYER AL, 1981, CELL, V26, P155, DOI 10.1016/0092-8674(81)90299-3; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BRAKENHOFF GJ, 1989, J MICROSC-OXFORD, V153, P151, DOI 10.1111/j.1365-2818.1989.tb00555.x; CARMOFONSECA M, 1991, EMBO J, V10, P1863, DOI 10.1002/j.1460-2075.1991.tb07712.x; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARRINGTON WA, 1990, P SOC PHOTO-OPT INS, V1205, P72, DOI 10.1117/12.17785; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CARTER KC, UNPUB; COLEMAN J, UNPUB; ELLIOTT DJ, 1992, EMBO J, V11, P3731, DOI 10.1002/j.1460-2075.1992.tb05458.x; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; Fakan S, 1980, Int Rev Cytol, V65, P255; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FAWCETT MD, 1981, CELL; FEY E G, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P127; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GALL JG, 1989, P NATL ACAD SCI USA, V86, P6635, DOI 10.1073/pnas.86.17.6635; GALL JG, 1991, SCIENCE, V252, P1499, DOI 10.1126/science.1828621; HUANG S, 1992, P NATL ACAD SCI USA, V89, P305, DOI 10.1073/pnas.89.1.305; HUTCHISON N, 1985, CELL, V43, P471, DOI 10.1016/0092-8674(85)90177-1; JACKSON DA, 1991, BIOESSAYS, V13, P1, DOI 10.1002/bies.950130102; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; KRYSTOSEK A, 1990, P NATL ACAD SCI USA, V87, P6560, DOI 10.1073/pnas.87.17.6560; LAWRENCE JB, 1988, CELL, V52, P51; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEWIN B, 1975, CELL, V4, P11, DOI 10.1016/0092-8674(75)90128-2; Maquat LE, 1991, CURR OPIN CELL BIOL, V3, P1004, DOI 10.1016/0955-0674(91)90121-E; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; Northway J.D., 1972, CLIN IMMUNOL IMMUNOP, V1, P140, DOI [10.1016/0090-1229(72)90013-X, DOI 10.1016/0090-1229(72)90013-X]; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; PUCKETT L, 1977, J CELL PHYSIOL, V90, P521, DOI 10.1002/jcp.1040900315; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; SCHEER U, 1990, BIOESSAYS, V12, P14, DOI 10.1002/bies.950120104; SINGER RH, 1986, BIOTECHNIQUES, V4, P230; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; SPECTOR DL, 1992, MOL BIOL CELL, V3, P555, DOI 10.1091/mbc.3.5.555; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055; [No title captured]	49	296	301	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1993	259	5099					1330	1335		10.1126/science.8446902	http://dx.doi.org/10.1126/science.8446902			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446902				2022-12-28	WOS:A1993KN88300033
J	TAGLE, DA; SWAROOP, M; LOVETT, M; COLLINS, FS				TAGLE, DA; SWAROOP, M; LOVETT, M; COLLINS, FS			MAGNETIC BEAD CAPTURE OF EXPRESSED SEQUENCES ENCODED WITHIN LARGE GENOMIC SEGMENTS	NATURE			English	Article							TRANSCRIBED SEQUENCES; SELECTION; GENE; DNA		UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Michigan System; University of Michigan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	TAGLE, DA (corresponding author), UNIV MICHIGAN,MED CTR,DEPT HUMAN GENET,ANN ARBOR,MI 48109, USA.			Swaroop, Manju/0000-0002-0576-1664				ADAMS MD, 1992, SCIENCE, V355, P632; BATES GP, 1991, AM J HUM GENET, V49, P7; BATES GP, 1992, NAT GENET, V1, P180, DOI 10.1038/ng0692-180; Britten R., 1985, NUCLEIC ACID HYBRIDI, P3; Britten R J, 1974, Methods Enzymol, V29, P363; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CORBO L, 1990, SCIENCE, V249, P652, DOI 10.1126/science.2382140; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; HAUKANES BI, 1993, BIO-TECHNOL, V11, P60, DOI 10.1038/nbt0193-60; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; LIU P, 1989, SCIENCE, V246, P813, DOI 10.1126/science.2479099; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; SNELL RG, IN PRESS HUM MOL GEN; Tagle D. A., 1992, American Journal of Human Genetics, V51, pA22; TAYLOR SAM, 1992, NAT GENET, V2, P223, DOI 10.1038/ng1192-223; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; YOUNG BD, 1985, NUCLEIC ACID HYBRIDI, P47	21	84	95	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					751	753		10.1038/361751a0	http://dx.doi.org/10.1038/361751a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441473	Green Published			2022-12-28	WOS:A1993KN78900065
J	BEARDSHAW, V; GORDON, P; PLAMPING, D				BEARDSHAW, V; GORDON, P; PLAMPING, D			LONDON AFTER TOMLINSON - PRIMARY CARE DEVELOPMENT ZONES	BRITISH MEDICAL JOURNAL			English	Article								Most commentators on the Tomlinson report have agreed with its emphasis on improving primary and community care. The three elements of such a strategy are a remedial programme to bring primary care up to national standards, a programme to provide such services to people with non-standard needs such as mobile Londoners, ethnic minorities, and homeless people, and the development of an expanded model of primary care. No one model will be appropriate across all of London. The process should start with an audit of existing resources and services within each community, together with an analysis of needs. From this would develop a local programme with specific plans for investment in premises, staffing, training, and management. New contractual mechanisms may be needed to attract practitioners, improve their premises, secure out of hours services, and provide medical cover for community beds. There should also be incentives for closer working between primary and secondary services. No developments on the scale needed for London have been carried out in primary care within the lifetime of the NHS-but their success will be critical to the calibre of health services for Londoners into the next century.	KINGS FUND CTR,LONDON NW1,ENGLAND; KINGS FUND COLL,LONDON W2,ENGLAND		BEARDSHAW, V (corresponding author), KINGS FUND LONDON,ACUTE SERV INITIAT,LONDON W2 4HS,ENGLAND.							BOYLE S, IN PRESS PRIMARY HLT; HUGHES J, 1992, OPTIMAL BALANCE PRIM; JARMAN B, 1992, BRIT MED J, V305, P1130, DOI 10.1136/bmj.305.6862.1130; METCALFE D, 1992, BMJ-BRIT MED J, V305, P1141, DOI 10.1136/bmj.305.6862.1141; MOSS F, 1992, BMJ-BRIT MED J, V305, P1211, DOI 10.1136/bmj.305.6863.1211; 1992, INQUIRY LONDONS HLTH	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					323	325		10.1136/bmj.306.6873.323	http://dx.doi.org/10.1136/bmj.306.6873.323			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461654	Bronze, Green Published			2022-12-28	WOS:A1993KK71800028
J	BELLIN, EY; FLETCHER, DD; SAFYER, SM				BELLIN, EY; FLETCHER, DD; SAFYER, SM			ASSOCIATION OF TUBERCULOSIS INFECTION WITH INCREASED TIME IN OR ADMISSION TO THE NEW-YORK-CITY JAIL SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK; PRISON	Objective.-To establish the association between time spent in jail or number of jail admissions and development of tuberculosis in a cohort of inmates incarcerated without evidence of tuberculosis infection on entry. Design.-Nested case-control design within a prospective cohort. A cohort of 2636 tuberculin skin test-negative inmates incarcerated in 1985 was matched against the Tuberculosis Registry of New York City. Each case of tuberculosis reported prior to May 15,1992, was assigned to three randomly selected controls from the cohort. We determined time spent in jail by reviewing the computer records of the New York City Inmate Information System. Conditional logistic regression modeling was performed to establish the association of jail time with the development of tuberculosis. Setting.-New York City Jail. Results.-Sixty inmates developed tuberculosis by May 15, 1992. Eighty-five percent of these had pulmonary tuberculosis. Univariate analysis identified the number of jail admissions (P=.02), age greater than or equal to 30 years (P=.001), and assignment to a methadone detoxification unit (P=.001) as significant in predicting tuberculosis. Multivariate modeling identified these same variables and jail time as significant. One year of jail time increased the odds of tuberculosis to 2.2 (95% confidence interval, 1.1 to 4.4). Conclusion.-The demonstrated association between jail time or jail admissions and development of tuberculosis suggests that the New York City jail system may be an important amplification point in the ongoing tuberculosis epidemic, deserving significant public health attention.	MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,UNIV HOSP,BRONX,NY	Montefiore Medical Center; State University of New York (SUNY) System; Yeshiva University; Albert Einstein College of Medicine	BELLIN, EY (corresponding author), MONTEFIORE MED CTR,RIKERS ISL HLTH SERV,15-15 HAZEN ST,ELMHURST,NY 11370, USA.							BELLIN E, 1993, AM J PUBLIC HEALTH, V83, P698, DOI 10.2105/AJPH.83.5.698; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; GATNER EMS, 1977, S AFR MED J, V51, P279; GAUNEY W, 1992, OUTBREAK MULTIPLE DR, P1; GUESS HA, 1987, AM J EPIDEMIOL, V125, P340, DOI 10.1093/oxfordjournals.aje.a114535; HAMBURG M, 1992, 1992 NEW YORK CIT TA, P1; KELLER AS, 1993, JAMA-J AM MED ASSOC, V269, P619, DOI 10.1001/jama.269.5.619; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; MEHTA C, 1991, STATXACT STATISTICAL; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; Rothman K, 1986, MODERN EPIDEMIOLOGY; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; WEISFUSE IB, 1991, AIDS, V5, P1133, DOI 10.1097/00002030-199109000-00013; YUE WY, 1967, DIS CHEST, V51, P614; ZOLOTH S, IN PRESS AM J PUBLIC; 1990, EGRET STATISTICAL SO; 1992, INFORMATION SUMMARY, P1; 1992, POPULATIONS RES UNIT	21	89	96	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1993	269	17					2228	2231		10.1001/jama.269.17.2228	http://dx.doi.org/10.1001/jama.269.17.2228			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ406	8474202				2022-12-28	WOS:A1993KZ40600030
J	BENSHOOF, J				BENSHOOF, J			PLANNED-PARENTHOOD V CASEY - THE IMPACT OF THE NEW UNDUE BURDEN STANDARD ON REPRODUCTIVE HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; ABORTION	The recent US Supreme Court decision in Planned Parenthood v Casey, by changing the legal standard by which restrictions on abortion are evaluated, will have a profound effect on access to reproductive health care in the United States. This article reviews the Pennsylvania antiabortion restrictions at issue in Casey and discusses the ways in which the new constitutional standard fundamentally weakens the legal protections previously afforded women and physicians in the 1973 case, Roe v Wade. While the majority opinion reaffirmed a woman's right to choose an abortion, the opinion opens the door to a multitude of new restrictive abortion laws, which diminish, and in some cases completely block, a woman's ability to exercise that right. The effect of weakened legal protection will fall most heavily on young, poor, minority, and rural women, who will be unable to overcome obstacles imposed by mandatory waiting periods, biased counseling, and parental notification requirements. The restrictions are also likely to exacerbate the shortage of physicians providing abortion services by making the procedure more costly and the providers' jobs more dangerous. Finally, the medical community can help to ensure women access to comprehensive and competent reproductive health care.			BENSHOOF, J (corresponding author), CTR REPROD LAW & POLICY,120 WALL ST,NEW YORK,NY 10005, USA.							BURKMAN RT, 1974, AM J OBSTET GYNECOL, V119, P131, DOI 10.1016/0002-9378(74)90327-5; DARNEY PD, 1987, FAM PLANN PERSPECT, V19, P158, DOI 10.2307/2135161; FREEDMAN MA, 1986, AM J PUBLIC HEALTH, V76, P550, DOI 10.2105/AJPH.76.5.550; GRIMES D, 1990, WHO WILL PROVIDE ABO; HALL M, 1991, US TODAY        0701, pA2; HENSHAW SK, 1991, FAM PLANN PERSPECT, V23, P246, DOI 10.2307/2135775; 1992, FACTS BRIEF; 1992, JAMA-J AM MED ASSOC, V268, P3231	8	12	12	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1993	269	17					2249	2257		10.1001/jama.269.17.2249	http://dx.doi.org/10.1001/jama.269.17.2249			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KZ406	8474205				2022-12-28	WOS:A1993KZ40600034
J	BAUER, DC; BROWNER, WS; CAULEY, JA; ORWOLL, ES; SCOTT, JC; BLACK, DM; TAO, JL; CUMMINGS, SR				BAUER, DC; BROWNER, WS; CAULEY, JA; ORWOLL, ES; SCOTT, JC; BLACK, DM; TAO, JL; CUMMINGS, SR			FACTORS ASSOCIATED WITH APPENDICULAR BONE MASS IN OLDER WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						BONE DENSITY; AGE FACTORS; BODY WEIGHT; ESTROGEN REPLACEMENT THERAPY; ASTERISK MUSCLE STRENGTH	QUANTITATIVE COMPUTED-TOMOGRAPHY; HEALTHY POSTMENOPAUSAL WOMEN; PHYSICAL-ACTIVITY; MINERAL DENSITY; RISK-FACTORS; PERIMENOPAUSAL WOMEN; RHEUMATOID-ARTHRITIS; CIGARETTE-SMOKING; MUSCLE STRENGTH; CALCIUM BALANCE	Objective: To determine the factors associated with appendicular bone mass in older women. Design: Cross-sectional analysis of baseline data collected for a multicenter, prospective study of osteoporotic fractures. Setting: Four clinical centers in Baltimore, Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela valley, Pennsylvania. Patients: A total of 9704 ambulatory, nonblack women, ages 65 years or older, recruited from population-based listings. Measurements: Demographic and historical information and anthropometric measurements were obtained from a baseline questionnaire, interview, and examination. Single-photon absorptiometry scans were obtained at three sites: the distal radius, midradius, and calcaneus. Multivariate associations with bone mass were first examined in a randomly selected half of the cohort (training group) and were then tested on the other half of the cohort (validation group). Results: In order of decreasing strength of association, estrogen use, non-insulin-dependent diabetes, thiazide use, increased weight, greater muscle strength, later age at menopause, and greater height were independently associated with higher bone mass. Gastric surgery, age, history of maternal fracture, smoking, and caffeine intake were associated with lower bone mass (all P < 0.05). For example, we found that 2 or more years of estrogen use was associated with a 7.2% increase in distal radius bone mass, whereas gastrectomy was associated with an 8.2% decrease in bone mass. The associations between bone mass and dietary calcium intake and rheumatoid arthritis were inconsistent. Alcohol use, physical activity, use of calcium supplements, pregnancy, breast-feeding, parental nationality, and hair color were among the many variables not associated with bone mass. Multivariate models accounted for 20% to 35% of the total variance of bone mass. Conclusions: A large number of factors influence the bone mass of elderly women; however, age, weight, muscle strength, and estrogen use are the most important factors.			BAUER, DC (corresponding author), UNIV CALIF SAN FRANCISCO, PREVENT SCI GRP, 74 NEW MONTGOMERY, SUITE 600, SAN FRANCISCO, CA 94143 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Orwoll, Eric/0000-0002-8520-7355	NIAMS NIH HHS [AR35582, AR35583] Funding Source: Medline; NIA NIH HHS [AG05394] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035583, R01AR035582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABDALLA HI, 1985, OBSTET GYNECOL, V66, P789; ALOIA JF, 1991, AM J CLIN NUTR, V53, P1378, DOI 10.1093/ajcn/53.6.1378; ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; BARGERLUX MJ, 1990, AM J CLIN NUTR, V52, P722, DOI 10.1093/ajcn/52.4.722; BEARD CM, 1990, J BONE MINER RES, V5, P691, DOI 10.1002/jbmr.5650050705; BEVIER WC, 1989, J BONE MINER RES, V4, P421; BIKLE DD, 1985, ANN INTERN MED, V103, P42, DOI 10.7326/0003-4819-103-1-42; BLACK DM, 1992, J BONE MINER RES, V7, P633; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BLOCK JE, 1987, JAMA-J AM MED ASSOC, V257, P3115, DOI 10.1001/jama.1987.03390220113033; Callaway CW., 1988, ANTHROPOMETRIC STAND, P39; CANN CE, 1980, JAMA-J AM MED ASSOC, V244, P2056; CARTER DR, 1992, J BONE MINER RES, V7, P137; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; CAVANAUGH DJ, 1988, BONE, V9, P201, DOI 10.1016/8756-3282(88)90031-2; CHOW R, 1987, BMJ-BRIT MED J, V295, P1441, DOI 10.1136/bmj.295.6611.1441; CUMMING RG, 1990, CALCIFIED TISSUE INT, V47, P194; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; GALLAGHER JC, 1991, AM J MED, V90, P171; GIACCA A, 1988, BONE, V9, P29, DOI 10.1016/8756-3282(88)90024-5; GOLDSMITH NF, 1975, J BONE JOINT SURG AM, V57, P657, DOI 10.2106/00004623-197557050-00014; Hansen M A, 1991, Osteoporos Int, V1, P95; HEANEY RP, 1982, J LAB CLIN MED, V99, P46; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; JOFFE I, 1991, SEMIN ARTHRITIS RHEU, V20, P256, DOI 10.1016/0049-0172(91)90021-Q; JOHNELL O, 1984, CALCIFIED TISSUE INT, V36, P354, DOI 10.1007/BF02405345; JOHNSTON CC, 1985, METABOLISM, V34, P544, DOI 10.1016/0026-0495(85)90192-1; KARANTANAS AH, 1991, BRIT J RADIOL, V64, P298, DOI 10.1259/0007-1285-64-760-298; KRALL EA, 1991, J BONE MINER RES, V6, P331; KRISKA AM, 1988, AM J EPIDEMIOL, V127, P1053, DOI 10.1093/oxfordjournals.aje.a114881; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; LAPORTE RE, 1985, PUBLIC HEALTH REP, V100, P131; LINDSAY R, 1978, CLIN SCI MOL MED, V54, P193, DOI 10.1042/cs0540193; LINDSAY R, 1986, J BONE MINER RES  S1, V1, P248; Lohman TG, 1988, ANTHROPOMETRIC STAND, P177, DOI DOI 10.1002/AJHB.1310040323; MARCUS R, 1989, ARCH INTERN MED, V149, P2170, DOI 10.1001/archinte.149.10.2170; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; NILSSON BE, 1969, SURG GYNECOL OBSTETR, V129, P27; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; POCOCK N, 1989, J BONE MINER RES, V4, P441; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002-9378(87)90203-1; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; SAMBROOK PN, 1989, ANN RHEUM DIS, V48, P535, DOI 10.1136/ard.48.7.535; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; Shaker J L, 1991, Osteoporos Int, V1, P177, DOI 10.1007/BF01625450; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SLEMENDA CW, 1990, BONE MINER, V11, P101, DOI 10.1016/0169-6009(90)90019-C; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SMITH EL, 1989, CALCIFIED TISSUE INT, V44, P312, DOI 10.1007/BF02556310; SOWERS M, 1985, PREV MED, P14; Sowers Maryfran, 1991, Annals of Epidemiology, V1, P245; SOWERS MR, 1985, AM J CLIN NUTR, V41, P1045, DOI 10.1093/ajcn/41.5.1045; STEIGER P, 1992, J BONE MINER RES, V7, P625; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; VARGAS S, 1990, CALCIFIED TISSUE INT, V47, P164, DOI 10.1007/BF02555982; Verstraeten A, 1991, CLIN ORTHOP RELAT R, V264, P169; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1986, OBSTET GYNECOL, V67, P457; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; YANO K, 1984, AM J EPIDEMIOL, V119, P751, DOI 10.1093/oxfordjournals.aje.a113796; ZIMMERMANN CL, 1990, PHYS THER, V70, P302, DOI 10.1093/ptj/70.5.302	71	445	453	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					657	665		10.7326/0003-4819-118-9-199305010-00001	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460853				2022-12-28	WOS:A1993KY50200001
J	GIRMENIA, C; DONATO, V; IORI, AP; MARTINO, P				GIRMENIA, C; DONATO, V; IORI, AP; MARTINO, P			SPONTANEOUS PNEUMOTHORAX IN PATIENTS WITH LEUKEMIA - 1ST SIGN OF INVASIVE MYCOSIS	ANNALS OF INTERNAL MEDICINE			English	Note						PNEUMOTHORAX; LEUKEMIA; NEUTROPENIA; MYCOSES; TOMOGRAPHY, X-RAY COMPUTED	PULMONARY ASPERGILLOSIS; EARLY DIAGNOSIS; CT	Two patients with leukemia, who underwent remission induction chemotherapy and allogeneic bone marrow transplantation, respectively, reported chest pain and dyspnea after recovery from neutropenia. In both patients, chest radiographs showed only a pneumothorax, whereas computed tomographic scanning also showed a peripheral pseudomycetoma. Antifungal treatment was instituted. The occurrence of spontaneous pneumothorax in patients with hematologic malignancies, particularly after recovery from neutropenia, may indicate the presence of a subpleural infection. Computed tomographic scanning can reveal peripheral pulmonary lesions that are not detected by chest roentgenography.	UNIV ROMA LA SAPIENZA, I-00185 ROME, ITALY	Sapienza University Rome			Girmenia, Corrado/AFP-5725-2022; GIRMENIA, Corrado/AAC-6492-2019	GIRMENIA, Corrado/0000-0002-3245-2357				ANAISSIE E, 1992, CLIN INFECT DIS, V14, pS43, DOI 10.1093/clinids/14.Supplement_1.S43; GERSON SL, 1985, J CLIN ONCOL, V3, P1109, DOI 10.1200/JCO.1985.3.8.1109; KUHLMAN JE, 1987, CHEST, V92, P95, DOI 10.1378/chest.92.1.95; KUHLMAN JE, 1985, RADIOLOGY, V157, P611, DOI 10.1148/radiology.157.3.3864189; KUHLMAN JE, 1988, AM J ROENTGENOL, V150, P1015, DOI 10.2214/ajr.150.5.1015; MARTINO P, 1990, REV INFECT DIS, V12, P611	6	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					707	708		10.7326/0003-4819-118-9-199305010-00008	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460857				2022-12-28	WOS:A1993KY50200008
J	BREO, DL				BREO, DL			ALTERED FATES - COUNSELING FAMILIES WITH INHERITED BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	15	15	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					2017	2022		10.1001/jama.269.15.2017	http://dx.doi.org/10.1001/jama.269.15.2017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464136				2022-12-28	WOS:A1993KX21500036
J	LEVITT, M; WARR, D; YELLE, L; RAYNER, HL; LOFTERS, WS; PERRAULT, DJ; WILSON, KS; LATREILLE, J; POTVIN, M; WARNER, E; PRITCHARD, KI; PALMER, M; ZEE, B; PATER, JL				LEVITT, M; WARR, D; YELLE, L; RAYNER, HL; LOFTERS, WS; PERRAULT, DJ; WILSON, KS; LATREILLE, J; POTVIN, M; WARNER, E; PRITCHARD, KI; PALMER, M; ZEE, B; PATER, JL			ONDANSETRON COMPARED WITH DEXAMETHASONE AND METOCLOPRAMIDE AS ANTIEMETICS IN THE CHEMOTHERAPY OF BREAST-CANCER WITH CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-DOSE METOCLOPRAMIDE; CISPLATIN-INDUCED EMESIS; DOUBLE-BLIND; SEROTONIN ANTAGONIST; NAUSEA; PROPHYLAXIS; MULTICENTER; PREVENTION; CROSSOVER	Background. Although ondansetron was found to be effective as an antiemetic in numerous clinical trials of highly emetogenic combination-chemotherapy regimens that included cisplatin, its role in milder emetogenic regimens has not been fully defined. To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil. Methods. A total of 165 women with breast cancer from 14 Canadian centers who were about to receive this chemotherapy for the first time were randomly assigned to receive either ondansetron (n = 85) or dexamethasone plus metoclopramide (n = 80), a widely used, standard antiemetic regimen. The patients recorded the incidence of nausea, emesis, and other side effects in diaries, and these data were compared in the two groups. Results. The patients who received dexamethasone and metoclopramide had significantly less less nausea during the first 24 hours after chemotherapy was wise, there were no statistically significant differences in efficacy between the regimens. The incidence of drowsiness and increased appetite was higher in the group given dexamethasone and metoclopramide. Conclusions. For women with breast cancer who are being treated with cyclophosphamide, methotrexate, and fluorouracil, the efficacy of dexamethasone and metoclopramide in controlling nausea and vomiting equaled or exceeded that of ondansetron.	PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA; ST MICHAELS HOSP, TORONTO M5B 1W8, ONTARIO, CANADA; TORONTO BAYVIEW REG CANC CTR, TORONTO, ON, CANADA; NOTRE DAME HOSP, MONTREAL, PQ, CANADA; HOP HOTEL DIEU, MONTREAL H2W 1T8, QUEBEC, CANADA; VICTORIA CLIN, BRITISH COLUMBIA CANC AGCY, VICTORIA, BC, CANADA; KINGSTON REG CANC CTR, KINGSTON, ON, CANADA; NATL CANC INST CANADA, CLIN TRIALS GRP, KINGSTON, ON, CANADA; OTTAWA REG CANC CTR, OTTAWA, ON, CANADA; LAVAL HOSP, ST FOY, PQ, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Universite de Montreal; Universite de Montreal; British Columbia Cancer Agency; Queens University - Canada; Canadian Cancer Trials Group; University of Ottawa; Ottawa Hospital Research Institute	LEVITT, M (corresponding author), UNIV MANITOBA, MANITOBA CANC TREATMENT & RES FDN, DEPT INTERNAL MED, 100 OLIVIA ST, WINNIPEG R3E 0V9, MANITOBA, CANADA.		Zee, Benny Chung Ying/G-5606-2017; Pritchard, Kathleen I/I-2184-2014	Zee, Benny Chung Ying/0000-0002-7238-845X; Pritchard, Kathleen I/0000-0003-0758-9666				ANDREWS DF, 1971, BIOMETRICS, V27, P825, DOI 10.2307/2528821; BONNETERRE J, 1990, J CLIN ONCOL, V8, P1063, DOI 10.1200/JCO.1990.8.6.1063; BUSER K, 1990, P AN M AM SOC CLIN, V9, P331; CANELLOS GP, 1976, CANCER, V38, P1882, DOI 10.1002/1097-0142(197611)38:5<1882::AID-CNCR2820380503>3.0.CO;2-H; CUBEDDU LX, 1990, J CLIN ONCOL, V8, P1721, DOI 10.1200/JCO.1990.8.10.1721; Demulder PHM, 1990, ANN INTERN MED, V113, P834, DOI 10.7326/0003-4819-113-11-834; FETTING JH, 1982, CANCER TREAT REP, V66, P1487; GRUNBERG SM, 1990, NEW ENGL J MED, V322, P846, DOI 10.1056/NEJM199003223221211; HAINSWORTH J, 1991, J CLIN ONCOL, V9, P721, DOI 10.1200/JCO.1991.9.5.721; HESKETH PJ, 1991, J NATL CANCER I, V83, P613, DOI 10.1093/jnci/83.9.613; JONES AL, 1991, LANCET, V338, P483, DOI 10.1016/0140-6736(91)90554-3; LANDIS JR, 1988, STAT MED, V7, P109, DOI 10.1002/sim.4780070114; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; PATER JL, 1991, EJC SUPPL, V27, pS298; ROILA F, 1991, J CLIN ONCOL, V9, P675, DOI 10.1200/JCO.1991.9.4.675; TANNOCK IF, 1988, J CLIN ONCOL, V6, P1377, DOI 10.1200/JCO.1988.6.9.1377; WILLAN AR, 1991, EFFECT CANCER QUALIT, P229	17	69	71	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1081	1084		10.1056/NEJM199304153281503	http://dx.doi.org/10.1056/NEJM199304153281503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8455665				2022-12-28	WOS:A1993KX17800003
J	DICKINSON, GM; MORHART, RE; KLIMAS, NG; BANDEA, CI; LARACUENTE, JM; BISNO, AL				DICKINSON, GM; MORHART, RE; KLIMAS, NG; BANDEA, CI; LARACUENTE, JM; BISNO, AL			ABSENCE OF HIV TRANSMISSION FROM AN INFECTED DENTIST TO HIS PATIENTS - AN EPIDEMIOLOGIC AND DNA-SEQUENCE ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BISEXUAL MEN; SURGEON; AIDS; COHORT	Objective.-To determine if a general dentist with human immunodeficiency virus (HIV) infection transmitted HIV to any of his patients. Design.-A cohort study in which all patients treated by a dentist who developed the acquired immunodeficiency syndrome (AIDS) were identified and attempts were made to contact all patients for HIV antibody testing. Setting.-A general dentistry clinic operated by the Department of Veterans Affairs in southeastern Florida. Participants.-All patients treated by a dentist during the 5 3/4 years before he developed AIDS were identified in a computerized registry of dental care. Main Outcome Measures.-Attempts were made to contact all living patients for counseling and HIV antibody testing. Living patients with newly identified HIV infection were interviewed, and DNA sequence analysis was performed to compare genetic relatedness of their HIV to that of the dentist. Death certificates were obtained for deceased patients, and the medical records of those with diagnoses suggestive of HIV disease or drug abuse and those dying under the age of 50 years were reviewed in detail. Results.-There were 1192 patients who had undergone 9267 procedures, of whom 124 were deceased. A review of the death certificates of the deceased patients identified five who had died with HIV infection, all of whom were either homosexuals or users of illicit intravenous drugs. We were able to locate 962 (92%) of the remaining 1048 patients, and 900 agreed to be tested. Infection with HIV was documented in five of the 900 patients, including four who had clear evidence of risk factors for acquiring HIV infection. One patient who had only a single evaluation by the dentist denied high-risk behavior. Comparative DNA sequence analysis demonstrated that the viruses from the dentist and these five patients were not closely related. Conclusion.-This study indicates that the risk for transmission of HIV from a general dentist to his patients is minimal in a setting in which universal precautions are strictly observed. Programs to ensure compliance with universal precautions would appear preferable to programs for widespread testing of dentists.	VET AFFAIRS MED CTR,DENT SERV,MIAMI,FL 33125; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33152; CTR DIS CONTR & PREVENT,DIV HIV AIDS,ATLANTA,GA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; Centers for Disease Control & Prevention - USA	DICKINSON, GM (corresponding author), VET AFFAIRS MED CTR,MED SERV 111-I,1201 NW 16TH ST,MIAMI,FL 33125, USA.							ARMSTRONG FP, 1987, MIL MED, V152, P414; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BURGER H, 1991, P NATL ACAD SCI USA, V88, P11236, DOI 10.1073/pnas.88.24.11236; CASTRO KG, 1988, JAMA-J AM MED ASSOC, V259, P1338, DOI 10.1001/jama.259.9.1338; CHAMBERLAND ME, 1992, ANN INTERN MED, V116, P871, DOI 10.7326/0003-4819-116-10-871; CICHUTEK K, 1991, AIDS, V5, P1185, DOI 10.1097/00002030-199110000-00005; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Comer R W, 1991, J Dent Educ, V55, P187; COMER RW, 1992, J AM DENT ASSOC, V123, P51, DOI 10.14219/jada.archive.1992.0219; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; MYERS G, 1991, HUMAN RETROVIRUSES A; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SACKS JJ, 1986, NEW ENGL J MED, V314, P1190; 1991, MMWR, V40, P377	19	46	46	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1802	1806		10.1001/jama.269.14.1802	http://dx.doi.org/10.1001/jama.269.14.1802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459511				2022-12-28	WOS:A1993KW25000034
J	VONREYN, CF; GILBERT, TT; SHAW, FE; PARSONNET, KC; ABRAMSON, JE; SMITH, MG				VONREYN, CF; GILBERT, TT; SHAW, FE; PARSONNET, KC; ABRAMSON, JE; SMITH, MG			ABSENCE OF HIV TRANSMISSION FROM AN INFECTED ORTHOPEDIC SURGEON - A 13-YEAR LOOK-BACK STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH; AIDS	Objective.-To determine the risk of human immunodeficiency virus (HIV) transmission from an HIV-infected orthopedic surgeon to patients undergoing invasive procedures. Design.-Retrospective epidemiologic follow-up study. Participants.-A total of 2317 former patients on whom the orthopedic surgeon performed invasive procedures between January 1, 1978, and June 30, 1992. Main Outcome Measures.-HIV infection or death from an acquired immunodeficiency syndrome (AIDS)-defining tumor or opportunistic infection. Results.-An orthopedic surgeon voluntarily withdrew from practice after testing positive for HIV. Testing for HIV was performed on 1174 former patients, representing 50.7% of patients on whom the orthopedic surgeon performed invasive procedures during the 13.5-year period. Patients were tested from each year and from each category of invasive procedure. All patients were HIV-negative by enzyme-linked immunosorbent assay. Two former patients reported known HIV infection prior to surgery. Review of AIDS case registries and vital records failed to detect cases of HIV infection among former surgical patients. The estimated cost of the initial patient notification and testing was $158 500. The patient notification and testing were conducted while maintaining the confidentiality of the orthopedic surgeon who was an active participant in the planning and execution of the study. Conclusions.-The risk of HIV transmission from an HIV-infected surgeon who adheres to recommended infection control practices is extremely low. Notification and HIV testing of former patients in this setting is both disruptive and expensive and is not routinely recommended.	BROWN UNIV,SCH MED,DEPT FAMILY MED,PROVIDENCE,RI 02912; NEW HAMPSHIRE DEPT HLTH & HUMAN SERV,DIV PUBL HLTH SERV,CONCORD,NH	Brown University	VONREYN, CF (corresponding author), DARTMOUTH COLL,MED CTR,INFECT DIS SECT,1 MED CTR DR,LEBANON,NH 03756, USA.				PHS HHS [U62/CCU107221-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMSTRONG FP, 1987, MIL MED, V152, P414; BELL DM, 1991, AM J MED, V91, pS294, DOI 10.1016/0002-9343(91)90385-B; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; HAMORY BH, 1992, 2ND ANN M SOC HOP EP, P34; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; POKROVSKY VV, 1992, 8TH INT C AIDS AMST; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; 1992, MMWR, V41, P575; 1987, MMWR, V36, pS3; 1992, MMWR, V41, P344; 1992, INFECT CONT HOSP EP, V13, P482	17	44	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1807	1811		10.1001/jama.269.14.1807	http://dx.doi.org/10.1001/jama.269.14.1807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459512				2022-12-28	WOS:A1993KW25000035
J	TYRER, P				TYRER, P			ABC OF SLEEP DISORDERS - WITHDRAWAL FROM HYPNOTIC DRUGS	BRITISH MEDICAL JOURNAL			English	Article											TYRER, P (corresponding author), ST MARYS HOSP,SCH MED,LONDON,ENGLAND.								0	17	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					706	708		10.1136/bmj.306.6879.706	http://dx.doi.org/10.1136/bmj.306.6879.706			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT216	8471930	Green Published, Bronze			2022-12-28	WOS:A1993KT21600031
J	MORIMOTO, RI				MORIMOTO, RI			CELLS IN STRESS - TRANSCRIPTIONAL ACTIVATION OF HEAT-SHOCK GENES	SCIENCE			English	Editorial Material							DNA-BINDING; MOLECULAR-CLONING; EXPRESSION; INVITRO				MORIMOTO, RI (corresponding author), NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,2153 SHERIDAN RD,EVANSTON,IL 60201, USA.							ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MORIMOTO R I, 1990, P1; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NAKAI A, IN PRESS MOL CELL BI, V13; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6910; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0	20	1168	1248	1	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1409	1410		10.1126/science.8451637	http://dx.doi.org/10.1126/science.8451637			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451637				2022-12-28	WOS:A1993KP97800023
J	WALTERS, S; BRITTON, J; HODSON, ME				WALTERS, S; BRITTON, J; HODSON, ME			DEMOGRAPHIC AND SOCIAL CHARACTERISTICS OF ADULTS WITH CYSTIC-FIBROSIS IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article								Objective-To obtain information about social and demographic characteristics and lifestyle of adult patients with cystic fibrosis, including those who do not attend major specialist clinics. Design-Confidential self completion postal questionnaire to adult patients with cystic fibrosis, asking about social and demographic characteristics, social class and occupation, employment, education, insurance and social security benefits, symptom severity, and medical care. Setting-National association for adults with cystic fibrosis. Subjects - 1052 adult members of the Association of Cystic Fibrosis Adults UK, accounting for 68% of those with cystic fibrosis in the United Kingdom population over 16 years of age and over 80% of those over 25 in June 1990. Results-The response rate was 82% (397 women, 423 men). Most adults with cystic fibrosis were found to be living fulfilling lives into adulthood. Significantly fewer men were married or cohabiting than women (110 (26%) men, 175 (44%) women). 420 (55%) responders were working, and of these 235 (56%) had less than two weeks' sick leave a year. Half of those not employed gave ill health as the reason. Revealing that they had cystic fibrosis at job interviews reduced likelihood of being employed for those with mild to moderate disease. People with cystic fibrosis had been less successful than the general population in achieving O level or equivalent qualifications, but more successful in achieving A level or higher qualifications. Achievement of any qualifications enhanced employment prospects irrespective of disease severity. Conclusion-Contrary to an image of chronic ill health and disability, a high proportion of adults with cystic fibrosis are living full and productive lives.	CITY HOSP NOTTINGHAM,NOTTINGHAM NG5 1PD,ENGLAND; NATL HEART & LUNG INST,LONDON SW3,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; Imperial College London	WALTERS, S (corresponding author), UNIV BIRMINGHAM,INST PUBL & ENVIRONM HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Britton, John R/G-9705-2011					ALLAN JL, MED J AUSTRALIA, V1, P600; Andersen DH, 1938, AM J DIS CHILD, V56, P344, DOI 10.1001/archpedi.1938.01980140114013; BRITTON JR, 1989, BRIT MED J, V298, P483, DOI 10.1136/bmj.298.6672.483; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; Fanconi G UE, 1936, WIEN MED WOCHENSCHR, V86, P753; Hodson ME, 1983, CYSTIC FIBROSIS; ROBSON M, 1991, WORKING HEALTHIER LU, P65; 1989, SOCIAL TRENDS; 1989, WORKING PATIENTS; 1991, GENERAL HOUSEHOLD SU; 1988, BMJ, V297, P1599; 1991, CYSTIC FIBROSIS ADUL	12	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					549	552		10.1136/bmj.306.6877.549	http://dx.doi.org/10.1136/bmj.306.6877.549			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KP886	8461767	Green Published, Bronze			2022-12-28	WOS:A1993KP88600019
J	BRADLEY, DM; PARSONS, EP; CLARKE, AJ				BRADLEY, DM; PARSONS, EP; CLARKE, AJ			EXPERIENCE WITH SCREENING NEWBORNS FOR DUCHENNE MUSCULAR-DYSTROPHY IN WALES	BRITISH MEDICAL JOURNAL			English	Article							CREATINE-KINASE; DIAGNOSIS; CDNA	Objectives-To assess the acceptability of screening newborn boys for Duchenne muscular dystrophy. Design-Screening is offered on the basis of informed consent in response to an information sheet entitled ''A new test for baby boys-Do you want it?'' The programme includes a prospective long term evaluation of family responses to early diagnosis and a comparison of their experiences and perceptions with those families who have undergone the later traditional clinical diagnosis. Setting-All maternity units throughout Wales. Samples obtained through screening programme for phenylketonuria and congenital hypothyroidism. Subjects-Those families whose son had a positive screening test. Main outcome measures-Creatine kinase activity. Venous blood test to confirm positive result. Molecular genetic mutation analysis. Muscle biopsy and dystrophin analysis. Qualitative measure of satisfaction among affected families. Results-34219 Boys have been screened and nine affected families have been identified. Eight families were very positive about the programme. Three chose not to complete the diagnostic process. Conclusion-The programme should continue to permit a full evaluation of the issues involved and should serve as a model for other initiatives within the community for genetic disease.			BRADLEY, DM (corresponding author), UNIV WALES COLL MED, INST MED GENET, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES.							DRUMMOND LM, 1978, LANCET, V1, P1258; GARDNERMEDWIN D, 1978, LANCET, V1, P1102; GREENBERG CR, 1992, J MED GENET, V29, P583, DOI 10.1136/jmg.29.8.583; JACOBS HK, 1989, INT CONGR SER, V848, P361; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; PLANCHU H, 1987, ADV NEONATAL SCREENI, P371; PLAUCHU H, 1989, LANCET, V1, P669; SCHEUERBRANDT G, 1986, MUSCLE NERVE, V9, P11, DOI 10.1002/mus.880090103; SCHEUERBRANDT G, 1983, NEONATAL SCREENING, P352; SCHEUERBRANDT G, 1987, ADV NEONATAL SCREENI, P361; SKINNER R, 1982, J MED GENET, V19, P1, DOI 10.1136/jmg.19.1.1; SMITH RA, 1990, BRIT MED J, V300, P1112, DOI 10.1136/bmj.300.6732.1112; SMITH RA, 1989, ARCH DIS CHILD, V64, P1017, DOI 10.1136/adc.64.7.1017; UPADHYAYA M, 1990, CLIN GENET, V37, P456; WILLIAMS H, 1984, LANCET, V2, P645; ZELLWEGER H, 1975, PEDIATRICS, V55, P30	16	71	72	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					357	360		10.1136/bmj.306.6874.357	http://dx.doi.org/10.1136/bmj.306.6874.357			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461680	Bronze, Green Published			2022-12-28	WOS:A1993KL71500017
J	ALTER, M				ALTER, M			GANGLIOSIDES AND NEUROLOGICAL DISEASES	BRITISH MEDICAL JOURNAL			English	Letter							THERAPY				ALTER, M (corresponding author), MED COLL PENN,DIV NEUROEPIDEMIOL,PHILADELPHIA,PA 19129, USA.							ALTER M, 1992, J STROKE CERREBROVAS, V2, pS12; ANGELERI F, 1992, J CEREBROVASC DIS, V2, P163; ARGENTINO C, 1989, STROKE, V20, P1143, DOI 10.1161/01.STR.20.9.1143; FIGUERAS A, 1992, BRIT MED J, V305, P1330, DOI 10.1136/bmj.305.6865.1330; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GRANIERI E, 1991, NEUROEPIDEMIOLOGY, V10, P161, DOI 10.1159/000110265; MATIASGUIU J, IN PRESS NEUROEPIDEM; PAPO I, 1991, STROKE, V22, P22, DOI 10.1161/01.STR.22.1.22; 1978, ANN NEUROL, V3, P565	9	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					204	204		10.1136/bmj.306.6871.204	http://dx.doi.org/10.1136/bmj.306.6871.204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443491	Green Published			2022-12-28	WOS:A1993KH51300047
J	HARRIS, A				HARRIS, A			THE FUTURE OF FHSAS .3. DEVELOPING A RESEARCH-AND-DEVELOPMENT STRATEGY FOR PRIMARY CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE				HARRIS, A (corresponding author), SOUTHWARK & LEWISHAM FAMILY HLTH SERV AUTHOR,LAMBETH,ENGLAND.							[Anonymous], 1979, CMND7615; ASHLEYMILLER M, 1985, OXFORD TXB PUBLIC HL, V3; BERWICK DM, 1992, BRIT MED J, V304, P304, DOI 10.1136/bmj.304.6822.304; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; EDWARDS PJ, 1992, BMJ-BRIT MED J, V305, P267, DOI 10.1136/bmj.305.6848.267; HILLAN KJ, 1991, BRIT MED J, V303, P1180, DOI 10.1136/bmj.303.6811.1180; HUTCHINSON A, 1992, BRIT J GEN PRACT, V42, P227; IRVINE D, 1990, MANAGING QUALITY GEN; JONES R, 1986, PRACTITIONER, V230, P627; LIGHT DW, 1991, BRIT MED J, V303, P1253, DOI 10.1136/bmj.303.6812.1253; Lomas J, 1990, Qual Assur Health Care, V2, P5; MCWILLIAM LJ, 1991, BRIT MED J, V303, P1177, DOI 10.1136/bmj.303.6811.1177; MORRELL DC, 1991, BMJ-BRIT MED J, V302, P1313, DOI 10.1136/bmj.302.6788.1313; MORRELL DC, 1988, EPIDEMIOLOGY GENERAL; Neuberger J, 1992, ETHICS HLTH CARE ROL; OPIT LJ, 1983, HLTH SERVICES RES; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; WILLIAMS RB, 1991, BRIT MED J, V303, P1179, DOI 10.1136/bmj.303.6811.1179; 1991, LOCAL RES ETHICS COM; 1989, GENERAL PRACTICE NHS; 1991, HLTH SERVICES MA DEC	21	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					189	192		10.1136/bmj.306.6871.189	http://dx.doi.org/10.1136/bmj.306.6871.189			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443486	Bronze, Green Published			2022-12-28	WOS:A1993KH51300028
J	MOSS, AJ; GOLDSTEIN, RE; HALL, WJ; BIGGER, JT; FLEISS, JL; GREENBERG, H; BODENHEIMER, M; KRONE, RJ; MARCUS, FI; WACKERS, FJT; BENHORIN, J; BROWN, MW; CASE, R; COROMILAS, J; DWYER, EM; GILLESPIE, JA; GREGORY, JJ; KLEIGER, R; LICHSTEIN, E; PARKER, JO; RAUBERTAS, RF; STERN, S; TZIVONI, D; VANVOORHEES, L				MOSS, AJ; GOLDSTEIN, RE; HALL, WJ; BIGGER, JT; FLEISS, JL; GREENBERG, H; BODENHEIMER, M; KRONE, RJ; MARCUS, FI; WACKERS, FJT; BENHORIN, J; BROWN, MW; CASE, R; COROMILAS, J; DWYER, EM; GILLESPIE, JA; GREGORY, JJ; KLEIGER, R; LICHSTEIN, E; PARKER, JO; RAUBERTAS, RF; STERN, S; TZIVONI, D; VANVOORHEES, L			DETECTION AND SIGNIFICANCE OF MYOCARDIAL-ISCHEMIA IN STABLE PATIENTS AFTER RECOVERY FROM AN ACUTE CORONARY EVENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TL-201 STRESS SCINTIGRAPHY; LONG-TERM PROGNOSIS; ARTERY DISEASE; ANGINA-PECTORIS; UNSTABLE ANGINA; NATURAL-HISTORY; CHEST PAIN; CLINICAL-SIGNIFICANCE; INFARCTION; SILENT	Objective.-To determine the clinical significance of silent and symptomatic myocardial ischemia detected by noninvasive testing in stable postcoronary patients. Design.-Cohort study with a mean 23-month follow-up. Setting.-Ambulatory outpatients after recent hospitalization for an acute coronary event. Patients.-Nine hundred thirty-six patients (76% male; mean age, 58 years) who were clinically stable 1 to 6 months after hospitalization for acute myocardial infarction or unstable angina. Interventions.-Noninvasive testing involved rest, ambulatory, and exercise electrocardiograms and stress thallium-201 scintigraphy. Main Outcome Measures.-Cox regression analysis was used to evaluate the risk (hazard ratio) of first recurrent primary events (cardiac death, nonfatal infarction, or unstable angina) or restricted events (cardiac death or nonfatal infarction) associated with ischemic noninvasive test results. Results.-ST segment depression on the rest electrocardiogram was the only noninvasive test variable that identified a significantly increased risk (P=.05) for first recurrent primary events (hazard ratio; 95% confidence limits): rest electrocardiogram ST depression (1.5; 1.00, 2.25); ambulatory electrocardiogram ST depression (0.86; 0.49, 1.51); exercise electrocardiogram ST depression (1.13; 0.82, 1.56); and stress thallium-201 reversible defects (1.3; 0.96, 1.74). Test results were similar for first recurrent restricted events, and in patients with and without angina. Significantly increased risk (P<.05) was noted when exercise-induced ST depression occurred in patients who also had reduced exercise duration (hazard ratio, 3.4) or when reversible thallium-201 defects occurred in patients who also had increased lung uptake (hazard ratio, 2.8). Each high-risk subset made up less than 3% of the population and contained less than 6% of patients with first primary events. Conclusion.-Detection of silent or symptomatic myocardial ischemia by noninvasive testing in stable patients 1 to 6 months after an acute coronary event is not useful in identifying patients at increased risk for subsequent coronary events.	UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814; BAYLOR COLL MED,HOUSTON,TX 77030; ROOSEVELT ST LUKES HOSP,NEW YORK,NY; LONG ISL JEWISH MED CTR,NEW HYDE PK,NY; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110; UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; BIKUR CHOLIM HOSP,JERUSALEM,ISRAEL; HIGHLAND HOSP,ROCHESTER,NY 14620; OVERLOOK HOSP,SUMMIT,NJ 07901; MAIMONIDES HOSP,BROOKLYN,NY 11219; KINGSTON GEN HOSP,KINGSTON K7L 2V7,ONTARIO,CANADA; WASHINGTON HOSP CTR,WASHINGTON,DC 20010	Uniformed Services University of the Health Sciences - USA; Baylor College of Medicine; Mount Sinai St. Luke's; Mount Sinai West; Northwell Health; Barnes-Jewish Hospital; University of Arizona; University of Arizona Health Sciences; Yale University; University of Rochester; Atlantic Health System; Maimonides Medical Center; Queens University - Canada; MedStar Washington Hospital Center	MOSS, AJ (corresponding author), UNIV ROCHESTER,MED CTR,POB 653,ROCHESTER,NY 14642, USA.				NHLBI NIH HHS [HL-38702] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038702] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSEY ME, 1987, AM J CARDIOL, V59, P497, DOI 10.1016/0002-9149(87)91155-6; BONOW RO, 1988, AM J CARDIOL, V60, P778; BRUCE R A, 1963, Pediatrics, V32, P742; CAPONE RJ, 1991, J AM COLL CARDIOL, V18, P1434, DOI 10.1016/0735-1097(91)90671-U; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COX DR, 1972, J R STAT SOC B, V34, P187; DEEDWANIA PC, 1990, CIRCULATION, V81, P748, DOI 10.1161/01.CIR.81.3.748; EPSTEIN SE, 1988, NEW ENGL J MED, V318, P1038, DOI 10.1056/NEJM198804213181606; FALCONE C, 1987, J AM COLL CARDIOL, V9, P295, DOI 10.1016/S0735-1097(87)80378-9; FRANK CW, 1973, CIRCULATION, V47, P509, DOI 10.1161/01.CIR.47.3.509; GAZES PC, 1973, CIRCULATION, V48, P331, DOI 10.1161/01.CIR.48.2.331; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; GIBSON RS, 1986, CIRCULATION, V73, P1186, DOI 10.1161/01.CIR.73.6.1186; GILL JB, 1987, NEW ENGL J MED, V317, P1485, DOI 10.1056/NEJM198712103172401; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; GREENBERG H, 1987, AM J CARDIOL, V59, P1057, DOI 10.1016/0002-9149(87)90848-4; HADDI A, 1987, J AM COLL CARDIOL, V10, P25; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; HLATKY MA, 1985, AM J CARDIOL, V55, P325, DOI 10.1016/0002-9149(85)90369-8; HUNG J, 1984, AM J CARDIOL, V53, P1221, DOI 10.1016/0002-9149(84)90068-7; KANNEL WB, 1972, AM J CARDIOL, V29, P154, DOI 10.1016/0002-9149(72)90624-8; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAUL S, 1988, CIRCULATION, V77, P745, DOI 10.1161/01.CIR.77.4.745; KRONE RJ, 1985, CIRCULATION, V71, P80, DOI 10.1161/01.CIR.71.1.80; LADENHEIM ML, 1986, J AM COLL CARDIOL, V7, P464, DOI 10.1016/S0735-1097(86)80454-5; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LANGER A, 1989, J AM COLL CARDIOL, V13, P1495, DOI 10.1016/0735-1097(89)90338-0; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MARK DB, 1989, J AM COLL CARDIOL, V14, P885, DOI 10.1016/0735-1097(89)90459-2; NADEMANEE K, 1987, J AM COLL CARDIOL, V10, P1, DOI 10.1016/S0735-1097(87)80152-3; REEVES TJ, 1974, AM J CARDIOL, V33, P423, DOI 10.1016/0002-9149(74)90327-0; ROZANSKI A, 1987, AM HEART J, V114, P627, DOI 10.1016/0002-8703(87)90761-7; SAVAMAKI KI, 1983, EUR HEART J, V4, P752; SIGAL SL, 1991, J NUCL MED, V32, P759; STANILOFF HM, 1986, J NUCL MED, V27, P1842; STONE PH, 1986, J AM COLL CARDIOL, V8, P1007, DOI 10.1016/S0735-1097(86)80374-6; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; TZIVONI D, 1989, AM J CARDIOL, V63, P273, DOI 10.1016/0002-9149(89)90329-9; WACKERS FJT, 1989, J AM COLL CARDIOL, V14, P861, DOI 10.1016/0735-1097(89)90456-7; WACKERS FJT, 1985, SEMIN NUCL MED, V15, P46, DOI 10.1016/S0001-2998(85)80043-X; WACKERS FJT, 1985, J AM COLL CARDIOL, V6, P27, DOI 10.1016/S0735-1097(85)80247-3; WEINER DA, 1987, AM J CARDIOL, V59, P725, DOI 10.1016/0002-9149(87)91081-2; WELD FM, 1981, CIRCULATION, V64, P6; WILLIAMS WL, 1984, J AM COLL CARDIOL, V4, P477, DOI 10.1016/S0735-1097(84)80090-X; YEUNG AC, 1991, CIRCULATION, V83, P1598, DOI 10.1161/01.CIR.83.5.1598; SAS P217 SAS I INC T	47	103	103	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2379	2385		10.1001/jama.269.18.2379	http://dx.doi.org/10.1001/jama.269.18.2379			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479063				2022-12-28	WOS:A1993LA67500031
J	PASTUSZAK, A; SCHICKBOSCHETTO, B; ZUBER, C; FELDKAMP, M; PINELLI, M; SIHN, S; DONNENFELD, A; MCCORMACK, M; LEENMITCHELL, M; WOODLAND, C; GARDNER, A; HORN, M; KOREN, G				PASTUSZAK, A; SCHICKBOSCHETTO, B; ZUBER, C; FELDKAMP, M; PINELLI, M; SIHN, S; DONNENFELD, A; MCCORMACK, M; LEENMITCHELL, M; WOODLAND, C; GARDNER, A; HORN, M; KOREN, G			PREGNANCY OUTCOME FOLLOWING 1ST-TRIMESTER EXPOSURE TO FLUOXETINE (PROZAC)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							DRUG	Objective.- To compare pregnancy outcome following first-trimester fluoxetine (Prozac) exposure with pregnancy outcome in two matched control groups. Fluoxetine is a new antidepressant used by many young women. Currently, no published data exist on its safety in pregnancy. Design.-We prospectively collected and followed up 128 pregnant women exposed to a mean daily dose of 25.8 mg (+/- 13 mg) of fluoxetine during the first trimester and compared pregnancy outcome with two matched groups of women exposed during the first trimester of pregnancy to either nonteratogens or tricyclic antidepressants. Results.-Rates of major malformations were comparable within the three groups and did not exceed those expected in the general population. Women treated with fluoxetine had a tendency for increased risk for miscarriage when compared with women exposed to nonteratogens (relative risk, 1.9; 95% confidence interval, 0.92 to 3.92). The rate of miscarriages in the fluoxetine group was comparable with the tricyclic group (13.5% and 12.2% vs 6.8% in the nonteratogens). Conclusions.-Our study suggests that the use of fluoxetine during embryogenesis is not associated with an increased risk of major malformations. Women exposed to both fluoxetine and tricyclic antidepressants tended to report higher rates of miscarriage; further studies will be needed to confirm this observation and to separate the effects of the psychiatric condition from the associated drugs. Long-term studies will be warranted to rule out potential developmental teratology of fluoxetine, which affects a central nervous system neurotransmitter.	HOSP SICK CHILDREN,DIV CLIN PHARMACOL,MOTHERISK PROGRAM,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; PREGNANCY RISK INFORMAT SERV,CAMDEN,NJ; OSHAWA GEN HOSP,DEPT GENET,OSHAWA,ON,CANADA; PENN HOSP,DEPT OBSTET & GYNECOL,PREGNANCY HEALTHLINE,PHILADELPHIA,PA 19107; UNIV UTAH,PREGNANCY RISKLINE,SALT LAKE CITY,UT 84112	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Pennsylvania; Pennsylvania Medicine; Utah System of Higher Education; University of Utah								BYRD RA, 1989, TERATOLOGY, V39, P444; COHEN LS, 1989, PSYCHOSOMATICS, V30, P25, DOI 10.1016/S0033-3182(89)72314-8; GOLDSTEIN DJ, 1991, 4TH P INT C TER INF; JACOBSON SJ, 1992, LANCET, V339, P530, DOI 10.1016/0140-6736(92)90346-5; KOREN G, 1990, TERATOLOGY, V41, P657, DOI 10.1002/tera.1420410602; OHARA MW, 1984, J ABNORM PSYCHOL, V93, P158, DOI 10.1037/0021-843X.93.2.158; SOPHOCLES AM, 1986, J FAM PRACTICE, V22, P45	7	319	322	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1993	269	17					2246	2248		10.1001/jama.269.17.2246	http://dx.doi.org/10.1001/jama.269.17.2246			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ406	8474204				2022-12-28	WOS:A1993KZ40600033
J	MANN, GB; FOWLER, KJ; GABRIEL, A; NICE, EC; WILLIAMS, RL; DUNN, AR				MANN, GB; FOWLER, KJ; GABRIEL, A; NICE, EC; WILLIAMS, RL; DUNN, AR			MICE WITH A NULL MUTATION OF THE TGF-ALPHA GENE HAVE ABNORMAL SKIN ARCHITECTURE, WAVY HAIR, AND CURLY WHISKERS AND OFTEN DEVELOP CORNEAL INFLAMMATION	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; TRANSGENIC MICE; MESSENGER-RNA; HUMAN KERATINOCYTES; FACTOR RECEPTORS; MAMMARY-GLAND; STEM-CELLS; MOUSE; EXPRESSION; BETA	Mice homozygous fora disrupted transforming growth factor alpha (TGFalpha) gene are healthy and fertile, although some older mice show evidence of corneal inflammation. In contrast with TGFalpha +/- and +/+ animals, TGFalpha -/- mice have a pronounced waviness of the coat. Histological examination of the skin from TGFalpha -/- mice reveals a dramatic derangement of hair follicles. Mice with a disrupted TGFalpha gene also have curly whiskers, first evident on the day of birth. The phenotype of TGFalpha -/- mice is remarkably similar to that of the mouse mutant waved-1 (wa-1). Offspring resulting from crosses between TGFalpha -/- and wa-1 mice display the curly whisker-coat phenotype, indicating that the basis of the wa-1 phenotype is a mutation in the TGFalpha gene. These observations suggest that TGFalpha plays a pivotal role in determining skin architecture and in regulating hair development.			MANN, GB (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, PARKVILLE, VIC 3050, AUSTRALIA.		Nice, Edouard C/B-1026-2011	Mann, Bruce/0000-0002-2508-9203				ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BENNETT JH, 1956, NATURE, V178, P272, DOI 10.1038/178272b0; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRIGHTWELL JR, 1985, INVEST OPHTH VIS SCI, V26, P105; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BUNKER H, 1948, J HERED, V39, P28, DOI 10.1093/oxfordjournals.jhered.a105758; BURGESS AW, 1982, P NATL ACAD SCI-BIOL, V79, P5753, DOI 10.1073/pnas.79.19.5753; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARTLIDGE SA, 1989, BRIT J CANCER, V60, P657, DOI 10.1038/bjc.1989.334; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; CLAXTON JH, 1966, ANAT RECORD, V154, P195, DOI 10.1002/ar.1091540202; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; COUCH JM, 1987, OPHTHALMOLOGY, V94, P1; Crew FAE, 1933, J GENET, V27, P95, DOI 10.1007/BF02984383; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1987, CANCER RES, V47, P707; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; GREEN MC, 1989, GENETIC VARIANTS STR, P8; GREEN MR, 1983, DEV BIOL, V100, P506, DOI 10.1016/0012-1606(83)90243-9; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P8; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HOGAN B, 1986, MANIPULATING MOUSE E, P174; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JIMENEZ JJ, 1992, CANCER RES, V52, P413; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KOLLER BH, 1992, ANNU REV IMMUNOL, V10, P705, DOI 10.1146/annurev.iy.10.040192.003421; LAZAR LM, 1992, J NEUROSCI, V12, P1688; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MARTIN P, 1992, Progress in Growth Factor Research, V4, P25, DOI 10.1016/0955-2235(92)90003-Z; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; NISTER M, 1988, CANCER RES, V48, P3910; Partanen A M, 1990, Curr Top Dev Biol, V24, P31, DOI 10.1016/S0070-2153(08)60083-6; QUINN P, 1982, J REPROD FERTIL, V66, P161; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; REISS M, 1991, CANCER RES, V51, P6254; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SAVAGE CR, 1973, EXP EYE RES, V15, P361, DOI 10.1016/0014-4835(73)90151-6; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; SMITH JM, 1985, NATURE, V315, P515, DOI 10.1038/315515a0; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Straile WE, 1969, ADV BIOL SKIN, V9, P369; TAM JP, 1985, SCIENCE, V229, P673, DOI 10.1126/science.3860952; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TRIGG MJ, 1972, J ZOOL, V68, P165, DOI 10.1111/j.1469-7998.1972.tb01346.x; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	64	518	534	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					249	261		10.1016/0092-8674(93)90227-H	http://dx.doi.org/10.1016/0092-8674(93)90227-H			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8477444				2022-12-28	WOS:A1993KY50500008
J	LEDERBERG, J				LEDERBERG, J			WHAT THE DOUBLE HELIX (1953) HAS MEANT FOR BASIC BIOMEDICAL SCIENCE - A PERSONAL COMMENTARY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											LEDERBERG, J (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.							Alberts B., 1989, MOL BIOL CELL; Berg P., 1992, DEALING GENES LANGUA; CASKEY CT, 1993, JAMA-J AM MED ASSOC, V269, P1986, DOI 10.1001/jama.269.15.1986; Crick F, 1988, WHAT MAD PURSUIT PER; Darnell J., 1990, MOL CELL BIOL; Dubos R., 1976, PROFESSOR I DNA; Fruton J. S., 1972, MOL LIFE; JUDSON HF, 1979, 8TH DAY CREATION; Kornberg A., 1992, DNA REPLICATION; LEDERBERG J, 1987, ANNU REV GENET, V21, P23; McCarty Maclyn., 1985, TRANSFORMING PRINCIP; Olby R, 1974, PATH DOUBLE HELIX DI; PEI D, 1991, SCIENCE, V253, P1408, DOI 10.1126/science.1716784; Portugal FH., 1977, CENTURY DNA; SAYRE A., 1975, R FRANKLIN DNA; Stryer L., 1988, BIOCHEMISTRY-US; Watson J. D., 1987, MOL BIOL GENE; Watson James, 1968, DOUBLE HELIX; WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WATSON JD, 1981, DNA STORY; Wells R.D., 1988, UNUSUAL DNA STRUCTUR	22	13	13	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1981	1985		10.1001/jama.269.15.1981	http://dx.doi.org/10.1001/jama.269.15.1981			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464131				2022-12-28	WOS:A1993KX21500030
J	BERNIER, RH; DIETZ, VJ; LYONS, AE; MCKNIGHT, HL; MULLEN, JH; OMARA, DJ; BENDER, K; BROOME, CV; CARY, AH; CASERTA, VM; FESSLER, KA; GUERRA, FA; GURSKY, EA; HUTCHINS, VL; KATZ, SE; LENART, JC; LEWIN, JC; MARCUSE, EK; MCGUIRE, ML; MITCHEM, F; MORTIMER, EA; MOUNTAIN, KL; NANNIS, PW; NORA, AH; NYE, CH; STRAIN, JE; STEVENS, D; STUBBS, PE; THOMPSON, FE; VANBUREN, RC; DIETZ, V; BART, KJ; BERNIER, R; ORENSTEIN, WA				BERNIER, RH; DIETZ, VJ; LYONS, AE; MCKNIGHT, HL; MULLEN, JH; OMARA, DJ; BENDER, K; BROOME, CV; CARY, AH; CASERTA, VM; FESSLER, KA; GUERRA, FA; GURSKY, EA; HUTCHINS, VL; KATZ, SE; LENART, JC; LEWIN, JC; MARCUSE, EK; MCGUIRE, ML; MITCHEM, F; MORTIMER, EA; MOUNTAIN, KL; NANNIS, PW; NORA, AH; NYE, CH; STRAIN, JE; STEVENS, D; STUBBS, PE; THOMPSON, FE; VANBUREN, RC; DIETZ, V; BART, KJ; BERNIER, R; ORENSTEIN, WA			STANDARDS FOR PEDIATRIC IMMUNIZATION PRACTICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									CTR DIS CONTROL & PREVENT,DIV IMMUNIZAT,ATLANTA,GA; ASSOC STATE & TERR DIRECTORS NURSING,JACKSON,MS; ASSOC COMMUNITY HLTH NURSING EDUCATORS,NEW ORLEANS,LA; NATL VACCINE INJURY COMPENSAT PROGRAM,ROCKVILLE,MD; MILWAUKEE DEPT HLTH,MILWAUKEE,WI; SAN ANTONIO METROPOLITAN HLTH DIST,SAN ANTONIO,TX; NATL ASSOC CTY HLTH OFFICIALS,CHEVERLY,MD; HLTH RESOURCES & SERV ADM,ROCKVILLE,MD; ADVISORY COMM IMMUNIZAT PRACTICES,DURHAM,NC; AMER NURSES ASSOC,SEATTLE,WA; NATL ASSOC COMMUNITY HLTH CTR INC,WASHINGTON,DC; ASSOC STATE & TERR HLTH OFFICIALS,HONOLULU,HI; UNIV WASHINGTON,SEATTLE,WA 98195; NATL ASSOC PEDIAT NURSE ASSOCIATES & PRACTITIONERS,CHERRY HILL,NJ; AMER MED ASSOC,CHICAGO,IL 60610; NATL MIGRANT RESOURCE PROGRAM,AUSTIN,TX; US CONFERENCE LOCAL HLTH OFFICERS,MILWAUKEE,WI; ASSOC MATERNAL & CHILD HLTH PROGRAMS,IOWA CITY,IA; HLTH RESOURCES & SERV ADM,ROCKVILLE,MD; HLTH CARE FINANCING ADM,BALTIMORE,MD; AMER ACAD PEDIAT,ELK GROVE VILLAGE,IL; CONFERENCE STATE TERR EPIDEMIOLOGISTS,JACKSON,MS; AMER ACAD FAMILY PHYSICIANS,COLUMBUS,OH	Centers for Disease Control & Prevention - USA; United States Health Resources & Service Administration (HRSA); University of Washington; University of Washington Seattle; American Medical Association; United States Health Resources & Service Administration (HRSA); American Academy of Pediatrics			Cary, Ann/AAE-7196-2021					CUTTS FT, 1992, ANNU REV PUBL HEALTH, V13, P385, DOI 10.1146/annurev.publhealth.13.1.385; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; 1990, PHS9150213 US DEP HL; 1989, MMWR, V38, P205; 1992, MMWR, V41, P1; 1991, MMWR, V40, P1; 1991, MMWR, V39, P55; 1992, MMWR, V41, P103; 1992, MMWR, V41, P623; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1991, REPORT COMMITTEE INF; 1989, MMWR, V38, P219	12	82	84	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1817	1822		10.1001/jama.1993.03500140069038	http://dx.doi.org/10.1001/jama.1993.03500140069038			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459514				2022-12-28	WOS:A1993KW25000037
J	GRUMBACH, K; FRY, J				GRUMBACH, K; FRY, J			MANAGING PRIMARY CARE IN THE UNITED-STATES AND IN THE UNITED-KINGDOM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV CALIF SAN FRANCISCO, DEPT FAMILY & COMMUNITY MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	GRUMBACH, K (corresponding author), UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, 1388 SUTTER ST, 11TH FL, SAN FRANCISCO, CA 94109 USA.		Grumbach, Kevin/L-9222-2016					AARON HJ, 1984, PAINFUL PRESCRIPTION; AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; COOK JV, 1988, J FAM PRACTICE, V26, P325; DAY P, 1991, HEALTH AFFAIR, V10, P39, DOI 10.1377/hlthaff.10.3.39; EPSTEIN AM, 1984, JAMA-J AM MED ASSOC, V252, P1723, DOI 10.1001/jama.252.13.1723; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FRY J, 1992, FACTS GENERAL PRACTI; FRY J, 1969, MED 3 SOC COMP MED C; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; HARMON RG, 1992, NATIONAL PRIMARY CAR; LEE PR, 1990, ANNU REV PUBL HEALTH, V11, P297; Nutting P, 1990, COMMUNITY ORIENTED P; PETERSDORF RG, 1992, NEW ENGL J MED, V326, P408, DOI 10.1056/NEJM199202063260610; ROSENBLATT RA, 1983, NEW ENGL J MED, V309, P892, DOI 10.1056/NEJM198310133091505; RUBLEE DA, 1992, INT HLTH CARE SYSTEM; SCHIEBER GJ, 1989, HLTH CARE FINANC R S, V7, P1; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; SCHROEDER SA, 1992, HEALTH AFFAIR, V11, P235, DOI 10.1377/hlthaff.11.1.235; Starfield B., 1992, PRIMARY CARE CONCEPT; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1991, FACTS FAMILY PRACTIC; 1991, DHHS PHS911250 PUBL; 1991, HLTH AFF MILLWOOD, V10, P106; 1986, 3RD NATIONAL MORBIDI; 1992, DHHS PHS911232 PUBL; 1992, PHYSICIAN CHARACTERI; 1991, PHYSICIAN MARKETPLAC; 1992, DOCTORS DENTISTS PAY; 1991, HMO IND PROFILE, V2; 1989, OFFICE HLTH EC	34	41	41	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 1	1993	328	13					940	945		10.1056/NEJM199304013281308	http://dx.doi.org/10.1056/NEJM199304013281308			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU177	8446142				2022-12-28	WOS:A1993KU17700008
J	[Anonymous]				[Anonymous]			ALARM, BUT LITTLE ACTION, ON POPULATION	NATURE			English	Editorial Material																		KENNEDY P, PREPARING 21 CENTURY; 1993, NATURE, V362, P275	2	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	1993	362	6419					379	379						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8464458				2022-12-28	WOS:A1993KV42400001
J	KAN, MK; WANG, F; XU, JM; CRABB, JW; HOU, JZ; MCKEEHAN, WL				KAN, MK; WANG, F; XU, JM; CRABB, JW; HOU, JZ; MCKEEHAN, WL			AN ESSENTIAL HEPARIN-BINDING DOMAIN IN THE FIBROBLAST GROWTH-FACTOR RECEPTOR KINASE	SCIENCE			English	Article							HIGH-AFFINITY RECEPTOR; SULFATE PROTEOGLYCAN; CELL-SURFACE; IDENTIFICATION; STIMULATION; CLONING	Heparin or heparin-like heparan sulfate proteoglycans are obligatory for activity of the heparin-binding fibroblast growth factor (FGF) family. Heparin interacts independently of FGF ligand with a specific sequence (K18K) in one of the immunoglobulin-like loops in the extracellular domain of the FGF receptor tyrosine kinase transmembrane glycoprotein. A synthetic peptide corresponding to K18K inhibited heparin and heparin-dependent FGF binding to the receptor. K18K and an antibody to K18K were antagonists of FGF-stimulated cell growth. Point mutations of lysine residues in the K18K sequence abrogated both heparin- and ligand-binding activities of the receptor kinase. The results indicate that the FGF receptor is a ternary complex of heparan sulfate proteoglycan, tyrosine kinase transmembrane glycoprotein, and ligand.	W ALTON JONES CELL SCI CTR INC,OLD BARN RD,LAKE PLACID,NY 12946									CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOU JZ, 1992, J BIOL CHEM, V267, P17804; KAN M, 1988, J BIOL CHEM, V263, P11306; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1990, IN VITRO CELL DEV B, V26, P1151; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; XU JM, 1992, J BIOL CHEM, V267, P17792; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	13	479	494	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1918	1921		10.1126/science.8456318	http://dx.doi.org/10.1126/science.8456318			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456318				2022-12-28	WOS:A1993KU17200038
J	LAIDLAW, JDD; ZAW, KM				LAIDLAW, JDD; ZAW, KM			EPILEPSY MISTAKEN FOR PANIC ATTACKS IN AN ADOLESCENT GIRL	BRITISH MEDICAL JOURNAL			English	Article							SEIZURES; CHILDREN		GLOUCESTERSHIRE ROYAL HOSP,DEPT CHILD & ADOLESCENT PSYCHIAT,GLOUCESTER GL1 3NN,ENGLAND	Gloucestershire Royal Hospital								BRAY PF, 1965, ARCH NEUROL-CHICAGO, V13, P233; FENTON GW, 1992, CURRENT OPINION PSYC, V5, P88; GIBBS FA, 1951, J NERV MENT DIS, V113, P522, DOI 10.1097/00005053-195111360-00005; GLASSMAN JN, 1986, GEN HOSP PSYCHIAT, V8, P61, DOI 10.1016/0163-8343(86)90066-6; JUULJENSEN P, 1983, EPILEPSIA, V24, P297, DOI 10.1111/j.1528-1157.1983.tb04893.x; LINDSAY J, 1979, DEV MED CHILD NEUROL, V21, P630; MESSNER E, 1986, AM J ORTHOPSYCHIAT, V56, P323, DOI 10.1111/j.1939-0025.1986.tb02735.x; REMICK RA, 1981, CAN J PSYCHIAT, V26, P49, DOI 10.1177/070674378102600110; STORES G, 1991, BRIT J PSYCHIAT, V158, P1, DOI 10.1192/bjp.158.1.1; TOONE BK, 1991, J ROY SOC MED, V84, P457, DOI 10.1177/014107689108400805; TRAVERS RF, 1991, J ROY SOC MED, V84, P454, DOI 10.1177/014107689108400804; WILLIAMSON PD, 1986, EPILEPSIA S2, V27, P546; ZIELINSKI JJ, 1988, TXB EPILEPSY, P21	13	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					709	710		10.1136/bmj.306.6879.709	http://dx.doi.org/10.1136/bmj.306.6879.709			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KT216	8471931	Bronze, Green Published			2022-12-28	WOS:A1993KT21600032
J	FORSTER, P				FORSTER, P			THE FORTYSOMETHING BARRIER - MEDICINE AND AGE-DISCRIMINATION	BRITISH MEDICAL JOURNAL			English	Article								Agism in the medical profession is mainly covert but it is not uncommon. Ir is widely believed that people become less productive as they get older. However, research has shown that older people have less absenteeism, more job stability, and greater output than younger workers. Job losses, which until recently were unheard of in the NHS, usually affect older people first, resulting in the loss of those with the most skill and experience. With an aging population it is important that the government takes steps to discourage age discrimination in the NHS and Britain as a whole.			FORSTER, P (corresponding author), BRITISH MED ASSOC,NW REG OFF,MANCHESTER M20 8RX,ENGLAND.							GINIGER S, 1983, J APPL PSYCHOL, V68, P215; NAYLOR P, 1990, AGE BARRIER, P30; WALDMAN DA, 1986, J APPL PSYCHOL, V71, P33, DOI 10.1037/0021-9010.71.1.33; 1989, LABOUR MARKET REPORT; 1978, WORKING OLDER PEOPLE, V1; 1922, CAREERS WOMEN MED PL, P6; 1983, DOCTORS RETAINER SCH; 1991, STOP AGEISM EMPLOYME; 1991, 2 EMPL I EC REP, V6, P10	9	7	7	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					637	639		10.1136/bmj.306.6878.637	http://dx.doi.org/10.1136/bmj.306.6878.637			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ859	8461818	Bronze, Green Published			2022-12-28	WOS:A1993KQ85900026
J	JAFFA, T; SCOTT, S; HENDRIKS, JH; SHAPIRO, CM				JAFFA, T; SCOTT, S; HENDRIKS, JH; SHAPIRO, CM			ABC OF SLEEP DISORDERS - SLEEP DISORDERS IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									INST PSYCHIAT,LONDON SE5 8AF,ENGLAND; UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA	University of London; King's College London; University of Toronto	JAFFA, T (corresponding author), ST GEORGE HOSP,LONDON,ENGLAND.								0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					640	643		10.1136/bmj.306.6878.640	http://dx.doi.org/10.1136/bmj.306.6878.640			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461819	Bronze, Green Published			2022-12-28	WOS:A1993KQ85900028
J	BENARON, DA; STEVENSON, DK				BENARON, DA; STEVENSON, DK			OPTICAL TIME-OF-FLIGHT AND ABSORBENCY IMAGING OF BIOLOGIC MEDIA	SCIENCE			English	Article							NEAR-INFRARED SPECTROSCOPY; BREAST-CANCER; SCATTERING; DIAPHANOGRAPHY; INFANTS; TRANSILLUMINATION; HEMODYNAMICS; SYSTEM; TISSUE; BRAIN	Imaging the interior of living bodies with light may assist in the diagnosis and treatment of a number of clinical problems, which include the early detection of tumors and hypoxic cerebral injury. An existing picosecond time-of-flight and absorbance (TOFA) optical system has been used to image a model biologic system and a rat. Model measurements confirmed TOFA principles in systems with a high degree of photon scattering; rat images, which were constructed from the variable time delays experienced by a fixed fraction of early-arriving transmitted photons, revealed identifiable internal structure. A combination of light-based quantitative measurement and TOFA localization may have applications in continuous, noninvasive monitoring for structural imaging and spatial chemometric analysis in humans.			BENARON, DA (corresponding author), STANFORD UNIV,SCH MED,DEPT PEDIAT,NEONATAL & DEV BIOL LAB,MED SPECT & IMAGING LAB SECT,PALO ALTO,CA 94305, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000081] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00081] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALEXANDER CM, 1989, ANESTH ANALG, V68, P368; AMATO I, 1992, SCIENCE, V258, P892; ANDERSSONENGELS S, 1990, OPT LETT, V15, P1179, DOI 10.1364/OL.15.001179; ARAKI R, 1991, SPIE, V1431, P321; ARRIDGE SR, 1992, PHYS MED BIOL, V37, P1531, DOI 10.1088/0031-9155/37/7/005; ARRIDGE SR, 1991, SPIE, V1431, P204; BARBOUR RL, 1992, SPIE P, V1641, P21; BENARON D, 1990, IEEE ENG MED BIOL, V12, P2004; BENARON DA, 1992, CLIN PEDIATR, V31, P258, DOI 10.1177/000992289203100501; BENARON DA, 1990, IEEE ENG MED BIOL, V12, P1117; BENARON DA, 1992, SPIE, V1641, P35; BRAZY JE, 1986, ADV EXP MED BIOL, V191, P843; CHANCE B, 1988, P NATL ACAD SCI USA, V85, P4971, DOI 10.1073/pnas.85.14.4971; CHANCE B, IN PRESS OXYGEN TRAN, V15; CHANCE B, 1992, SPIE, V1641, P162; DAMADIAN R, 1977, PHYSIOL CHEM PHYS M, V9, P97; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; DREXLER B, 1985, RADIOLOGY, V157, P41, DOI 10.1148/radiology.157.1.4034975; DUGUAY MA, 1971, APPL OPTICS, V10, P2162, DOI 10.1364/AO.10.002162; EDWARDS AD, 1990, LANCET, V335, P1491, DOI 10.1016/0140-6736(90)93030-S; FERRARI M, IN PRESS J PHOTOCHEM; FISHKIN F, 1991, SPIE, V1431, P123; FLOCK ST, 1987, MED PHYS, V14, P835, DOI 10.1118/1.596010; GORBACH AM, 1990, P IEEE ENG MED BIOL, V12, P1245; HEBDEN JC, 1990, MED PHYS, V17, P41, DOI 10.1118/1.596526; HEBDEN JC, 1991, APPL OPTICS, V30, P788, DOI 10.1364/AO.30.000788; HOUNDFIELD GN, 1973, BRIT J RADIOL, V46, P1016, DOI 10.1259/0007-1285-46-552-1016; HUTCHINS GD, 1985, IEEE T NUCL SCI, V32, P835, DOI 10.1109/TNS.1985.4336951; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; KNUTTEL A, IN PRESS APPL OPT; KURTH CD, IN PRESS J CLIN MONI; LAKOWICZ JR, 1984, BIOPHYS J, V46, P463, DOI 10.1016/S0006-3495(84)84043-6; MARK H, 1989, ANAL CHIM ACTA, V223, P75, DOI 10.1016/S0003-2670(00)84075-1; MARSHALL V, 1984, RADIOLOGY, V150, P339, DOI 10.1148/radiology.150.2.6691086; MCCORMICK PW, 1992, J NEUROSURG, V76, P315, DOI 10.3171/jns.1992.76.2.0315; MCCORMICK PW, 1991, CRIT CARE MED, V19, P89, DOI 10.1097/00003246-199101000-00020; Millikan GA, 1942, REV SCI INSTRUM, V13, P434, DOI 10.1063/1.1769941; NAVARRO GA, 1988, MED PHYS, V15, P181, DOI 10.1118/1.596249; NEWLEE JC, 1988, IEEE T BIOMED ENG, V35, P828; PATTERSON MS, 1989, APPL OPTICS, V28, P2331, DOI 10.1364/AO.28.002331; SCHLERETH FH, 1992, SPIE, V1641, P46; SEVICK EM, IN PRESS J PHOTOCHEM; SEVICK EM, IN PRESS OXYGEN TRAN, V15; SINGER JR, 1990, SCIENCE, V248, P990, DOI 10.1126/science.248.4958.990; SVAASAND LO, 1983, J CEREB BLOOD FLOW M, V3, P293; WANG L, 1991, SCIENCE, V253, P769, DOI 10.1126/science.253.5021.769; WANG L, 1991, SPIE S TIM RES SPECT, V1431, P97; WILD JJ, 1952, SCIENCE, V115, P226, DOI 10.1126/science.115.2983.226; WILSON BC, 1990, PHOTON MIGRATION TIS, P29; WYATT JS, 1990, J APPL PHYSIOL, V68, P1086; WYATT JS, 1990, DEV NEUROSCI-BASEL, V12, P140, DOI 10.1159/000111843; WYATT JS, 1989, ARCH DIS CHILD-FETAL, V64, P953, DOI 10.1136/adc.64.7_Spec_No.953; YOO KM, 1990, OPT LETT, V15, P320, DOI 10.1364/OL.15.000320; YOO KM, 1991, OPT LETT, V16, P1068, DOI 10.1364/OL.16.001068	54	182	523	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1463	1466		10.1126/science.8451643	http://dx.doi.org/10.1126/science.8451643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451643				2022-12-28	WOS:A1993KP97800039
J	SHOICHET, BK; STROUD, RM; SANTI, DV; KUNTZ, ID; PERRY, KM				SHOICHET, BK; STROUD, RM; SANTI, DV; KUNTZ, ID; PERRY, KM			STRUCTURE-BASED DISCOVERY OF INHIBITORS OF THYMIDYLATE SYNTHASE	SCIENCE			English	Article							MULTIWIRE AREA DETECTOR; NUCLEIC-ACIDS; BINDING; REFINEMENT; PROTEINS; DESIGN; SYSTEM; SITE	A molecular docking computer program (DOCK) was used to screen the Fine Chemical Directory, a database of commercially available compounds, for molecules that are complementary to thymidylate synthase (TS), a chemotherapeutic target. Besides retrieving the substrate and several known inhibitors, DOCK proposed putative inhibitors previously unknown to bind to the enzyme. Three of these compounds inhibited Lactobacillus casei TS at submillimolar concentrations. One of these inhibitors, sulisobenzone, crystallized with TS in two configurations that differed from the DOCK-favored geometry: a counterion was bound in the substrate site, which resulted in a 6 to 9 angstrom displacement of the inhibitor. The structure of the complexes suggested another binding region in the active site that could be exploited. This region was probed with molecules sterically similar to sulisobenzone, which led to the identification of a family of phenolphthalein analogs that inhibit TS in the 1 to 30 micromolar range. These inhibitors do not resemble the substrates of the enzyme. A crystal structure of phenolphthalein with TS shows that it binds in the target site in a configuration that resembles the one suggested by DOCK.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM39553, GM31497, GM24485] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024485, R37GM024485, R01GM031497, R01GM039553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELT K, 1991, J MED CHEM, V34, P1925, DOI 10.1021/jm00111a001; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAMBERS JL, 1977, ACTA CRYSTALLOGR B, V33, P1824, DOI 10.1107/S0567740877007146; CHEN SC, 1989, INT J BIOCHEM, V21, P1217, DOI 10.1016/0020-711X(89)90006-2; CLIMIE S, 1990, P NATL ACAD SCI USA, V87, P633, DOI 10.1073/pnas.87.2.633; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FINERMOORE J, IN PRESS J MOL BIOL; FINERMOORE JS, 1990, BIOCHEMISTRY-US, V29, P6977, DOI 10.1021/bi00482a005; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GUNER OF, 1991, J CHEM INF COMP SCI, V31, P408, DOI 10.1021/ci00003a007; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KALMAN TI, 1973, BIOCHEM BIOPH RES CO, V55, P210, DOI 10.1016/S0006-291X(73)80081-6; KAMB A, 1992, BIOCHEMISTRY-US, V31, P9883, DOI 10.1021/bi00156a005; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653; RASHIN AA, 1990, J PHYS CHEM-US, V94, P1725, DOI 10.1021/j100368a005; REYES P, 1965, MOL PHARMACOL, V1, P14; SANTI DV, 1984, FOLATES PTERINS, V1, P345; SHOICHET BK, 1992, J COMPUT CHEM, V13, P380, DOI 10.1002/jcc.540130311; VARNEY MD, 1992, J MED CHEM, V35, P663, DOI 10.1021/jm00082a006; WAHBA AJ, 1961, J BIOL CHEM, V236, pPC11; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	31	277	288	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1993	259	5100					1445	1450		10.1126/science.8451640	http://dx.doi.org/10.1126/science.8451640			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451640				2022-12-28	WOS:A1993KP97800034
J	KEKULE, AS; LAUER, U; WEISS, L; LUBER, B; HOFSCHNEIDER, PH				KEKULE, AS; LAUER, U; WEISS, L; LUBER, B; HOFSCHNEIDER, PH			HEPATITIS-B VIRUS TRANSACTIVATOR HBX USES A TUMOR PROMOTER SIGNALING PATHWAY	NATURE			English	Article							PROTEIN-KINASE-C; MAMMALIAN-CELLS; X-PROTEIN; POTENT INHIBITOR; GENE; DNA; EXPRESSION; PHOSPHATIDYLCHOLINE; HEPATOCYTES; ACTIVATION	THE hepatitis B virus (HBV) transactivator protein HBx is enigmatic in that it stimulates a striking variety of promoters which do not share a common cis-regulatory element1-5. As it does not bind to DNA6,7, it has been speculated that HBx acts indirectly through cellular pathways4,6-8. Under certain conditions HBx can have an oncogenic potential, which may be relevant for HBV-associated liver carcinogenesis9-11, but until now the mechanism for transactivation and cell transformation by HBx was unclear. We report here that HBx uses a complex signal transduction pathway for transactivation. An increase in the endogenous protein kinase C (PKC) activator sn-1,2-diacylglycerol and the subsequent activation of PKC give rise to activation of the transcription factor AP-1 (Jun-Fos). As a result, HBx transactivates through binding sites for AP-1 and other PKC-dependent transcription factors (AP-2, NF-kappaB), thereby explaining the as-yet incomprehensible variety of HBx-inducible genes. As the PKC signal cascade also mediates cell transformation by tumour-promoting agents, the mechanism presented here might account for the oncogenic potential of HBx.			KEKULE, AS (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; BUSCHER M, 1988, ONCOGENE, V3, P301; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EXTON JH, 1990, J BIOL CHEM, V265, P1; FABBRO D, 1985, ARCH BIOCHEM BIOPHYS, V239, P102, DOI 10.1016/0003-9861(85)90816-1; FAKTOR O, 1990, ONCOGENE, V5, P867; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SEIFER M, 1991, J HEPATOL, V13, pS61, DOI 10.1016/0168-8278(91)90026-8; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15571; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WOLLERSHEIM M, 1988, VIRAL HEPATITIS LIVE, P334; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; ZAHM P, 1988, ONCOGENE, V3, P169	41	358	369	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					742	745		10.1038/361742a0	http://dx.doi.org/10.1038/361742a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441471				2022-12-28	WOS:A1993KN78900062
J	STROM, M; VOLLMER, P; TAN, TJ; GALLWITZ, D				STROM, M; VOLLMER, P; TAN, TJ; GALLWITZ, D			A YEAST GTPASE-ACTIVATING PROTEIN THAT INTERACTS SPECIFICALLY WITH A MEMBER OF THE YPT/RAB FAMILY	NATURE			English	Article							GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; BINDING PROTEINS; RAS P21; GAP; MUTANTS; RAS-P21; CLONING; DOMAIN	MEMBERS of the Ras superfamily of GTP-binding proteins are involved in a variety of cellular processes, including signal transduction, cytoskeletal organization and protein transport1,2. GTP-binding proteins of the Ypt/Rab family direct vesicular protein transport in the secretory and endocytic pathways in the yeast Saccharomyces cerevisiae (Ypt proteins) and in mammalian systems (Rab proteinS)3,4. The cellular activity of monomeric GTP-binding proteins is influenced by proteins that regulate GDP/GTP exchange and GTP hydrolysis5. GTPase-activating proteins (GAPs) can increase the slow intrinsic GTPase activity of GTP-binding proteins by several orders of magnitude6,7. As GAPs modulate the activity of GTP-binding proteins, they are thought to give a biochemical handle on the functioning of Ypt/Rab proteins in transport vesicle budding and docking or fusion at donor and acceptor membranes1,2. We report here the first cloned GTPase-activating protein for the Ypt/Rab protein family. The gene, GYP6 (GAP of Ypt6 protein), encodes a protein of 458 amino acids which is highly specific for the Ypt6 protein and shows little or no cross-reactivity with other Ypt/Rab family members or with H-Ras p21.	MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC GENET, POB 2841, W-3400 GOTTINGEN, GERMANY	Max Planck Society								BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; RINE J, 1991, METHOD ENZYMOL, V194, P239; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	14	146	153	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1993	361	6414					736	739		10.1038/361736a0	http://dx.doi.org/10.1038/361736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441469				2022-12-28	WOS:A1993KN78900060
J	PARSONS, D				PARSONS, D			THE DANGERS OF LIBEL AND HOW TO AVOID THEM	BRITISH MEDICAL JOURNAL			English	Article																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					253	255		10.1136/bmj.306.6872.253	http://dx.doi.org/10.1136/bmj.306.6872.253			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443529	Green Published, Bronze			2022-12-28	WOS:A1993KJ59100026
J	HUNTINGTON, J				HUNTINGTON, J			THE FUTURE OF FHSAS .1. FROM FPC TO FHSA TO ... HEALTH COMMISSION	BRITISH MEDICAL JOURNAL			English	Article											HUNTINGTON, J (corresponding author), KINGS FUND COLL,LONDON W2 4HS,ENGLAND.							FOSTER A, 1991, FHSAS TODAYS TOMORRO; HAFFENDEN S, 1992, PRIMARY HLTH CARE MA, V11, P9; MARCHMENT M, 1992, PRIMARY HLTH CARE MA, V10, P3; MEADS G, 1992, PRIMARY HLTH CARE MA, V11, P3; Peters T., 2014, SEARCH EXCELLENCE LE; 1992, DOCTOR          0723, P11; 1985, QUALITY GENERAL PRAC; 1990, CMND555; 1987, CM249	9	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					33	36		10.1136/bmj.306.6869.33	http://dx.doi.org/10.1136/bmj.306.6869.33			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8452592	Green Published, Bronze			2022-12-28	WOS:A1993KE98400024
J	LAM, KSL; SHAM, MMK; TAM, SCF; NG, MMT; MA, HTG				LAM, KSL; SHAM, MMK; TAM, SCF; NG, MMT; MA, HTG			HYPOPITUITARISM AFTER TUBERCULOUS MENINGITIS IN CHILDHOOD	ANNALS OF INTERNAL MEDICINE			English	Article						HYPOPITUITARISM; TUBERCULOSIS, MENINGEAL; HYPOTHALAMOHYPOPHYSEAL SYSTEM; SOMATOTROPIN; GONADOTROPINS	GROWTH-HORMONE DEFICIENCY; CRANIAL IRRADIATION; PITUITARY	Objective: To study the prevalence and pathogenesis of hypopituitarism following tuberculous meningitis in childhood. Design: A retrospective cross-sectional study. Setting: A university teaching hospital and a tuberculosis referral center. Patients: Forty-nine patients, aged 23.4 +/- 6.0 years (mean +/- SD), who had tuberculous meningitis in childhood (age at diagnosis, 5.9 +/- 5.0 years) were studied. Measurements: A detailed assessment of hypothalamic-pituitary function, including conventional stimulation tests and responses to four hypothalamic releasing hormones, was done. Magnetic resonance imaging of the hypothalamic-pituitary region was performed in patients with abnormal endocrine function. Results: Ten patients were found to have abnormal pituitary function: Seven had growth hormone deficiency, four of whom also had gonadotropin deficiency; the other three had gonadotropin deficiency, corticotropin deficiency, and mild hyperprolactinemia, respectively; none had diabetes insipidus. Among those with growth hormone deficiency, a significant correlation (r = 0.749, P < 0.05) was found between the height standard deviation score and the age at diagnosis of tuberculous meningitis. Growth hormone, corticotropin, and gonadotropin responses to growth hormone releasing hormone, corticotropin releasing hormone, and gonadotropin releasing hormone, respectively, suggested a hypothalamic defect in five patients. Magnetic resonance imaging scans of the hypothalamic-pituitary region were abnormal in five patients. Conclusions: Hypopituitarism was documented in 20% of a small subset of patients years after recovery from tuberculous meningitis in childhood. The cause appears to be tuberculous lesions affecting the hypothalamus, pituitary stalk and, directly or indirectly, the pituitary itself. Early recognition and treatment can be beneficial.	RUTTONJE HOSP, HONG KONG, HONG KONG		LAM, KSL (corresponding author), UNIV HONG KONG, QUEEN MARY HOSP, DEPT MED, POKFULAM RD, HONG KONG, HONG KONG.		/C-4315-2009	/0000-0001-5757-541X				BHARUCHA NE, 1991, NEUROLOGY CLIN PRACT, P1925; GARG SK, 1987, TROP GEOGR MED, V39, P296; HALL R, 1980, FUNDAMENTALS CLIN EN, P37; HASLAM RHA, 1969, AM J DIS CHILD, V118, P903, DOI 10.1001/archpedi.1969.02100040905017; HERBER SM, 1986, ARCH DIS CHILD, V61, P110, DOI 10.1136/adc.61.2.110; LAM KSL, 1991, Q J MED, V78, P165; LAM KSL, 1986, CLIN ENDOCRINOL, V24, P643, DOI 10.1111/j.1365-2265.1986.tb01660.x; LAM KSL, 1987, J CLIN ENDOCR METAB, V64, P418, DOI 10.1210/jcem-64-3-418; MILNER RDG, 1982, ARCH DIS CHILD, V57, P944, DOI 10.1136/adc.57.12.944; SCHRIOCK EA, 1984, J CLIN ENDOCR METAB, V58, P1043, DOI 10.1210/jcem-58-6-1043; STACPOOLE PW, 1982, MEDICINE, V61, P13, DOI 10.1097/00005792-198201000-00002; STEWART PM, 1988, LANCET, V1, P1208; TANDON PN, 1978, HDB CLIN NEUROLOGY I, P193; TSUKADA T, 1984, J CLIN ENDOCR METAB, V58, P758, DOI 10.1210/jcem-58-4-758; WASS JAH, 1989, ENDOCRINOLOGY, P492; WASZHOCKERT O, 1962, ACTA PAEDIAT S141, V51, P26	16	24	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					701	706		10.7326/0003-4819-118-9-199305010-00007	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460856				2022-12-28	WOS:A1993KY50200007
J	BLACK, WC; WELCH, HG				BLACK, WC; WELCH, HG			ADVANCES IN DIAGNOSTIC-IMAGING AND OVERESTIMATIONS OF DISEASE PREVALENCE AND THE BENEFITS OF THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LUNG-CANCER DETECTION; ABDOMINAL AORTIC-ANEURYSMS; DIGITAL RECTAL EXAMINATION; RENAL-CELL CARCINOMA; BREAST-CANCER; PHYSICAL-EXAMINATION; PROSTATE-CANCER; FOLLOW-UP; POPULATION; TRIAL		DARTMOUTH HITCHCOCK MED CTR,DEPT RADIOL,LEBANON,NH; VET AFFAIRS HOSP,MED SERV,WHITE RIVER JCT,VT	Dartmouth College	BLACK, WC (corresponding author), DARTMOUTH COLL SCH MED,CTR EVALUAT CLIN SCI,318 STRAUSENBURGH HALL,HANOVER,NH 03755, USA.			Welch, H. Gilbert/0000-0002-3448-1207				ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; BLACK WC, 1990, AM J ROENTGENOL, V155, P625, DOI 10.2214/ajr.155.3.2117366; BLACK WC, 1990, MED DECIS MAKING, V10, P226; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BOSNIAK MA, 1991, RADIOLOGY, V181, P289; BOTTIGER L. E., 1964, ACTA CHIR SCAND, V127, P158; COLE P, 1980, JNCI-J NATL CANCER I, V64, P1263; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; FEINLEIB M, 1969, ARCH ENVIRON HEALTH, V19, P412, DOI 10.1080/00039896.1969.10666863; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P597; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FLEHINGER BJ, 1984, AM REV RESPIR DIS, V130, P555; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; GRAUNT J, 1988, WORLD MATH, V3, P1399; GRINNELL R S, 1958, Int Abstr Surg, V106, P519; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; HEALY ME, 1987, RADIOLOGY, V165, P619, DOI 10.1148/radiology.165.3.3317496; HELLSTEN S, 1981, SCAND J UROL NEPHROL, V15, P269, DOI 10.3109/00365598109179615; HICKS MJ, 1979, JAMA-J AM MED ASSOC, V242, P2080, DOI 10.1001/jama.242.19.2080; HOPPER KD, 1991, INVEST RADIOL, V26, P939, DOI 10.1097/00004424-199111000-00004; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; KOPANS DB, 1992, AM J ROENTGENOL, V158, P521, DOI 10.2214/ajr.158.3.1310825; KORNICK J, 1990, RADIOLOGY, V177, P463, DOI 10.1148/radiology.177.2.2217786; KUBIK A, 1986, CANCER-AM CANCER SOC, V57, P2427, DOI 10.1002/1097-0142(19860615)57:12<2427::AID-CNCR2820571230>3.0.CO;2-M; KUBIK A, 1990, INT J CANCER, V45, P26, DOI 10.1002/ijc.2910450107; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; LEE F, 1988, RADIOLOGY, V168, P389, DOI 10.1148/radiology.168.2.3293108; LINVER MN, 1992, RADIOLOGY, V184, P39, DOI 10.1148/radiology.184.1.1609100; LINVER MN, 1992, RADIOLOGY, V184, P878; Mandelbrot B. B., 1983, FRACTAL GEOMETRY NAT, P116; MARTINI N, 1986, CHEST, V89, pS325, DOI 10.1378/chest.89.4_Supplement.325S; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; MEYER JE, 1990, JAMA-J AM MED ASSOC, V263, P2341, DOI 10.1001/jama.263.17.2341; MILLER AB, 1991, BREAST, P419; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; MONTIE JE, 1989, CANCER, V63, P381, DOI 10.1002/1097-0142(19890115)63:2<381::AID-CNCR2820630230>3.0.CO;2-O; MORRISON AS, 1985, MONOGRAPHS EPIDEMIOL, V7, P22; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; REINIG JW, 1987, RADIOLOGY, V162, P43, DOI 10.1148/radiology.162.1.3786786; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SANDERSON DR, 1986, CHEST, V89, pS324, DOI 10.1378/chest.89.4_Supplement.324S; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; SEIDMAN H, 1985, CA-CANCER J CLIN, V35, P36, DOI 10.3322/canjclin.35.1.36; SHAPIRO S, 1977, CANCER, V39, P2772, DOI 10.1002/1097-0142(197706)39:6<2772::AID-CNCR2820390665>3.0.CO;2-K; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SICKLES EA, 1991, RADIOLOGY, V179, P463, DOI 10.1148/radiology.179.2.2014293; SMITH SJ, 1989, RADIOLOGY, V170, P699, DOI 10.1148/radiology.170.3.2644658; STACEYCLEAR A, 1992, LANCET, V340, P991; TOCKMAN MS, 1986, CHEST, V89, pS324, DOI 10.1378/chest.89.4_Supplement.324S-a; VACCARO JP, 1990, RADIOLOGY, V175, P645, DOI 10.1148/radiology.175.3.2188294; WHITE E, 1990, J NATL CANCER I, V82, P1524; XIPELL JM, 1971, J UROLOGY, V106, P503, DOI 10.1016/S0022-5347(17)61327-2; 1986, DHHS PHS881114 PUBL; 1988, DORLANDS ILLUSTRATED, P261	57	430	437	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1237	1243		10.1056/NEJM199304293281706	http://dx.doi.org/10.1056/NEJM199304293281706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464435				2022-12-28	WOS:A1993KZ06100006
J	THIBAULT, GE				THIBAULT, GE			TOO OLD FOR WHAT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ARTERY BYPASS-SURGERY; OCTOGENARIANS; AGE				THIBAULT, GE (corresponding author), VET AFFAIRS MED CTR, 1400 VFW PKY, BOSTON, MA 02132 USA.							ABRAMS FR, 1993, NEW ENGL J MED, V328, P975, DOI 10.1056/NEJM199304013281320; BARRINGER F, 1992, NY TIMES        1110, pA1; EDMUNDS LH, 1988, NEW ENGL J MED, V319, P131, DOI 10.1056/NEJM198807213190302; GERSH BJ, 1983, CIRCULATION, V68, P190; HORNEFFER PJ, 1987, CIRCULATION, V76, P6; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; LEVINSON JR, 1989, CIRCULATION, V80, P49; MORROW AG, 1968, ANN INTERN MED, V69, P1255, DOI 10.7326/0003-4819-69-6-1255; NAUNHEIM KS, 1987, AM J CARDIOL, V59, P804, DOI 10.1016/0002-9149(87)91095-2; POKORSKI RJ, 1988, J INSUR MED, V20, P20; ROSE DM, 1985, AM HEART J, V110, P341, DOI 10.1016/0002-8703(85)90154-1; THIBAULT GE, 1989, PRACTICE CARDIOLOGY, P701; TSAI TP, 1986, J THORAC CARDIOV SUR, V91, P924; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WONG JB, 1993, NEW ENGL J MED, V328, P971, DOI 10.1056/NEJM199304013281319	15	25	25	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 1	1993	328	13					946	950		10.1056/NEJM199304013281309	http://dx.doi.org/10.1056/NEJM199304013281309			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU177	8446143				2022-12-28	WOS:A1993KU17700009
J	ZHANG, LH; MURPHY, PJ; KERR, A; TATE, ME				ZHANG, LH; MURPHY, PJ; KERR, A; TATE, ME			AGROBACTERIUM CONJUGATION AND GENE-REGULATION BY N-ACYL-L-HOMOSERINE LACTONES	NATURE			English	Article							STRUCTURAL IDENTIFICATION; TI-PLASMID; AUTOINDUCER; FISCHERI	CONJUGAL opines secreted by crown gall tumours induce strains of Agrobacterium tumefaciens that are donors of Ti plasmids to produce a diffusible conjugation factor1. This enhances the conjugal transfer efficiency of the Ti plasmid in other strains of A. tumefaciens. This factor behaves as a secondary messenger, transmitting the environmental information to tra genes. Here we report the use of spectrometry to show that this factor is identical to synthetic N-(beta-oxo-octan-1-oyl)-L-homoserine lactone and confirm that the synthetic compound is biologically active. N-(Hexan-1-oyl)-L-homoserine lactone has also been detected. A closely related molecule, N-(beta-oxo-hexan-1-oyl)-L-homoserine lactone, autoinduces bioluminescence in the distantly related bacterium, Vibrio fischeri2. N-Acyl-homoserine lactones thus seem to be conserved molecules in which the length and nature of the lipophilic acyl chain determines the biological function to be regulated. Mutants that do not produce the factor fail to conjugate unless supplied with it in the induction medium (our unpublished data). These data indicate that the conjugation factor is an autoinducer and a key signal molecule in the conjugation system of A. tumefaciens. It is, to our knowledge, the first example of a second messenger molecule in a bacterial conjugation system.	UNIV ADELAIDE,WAITE AGR RES INST,DEPT CROP PROTECT,GLEN OSMOND,SA 5064,AUSTRALIA; UNIV ADELAIDE,WAITE AGR RES INST,DEPT PLANT SCI,GLEN OSMOND,SA 5064,AUSTRALIA	University of Adelaide; University of Adelaide								BAINTON NJ, 1992, GENE, V116, P87, DOI 10.1016/0378-1119(92)90633-Z; CAO JG, 1989, J BIOL CHEM, V264, P21670; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; EBERHARD A, 1986, ARCH MICROBIOL, V146, P35, DOI 10.1007/BF00690155; Miller J. H, 1972, EXPT MOL GENETICS; OIKAWA Y, 1978, J ORG CHEM, V43, P2087, DOI 10.1021/jo00404a066; PETIT A, 1978, MOL GEN GENET, V167, P147, DOI 10.1007/BF00266908; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; STACHEL SE, 1985, EMBO J, V4, P891, DOI 10.1002/j.1460-2075.1985.tb03715.x; STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041; ZHANG LH, 1991, J BACTERIOL, V173, P1867, DOI 10.1128/jb.173.6.1867-1872.1991	11	368	401	3	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					446	448		10.1038/362446a0	http://dx.doi.org/10.1038/362446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8464475				2022-12-28	WOS:A1993KV42400082
J	MCKIM, KS; JANG, JK; THEURKAUF, WE; HAWLEY, RS				MCKIM, KS; JANG, JK; THEURKAUF, WE; HAWLEY, RS			MECHANICAL BASIS OF MEIOTIC METAPHASE ARREST	NATURE			English	Article							DROSOPHILA-MELANOGASTER; SEGREGATION	CONTROL of the metaphase to anaphase transition is a central component of cell-cycle regulation. Arrest at either metaphase I or II before fertilization is a common component of oogenesis in many organisms1. In Drosophila melanogaster females, this arrest occurs at meiosis I with the chiasmate bivalents tightly massed at the metaphase plate and the nonexchange chromosomes positioned between the plate and the poles on long tapered spindles2. Meiosis resumes only after passage through the oviduct 3,4. Thus, metaphase arrest defines an important checkpoint in the meiotic cell cycle'. We report here that this arrest results from the balancing of chiasmate bivalents at the metaphase plate. Two meiotic mutations, mei-9b and mei-218a4, both of which greatly reduce the frequency of chiasma formation, bypass the metaphase block and allow stage 14 oocytes to finish both meiotic divisions without arrest. We conclude that metaphase arrest results from the balancing of kinetochore forces due to chiasmata.	UNIV CALIF DAVIS,DEPT GENET,DAVIS,CA 95616; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	University of California System; University of California Davis; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Theurkauf, William/0000-0001-7342-1912; Hawley, R. Scott/0000-0002-6478-0494				Baker BS, 1976, GENETICS BIOL DROS B, P351; CARPENTER AT, 1974, GENETICS, V76, P453; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1984, COLD SPRING HARB SYM, V49, P23, DOI 10.1101/SQB.1984.049.01.005; CARPENTER ATC, 1972, GENETICS, V71, P255; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; King R. C., 1970, OVARIAN DEV DROSOPHI; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1974, GENETICS, V78, P205; PURO J, 1977, CHROMOSOMA, V63, P273, DOI 10.1007/BF00327454; Sonnenblick BP, 1965, BIOLOGY DROSOPHILA, P62; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; ZHANG P, 1990, GENETICS, V125, P115	14	70	70	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					364	366		10.1038/362364a0	http://dx.doi.org/10.1038/362364a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455723				2022-12-28	WOS:A1993KU17600068
J	POULTER, NR; SANDERSON, JE; THOMPSON, AV; SEVER, PS; CHANG, CL				POULTER, NR; SANDERSON, JE; THOMPSON, AV; SEVER, PS; CHANG, CL			COMPARISON OF NIFEDIPINE AND PROPRANOLOL AS 2ND LINE AGENT FOR HYPERTENSION IN BLACK KENYANS	BRITISH MEDICAL JOURNAL			English	Article							TRIAL		WELLCOME TRUST RES LABS,NAIROBI,KENYA									ERNE P, 1983, HYPERTENSION S2, V5, pS97; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; POULTER N, 1986, J HYPERTENS, V4, P792, DOI 10.1097/00004872-198612000-00021; SEEDAT YK, 1980, BRIT MED J, V281, P1241, DOI 10.1136/bmj.281.6250.1241; ZING W, 1991, ARCH INTERN MED, V151, P2154, DOI 10.1001/archinte.151.11.2154	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					621	622		10.1136/bmj.306.6878.621	http://dx.doi.org/10.1136/bmj.306.6878.621			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461812	Green Published, Bronze			2022-12-28	WOS:A1993KQ85900020
J	PRINGLE, M; STEWARTEVANS, C; COUPLAND, C; WILLIAMS, I; ALLISON, S; STERLAND, J				PRINGLE, M; STEWARTEVANS, C; COUPLAND, C; WILLIAMS, I; ALLISON, S; STERLAND, J			INFLUENCES ON CONTROL IN DIABETES-MELLITUS - PATIENT, DOCTOR, PRACTICE, OR DELIVERY OF CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MANAGEMENT; PREVALENCE; KNOWLEDGE; LONDON	Objective-To assess patient, doctor, practice, and process of care variables for their effect on glycaemic control in diabetes mellitus, and to quantify their relative effects. Design-Search of general practice medical records, patient questionnaires and examination, doctor questionnaire, videotaping and analysis of consultations, and practice questionnaire. Setting- 12 practices with 32 participating general practitioners in Nottinghamshire. Subjects-318 patients randomly selected from those with diabetes in each practice, 10 for each participating doctor. Main outcome measure-Glycaemic control as measured by random glycated haemoglobin A1c estimation (random haemoglobin A1 measurement). Results-Glycaemic control was significantly related to the disease process as measured by years since diagnosis, treatment group, and number of diabetes related clinical events. Females had significantly worse control than males. Other patient factors, such as age, social class, lifestyle, attitudes, satisfaction, and knowledge, had no association with glycaemic control. Of all the doctor factors examined, only doctors who professed a special interest in diabetes achieved significantly better glycaemic control. Bigger and better equipped practices and those with a diabetic miniclinic had patients with significantly better glycaemic control, as did those with access to dietetic advice. Patients attending hospital clinics had worse glycaemic control, but this seemed to be attributable to the case mix and practice characteristics. Shared care did not contribute to the multiple linear regression model. Conclusion-Glycaemic control among diabetic patients in the community is related to such factors as treatment group, sex, and years since diagnosis; it is also related to the organisation and process of care. The findings support concentrating diabetic care on partners with special interests in diabetes in well equipped practices with adequate dietetic support.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,SCH MED,DEPT PUBL HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,SCH MED,DEPT MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham; University of Nottingham	PRINGLE, M (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,SCH MED,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.			Coupland, Carol/0000-0002-2327-3306				BASDEVANT A, 1982, DIABETOLOGIA, V22, P309; Bradley C, 1984, Diabet Med, V1, P213; BRADLEY C, 1986, DIABETES ANN; BURROWS PJ, 1987, J ROY COLL GEN PRACT, V37, P65; CAHILL GF, 1976, NEW ENGL J MED, V294, P1004, DOI 10.1056/NEJM197604292941811; CHESOVER D, 1991, BRIT J GEN PRACT, V41, P282; FOULKES A, 1989, J ROY COLL GEN PRACT, V39, P444; GATLING W, 1985, J R COLL PHYSICIANS, V4, P248; GIBBINS RL, 1988, BRIT MED J, V297, P187, DOI 10.1136/bmj.297.6642.187; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; HESS GE, 1983, DIABETES CARE, V6, P591, DOI 10.2337/diacare.6.6.591; HOLMAN RR, 1983, LANCET, V1, P204; KINMONTH AL, 1989, FAM PRACT, V6, P193, DOI 10.1093/fampra/6.3.193; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MCCANCE DR, 1989, LANCET, V2, P824; NEIL HAW, 1987, DIABETIC MED, V4, P539, DOI 10.1111/j.1464-5491.1987.tb00926.x; Pendleton D., 1984, CONSULTATION APPROAC; PICKUP J, 1988, BMJ-BRIT MED J, V297, P929, DOI 10.1136/bmj.297.6654.929; PRINGLE M, 1990, BRIT J GEN PRACT, V40, P455; RASKIN P, 1986, ANN INTERN MED, V105, P254, DOI 10.7326/0003-4819-105-2-254; ROBINSON N, 1985, J PSYCHOSOM RES, V29, P583, DOI 10.1016/0022-3999(85)90067-4; RUTTEN G, 1990, FAM PRACT, V7, P273, DOI 10.1093/fampra/7.4.273; SINGH BM, 1984, BRIT MED J, V289, P726, DOI 10.1136/bmj.289.6447.726; THORN PA, 1982, BRIT MED J, V285, P787, DOI 10.1136/bmj.285.6344.787; WATKINS PJ, 1983, BRIT MED J, V286, P269, DOI 10.1136/bmj.286.6361.269; WEINBERGER M, 1984, SOC SCI MED, V19, P965, DOI 10.1016/0277-9536(84)90326-5; Wilkes E, 1980, J R Coll Gen Pract, V30, P199; Wood J, 1990, Health Trends, V22, P39; YUDKIN JS, 1980, J EPIDEMIOL COMMUN H, V34, P277, DOI 10.1136/jech.34.4.277; 1986, ADM MANUAL 16 PERSON	30	128	130	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					630	634		10.1136/bmj.306.6878.630	http://dx.doi.org/10.1136/bmj.306.6878.630			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461816	Bronze, Green Published			2022-12-28	WOS:A1993KQ85900024
J	FLEISSIG, A				FLEISSIG, A			PREVALENCE OF PROCEDURES IN CHILDBIRTH	BRITISH MEDICAL JOURNAL			English	Article							MATERNITY				FLEISSIG, A (corresponding author), INST SOCIAL STUDIES MED CARE,LONDON NW3 2SB,ENGLAND.							Chalmers I, 1989, EFFECTIVE CARE PREGN; CLARK L, 1991, BRIT J OBSTET GYNAEC, V98, P519, DOI 10.1111/j.1471-0528.1991.tb10362.x; MACARTHUR C, 1991, HLTH CHILDBIRTH; MARTIN CJ, 1987, STAT MED, V6, P613, DOI 10.1002/sim.4780060510; 1992, 2ND REPORT MATERNITY	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					494	495		10.1136/bmj.306.6876.494	http://dx.doi.org/10.1136/bmj.306.6876.494			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448462	Bronze, Green Published			2022-12-28	WOS:A1993KN78600021
J	GLASZIOU, PP; MACKERRAS, DEM				GLASZIOU, PP; MACKERRAS, DEM			VITAMIN-A SUPPLEMENTATION IN INFECTIOUS-DISEASES - A METAANALYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIAL; SOUTHERN INDIA; CHILDREN; MORTALITY; MORBIDITY; MEASLES; PRESCHOOL; DIARRHEA; EFFICACY	Objective-To study the effect of vitamin A supplementation on morbidity and mortality from infectious disease. Design-A meta-analysis aimed at identifying and combining mortality and morbidity data from all randomised controlled trials of vitamin A. Results-Of 20 controlled trials identified, 12 trials were randomised trials and provided ''intention to treat'' data: six community trials in developing countries, three in children admitted to hospital with measles, and three in very low birth weight infants. Combined results for community studies suggest a reduction of 30% (95% confidence interval 21% to 38%; two tailed p < 0.0000001) in all cause mortality. Analysis of cause specific mortality showed a reduction in deaths from diarrhoeal disease (in community studies) by 39% (24% to 50%; two tailed p < 0.00001); from respiratory disease (in measles studies) by 70% (15% to 90%; two tailed p=0.02); and from other causes of death (in community studies) by 34% (15% to 48%; two tailed p=0.001). Reductions in morbidity were consistent with the findings for mortality. but fewer data were available. Conclusions-Adequate supply of vitamin A, either through supplementation or adequate diet, has a major role in preventing morbidity and mortality in children in developing countries. In developed countries vitamin A may also have a role in those with life threatening infections such as measles and those who may have a relative deficiency, such as premature infants.	UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney	GLASZIOU, PP (corresponding author), UNIV QUEENSLAND, SCH MED, DEPT SOCIAL & PREVENT MED, HERSTON, QLD 4006, AUSTRALIA.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X				ABDELJABER MH, 1991, AM J PUBLIC HEALTH, V81, P1654, DOI 10.2105/AJPH.81.12.1654; ARTHUR P, 1992, LANCET, V339, P361, DOI 10.1016/0140-6736(92)91677-Z; BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; BLOEM MW, 1990, AM J EPIDEMIOL, V131, P332, DOI 10.1093/oxfordjournals.aje.a115502; BRESLOW N, 1979, IARC SCI PUBLICATION, V32; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; DARNTON-HILL I, 1988, Food and Nutrition Bulletin, V10, P60; DAULAIRE NMP, 1992, BMJ-BRIT MED J, V304, P207, DOI 10.1136/bmj.304.6821.207; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; Ellison JB, 1932, BRIT MED J, V1932, P708, DOI 10.1136/bmj.2.3745.708; Green HN, 1928, BRIT MED J, V1928, P691, DOI 10.1136/bmj.2.3537.691; HENNING B, 1992, EUR J CLIN NUTR, V46, P437; HERRERA MG, 1992, LANCET, V340, P267, DOI 10.1016/0140-6736(92)92357-L; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; KOTHARI G, 1991, J TROP PEDIATRICS, V37, P141, DOI 10.1093/tropej/37.3.141; MUHILAL, 1988, AM J CLIN NUTR, V48, P1271, DOI 10.1093/ajcn/48.5.1271; PAPAGAROUFALIS C, 1991, J PERINAT MED, V19, P382; PAPAGAROUFALIS C, 1988, Pediatric Research, V23, p518A; PATEL MS, 1990, UNICEF5 STAFF WORK P; PINNOCK CB, 1988, AUST PAEDIATR J, V24, P286; PINNOCK CB, 1986, AUST PAEDIATR J, V22, P95; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; RAHMATHULLAH L, 1991, AM J CLIN NUTR, V54, P568, DOI 10.1093/ajcn/54.3.568; REDDY V, 1991, LANCET, V337, P232; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SHENAI JP, 1987, J PEDIATR-US, V111, P269, DOI 10.1016/S0022-3476(87)80086-0; SOMMER A, 1991, STAT MED, V10, P45, DOI 10.1002/sim.4780100110; SOMMER A, 1986, LANCET, V1, P1169; THURNHAM DI, 1991, LANCET, V337, P232, DOI 10.1016/0140-6736(91)92191-4; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; VITAMIN A, 1990, LANCET, V336, P1349; WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6; 1989, STATEXACT STATISTICA; 1987, WKLY EPIDEMIOL REC, V62, P133	35	219	225	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 6	1993	306	6874					366	370		10.1136/bmj.306.6874.366	http://dx.doi.org/10.1136/bmj.306.6874.366			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461682	Green Published, Bronze			2022-12-28	WOS:A1993KL71500019
J	MIENTJES, GHC; VANAMEIJDEN, EJC; WEIGEL, HM; VANDENHOEK, JAR; COUTINHO, RA				MIENTJES, GHC; VANAMEIJDEN, EJC; WEIGEL, HM; VANDENHOEK, JAR; COUTINHO, RA			CLINICAL SYMPTOMS ASSOCIATED WITH SEROCONVERSION FOR HIV-1 AMONG MISUSERS OF INTRAVENOUS DRUGS - COMPARISON WITH HOMOSEXUAL SEROCONVERTERS AND INFECTED AND NONINFECTED INTRAVENOUS DRUG MISUSERS	BRITISH MEDICAL JOURNAL			English	Article							AIDS-RELATED COMPLEX; USERS; DEFICIENCY; AMSTERDAM; ABUSERS	Objective-To study the clinical symptoms associated with seroconversion for HIV-1 among misusers of intravenous drugs. Design-Case-control study in cohorts of drug misusers and homosexual men. Setting-Outpatient clinic, Municipal Health Service, Amsterdam. Subjects-Misusers of intravenous drugs from our prospective cohort who seroconverted for HIV. Controls were drug users positive for HIV, drug users negative for HIV, and homosexual men who had seroconverted. Results-Five out of 18 (28%) drug users were admitted to hospital with bacterial pneumonia in the four to six months between their last visit at which they were HIV negative and their first visit when they were HIV positive. For comparison none of the 27 homosexual men who seroconverted for HIV, three out of 177 (2%) drug users negative for HIV, and 10 out of 112 (9%) drug users positive for HIV reported bacterial pneumonia. One out of the 18 drug users who seroconverted suffered from oesophageal candidiasis at the time of seroconversion. Other clinical symptoms did not differ between drug users who seroconverted and those who remained negative for HIV, probably due to the high background morbidity among the drug users. Conclusions-Seroconversion to HIV-1 among intravenous drug misusers is associated with bacterial pneumonia. Those drug users with previously negative test results for HIV who are admitted to hospital for bacterial pneumonia should be tested to detect primary infection with HIV-1.	HOSP ONZE LIEVE VROUWE GASTHUIS,AMSTERDAM,NETHERLANDS		MIENTJES, GHC (corresponding author), MUNICIPAL HLTH SERV,DEPT PUBL HLTH & ENVIRONM,POB 20244,1000 HE AMSTERDAM,NETHERLANDS.							BLOEMENA E, 1989, J IMMUNOL METHODS, V122, P161, DOI 10.1016/0022-1759(89)90260-3; DEJONG MD, 1991, GENITOURIN MED, V67, P367; DEWOLF F, 1989, AIDS, V3, P235; LOURIA DB, 1967, ANN INTERN MED, V67, P1, DOI 10.7326/0003-4819-67-1-1; MANOS GE, 1990, LANCET, V336, P939, DOI 10.1016/0140-6736(90)92308-5; MIENTJES GH, 1992, AIDS, V6, P207, DOI 10.1097/00002030-199202000-00012; MIENTJES GH, 1991, AIDS, V5, P35, DOI 10.1097/00002030-199101000-00005; PARKIN JM, 1989, AIDS, V3, P37, DOI 10.1097/00002030-198903010-00008; PENA JM, 1991, REV INFECT DIS, V13, P872; SCHEIDEGGER C, 1989, REV INFECT DIS, V11, P486; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; TINDALL B, 1989, AIDS, V3, P747, DOI 10.1097/00002030-198911000-00010; VANDENHOEK JAR, 1988, AIDS, V2, P55, DOI 10.1097/00002030-198802000-00010; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1	14	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					371	373		10.1136/bmj.306.6874.371	http://dx.doi.org/10.1136/bmj.306.6874.371			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461683	Green Published, Bronze			2022-12-28	WOS:A1993KL71500020
J	BUTLAND, G				BUTLAND, G			THE FUTURE OF FHSAS - COMMISSIONING FOR QUALITY	BRITISH MEDICAL JOURNAL			English	Article											BUTLAND, G (corresponding author), ESSEX FAMILY HLTH SERV AUTHOR,CLACTON ON SEA CO15 6QD,ESSEX,ENGLAND.							1992, QUALITY GENERAL PRAC; 1992, INQUIRY LONDONS HLTH	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					251	252		10.1136/bmj.306.6872.251	http://dx.doi.org/10.1136/bmj.306.6872.251			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443528	Green Published, Bronze			2022-12-28	WOS:A1993KJ59100025
J	LOWE, G; GREEN, C; JENNINGS, P				LOWE, G; GREEN, C; JENNINGS, P			HEPATITIS ASSOCIATED WITH TERBINAFINE TREATMENT	BRITISH MEDICAL JOURNAL			English	Letter											LOWE, G (corresponding author), NINEWELLS HOSP,DUNDEE DD1 9SY,SCOTLAND.							Villers V, 1990, J DERMATOL TREAT S2, V1, P33	1	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					248	248		10.1136/bmj.306.6872.248-a	http://dx.doi.org/10.1136/bmj.306.6872.248-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443524	Green Published, Bronze			2022-12-28	WOS:A1993KJ59100022
J	GILBERT, RE; TOOKEY, PA; CUBITT, WD; ADES, AE; MASTERS, J; PECKHAM, CS				GILBERT, RE; TOOKEY, PA; CUBITT, WD; ADES, AE; MASTERS, J; PECKHAM, CS			PREVALENCE OF TOXOPLASMA IGG AMONG PREGNANT-WOMEN IN WEST LONDON ACCORDING TO COUNTRY OF BIRTH AND ETHNIC-GROUP	BRITISH MEDICAL JOURNAL			English	Article									HOSP SICK CHILDREN,DEPT VIROL,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	GILBERT, RE (corresponding author), INST CHILD HLTH,EPIDEMIOL & BIOSTAT UNIT,LONDON WC1N 1EH,ENGLAND.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gilbert, Ruth/0000-0001-9347-2709				ADES AE, 1992, EPIDEMIOL INFECT, V108, P367, DOI 10.1017/S0950268800049839; CUBITT WD, 1992, J CLIN PATHOL, V45, P435, DOI 10.1136/jcp.45.5.435; FORSGREN M, 1991, LANCET, V337, P1413, DOI 10.1016/0140-6736(91)93095-Q; REMINGTON JS, 1990, INFECT DIS, P90; WALKER J, 1992, EPIDEMIOL INFECT, V108, P99, DOI 10.1017/S0950268800049542	5	22	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					185	185		10.1136/bmj.306.6871.185	http://dx.doi.org/10.1136/bmj.306.6871.185			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443482	Bronze, Green Published			2022-12-28	WOS:A1993KH51300023
J	MARKELLO, TC; BERNARDINI, IM; GAHL, WA				MARKELLO, TC; BERNARDINI, IM; GAHL, WA			IMPROVED RENAL-FUNCTION IN CHILDREN WITH CYSTINOSIS TREATED WITH CYSTEAMINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEPHROPATHIC CYSTINOSIS; SERUM CREATININE; COMPLICATIONS; INSUFFICIENCY; PATIENT; AGE	Background. The lysosomal storage disease cystinosis results in renal failure at approximately 10 years of age. Although oral cysteamine therapy is recognized to preserve kidney function, the extent of renal benefit has not been determined. Methods. Between 1960 and 1992, we determined 24-hour creatinine clearances in 76 children with cystinosis during 1081 admissions to the National Institutes of Health. Seventeen children were considered to have received adequate treatment with cysteamine, since they had depletion of cystine from leukocytes and began therapy before the age of 2 years; treatment lasted a mean of 7.1 years. Thirty-two children were considered to have received partial treatment, since they had poor compliance with therapy or began treatment after the age of 2; treatment lasted a mean of 4.5 years. Twenty-seven children were followed in the era before cysteamine therapy and thus never received cysteamine. Results. Of the 27 children who never received cysteamine, 16 were followed at the National Institutes of Health until renal failure occurred: their mean (+/-SD) creatinine clearance was 8.0+/-4.8 ml per minute per 1.73 m2 of body-surface area at a mean age of 8.3+/-1.9 years. Of the 17 children who received adequate treatment, none had renal failure; their mean creatinine clearance was 57+/-20 ml per minute per 1.73 m2 at 8.3+/-3.8 years of age. The mean creatinine clearance of the children who received partial or adequate treatment with cysteamine increased with age up to the age of five years and then declined linearly with age at a normal rate. For the children who received adequate treatment, the mean creatinine clearance was predicted to reach 0 ml per minute per 1.73 m2 at the age of 74 years, as compared with 20 years of age for the children who received partial treatment. With no therapy, the mean creatinine clearance reaches 0 ml per minute per 1.73 m2 at 10 years of age. Conclusions. Children with cystinosis who are treated early and adequately with cysteamine have renal function that increases during the first five years of life and then declines at a normal rate. Patients with poorer compliance and those who are treated at an older age do less well.	NICHHD, HUMAN GENET BRANCH,HUMAN BIOL CHEM & GENET SECT, BLDG 10,RM 9S-242, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ANDERSSON HC, 1992, J PEDIATR-US, V120, P716, DOI 10.1016/S0022-3476(05)80233-1; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P1542; Brodehl J, 1973, Clin Nephrol, V1, P149; CLARK KF, 1992, CLIN RES, V40, pA113; FINK JK, 1989, ARCH NEUROL-CHICAGO, V46, P543, DOI 10.1001/archneur.1989.00520410077027; FIVUSH B, 1988, J PEDIATR-US, V112, P49, DOI 10.1016/S0022-3476(88)80119-7; FIVUSH B, 1987, AM J DIS CHILD, V141, P1087, DOI 10.1001/archpedi.1987.04460100065027; Gahl W A, 1986, Adv Pediatr, V33, P95; GAHL WA, 1990, PEDIATR NEPHROL, V4, P129, DOI 10.1007/BF00858823; GAHL WA, 1987, NEW ENGL J MED, V316, P971, DOI 10.1056/NEJM198704163161602; GAHL WA, 1982, J BIOL CHEM, V257, P9570; GAHL WA, 1987, PEDIATR NEPHROL, V1, P260, DOI 10.1007/BF00849221; GAHL WA, 1988, NEW ENGL J MED, V319, P1461, DOI 10.1056/NEJM198812013192206; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; GAHL WA, 1989, METABOLIC BASIS INHE, V2, P2619; GRETZ N, 1982, P EUR DIAL TRANS, V19, P582; HEINEGAR.D, 1973, CLIN CHIM ACTA, V43, P305, DOI 10.1016/0009-8981(73)90466-X; JONAS AJ, 1987, AM J MED, V83, P966, DOI 10.1016/0002-9343(87)90661-9; JONAS AJ, 1982, J BIOL CHEM, V257, P13185; JONES RH, 1991, BIOMETRICS, V47, P161, DOI 10.2307/2532504; KAISERKUPFER MI, 1987, NEW ENGL J MED, V316, P775, DOI 10.1056/NEJM198703263161304; KAISERKUPFER MI, 1990, ARCH OPHTHALMOL-CHIC, V108, P689, DOI 10.1001/archopht.1990.01070070075038; KAISERKUPFER MI, 1986, ARCH OPHTHALMOL-CHIC, V104, P706, DOI 10.1001/archopht.1986.01050170096030; KRASNEWICH DM, 1991, ENDOCRINOLOGIST, V1, P111; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; SMOLIN LA, 1988, PEDIATR RES, V23, P616, DOI 10.1203/00006450-198806000-00018; SONIES BC, 1990, NEW ENGL J MED, V323, P565, DOI 10.1056/NEJM199008303230903; THOENE JG, 1976, J CLIN INVEST, V58, P180, DOI 10.1172/JCI108448; WINBERG J, 1959, Acta Paediatr, V48, P443	30	209	221	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1157	1162		10.1056/NEJM199304223281604	http://dx.doi.org/10.1056/NEJM199304223281604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY447	8455682				2022-12-28	WOS:A1993KY44700004
J	BLUM, ML; DOWN, JA; GURNETT, AM; CARRINGTON, M; TURNER, MJ; WILEY, DC				BLUM, ML; DOWN, JA; GURNETT, AM; CARRINGTON, M; TURNER, MJ; WILEY, DC			A STRUCTURAL MOTIF IN THE VARIANT SURFACE GLYCOPROTEINS OF TRYPANOSOMA-BRUCEI	NATURE			English	Article							AMINO-ACID SEQUENCES; ANTIGENIC VARIATION; POINT MUTATIONS; PROTEINS; DOMAINS; GENES; VIRUS; PURIFICATION; RECOGNITION; RHODESIENSE	The variable domain of the trypanosome variant surface glycoprotein (VSG) ILTat 1.24 has been shown by X-ray crystallography to resemble closely the structures of VSG MITat 1.2, despite their low sequence similarity. Specific structural features of these VSGs, including substitution of carbohydrate for an alpha-helix, can be found in other VSG sequences. Thus antigenic variation in trypanosomes is accomplished by sequence variation, not gross structural alteration; the extensive sequence differences among VSGs may be required for another reason, such as the avoidance of recognition by helper T cells. Additionally, VSG sequences are found to define families, within a VSG superfamily, which have evolved in the trypanosome genome.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	Harvard University; Howard Hughes Medical Institute; Harvard University; Merck & Company; University of Cambridge			Carrington, Mark/N-4892-2018; Carrington, Mark/N-3653-2019	Carrington, Mark/0000-0002-6435-7266; Carrington, Mark/0000-0002-6435-7266				ALLEN G, 1983, BIOCHEM J, V209, P481, DOI 10.1042/bj2090481; BALTZ T, 1991, EMBO J, V10, P1653, DOI 10.1002/j.1460-2075.1991.tb07688.x; BLUM M, 1990, THESIS HARVARD U; BOOTHROYD JC, 1982, J MOL BIOL, V157, P547, DOI 10.1016/0022-2836(82)90475-2; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; CARRINGTON M, 1991, J MOL BIOL, V221, P823, DOI 10.1016/0022-2836(91)80178-W; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COHEN C, 1984, NATURE, V311, P169, DOI 10.1038/311169a0; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Donelson J E, 1987, Contrib Microbiol Immunol, V8, P138; DONELSON JE, 1985, MICROBIOL REV, V49, P107, DOI 10.1128/MMBR.49.2.107-125.1985; FRASCH ACC, 1982, GENE, V17, P197, DOI 10.1016/0378-1119(82)90073-7; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; FREYMANN DM, 1988, THESIS HARVARD U; GUYAUX M, 1985, EMBO J, V4, P995, DOI 10.1002/j.1460-2075.1985.tb03729.x; HUBLART M, 1989, COMP BIOCHEM PHYS B, V92, P705, DOI 10.1016/0305-0491(89)90253-8; JOHNSON JG, 1979, BIOCHEM J, V178, P689, DOI 10.1042/bj1780689; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LALOR TM, 1984, P NATL ACAD SCI-BIOL, V81, P998, DOI 10.1073/pnas.81.4.998; LENARDO MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6642, DOI 10.1073/pnas.81.21.6642; LESK AM, 1986, PROTEIN ENG, V1, P77, DOI 10.1093/protein/1.1.77; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; MCLACHLAN AD, 1971, J MOL BIOL, V61, P409, DOI 10.1016/0022-2836(71)90390-1; METCALF P, 1987, NATURE, V325, P84, DOI 10.1038/325084a0; METCALF P, 1988, J BIOL CHEM, V263, P17030; MILLER EN, 1984, MOL BIOCHEM PARASIT, V13, P309, DOI 10.1016/0166-6851(84)90122-1; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; OLAFSON RW, 1984, MOL BIOCHEM PARASIT, V12, P287, DOI 10.1016/0166-6851(84)90085-9; ORCUTT BC, 1986, ALIGN; PAYS E, 1983, CELL, V34, P371, DOI 10.1016/0092-8674(83)90371-9; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; REDDY LV, 1990, BIOCHEM BIOPH RES CO, V169, P730, DOI 10.1016/0006-291X(90)90392-Z; REINITZ DM, 1990, INFECT IMMUN, V58, P2337, DOI 10.1128/IAI.58.7.2337-2342.1990; REINITZ DM, 1992, MOL BIOCHEM PARASIT, V51, P119, DOI 10.1016/0166-6851(92)90207-Z; RICEFICHT AC, 1982, NATURE, V298, P676, DOI 10.1038/298676a0; RICEFICHT AC, 1981, NATURE, V294, P53, DOI 10.1038/294053a0; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROOST HP, 1990, EUR J IMMUNOL, V20, P2547, DOI 10.1002/eji.1830201204; Ross R, 1910, P R SOC LOND B-CONTA, V82, P411, DOI 10.1098/rspb.1910.0035; ROSSMANN MG, 1976, J MOL BIOL, V105, P75, DOI 10.1016/0022-2836(76)90195-9; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; STRICKLER JE, 1987, BIOCHEMISTRY-US, V26, P796, DOI 10.1021/bi00377a021; SUBBIAH S, 1989, J MOL BIOL, V209, P539, DOI 10.1016/0022-2836(89)90592-5; THON G, 1989, GENE DEV, V3, P1247, DOI 10.1101/gad.3.8.1247; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; VICKERMAN K, 1969, J CELL SCI, V5, P163; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053	53	180	181	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					603	609		10.1038/362603a0	http://dx.doi.org/10.1038/362603a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8464512				2022-12-28	WOS:A1993KX43800037
J	QUIGLEY, HA				QUIGLEY, HA			MEDICAL PROGRESS - OPEN-ANGLE GLAUCOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OPTIC-NERVE HEAD; VISUAL-FIELD DEFECTS; ARGON-LASER TRABECULOPLASTY; RETINAL GANGLION-CELLS; FIBER ATROPHY PRECEDES; MESHWORK ORGAN-CULTURE; HUMAN LAMINA-CRIBROSA; TERM CLINICAL-TRIAL; INTRAOCULAR-PRESSURE; OCULAR HYPERTENSION		JOHNS HOPKINS UNIV,SCH MED,GLAUCOMA SERV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DANA CTR PREVENT OPHTHALMOL,WILMER OPHTHALMOL INST,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine								ACOTT TS, 1988, INVEST OPHTH VIS SCI, V29, P90; AGUAYO AJ, 1986, RETINAL SIGNAL SYSTE, P257; ALLEN RC, 1986, AM J OPHTHALMOL, V101, P535, DOI 10.1016/0002-9394(86)90942-6; ALVARADO J, 1981, INVEST OPHTH VIS SCI, V21, P714; ARMALY MF, 1980, ARCH OPHTHALMOL-CHIC, V98, P2163, DOI 10.1001/archopht.1980.01020041015002; ARMALY MF, 1965, ARCH OPHTHALMOL-CHIC, V73, P11, DOI 10.1001/archopht.1965.00970030013005; ARMALY MF, 1969, ARCH OPHTHALMOL-CHIC, V81, P25, DOI 10.1001/archopht.1969.00990010027005; BALAZSI AG, 1984, AM J OPHTHALMOL, V97, P760, DOI 10.1016/0002-9394(84)90509-9; BECKER B, 1960, AM J OPHTHALMOL, V50, P557, DOI 10.1016/0002-9394(60)90233-6; BECKMAN H, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P423; BENGTSSON B, 1981, BRIT J OPHTHALMOL, V65, P46, DOI 10.1136/bjo.65.1.46; BYLSMA SS, 1988, ARCH OPHTHALMOL-CHIC, V106, P544; CAPRIOLI J, 1984, AM J OPHTHALMOL, V97, P730, DOI 10.1016/0002-9394(84)90505-1; CAPRIOLI J, 1989, AM J OPHTHALMOL, V108, P404, DOI 10.1016/S0002-9394(14)73308-2; CAPRIOLI J, 1985, ARCH OPHTHALMOL-CHIC, V103, P1145; CINOTTI A, 1985, AM J OPHTHALMOL, V99, P11; COLEMAN AL, 1990, ARCH OPHTHALMOL-CHIC, V108, P1260, DOI 10.1001/archopht.1990.01070110076028; DANDONA L, 1991, INVEST OPHTH VIS SCI, V32, P1593; DANDONA L, 1990, ARCH OPHTHALMOL-CHIC, V108, P393, DOI 10.1001/archopht.1990.01070050091039; DAUBS JG, 1981, T OPHTHAL SOC UK, V101, P121; DIEHL DLC, 1990, ARCH OPHTHALMOL-CHIC, V108, P545, DOI 10.1001/archopht.1990.01070060093056; DRANCE SM, 1977, ARCH OPHTHALMOL-CHIC, V95, P226; DRANCE SM, 1981, ARCH OPHTHALMOL-CHIC, V99, P1019, DOI 10.1001/archopht.1981.03930011019007; DREHER AW, 1991, AM J OPHTHALMOL, V111, P221, DOI 10.1016/S0002-9394(14)72263-9; ENROTHCUGELL C, 1984, INVEST OPHTH VIS SCI, V25, P250; EPSTEIN DL, 1989, OPHTHALMOLOGY, V96, P1460; FAZIO P, 1990, ARCH OPHTHALMOL-CHIC, V108, P705, DOI 10.1001/archopht.1990.01070070091042; FLAMMER J, 1985, INVEST OPHTH VIS SCI, V26, P176; GAASTERLAND D, 1978, INVEST OPHTH VIS SCI, V17, P838; GLOVINSKY Y, 1992, ARCH OPHTHALMOL-CHIC, V110, P486, DOI 10.1001/archopht.1992.01080160064031; GLOVINSKY Y, 1991, INVEST OPHTH VIS SCI, V32, P484; Graham P A, 1969, Trans Ophthalmol Soc U K, V88, P153; GRUNWALD JE, 1984, OPHTHALMOLOGY, V91, P1690; HART WM, 1979, ARCH OPHTHALMOL-CHIC, V97, P1455; HEIJL A, 1989, ARCH OPHTHALMOL-CHIC, V107, P204, DOI 10.1001/archopht.1989.01070010210024; HEIJL A, 1980, ARCH OPHTHALMOL-CHIC, V98, P1560, DOI 10.1001/archopht.1980.01020040412002; HERNANDEZ MR, 1987, AM J OPHTHALMOL, V104, P567, DOI 10.1016/0002-9394(87)90165-6; HERNANDEZ MR, 1990, AM J OPHTHALMOL, V109, P180, DOI 10.1016/S0002-9394(14)75984-7; HOLLOWS FC, 1966, BRIT J OPHTHALMOL, V50, P570, DOI 10.1136/bjo.50.10.570; HOSKINS HD, 1984, OPHTHALMIC SURG LAS, V15, P731; JAVITT JC, 1991, NEW ENGL J MED, V325, P1418, DOI 10.1056/NEJM199111143252005; JOHNSON DH, 1987, INVEST OPHTH VIS SCI, V28, P945; JOHNSON DH, 1984, AM J OPHTHALMOL, V97, P723, DOI 10.1016/0002-9394(84)90504-X; JONAS JB, 1988, GRAEF ARCH CLIN EXP, V226, P522, DOI 10.1007/BF02169199; JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P1893; JONAS JB, 1988, INVEST OPHTH VIS SCI, V29, P1151; JONAS JB, 1990, INVEST OPHTH VIS SCI, V31, P736; JONAS JB, 1992, INVEST OPHTH VIS SCI, V33, P474; KASS MA, 1986, AM J OPHTHALMOL, V101, P515, DOI 10.1016/0002-9394(86)90939-6; KASS MA, 1989, AM J OPHTHALMOL, V107, P280, DOI 10.1016/0002-9394(89)90313-9; KASS MA, 1989, ARCH OPHTHALMOL-CHIC, V107, P1590, DOI 10.1001/archopht.1989.01070020668025; KATZ J, 1991, ARCH OPHTHALMOL-CHIC, V109, P1684, DOI 10.1001/archopht.1991.01080120068028; KATZ J, 1988, AM J PREV MED, V4, P110, DOI 10.1016/S0749-3797(18)31205-4; KATZ LJ, 1989, AM J OPHTHALMOL, V107, P485, DOI 10.1016/0002-9394(89)90492-3; KING D, 1986, AM J OPHTHALMOL, V101, P204, DOI 10.1016/0002-9394(86)90596-9; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; LESKE MC, 1983, AM J EPIDEMIOL, V118, P280, DOI 10.1093/oxfordjournals.aje.a113634; LEVIN PS, 1983, AM J OPHTHALMOL, V95, P295, DOI 10.1016/S0002-9394(14)78297-2; LUTJENDRECOLL E, 1986, EXP EYE RES, V42, P443, DOI 10.1016/0014-4835(86)90004-7; MASON RP, 1989, OPHTHALMOLOGY, V96, P1363; MCLEOD SD, 1990, INVEST OPHTH VIS SCI, V31, P2361; MCMAHON CD, 1979, AM J OPHTHALMOL, V88, P736, DOI 10.1016/0002-9394(79)90674-3; MIKELBERG FS, 1989, OPHTHALMOLOGY, V96, P1325; MIKELBERG FS, 1985, AM J OPHTHALMOL, V100, P417, DOI 10.1016/0002-9394(85)90504-5; MILLER KM, 1987, OPHTHALMIC SURG LAS, V18, P882; MOLTENO ACB, 1977, BRIT J OPHTHALMOL, V61, P120, DOI 10.1136/bjo.61.2.120; MORGAN RW, 1975, BRIT J OPHTHALMOL, V59, P211, DOI 10.1136/bjo.59.4.211; MORRISON JC, 1990, ARCH OPHTHALMOL-CHIC, V108, P1020, DOI 10.1001/archopht.1990.01070090122053; PASSO MS, 1987, AM J OPHTHALMOL, V103, P754, DOI 10.1016/S0002-9394(14)74388-0; PATEL A, 1986, OPHTHALMOLOGY, V93, P825; PERKINS ES, 1973, BRIT J OPHTHALMOL, V57, P179, DOI 10.1136/bjo.57.3.179; POLANSKY J, 1985, INVEST OPHTH VIS SCI, V26, P805; QUIGLEY HA, 1985, ARCH OPHTHALMOL-CHIC, V103, P956; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P137; QUIGLEY HA, 1990, ARCH OPHTHALMOL-CHIC, V108, P51, DOI 10.1001/archopht.1990.01070030057028; QUIGLEY HA, 1991, BRIT J OPHTHALMOL, V75, P552, DOI 10.1136/bjo.75.9.552; QUIGLEY HA, 1983, AM J OPHTHALMOL, V95, P673, DOI 10.1016/0002-9394(83)90389-6; QUIGLEY HA, 1988, OPHTHALMOLOGY, V95, P357; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009; QUIGLEY HA, 1982, ARCH OPHTHALMOL-CHIC, V100, P135, DOI 10.1001/archopht.1982.01030030137016; QUIGLEY HA, 1984, INVEST OPHTH VIS SCI, V25, P918; RADIUS RL, 1979, ARCH OPHTHALMOL-CHIC, V97, P1154; REPKA MX, 1989, OPHTHALMOLOGY, V96, P26; ROBIN AL, 1987, ARCH OPHTHALMOL-CHIC, V105, P646; ROHEN JW, 1983, OPHTHALMOLOGY, V90, P758; SADUN AA, 1990, OPHTHALMOLOGY, V97, P9; SCHOCKET SS, 1985, OPHTHALMOLOGY, V92, P553; SCHULZER M, 1991, OPHTHALMOLOGY, V98, P301; SCHULZER M, 1990, BRIT J OPHTHALMOL, V74, P196, DOI 10.1136/bjo.74.4.196; SCHWARTZ LW, 1986, OPHTHALMIC LASER THE, V1, P135; SHIOSE Y, 1984, ARCH OPHTHALMOL-CHIC, V102, P883; SILVERMAN SE, 1990, INVEST OPHTH VIS SCI, V31, P722; SKUTA GL, 1992, OPHTHALMOLOGY, V99, P438; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; SOMMER A, 1989, AM J OPHTHALMOL, V107, P186, DOI 10.1016/0002-9394(89)90221-3; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P77, DOI 10.1001/archopht.1991.01080010079037; SPERBER GO, 1985, EXP EYE RES, V41, P639, DOI 10.1016/0014-4835(85)90036-3; TAKAMOTO T, 1989, OPHTHALMOLOGY, V96, P1315; TENGROTH B, 1985, ACTA OPHTHALMOL, V63, P91; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; TIELSCH JM, 1991, AM J EPIDEMIOL, V134, P1102, DOI 10.1093/oxfordjournals.aje.a116013; TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027; Tielsch JM, 1991, OPHTHALMOL CLIN N AM, V4, P649; TYLER CW, 1981, INVEST OPHTH VIS SCI, V20, P204; VARMA R, 1989, ARCH OPHTHALMOL-CHIC, V107, P526, DOI 10.1001/archopht.1989.01070010540027; WEINSTEIN BI, 1985, INVEST OPHTH VIS SCI, V26, P890; WEINSTEIN JM, 1983, INVEST OPHTH VIS SCI, V24, P1559; WERNER EB, 1977, ARCH OPHTHALMOL-CHIC, V95, P1374; WILSON MR, 1987, ARCH OPHTHALMOL-CHIC, V105, P1066; WILSON RP, 1986, GLAUCOMA, P229; ZEIMER RC, 1991, OPHTHALMOLOGY, V98, P64; 1989, AM J OPHTHALMOL, V108, P625; 1983, VITAL HLTH STATIS 11, V11; 1990, OPHTHALMOLOGY, V97, P1403	114	433	440	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1097	1106		10.1056/NEJM199304153281507	http://dx.doi.org/10.1056/NEJM199304153281507			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8455668				2022-12-28	WOS:A1993KX17800007
J	ASSAMUNT, N; MORTISHIRESMITH, RJ; AURORA, R; HERR, W; WRIGHT, PE				ASSAMUNT, N; MORTISHIRESMITH, RJ; AURORA, R; HERR, W; WRIGHT, PE			THE SOLUTION STRUCTURE OF THE OCT-1 POU-SPECIFIC DOMAIN REVEALS A STRIKING SIMILARITY TO THE BACTERIOPHAGE-LAMBDA REPRESSOR DNA-BINDING DOMAIN	CELL			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HEAVY-CHAIN PROMOTER; TRANSCRIPTION FACTOR; ANTENNAPEDIA HOMEODOMAIN; CAENORHABDITIS-ELEGANS; PROTEIN CONFORMATIONS; IMMUNOGLOBULIN GENES; REGULATORY PROTEINS; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY	The POU-specific (POU(s)) domain, in association with a POU-type homeodomain, forms the bipartite DNA-binding POU domain. The solution structure of the Oct-1 POU(s) domain has been determined by multidimensional nuclear magnetic resonance spectroscopy and consists of four alpha helices surrounding a conserved hydrophobic core. The POU(s) domain is structurally similar to the DNA-binding domains of the bacteriophage lambda and 434 repressors and 434 Cro. These domains exhibit superimposable helix-turn-helix (HTH) motifs, except that in the POU(s) domain, the first helix and the linker to the second helix of the motif are extended. The conserved structural features have been used to propose a plausible model for DNA binding by the POU(s) domain. A human dwarfism mutation that affects positive control in the related POU domain protein Pit-1 maps to the same region of the HTH motif as do positive control mutations in lambda repressor.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; SUNY STONY BROOK, DEPT MOLEC MICROBIOL, STONY BROOK, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	ASSAMUNT, N (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546; Wright, Peter/0000-0002-1368-0223; Aurora, Rajeev/0000-0002-6609-6055	NCI NIH HHS [CA-13106] Funding Source: Medline; NIGMS NIH HHS [GM-36643] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036643] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGARWAL VR, 1991, DEV BIOL, V147, P363, DOI 10.1016/0012-1606(91)90294-D; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; BILLIN AN, 1991, MECH DEVELOP, V34, P75, DOI 10.1016/0925-4773(91)90045-8; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOTFIELD MC, 1992, BIOCHEMISTRY-US, V31, P5841, DOI 10.1021/bi00140a020; BROWN LR, 1992, J MOL BIOL, V227, P1118, DOI 10.1016/0022-2836(92)90525-O; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; FINNEY M, 1990, CELL, V60, P5, DOI 10.1016/0092-8674(90)90708-M; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GROSSCHEDL R, 1979, NUCLEIC ACIDS RES, V6, P867, DOI 10.1093/nar/6.3.867; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; GUNTERT P, 1991, J MOL BIOL, V217, P531, DOI 10.1016/0022-2836(91)90755-U; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HAWLEY DK, 1983, CELL, V32, P327, DOI 10.1016/0092-8674(83)90452-X; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEMOINE C, 1992, P NATL ACAD SCI USA, V89, P3285, DOI 10.1073/pnas.89.8.3285; LLOYD A, 1991, MECH DEVELOP, V36, P87, DOI 10.1016/0925-4773(91)90075-H; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NERI D, 1992, J MOL BIOL, V223, P743, DOI 10.1016/0022-2836(92)90987-U; NERI D, 1990, J AM CHEM SOC, V112, P3663, DOI 10.1021/ja00165a064; OHTA K, 1992, BIOCHEM BIOPH RES CO, V189, P851, DOI 10.1016/0006-291X(92)92281-2; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OVCHINNIKOV YA, 1979, GENE, V6, P235, DOI 10.1016/0378-1119(79)90060-X; PABO CO, 1990, SCIENCE, V247, P1210, DOI 10.1126/science.2315694; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Sauer R T, 1990, Adv Protein Chem, V40, P1, DOI 10.1016/S0065-3233(08)60286-7; SAUER RT, 1978, BIOCHEMISTRY-US, V17, P1092, DOI 10.1021/bi00599a024; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	83	124	126	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	1993	73	1					193	205		10.1016/0092-8674(93)90171-L	http://dx.doi.org/10.1016/0092-8674(93)90171-L			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462099				2022-12-28	WOS:A1993KW75300019
J	TACCIOLI, GE; RATHBUN, G; OLTZ, E; STAMATO, T; JEGGO, PA; ALT, FW				TACCIOLI, GE; RATHBUN, G; OLTZ, E; STAMATO, T; JEGGO, PA; ALT, FW			IMPAIRMENT OF V(D)J RECOMBINATION IN DOUBLE-STRAND BREAK REPAIR MUTANTS	SCIENCE			English	Article							CELL RECEPTOR GAMMA; PRE-B CELLS; SCID MUTATION; SACCHAROMYCES-CEREVISIAE; JUNCTIONAL SEQUENCES; DNA; GENES; MICE; TRANSPOSITION; INTERMEDIATE	Cells maintain the integrity of their genome through an intricate network of repair systems that recognize and remove lesions from DNA. The only known site-directed recombination process in vertebrates is the V(D)J recombination of lymphocyte antigen receptor genes. A large panel of cell lines deficient in DNA repair were tested for the ability to perform V(D)J recombination after introduction of the RAG-1 and RAG-2 genes. Two mutants failed to generate normal V(D)J recombination, and further analysis provided evidence for two distinct nonlymphoid-specific genes that encode factors involved in both DNA repair and V(D)J recombination.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; LANKENAU MED RES CTR,WYNNEWOOD,PA 19096; UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,ENGLAND	Harvard University; Harvard Medical School; Lankenau Medical Center; Lankenau Institute for Medical Research; University of Sussex	TACCIOLI, GE (corresponding author), CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R01CA045277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020047, R37AI020047] Funding Source: NIH RePORTER; NCI NIH HHS [CA45277] Funding Source: Medline; NIAID NIH HHS [AI 20047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BANGA SS, 1991, MUTAT RES, V255, P79, DOI 10.1016/0921-8777(91)90020-P; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GIACCIA AJ, 1990, AM J HUM GENET, V47, P459; HANIFORD DB, 1991, CELL, V64, P171; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; ROBSON CN, 1989, MUTAT RES, V217, P93, DOI 10.1016/0921-8777(89)90060-8; ROTH DB, 1992, CELL, V70, P1; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K	28	432	435	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					207	210		10.1126/science.8469973	http://dx.doi.org/10.1126/science.8469973			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8469973				2022-12-28	WOS:A1993KW45200036
J	BAYERDORFFER, E; MANNES, GA; RICHTER, WO; OCHSENKUHN, T; SEEHOLZER, G; KOPCKE, W; WIEBECKE, B; PAUMGARTNER, G				BAYERDORFFER, E; MANNES, GA; RICHTER, WO; OCHSENKUHN, T; SEEHOLZER, G; KOPCKE, W; WIEBECKE, B; PAUMGARTNER, G			DECREASED HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND INCREASED LOW-DENSITY CHOLESTEROL LEVELS IN PATIENTS WITH COLORECTAL ADENOMAS	ANNALS OF INTERNAL MEDICINE			English	Article						LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; LIPOPROTEINS, VLDL CHOLESTEROL; ADENOMA; COLORECTAL NEOPLASMS	CORONARY HEART-DISEASE; LARGE-BOWEL CANCER; SERUM-CHOLESTEROL; COLON CANCER; PLASMA TRIGLYCERIDE; HAWAIIAN-JAPANESE; RISK FACTOR; BILE-ACIDS; MORTALITY; RECTUM	Objective: To study the relation between serum lipoprotein levels and the frequency of colorectal adenomas, the benign precursors of colorectal cancer. Design: Cross-sectional. Setting: University hospital in Germany. Patients: The study included 822 of 1124 consecutive patients who underwent colonoscopy at our institution (302 patients were excluded because of malignant disease, chronic inflammatory bowel disease, familial polyposis, partial colectomy, or other chronic diseases). Of the 822 study patients, 194 had colorectal adenoma. Measurements: Serum cholesterol fractions (high-density lipoprotein [HDL], low-density lipoprotein [LDL], and very low-density lipoprotein [VLDL]) and presence or absence of adenomas; univariate and logistic regression analyses were carried out to evaluate the association between serum HDL, LDL, and VLDL cholesterol levels and the frequency of colorectal adenoma. Results: Univariate analysis of the total patient group showed that the HDL cholesterol level was inversely related to the frequency of colorectal adenoma (odds ratio, 0.36; 95% Cl, 0.21 to 0.62) and that LDL and VLDL cholesterol levels were positively associated with adenoma frequency (odds ratio, 2.31 [Cl, 1.36 to 3.92] and 1.72 [Cl, 1.03 to 2.86], respectively). Univariate analysis of the subgroup of 89 patients with high-risk adenomas showed an inverse association between such adenomas and HDL cholesterol (odds ratio, 0.37; Cl, 0.18 to 0.76). A logistic regression analysis that included age and body mass index showed an association between lipoprotein levels and the presence of adenomas. The relative strength (in descending order) of these associations was as follows: HDL, LDL, VLDL, and total serum cholesterol. A logistic regression analysis of patients with high-risk adenoma showed a significant association between such adenomas and the HDL cholesterol level. Conclusions: Patients with colorectal adenomas have lower HDL cholesterol levels and higher LDL and VLDL cholesterol levels; these lipoproteins may have prognostic significance for the development of colorectal adenomas.	UNIV MUNICH, KLINIKUM GROSSHADERN, INST PATHOL, W-8000 MUNICH 2, GERMANY	University of Munich	BAYERDORFFER, E (corresponding author), UNIV MUNICH, KLINIKUM GROSSHADERN, DEPT MED 2, MARCHIONINISTR 15, W-8000 MUNICH 70, GERMANY.							[Anonymous], 1982, JAMA-J AM MED ASSOC, V248, P2853; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1989, AM J EPIDEMIOL, V129, P249, DOI 10.1093/oxfordjournals.aje.a115130; BRUNZELL JD, 1989, NEW ENGL J MED, V320, P1273, DOI 10.1056/NEJM198905113201910; BULL AW, 1983, CARCINOGENESIS, V4, P207, DOI 10.1093/carcin/4.2.207; CAMBIEN F, 1980, AM J EPIDEMIOL, V112, P388, DOI 10.1093/oxfordjournals.aje.a113004; Correa P, 1978, Major Probl Pathol, V10, P126; CUMMINGS JH, 1978, J CLIN INVEST, V61, P953, DOI 10.1172/JCI109020; DAY DW, 1978, MAJOR PROBLEMS PATHO, V10, P126; DESCHNER EE, 1982, AM J GASTROENTEROL, V77, P207; DESCHNER EE, 1981, DIGESTION, V21, P290, DOI 10.1159/000198579; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; ENSTROM JE, 1975, BRIT J CANCER, V32, P432, DOI 10.1038/bjc.1975.244; FREEDMAN DS, 1988, AM J EPIDEMIOL, V127, P1118, DOI 10.1093/oxfordjournals.aje.a114906; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; HAENSZEL W, 1971, CANCER, V28, P14, DOI 10.1002/1097-0142(197107)28:1<14::AID-CNCR2820280105>3.0.CO;2-I; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; HERMANEK P, 1983, ENDOSCOPY, V15, P16, DOI 10.1055/s-2007-1018598; HILL MJ, 1975, CANCER RES, V35, P3398; HOLTZMAN EJ, 1987, NEW ENGL J MED, V317, P114; HOWELL MA, 1975, J CHRON DIS, V28, P67, DOI 10.1016/0021-9681(75)90063-6; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JAIN M, 1980, INT J CANCER, V26, P757, DOI 10.1002/ijc.2910260609; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KEYS A, 1970, CIRCULATION S4, V41; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; MANNES GA, 1986, NEW ENGL J MED, V315, P1634, DOI 10.1056/NEJM198612253152602; MILLER SR, 1981, JNCI-J NATL CANCER I, V67, P297; Morson B, 1976, HISTOLOGICAL TYPING; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NARISAWA T, 1974, JNCI-J NATL CANCER I, V53, P1093, DOI 10.1093/jnci/53.4.1093; PETERSSON B, 1984, BRIT MED J, V288, P1264, DOI 10.1136/bmj.288.6426.1264; PHILLIPS RL, 1975, CANCER RES, V35, P3513; ROSE G, 1974, LANCET, V1, P181, DOI 10.1016/S0140-6736(74)92492-1; ROSE G, 1980, LANCET, V1, P523; SCHATZKIN A, 1987, LANCET, V2, P298; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; STEMMERMANN GN, 1981, J NATL CANCER I, V67, P1179; THOMAS CB, 1982, JOHNS HOPKINS MED J, V150, P89; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; WYNDER EL, 1975, CANCER RES, V35, P3388; YAARI S, 1981, LANCET, V1, P1011; 1981, JAMA-J AM MED ASSOC, V246, P731	51	72	73	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					481	487		10.7326/0003-4819-118-7-199304010-00001	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442619				2022-12-28	WOS:A1993KU07900001
J	SHING, Y; CHRISTOFORI, G; HANAHAN, D; ONO, Y; SASADA, R; IGARASHI, K; FOLKMAN, J				SHING, Y; CHRISTOFORI, G; HANAHAN, D; ONO, Y; SASADA, R; IGARASHI, K; FOLKMAN, J			BETACELLULIN - A MITOGEN FROM PANCREATIC BETA-CELL TUMORS	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-ALPHA; NEU ONCOGENE; RECEPTOR; PROTEIN; ANGIOGENESIS; EXPRESSION; PRECURSOR; BINDING; ENCODES	Betacellulin, a member of the epidermal growth factor family, has been identified in the conditioned medium of cell lines derived from mouse pancreatic beta cell tumors. Betacellulin is a 32-kilodalton glycoprotein that appears to be processed from a larger transmembrane precursor by proteolytic cleavage. The carboxyl-terminal domain of betacellulin has 50 percent sequence similarity with that of rat transforming growth factor alpha. Betacellulin is a potent mitogen for retinal pigment epithelial cells and vascular smooth muscle cells.	CHILDRENS HOSP MED CTR, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, HORMONE RES INST, SAN FRANCISCO, CA 94143 USA; TAKEDA CHEM IND LTD, DIV CENT RES, BIOL RES LABS, OSAKA 532, JAPAN	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Takeda Chemical Industries					NCI NIH HHS [CA 70118] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHRISTOFORI G, UNPUB; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; ONO Y, 1988, J BIOL CHEM, V263, P6927; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; POWERS JC, 1977, BIOCHIM BIOPHYS ACTA, V485, P156, DOI 10.1016/0005-2744(77)90203-0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASADA R, IN PRESS BIOCH BIOPH; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YUEN S, 1987, METHOD ENZYMOL, V146, P42; [No title captured]	30	377	393	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	1993	259	5101					1604	1607		10.1126/science.8456283	http://dx.doi.org/10.1126/science.8456283			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8456283				2022-12-28	WOS:A1993KR54300037
J	HYLAND, ME; KENYON, CAP; ALLEN, R; HOWARTH, P				HYLAND, ME; KENYON, CAP; ALLEN, R; HOWARTH, P			DIARY KEEPING IN ASTHMA - COMPARISON OF WRITTEN AND ELECTRONIC METHODS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the extent to which symptom diaries of asthmatic patients are inaccurate or based on retrospective recall. Design-Comparison of electronic and pencil and paper diaries. Both forms were completed twice daily at home for 14 days. Setting-Outpatient clinic. Subjects-24 asthmatic outpatients also tested for severity of asthma and for anxiety. Results-More sessions were missed in the evening than in the morning for both types of diaries. Significantly more retrospective entries were made in the evening (26 entries, 14 patients) than in the morning (6 entries, 3 patients). Discrepant entries of peak expiratory flow accounted for 15% of those made on the appropriate day, and three quarters of patients made at least one discrepant entry. Variation in peak expiratory flow was significantly related to number of discrepancies and number of missing days, and anxiety score was significantly related to number of missing days. About a fifth of written entries may have errors. Conclusion-Poor diary completion may result from having unreasonable expectations of patients and giving incomplete instructions. Electronic, time coded diaries could ensure better quality of records.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton	HYLAND, ME (corresponding author), UNIV PLYMOUTH,DEPT PSYCHOL,PLYMOUTH PL4 8AA,ENGLAND.			Hyland, Michael/0000-0003-3879-0469; Howarth, Peter/0000-0003-0619-7927				Baddeley AD., 1990, HUMAN MEMORY THEORY; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1020, DOI 10.1037/0022-3514.54.6.1020	3	123	127	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					487	489		10.1136/bmj.306.6876.487	http://dx.doi.org/10.1136/bmj.306.6876.487			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KN786	8448458	Green Published			2022-12-28	WOS:A1993KN78600017
J	WICKHAM, TJ; MATHIAS, P; CHERESH, DA; NEMEROW, GR				WICKHAM, TJ; MATHIAS, P; CHERESH, DA; NEMEROW, GR			INTEGRIN-ALPHA-V-BETA-3 AND INTEGRIN-ALPHA-V-BETA-5 PROMOTE ADENOVIRUS INTERNALIZATION BUT NOT VIRUS ATTACHMENT	CELL			English	Article							CELL ATTACHMENT; HELA-CELLS; RECEPTOR INTERACTION; ADHESION RECEPTOR; PENTON-BASE; VITRONECTIN; TYPE-2; ENTRY; SURFACE; PURIFICATION	Adenovirus contains a heterodimeric protein complex consisting of 186 kd fiber protein that mediates high affinity virus attachment to cells and a 400 kd pentavalent subunit (penton base) that contains five Arg-Gly-Asp sequences, implying a role for integrins in adenovirus infection. We demonstrate that the vitronectin-binding integrins alpha(v)beta3 and alpha(v)beta5 promote viral infection in a novel way since antibodies against these receptors or soluble penton base block virus internalization without affecting attachment. Moreover, adenovirus binds to cultured cells lacking alpha(v) integrins but fail to become internalized, thus restricting infection of these cells. Transfection of alpha(v)(-) cells with a cDNA encoding alpha(v) results in the expression of integrins alpha(v)beta3 and alpha(v)beta5 and allows virus internalization and infection. These data indicate that adenovirus attachment and uptake into cells are separate but cooperative events that result from the interaction of distinct viral coat proteins with a receptor for attachment and alpha(v) integrin receptors for internalization.			WICKHAM, TJ (corresponding author), Scripps Clinic, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA45726] Funding Source: Medline; NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAID NIH HHS [AI07354-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045726] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007354] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BOUDIN ML, 1982, VIROLOGY, V116, P589, DOI 10.1016/0042-6822(82)90151-9; BOUDIN ML, 1979, VIROLOGY, V92, P125, DOI 10.1016/0042-6822(79)90219-8; BRANDT CD, 1969, AM J EPIDEMIOL, V90, P484, DOI 10.1093/oxfordjournals.aje.a121094; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BUMOL TF, 1982, P NATL ACAD SCI-BIOL, V79, P1245, DOI 10.1073/pnas.79.4.1245; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHARDONN.Y, 1970, VIROLOGY, V40, P462, DOI 10.1016/0042-6822(70)90189-3; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CHROBOCZEK J, 1992, VIROLOGY, V186, P280, DOI 10.1016/0042-6822(92)90082-Z; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; DEVAUX C, 1987, VIROLOGY, V161, P121, DOI 10.1016/0042-6822(87)90177-2; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; EVERETT SF, 1958, VIROLOGY, V6, P770, DOI 10.1016/0042-6822(58)90123-5; EVERITT E, 1977, J VIROL, V21, P199, DOI 10.1128/JVI.21.1.199-214.1977; FELDING-HABERMANN B, 1992, J CLIN INVEST, V89, P1; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; GREEN M, 1967, P NATL ACAD SCI USA, V57, P1302, DOI 10.1073/pnas.57.5.1302; HORWITZ MS, 1990, VIROLOGY, V2, P1679; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; JOHNSON DC, 1990, J VIROL, V64, P2569, DOI 10.1128/JVI.64.6.2569-2576.1990; NEUMANN R, 1988, GENE, V69, P153, DOI 10.1016/0378-1119(88)90389-7; NOMOTO A, 1992, SEMINARS VIROLOGY; PEREIRA HG, 1958, VIROLOGY, V6, P601, DOI 10.1016/0042-6822(58)90109-0; PERSSON R, 1983, J VIROL, V46, P956, DOI 10.1128/JVI.46.3.956-963.1983; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; ROIVAINEN M, 1991, J VIROL, V65, P4735, DOI 10.1128/JVI.65.9.4735-4740.1991; SILVER L, 1988, VIROLOGY, V165, P377, DOI 10.1016/0042-6822(88)90582-X; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SPEAR PG, 1992, ADV EXP MED BIOL, V313, P341; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; SVENSSON U, 1984, J VIROL, V51, P687, DOI 10.1128/JVI.51.3.687-694.1984; SVENSSON U, 1981, J VIROL, V38, P70, DOI 10.1128/JVI.38.1.70-81.1981; THIEL JF, 1967, P SOC EXP BIOL MED, V125, P892, DOI 10.3181/00379727-125-32232; VARGA MJ, 1991, J VIROL, V65, P6061, DOI 10.1128/JVI.65.11.6061-6070.1991; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WADELL G, 1969, J VIROL, V4, P671, DOI 10.1128/JVI.4.5.671-680.1969; WADELL G, 1987, CIBA F SYMP, V128, P63; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WICKHAM TJ, 1992, BIOTECHNOL PROGR, V8, P391, DOI 10.1021/bp00017a003; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	46	1857	1965	0	41	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 23	1993	73	2					309	319		10.1016/0092-8674(93)90231-E	http://dx.doi.org/10.1016/0092-8674(93)90231-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8477447				2022-12-28	WOS:A1993KY50500012
J	IGLEHART, JK				IGLEHART, JK			MANAGED COMPETITION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNIVERSAL HEALTH-INSURANCE; PROMOTE QUALITY; ECONOMY; REFORM; 1990S; PLAN; CARE											BERGTHOLD LA, 1993, HLTH AFF MILLWOOD S, V12, P49; ELLWOOD P, 1992, HLTH EC, V149, P68; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1978, NEW ENGL J MED, V298, P709, DOI 10.1056/NEJM197803302981304; ENTHOVEN AC, 1978, NEW ENGL J MED, V298, P650, DOI 10.1056/NEJM197803232981204; ENTHOVEN AC, 1991, JAMA-J AM MED ASSOC, V265, P2532, DOI 10.1001/jama.265.19.2532; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; ENTHOVEN AC, 1992, NEW ENGL J MED, V327, P807, DOI 10.1056/NEJM199209103271113; Enthoven Alain C., 1988, THEORY PRACTICE MANA; FLEMING S, 1973, STRUCTURED COMPETITI; GARAMENDI J, 1992, CALIFORNIA HLTH CARE; IGLEHART JK, 1982, NEW ENGL J MED, V307, P451, DOI 10.1056/NEJM198208123070734; IGLEHART JK, 1993, NEW ENGL J MED, V328, P896, DOI 10.1056/NEJM199303253281226; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; MADDREY WC, 1992, ANN INTERN MED, V117, P528, DOI 10.7326/0003-4819-117-6-528; McConnell Grant, 1966, PRIVATE POWER AM DEM; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; Pear Robert, 1993, N Y Times Web, pB7; STARR P, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.suppl_1.7; STARR P, 1993, HEALTH AFFAIR, V12, P58, DOI 10.1377/hlthaff.12.suppl_1.58; STOUT H, 1993, WALL STREET J   0316, pA3; STOUT H, 1993, WALL ST J       0422, pA1; Wartzman Rich, 1993, WALL STREET J   0604, pA2; WINSLOW R, 1993, WALL STREET J, pB1; Winslow Ron, 1993, WALL STREET J   1230, pA1; 1992, NY TIMES        1202, pA22; 1992, NY TIMES        1203, pA24; 1992, ANN INTERN MED, V117, P511	29	25	25	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1208	1212		10.1056/NEJM199304223281627	http://dx.doi.org/10.1056/NEJM199304223281627			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY447	8455701				2022-12-28	WOS:A1993KY44700036
J	BARLOW, DP				BARLOW, DP			METHYLATION AND IMPRINTING - FROM HOST DEFENSE TO GENE-REGULATION	SCIENCE			English	Editorial Material							DNA METHYLATION; MOUSE; EMBRYOGENESIS; GAMETOGENESIS; GENOMES				BARLOW, DP (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.							BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; CEDAR H, COMMUNICATION; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; JAHNER D, 1985, MOL CELL BIOL, V5, P2212; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MONK M, 1990, GENOMIC IMPRINTING S; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Stager R., 1993, CELL, V73, P1; Surani MA, 1991, CURR OPIN GENET DEV, V1, P241, DOI 10.1016/S0959-437X(05)80077-2; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0	19	250	253	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					309	310		10.1126/science.8469984	http://dx.doi.org/10.1126/science.8469984			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8469984				2022-12-28	WOS:A1993KX80000024
J	KOI, M; JOHNSON, LA; KALIKIN, LM; LITTLE, PFR; NAKAMURA, Y; FEINBERG, AP				KOI, M; JOHNSON, LA; KALIKIN, LM; LITTLE, PFR; NAKAMURA, Y; FEINBERG, AP			TUMOR-CELL GROWTH ARREST CAUSED BY SUBCHROMOSOMAL TRANSFERABLE DNA FRAGMENTS FROM CHROMOSOME-11	SCIENCE			English	Article							WILMS-TUMOR; SHORT ARM; HETEROZYGOSITY; LOCUS; GENE; CARCINOMA; SEQUENCE; POLYMORPHISMS; SUPPRESSION; EXPRESSION	A fundamental problem in the identification and isolation of tumor suppressor and other growth-inhibiting genes is the loss of power of genetic complementation at the subchromosomal level. A direct genetic strategy was developed to isolate subchromosomal transferable fragments (STFs) from any chromosome, each containing a selectable marker within the human DNA, that could be transferred to any mammalian cell. As a test of the method, several overlapping STFs from 11p15 were shown to cause in vitro growth arrest of rhabdomyosarcoma cells. This activity mapped between the beta-globin and insulin genes.	UNIV MICHIGAN, SCH MED, HOWARD HUGHES MED INST, DEPT INTERN MED, ANN ARBOR, MI 48109 USA; JAPANESE FDN CANC RES, INST CANC, DEPT BIOCHEM, TOSHIMA KU, TOKYO 170, JAPAN; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, WOLFSON LABS, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND; UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, PROGRAM CELLULAR & MOLEC BIOL, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Japanese Foundation for Cancer Research; Imperial College London; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Koi, Minoru/G-9197-2014; Little, Peter. F.R./C-9971-2009; Koi, Minoru/C-3489-2012; Feinberg, Andrew/AAY-7666-2020	Feinberg, Andrew/0000-0002-8364-1991	NATIONAL CANCER INSTITUTE [R01CA054358, R37CA054358] Funding Source: NIH RePORTER; NCI NIH HHS [CA54358, R01 CA054358] Funding Source: Medline; NIGMS NIH HHS [T32GM07314] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARKER D, 1984, AM J HUM GENET, V36, P1159; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BRUNS G A P, 1984, American Journal of Human Genetics, V36, p25S; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLE CG, 1991, GENOMICS, V10, P816, DOI 10.1016/0888-7543(91)90468-T; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; EHLEN T, 1990, ONCOGENE, V5, P219; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIDLER AE, 1992, LANCET, V339, P243, DOI 10.1016/0140-6736(92)90042-2; FUJIMORI M, 1991, CANCER RES, V51, P89; GARCIA I, 1991, CANCER RES, V51, P294; GOSS SJ, 1977, J CELL SCI, V25, P17; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; KOI M, 1989, JPN J CANCER RES, V80, P122, DOI 10.1111/j.1349-7006.1989.tb02278.x; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOI M, UNPUB; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1991, CYTOGENET CELL GENET, V58, P1967; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; NELKIN BD, 1984, BIOCHEM BIOPH RES CO, V123, P648, DOI 10.1016/0006-291X(84)90278-X; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REDEKER E, COMMUNICATION; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SCHMIDTKE J, 1984, HUM GENET, V67, P428, DOI 10.1007/BF00291404; SCHOFIELD PN, 1991, BRIT J CANCER, V63, P687, DOI 10.1038/bjc.1991.156; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SKINNER MA, 1990, CANCER RES, V50, P2303; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TANIGAMI A, 1992, AM J HUM GENET, V50, P56; TOKINO T, 1991, AM J HUM GENET, V48, P258; WADEY RB, 1990, HUM GENET, V84, P417; WADEY RB, 1990, ONCOGENE, V5, P901; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; YI N, 1991, EXP CELL RES, V192, P220, DOI 10.1016/0014-4827(91)90179-X	47	195	204	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1993	260	5106					361	364		10.1126/science.8469989	http://dx.doi.org/10.1126/science.8469989			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8469989				2022-12-28	WOS:A1993KX80000041
J	HINOHARA, S				HINOHARA, S			OSLER,WILLIAM PHILOSOPHY ON DEATH	ANNALS OF INTERNAL MEDICINE			English	Biographical-Item						OSLER, WILLIAM; HISTORY OF MEDICINE; ATTITUDE TO DEATH; PHILOSOPHY, MEDICAL; HUMANISM		To understand Osler's philosophy of death, 52 major essays and lectures written by Sir William Osler while he was in the United States and Great Britain were reviewed. Other factors, such as the spiritual environment in which he was brought up, and personal experiences with deaths of family members, his teachers, close friends, and the many patients for whom he cared, help us to understand this reknowned physician's philosophy on death and dying.	ST LUKES INT HOSP, TOKYO, JAPAN	St. Luke's International Hospital								CUSHING H, 1977, LIFE W OSLER, V1, P136; CUSHING H, 1977, LIFE W OSLER, V2, P620; FULLER T, 1865, HOLY PROFANE STATES, P76; HINOHARA S, 1983, AEQUANIMITAS OTHER A; HINOHARA S, 1948, LIFE W OSLER PIONEER; MASTERLINCK M, 1912, DEATH; MUNK W, 1887, EUTHANASIA MED TREAT, P105; MUNK W, 1887, EUTHANASIA MED TREAT, P77; OSLER W, PUBLICATION LIST; PLATO, 1989, TIMAEUS LOEB CLASSIC, V234, P219; PLATO, 1990, PHAEDO LOEB CLASSICA, V118, P403; TENNYSON A, 1902, POETICAL WORKS A TEN, P201; 1888, CANADA MED SURGI MAR, P511; BIBLIOTHECA OSLERIAN	14	15	15	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					638	642		10.7326/0003-4819-118-8-199304150-00012	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	KW470	8452331				2022-12-28	WOS:A1993KW47000012
J	CLEWELL, DB				CLEWELL, DB			BACTERIAL SEX PHEROMONE-INDUCED PLASMID TRANSFER	CELL			English	Review							STREPTOCOCCUS-FAECALIS; ENTEROCOCCUS-FAECALIS; SURFACE-PROTEINS; GENETIC-ANALYSIS; PAD1; RESISTANCE; AGGREGATION; CONJUGATION; REGION		UNIV MICHIGAN,DEPT MICROBIOL IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	CLEWELL, DB (corresponding author), UNIV MICHIGAN,DEPT BIOL MAT SCI,ANN ARBOR,MI 48109, USA.							CHUNG JWW, 1992, P NATL ACAD SCI USA, V89, P9020, DOI 10.1073/pnas.89.19.9020; CLEWELL DB, 1981, MICROBIOL REV, V45, P409, DOI 10.1128/MMBR.45.3.409-436.1981; CLEWELL DB, 1990, EUR J CLIN MICROBIOL, V9, P90, DOI 10.1007/BF01963632; CLEWELL DB, 1989, PLASMID, V21, P175, DOI 10.1016/0147-619X(89)90041-3; CLEWELL DB, 1993, IN PRESS BACTERIAL C; DUNNY GM, 1990, MOL MICROBIOL, V4, P689, DOI 10.1111/j.1365-2958.1990.tb00639.x; DUNNY GM, 1978, P NATL ACAD SCI USA, V75, P3479, DOI 10.1073/pnas.75.7.3479; DUNNY GM, 1979, PLASMID, V2, P454, DOI 10.1016/0147-619X(79)90029-5; EHRENFELD EE, 1987, J BACTERIOL, V169, P3473, DOI 10.1128/jb.169.8.3473-3481.1987; EHRENFELD EE, 1986, J BACTERIOL, V168, P6, DOI 10.1128/jb.168.1.6-12.1986; EMBER JA, 1989, AM J PATHOL, V134, P797; GALLI D, 1992, MOL MICROBIOL, V6, P1297, DOI 10.1111/j.1365-2958.1992.tb00851.x; GALLI D, 1990, MOL MICROBIOL, V4, P895, DOI 10.1111/j.1365-2958.1990.tb00662.x; IKE Y, 1984, J BACTERIOL, V158, P777, DOI 10.1128/JB.158.3.777-783.1984; KAO SM, 1991, J BACTERIOL, V173, P7650, DOI 10.1128/jb.173.23.7650-7664.1991; KREFT B, 1992, INFECT IMMUN, V60, P25, DOI 10.1128/IAI.60.1.25-30.1992; MORI M, 1986, AGR BIOL CHEM TOKYO, V50, P539, DOI 10.1080/00021369.1986.10867423; MORI M, 1988, J BIOL CHEM, V263, P14574; PONTIUS LT, 1992, J BACTERIOL, V174, P3152, DOI 10.1128/jb.174.10.3152-3160.1992; PONTIUS LT, 1991, PLASMID, V26, P172, DOI 10.1016/0147-619X(91)90041-T; SANNOMIYA P, 1990, P NATL ACAD SCI USA, V87, P66, DOI 10.1073/pnas.87.1.66; SUZUKI A, 1984, SCIENCE, V226, P849, DOI 10.1126/science.6436978; TANIMOTO K, 1993, J BACTERIOL, V175, P1008, DOI 10.1128/JB.175.4.1008-1018.1993; WEAVER KE, 1988, J BACTERIOL, V170, P4343, DOI 10.1128/jb.170.9.4343-4352.1988; WEAVER KE, 1993, IN PRESS J BACTERIOL; WEIDLICH G, 1992, MOL GEN GENET, V233, P161, DOI 10.1007/BF00587575	26	182	188	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					9	12		10.1016/0092-8674(93)90153-H	http://dx.doi.org/10.1016/0092-8674(93)90153-H			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462105	Green Published			2022-12-28	WOS:A1993KW75300003
J	BRANCH, WT; MALIK, TK				BRANCH, WT; MALIK, TK			USING WINDOWS OF OPPORTUNITIES IN BRIEF INTERVIEWS TO UNDERSTAND PATIENTS CONCERNS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							TEACHING PSYCHIATRY; PHYSICIAN; COMMUNICATION		HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; NASSAU CTY MED CTR,DIV INTERNAL MED,E MEADOW,NY 11554; SUNY STONY BROOK,SCH MED,DEPT CLIN MED,STONY BROOK,NY 11794	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	BRANCH, WT (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.							BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BIRD J, 1983, GEN HOSP PSYCHIAT, V5, P247, DOI 10.1016/0163-8343(83)90003-8; COHENCOLE SA, 1984, GEN HOSP PSYCHIAT, V6, P1, DOI 10.1016/0163-8343(84)90052-5; COHENCOLE SA, 1985, QUAL LIFE CARDIOVASC, V2, P7; HALL JA, 1981, J HEALTH SOC BEHAV, V22, P18, DOI 10.2307/2136365; KORSCH BM, 1968, PEDIATRICS, V42, P855; LARSEN KM, 1981, J FAM PRACTICE, V12, P481; LIPKIN M, 1987, OFFICE PRACTICE MED, P1287; MISHLER EG, 1989, J GEN INTERN MED, V4, P325, DOI 10.1007/BF02597407; Smith III A.C., 1989, TEACH LEARN MED, V1, P101	10	84	84	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1667	1668		10.1001/jama.269.13.1667	http://dx.doi.org/10.1001/jama.269.13.1667			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KV349	8455300				2022-12-28	WOS:A1993KV34900031
J	GROVES, AK; BARNETT, SC; FRANKLIN, RJM; CRANG, AJ; MAYER, M; BLAKEMORE, WF; NOBLE, M				GROVES, AK; BARNETT, SC; FRANKLIN, RJM; CRANG, AJ; MAYER, M; BLAKEMORE, WF; NOBLE, M			REPAIR OF DEMYELINATED LESIONS BY TRANSPLANTATION OF PURIFIED 0-2A PROGENITOR CELLS	NATURE			English	Article							RAT SPINAL-CORD; MYELIN-DEFICIENT RAT; SCHWANN-CELLS; TYPE-1 ASTROCYTES; GROWTH-HORMONE; NERVOUS-SYSTEM; OLIGODENDROCYTES; DIFFERENTIATION; GALACTOCEREBROSIDE; INJECTION	THE transplantation of well defined populations of precursor cells offers a means of repairing damaged tissue and of delivering therapeutic compounds to sites of injury or degeneration. For example, a functional immune system can be reconstituted by transplantation of purified haematopoietic stem cells1, and transplanted skeletal myoblasts and keratinocytes can participate in the formation of normal tissue in host animals2-4. Cell transplantation in the central nervous system (CNS) has been proposed as a means of correcting neuronal dysfunction in diseases associated with neuronal loss5-7; it might also rectify glial cell dysfunction, with transplanted oligodendrocyte precursor cells eventually allowing repair of demyelinating damage in the CNS. Here we use co-operating growth factors to expand purified populations of oligodendrocyte type-2 astrocyte (O-2A) progenitor cells for several weeks in vitro. When injected into demyelinating lesions in spinal cords of adult rats, created in such a way as to preclude host-mediated remyelination, these expanded populations are capable of producing extensive remyelination. In addition, transplantation of O-2A progenitor cells genetically modified to express the bacterial beta-galactosidase gene gives rise to beta-galactosidase-positive oligodendrocytes which remyelinate demyelinated axons within the lesion. These results offer a viable strategy for the manipulation of neural precursor cells which is compatible with attempts to repair damaged CNS tissue by precursor transplantation.	UNIV CAMBRIDGE,MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE CB3 0ES,ENGLAND; LUDWIG INST CANC RES,CELLULAR NEUROBIOL LAB,LONDON W1P 8BT,ENGLAND; CRC BEATSON LABS,DEPT MED ONCOL & NEUROBIOL,GLASGOW G61 1BD,SCOTLAND; UNIV CAMBRIDGE,DEPT CLIN VET MED,CAMBRIDGE CB3 0ES,ENGLAND	University of Cambridge; Ludwig Institute for Cancer Research; Beatson Institute; University of Cambridge			Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Franklin, Robin/0000-0001-6522-2104; Groves, Andrew/0000-0002-0784-7998	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BLAKEMORE WF, 1989, J NEUROCYTOL, V18, P519, DOI 10.1007/BF01474547; BLAKEMORE WF, 1988, DEV NEUROSCI-BASEL, V10, P1, DOI 10.1159/000111949; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; CRANG AJ, 1992, J NEUROIMMUNOL, V40, P243, DOI 10.1016/0165-5728(92)90140-G; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DUNCAN ID, 1988, J NEUROCYTOL, V17, P351, DOI 10.1007/BF01187857; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANKLIN RJM, 1991, ACTA NEUROPATHOL, V81, P686, DOI 10.1007/BF00296381; FRANKLIN RJM, 1991, J NEUROCYTOL, V20, P420, DOI 10.1007/BF01355538; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANSMULLER A, 1991, GLIA, V4, P580; GUMPEL M, 1983, NEUROSCI LETT, V37, P307, DOI 10.1016/0304-3940(83)90449-4; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; MAYER MM, IN PRESS; MORGAN JR, 1987, SCIENCE, V237, P1476; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROSENBLUTH J, 1990, J NEUROCYTOL, V19, P718, DOI 10.1007/BF01188040; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9	27	322	340	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					453	455		10.1038/362453a0	http://dx.doi.org/10.1038/362453a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8464477				2022-12-28	WOS:A1993KV42400085
J	RABINOWITZ, HK				RABINOWITZ, HK			RECRUITMENT, RETENTION, AND FOLLOW-UP OF GRADUATES OF A PROGRAM TO INCREASE THE NUMBER OF FAMILY PHYSICIANS IN RURAL AND UNDERSERVED AREAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL-SCHOOL	Background. To help address the geographic and specialty maldistribution of physicians, Jefferson Medical College initiated the Physician Shortage Area Program (PSAP) in 1974. This unique program, which combines a selective medical school admissions policy with a special educational program, has been shown to be successful in increasing the number of family physicians in rural and underserved areas, but it is not known whether they remain in this type of practice. Methods. Graduates of the PSAP were tracked longitudinally and compared with their non-PSAP classmates. Information was obtained about the retention of family physicians in rural areas and areas with a physician shortage over the previous five years, the geographic and specialty choices of more recent graduates, and the recruitment of applicants into the program. Results. Of the 47 PSAP graduates from the classes of 1978 through 1981, reported on earlier, the number who combined a career in family medicine with practice in a rural area or one with a physician shortage remained unchanged, although there was substantial attrition among non-PSAP graduates practicing family medicine in rural (32 percent) and underserved (40 percent) areas. Among the 101 PSAP graduates of the classes of 1982 through 1986, the results were similar to those for the first four classes. Overall, PSAP graduates from the classes of 1978 through 1986 were approximately four times as likely as non-PSAP graduates to practice family medicine (55 percent vs. 13 percent), to practice in a rural area (39 percent vs. 11 percent), and to practice in underserved areas (33 percent vs. 8 percent). They were approximately 10 times more likely to combine a career in family medicine with practice in a rural (26 percent vs. 3 percent) or underserved (23 percent vs. 2 percent) area. Overall, 85 percent of PSAP graduates were either practicing a primary care specialty or practicing in a rural or small metropolitan area or one with a shortage of physicians. In parallel with national trends, the number of applicants and matriculants to the program decreased during the past decade, so that the percentage of available places filled decreased from 97 percent to 33 percent. However, there has been a recent increase in the number of applicants and matriculants. Conclusions. The results of this study indicate that the PSAP was successful in increasing the number of family physicians in rural and underserved areas as well as in retaining them. This suggests that medical schools can have a substantial influence on the distribution of physicians according to specialty choice and the geographic location of their practices, principally through admission criteria.			RABINOWITZ, HK (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT FAMILY MED, SUITE 401, 1015 WALNUT ST, PHILADELPHIA, PA 19107 USA.							ADKINS RJ, 1987, J MED EDUC, V62, P810; Boulger J G, 1991, J Rural Health, V7, P105, DOI 10.1111/j.1748-0361.1991.tb00713.x; Brazeau N K, 1990, Fam Med, V22, P350; CARLINE JD, 1991, ACAD MED, V66, P44, DOI 10.1097/00001888-199101000-00013; Cohen J, 1977, STATISTICAL POWER AN; COLWILLJM, 1992, NEW ENGL J MED, V326, P387; Ernst R. L., 1985, PHYSICIAN LOCATION S; HERMAN MW, 1977, J MED EDUC, V52, P99; HOJAT M, 1986, EDUC PSYCHOL MEAS, V46, P761, DOI 10.1177/0013164486463034; KINDIG DA, 1989, HEALTH AFFAIR, V8, P63, DOI 10.1377/hlthaff.8.2.63; PATHMAN DE, 1992, JAMA-J AM MED ASSOC, V268, P1552; Rabinowitz H K, 1990, Fam Med, V22, P62; RABINOWITZ HK, 1983, JAMA-J AM MED ASSOC, V249, P1038, DOI 10.1001/jama.249.8.1038; RABINOWITZ HK, 1988, NEW ENGL J MED, V319, P480, DOI 10.1056/NEJM198808253190805; RABINOWITZ HK, 1988, J MED EDUC, V63, P732; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V268, P1559, DOI 10.1001/jama.268.12.1559; ROSENTHAL MP, 1992, 25TH ANN SPRING C SO; SCHEFFLER RM, 1978, NEW ENGL J MED, V298, P1058, DOI 10.1056/NEJM197805112981905; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; 1992, JAMA-J AM MED ASSOC, V268, P1092; 1991, 1990 CENSUS POPULATI; 1991, AAMC DATA BOOK; 1990, SUPPLYING PHYSICIANS; 1992, TASK FORCE GENERALIS; 1988, 1ST COUNC GRAD MED E, V1; 1980, DHHS HRA81651 PUBL; 1990, PHYSICIAN MANPOWER P	27	134	137	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 1	1993	328	13					934	939		10.1056/NEJM199304013281307	http://dx.doi.org/10.1056/NEJM199304013281307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU177	8446141	Bronze			2022-12-28	WOS:A1993KU17700007
J	GOODFELLOW, PN				GOODFELLOW, PN			PLANTING ALFALFA AND CLONING THE HUNTINGTONS-DISEASE GENE	CELL			English	Review							POLYMORPHIC DNA MARKER; MAMMALIAN GENOMIC DNA; LINKAGE DISEQUILIBRIUM				GOODFELLOW, PN (corresponding author), UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND.							Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; [Anonymous], 1993, CELL, V72, P971; BATES GP, 1992, NAT GENET, V1, P180, DOI 10.1038/ng0692-180; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BROWN WRA, 1986, NATURE, V322, P477, DOI 10.1038/322477a0; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARLEY HG, 1991, AM J HUM GENET, V49, P68; Harper PS, 1991, HUNTINGTONS DISEASE; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MACDONALD ME, 1989, NEURON, V3, P183, DOI 10.1016/0896-6273(89)90031-7; PRITCHARD C, 1992, AM J HUM GENET, V50, P1218; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; SNELL RG, 1989, J MED GENET, V26, P673, DOI 10.1136/jmg.26.11.673; TAYLOR SAM, 1992, NAT GENET, V2, P223, DOI 10.1038/ng1192-223; THEILMANN J, 1989, J MED GENET, V26, P676, DOI 10.1136/jmg.26.11.676; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0	21	11	16	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					817	818		10.1016/0092-8674(93)90569-C	http://dx.doi.org/10.1016/0092-8674(93)90569-C			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458076				2022-12-28	WOS:A1993KU17500001
J	ESMAIL, A; EVERINGTON, S				ESMAIL, A; EVERINGTON, S			RACIAL-DISCRIMINATION AGAINST DOCTORS FROM ETHNIC-MINORITIES	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	St Georges University London			Esmail, Aneez/I-6903-2013					Anwar M., 1987, OVERSEAS DOCTORS EXP; MCKEIGUE PM, 1990, BRIT MED J, V301, P961, DOI 10.1136/bmj.301.6758.961; 1976, DOCTORS OVERSEAS CAS	3	115	115	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					691	692		10.1136/bmj.306.6879.691	http://dx.doi.org/10.1136/bmj.306.6879.691			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KT216	8471921	Bronze, Green Published			2022-12-28	WOS:A1993KT21600021
J	KEELEY, D				KEELEY, D			THE FUNDHOLDING DEBATE - SHOULD PRACTICES RECONSIDER THE DECISION NOT TO FUNDHOLD	BRITISH MEDICAL JOURNAL			English	Article																			0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					697	698		10.1136/bmj.306.6879.697	http://dx.doi.org/10.1136/bmj.306.6879.697			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT216	8471926	Green Published, Bronze			2022-12-28	WOS:A1993KT21600026
J	MCLEAN, AD; STONEBRIDGE, PA; BRADBURY, AW; RAINEY, JB; MACLEOD, DAD				MCLEAN, AD; STONEBRIDGE, PA; BRADBURY, AW; RAINEY, JB; MACLEOD, DAD			TIME OF PRESENTATION, TIME OF OPERATION, AND UNNECESSARY APPENDECTOMY	BRITISH MEDICAL JOURNAL			English	Article							APPENDICITIS		ST JOHNS HOSP,DEPT SURG,LIVINGSTON EH54 6PP,W LOTHIAN,SCOTLAND									CAMPLING EA, 1992, REPORT NATIONAL CONF; HOFFMANN J, 1989, BRIT J SURG, V76, P774, DOI 10.1002/bjs.1800760803; JACOB ET, 1975, LANCET, V2, P1032; MALT RA, 1986, NEW ENGL J MED, V315, P1546, DOI 10.1056/NEJM198612113152409; 1987, LANCET, V24, P198	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					307	307		10.1136/bmj.306.6873.307	http://dx.doi.org/10.1136/bmj.306.6873.307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461650	Bronze, Green Published			2022-12-28	WOS:A1993KK71800022
J	HAMMERMEISTER, KE; SETHI, GK; HENDERSON, WG; OPRIAN, C; KIM, T; RAHIMTOOLA, S				HAMMERMEISTER, KE; SETHI, GK; HENDERSON, WG; OPRIAN, C; KIM, T; RAHIMTOOLA, S			A COMPARISON OF OUTCOMES IN MEN 11 YEARS AFTER HEART-VALVE REPLACEMENT WITH A MECHANICAL VALVE OR BIOPROSTHESIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY TISSUE FAILURE; CARPENTIER-EDWARDS; BJORK-SHILEY; FOLLOW-UP; PORCINE BIOPROSTHESES; 15-YEAR EXPERIENCE; RANDOMIZED TRIAL; HANCOCK; 10-YEAR; PROSTHESES	Background. Mechanical heart valves are durable but thrombogenic, and their use requires that the patient receive anticoagulants. in contrast, bioprosthetic valves are less thrombogenic, but they have limited durability because of tissue deterioration. Methods. To compare the outcomes of patients who receive these two types of valves, we randomly assigned 575 men scheduled to undergo aortic-valve or mitral-valve replacement to receive either a mechanical or a bioprosthetic valve. The primary end points were death from any cause and any valve-related complication. Results. During an average follow-up of 11 years, there was no difference between the two groups in the probability of death from any cause (11-year probability for mechanical valves, 0.57; for bioprostheses, 0.62; P = 0.57) or in the probability of any valve-related complication (0.65 and 0.69, respectively; P = 0.39). There was a much higher rate of structural valve failure among patients who received bioprosthetic valves (11-year probability, 0.15 for the aortic valves and 0.36 for the mitral valves) than among those who received mechanical valves (no valve failures; P < 0.001). However, this difference was offset by a higher rate of bleeding complications among patients with mechanical valves than among those with bioprosthetic valves (11-year probability, 0.42 and 0.26, respectively; P < 0.001) and by a greater frequency of periprosthetic valvular regurgitation among patients with mechanical mitral valves than among those with mitral bioprostheses (11-year probability, 0.17 and 0.09, respectively; P = 0.05). Conclusions. After 11 years, the rates of survival and freedom from all valve-related complications were similar for patients who received mechanical heart valves and those who received bioprosthetic heart valves. However, structural failure was observed only with the bioprosthetic valves, whereas bleeding complications were more frequent among patients who received mechanical valves.	UNIV COLORADO,SCH MED,DEPT MED,BOULDER,CO 80309; VET AFFAIRS MED CTR,CARDIOTHORAC SURG SECT,TUCSON,AZ; UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT SURG,TUCSON,AZ 85724; VET AFFAIRS MED CTR,CTR COORDINATING,COOPERAT STUDIES PROGRAM,HINES,IL; UNIV SO CALIF,DEPT MED,CARDIOL SECT,LOS ANGELES,CA 90089	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; University of Arizona; University of Arizona Health Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Southern California	HAMMERMEISTER, KE (corresponding author), VET AFFAIRS MED CTR,CARDIOL SECT 111B,1055 CLERMONT,DENVER,CO 80220, USA.							ATKINS CW, 1990, CIRCULATION S4, V82, P65; BLOOMFIELD P, 1991, NEW ENGL J MED, V324, P573, DOI 10.1056/NEJM199102283240901; BORDOLOTTI U, 1991, J CARD SURG S, V6, P638; BURDON TA, 1992, J THORAC CARDIOV SUR, V103, P238; COBANOGLU A, 1987, ANN THORAC SURG, V43, P245, DOI 10.1016/S0003-4975(10)60606-6; COHN LH, 1989, ANN SURG, V210, P435, DOI 10.1097/00000658-198910000-00003; CZER LSC, 1987, CHEST, V91, P503, DOI 10.1378/chest.91.4.503; DISESA VJ, 1987, J THORAC CARDIOV SUR, V94, P220; FOSTER AH, 1987, ANN THORAC SURG, V44, P568, DOI 10.1016/S0003-4975(10)62137-6; GALLO I, 1988, AM J CARDIOL, V61, P812, DOI 10.1016/0002-9149(88)91072-7; Gallucci V, 1988, J Card Surg, V3, P337; HAMMERMEISTER KE, 1987, J AM COLL CARDIOL, V10, P719, DOI 10.1016/S0735-1097(87)80263-2; HAMMOND GL, 1987, J THORAC CARDIOV SUR, V93, P182; HARKEN DE, 1960, J THORAC CARDIOV SUR, V40, P744, DOI 10.1016/S0022-5223(19)32572-3; HIRSH J, 1987, ARCH INTERN MED, V147, P769, DOI 10.1001/archinte.147.4.769; JAMIESON WRE, 1988, ANN THORAC SURG, V46, P155, DOI 10.1016/S0003-4975(10)65888-2; JONES EL, 1990, ANN THORAC SURG, V49, P370, DOI 10.1016/0003-4975(90)90240-7; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P12; KAWACHI Y, 1990, JPN CIRC J, V54, P137, DOI 10.1253/jcj.54.137; KAWACHI Y, 1990, JPN CIRC J, V54, P1525, DOI 10.1253/jcj.54.12_1525; KHURI SF, 1988, J AM COLL CARDIOL, V12, P8, DOI 10.1016/0735-1097(88)90349-X; LANDEFELD CS, 1989, J CLIN EPIDEMIOL, V42, P711, DOI 10.1016/0895-4356(89)90066-8; LEE ET, 1992, STATISTICAL METHODS, P104; LEVINE FH, 1981, CIRCULATION, V64, P192; MacArthur K J, 1988, Eur J Cardiothorac Surg, V2, P143, DOI 10.1016/1010-7940(88)90062-0; MAGILLIGAN DJ, 1989, ANN THORAC SURG, V48, P324, DOI 10.1016/S0003-4975(10)62850-0; MITCHELL RS, 1986, J THORAC CARDIOV SUR, V91, P807; MORISHITA Y, 1990, JPN J SURG, V20, P384, DOI 10.1007/BF02470821; MUDRA H, 1986, Z KARDIOL, V75, P277; NASHEF SAM, 1987, J THORAC CARDIOV SUR, V93, P394; PANSINI S, 1990, ANN THORAC SURG, V50, P590, DOI 10.1016/0003-4975(90)90195-C; PELLETIER LC, 1989, ANN THORAC SURG, V47, P352, DOI 10.1016/0003-4975(89)90373-1; PERIER P, 1989, ANN THORAC SURG, V48, P54, DOI 10.1016/0003-4975(89)90176-8; RAHIMTOOLA SH, 1989, CIRCULATION, V79, P732; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SETHI GK, 1987, J THORAC CARDIOV SUR, V93, P884; STARR A, 1961, ANN SURG, V154, P726, DOI 10.1097/00000658-196110000-00017; TEOH KH, 1989, CIRCULATION, V80, P8; VANHEURN LWE, 1991, THORAC CARDIOVASC SU, V39, P3; VOGT S, 1990, EUR HEART J, V11, P583, DOI 10.1093/oxfordjournals.eurheartj.a059763; 1983, CONTROLLED CLIN TRIA, V6, P51	41	323	333	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1993	328	18					1289	1296		10.1056/NEJM199305063281801	http://dx.doi.org/10.1056/NEJM199305063281801			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ640	8469251				2022-12-28	WOS:A1993KZ64000001
J	COLTON, T; GREENBERG, ER; NOLLER, K; RESSEGUIE, L; VANBENNEKOM, C; HEEREN, T; ZHANG, YQ				COLTON, T; GREENBERG, ER; NOLLER, K; RESSEGUIE, L; VANBENNEKOM, C; HEEREN, T; ZHANG, YQ			BREAST-CANCER IN MOTHERS PRESCRIBED DIETHYLSTILBESTROL IN PREGNANCY - FURTHER FOLLOW-UP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPRODUCTIVE FACTORS; EARLY ABORTION; YOUNG-WOMEN; RISK; STILBESTROL; TRIAL	Objective.-Further assessment of the long-term risk of breast cancer associated with diethylstilbestrol (DES) during pregnancy. Design.-Follow-up continuation through June 1, 1989, of a historical cohort of DES-exposed and unexposed mothers ascertained by review of obstetric records. Participants.-Totals of 3029 each of DES-exposed and unexposed mothers who had delivered live babies at four centers in the United States during 1940 through 1960. Questionnaires were returned for 92.6% of the DES-exposed and 88.8% of the unexposed women. Main Outcome Measures.-Breast cancer incidence and mortality assessed from returned questionnaires and review of medical records and death certificates. Main Results.-The relative rate of breast cancer associated with DES exposure, after adjustment for demographic and reproductive variables, was 1.35 (95% confidence interval, 1.05 to 1.74). For 30 years or more following exposure, the relative rate was not appreciably higher (relative rate, 1.33; 95% confidence interval, 0.95 to 1.87) than that in earlier periods. Surveillance and increased detection seemed unlikely explanations for the increased risk, since DES-exposed women had excesses of both large and small breast cancers and the two cohorts reported similar breast cancer detection practices. A history of miscarriage before first term delivery was not associated with breast cancer occurrence. Conclusion.-Exposure to DES during pregnancy is associated with a modest but statistically significant increased risk of breast cancer. Contrary to prior indications, the risk does not appear to increase greatly over time. The findings are sufficient to exclude the possibility of a doubling of risk for the period of 30 or more years following exposure.	NORRIS COTTON CANC CTR,HANOVER,NY; DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT FAMILY & COMMUNITY MED,HANOVER,NH 03756; UNIV MASSACHUSETTS,SCH MED,DEPT OBSTET & GYNECOL,WORCESTER,MA 01605	Norris Cotton Cancer Center; Dartmouth College; University of Massachusetts System; University of Massachusetts Worcester	COLTON, T (corresponding author), BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,80 E CONCORD ST,BOSTON,MA 02118, USA.			Heeren, Timothy/0000-0001-5643-3559; Zhang, Yuqing/0000-0001-7954-1149	NATIONAL CANCER INSTITUTE [R01CA040240] Funding Source: NIH RePORTER; NCI NIH HHS [5 R01 CA 40240-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adami H O, 1990, Int J Cancer Suppl, V5, P22; ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; BERAL V, 1980, BRIT MED J, V281, P1098, DOI 10.1136/bmj.281.6248.1098; BIBBO M, 1978, NEW ENGL J MED, V298, P763, DOI 10.1056/NEJM197804062981403; BRIAN DD, 1980, MAYO CLIN PROC, V55, P89; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; COX DR, 1972, J R STAT SOC B, V34, P187; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; HADJIMICHAEL OC, 1986, BRIT J CANCER, V53, P281, DOI 10.1038/bjc.1986.46; HADJIMICHAEL OC, 1984, J NATL CANCER I, V73, P831; HOWE HL, 1989, INT J EPIDEMIOL, V18, P300, DOI 10.1093/ije/18.2.300; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEY JL, 1990, EPIDEMIOL REV, V12, P228, DOI 10.1093/oxfordjournals.epirev.a036056; KVALE G, 1987, AM J EPIDEMIOL, V126, P831, DOI 10.1093/oxfordjournals.aje.a114720; PIKE MC, 1981, BRIT J CANCER, V43, P72, DOI 10.1038/bjc.1981.10; ROSENBERG L, 1988, AM J EPIDEMIOL, V127, P981, DOI 10.1093/oxfordjournals.aje.a114901; ROSS RK, 1985, NEW ENGL J MED, V312, P1059; STEVENS M, 1985, American Journal of Preventive Medicine, V1, P11; VESSEY MP, 1983, BRIT J OBSTET GYNAEC, V90, P1007, DOI 10.1111/j.1471-0528.1983.tb06438.x; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; 1987, IARC MONOGRAPHS S7, V1, P273	21	96	99	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2096	2100		10.1001/jama.269.16.2096	http://dx.doi.org/10.1001/jama.269.16.2096			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468763				2022-12-28	WOS:A1993KY36600030
J	WEISS, A				WEISS, A			T-CELL ANTIGEN RECEPTOR SIGNAL TRANSDUCTION - A TALE OF TAILS AND CYTOPLASMIC PROTEIN-TYROSINE KINASES	CELL			English	Review							ZETA-CHAIN; ACTIVATION; PHOSPHORYLATION; ASSOCIATION; P56LCK; CD45		UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	WEISS, A (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, IN PRESS J EXP MED; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; QIAN D, 1993, IN PRESS J BIOL CHEM; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; Veillette A, 1991, Semin Immunol, V3, P143; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T	33	551	573	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					209	212		10.1016/0092-8674(93)90221-B	http://dx.doi.org/10.1016/0092-8674(93)90221-B			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8477442				2022-12-28	WOS:A1993KY50500002
J	NISHIMI, RY				NISHIMI, RY			CYSTIC-FIBROSIS AND DNA TESTS - THE IMPLICATIONS OF CARRIER SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	5	5	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1921	1921		10.1001/jama.269.15.1921	http://dx.doi.org/10.1001/jama.269.15.1921			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464112	Green Submitted			2022-12-28	WOS:A1993KX21500004
J	CHIBA, T; NAGATA, Y; MACHIDE, M; KISHI, A; AMANUMA, H; SUGIYAMA, M; TODOKORO, K				CHIBA, T; NAGATA, Y; MACHIDE, M; KISHI, A; AMANUMA, H; SUGIYAMA, M; TODOKORO, K			TYROSINE KINASE ACTIVATION THROUGH THE EXTRACELLULAR DOMAINS OF CYTOKINE RECEPTORS	NATURE			English	Article							CELL-LINES; PHOSPHORYLATION; ERYTHROPOIETIN; PROTEINS; GENES	INTERACTION of cytokines with their membrane receptors induces the proliferation and differentiation of a specific lineage of haematopoietic progenitors1. The molecular mechanism of cytokine receptor-mediated signal transduction is unclear because these receptors do not have tyrosine kinase activity1-2. Interleukin-3 and erythropoietin, however, induce transient tyrosine phosphorylation of a common set of proteins as a growth signal3-6 and interleukin-2 induces phosphorylation of an overlapping but distinct set of proteins6-8. Here we show that chimaeric receptors consisting of the extracellular domains of the erythropoietin receptor and the cytoplasmic domains of the interleukin-2 (or interleukin-3) receptor induce an erythropoietin-dependent tyrosine phosphorylation in interleukin-3-dependent Ba/F3 cells; however, chimaeric receptors composed of the extracellular domains of the interleukin-2 receptor and the cytoplasmic domains of the erythropoietin (or interleukin-3) receptor apparently transmit an interleukin-2-dependent signal. Our results indicate that these cytokines transmit distinct signals for activation of specific tyrosine kinases through the extracellular rather than cytoplasmic domains of the receptors.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,3-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN	RIKEN								ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V184, P485, DOI 10.1016/0006-291X(92)91220-K; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KURAMOCHI S, 1991, BIOCHEM BIOPH RES CO, V181, P1103, DOI 10.1016/0006-291X(91)92052-L; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SABE H, 1991, INT IMMUNOL, V3, P1137, DOI 10.1093/intimm/3.11.1137; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; TODOKORO K, 1987, P NATL ACAD SCI USA, V84, P4126, DOI 10.1073/pnas.84.12.4126	17	76	77	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					646	648		10.1038/362646a0	http://dx.doi.org/10.1038/362646a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8464516				2022-12-28	WOS:A1993KX43800053
J	COLGAN, J; WAMPLER, S; MANLEY, JL				COLGAN, J; WAMPLER, S; MANLEY, JL			INTERACTION BETWEEN A TRANSCRIPTIONAL ACTIVATOR AND TRANSCRIPTION FACTOR-IIB INVIVO	NATURE			English	Article							RNA POLYMERASE-II; DNA-BINDING; INITIATION; PROTEINS; COMPLEX; MEDIATE	TRANSCRIPTION of messenger RNA-encoding genes in vitro requires many protein factors1,2. Transcription factor IID, possibly with the cooperation of TFIIA, binds to the TATA element of the promoter3-5, forming a complex that can bind TFIIB (refs 6, 7) followed by RNA polymerase II (refs 6, 8) and other factors9. One or more of these steps is thought to be facilitated by gene-specific transcriptional activation proteins10-12; this seems to require TFIID-associated auxiliary factors13-15 and may involve direct contact between the activator and TFIID16,17 and/or TFIIB18,19. If such contact is necessary in vivo, activation might conceivably be blocked by a TFIIB derivative containing the sequences necessary for this interaction, but lacking those necessary for binding to the rest of the transcriptional apparatus, an effect similar to that referred to as squelching20 or transcriptional interference21. Here we show that the activity of the glutamine-rich fushi tarazu activation domain is indeed blocked by truncated TFIIB derivatives in Drosophila Schneider L2 cells, suggesting that it is mediated by interactions with TFIIB.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	COLGAN, J (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Colgan, John/0000-0001-9273-2644; Manley, James/0000-0002-8341-1459				BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; RANISH JA, 1991, J BIOL CHEM, V266, P19320; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	31	78	78	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					549	553		10.1038/362549a0	http://dx.doi.org/10.1038/362549a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464496				2022-12-28	WOS:A1993KW45300057
J	HAUSER, P; ZAMETKIN, AJ; MARTINEZ, P; VITIELLO, B; MATOCHIK, JA; MIXSON, AJ; WEINTRAUB, BD				HAUSER, P; ZAMETKIN, AJ; MARTINEZ, P; VITIELLO, B; MATOCHIK, JA; MIXSON, AJ; WEINTRAUB, BD			ATTENTION-DEFICIT HYPERACTIVITY DISORDER IN PEOPLE WITH GENERALIZED RESISTANCE TO THYROID-HORMONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ERBA-BETA GENE; RECEPTOR; KINDREDS; BINDING; BRAIN; TRIIODOTHYRONINE; INTERVIEW; MUTATION; CHILDREN; PROTEIN	Background. Attention deficit-hyperactivity disorder is a well-recognized psychiatric disorder of childhood. Its cause is unknown, but there is evidence of a familial predisposition. Symptoms suggestive of this disorder have been reported in subjects with generalized resistance to thyroid hormone, a disease caused by mutations in the thyroid receptor-beta gene and characterized by reduced responsiveness of peripheral and pituitary tissues to the actions of thyroid hormone. We systematically evaluated the presence and severity of attention deficit-hyperactivity disorder in 18 families with a history of generalized resistance to thyroid hormone. Methods. We studied 49 affected and 55 unaffected family members; 52 were adults, and 52 were children. All subjects were evaluated with structured psychiatric questionnaires by interviewers who were unaware of the medical diagnosis. The number of symptoms of attention deficit-hyperactivity disorder was calculated for each subject. Results. Among the adults, 11 of 22 subjects with generalized resistance to thyroid hormone (50 percent) and 2 of 30 unaffected subjects (7 percent) had met the criteria for attention deficit-hyperactivity disorder as children (P less-than-or-equal-to 0.001). Among the children, 19 of 27 subjects resistant to thyroid hormone (70 percent) and 5 of 25 unaffected subjects (20 percent) met the criteria for the disorder (P<0.001). The odds of having attention deficit-hyperactivity disorder were 3.2 times higher for affected male subjects than for affected female subjects and 2.7 times higher for unaffected male subjects than for unaffected female subjects. The mean symptom score was 2.5 times higher in the affected group than in the unaffected group (7.0 vs. 2.8, P<0.001). The frequency of other psychiatric diagnoses was similar in the two groups. Conclusions. In our study sample, attention deficit-hyperactivity disorder is strongly associated with generalized resistance to thyroid hormone.	NIMH,CEREBRAL METAB LAB,CLIN BRAIN IMAGING SECT,BETHESDA,MD 20892; NIMH,DEV PSYCHOL LAB,BETHESDA,MD 20892; NIMH,DIV BASIC BRAIN & BEHAV SCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	HAUSER, P (corresponding author), NIDDKD,MOLEC & CELLULAR ENDOCRINOL BRANCH,RM 8D-14,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Vitiello, Benedetto/AAC-1758-2022; Mixson, Archibald/Q-5659-2019					ANDERSON JC, 1987, ARCH GEN PSYCHIAT, V44, P69; BERNAL J, 1984, ENDOCRINOLOGY, V114, P677, DOI 10.1210/endo-114-2-677; BIEDERMAN J, 1991, AM J PSYCHIAT, V148, P564; BIEDERMAN J, 1990, J AM ACAD CHILD PSY, V29, P526, DOI 10.1097/00004583-199007000-00004; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; FARSETTI A, 1992, J BIOL CHEM, V267, P17478; GAREAU JLP, 1988, NUCLEIC ACIDS RES, V16, P1223, DOI 10.1093/nar/16.3.1223; HERJANIC B, 1982, J ABNORM CHILD PSYCH, V10, P307, DOI 10.1007/BF00912324; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; JADRESIC DP, 1990, J PSYCHOSOM RES, V34, P603, DOI 10.1016/0022-3999(90)90104-C; MAGNER JA, 1986, J ENDOCRINOL INVEST, V9, P459, DOI 10.1007/BF03346968; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MIXSON AJ, 1992, J CLIN ENDOCR METAB, V75, P1039, DOI 10.1210/jc.75.4.1039; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; PIPAON C, 1992, J BIOL CHEM, V267, P21, DOI 10.1016/S0021-9258(18)48449-9; Reeve E, 1991, RITALIN THEORY PATIE, P289; REFETOFF S, 1972, METABOLISM, V21, P723, DOI 10.1016/0026-0495(72)90121-7; REFETOFF S, 1990, THYROID TODAY, V13, P1; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Shenker A, 1992, Adv Pediatr, V39, P337; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P712, DOI 10.1210/jc.74.4.712; USALA SJ, 1991, J CLIN ENDOCR METAB, V72, P32, DOI 10.1210/jcem-72-1-32; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; USALA SJ, 1988, MOL ENDOCRINOL, V2, P1217, DOI 10.1210/mend-2-12-1217; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZAMETKIN AJ, 1987, J AM ACAD CHILD PSY, V26, P676, DOI 10.1097/00004583-198709000-00011; ZAMETKIN AJ, 1988, J AM ACAD CHILD ADOL, V27, P338; 1987, DIAGNOSTIC STATISTIC	32	242	246	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					997	1001		10.1056/NEJM199304083281403	http://dx.doi.org/10.1056/NEJM199304083281403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KW282	8450877	Green Published			2022-12-28	WOS:A1993KW28200003
J	PEPYS, MB; HAWKINS, PN; BOOTH, DR; VIGUSHIN, DM; TENNENT, GA; SOUTAR, AK; TOTTY, N; NGUYEN, O; BLAKE, CCF; TERRY, CJ; FEEST, TG; ZALIN, AM; HSUAN, JJ				PEPYS, MB; HAWKINS, PN; BOOTH, DR; VIGUSHIN, DM; TENNENT, GA; SOUTAR, AK; TOTTY, N; NGUYEN, O; BLAKE, CCF; TERRY, CJ; FEEST, TG; ZALIN, AM; HSUAN, JJ			HUMAN LYSOZYME GENE-MUTATIONS CAUSE HEREDITARY SYSTEMIC AMYLOIDOSIS	NATURE			English	Article							DNA	HEREDITARY non-neuropathic systemic amyloidosis (Ostertag-type)1 is a rare autosomal dominant disease in which amyloid deposition in the viscera is usually fatal by the fifth decade. In some families it is caused by mutations in the apolipoprotein AI gene2,3 but in two unrelated English families under our care the amyloid deposits did not contain apoAI, despite a report that this may have been the case in one of them4. Lysozyme is a ubiquitous bacteriolytic enzyme present in external secretions5 and in polymorphs and macrophages, but its physiological role is not always clear6. Here we report that in these two families, lysozyme is the amyloid fibril protein. Affected individuals are heterozygous for point mutations in the lysozyme gene that cause substitution of highly conserved residues, namely threonine for isoleucine at position 56 in one family, and histidine for aspartic acid at residue 67 in the other. Amyloid fibrils from one individual were composed of the full-length Thr-56 variant lysozyme molecule. To our knowledge, this is the first report of naturally occurring variants of human lysozyme and of lysozyme-associated disease. As the structures of human7 and hen egg-white lysozyme8 are known to atomic resolution and their folding and structure-function relationships have been exhaustively analysed, our observations should provide a powerful model for understanding amyloidogenesis.	UNIV COLL & MIDDLESEX SCH MED,LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; WORDSLEY HOSP,STOURBRIDGE CY8 5QX,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,LIPOPROT TEAM,LONDON W12 0NN,ENGLAND; UNIV OXFORD,MOLEC BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; SOUTHMEAD GEN HOSP,DEPT RENAL MED,BRISTOL BS10 5NB,AVON,ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; Imperial College London; University of Oxford; Southmead Hospital	PEPYS, MB (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,IMMUNOL MED UNIT,LONDON W12 0NN,ENGLAND.		Hawkins, Philip N/C-5573-2008; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; ARTYMIUK PJ, 1979, NATURE, V280, P563, DOI 10.1038/280563a0; ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; ATHANASOU NA, 1992, HISTOPATHOLOGY, V20, P41, DOI 10.1111/j.1365-2559.1992.tb00914.x; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; Fleming A, 1922, P R SOC LOND B-CONTA, V93, P306, DOI 10.1098/rspb.1922.0023; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; Imoto T., 1972, ENZYMES, V7, P665; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; JONES LA, 1991, AMYLOID AND AMYLOIDOSIS 1990, P385; LANHAM JG, 1982, Q J MED, V51, P25; Ostertag B., 1932, ZENTRALBL AUG PATHOL, V56, P253; PATRINELY JR, 1992, ARCH OPHTHALMOL-CHIC, V110, P882, DOI 10.1001/archopht.1992.01080180154045; Pepys M. B, 1988, IMMUNOLOGICAL DISEAS, V1, P631; PETERS CWB, 1989, EUR J BIOCHEM, V182, P507, DOI 10.1111/j.1432-1033.1989.tb14857.x; PRAS M, 1968, J CLIN INVEST, V47, P924; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; RUPLEY JA, 1974, LYSOZYME, P251; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; SIDMAN K, 1988, NUCLEIC ACIDS RES, V16, P869; SOUTAR AK, 1992, P NATL ACAD SCI USA, V89, P7389, DOI 10.1073/pnas.89.16.7389; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; TALMUD P, 1991, ATHEROSCLEROSIS, V89, P137, DOI 10.1016/0021-9150(91)90053-6; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WILSON KP, 1992, J BIOL CHEM, V267, P10842; YAP KW, 1987, PARASITOL TODAY, V3, P220, DOI 10.1016/0169-4758(87)90065-2; ZALIN AM, 1991, Q J MED, V81, P945	31	548	573	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					553	557		10.1038/362553a0	http://dx.doi.org/10.1038/362553a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464497				2022-12-28	WOS:A1993KW45300058
J	SCHAEFFER, L; ROY, R; HUMBERT, S; MONCOLLIN, V; VERMEULEN, W; HOEIJMAKERS, JHJ; CHAMBON, P; EGLY, JM				SCHAEFFER, L; ROY, R; HUMBERT, S; MONCOLLIN, V; VERMEULEN, W; HOEIJMAKERS, JHJ; CHAMBON, P; EGLY, JM			DNA-REPAIR HELICASE - A COMPONENT OF BTF2 (TFIIH) BASIC TRANSCRIPTION FACTOR	SCIENCE			English	Article							RNA-POLYMERASE-II; PUTATIVE HELICASES; INITIATION-FACTOR; REPLICATION; PHOSPHORYLATION; PROTEINS; PROMOTER; REQUIREMENT; COMPLEXES; CLONING	The human BTF2 basic transcription factor (also called TFIIH), which is similar to the delta factor in rat and factor b in yeast, is required for class II gene transcription. A strand displacement assay was used to show that highly purified preparation of BTF2 had an adenosine triphosphate-dependent DNA helicase activity, in addition to the previously characterized carboxyl-terminal domain kinase activity. Amino acid sequence analysis of the tryptic digest generated from the 89-kilodalton subunit of BTF2 indicated that this polypeptide corresponded to the ERCC-3 gene product, a presumed helicase implicated in the human DNA excision repair disorders xeroderma pigmentosum and Cockayne's syndrome. These findings suggest that transcription and nucleotide excision repair may share common factors and hence may be considered to be functionally related.	FAC MED STRASBOURG, CNRS, UPR 6520, INSERM, U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE; ERASMUS UNIV, CTR MED GENET, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Erasmus University Rotterdam			MONCOLLIN, Vincent/R-1941-2017; Vermeulen, Wim/W-8708-2019; Hoeijmakers, Jan/AAX-6972-2021; Humbert, Sandrine/S-2981-2016	MONCOLLIN, Vincent/0000-0002-4163-0231; Vermeulen, Wim/0000-0003-3616-734X; schaeffer, laurent/0000-0001-6600-503X; Humbert, Sandrine/0000-0002-9501-2658				ARIAS JA, 1991, J BIOL CHEM, V266, P8055; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAI H, 1987, J BIOL CHEM, V262, P298; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FINKELSTEIN A, 1992, J BIOL CHEM, V355, P464; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; GERARD M, 1991, J BIOL CHEM, V266, P20940; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HEINTZ NH, 1992, TRENDS GENET, V8, P376, DOI 10.1016/0168-9525(92)90298-I; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HUMBERT S, UNPUB; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Ma L., UNPUB; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MATSON SW, 1986, J BIOL CHEM, V261, P169; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MOUNKES LC, IN PRESS CELL; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PUGH BF, 1992, J BIOL CHEM, V267, P679; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, UNPUB; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WASYLYK C, 1990, ONCOGENE, V5, P1055; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	64	715	728	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	1993	260	5104					58	63		10.1126/science.8465201	http://dx.doi.org/10.1126/science.8465201			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8465201				2022-12-28	WOS:A1993KV42300024
J	MATERSON, BJ; REDA, DJ; CUSHMAN, WC; MASSIE, BM; FREIS, ED; KOCHAR, MS; HAMBURGER, RJ; FYE, C; LAKSHMAN, R; GOTTDIENER, J; RAMIREZ, EA; HENDERSON, WG				MATERSON, BJ; REDA, DJ; CUSHMAN, WC; MASSIE, BM; FREIS, ED; KOCHAR, MS; HAMBURGER, RJ; FYE, C; LAKSHMAN, R; GOTTDIENER, J; RAMIREZ, EA; HENDERSON, WG			SINGLE-DRUG THERAPY FOR HYPERTENSION IN MEN - A COMPARISON OF 6 ANTIHYPERTENSIVE AGENTS WITH PLACEBO	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-PRESSURE; HYDROCHLOROTHIAZIDE; EFFICACY	Background. Characteristics such as age and race are often cited as determinants of the response of blood pressure to specific antihypertensive agents, but this clinically important issue has not been examined in sufficiently large trials, involving all standard treatments, to determine the effect of such factors. Methods. In a randomized, double-blind study at 15 clinics, we assigned 1292 men with diastolic blood pressures of 95 to 109 mm Hg, after a placebo washout period, to receive placebo or one of six drugs: hydrochlorothiazide (12.5 to 50 mg per day), atenolol (25 to 100 mg per day), captopril (25 to 100 mg per day), clonidine (0.2 to 0.6 mg per day), a sustained-release preparation of diltiazem (120 to 360 mg per day), or prazosin (4 to 20 mg per day). The drug doses were titrated to a goal of less than 90 mm Hg for maximal diastolic pressure, and the patients continued to receive therapy for at least one year. Results. The mean (+/- SD) age of the randomized patients was 59 +/- 10 years, and 48 percent were black. The average blood pressure at base line was 152 +/- 14/99 +/- 3 mm Hg. Diltiazem therapy had the highest rate of success: 59 percent of the treated patients had reached the blood-pressure goal at the end of the titration phase and had a diastolic blood pressure of less than 95 mm Hg at one year. Atenolol was successful by this definition in 51 percent of the patients, clonidine in 50 percent, hydrochlorothiazide in 46 percent, captopril in 42 percent, and prazosin in 42 percent; all these agents were superior to placebo (success rate, 25 percent). Diltiazem ranked first for younger blacks (< 60 years) and older blacks (greater-than-or-equal-to 60 years), among whom the success rate was 64 percent, captopril for younger whites (success rate, 55 percent), and atenolol for older whites (68 percent). Drug intolerance was more frequent with clonidine (14 percent) and prazosin (1 2 percent) than with the other drugs. Conclusions. Among men, race and age have an important effect on the response to single-drug therapy for hypertension. In addition to cost and quality of life, these factors should be considered in the initial choice of a drug.	DEPT VET AFFAIRS, MED RES SERV,COOPERAT STUDIES PROGRAM, MIAMI, FL USA					LAKSHMAN, RAJ/0000-0003-2415-4509; , Domenic/0000-0003-1831-4270				AMERY A, 1986, LANCET, V2, P589; [Anonymous], 1991, Arch Intern Med, V151, P1413; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; CODY RJ, 1983, HYPERTENSION, V5, P36; CUSHMAN WC, 1991, ARCH INTERN MED, V151, P1954, DOI 10.1001/archinte.151.10.1954; DRAYER JIM, 1983, HYPERTENSION, V5, P108; FREIS ED, 1983, HYPERTENSION, V5, P139; FREIS ED, 1983, AM J MED, V74, P1029, DOI 10.1016/0002-9343(83)90812-4; FREIS ED, 1988, AM J CARDIOL, V61, P117, DOI 10.1016/0002-9149(88)91316-1; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; MATERSON BJ, 1984, ARCH INTERN MED, V144, P1947; MATERSON BJ, 1982, BRIT J CLIN PHARMACO, V14, pS97; MATERSON BJ, 1990, HYPERTENSION, V15, P348, DOI 10.1161/01.HYP.15.4.348; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; SAUNDERS E, 1990, ARCH INTERN MED, V150, P1707, DOI 10.1001/archinte.150.8.1707; WASSERTHEILSMOLLER S, 1992, AM J HYPERTENS, V5, P37, DOI 10.1093/ajh/5.1.37; WOOLSON RF, 1987, STAT METHODS; 1989, SAS STAT USERS GUIDE, V1; 1982, JAMA-J AM MED ASSOC, V248, P2004; 1982, JAMA J AM MED ASS, V248, P1996	22	969	990	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 1	1993	328	13					914	921		10.1056/NEJM199304013281303	http://dx.doi.org/10.1056/NEJM199304013281303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU177	8446138				2022-12-28	WOS:A1993KU17700003
J	DALTON, DK; PITTSMEEK, S; KESHAV, S; FIGARI, IS; BRADLEY, A; STEWART, TA				DALTON, DK; PITTSMEEK, S; KESHAV, S; FIGARI, IS; BRADLEY, A; STEWART, TA			MULTIPLE DEFECTS OF IMMUNE CELL-FUNCTION IN MICE WITH DISRUPTED INTERFERON-GAMMA GENES	SCIENCE			English	Article							NATURAL-KILLER CELLS; MACROPHAGE ACTIVATION; CYTO-TOXICITY; IFN-GAMMA; MOUSE; EXPRESSION; INDUCTION; PROLIFERATION; LYMPHOKINE; CYTOKINES	Interferon-gamma (IFN-gamma) is a pleiotrophic cytokine with immunomodulatory effects on a variety of immune cells. Mice with a targeted disruption of the IFN-gamma gene were generated. These mice developed normally and were healthy in the absence of pathogens. However, mice deficient in IFN-gamma had impaired production of macrophage antimicrobial products and reduced expression of macrophage major histocompatibility complex class II antigens. IFN-gamma-deficient mice were killed by a sublethal dose of the intracellular pathogen Mycobacterium bovis. Splenocytes exhibited uncontrolled proliferation in response to mitogen and alloantigen. After a mixed lymphocyte reaction, T cell cytolytic activity was enhanced against allogeneic target cells. Resting splenic natural killer cell activity was reduced in IFN-gamma-deficient mice. Thus, IFN-gamma is essential for the function of several cell types of the murine immune system.	BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND; GENENTECH INC,S SAN FRANCISCO,CA 94080	Baylor College of Medicine; University of Oxford; Roche Holding; Genentech			Dalton, Dyana/D-2460-2009	Keshav, Satish/0000-0003-0508-8665; Bradley, Allan/0000-0002-2349-8839				BANCROFT GJ, 1989, J IMMUNOL, V143, P127; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BRENNAN GL, 1983, BIOTECHNIQUES, V1, P78; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; BUCY RP, 1988, J IMMUNOL, V140, P1148; CRAWFORD RM, 1987, J IMMUNOL, V139, P135; DALTON DA, UNPUB; DING AH, 1988, J IMMUNOL, V141, P2407; DJEU JY, 1982, J EXP MED, V156, P1222, DOI 10.1084/jem.156.4.1222; DJEU JY, 1979, J IMMUNOL, V122, P175; EZEKOWITZ RAB, 1981, J EXP MED, V154, P60, DOI 10.1084/jem.154.1.60; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GIDLUND M, 1978, NATURE, V273, P759, DOI 10.1038/273759a0; GIOVARELLI M, 1988, J IMMUNOL, V141, P2831; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HANDA K, 1983, J IMMUNOL, V130, P988; KESHAV S, 1991, J EXP MED, V174, P1049, DOI 10.1084/jem.174.5.1049; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; KIRCHNER H, 1979, EUR J IMMUNOL, V9, P824, DOI 10.1002/eji.1830091015; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRISSEY PJ, 1987, J IMMUNOL, V139, P1113; MURRAY HW, 1980, J EXP MED, V152, P1596, DOI 10.1084/jem.152.6.1596; NATHAN CF, 1984, J EXP MED, V160, P600, DOI 10.1084/jem.160.2.600; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PERUSSIA B, 1980, J IMMUNOL, V125, P1589; RANGES GE, 1987, J EXP MED, V166, P991, DOI 10.1084/jem.166.4.991; REED SG, 1987, J EXP MED, V166, P1734, DOI 10.1084/jem.166.6.1734; SCHREIBER R, 1991, CURRENT PROTOCOLS IM, V1, pCH6; SCHREIBER RD, 1985, J IMMUNOL, V134, P1609; SCHREIBER RD, 1985, LYMPHOKINES, V11, P87; STEIN M, 1991, CYTOKINES PRACTICAL, P245; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VILCEK J, 1985, LYMPHOKINES, V11, P1; WALLICK SC, 1990, J EXP MED, V172, P1777, DOI 10.1084/jem.172.6.1777; WEIGENT DA, 1983, INFECT IMMUN, V41, P992, DOI 10.1128/IAI.41.3.992-997.1983; WELSH RM, 1978, J IMMUNOL, V121, P1631	40	1503	1545	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1739	1742		10.1126/science.8456300	http://dx.doi.org/10.1126/science.8456300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456300				2022-12-28	WOS:A1993KT81000033
J	SONG, FJ; FREEMANTLE, N; SHELDON, TA; HOUSE, A; WATSON, P; LONG, A; MASON, J				SONG, FJ; FREEMANTLE, N; SHELDON, TA; HOUSE, A; WATSON, P; LONG, A; MASON, J			SELECTIVE SEROTONIN REUPTAKE INHIBITORS - METAANALYSIS OF EFFICACY AND ACCEPTABILITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAJOR DEPRESSIVE DISORDER; CONTROLLED CLINICAL-TRIAL; DOUBLE-BLIND PARALLEL; OUT-PATIENTS; FLUOXETINE; IMIPRAMINE; FLUVOXAMINE; PLACEBO; OUTPATIENTS; PAROXETINE	Objective-To examine the evidence for using selective serotonin reuptake inhibitors instead of tricyclic antidepressants in the first line treatment of depression. Design-Meta-analysis of 63 randomised controlled trials comparing the efficacy and acceptability of selective serotonin reuptake inhibitors with those of tricyclic and related antidepressants. Main outcome measures-Improvement in mean scores on Hamilton depression rating scale for 53 randomised controlled trials. Pooled drop out rates from the 58 trials which reported drop out by treatment group. Results-Among the 20 studies reporting standard deviation for the Hamilton score no difference was found in efficacy between serotonin reuptake inhibitors and tricyclic and related antidepressants (standardised mean difference 0.004, 95% confidence interval -0.096 to 0.105). The difference remained insignificant when the remaining 33 studies that used the 17 item and 21 item Hamilton score were included by ascribing weighted standard deviations. The odds ratio for drop out rate in patients receiving serotonin reuptake inhibitors compared with those receiving tricyclic antidepressants was 0.95 (0.86 to 1.07). Similar proportions in both groups cited lack of efficacy as the reason for dropping out but slightly more patients in the tricyclic group cited side effects (18.8%) v 15.4% in serotonin reuptake group). Conclusions-Routine use of selective serotonin reuptake inhibitors as the first line treatment of depressive illness may greatly increase cost with only questionable benefit.	UNIV YORK, CTR HLTH ECON, YORK YO1 5DD, N YORKSHIRE, ENGLAND; UNIV LEEDS, SCH PUBL HLTH, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; UNIV LEEDS, ACAD UNIT PUBL HLTH MED, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; GEN INFIRM, DEPT LIAISON PSYCHIAT, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND; UNIV LEEDS, NUFFIELD INST HLTH SERV STUDIES, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of York - UK; University of Leeds; University of Leeds; Leeds General Infirmary; University of Leeds			Mason, James M/D-9904-2011; Sheldon, Trevor/AAK-7088-2021; Song, Fujian/B-3516-2013	Mason, James M/0000-0001-9210-4082; Sheldon, Trevor/0000-0002-7479-5913; Freemantle, Nick/0000-0001-5807-5740; House, Allan/0000-0001-8721-8026				ALTAMURA AC, 1989, INT J CLIN PHARM RES, V9, P391; AMORE M, 1989, CURR THER RES CLIN E, V46, P815; BASCARA L, 1989, ACTA PSYCHIAT SCAND, V80, P141, DOI 10.1111/j.1600-0447.1989.tb07196.x; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BIGNAMINI A, 1992, INT CLIN PSYCHOPHARM, V6, P37, DOI 10.1097/00004850-199206004-00008; BRAMANTI P, 1988, CURR THER RES CLIN E, V43, P718; BRASSEUR R, 1989, INT CLIN PSYCHOPHARM, V4, P107; BREMNER JD, 1984, J CLIN PSYCHIAT, V45, P414; BRESSA GM, 1989, INT CLIN PSYCHOPHARM, V4, P69; CHOUINARD G, 1985, J CLIN PSYCHIAT, V46, P32; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; COHN CK, 1990, J CLIN PSYCHIAT, V51, P28; COHN JB, 1990, PSYCHOPHARMACOL BULL, V26, P185; COHN JB, 1985, J CLIN PSYCHIAT, V46, P26; CORNE SJ, 1989, INT CLIN PSYCHOPHARM, V4, P245, DOI 10.1097/00004850-198907000-00007; DEBUS JR, 1988, J CLIN PSYCHIAT, V49, P422; DEJONGHE F, 1991, PHARMACOPSYCHIATRY, V24, P21; DEJONGHE F, 1991, PHARMACOPSYCHIATRY, V24, P62, DOI 10.1055/s-2007-1014440; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEWILDE JE, 1983, BRIT J CLIN PHARMACO, V15, pS427; DICK P, 1983, BRIT J CLIN PHARMACO, V15, pS419, DOI 10.1111/j.1365-2125.1983.tb02132.x; DOMINGUEZ RA, 1985, J CLIN PSYCHIAT, V46, P84; DORMAN T, 1992, INT CLIN PSYCHOPHARM, V6, P53; DUNBAR GC, 1991, BRIT J PSYCHIAT, V159, P394, DOI 10.1192/bjp.159.3.394; DUNNER DL, 1992, J CLIN PSYCHIAT, V53, P57; EDWARDS JG, 1992, BRIT MED J, V304, P1644, DOI 10.1136/bmj.304.6843.1644; FABRE LF, 1991, J CLIN PSYCHIAT, V52, P62; Falk W E, 1989, J Geriatr Psychiatry Neurol, V2, P208, DOI 10.1177/089198878900200407; FEIGHNER JP, 1985, J CLIN PSYCHIAT, V46, P20; FEIGHNER JP, 1989, INT CLIN PSYCHOPHARM, V4, P239, DOI 10.1097/00004850-198907000-00006; FEIGHNER JP, 1991, J CLIN PSYCHIAT, V52, P329; FEIGHNER JP, 1985, J CLIN PSYCHIAT, V46, P369; FERRERI M, 1989, INT CLIN PSYCHOPHARM, V4, P97; FRADD SO, 1992, BRIT MED J, V305, P366, DOI 10.1136/bmj.305.6849.366-c; GINESTET D, 1989, INT CLIN PSYCHOPHARM, V4, P37; GONELLA G, 1990, CURR MED RES OPIN, V12, P177, DOI 10.1185/03007999009111499; GUELFI JD, 1983, BRIT J CLIN PHARMACO, V15, pS411, DOI 10.1111/j.1365-2125.1983.tb02131.x; GUILLIBERT E, 1989, ACTA PSYCHIAT SCAND, V80, P132, DOI 10.1111/j.1600-0447.1989.tb07192.x; GUY W, 1984, PSYCHOPHARMACOL BULL, V20, P73; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; HUTCHINSON DR, 1992, INT CLIN PSYCHOPHARM, V6, P43, DOI 10.1097/00004850-199206004-00009; ITIL TM, 1983, BRIT J CLIN PHARMACO, V15, pS433, DOI 10.1111/j.1365-2125.1983.tb02134.x; KUHS H, 1989, ACTA PSYCHIAT SCAND, V80, P145, DOI 10.1111/j.1600-0447.1989.tb07198.x; LAAKMANN G, 1988, BRIT J PSYCHIAT, V153, P64, DOI 10.1192/S0007125000297316; LADER M, 1988, BRIT J PSYCHIAT, V153, P51, DOI 10.1192/S0007125000297298; LAPIERRE YD, 1987, J CLIN PSYCHIAT, V48, P65; LAURSEN AL, 1985, ACTA PSYCHIAT SCAND, V71, P249, DOI 10.1111/j.1600-0447.1985.tb01281.x; LEIZOROVICZ A, 1992, LANCET, V340, P1102, DOI 10.1016/0140-6736(92)93126-8; LEVINE S, 1987, BRIT J PSYCHIAT, V150, P653, DOI 10.1192/bjp.150.5.653; LOEB C, 1989, INT CLIN PSYCHOPHARM, V4, P75; Long A F, 1992, Qual Health Care, V1, P74, DOI 10.1136/qshc.1.1.74; MANN A, 1987, ESSENTIALS POSTGRADU; MANNA V, 1989, INT CLIN PSYCHOPHARM, V4, P81; MARCH JS, 1990, J CLIN PSYCHIAT, V51, P200; MERTENS C, 1988, ACTA PSYCHIAT SCAND, V77, P683, DOI 10.1111/j.1600-0447.1988.tb05188.x; MUIJEN M, 1988, ACTA PSYCHIAT SCAND, V78, P384, DOI 10.1111/j.1600-0447.1988.tb06353.x; MULLIN JM, 1988, BRIT J CLIN PRACT, V42, P51; NIELSEN OA, 1991, ACTA PSYCHIAT SCAND, V84, P233, DOI 10.1111/j.1600-0447.1991.tb03136.x; NORTON KRW, 1984, J AFFECT DISORDERS, V7, P297, DOI 10.1016/0165-0327(84)90051-X; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; PEREZ A, 1990, CURR MED RES OPIN, V12, P234, DOI 10.1185/03007999009111652; PERRY PJ, 1989, J CLIN PSYCHIAT, V50, P290; PESELOW ED, 1989, PSYCHOPHARMACOL BULL, V25, P267; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PHANJOO AL, 1991, ACTA PSYCHIAT SCAND, V83, P476, DOI 10.1111/j.1600-0447.1991.tb05579.x; POELINGER W, 1989, INT CLIN PSYCHOPHARM, V4, P47; RAHMAN MK, 1991, BRIT J CLIN PRACT, V45, P255; REIMHERR FW, 1990, J CLIN PSYCHIAT, V51, P18; ROPERT R, 1989, INT CLIN PSYCHOPHARM, V4, P89; ROTH D, 1990, PROG NEURO-PSYCHOPH, V14, P929, DOI 10.1016/0278-5846(90)90078-U; SCHMIDT MJ, 1988, BRIT J PSYCHIAT, V153, P40, DOI 10.1192/S0007125000297274; STARK P, 1985, J CLIN PSYCHIAT, V46, P53; TAMMINEN TTA, 1989, INT CLIN PSYCHOPHARM, V4, P51; TANERI Z, 1989, INT CLIN PSYCHOPHARM, V4, P57; YOUNG JPR, 1987, BRIT J PSYCHIAT, V151, P337, DOI 10.1192/bjp.151.3.337; 1992, GUIDELINES TREATING; 1992, MED LETT DRUGS THER, V34, P47; 1988, INT CLIN PSYCHOPHARM, V3, P75; 1990, J AFFECTIVE DISORDS, V18, P289	80	355	361	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	1993	306	6879					683	687		10.1136/bmj.306.6879.683	http://dx.doi.org/10.1136/bmj.306.6879.683			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT216	8471919	Green Published, Bronze			2022-12-28	WOS:A1993KT21600019
J	NINAN, G; PURI, P				NINAN, G; PURI, P			LESSON OF THE WEEK - LATE PRESENTATION OF TRAUMATIC RUPTURE OF THE DIAPHRAGM IN A CHILD	BRITISH MEDICAL JOURNAL			English	Article							BLUNT TRAUMA; HERNIA		CHILDRENS HOSP,DUBLIN 1,IRELAND	Trinity College Dublin								BEAL SL, 1988, ARCH SURG-CHICAGO, V123, P828; BELGERDEN S, 1990, ZBL CHIR, V115, P603; BROOS PLO, 1989, INT SURG, V74, P88; GELMAN R, 1991, AM J ROENTGENOL, V156, P51, DOI 10.2214/ajr.156.1.1898570; GRIMES OF, 1974, AM J SURG, V128, P175; HALLER JA, 1980, SURG ROUNDS, V3, P23; MCCOLLUM C, 1987, BRIT J SURG, V74, P181, DOI 10.1002/bjs.1800740308; RUBIO PA, 1990, SOUTHERN MED J, V83, P260, DOI 10.1097/00007611-199002000-00036; Toh C L, 1991, J R Coll Surg Edinb, V36, P25; 1991, ROAD ACCIDENT FACTS; 1987, HOSPITAL PREHOSPITAL	11	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					643	644		10.1136/bmj.306.6878.643	http://dx.doi.org/10.1136/bmj.306.6878.643			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461820	Green Published, Bronze			2022-12-28	WOS:A1993KQ85900029
J	SCHIMMEL, P				SCHIMMEL, P			GTP HYDROLYSIS IN PROTEIN-SYNTHESIS - 2 FOR TU	SCIENCE			English	Editorial Material							POLYPEPTIDE-CHAIN ELONGATION; TRANSFER-RNA-BINDING; EF-TU; ESCHERICHIA-COLI; MOLECULES PARTICIPATE; DOMAIN				SCHIMMEL, P (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.							ANBORGH PH, 1991, FEBS LETT, V292, P232, DOI 10.1016/0014-5793(91)80874-3; BENSCH K, 1991, BIOCHIMIE, V73, P1045, DOI 10.1016/0300-9084(91)90146-R; BERG P, 1961, ANN REV BIOCH, V30, P292; CABRER B, 1976, J BIOL CHEM, V251, P1718; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HWANG YW, 1987, J BILL CHEM, V262; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; MILLER DL, 1978, MOL MECHANISMS PROTE, P323; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NISHIZUKA Y, 1966, ARCH BIOCHEM BIOPHYS, V116, P344, DOI 10.1016/0003-9861(66)90040-3; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; THOMPSON RC, 1981, J BIOL CHEM, V256, P81; VIJGENBOOM E, 1985, EMBO J, V4, P1049, DOI 10.1002/j.1460-2075.1985.tb03737.x; VIJGENBOOM E, 1989, J BIOL CHEM, V264, P13012; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899	20	19	19	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1264	1265		10.1126/science.8446896	http://dx.doi.org/10.1126/science.8446896			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446896				2022-12-28	WOS:A1993KN88300017
J	SAMUELS, MP; POETS, CF; NOYES, JP; HARTMANN, H; HEWERTSON, J; SOUTHALL, DP				SAMUELS, MP; POETS, CF; NOYES, JP; HARTMANN, H; HEWERTSON, J; SOUTHALL, DP			DIAGNOSIS AND MANAGEMENT AFTER LIFE THREATENING EVENTS IN INFANTS AND YOUNG-CHILDREN WHO RECEIVED CARDIOPULMONARY-RESUSCITATION	BRITISH MEDICAL JOURNAL			English	Article							SEVERE ARTERIAL HYPOXEMIA; BLOOD-TRANSFUSION; PARTIAL SEIZURES; SUDDEN-DEATH; APNEA; OBSTRUCTION; EPISODES	Objective-To determine the mechanisms and thereby appropriate management for apparent life threatening events treated with cardiopulmonary resuscitation in infants and young children. Design-Prospective clinical and physiological study. Setting-Royal Brompton Hospital or in patients' homes, or both. Subjects-157 Patients referred at median age 2.8 months (range 1 week to 96 months), 111 (71%) had recurrent events, 44 were born preterm, 19 were siblings of infants who had died suddenly and unexpectedly, and 18 were over 12 months old. Interventions-Multichannel physiological recordings, including oxygenation, in hospital (n=150) and at home (n=61). Additional recordings with electroencephalogram, video, or other respiratory measures were used to confirm diagnoses. Management involved monitoring of oxygen at home, additional inspired oxygen, anticonvulsant treatment, or child protection procedures. Main outcome measures-Abnormalities on recordings compared to published normal data and their correlation with clinical events; sudden death. Results-53 of 150 patients had abnormalities of oxygenation on hospital recordings, 28 of whom had an accompanying clinical event. Home recordings produced physiological data from 34 of 61 patients during subsequent clinical events. Final diagnoses were reached in 77 patients: deliberate suffocation by a parent (18), hypoxaemia induced by epileptic seizure (10), fabricated history and data (Munchausen syndrome by proxy; seven), acute hypoxaemia of probable respiratory origin (40), and changes in peripheral perfusion and skin colour without hypoxaemia (two). Four patients died: three suddenly and unexpectedly (none on home oxygen monitors) and one from pneumonia. Conclusions-Identification of mechanisms is essential to the appropriate management of infants with apparent fife threatening events.			SAMUELS, MP (corresponding author), UNIV KEELE,N STAFFORDSHIRE HOSP CTR,ACAD DEPT PAEDIAT,STOKE ON TRENT ST4 6QG,ENGLAND.							ABRAHAM NG, 1990, PEDIATR PULM, V8, P259, DOI 10.1002/ppul.1950080409; BROWN DC, 1991, ARCH DIS CHILD, V66, P986, DOI 10.1136/adc.66.8.986; DEMAIO JG, 1989, J PEDIATR-US, V114, P1039, DOI 10.1016/S0022-3476(89)80459-7; HOLOWACH J, 1963, NEW ENGL J MED, V268, P21, DOI 10.1056/NEJM196301032680105; JAMES LS, 1957, J PEDIATR-US, V51, P5, DOI 10.1016/S0022-3476(57)80274-1; JOSHI A, 1987, PEDIATRICS, V80, P79; KEETON BR, 1977, BRIT MED J, V2, P600, DOI 10.1136/bmj.2.6087.600; Little G., 1987, PEDIATRICS, V79, P292; OREN J, 1986, PEDIATRICS, V77, P495; POETS CF, 1992, PEDIATRICS, V90, P385; POETS CF, 1991, ARCH DIS CHILD, V66, P676, DOI 10.1136/adc.66.6.676; POETS CF, 1992, ACTA PAEDIATR, V81, P319, DOI 10.1111/j.1651-2227.1992.tb12234.x; POETS CF, 1992, ACTA PAEDIATR, V81, P536, DOI 10.1111/j.1651-2227.1992.tb12290.x; POETS CF, 1992, J PEDIATR-US, V120, P447, DOI 10.1016/S0022-3476(05)80919-9; POETS CF, 1992, PEDIATR PULM, V14, P257; SAMUELS MP, 1991, ARCH DIS CHILD, V66, P257, DOI 10.1136/adc.66.2.257; SAMUELS MP, 1992, ACTA PAEDIATR, V81, P875, DOI 10.1111/j.1651-2227.1992.tb12127.x; SAMUELS MP, 1992, BRIT J HOSP MED, V47, P759; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P162, DOI 10.1136/adc.67.2.162; SMITH PEM, 1989, ELECTROEN CLIN NEURO, V72, P207, DOI 10.1016/0013-4694(89)90245-9; SOUTHALL DP, 1988, ARCH DIS CHILD, V63, P598, DOI 10.1136/adc.63.6.598; SOUTHALL DP, 1987, DEV MED CHILD NEUROL, V29, P784; SOUTHALL DP, 1990, ARCH DIS CHILD, V65, P953, DOI 10.1136/adc.65.9.953; SOUTHALL DP, 1989, EUR J PEDIATR, V148, P353, DOI 10.1007/BF00444133; SOUTHALL DP, 1989, MATERN CHILD HLTH J, V14, P210; STEBBENS VA, 1991, ARCH DIS CHILD, V66, P569, DOI 10.1136/adc.66.5.569; TAYUYBOCO JS, 1989, J PEDIATR-US, V115, P456, DOI 10.1016/S0022-3476(89)80855-8; UPTON CJ, 1992, ARCH DIS CHILD-FETAL, V67, P419, DOI 10.1136/adc.67.4_Spec_No.419	28	54	58	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					489	492		10.1136/bmj.306.6876.489	http://dx.doi.org/10.1136/bmj.306.6876.489			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448459	Green Published, Bronze			2022-12-28	WOS:A1993KN78600018
J	VEEKEN, H				VEEKEN, H			LETTER FROM ALBANIA - A COUNTRY IN TRANSITION	BRITISH MEDICAL JOURNAL			English	Article									MED SANS FRONTIERES,TIRANE,ALBANIA	Doctors Without Borders									0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					446	447		10.1136/bmj.306.6875.446	http://dx.doi.org/10.1136/bmj.306.6875.446			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461730	Bronze, Green Published			2022-12-28	WOS:A1993KM70000029
J	MCCULLOUGH, J				MCCULLOUGH, J			THE NATIONS CHANGING BLOOD-SUPPLY SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK; TRANSFUSION; TRANSMISSION; EXPOSURE; HIV-1		AMER RED CROSS,BLOOD SERV,ST PAUL,MN; UNIV MINNESOTA HOSP & CLIN,TRANSFUS MED SECT,MINNEAPOLIS,MN 55455	American Red Cross; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital	MCCULLOUGH, J (corresponding author), UNIV MINNESOTA HOSP & CLIN,DEPT LAB MED & PATHOL,DIV LAB MED,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.							BIRKMEYER JD, IN PRESS TRANSFUSION; BRECHER ME, 1988, LAB MED, V19, P103; BUSCH MP, 1992, TRANSFUSION, V32, P800, DOI 10.1046/j.1537-2995.1992.32993110749.x; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; CATES W, 1992, NEW ENGL J MED, V327, P492, DOI 10.1056/NEJM199208133270711; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DINMAN BD, 1980, JAMA-J AM MED ASSOC, V244, P1226, DOI 10.1001/jama.244.11.1226; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; FREUDENBURG WR, 1988, SCIENCE, V242, P44, DOI 10.1126/science.3175635; GALDWELL M, 1989, WASHINGTON POST 0819; GRINDON AJ, 1991, TRANSFUSION, V31, P872, DOI 10.1046/j.1537-2995.1991.31992094680.x; GROSSMAN BJ, 1992, TRANSFUSION, V32, P868, DOI 10.1046/j.1537-2995.1992.32993110762.x; HILTS PJ, 1991, NY TIMES        0321, pA1; HILTS PJ, 1991, NY TIMES        0520, pA6; INGERSOLL B, 1991, WALL STREET J   0913; KLEIN RS, 1990, ANN INTERN MED, V113, P729, DOI 10.7326/0003-4819-113-10-729; KLEINMAN S, 1992, TRANSFUSION, V32, P805, DOI 10.1046/j.1537-2995.1992.32993110750.x; MACPHERSON JL, 1990, FEB P NAT C SPONS AM; MOYER LA, 1992, TRANSFUSION, V32, P702, DOI 10.1046/j.1537-2995.1992.32893032094.x; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; NIGHTINGALE SL, 1992, MMWR, V41, P28; SAYERS MH, 1992, TRANSFUSION, V32, P465, DOI 10.1046/j.1537-2995.1992.32592327722.x; SILBERSTEIN LE, 1989, JAMA-J AM MED ASSOC, V262, P1993, DOI 10.1001/jama.262.14.1993; SOLOMON JM, 1981, FEDERAL LEGISLATION, P143; STARKEY JM, 1989, JAMA-J AM MED ASSOC, V262, P3452, DOI 10.1001/jama.262.24.3452; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WILLIAMS AE, 1992, TRANSFUSION, V32, P455; ZECKHAUSER RJ, 1990, SCIENCE, V248, P559, DOI 10.1126/science.2333509; 1989, MMWR, V38, P11	32	75	76	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1993	269	17					2239	2245		10.1001/jama.269.17.2239	http://dx.doi.org/10.1001/jama.269.17.2239			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ406	8474203				2022-12-28	WOS:A1993KZ40600032
J	LUNDBLAD, V; BLACKBURN, EH				LUNDBLAD, V; BLACKBURN, EH			AN ALTERNATIVE PATHWAY FOR YEAST TELOMERE MAINTENANCE RESCUES EST1- SENESCENCE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-SEQUENCES; DROSOPHILA-MELANOGASTER; CHROMOSOME ENDS; HET DNA; RECOMBINATION; POLYMORPHISM; RNA; IDENTIFICATION; BEHAVIOR	Yeast cells lacking a functional EST1 gene show progressive shortening of the terminal G1-3T telomeric repeats and a parallel increase in the frequency of cell death. Although the majority of the cells in an est1-culture die, a minor subpopulation survives the potentially lethal consequences of the est1 mutation. We show that these est1- survivors arise as a result of the amplification and acquisition of subtelomeric elements (and their deletion derivatives) by a large number of telomeres. Hence, even when the primary pathway for telomere replication is defective, an alternative backup pathway can restore telomere function and keep the cell alive.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [GM26259, GM32565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032565, R37GM026259, R01GM026259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIESSMANN H, 1988, EMBO J, V7, P1081, DOI 10.1002/j.1460-2075.1988.tb02916.x; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BIESSMANN H, 1992, MOL CELL BIOL, V12, P3910, DOI 10.1128/MCB.12.9.3910; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; BUDARF M, 1987, NUCLEIC ACIDS RES, V15, P6273, DOI 10.1093/nar/15.15.6273; BUTTON LL, 1986, MOL CELL BIOL, V6, P1352, DOI 10.1128/MCB.6.4.1352; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; HABER JE, 1984, GENETICS, V106, P185; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HOROWITZ H, 1984, MOL CELL BIOL, V4, P2509, DOI 10.1128/MCB.4.11.2509; HOROWITZ H, 1985, MOL CELL BIOL, V5, P2369, DOI 10.1128/MCB.5.9.2369; JAGER D, 1989, MOL CELL BIOL, V9, P5754; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; LICHTEN M, 1987, GENETICS, V115, P233; LOUIS EJ, 1990, GENETICS, V124, P533; LOUIS EJ, 1990, GENETICS, V124, P547; LOUIS EJ, 1991, CURR GENET, V20, P411, DOI 10.1007/BF00317070; LOUIS EJ, 1992, GENETICS, V131, P559; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1990, CELL, V60, P529; MURRAY AW, 1988, MOL CELL BIOL, V8, P4642, DOI 10.1128/MCB.8.11.4642; MURRAY AW, 1986, MOL CELL BIOL, V6, P3166, DOI 10.1128/MCB.6.9.3166; NICHOLAS A, 1989, NATURE, V338, P35; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PACE T, 1990, MOL CELL BIOL, V10, P6759, DOI 10.1128/MCB.10.12.6759; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; PLUTA AF, 1984, P NATL ACAD SCI-BIOL, V81, P1475, DOI 10.1073/pnas.81.5.1475; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; ROSS LO, 1992, GENETICS, V131, P541; Sambrook J, 1989, MOL CLONING LABORATO; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; VALGEIRSDOTTIR K, 1990, P NATL ACAD SCI USA, V87, P7998, DOI 10.1073/pnas.87.20.7998; VANDERWERF A, 1990, EMBO J, V9, P1035, DOI 10.1002/j.1460-2075.1990.tb08207.x; VOYTAS DF, 1992, NATURE, V358, P717, DOI 10.1038/358717a0; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1988, MOL CELL BIOL, V8, P2257, DOI 10.1128/MCB.8.5.2257; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	51	787	801	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					347	360		10.1016/0092-8674(93)90234-H	http://dx.doi.org/10.1016/0092-8674(93)90234-H			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8477448				2022-12-28	WOS:A1993KY50500015
J	JOHNSON, PA; LEE, TH; COOK, EF; ROUAN, GW; GOLDMAN, L				JOHNSON, PA; LEE, TH; COOK, EF; ROUAN, GW; GOLDMAN, L			EFFECT OF RACE ON THE PRESENTATION AND MANAGEMENT OF PATIENTS WITH ACUTE CHEST PAIN	ANNALS OF INTERNAL MEDICINE			English	Article						CHEST PAIN; BLACKS; WHITES; HEALTH SERVICES, ACCESSIBILITY; EMERGENCY SERVICE, HOSPITAL	ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; ISCHEMIC HEART-DISEASE; BLACK POPULATIONS; NATURAL-HISTORY; EMERGENCY ROOM; MORTALITY; RATES; CARE; TRIAGE	Objective: To compare racial differences in clinical presentation, natural history, and access to medical care and procedures among emergency-department patients with acute chest pain. Design: Prospective follow-up study of consecutive patients coming to the emergency department because of acute chest pain. Setting: Two university medical centers. Patients: A total of 3031 patients who were 30 years or older and who came to the emergency department with acute chest pain from 1984 to 1986. Main Results: African-Americans tended to have slightly, but not always significantly, lower rates of acute myocardial infarction, acute ischemic heart disease, and major complications, after adjusting for presenting symptoms and signs; the adjusted odds ratios for African-Americans were as follows: 0.77 (95% CI, 0.54 to 1.1) for acute myocardial infarction, 0.75 (CI, 0.59 to 0.95) for ischemic heart disease, and 0.79 (CI, 0.45 to 1.4) for death or major complications. Clinical factors classically associated with acute myocardial infarction were equally predictive in African-Americans and whites. After adjustments were made for multiple clinical factors, a lower proportion of African-Americans were admitted to the hospital (odds ratio, 0.69; CI, 0.56 to 0.84), and, once admitted, were somewhat less likely to be triaged to the coronary care unit (odds ratio, 0.81; CI, 0.65 to 1.0). In adjusted analyses, African-Americans were as likely to undergo cardiac catheterization as whites (odds ratio, 0.86; CI, 0.64 to 1.2) but were less likely to undergo coronary artery bypass procedures once severity of coronary disease was included in the analysis (odds ratio, 0.24; CI, 0.08 to 0.71). Conclusion: African-Americans and whites had a similar presentation and natural history of acute myocardial infarction and, after adjusting for probability of clinical events, similar access to most medical care and cardiac procedures. However, the rate of coronary artery bypass procedures was much lower among African-Americans than among whites. Reasons for this difference should be studied.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV CLIN EPIDEMIOL,75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; UNIV CINCINNATI HOSP, CINCINNATI, OH USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University System of Ohio; University of Cincinnati					AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006452, R03HS005927] Funding Source: NIH RePORTER; AHRQ HHS [HS-5927, R01HS06452] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BEAMER AD, 1987, AM J CARDIOL, V60, P998, DOI 10.1016/0002-9149(87)90340-7; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CASTANER A, 1988, ANN INTERN MED, V109, P33, DOI 10.7326/0003-4819-109-1-33; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; CUNNINGHAM MA, 1989, J GEN INTERN MED, V4, P392, DOI 10.1007/BF02599688; CURRY CL, 1991, CIRCULATION, V83, P1474, DOI 10.1161/01.CIR.83.4.1474; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GILLUM RF, 1982, AM HEART J, V104, P839, DOI 10.1016/0002-8703(82)90021-7; GILLUM RF, 1984, AM HEART J, V108, P728, DOI 10.1016/0002-8703(84)90665-3; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; KEIL JE, 1985, AM HEART J, V109, P776, DOI 10.1016/0002-8703(85)90638-6; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEE TH, 1987, ARCH INTERN MED, V147, P115, DOI 10.1001/archinte.147.1.115; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; LEE TH, 1990, J GEN INTERN MED, V5, P381, DOI 10.1007/BF02599421; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; OBERMAN A, 1984, AM HEART J, V108, P688, DOI 10.1016/0002-8703(84)90656-2; ROIG E, 1987, CIRCULATION, V76, P280, DOI 10.1161/01.CIR.76.2.280; SOLOMON CG, 1989, AM J CARDIOL, V63, P772, DOI 10.1016/0002-9149(89)90040-4; STERN MP, 1979, ANN INTERN MED, V91, P630, DOI 10.7326/0003-4819-91-4-630; STROGATZ DS, 1990, AM J PUBLIC HEALTH, V80, P290, DOI 10.2105/AJPH.80.3.290; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; 1990, HEART STROKE FACTS	29	215	215	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					593	601		10.7326/0003-4819-118-8-199304150-00004	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8452325				2022-12-28	WOS:A1993KW47000004
J	ROGERS, AS; FROGGATT, JW; TOWNSEND, T; GORDON, T; BROWN, AJL; HOLMES, EC; ZHANG, LQ; MOSES, H				ROGERS, AS; FROGGATT, JW; TOWNSEND, T; GORDON, T; BROWN, AJL; HOLMES, EC; ZHANG, LQ; MOSES, H			INVESTIGATION OF POTENTIAL HIV TRANSMISSION TO THE PATIENTS OF AN HIV-INFECTED SURGEON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDIVIDUALS; AIDS	Objective.-To ascertain if a surgeon infected with the human immunodeficiency virus (HIV) transmitted HIV to patients during invasive surgical procedures. Design.-Survey of patients and acquired immunodeficiency syndrome (AIDS) case registries, and laboratory analysis of nucleotide sequence data. Setting.-One surgeon's private and institutional practices within one academic referral hospital. Patients.-A total of 1131 persons identified in hospital databases who under-went invasive surgical procedures from 1984 through 1990 and for whom the surgeon was listed as the admitting or operating surgeon. Measurement.-Patients presumed to be living were surveyed by mailed questionnaire. The AIDS case registries were reviewed for all patients having undergone invasive procedures and death certificates were obtained. Person-hours of surgery during which exposure might have occurred were calculated for surgical procedures. Results.-Of 1131 patients, 101 were dead, 119 had no address, 413 had test results known, and 498 did not respond to the questionnaire. No study patient name was found in reported AIDS case registries. One newly detected, HIV-seropositive patient was determined (through nucleotide sequencing) to have been most probably infected in 1985 during a transfusion. There was no HIV transmission in 369 person-hours of surgical exposure, indicating that HIV transmission to patients is unlikely to occur more frequently than once per 1000 person-hours of surgical exposure. Conclusions.-If study validity and resources permit, investigation of publicly disclosed, HIV-infected health care workers whose practices involve invasive procedures should be pursued. The risk of HIV transmission during surgery may be so small that it will be quantified only by pooling data from multiple, methodologically similar investigations.	MARYLAND DEPT HLTH & MENTAL HYG,AIDS ADM,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; UNIV EDINBURGH,DEPT BIOL SCI,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; JOHNS HOPKINS UNIV HOSP,BALTIMORE,MD 21205	Maryland Department of Health & Mental Hygiene; Johns Hopkins University; University of Edinburgh; Johns Hopkins University; Johns Hopkins Medicine			Gordon, Toby/AAG-1436-2019; Brown, Andrew Leigh/ABF-8269-2020; Holmes, Edward/GVR-9499-2022; Leigh Brown, Andrew/F-3802-2010	Brown, Andrew Leigh/0000-0002-5700-3128; Leigh Brown, Andrew/0000-0002-5700-3128; Holmes, Edward/0000-0001-9596-3552	PHS HHS [U62/CCU307194-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMSTRONG FP, 1987, MIL MED, V152, P414; BELL DM, 1991, 7TH INT C AIDS FLOR; CHAMBERLAND ME, 1992, ANN INTERN MED, V116, P871, DOI 10.7326/0003-4819-116-10-871; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Comer R W, 1991, J Dent Educ, V55, P187; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; FELSENSTEIN J, 1991, PHYLIP 3 4 MANUAL; HOLMES EC, IN PRESS J INFECT DI; LOWENFELS A, 1991, 7TH INT C AIDS FLOR; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; STAVER S, 1990, AM MED NEWS     1228, P3; URY HK, 1980, BIOMETRICS, V36, P347, DOI 10.2307/2529991; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006; 1986, MMWR, V35, P237; 1987, SAS RELEASE 6 04; 1991, MMWR, V40, P33; 1988, J AM DENT ASSOC, V116, P248; 1991, AIDS ALERT, V6, P1; 1991, MMWR, V40, P1; 1988, J AM DENT ASSOC, V116, P241; 1992, MMWR, V41, P344; 1989, AM J INFECT CONTROL, V17, pA24; 1990, INFECT CONT HOSP EP, V11, P647; 1986, MMWR, V35, P221; 1990, MMWR, V39, P489; 1991, MMWR, V40, P377; 1991, MMWR, V40, P21	30	44	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1795	1801		10.1001/jama.269.14.1795	http://dx.doi.org/10.1001/jama.269.14.1795			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459510				2022-12-28	WOS:A1993KW25000033
J	HEPPNER, DG; MAGILL, AJ; GASSER, RA; OSTER, CN				HEPPNER, DG; MAGILL, AJ; GASSER, RA; OSTER, CN			THE THREAT OF INFECTIOUS-DISEASES IN SOMALIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							JARISCH-HERXHEIMER REACTION; CRIMEAN HEMORRHAGIC-FEVER; BORNE RELAPSING FEVER; RENAL-TRANSPLANT RECIPIENTS; CHRONIC LIVER-DISEASE; PLASMODIUM-FALCIPARUM; TYPHOID-FEVER; DISSEMINATED HISTOPLASMOSIS; VISCERAL LEISHMANIASIS; UNITED-STATES		WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center								ACETI A, 1991, T ROY SOC TROP MED H, V85, P541, DOI 10.1016/0035-9203(91)90249-X; ACETI A, 1989, T ROY SOC TROP MED H, V83, P399, DOI 10.1016/0035-9203(89)90516-6; ALTIKRITI SK, 1981, B WORLD HEALTH ORGAN, V59, P85; ARFAA F, 1975, AM J TROP MED HYG, V24, P280, DOI 10.4269/ajtmh.1975.24.280; BADARO R, 1986, LANCET, V1, P647; BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; BARUFFA G, 1965, T ROY SOC TROP MED H, V59, P705, DOI 10.1016/0035-9203(65)90103-3; BEHM A W, 1946, Am J Med Sci, V211, P385, DOI 10.1097/00000441-194621140-00001; BENENSON AS, 1990, CONTROL COMMUNICABLE, P261; BERMAN SJ, 1973, ANN INTERN MED, V79, P167, DOI 10.7326/0003-4819-79-2-167; BILE K, 1991, J TROP MED HYG, V94, P367; BILE K, 1992, AM J TROP MED HYG, V47, P357, DOI 10.4269/ajtmh.1992.47.357; BILE KM, 1991, T ROY SOC TROP MED H, V85, P104, DOI 10.1016/0035-9203(91)90177-Z; BOSLEGO JW, 1992, INFECT DIS, P1452; BOTROS BAM, 1989, J MED VIROL, V29, P79, DOI 10.1002/jmv.1890290202; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRASSEUR P, 1990, LANCET, V336, P59, DOI 10.1016/0140-6736(90)91578-X; BROWN V, 1988, ANN TROP MED PARASIT, V82, P499, DOI 10.1080/00034983.1988.11812282; BRYCESON AD, 1970, Q J MED, V39, P129; BUCHANAN TM, 1974, MEDICINE, V53, P403, DOI 10.1097/00005792-197411000-00001; BUCKLEY JJC, 1958, E AFR MED J, V35, P494; BURANS JP, 1989, T ROY SOC TROP MED H, V83, P836, DOI 10.1016/0035-9203(89)90347-7; BURNEY MI, 1980, AM J TROP MED HYG, V29, P941, DOI 10.4269/ajtmh.1980.29.941; BURTON R, 1987, 1ST FOOTSTEPS E AFRI, P276; BUSCHKENS WFL, 1990, COMMUNITY HLTH DEV W; BUTLER T, 1974, J INFECT DIS, V129, pS78, DOI 10.1093/infdis/129.Supplement_1.S78; BUTLER T, 1978, J INFECT DIS, V137, P573, DOI 10.1093/infdis/137.5.573; CACCIAPUOTI B, 1982, T ROY SOC TROP MED H, V76, P178, DOI 10.1016/0035-9203(82)90270-X; CAHILL KM, 1967, T ROY SOC TROP MED H, V61, P340, DOI 10.1016/0035-9203(67)90006-5; CAHILL KM, 1966, AM J TROP MED HYG, V15, P52, DOI 10.4269/ajtmh.1966.15.52; CAHILL KM, 1971, T ROY SOC TROP MED H, V65, P28, DOI 10.1016/0035-9203(71)90182-9; CAHILL KM, 1969, HLTH HORN AFRICA STU, P1; CARPENTER CCJ, 1992, J INFECT DIS, V166, P2, DOI 10.1093/infdis/166.1.2; CASALINO M, 1988, T ROY SOC TROP MED H, V82, P637, DOI 10.1016/0035-9203(88)90542-1; Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P131; Centers for Disease Control (CDC), 1987, MMWR Morb Mortal Wkly Rep, V36, P241; CHARTERS AD, 1950, T ROY SOC TROP MED H, V43, P427, DOI 10.1016/0035-9203(50)90038-1; COCKSHOTT WP, 1964, Q J MED, V33, P223; COLE ACE, 1965, J TROP MED HYG, V68, P92; CORWIN AL, 1991, AIDS, V5, P902, DOI 10.1097/00002030-199107000-00023; CRUZ T, 1966, NEW ENGL J MED, V275, P1093, DOI 10.1056/NEJM196611172752003; CULLINAN ER, 1946, T ROY SOC TROP MED H, V39, P353, DOI 10.1016/0035-9203(46)90014-4; DAVIES SF, 1979, AM J SURG, V137, P686, DOI 10.1016/0002-9610(79)90050-3; DAWSON GJ, 1992, J VIROL METHODS, V38, P175, DOI 10.1016/0166-0934(92)90180-L; DUMLER JS, 1991, JAMA-J AM MED ASSOC, V266, P1365, DOI 10.1001/jama.266.10.1365; DUNCAN J. T., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P468, DOI 10.1016/0035-9203(58)90135-4; EITREM R, 1990, AM J TROP MED HYG, V43, P207, DOI 10.4269/ajtmh.1990.43.207; FARAH AA, 1989, REV INFECT DIS, V11, pS512; FERNANDEZGUERRERO ML, 1987, AM J MED, V83, P1098, DOI 10.1016/0002-9343(87)90948-X; GELFAND M, 1965, J TROP MED HYG, V68, P245; GILL GV, 1979, BRIT MED J, V2, P572, DOI 10.1136/bmj.2.6190.572; GILMAN RH, 1975, LANCET, V1, P1211; GOODWIN RA, 1980, MEDICINE, V59, P1, DOI 10.1097/00005792-198001000-00001; GREENWOOD BM, 1991, HUNTERS TROPICAL MED, P385; GROVE DI, 1980, BRIT MED J, V280, P598, DOI 10.1136/bmj.280.6214.598; GUERRACACERES JG, 1979, T ROY SOC TROP MED H, V73, P680, DOI 10.1016/0035-9203(79)90020-8; HALL WT, 1977, AM J EPIDEMIOL, V106, P72, DOI 10.1093/oxfordjournals.aje.a112435; Harinasuta T., 1988, Malaria: principles and practice of malariology. Volume 1., P709; HARINASUTA T, 1983, B WORLD HEALTH ORGAN, V61, P299; HEATH CW, 1965, NEW ENGL J MED, V273, P915, DOI 10.1056/NEJM196510212731706; HEATH CW, 1965, NEW ENGL J MED, V273, P857, DOI 10.1056/NEJM196510142731606; HODGE IG, 1945, AM J MED SCI, V210, P207, DOI 10.1097/00000441-194508000-00012; HOFFMAN SL, 1984, NEW ENGL J MED, V310, P82, DOI 10.1056/NEJM198401123100203; HOFFMAN SL, 1992, MED CLIN N AM, V76, P1327, DOI 10.1016/S0025-7125(16)30290-5; HOOGSTRAAL H, 1979, J MED ENTOMOL, V15, P307, DOI 10.1093/jmedent/15.4.307; HORTON J, 1991, T ROY SOC TROP MED H, V85, P697, DOI 10.1016/0035-9203(91)90400-S; HUGGINS JW, 1989, REV INFECT DIS, V11, pS750; HUSSEY GD, 1992, ANN NY ACAD SCI, V669, P188; ILARDI I, 1987, T ROY SOC TROP MED H, V81, P771, DOI 10.1016/0035-9203(87)90027-7; ILARDI I, 1987, T ROY SOC TROP MED H, V81, P336, DOI 10.1016/0035-9203(87)90256-2; ILARDI I, 1982, TROP DIS B, V79, P628; INNES JRM, 1953, AMA ARCH NEUROL PSY, V70, P325, DOI 10.1001/archneurpsyc.1953.02320330050006; ISLAM A, 1988, J INFECT DIS, V158, P742, DOI 10.1093/infdis/158.4.742; Ismail S O, 1990, Int J STD AIDS, V1, P102; ISMAIL SO, 1990, GENITOURIN MED, V66, P70; JAMA H, 1987, GENITOURIN MED, V63, P326; JAMA H, 1987, GENITOURIN MED, V63, P329; JOHNSON BK, 1983, TROP GEOGR MED, V35, P43; JOHNSON PC, 1988, AM J MED, V85, P152, DOI 10.1016/S0002-9343(88)80334-6; JOHNSTONE G, 1965, J TROP MED HYG, V68, P85; KAGAN IG, 1968, AM J TROP MED HYG, V17, P392, DOI 10.4269/ajtmh.1968.17.392; KAPLAN M M, 1955, Bull World Health Organ, V13, P829; KAUFFMAN CA, 1978, AM J MED, V64, P923, DOI 10.1016/0002-9343(78)90445-X; KEYSTONE JS, 1991, HUNTERS TROPICAL MED, P1038; KOURA M, 1981, ANN TROP MED PARASIT, V75, P53, DOI 10.1080/00034983.1981.11687408; LEE C. U., 1935, Chinese Medical Journal, V49, P1281; LOBEL HO, 1991, JAMA-J AM MED ASSOC, V265, P361, DOI 10.1001/jama.265.3.361; LONGWORTH DL, 1986, CURRENT CLIN TOPICS, V7, P1; LUCAS AO, 1970, BRIT J DERMATOL, V82, P435, DOI 10.1111/j.1365-2133.1970.tb02203.x; MA DDF, 1979, LANCET, V2, P311; MAIMONE F, 1986, J INFECT DIS, V153, P802, DOI 10.1093/infdis/153.4.802; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; Manson-Bahr P, 1941, LANCET, V1, P609; MANSON-BAHR P E, 1958, East Afr Med J, V35, P625; MARESCA B, 1987, MYCOPATHOLOGIA, V98, P77, DOI 10.1007/BF00437292; Marrie T. J., 1988, Biology of rickettsial diseases. Volume II., P1; MCCLAIN JBL, 1984, ANN INTERN MED, V100, P696, DOI 10.7326/0003-4819-100-5-696; McClatchie S, 1969, East Afr Med J, V46, P166; MERO E, 1976, B WORLD HEALTH ORGAN, V54, P473; MEYERS WM, 1991, HUNTERS TROPICAL MED, P483; MILLER KD, 1989, NEW ENGL J MED, V321, P65, DOI 10.1056/NEJM198907133210201; MORGAN JS, 1986, TRANSPLANTATION, V42, P518, DOI 10.1097/00007890-198611000-00016; MOST H, 1947, MEDICINE, V26, P221, DOI 10.1097/00005792-194709000-00001; NELSON G. S., 1962, TRANS ROY SOC TROP MED AND HYG, V56, P202, DOI 10.1016/0035-9203(62)90155-4; NEVILL CG, 1991, E AFR MED J, V68, P149; NICOLETTI M, 1988, J CLIN MICROBIOL, V26, P524, DOI 10.1128/JCM.26.3.524-529.1988; Nuti M, 1979, Biochem Exp Biol, V15, P111; NUTI M, 1979, T ROY SOC TROP MED H, V73, P185, DOI 10.1016/0035-9203(79)90207-4; PARRY EHO, 1967, LANCET, V1, P81; PATTERSON M, 1980, GASTROENTEROLOGY, V78, P136; PELLETIER LL, 1985, AM J MED, V78, P139, DOI 10.1016/0002-9343(85)90474-7; PELLETIER LL, 1984, AM J TROP MED HYG, V33, P55, DOI 10.4269/ajtmh.1984.33.55; PELTOLA H, 1988, PEDIATR INFECT DIS J, V7, P488, DOI 10.1097/00006454-198807000-00008; PERINE PL, 1983, AM J TROP MED HYG, V32, P1096, DOI 10.4269/ajtmh.1983.32.1096; PETERS BS, 1990, Q J MED, V77, P1101, DOI 10.1093/qjmed/77.2.1101; POWELL RD, 1989, TROPICAL MED PARASIT, P303; RAMIREZ CA, 1985, ANTIMICROB AGENTS CH, V28, P128, DOI 10.1128/AAC.28.1.128; ROGERS AM, 1946, AM J MED SCI, V211, P531, DOI 10.1097/00000441-194621150-00002; ROSS R, 1898, LANCET, V2, P488; Sabin AB, 1944, J AMER MED ASSOC, V125, P693, DOI 10.1001/jama.1944.02850280009003; SALEH AS, 1985, LANCET, V2, P211; SALVA M, 1986, VISCERAL LEISHMANIAS, P134; SCOTT DA, 1991, AM J TROP MED HYG, V45, P653, DOI 10.4269/ajtmh.1991.45.653; SCOWDEN EB, 1978, MEDICINE, V57, P527, DOI 10.1097/00005792-197811000-00004; SCRIMGEOUR EM, 1985, BRAIN, V108, P1023, DOI 10.1093/brain/108.4.1023; SHEARS P, 1984, TUBERCLE, V65, P111, DOI 10.1016/0041-3879(84)90062-X; SHEARS P, 1983, BRIT MED J, V287, P422, DOI 10.1136/bmj.287.6389.422; SHIDDO S, 1990, T ROY SOC TROP MED H, V84, P832, DOI 10.1016/0035-9203(90)90100-S; SHORE H., 1961, TRANS ROY SOC TROP MED AND HYG, V55, P361, DOI 10.1016/0035-9203(61)90106-7; SHUNZHANG YU, 1980, Chinese Medical Journal (English Edition), V93, P637; SIMON HB, 1988, CLIN APPROACH INFECT, P221; SMADEL JE, 1953, AM J PUBLIC HEALTH, V43, P1327; SMITH JS, 1991, NEW ENGL J MED, V324, P205, DOI 10.1056/NEJM199101243240401; STANLEY SL, 1991, JAMA-J AM MED ASSOC, V266, P1984, DOI 10.1001/jama.266.14.1984; STUART BM, 1945, ANN INTERN MED, V23, P520, DOI 10.7326/0003-4819-23-4-520; SULEIMAN MNEH, 1980, LANCET, V2, P939; SWARTZWELDER C, 1958, COMMUNICABLE DISEASE, P503; TEKLU B, 1983, LANCET, V1, P835; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TRENT SC, 1963, AM J TROP MED HYG, V12, P877, DOI 10.4269/ajtmh.1963.12.877; TURNER LH, 1973, BRIT MED J, V1, P537, DOI 10.1136/bmj.1.5852.537; Walsh N., 1945, East African Medical Journal, V22, P11; WALSH TJ, 1991, MANUAL CLIN MICROBIO, P636; WARRELL DA, 1970, CLIN SCI, V39, P123, DOI 10.1042/cs0390123; WARRELL DA, 1988, REV INFECT DIS, V10, pS726; WARSAME M, 1988, T ROY SOC TROP MED H, V82, P202, DOI 10.1016/0035-9203(88)90409-9; WARSAME M, 1989, TROP MED PARASITOL, V40, P412; WARSAME M, 1991, T ROY SOC TROP MED H, V85, P200, DOI 10.1016/0035-9203(91)90018-T; WARSAME M, 1991, T ROY SOC TROP MED H, V85, P565, DOI 10.1016/0035-9203(91)90343-W; WARSAME M, 1990, J TROP MED HYG, V93, P284; WARTMAN WB, 1947, MEDICINE, V26, P333, DOI 10.1097/00005792-194712000-00001; WATSON W, 1982, TROP DOCT, V12, P92, DOI 10.1177/004947558201200223; WATT G, 1988, LANCET, V1, P433; WATT G, 1988, J INFECT DIS, V157, P840, DOI 10.1093/infdis/157.4.840; WATT G, 1991, TROPICAL MED, P317; WATTS DM, 1989, AM J TROP MED HYG, V41, P581, DOI 10.4269/ajtmh.1989.41.581; WEBER DR, 1969, AM J MED, V46, P234, DOI 10.1016/0002-9343(69)90008-4; WILSON D. Bagster, 1943, East African Medical Journal, V20, P255; WILSON HG, 1976, CIRCULATION, V53, P680, DOI 10.1161/01.CIR.53.4.680; WINTERS RA, 1992, AM J MED, V93, P243, DOI 10.1016/0002-9343(92)90228-4; WISSEMAN CL, 1991, HUNTERS TROPICAL MED, P267; WOOD OL, 1978, AM J TROP MED HYG, V27, P600, DOI 10.4269/ajtmh.1978.27.600; WRIGHT MI, 1959, BMJ-BRIT MED J, V1, P1218, DOI 10.1136/bmj.1.5131.1218; YOUNG EJ, 1991, REV INFECT DIS, V13, P359; ZEIN ZA, 1987, J ROY SOC HEALTH, V107, P146, DOI 10.1177/146642408710700410; 1992, WKLY EPIDEMIOL REC, V67, P253; 1988, MMWR MORB MORTAL WKL, V37; 1992, WKLY EPIDEMIOL REC, V67, P245; 1992, WKLY EPIDEMIOL REC, V67, P201; 1992, MMWR MORB MORTAL WKL, V41; 1991, MMWR MORB MORTAL WKL, V40, P21; 1982, SCHISTOSOMIASIS EGYP, P101; 1974, WHO TECH REP SER, V542, P1; 1992, WKLY EPIDEMIOL REC, V44, P330; 1992, MMWR MORB MORTAL WKL, V41, P913; [No title captured]; 1992, MED LETT, V34, P17; 1993, MMWR MORB MORTAL WKL, V42, P1	179	13	13	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1061	1068		10.1056/NEJM199304083281430	http://dx.doi.org/10.1056/NEJM199304083281430			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	8450874				2022-12-28	WOS:A1993KW28200039
J	BURATOWSKI, S				BURATOWSKI, S			DNA-REPAIR AND TRANSCRIPTION - THE HELICASE CONNECTION	SCIENCE			English	Editorial Material							RNA-POLYMERASE-II; INITIATION; REQUIREMENT; PROMOTERS; COMPLEX				BURATOWSKI, S (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAI H, 1987, MOL CELL BIOL, V7, P3371, DOI 10.1128/MCB.7.10.3371; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MOUNKES LC, 1992, CELL, V71, P925, DOI 10.1016/0092-8674(92)90389-T; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U	19	52	53	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					37	38		10.1126/science.8465198	http://dx.doi.org/10.1126/science.8465198			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8465198				2022-12-28	WOS:A1993KV42300019
J	COX, FEG				COX, FEG			MALARIA - THAT VACCINE PASSES A TRIAL	NATURE			English	Editorial Material											COX, FEG (corresponding author), KINGS COLL LONDON,DIV LIFE SCI,CAMPDEN HILL RD,LONDON W8 7AH,ENGLAND.							COX FEG, 1991, TRENDS BIOTECHNOL, V9, P389, DOI 10.1016/0167-7799(91)90131-Z; KASLOW DC, 1988, NATURE, V333, P74, DOI 10.1038/333074a0; PATARROYO G, 1992, VACCINE, V10, P175, DOI 10.1016/0264-410X(92)90008-8; PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0; PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0; PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25; SEMPERTEGUI F, IN PRESS VACCINE; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W	8	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					410	410		10.1038/362410a0	http://dx.doi.org/10.1038/362410a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8464470	Bronze			2022-12-28	WOS:A1993KV42400055
J	WRENN, K				WRENN, K			LETHAL CASCADE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN-PATIENT RELATIONS EMBOLISM, FAT TREATMENT REFUSAL; PATIENT ACCEPTANCE OF HEALTH CARE; RESTRAINT, PHYSICAL		A physician's anguish over having set in motion a series of events which, despite good intentions, result in the iatrogenic death of a patient.			WRENN, K (corresponding author), VANDERBILT UNIV HOSP, DEPT EMERGENCY MED, ROOM 1368, NASHVILLE, TN 37232 USA.		Wrenn, Keith/AAI-7651-2020						0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					562	563		10.7326/0003-4819-118-7-199304010-00012	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442627				2022-12-28	WOS:A1993KU07900012
J	GOGUEL, V; ROSBASH, M				GOGUEL, V; ROSBASH, M			SPLICE SITE CHOICE AND SPLICING EFFICIENCY ARE POSITIVELY INFLUENCED BY PREMESSENGER RNA INTRAMOLECULAR BASE-PAIRING IN YEAST	CELL			English	Article							SECONDARY STRUCTURE; RIBOSOMAL PROTEIN-51; BETA-GLOBIN; U1 SNRNP; SEQUENCES; SELECTION; GENE; INVITRO; INTRON; EXON	Many of the mechanisms that govern splice site selection and splice site partner assignment during pre-mRNA splicing are obscure. To address this problem, we analyzed the splicing of transcripts containing chimeric introns or splice site duplications derived from two natural yeast genes. Our experiments indicate that there are strong context effects that influence splicing efficiency and relative splice site strength. Cis-competition experiments showed that the context effects are not only local, as the source of the 3' splice site region influences 5' splice site selection and the source of the 5' splice site affects 3' splice site selection. A significant fraction of the long-range context effect appears to be due to base pairing between two intronic regions near the 5' splice site and branchpoint, an interaction that positively affects splicing efficiency as well as splice site selection.	ECOLE NORM SUPER,GENET MOLEC LAB,F-75230 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	GOGUEL, V (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,DEPT BIOL,WALTHAM,MA 02254, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023549] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-23549] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1984, MOL CELL BIOL, V4, P1871, DOI 10.1128/MCB.4.9.1871; ABOVICH N, 1988, THESIS BRANDEIS U WA; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; CHU G, 1981, NATURE, V289, P378, DOI 10.1038/289378a0; DESHLER JO, 1991, GENE DEV, V5, P1252, DOI 10.1101/gad.5.7.1252; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; FURDON PJ, 1988, MOL CELL BIOL, V8, P860, DOI 10.1128/MCB.8.2.860; GALLEGO ME, 1990, MOL CELL BIOL, V10, P2133, DOI 10.1128/MCB.10.5.2133; GOGUEL V, 1991, GENE DEV, V5, P1430, DOI 10.1101/gad.5.8.1430; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; LIAO XL, 1990, GENE DEV, V4, P1766, DOI 10.1101/gad.4.10.1766; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; MAYEDA A, 1988, MOL CELL BIOL, V8, P4484, DOI 10.1128/MCB.8.10.4484; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; MOLENAAR CMT, 1984, NUCLEIC ACIDS RES, V12, P7345, DOI 10.1093/nar/12.19.7345; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; NEWMAN A, 1987, EMBO J, V6, P3833, DOI 10.1002/j.1460-2075.1987.tb02720.x; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2; Sambrook J, 1989, MOL CLONING LABORATO; SERAPHIN B, 1989, GENE, V82, P145, DOI 10.1016/0378-1119(89)90039-5; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; ULFENDAHL PJ, 1989, NUCLEIC ACIDS RES, V17, P925, DOI 10.1093/nar/17.3.925; WAIGMANN E, 1992, NUCLEIC ACIDS RES, V20, P75, DOI 10.1093/nar/20.1.75; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604	41	90	90	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					893	901		10.1016/0092-8674(93)90578-E	http://dx.doi.org/10.1016/0092-8674(93)90578-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458083				2022-12-28	WOS:A1993KU17500010
J	PAULESU, E; FRITH, CD; FRACKOWIAK, RSJ				PAULESU, E; FRITH, CD; FRACKOWIAK, RSJ			THE NEURAL CORRELATES OF THE VERBAL COMPONENT OF WORKING MEMORY	NATURE			English	Article							SHORT-TERM-MEMORY; PET IMAGES; SPEECH; COMPREHENSION; STORE	BY repeating words 'in our head', verbal material (such as telephone numbers) can be kept in working memory1 almost indefinitely. This 'articulatory loop' includes a subvocal rehearsal system2-6 and a phonological store3,6-10. Little is known about neural correlates of this model of verbal short-term memory. We therefore measured regional cerebral blood flow, an index of neuronal activity, in volunteers performing a task engaging both components of the articulatory loop (short-term memory for letters)5-10 and a task which engages only the subvocal rehearsal system (rhyming judgement for letters)4,11. Stimuli were presented visually and the subjects did not speak. We report here that comparisons of distribution of cerebral blood flow in these conditions localized the phonological store to the left supramarginal gyrus whereas the subvocal rehearsal system was associated with Broca's area. This is, to our knowledge, the first demonstration of the normal anatomy of the components of the 'articulatory loop'.	HAMMERSMITH HOSP, MRC, CYCLOTRON UNIT, DUCANE RD, LONDON W12 0HS, ENGLAND; IST SCI SAN RAFFAELE, I-20132 MILAN, ITALY; UCL, DEPT PSYCHOL, LONDON WC1E 6TB, ENGLAND	Imperial College London; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of London; University College London			Frackowiak, Richard S/I-1809-2013; Frackowiak, Richard/H-4383-2011; Frith, Chris D/A-2171-2009; PAULESU, ERALDO/C-2737-2017	Frackowiak, Richard/0000-0002-3151-822X; Frith, Chris D/0000-0002-8665-0690; PAULESU, ERALDO/0000-0002-9224-754X				BADDELEY A, 1984, Q J EXP PSYCHOL-A, V36, P233, DOI 10.1080/14640748408402157; BADDELEY A, 1985, J MEM LANG, V24, P490, DOI 10.1016/0749-596X(85)90041-5; BADDELEY AD, 1975, J VERB LEARN VERB BE, V14, P575, DOI 10.1016/S0022-5371(75)80045-4; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BESNER D, 1987, Q J EXP PSYCHOL-A, V39, P467, DOI 10.1080/14640748708401799; Burani C., 1991, EUR J COGN PSYCHOL, V3, P379, DOI [10.1080/09541449108406235, DOI 10.1080/09541449108406235]; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; FOX PT, 1989, J NUCL MED, V30, P141; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; SALAME P, 1982, J VERB LEARN VERB BE, V21, P150, DOI 10.1016/S0022-5371(82)90521-7; SHALLICE T, 1977, NEUROPSYCHOLOGIA, V15, P729, DOI 10.1016/0028-3932(77)90002-1; Shallice T., 1990, NEUROPSYCHOLOGICAL I, P11, DOI [10.1017/CBO9780511665547.003, DOI 10.1017/CBO9780511665547.003]; SPINKS TJ, 1992, PHYS MED BIOL, V37, P1637, DOI 10.1088/0031-9155/37/8/002; Talairach I., 1988, COPLANAR STEREOTACTI; TOWNSEND DW, 1991, IEEE T MED IMAGING, V10, P505, DOI 10.1109/42.108584; VALLAR G, 1984, COGNITIVE NEUROPSYCH, V1, P121, DOI 10.1080/02643298408252018; VALLAR G, 1984, J VERB LEARN VERB BE, V23, P151, DOI 10.1016/S0022-5371(84)90104-X; VALLAR G, 1987, COGNITIVE NEUROPSYCH, V4, P55, DOI 10.1080/02643298708252035; WARRINGTON EK, 1969, BRAIN, V92, P885, DOI 10.1093/brain/92.4.885; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767	24	1771	1794	0	122	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 25	1993	362	6418					342	345		10.1038/362342a0	http://dx.doi.org/10.1038/362342a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455719				2022-12-28	WOS:A1993KU17600060
J	MADDOCK, JR; SHAPIRO, L				MADDOCK, JR; SHAPIRO, L			POLAR LOCATION OF THE CHEMORECEPTOR COMPLEX IN THE ESCHERICHIA-COLI CELL	SCIENCE			English	Article							BACTERIAL CHEMOTAXIS; SIGNAL TRANSDUCTION; PROTEIN-PHOSPHORYLATION; GENETIC-EVIDENCE; LOCALIZATION; DIVISION; YEAST; MICROSCOPY; MECHANISM; RECEPTOR	The eukaryotic cell exhibits compartmentalization of functions to various membrane-bound organelles and to specific domains within each membrane. The spatial distribution of the membrane chemoreceptors and associated cytoplasmic chemotaxis proteins in Escherichia coli were examined as a prototypic functional aggregate in bacterial cells. Bacterial chemotaxis involves a phospho-relay system brought about by ligand association with a membrane receptor, culminating in a switch in the direction of flagellar rotation. The transduction of the chemotaxis signal is initiated by a chemoreceptor-CheW-CheA ternary complex at the inner membrane. These ternary complexes aggregate predominantly at the cell poles. Polar localization of the cytoplasmic CheA and CheW proteins is dependent on membrane-bound chemoreceptor. Chemoreceptors are not confined to the cell poles in strains lacking both CheA and CheW. The chemoreceptor-CheW binary complex is polarly localized in the absence of CheA, whereas the chemoreceptor-CheA binary complex is not confined to the cell poles in strains lacking CheW. The subcellular localization of the chemotaxis proteins may reflect a general mechanism by which the bacterial cell sequesters different regions of the cell for specialized functions.			MADDOCK, JR (corresponding author), STANFORD UNIV, MED CTR, SCH MED, BECKMAN CTR, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032506, F32GM013929, R37GM032506] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32506, GM13929] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BOOS W, 1981, ARCH MICROBIOL, V129, P240, DOI 10.1007/BF00425258; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; COOK WR, 1987, P NATL ACAD SCI USA, V84, P7144, DOI 10.1073/pnas.84.20.7144; DIETZEL I, 1978, ARCH MICROBIOL, V118, P207, DOI 10.1007/BF00415731; DREWS G, 1990, PROKARYOTIC STRUCTUR, P249; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; ENGSTROM P, 1982, BIOCHIM BIOPHYS ACTA, V686, P19, DOI 10.1016/0005-2736(82)90147-X; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GOLLOP N, 1991, RES MICROBIOL, V142, P301, DOI 10.1016/0923-2508(91)90045-C; Harlow E., 1988, ANTIBODIES LABORATOR, P633; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; MACALISTER TJ, 1983, P NATL ACAD SCI-BIOL, V80, P1372, DOI 10.1073/pnas.80.5.1372; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MANSON MD, 1985, J BIOL CHEM, V260, P9727; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLER JH, 1977, EXPT MOL GENETICS, P432; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; NINFA EG, 1991, J BIOL CHEM, V266, P9764; OOSAWA K, 1988, J BACTERIOL, V170, P2521, DOI 10.1128/jb.170.6.2521-2526.1988; PARKINSON JS, 1983, J BACTERIOL, V155, P265, DOI 10.1128/JB.155.1.265-274.1983; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RIDGWAY HF, 1977, J BACTERIOL, V132, P657, DOI 10.1128/JB.132.2.657-665.1977; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; SEGALL JE, 1982, NATURE, V296, P855, DOI 10.1038/296855a0; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; SEGALL JE, 1985, J BACTERIOL, V161, P51, DOI 10.1128/JB.161.1.51-59.1985; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; WALTER RJ, 1980, NATURE, V286, P724, DOI 10.1038/286724a0; WEINBAUM DL, 1980, NATURE, V286, P725, DOI 10.1038/286725a0; WIEGEL FW, 1983, PHYS REP, V95, P283, DOI 10.1016/0370-1573(83)90078-9; WRIGHT R, 1989, METHOD CELL BIOL, V31, P473; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986	43	618	624	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1993	259	5102					1717	1723						7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456299				2022-12-28	WOS:A1993KT81000027
J	BURY, B				BURY, B			LETTER TO BOTTOMLEY	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					702	703		10.1136/bmj.306.6879.702	http://dx.doi.org/10.1136/bmj.306.6879.702			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT216	8471928	Green Published, Bronze			2022-12-28	WOS:A1993KT21600029
J	LEE, J; ISHIHARA, A; THERIOT, JA; JACOBSON, K				LEE, J; ISHIHARA, A; THERIOT, JA; JACOBSON, K			PRINCIPLES OF LOCOMOTION FOR SIMPLE-SHAPED CELLS	NATURE			English	Article							NEURONAL GROWTH CONE; LEADING-EDGE; FLOW; MICROFILAMENT; MICROTUBULES; ORGANIZATION; FIBROBLASTS; MOVEMENT; CULTURE; INVITRO	MOVING cells display a variety of shapes and modes of locomotion1, but it is not clear how motility at the molecular level relates to the locomotion of a whole cell, a problem compounded in studies of cells with complex shapes2-5. A striking feature of fish epidermal keratocyte locomotion is its apparent simplicity6. Here we present a kinematic description of locomotion which is consistent with the semicircular shape and persistent 'gliding' motion of fish epidermal keratocytes. We propose that extension of the front and retraction of the rear of these cells occurs perpendicularly to the cell edge, and that a graded distribution of extension and retraction rates along the cell margin maintains cell shape and size during locomotion. Evidence for this description is provided by the predicted circumferential motion of lamellar features and the curvature of 'photo-marked' lines within specific molecular components of moving keratocytes. Our description relates the dynamics of molecular assemblies to the movement of a whole cell.	UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOPHYS,SAN FRANCISCO,CA 94143	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LEE, J (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599, USA.		Theriot, Julie/HHN-2034-2022	Theriot, Julie/0000-0002-2334-2535				BEREITERHAHN J, 1981, J CELL SCI, V52, P289; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRAY D, 1985, J NEUROSCI, V5, P3204; DEBIOSFLEURYCHE.A, 1989, BLOOD CELLS, V15, P334; DIPASQUALE A, 1975, EXP CELL RES, V95, P425, DOI 10.1016/0014-4827(75)90568-6; DUNN GA, 1987, J CELL SCI S, V8, P81; Dunn GA, 1980, CELL ADHESION MOTILI, P409; EUTENEUER U, 1984, NATURE, V310, P58, DOI 10.1038/310058a0; EVANS E, 1990, BIOMECHANICS ACTIVE, P185; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; GUDIMA GO, 1988, J CELL SCI, V89, P225; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; KOLEGA J, 1981, J CELL SCI, V49, P15; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; RINNERTHALER G, 1991, J STRUCT BIOL, V106, P1, DOI 10.1016/1047-8477(91)90058-5; ROBERTS TM, 1991, CELL MOTIL CYTOSKEL, V20, P228, DOI 10.1002/cm.970200306; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TRINKAUS JP, 1984, CELLS ORGANS FORCES, P179; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597	21	188	190	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					167	171		10.1038/362167a0	http://dx.doi.org/10.1038/362167a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8450887				2022-12-28	WOS:A1993KR02800063
J	NISHIMOTO, I; OKAMOTO, T; MATSUURA, Y; TAKAHASHI, S; OKAMOTO, T; MURAYAMA, Y; OGATA, E				NISHIMOTO, I; OKAMOTO, T; MATSUURA, Y; TAKAHASHI, S; OKAMOTO, T; MURAYAMA, Y; OGATA, E			ALZHEIMER AMYLOID PROTEIN-PRECURSOR COMPLEXES WITH BRAIN GTP-BINDING PROTEIN-G(O)	NATURE			English	Article							GROWTH FACTOR-II; PERTUSSIS-TOXIN; DISEASE; RECEPTOR; EXPRESSION; G0; FRAGMENT; PEPTIDE; GAP-43	THE most characteristic change in progressive dementia of Alzheimer's type is a tissue deposit of amyloid beta/A4 protein1, which is derived from its precursor protein APP (ref. 2). Structural alterations of APP are implicated in the pathogenesis of Alzheimer's disease, but it is not known how they cause the disease. Although APP has a receptor-like architecture 2-5, is located on the neuronal surface6, and has a conserved cytoplasmic domain7, no receptor function has been demonstrated for APP. Here we report that APP forms a complex with G(o), a major GTP-binding protein in brain. The cytoplasmic APP sequence His 657-Lys 676 shows a specific G(o)-activating function and is necessary for complex formation. G(o) protein treated with GTP-gammaS lost the ability to associate with APP. This suggests that APP is a receptor coupled to G(o) and that abnormal APP-G(o) signalling is involved in the Alzheimer's disease process.	UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,LIFE SCI LAB,BUNKYO KU,TOKYO 112,JAPAN; NATL INST HLTH,DEPT VIROL 2,HEPATITIS VIRUSES LAB,SHINJUKU KU,TOKYO 160,JAPAN; SAPPORO MED COLL,DEPT PATHOL,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	University of Tokyo; Sapporo Medical University								ABRAHAM CR, 1989, BIO-TECHNOL, V7, P147, DOI 10.1038/nbt0289-147; BIRNBAUMER L, 1983, EUR J BIOCHEM, V136, P107, DOI 10.1111/j.1432-1033.1983.tb07712.x; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRANNEMAN JG, 1990, J NEUROCHEM, V54, P1995, DOI 10.1111/j.1471-4159.1990.tb04903.x; GUILLEN A, 1990, EMBO J, V9, P1449, DOI 10.1002/j.1460-2075.1990.tb08261.x; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; KAMETANI F, 1989, BIOMED RES-TOKYO, V10, P179, DOI 10.2220/biomedres.10.179; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MORISHITA R, 1988, EUR J BIOCHEM, V174, P87, DOI 10.1111/j.1432-1033.1988.tb14066.x; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SELKOE DJ, 1989, CELL, V58, P611, DOI 10.1016/0092-8674(89)90093-7; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUMMERS MD, 1987, TEX AGR EXP STN B, P1555; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	27	389	401	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					75	79		10.1038/362075a0	http://dx.doi.org/10.1038/362075a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8446172				2022-12-28	WOS:A1993KP97600065
J	MOSSER, J; DOUAR, AM; SARDE, CO; KIOSCHIS, P; FEIL, R; MOSER, H; POUSTKA, AM; MANDEL, JL; AUBOURG, P				MOSSER, J; DOUAR, AM; SARDE, CO; KIOSCHIS, P; FEIL, R; MOSER, H; POUSTKA, AM; MANDEL, JL; AUBOURG, P			PUTATIVE X-LINKED ADRENOLEUKODYSTROPHY GENE SHARES UNEXPECTED HOMOLOGY WITH ABC TRANSPORTERS	NATURE			English	Article							CLASS-II REGION; CHILDHOOD ADRENOLEUKODYSTROPHY; COLOR-VISION; DNA PROBE; PROTEIN; LINKAGE; GREEN; ACID; ADRENOMYELONEUROPATHY; IDENTIFICATION	ADRENOLEUKODYSTROPHY (ALD) is an X-linked disease affecting 1/20,000 males either as cerebral ALD in childhood or as adrenomyeloneuropathy (AMN) in adults1. Childhood ALD is the more severe form, with onset of neurological symptoms between 5-12 years of age. Central nervous system demyelination progresses rapidly and death occurs within a few years. AMN is a milder form of the disease with onset at 15-30 years of age and a more progressive course. Adrenal insufficiency (Addison's disease) may remain the only clinical manifestation of ALD. The principal biochemical abnormality of ALD is the accumulation of very-long-chain fatty acids (VLCFA) because of impaired beta-oxidation in peroxisomes1-2. The normal oxidation of VLCFA-CoA in patients' fibroblasts3-5 suggested that the gene coding for the VLCFA-CoA synthetase could be a candidate gene for ALD. Here we use positional cloning to identify a gene partially deleted in 6 of 85 independent patients with ALD. In familial cases, the deletions segregated with the disease. An identical deletion was detected in two brothers presenting with different clinical ALD phenotypes. Candidate exons were identified by computer analysis of genomic sequences6 and used to isolate complementary DNAs by exon connection7 and screening of cDNA libraries. The deduced protein sequence shows significant sequence identity to a peroxisomal membrane protein of M(r) 70K that is involved in peroxisome biogenesis and belongs to the 'ATP-binding cassette' superfamily of transporters.	UNIV PARIS 05,HOP ST VINCENT DE PAUL,FAC COCHIN,INSERM,U342,82 AVE DENFERT ROCHEREAU,F-75014 PARIS,FRANCE; FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE; GERMAN CANC RES CTR,INST VIRUSFORSCH,W-6900 HEIDELBERG 1,GERMANY; KENNEDY KRIEGER INST,BALTIMORE,MD 21205	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Helmholtz Association; German Cancer Research Center (DKFZ); Kennedy Krieger Institute			Feil, Robert P/D-2087-2013	Feil, Robert P/0000-0002-5671-5860				AUBOURG P, 1990, AM J HUM GENET, V46, P459; AUBOURG P, 1988, AM J HUM GENET, V442, P408; AUBOURG PR, 1987, ANN NEUROL, V21, P349, DOI 10.1002/ana.410210406; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BOUE J, 1985, HUM GENET, V69, P272, DOI 10.1007/BF00293039; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEIL R, 1991, AM J HUM GENET, V49, P1361; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; HASHMI M, 1986, FEBS LETT, V196, P247, DOI 10.1016/0014-5793(86)80256-3; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KAMIJO K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P323, DOI 10.1016/0167-4781(92)90510-7; KIOSCHIS P, 1991, CYTOGENET CELL GENET, V58, P2070; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MIGEON BR, 1981, P NATL ACAD SCI-BIOL, V78, P5066, DOI 10.1073/pnas.78.8.5066; MOSER HW, 1992, J INHERIT METAB DIS, V15, P645, DOI 10.1007/BF01799621; MOSER HW, 1989, METABOLIC BASIS INHE, P1511; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBINSON IB, 1991, MOL CELLULAR BIOL MU; SACK GH, 1989, AM J HUM GENET, V44, P794; Sambrook J, 1989, MOL CLONING LABORATO; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SINGH I, 1992, J BIOL CHEM, V267, P13306; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANDERS RJA, 1988, J INHERIT METAB DIS, V11, P173, DOI 10.1007/BF01804228; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	39	964	988	0	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					726	730		10.1038/361726a0	http://dx.doi.org/10.1038/361726a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441467				2022-12-28	WOS:A1993KN78900057
J	FRISCH, M; MELBYE, M; MOLLER, H				FRISCH, M; MELBYE, M; MOLLER, H			TRENDS IN INCIDENCE OF ANAL CANCER IN DENMARK	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRAEPITHELIAL NEOPLASIA; PAPILLOMAVIRUS INFECTION; HOMOSEXUAL MEN; MARITAL-STATUS; DISEASE; IMMUNODEFICIENCY; ASSOCIATION; CARCINOMA; RISK	Objective-To study long term trends in incidence of anal cancer in a well monitored, unselected population. Design-Descriptive epidemiological study based on data from the Danish Cancer Registry. Setting-Denmark, 1943-87. Main outcome measures-Time related changes in anal cancer incidence according to sex, age, birth cohort, urban or rural residence, and marital status. Results-The incidence of anal cancer remained fairly constant in the period 1943-57 and was similar for men and women, but it increased 1.5-fold among men and nearly tripled among women thereafter. Among men the incidence increased from 0.25 per 100000 population (world standardised) in 1958-62 to 0.38 in 1983-7 (p=0.01) and among women from 0.28 to 0.74 (p<0.01). The greatest increase was among residents of the capital (Copenhagen). During 1943-87 age specific trends increased in young and middle aged men and in all age groups among women. Men with anal cancer were significantly more likely throughout the study period to be unmarried than were patients with cancer of the colon (adjusted odds ratio 2.7; 95% confidence interval 2.0 to 3.6) and stomach (2.1; 1.5 to 2.8), but no association with marital status was found among women. Conclusions-The distribution and incidence of anal cancer have changed appreciably since around 1960, especially among women, which indicates important aetiological changes. Changes in sexual behaviour may have facilitated the spread of a transmittable agent of aetiological importance. It has recently been suggested that cigarette smoking promotes anal cancer, and this finds indirect support in the synchronism between changes in anal cancer incidence and heavy smoking behaviour. Factors associated with homosexuality are likely to explain some of the cases among men.	DANISH CANC SOC, RES CTR, DIV CANC EPIDEMIOL, COPENHAGEN, DENMARK	Danish Cancer Society	FRISCH, M (corresponding author), STATE SERUM INST, EPIDEMIOL RES UNIT, ARTILLERIVEJ 5, DK-2300 COPENHAGEN S, DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785; Moller, Henrik/0000-0001-8200-5929				Austin D F, 1982, Natl Cancer Inst Monogr, V62, P89; BECKMANN AM, 1989, INT J CANCER, V43, P1042, DOI 10.1002/ijc.2910430615; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BLOHME I, 1985, TRANSPLANTATION, V39, P23; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; Daling J R, 1992, IARC Sci Publ, P223; DALING JR, 1982, JAMA-J AM MED ASSOC, V247, P1988; DALING JR, 1992, AM J EPIDEMIOL, V135, P180, DOI 10.1093/oxfordjournals.aje.a116270; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HEVER D, 1989, 5TH INT C AIDS MONTR; HOLLY EA, 1989, JNCI, V81, P726; HOLMES F, 1988, GASTROENTEROLOGY, V95, P107, DOI 10.1016/0016-5085(88)90297-1; MELBYE M, 1992, AM J EPIDEMIOL, V135, P593, DOI 10.1093/oxfordjournals.aje.a116338; MELBYE M, 1984, BRIT MED J, V289, P573, DOI 10.1136/bmj.289.6445.573; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; OSLER M, 1992, INT J EPIDEMIOL, V21, P862, DOI 10.1093/ije/21.5.862; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; PALEFSKY JM, 1991, CANCER RES, V51, P1014; PENN I, 1986, CANCER-AM CANCER SOC, V58, P611, DOI 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M; PETERS RK, 1983, BRIT J CANCER, V48, P629, DOI 10.1038/bjc.1983.244; RABKIN CS, 1992, AM J EPIDEMIOL, V136, P54, DOI 10.1093/oxfordjournals.aje.a116420; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; Smith P., 1987, CANC INCIDENCE 5 CON, V88, P790; Storm H H, 1991, IARC Sci Publ, P220; Wagner G, 1991, IARC Sci Publ, P3; WEXNER SD, 1987, DIS COLON RECTUM, V30, P942, DOI 10.1007/BF02554281; 1989, SAS STAT USERS GUIDE, V2, P1325	30	133	135	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	1993	306	6875					419	422		10.1136/bmj.306.6875.419	http://dx.doi.org/10.1136/bmj.306.6875.419			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461721	Green Published, Bronze			2022-12-28	WOS:A1993KM70000018
J	PANTON, R				PANTON, R			THE FUTURE OF FHSAS .5. FHSAS AND PRESCRIBING	BRITISH MEDICAL JOURNAL			English	Article											PANTON, R (corresponding author), UNIV KEELE,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND.							BAKER JA, 1988, BRIT MED J, V297, P465, DOI 10.1136/bmj.297.6646.465; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; KESSLER A, 1992, CHEM DRUGGIST, V236, P605; NEWTONSYMS FAO, 1988, PHARM J, V294, pR2; PARR C, 1992, PHARM J, V248, P616; 1992, DETERMINING DRUG INF; 1992, LANCET, V340, P341; 1992, STATISTICAL B GENERA; 1990, IMPROVING PRESCRIBIN; 1992, PHARM CARE FUTURE CO; 1991, PHARMACEUTICALS CONS; 1992, IMPEDIMENTS PARALLEL; 1992, EXCESSIVE PRESCRIBIN	13	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					310	314		10.1136/bmj.306.6873.310	http://dx.doi.org/10.1136/bmj.306.6873.310			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461652	Green Published, Bronze			2022-12-28	WOS:A1993KK71800024
J	HALLAB, M; GALLOIS, Y; CHATELLIER, G; ROHMER, V; FRESSINAUD, P; MARRE, M				HALLAB, M; GALLOIS, Y; CHATELLIER, G; ROHMER, V; FRESSINAUD, P; MARRE, M			COMPARISON OF REDUCTION IN MICROALBUMINURIA BY ENALAPRIL AND HYDROCHLOROTHIAZIDE IN NORMOTENSIVE PATIENTS WITH INSULIN-DEPENDENT DIABETES	BRITISH MEDICAL JOURNAL			English	Article							CONVERTING-ENZYME-INHIBITION; GLOMERULAR-FILTRATION RATE; URINARY ALBUMIN EXCRETION; BLOOD-PRESSURE; INCIPIENT NEPHROPATHY; SHORT-TERM; ANTIHYPERTENSIVE TREATMENT; METABOLIC CONTROL; KIDNEY-FUNCTION; ANGIOTENSIN	Objective-To compare the effects of sodium depletion and of angiotensin I converting enzyme inhibition on microalbuminuria in insulin dependent diabetes. Design-Randomised, double blind, double dummy parallel study of normotensive diabetic patients with persistent microalbuminuria (30-300 mg/24 h) treated with enalapril or hydrochlorothiazide for one year after a three month, single blind placebo period. Setting-Diabetic clinic in a tertiary referral centre. Patients-10 diabetic patients with low microalbuminuria (30-99 mg/24 h) and 11 with high microalbuminuria (100-300 mg/24 h). Interventions-11 subjects (six with low microalbuminuria, five with high microalbuminuria) were given enalapril 20 mg plus placebo hydrochlorothiazide once daily and 10 (four with low microalbuminuria, six with high microalbuminuria) hydrochlorothiazide 25 mg plus placebo enalapril once daily. Main outcome measures-Monthly assessment of urinary albumin excretion and mean arterial pressure; plasma active renin and aldosterone concentrations and renal function studies at 0, 6, and 12 months. Results-Median urinary albumin excretion decreased from 59 (range 37-260) to 38 (14-146) mg/24 h with enalapril and from 111 (33-282) to 109 (33-262) mg/24 h with hydrochlorothiazide (analysis of variance, p=0.0436). During the last three months of treatment with enalapril five patients had persistent normoalbuminuria (2-3 times below 30 mg/24 h), five low microalbuminuria, and one high microalbuminuria; in the hydrochlorothiazide group one had normoalbuminuria, three low microalbuminuria, and six high microalbuminuria (chi2 test=6.7; p=0.03). Mean arterial pressure did not differ before (98 (SD 7) with enalapril v 97 (9) mm Hg with hydrochlorothiazide) or during treatment (88 (7) with enalapril v 90 (7) mm Hg with hydrochlorothiazide (analysis of variance, p=0.5263)). Glomerular filtration rate did not vary. The aldosterone to active renin ratio was decreased by angiotensin I converting enzyme inhibition and increased by sodium depletion, showing treatment efficacy. Conclusion-Angiotensin I converting enzyme inhibition by enalapril effectively reduces microalbuminuria in normotensive diabetic patients whereas hydrochlorothiazide is not effective. Changes in blood pressure and activity of the renin-angiotensin-aldosterone system may contribute to these different effects.	CHU ANGERS,SERV MED B,F-49033 ANGERS 1,FRANCE; CHU ANGERS,BIOCHIM LAB,F-49033 ANGERS,FRANCE; HOP BROUSSAIS,SERV INFORMAT MED,F-75674 PARIS 14,FRANCE	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite								ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; ANDERSON S, 1989, KIDNEY INT, V36, P5526; BJORCK S, 1990, BMJ-BRIT MED J, V300, P904, DOI 10.1136/bmj.300.6729.904; BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; CHRISTENSEN CK, 1985, HYPERTENSION, V7, P109; COHEN D, 1987, BRIT MED J, V294, P795, DOI 10.1136/bmj.294.6575.795; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; FELDTRASMUSSEN B, 1987, DIABETOLOGIA, V30, P610; FRANKEN AAM, 1990, J CLIN ENDOCR METAB, V71, P1008, DOI 10.1210/jcem-71-4-1008; Goldstein DE, 1986, METHODS DIABETES RES, V2, P475; HALL JE, 1977, AM J PHYSIOL, V233, pF366, DOI 10.1152/ajprenal.1977.233.5.F366; HANNEDOUCHE TP, 1990, KIDNEY INT, V37, P1126, DOI 10.1038/ki.1990.95; HOMMEL E, 1986, DIABETOLOGIA, V29, P211, DOI 10.1007/BF00454877; HOSTETTER TH, 1981, KIDNEY INT, V19, P410, DOI 10.1038/ki.1981.33; KEETON TK, 1980, PHARMACOL REV, V32, P81; MACGREGOR GA, 1983, CLIN EXP HYPERTENS A, V5, P1367, DOI 10.3109/10641968309048863; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MARRE M, 1987, CLIN CHEM, V33, P209; MARRE M, 1991, J CARDIOVASC PHARM, V18, pS165, DOI 10.1097/00005344-199100182-00038; MARRE M, 1987, BMJ-BRIT MED J, V294, P1448, DOI 10.1136/bmj.294.6585.1448; MARRE M, 1987, DIABETES METAB, V13, P480; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MENARD J, 1985, J HYPERTENSION S3, V3, P275; MIMRAN A, 1988, DIABETES CARE, V11, P850, DOI 10.2337/diacare.11.10.850; MOGENSEN CE, 1990, DIABETES, V39, P761, DOI 10.2337/diabetes.39.7.761; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; MOGENSEN CE, 1971, SCAND J CLIN LAB INV, V28, P91, DOI 10.3109/00365517109090667; MORELLI E, 1990, DIABETES, V39, P76, DOI 10.2337/diabetes.39.1.76; NEELS HM, 1983, CLIN CHEM, V29, P1399; PEDERSEN MM, 1988, DIABETIC MED, V5, P562, DOI 10.1111/j.1464-5491.1988.tb01052.x; ROMANELLI G, 1990, DIABETES, V39, P1333, DOI 10.2337/diabetes.39.11.1333; RUDBERG S, 1990, DIABETOLOGIA, V33, P470, DOI 10.1007/BF00405108; SUTTON RAL, 1980, NEW ENGL J MED, V302, P709, DOI 10.1056/NEJM198003273021302; TRUNG MTP, 1974, STEROIDS, V24, P587; 1991, BMJ, V302, P210	37	71	71	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					175	182		10.1136/bmj.306.6871.175	http://dx.doi.org/10.1136/bmj.306.6871.175			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443481	Green Published, Bronze			2022-12-28	WOS:A1993KH51300021
J	LEESE, GP; AHMED, S; NEWTON, RW; JUNG, RT; ELLINGFORD, A; BAINES, P; ROXBURGH, S; COLEIRO, J				LEESE, GP; AHMED, S; NEWTON, RW; JUNG, RT; ELLINGFORD, A; BAINES, P; ROXBURGH, S; COLEIRO, J			USE OF MOBILE SCREENING UNIT FOR DIABETIC-RETINOPATHY IN RURAL AND URBAN AREAS	BRITISH MEDICAL JOURNAL			English	Article							PHOTOGRAPHY; COMMUNITY; CARE	Objectives-To compare the effectiveness of a mobile screening unit with a non-mydriatic polaroid camera in detecting diabetic retinopathy in rural and urban areas. To estimate the cost of the service. Design-Prospective data collection over two years of screening for diabetic retinopathy throughout Tayside. Setting-Tayside region, population 390 000, area 7770 km2. Subjects-961 patients in rural areas and 1225 in urban areas who presented for screening. Main outcome measures-Presence of diabetic retinopathy, need for laser photocoagulation, age, duration of diabetes, and diabetic treatment. Results-Compared with diabetic patients in urban areas, those in rural areas were less likely to attend a hospital based diabetic clinic (46% (442) v 86% (1054), p < 0.001); less likely to be receiving insulin (260 (27%) v 416 (34%), p < 0.001 and also after correction for differences in age distribution); more likely to have advanced (maculopathy or proliferative retinopathy) diabetic retinopathy (13% (122) v 7% (89), p < 0.001); and more likely to require urgent laser photocoagulation for previously unrecognised retinopathy (1.4% (13) v 0.5% (6), p < 0.02). The screening programme cost 10 Pound per patient screened and 1000 Pound per patient requiring laser treatment. Conclusion-The mobile diabetic eye screening programme detected a greater prevalence of advanced retinopathy in diabetic patients living in rural areas. Patients in rural areas were also more likely to need urgent laser photocoagulation. Present screening procedures seem to be less effective in rural areas and rural patients may benefit more from mobile screening units than urban patients.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT OPHTHALMOL,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT COMMUNITY MED,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee	LEESE, GP (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT MED,DUNDEE DD1 9SY,SCOTLAND.							Carstairs V., 1991, DEPRIVATION HLTH SCO; CHALLEN AH, 1990, PRACTICAL DIABETES, V7, P26; DORNAN C, 1983, J ROY COLL GEN PRACT, V33, P151; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; HIGGS ER, 1991, DIABETIC MED, V8, P551, DOI 10.1111/j.1464-5491.1991.tb01650.x; HIGGS ER, 1987, DIABETIC MED, V4, pA577; HILL RD, 1976, BRIT MED J, V1, P1137, DOI 10.1136/bmj.1.6018.1137; HOUGHTON G, 1990, PRAC DIAB, V7, P174; JONES RB, 1989, DIABETIC MED, V6, P262, DOI 10.1111/j.1464-5491.1989.tb01158.x; KOHNER EM, 1987, DIABETES S1, V36, pA42; LEESE GP, 1992, DIABETIC MED, V9, P459, DOI 10.1111/j.1464-5491.1992.tb01817.x; NATHAN DM, 1991, DIABETES CARE, V14, P26, DOI 10.2337/diacare.14.1.26; REITH S, 1985, LONDON UPDATE, V10, P24; ROGERS D, 1990, DIABETIC MED, V7, P165, DOI 10.1111/j.1464-5491.1990.tb01353.x; SCULPHER MJ, 1991, DIABETIC MED, V8, P644, DOI 10.1111/j.1464-5491.1991.tb01671.x; Snedecor G.W., 1980, STAT METHODS, V7; SPATHIS GS, 1986, DIABETIC MED, V3, P131, DOI 10.1111/j.1464-5491.1986.tb00723.x; Tattersall R, 1986, Diabet Med, V3, P166; TAYLOR R, 1990, BRIT MED J, V301, P1243, DOI 10.1136/bmj.301.6763.1243; WAREHAM N, 1990, DIABETIC MED S2, V7, pA32; WHITFORD DL, 1989, PRACT DIABET, V6, P114; WILLIAMS R, 1986, BRIT MED J, V293, P1140, DOI 10.1136/bmj.293.6555.1140; YUDKIN JS, 1980, J EPIDEMIOL COMMUN H, V34, P277, DOI 10.1136/jech.34.4.277	23	61	61	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					187	189		10.1136/bmj.306.6871.187	http://dx.doi.org/10.1136/bmj.306.6871.187			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443485	Green Published, Bronze			2022-12-28	WOS:A1993KH51300027
J	CHABNER, BA				CHABNER, BA			BIOLOGICAL BASIS FOR CANCER-TREATMENT	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; MOLECULAR BIOLOGY; DRUG RESISTANCE; GENE THERAPY	HAIRY-CELL LEUKEMIA; P-GLYCOPROTEIN EXPRESSION; MULTIDRUG RESISTANCE; DRUG-RESISTANCE; BREAST-CANCER; CARCINOMA; VERAPAMIL; THERAPY; TAXOL; GENE	The new knowledge of the regulation of cell growth and the genetic and biochemical changes that lead to malignancy have created many new opportunities for cancer drug discovery. These new targets include oncogenes, growth factors and their receptors, signal transduction pathways, and cell differentiation signals. Attempts to identify new therapies based on these targets can complement traditional drug discovery efforts that rely on high-volume screening of candidate natural products and synthetic chemicals against human tumor cell lines and against defined molecular reactions. Through modern computer-based data analysis, drug screening data can be used to establish mechanisms of drug action of new agents; these analyses shed light on patterns of cross-resistance of new compounds and their interactions with defined molecular targets as well as allow selection of chemically and biologically unique agents as candidates for clinical development.			CHABNER, BA (corresponding author), NCI, DIV CANC TREATMENT, BETHESDA, MD 20892 USA.							ADVANI R, 1992, ANN INTERN MED, V116, P183, DOI 10.7326/0003-4819-116-3-183; ASANO S, 1990, BLOOD, V75, P1602; ASHER AL, 1991, J IMMUNOL, V146, P3227; BERMAN E, 1990, BLOOD, V75, P839; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BRAVERMAN AS, 1993, ANN INTERN MED, V118, P630, DOI 10.7326/0003-4819-118-8-199304150-00010; CHABNER BA, 1990, J NATL CANCER I, V82, P1083, DOI 10.1093/jnci/82.13.1083; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; DURIE BGM, 1988, BRIT J HAEMATOL, V68, P203, DOI 10.1111/j.1365-2141.1988.tb06190.x; ERLICHMAN C, 1988, J CLIN ONCOL, V6, P469, DOI 10.1200/JCO.1988.6.3.469; FUKUOKA M, 1992, J CLIN ONCOL, V10, P16, DOI 10.1200/JCO.1992.10.1.16; GOEY H, 1989, J IMMUNOL, V143, P877; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HSIANG YH, 1988, CANCER RES, V48, P1722; JOHNSON RK, 1990, J NATL CANCER I, V82, P1082, DOI 10.1093/jnci/82.13.1082; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEATING MJ, 1989, BLOOD, V74, P19; KORSMEYER SJ, 1992, BLOOD, V80, P879; KRAUT EH, 1986, BLOOD, V68, P1119; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; LIPPMAN SM, 1991, P AN M AM SOC CLIN, V10, pA650; MARIE JP, 1991, BLOOD, V78, P586; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MEEK TD, 1992, J ENZYM INHIB, V6, P65, DOI 10.3109/14756369209041357; Migdalska A, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104820; MILLER TP, 1991, J CLIN ONCOL, V9, P17, DOI 10.1200/JCO.1991.9.1.17; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; PARDOLL DM, 1992, BONE MARROW TRANSPL, V9, P182; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROSENBERG SA, 1992, J CLIN ONCOL, V10, P180, DOI 10.1200/JCO.1992.10.2.180; SANFILIPPO O, 1991, EUR J CANCER, V27, P155, DOI 10.1016/0277-5379(91)90476-T; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SCHWARTZ MA, 1992, CANCER CHEMOTHERAPY, P156; SHIMADA Y, 1991, P AM ASS CLIN ONCOL, V10, pA408; Takeuchi S, 1991, Gan To Kagaku Ryoho, V18, P579; TSIFTSOGLOU AS, 1992, CONCISE REV CLIN EXP, P295; TSURUO T, 1982, BIOCHEM PHARMACOL, V31, P3138, DOI 10.1016/0006-2952(82)90097-1; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VOGLER WR, 1992, J CLIN ONCOL, V10, P1103, DOI 10.1200/JCO.1992.10.7.1103; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEINSTEIN JN, 1992, SCIENCE, V258, P447, DOI 10.1126/science.1411538; WU L, 1992, CANCER RES, V52, P3029; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404	53	16	16	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					633	637		10.7326/0003-4819-118-8-199304150-00011	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8452330				2022-12-28	WOS:A1993KW47000011
J	KUO, SC; SHEETZ, MP				KUO, SC; SHEETZ, MP			FORCE OF SINGLE KINESIN MOLECULES MEASURED WITH OPTICAL TWEEZERS	SCIENCE			English	Article							LASER; MICROTUBULES; GENERATION; TRANSPORT; MOVEMENT; INVITRO	Isometric forces generated by single molecules of the mechanochemical enzyme kinesin were measured with a laser-induced, single-beam optical gradient trap, also known as optical tweezers. For the microspheres used in this study, the optical tweezers was spring-like for a radius of 100 nanometers and had a maximum force region at a radius of approximately 150 nanometers. With the use of biotinylated microtubules and special streptavidin-coated latex microspheres as handles, microtubule translocation by single squid kinesin molecules was reversibly stalled. The stalled microtubules escaped optical trapping forces of 1.9 +/- 0.4 piconewtons. The ability to measure force parameters of single macromolecules now allows direct testing of molecular models for contractility.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM 36277] Funding Source: Medline; NINDS NIH HHS [NS 23345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHKIN A, 1992, BIOPHYS J, V61, P569, DOI 10.1016/S0006-3495(92)81860-X; ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BLOCK SM, 1992, NATURE, V360, P493, DOI 10.1038/360493a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; FU J, 1992, REV SCI INSTRUM, V63, P2200, DOI 10.1063/1.1143139; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P637, DOI 10.1016/0009-2509(67)80047-2; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KAMIMURA S, 1981, NATURE, V293, P566, DOI 10.1038/293566a0; Kuo S C, 1992, Trends Cell Biol, V2, P116, DOI 10.1016/0962-8924(92)90016-G; KUO SC, 1991, J CELL SCI, P135; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; SATO S, 1991, OPT LETT, V16, P282, DOI 10.1364/OL.16.000282; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4	21	337	353	4	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1993	260	5105					232	234		10.1126/science.8469975	http://dx.doi.org/10.1126/science.8469975			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8469975				2022-12-28	WOS:A1993KW45200044
J	PIPER, KR; VONBODMAN, SB; FARRAND, SK				PIPER, KR; VONBODMAN, SB; FARRAND, SK			CONJUGATION FACTOR OF AGROBACTERIUM-TUMEFACIENS REGULATES TI-PLASMID TRANSFER BY AUTOINDUCTION	NATURE			English	Article							CROWN GALL TUMORS; GENETIC-ANALYSIS; EXPRESSION; NOPALINE; PTIC58; BIOLUMINESCENCE; SEQUENCE; FISCHERI; CLONING; LOCUS	CONJUGAL transfer of Ti plasmids from Agrobacterium donors to bacterial recipients is controlled by two types of diffusible signal molecules. Induction is mediated by novel compounds, called opines, that are secreted by crown gall tumours. These neoplasias result from infection of susceptible plants by virulent agrobacteria. The second diffusible signal, called conjugation factor, is synthesized by the donor bacteria themselves. Production of this factor is induced by the opine. Here we show that conjugation is regulated directly by a transcriptional activator, TraR, which requires conjugation factor as a coinducer to activate tra gene expression. TraR is a homologue of LuxR, the lux gene activator from Vibrio fischeri which also requires an endogenously synthesized diffusible coinducer. The two regulatory systems are related; the two activator proteins show amino-acid sequence similarities and the lux system cofactor, autoinducer, will substitute for conjugation factor in the TraR-dependent activation of Ti plasmid tra genes.	UNIV ILLINOIS, DEPT PLANT PATHOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign								CANGELOSI GA, 1991, METHOD ENZYMOL, V204, P384; CHILTON MD, 1974, P NATL ACAD SCI USA, V71, P3672, DOI 10.1073/pnas.71.9.3672; DEPICKER A, 1980, PLASMID, V3, P193, DOI 10.1016/0147-619X(80)90109-2; Dunlap P.V., 1991, MICROBIAL CELL CELL, P219; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; ELLIS JG, 1982, MOL GEN GENET, V186, P269, DOI 10.1007/BF00331861; ELLIS JG, 1981, MOL GEN GENET, V181, P36, DOI 10.1007/BF00339002; ENGEBRECHT J, 1987, NUCLEIC ACIDS RES, V15, P10455, DOI 10.1093/nar/15.24.10455; ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6; GAMBELLO MJ, 1991, J BACTERIOL, V173, P3000, DOI 10.1128/JB.173.9.3000-3009.1991; HAYMAN GT, 1988, J BACTERIOL, V170, P1759, DOI 10.1128/jb.170.4.1759-1767.1988; HOLSTERS M, 1978, MOL GEN GENET, V163, P181, DOI 10.1007/BF00267408; Miller J. H, 1972, EXPT MOL GENETICS; NEALSON KH, 1970, J BACTERIOL, V104, P313, DOI 10.1128/JB.104.1.313-322.1970; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RYDER MH, 1984, J BIOL CHEM, V259, P9704; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STACHEL SE, 1985, EMBO J, V4, P891, DOI 10.1002/j.1460-2075.1985.tb03715.x; TATE RC, 1983, BIOTECHNOLOGY, V1, P269; VONBODMAN SB, 1992, P NATL ACAD SCI USA, V89, P643, DOI 10.1073/pnas.89.2.643; VONBODMAN SB, 1989, J BACTERIOL, V171, P5281, DOI 10.1128/jb.171.10.5281-5289.1989; WATSON B, 1975, J BACTERIOL, V123, P255, DOI 10.1128/JB.123.1.255-264.1975; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0; ZHANG LH, 1991, J BACTERIOL, V173, P1867, DOI 10.1128/jb.173.6.1867-1872.1991	24	409	434	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	1993	362	6419					448	450		10.1038/362448a0	http://dx.doi.org/10.1038/362448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8464476				2022-12-28	WOS:A1993KV42400083
J	TESTA, MA; ANDERSON, RB; NACKLEY, JF; HOLLENBERG, NK				TESTA, MA; ANDERSON, RB; NACKLEY, JF; HOLLENBERG, NK			QUALITY-OF-LIFE AND ANTIHYPERTENSIVE THERAPY IN MEN - A COMPARISON OF CAPTOPRIL WITH ENALAPRIL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OF-LIFE; COST-EFFECTIVENESS; HEART-FAILURE; STRESS; HYPERTENSION; INSTRUMENTS; MEDICATIONS; ARTHRITIS; ATENOLOL; ILLNESS	Background. We conducted a multicenter trial comparing two angiotensin-converting-enzyme inhibitors to determine whether effects on quality of life during antihypertensive therapy are uniform within this pharmacologic class of agents, and to relate the effects of the drugs on quality of life to objective adverse events, such as the loss of a job or the death of a spouse. Methods. After a four-week washout period when they received placebo, 379 men with mild-to-moderately-severe hypertension were randomly assigned to receive captopril (25 to 50 mg twice daily, with or without hydrochlorothiazide) or enalapril (5 to 20 mg per day, with or without hydrochlorothiazide) for 24 weeks. Blood pressure, quality of life, and life events were monitored. Differences between treatments were evaluated by calibrating measures of quality of life with objective life events. Results. Throughout the treatment period, no differences were found in blood pressure, frequency of withdrawal of patients from the study, or major side effects. Patients treated with captopril had more favorable changes in overall quality of life, general perceived health, vitality, health status, sleep, and emotional control (P<0.05 for each). The changes varied according to the quality of life at base line (P<0.001); patients with a low quality of life at base line remained stable or improved with either drug, whereas those with a higher quality of life remained stable with captopril but worsened with enalapril. The quality-of-life scales correlated with life events and symptom distress (P<0.001), and calibration analysis indicated that differences between treatments were clinically important. Conclusions. Two angiotensin-converting-enzyme inhibitors, captopril and enalapril, indistinguishable according to clinical assessments of efficacy and safety, had different effects on quality of life. Calibration with life events showed that drug-induced changes are substantial and that the different effects of these two agents on quality of life can be clinically meaningful.	PHASE V TECHNOL INC, WELLESLEY HILLS, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	TESTA, MA (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Testa, Marianna/L-9768-2019					[Anonymous], 1990, SPSS REFERENCE GUIDE; BARNES JM, 1989, CURRENT ADV ACE INHI, P159; BERENSON ML, 1983, INTERMEDIATE STATIST; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; BRAVO G, 1991, J CLIN EPIDEMIOL, V44, P381, DOI 10.1016/0895-4356(91)90076-L; BROWN GW, 1968, J HEALTH SOC BEHAV, V9, P203; Brown GW, 1989, LIFE EVENTS ILLNESS; Bulpitt C J, 1992, Pharmacoeconomics, V1, P95, DOI 10.2165/00019053-199201020-00006; CASSILETH BR, 1984, NEW ENGL J MED, V311, P506, DOI 10.1056/NEJM198408233110805; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; CROOG SH, 1987, J HYPERTENS, V5, pS47; DeLongis A., 1982, HEALTH PSYCHOL, V1, P119, DOI [DOI 10.1037/0278-6133.1.2.119, 10.1037/0278-6133.1.2.119]; Dupuy H.J., 1984, ASSESSMENT QUALITY L, P170; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FREEDBERG KA, 1991, J ACQ IMMUN DEF SYND, V4, P521; GELBER RD, 1986, J CLIN ONCOL, V4, P1772, DOI 10.1200/JCO.1986.4.12.1772; GELBER RD, 1992, ANN INTERN MED, V116, P961, DOI 10.7326/0003-4819-116-12-961; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; HANDA K, 1991, AM HEART J, V122, P1389, DOI 10.1016/0002-8703(91)90582-3; HANEY CA, 1980, SOC SCI MED-MED SOC, V14, P119, DOI 10.1016/S0271-7123(80)80030-7; HARRIS T, 1986, PSYCHOL MED, V16, P641, DOI 10.1017/S0033291700010394; HOLLENBERG NK, 1991, DRUG SAFETY, V6, P83, DOI 10.2165/00002018-199106020-00001; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; JENKINS CD, 1983, JAMA-J AM MED ASSOC, V250, P782, DOI 10.1001/jama.250.6.782; JOHNSON JR, 1985, CANCER TREAT REP, V69, P1155; KIECOLTGLASER JK, 1984, PSYCHOSOM MED, V46, P7, DOI 10.1097/00006842-198401000-00003; LEVINE S, 1987, J FAM PRACTICE, V25, P357; LIANG MH, 1985, ARTHRITIS RHEUM, V28, P542, DOI 10.1002/art.1780280513; LOCKE SE, 1984, PSYCHOSOM MED, V46, P441, DOI 10.1097/00006842-198409000-00005; MOINPOUR CM, 1989, J NATL CANCER I, V81, P485, DOI 10.1093/jnci/81.7.485; NOVICK FM, 1968, STATISTICAL THEORIES, P261; PAYKEL ES, 1984, PSYCHOL MED, V14, P559, DOI 10.1017/S0033291700015166; RABKIN JG, 1976, SCIENCE, V194, P1013, DOI 10.1126/science.790570; ROSE RM, 1978, PSYCHOSOM MED, V40, P142, DOI 10.1097/00006842-197803000-00006; SARASON IG, 1978, J CONSULT CLIN PSYCH, V46, P932, DOI 10.1037/0022-006X.46.5.932; STEINER SS, 1990, J HUM HYPERTENS, V4, P217; SUDILOVSKY A, 1989, PSYCHOPHARMACOL BULL, V25, P133; TANDON PK, 1989, J CLIN EPIDEMIOL, V42, P955, DOI 10.1016/0895-4356(89)90160-1; TARLOV AR, 1992, ANN INTERN MED, V116, P166, DOI 10.7326/0003-4819-116-2-166; TESTA MA, 1991, AM J HYPERTENS, V4, P363, DOI 10.1093/ajh/4.4.363; TESTA MA, 1989, AM J PREV MED, V5, P82, DOI 10.1016/S0749-3797(18)31109-7; TESTA MA, 1988, POSTGRAD MED J, V64, P50; THEORELL T, 1975, INT J EPIDEMIOL, V4, P281, DOI 10.1093/ije/4.4.281; TULEY MR, 1991, J CLIN EPIDEMIOL, V44, P417, DOI 10.1016/0895-4356(91)90080-S; VEIT CT, 1983, J CONSULT CLIN PSYCH, V51, P730, DOI 10.1037/0022-006X.51.5.730; WACHTEL T, 1992, ANN INTERN MED, V116, P129, DOI 10.7326/0003-4819-116-2-129; WALLER DG, 1991, DRUG SAFETY, V6, P241, DOI 10.2165/00002018-199106040-00002; WARREN S, 1982, J CHRON DIS, V35, P821, DOI 10.1016/0021-9681(82)90047-9	49	236	239	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 1	1993	328	13					907	913		10.1056/NEJM199304013281302	http://dx.doi.org/10.1056/NEJM199304013281302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU177	8446137				2022-12-28	WOS:A1993KU17700002
J	ALLEY, MRK; MADDOCK, JR; SHAPIRO, L				ALLEY, MRK; MADDOCK, JR; SHAPIRO, L			REQUIREMENT OF THE CARBOXYL TERMINUS OF A BACTERIAL CHEMORECEPTOR FOR ITS TARGETED PROTEOLYSIS	SCIENCE			English	Article							CAULOBACTER-CRESCENTUS; ESCHERICHIA-COLI; PROTEINS; CELLS	The bacterium Caulobacter crescentus yields two different progeny at each cell division; a chemotactically competent swarmer cell and a sessile stalked cell. The chemotaxis proteins are synthesized in the predivisional cell and then partition only to the swarmer cell upon division. The chemoreceptors that were newly synthesized were located at the nascent swarmer pole of the predivisional cell, an indication that asymmetry was established prior to cell division. When the swarmer cell differentiated into a stalked cell, the chemoreceptor was specifically degraded by virtue of an amino acid sequence located at its carboxyl terminus. Thus, a temporally and spatially restricted proteolytic event was a component of this differentiation process.	STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM32506, GM13929] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013929, R37GM032506, R01GM032506] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEY MRK, 1991, GENETICS, V129, P333; ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; ALLEY MRK, UNPUB; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; EVINGER M, 1977, J BACTERIOL, V132, P294, DOI 10.1128/JB.132.1.294-301.1977; FREDERIKSE P, UNPUB; GILL R, COMMUNICATION; GOMES SL, 1984, J MOL BIOL, V178, P551, DOI 10.1016/0022-2836(84)90238-9; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JOHNSON RC, 1977, GENETICS, V86, P25; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDOCK J, UNPUB; MADDOCK JR, 1993, SCIENCE, V259, P1717; PARKINSON JS, COMMUNICATION; REUTER SH, 1987, J MOL BIOL, V194, P653, DOI 10.1016/0022-2836(87)90242-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889	20	107	108	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1754	1757		10.1126/science.8456303	http://dx.doi.org/10.1126/science.8456303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456303				2022-12-28	WOS:A1993KT81000037
J	ULMER, JB; DONNELLY, JJ; PARKER, SE; RHODES, GH; FELGNER, PL; DWARKI, VJ; GROMKOWSKI, SH; DECK, RR; DEWITT, CM; FRIEDMAN, A; HAWE, LA; LEANDER, KR; MARTINEZ, D; PERRY, HC; SHIVER, JW; MONTGOMERY, DL; LIU, MA				ULMER, JB; DONNELLY, JJ; PARKER, SE; RHODES, GH; FELGNER, PL; DWARKI, VJ; GROMKOWSKI, SH; DECK, RR; DEWITT, CM; FRIEDMAN, A; HAWE, LA; LEANDER, KR; MARTINEZ, D; PERRY, HC; SHIVER, JW; MONTGOMERY, DL; LIU, MA			HETEROLOGOUS PROTECTION AGAINST INFLUENZA BY INJECTION OF DNA ENCODING A VIRAL PROTEIN	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; A VIRUS NUCLEOPROTEIN; ANTIGEN PRESENTATION; SYNTHETIC PEPTIDES; MAMMALIAN-CELLS; TARGET-CELLS; INVIVO; EXPRESSION; GENE; VACCINIA	Cytotoxic T lymphocytes (CTLs) specific for conserved viral antigens can respond to different strains of virus, in contrast to antibodies, which are generally strain-specific. The generation of such CTLs in vivo usually requires endogenous expression of the antigen, as occurs in the case of virus infection. To generate a viral antigen for presentation to the immune system without the limitations of direct peptide delivery or viral vectors, plasmid DNA encoding influenza A nucleoprotein was injected into the quadriceps of BALB/c mice. This resulted in the generation of nucleoprotein-specific CTLs and protection from a subsequent challenge with a heterologous strain of influenza A virus, as measured by decreased viral lung titers, inhibition of mass loss, and increased survival.	MERCK RES LABS, DEPT CANC RES, West Point, PA 19486 USA; VICAL, SAN DIEGO, CA 92121 USA	Merck & Company								ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; ALDOVINI A, 1991, NATURE, V351, P479, DOI 10.1038/351479a0; BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BENNINK JR, 1984, NATURE, V311, P578, DOI 10.1038/311578a0; BENNINK JR, 1990, CURR TOP MICROBIOL, V163, P153; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; COLLINS DS, 1992, J IMMUNOL, V148, P3336; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONNELLY JJ, 1990, J IMMUNOL, V145, P3071; DONNELLY JJ, UNPUB; GAMMELIN M, 1989, VIROLOGY, V170, P71, DOI 10.1016/0042-6822(89)90353-X; GARDNER I, 1974, EUR J IMMUNOL, V4, P68, DOI 10.1002/eji.1830040203; GERMAIN RN, 1991, NATURE, V353, P605, DOI 10.1038/353605a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GORMAN OT, 1991, J VIROL, V65, P3704, DOI 10.1128/JVI.65.7.3704-3714.1991; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HANSEN E, 1991, FEBS LETT, V290, P73, DOI 10.1016/0014-5793(91)81229-2; HAWE LA, UNPUB; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; MASCOLA L, 1989, ARCH INTERN MED, V149, P1569, DOI 10.1001/archinte.149.7.1569; MBAWUIKE I, COMMUNICATION; MCMICHAEL AJ, 1986, J GEN VIROL, V67, P719, DOI 10.1099/0022-1317-67-4-719; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; MORAN TM, 1991, J IMMUNOL, V146, P321; NEWMAN MJ, 1992, J IMMUNOL, V148, P2357; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PARKER SC, UNPUB; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER R, 1992, J IMMUNOL, V149, P53; SCHULMAN JL, 1963, J EXP MED, V118, P257, DOI 10.1084/jem.118.2.257; SCOTT GH, 1976, INFECT IMMUN, V13, P696, DOI 10.1128/IAI.13.3.696-703.1976; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TAYLOR PM, 1986, IMMUNOLOGY, V58, P417; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VIEIRA P, 1990, INT IMMUNOL, V2, P487, DOI 10.1093/intimm/2.6.487; WHANG Y, 1987, J VIROL, V61, P1796, DOI 10.1128/JVI.61.6.1796-1807.1987; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; YETTER RA, 1980, INFECT IMMUN, V29, P654; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YOUNG JF, 1983, ORIGIN PANDEMIC INFL, P129; ZINKERNAGEL RM, 1975, J EXP MED, V141, P1427, DOI 10.1084/jem.141.6.1427	60	2022	2477	1	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1993	259	5102					1745	1749		10.1126/science.8456302	http://dx.doi.org/10.1126/science.8456302			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456302				2022-12-28	WOS:A1993KT81000035
J	CORNWALL, PL				CORNWALL, PL			COMMUNICATION BETWEEN GENERAL-PRACTITIONERS AND CHILD-PSYCHIATRISTS	BRITISH MEDICAL JOURNAL			English	Article											CORNWALL, PL (corresponding author), SUNDERLAND DIST GEN HOSP,DEPT CHILD & FAMILY PSYCHIAT,SUNDERLAND SR4 7TP,ENGLAND.		Cornwall, Lenny/AAM-9428-2020	Cornwall, Lenny/0000-0001-8227-6980				KENTISH R, 1987, J ROY COLL GEN PRACT, V37, P162; MARINKER M, 1988, BRIT MED J, V297, P461, DOI 10.1136/bmj.297.6646.461; NEWTON J, 1992, BRIT MED J, V304, P821, DOI 10.1136/bmj.304.6830.821; PULLEN IM, 1985, BRIT MED J, V290, P31, DOI 10.1136/bmj.290.6461.31; WILLIAMS P, 1974, BRIT MED J, V1, P505, DOI 10.1136/bmj.1.5906.505	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					692	693		10.1136/bmj.306.6879.692	http://dx.doi.org/10.1136/bmj.306.6879.692			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KT216	8471922	Bronze, Green Published			2022-12-28	WOS:A1993KT21600022
J	BOURS, V; FRANZOSO, G; AZARENKO, V; PARK, S; KANNO, T; BROWN, K; SIEBENLIST, U				BOURS, V; FRANZOSO, G; AZARENKO, V; PARK, S; KANNO, T; BROWN, K; SIEBENLIST, U			THE ONCOPROTEIN BCL-3 DIRECTLY TRANSACTIVATES THROUGH KAPPA-B MOTIFS VIA ASSOCIATION WITH DNA-BINDING P50B HOMODIMERS	CELL			English	Article							V-REL ONCOGENE; RECEPTOR-ALPHA GENE; CELL-CYCLE CONTROL; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; C-REL; P65 SUBUNIT; CHLORAMPHENICOL ACETYLTRANSFERASE; 65-KD SUBUNIT	Bcl-3 is an IkappaB-related protein with ankyrin repeat motifs. Its gene is located at a site of recurrent translocations in a subset of B cell chronic lymphocytic leukemias. Bcl-3 associates tightly with p50B (NFKB2, p52) homodimers in cells, and together these proteins form a ternary complex with DNA at kappaB sites. Such an association functionally leads to a novel and potent form of transactivation through the kappaB motif: the tethering of Bcl-3 to DNA via the p50B homodimers allows Bcl-3 to transactivate directly, while p50B homodimers alone cannot. Transactivation mediated by Bcl-3 requires two cooperating domains located amino- and carboxy-terminal to the ankyrin domain. Bcl-3 is localized to the nucleus, and a Bcl-3-p50B complex is detected in certain lymphoid cells. Our data reveal a novel role for Bcl-3, distinct from that of the inhibitor IkappaB. The results have implications for tumorigenesis.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Franzoso, Guido/GRR-8628-2022	Franzoso, Guido/0000-0002-0778-988X				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BHATIA K, 1991, ONCOGENE, V6, P1569; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOHNLEIN E, 1989, J BIOL CHEM, V264, P8475; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWNELL E, 1989, ONCOGENE, V4, P935; COHEN L, 1992, J CELL PHYSIOL, V152, P10, DOI 10.1002/jcp.1041520103; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRILLI M, 1993, INT REV CYTOL, V148, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HISSE C, 1991, CELL, V65, P1191; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE BE, 1988, MUTAT RES, V195, P79, DOI 10.1016/0165-1110(88)90016-4; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VANKRIEKEN JHJM, 1990, LEUKEMIA, V4, P811; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	79	400	419	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					729	739		10.1016/0092-8674(93)90401-B	http://dx.doi.org/10.1016/0092-8674(93)90401-B			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453667	Bronze			2022-12-28	WOS:A1993KR43600009
J	CASANOVA, J; STRUHL, G				CASANOVA, J; STRUHL, G			THE TORSO RECEPTOR LOCALIZES AS WELL AS TRANSDUCES THE SPATIAL SIGNAL SPECIFYING TERMINAL BODY PATTERN IN DROSOPHILA	NATURE			English	Article							TYROSINE KINASE; VULVAR INDUCTION; GENE TORSO; EMBRYO; EXPRESSION; MUTATIONS; ELEMENTS; ANLAGEN; ENCODES; LET-23	SPECIFICATION of the end portions of the Drosophila body depends on the torso (tor) protein, a receptor tyrosine kinase that accumulates uniformly along the entire surface of the embryo but is activated only in the vicinity of the poles1-6. Several genes are normally required for activating tor and appear to define a system in which a gene product tethered to the extracellular vitelline membrane at each end of the egg provides a local source for an extracellular tor ligand2,5-7. This ligand would have to diffuse from the membrane to the cell surface of the embryo without losing its spatial localization. Here we report that the failure to accumulate tor protein at one or both poles leads to spatially inappropriate activity of more centrally located receptor. This ectopic activity depends on the same gene functions normally required for activating tor; thus we infer that it reflects inappropriate diffusion of the ligand to more central regions of the body. We conclude that the receptor not only transduces the spatial signal imparted by the tor ligand, but also ensures its correct localization by sequestering the ligand. Ligand trapping by receptor, may also localize spatial signals in other patterning systems, including specification of the dorsal-ventral axis in Drosophila and of vulval cell fates in Caenorhabditis elegans.	CSIC,CTR INVESTIGACIO & DESENVOLUPAMENT,E-08034 BARCELONA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC)	CASANOVA, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,701 W 168TH ST,NEW YORK,NY 10032, USA.		Casanova, Jordi/L-5181-2014	Casanova, Jordi/0000-0001-6121-8589				AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1991, MECH DEVELOP, V36, P41, DOI 10.1016/0925-4773(91)90070-M; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOCH M, 1990, EMBO J, V9, P2587, DOI 10.1002/j.1460-2075.1990.tb07440.x; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; RAY RP, 1991, DEVELOPMENT, V113, P35; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SCHUPBACH T, 1989, GENETICS, V121, P101; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	17	81	82	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					152	155		10.1038/362152a0	http://dx.doi.org/10.1038/362152a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8450886				2022-12-28	WOS:A1993KR02800058
J	SPIGSET, O; MJORNDAL, T; LOVHEIM, O				SPIGSET, O; MJORNDAL, T; LOVHEIM, O			SEROTONIN SYNDROME CAUSED BY A MOCLOBEMIDE-CLOMIPRAMINE INTERACTION	BRITISH MEDICAL JOURNAL			English	Letter									ORNSKOLDSVIK HOSP,DEPT INTERNAL MED,ORNSKOLDSVIK,SWEDEN		SPIGSET, O (corresponding author), UMEA UNIV HOSP,S-90185 UMEA,SWEDEN.							BALANTGORGIA AE, 1991, CLIN PHARMACOKINET, V20, P447, DOI 10.2165/00003088-199120060-00002; RAINER C, 1991, POSTGRAD MED, V89, P175; STERNBACH H, 1991, AM J PSYCHIAT, V148, P705; STOCKLEY IH, 1991, DRUG INTERACTIONS	4	57	57	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					248	248		10.1136/bmj.306.6872.248	http://dx.doi.org/10.1136/bmj.306.6872.248			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443525	Bronze, Green Published			2022-12-28	WOS:A1993KJ59100021
J	HUNNINGHAKE, DB; STEIN, EA; DUJOVNE, CA; HARRIS, WS; FELDMAN, EB; MILLER, VT; TOBERT, JA; LASKARZEWSKI, PM; QUITER, E; HELD, J; TAYLOR, AM; HOPPER, S; LEONARD, SB; BREWER, BK				HUNNINGHAKE, DB; STEIN, EA; DUJOVNE, CA; HARRIS, WS; FELDMAN, EB; MILLER, VT; TOBERT, JA; LASKARZEWSKI, PM; QUITER, E; HELD, J; TAYLOR, AM; HOPPER, S; LEONARD, SB; BREWER, BK			THE EFFICACY OF INTENSIVE DIETARY THERAPY ALONE OR COMBINED WITH LOVASTATIN IN OUTPATIENTS WITH HYPERCHOLESTEROLEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; LOW-FAT DIETS; ENERGY-INTAKE; PRECIPITATION PROCEDURE; PLASMA-LIPOPROTEINS; MONOCLONAL-ANTIBODY; STANDARDIZATION; WEIGHT; ACCURATE; DISEASE	Background. A diet low in saturated fat and cholesterol is the standard initial treatment for hypercholesterolemia. However, little quantitative information is available about the efficacy of dietary therapy in clinical practice or about the combined effects of diet and drug therapy. Methods. One hundred eleven outpatients with moderate hypercholesterolemia were treated at five lipid clinics with the National Cholesterol Education Program Step 2 diet (which is low in fat and cholesterol) and lovastatin (20 mg once daily), both alone and together. A diet high in fat and cholesterol and a placebo identical in appearance to the lovastatin were used as the respective controls. Each of the 97 patients completing the study (58 men and 39 women) underwent four consecutive nine-week periods of treatment according to a randomized, balanced design: a high-fat diet-placebo period, a low-fat diet-placebo period, a high-fat diet-lovastatin period, and a low-fat diet-lovastatin period. Results. The level of low-density lipoprotein (LDL) cholesterol was a mean of 5 percent (95 percent confidence interval, 3 to 7 percent) lower during the low-fat diet than during the high-fat diet (P<0.001). With lovastatin therapy as compared with placebo, the reduction was 27 percent. Together, the low-fat diet and lovastatin led to a mean reduction of 32 percent in the level of LDL cholesterol. The level of high-density lipoprotein (HDL) cholesterol fell by 6 percent (95 percent confidence interval, 4 to 8 percent) during the low-fat diet (P<0.001) and rose by 4 percent during treatment with lovastatin (P<0.001). The ratio of LDL to HDL cholesterol and the level of total triglycerides were reduced by lovastatin (P<0.001), but not by the low-fat diet. Conclusions, The effects of the low-fat-low-cholesterol diet and lovastatin on lipoprotein levels were independent and additive. However, the reduction in LDL cholesterol produced by the diet was small, and its benefit was possibly offset by the accompanying reduction in the level of HDL cholesterol.	CHRIST HOSP, CARDIOVASC RES CTR, CINCINNATI, OH 45219 USA; MED RES LABS, CINCINNATI, OH USA; UNIV KANSAS, MED CTR, KANSAS CITY, KS 66103 USA; MED COLL GEORGIA, AUGUSTA, GA 30912 USA; GEORGE WASHINGTON UNIV, WASHINGTON, DC 20052 USA; MERCK SHARP & DOHME LTD, RAHWAY, NJ 07065 USA; PROFESS NUTR SYST, KANSAS CITY, KS USA	Christ Hospital - Ohio; University of Kansas; University of Kansas Medical Center; University System of Georgia; Augusta University; George Washington University; Merck & Company	HUNNINGHAKE, DB (corresponding author), HEART DIS PREVENT CLIN, 151 VARIETY CLUB HEART & RES CTR, 401 E RIVER RD, MINNEAPOLIS, MN 55455 USA.		Tobert, Jonathan/J-4294-2019; Tobert, Jonathan/AAD-2155-2020; Harris, William Stephen/T-1674-2019	Tobert, Jonathan/0000-0001-7105-299X; Harris, William Stephen/0000-0003-3042-9353				Bishop YM., 2007, DISCRETE MULTIVARIAT; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRRAY GA, 1983, NUTRITIONAL SUPPORT, P466; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CLIFTON PM, 1992, ATHEROSCLEROSIS, V93, P59, DOI 10.1016/0021-9150(92)90200-Z; CLOEY TA, 1989, CLIN CHEM, V35, P1390; COBB MM, 1991, JAMA-J AM MED ASSOC, V265, P997, DOI 10.1001/jama.265.8.997; CONNOR SL, 1986, LANCET, V1, P1229; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; DUNCAN KH, 1983, AM J CLIN NUTR, V37, P763, DOI 10.1093/ajcn/37.5.763; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HARRIS WS, 1988, ARTERIOSCLEROSIS, V8, pA633; HAVEL RJ, 1987, ANN INTERN MED, V107, P609, DOI 10.7326/0003-4819-107-5-609; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LABEUR C, 1990, 55TH EUR ATH SOC M B; LASKA E, 1983, BIOMETRICS, V39, P1087, DOI 10.2307/2531343; LEWIS B, 1981, LANCET, V2, P1310; MATTSON FH, 1985, J LIPID RES, V26, P194; MCDOWELL IFW, 1989, CLIN CHEM, V35, P2070; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MERTZ W, 1991, AM J CLIN NUTR, V54, P291, DOI 10.1093/ajcn/54.2.291; MILLER JA, 1990, CLIN CHEM, V36, P964; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; SACKS FM, 1991, NEW ENGL J MED, V325, P1740, DOI 10.1056/NEJM199112123252411; SCHOELLER DA, 1990, NUTR REV, V48, P373, DOI 10.1111/j.1753-4887.1990.tb02882.x; Searle S.R., 1971, LINEAR MODELS; SHEPPARD L, 1991, AM J CLIN NUTR, V54, P821, DOI 10.1093/ajcn/54.5.821; SMITH SJ, 1987, CLIN CHEM, V33, P2240; SPRECHER DL, 1984, CLIN CHEM, V30, P2084; STEIN E, 1992, Clinical Chemistry, V38, P1067; STEIN E, 1990, ARCH INTERN MED, V150, P341, DOI 10.1001/archinte.150.2.341; STEIN EA, 1986, CLIN CHEM, V32, P967; STEINER PM, 1981, J CLIN CHEM CLIN BIO, V19, P850; TOBERT JA, 1986, JAMA-J AM MED ASSOC, V256, P2829; WARNICK GR, 1979, CLIN CHEM, V25, P279; WARNICK GR, 1978, J LIPID RES, V19, P65; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703; 1989, DIET HLTH IMPLICATIO, P159; 1974, DHEW NIH75628 PUBL; 1991, MARKET RES DATA; IN PRESS LOVASTATIN	44	235	238	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1213	1219		10.1056/NEJM199304293281701	http://dx.doi.org/10.1056/NEJM199304293281701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464431				2022-12-28	WOS:A1993KZ06100001
J	GROUSE, LD				GROUSE, LD			SABIN,ALBERT,BRUCE - OBITUARY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Item About an Individual																		SABIN AB, PUBLICATION LIST	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2140	2140						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468772				2022-12-28	WOS:A1993KY36600040
J	PENNINGER, J; KISHIHARA, K; MOLINA, T; WALLACE, VA; TIMMS, E; HEDRICK, SM; MAK, TW				PENNINGER, J; KISHIHARA, K; MOLINA, T; WALLACE, VA; TIMMS, E; HEDRICK, SM; MAK, TW			REQUIREMENT FOR TYROSINE KINASE P56(LCK) FOR THYMIC DEVELOPMENT OF TRANSGENIC GAMMA-DELTA-T-CELLS	SCIENCE			English	Article							INTESTINAL INTRAEPITHELIAL LYMPHOCYTES; HEAT-SHOCK PROTEINS; TRANSIENT EXPRESSION; IL-2 RECEPTOR; ANTIGEN; CD4; RECOGNITION; P56LCK; SELECTION; GENE	The Src-related protein tyrosine kinase p56lck is essential for antigen-specific signal transduction and thymic maturation of T cells that have an alphabeta T cell receptor (TCR), presumably by physical association with CD4 or CD8 molecules. To evaluate the requirement for p56lck in the development of T cells that have gammadelta TCRs, which generally do not express CD4 or CDB, p56lck mutant mice were bred with TCRgammadelta transgenic mice. Few peripheral cells that carried the transgenes could be detected in p56lck-/- mice, although 70 percent of thymocytes were transgenic. Development of transgenic gammadelta+ thymocytes was blocked at an early stage, defined by interleukin-2 receptor alpha expression. However, extrathymic development of CD8alphaalpha+TCR-gammadelta+ intestinal intraepithelial lymphocytes appeared to be normal. Thus, p56lck is crucial for the thymic, but not intestinal, maturation of gammadelta T cells and may function in thymic development independently of CD4 or CD8.	UNIV TORONTO, ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA; HOP HOTEL DIEU, DEPT PATHOL, F-75181 PARIS 04, FRANCE; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4X 1K9, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Diego; University of Toronto; University of Toronto			Hedrick, Stephen M/E-9171-2010; Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Hedrick, Stephen/0000-0002-6345-8751				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; COLLINS TL, 1992, J IMMUNOL, V148, P2159; CRISPE IN, 1987, J IMMUNOL, V138, P2013; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; EGHTESADY P, 1992, IMMUNOGENETICS, V36, P377, DOI 10.1007/BF00218045; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; IMANI F, 1991, P NATL ACAD SCI USA, V88, P10475, DOI 10.1073/pnas.88.23.10475; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KYES S, 1989, P NATL ACAD SCI USA, V86, P5527, DOI 10.1073/pnas.86.14.5527; LEFRANCOIS L, 1990, CELL, V63, P333, DOI 10.1016/0092-8674(90)90166-C; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LEUNG WPF, 1991, CELL, V65, P443; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOSLEY RL, 1990, INT IMMUNOL, V2, P361, DOI 10.1093/intimm/2.4.361; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; ROCHA B, 1992, J EXP MED, V176, P187; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHILHAM M, IN PRESS EUR J IMMUN; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHIMONKEVITZ RP, 1987, NATURE, V329, P157, DOI 10.1038/329157a0; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TORIBIO ML, 1989, NATURE, V342, P82, DOI 10.1038/342082a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WELLS FB, 1991, SCIENCE, V253, P903, DOI 10.1126/science.1831565; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	46	66	67	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1993	260	5106					358	361		10.1126/science.8469988	http://dx.doi.org/10.1126/science.8469988			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8469988				2022-12-28	WOS:A1993KX80000040
J	SOLDATI, D; BOOTHROYD, JC				SOLDATI, D; BOOTHROYD, JC			TRANSIENT TRANSFECTION AND EXPRESSION IN THE OBLIGATE INTRACELLULAR PARASITE TOXOPLASMA-GONDII	SCIENCE			English	Article							CHLORAMPHENICOL ACETYLTRANSFERASE GENE; HOMOLOGOUS RECOMBINATION; LEISHMANIA-ENRIETTII; TRYPANOSOMA-BRUCEI; SURFACE-ANTIGEN; PROTOZOAN	Toxoplasma gondii is a protozoan pathogen that produces severe disease in humans and animals. This obligate intracellular parasite provides an excellent model for the study of how such pathogens are able to invade, survive, and replicate intracellularly. DNA encoding chloramphenicol acetyltransferase was introduced into T. gondii and transiently expressed with the use of three vectors based on different Toxoplasma genes. The ability to introduce genes and have them efficiently and faithfully expressed is an essential tool for understanding the structure-function relation of genes and their products.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University			Soldati-Favre, Dominique/A-2999-2009	Boothroyd, John C./0000-0001-9719-745X				BELLOFATTO V, 1989, SCIENCE, V244, P1167, DOI 10.1126/science.2499047; BURG JL, 1988, J IMMUNOL, V141, P3584; COBURN CM, 1991, MOL BIOCHEM PARASIT, V46, P169, DOI 10.1016/0166-6851(91)90210-W; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; ELMENDORF HG, 1992, MOL BIOCHEM PARASIT, V52, P215, DOI 10.1016/0166-6851(92)90054-N; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KASPER LH, 1987, PARASITE IMMUNOL, V9, P433, DOI 10.1111/j.1365-3024.1987.tb00521.x; KASPER LH, 1992, IMMUNOLOGY PARASITIC, P264; KIM KK, UNPUB; LABAN A, 1989, P NATL ACAD SCI USA, V86, P9119, DOI 10.1073/pnas.86.23.9119; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; NAGEL SD, 1988, MOL BIOCHEM PARASIT, V29, P261, DOI 10.1016/0166-6851(88)90081-3; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OBRIG TG, 1971, J BIOL CHEM, V246, P174; OSSORIO PN, 1992, MOL BIOCHEM PARASIT, V50, P1, DOI 10.1016/0166-6851(92)90239-G; Sambrook J, 1989, MOL CLONING LABORATO; SIBLEY LD, 1992, GENETICS, V132, P1003; SOLDATI D, UNPUB; TANABE K, 1977, Japanese Journal of Parasitology, V26, P113; TOBIN JF, 1991, P NATL ACAD SCI USA, V88, P864, DOI 10.1073/pnas.88.3.864; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902	23	291	310	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					349	352		10.1126/science.8469986	http://dx.doi.org/10.1126/science.8469986			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8469986				2022-12-28	WOS:A1993KX80000037
J	MURPHY, GS; BODHIDATTA, L; ECHEVERRIA, P; TANSUPHASWADIKUL, S; HOGE, CW; IMLARP, S; TAMURA, K				MURPHY, GS; BODHIDATTA, L; ECHEVERRIA, P; TANSUPHASWADIKUL, S; HOGE, CW; IMLARP, S; TAMURA, K			CIPROFLOXACIN AND LOPERAMIDE IN THE TREATMENT OF BACILLARY DYSENTERY	ANNALS OF INTERNAL MEDICINE			English	Article						DYSENTERY, BACILLARY; CIPROFLOXACIN; LOPERAMIDE; DIARRHEA; SHIGELLA-DYSENTERIAE	ESCHERICHIA-COLI; TRAVELERS DIARRHEA; STOOL SPECIMENS; TRIMETHOPRIM; SHIGELLOSIS; CHILDREN; THERAPY; DISEASE; TRIAL	Objective: To compare the safety and efficacy of loperamide plus ciprofloxacin with those of ciprofloxacin alone in the treatment of bacillary dysentery. Design: Double-blind, placebo-controlled, randomized clinical trial. Setting: Hospital in Thailand. Participants: Eighty-eight adults with dysentery seeking medical care between November 1990 and February 1992. Patients who had received prior antibiotics or antimotility drugs were excluded. Intervention: All 88 patients with dysentery were treated with ciprofloxacin, 500 mg twice daily for 3 days. Forty-two of these patients were randomly assigned to receive loperamide, a 4-mg initial dose followed by 2 mg after every loose stool (as many as eight caplets [16 mg] daily), and 46 were randomly assigned to receive placebo. Measurements: Stools were collected daily until resolution of diarrhea and again after 10 days. The time to passage of the last unformed stool, number of unformed stools, and symptoms were recorded after treatment. Results: Shigella or enteroinvasive Escherichia coli (53%), Vibrio parahaemolyticus (16%), and Salmonella (7%) were the most common bacterial enteric pathogens identified in 88 patients with dysentery. In patients infected with Shigella or enteroinvasive E. coli, the median duration of diarrhea was 19 hours (25th to 75th percentiles, 6 to 42 hours) for those receiving loperamide plus ciprofloxacin compared with 42 hours (21 to 46 hours) for those receiving ciprofloxacin alone (P = 0.028). The median number of diarrheal stools for those receiving ciprofloxacin and loperamide was 2.0 (1 to 5 stools) compared with 6.5 (2 to 9 stools) for those receiving ciprofloxacin alone (P = 0.016). None of the participants had a temperature greater than 38-degrees-C after 24 hours of treatment. None of the patients was infected with the same bacterial enteric pathogen more than 1 day after receiving treatment. Conclusions: Loperamide decreases the number of unformed stools and shortens the duration of diarrhea in dysentery caused by Shigella in adults treated with ciprofloxacin.	NATL INST HLTH, TOKYO 141, JAPAN; ARMED FORCES RES INST MED SCI, BANGKOK, THAILAND; BAMRASNARADURA HOSP, NONTHABURI, THAILAND; ARMY INST CLIN PATHOL, BANGKOK, THAILAND	National Institute of Health Sciences - Japan; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)								BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BENNISH ML, 1990, J INFECT DIS, V162, P711, DOI 10.1093/infdis/162.3.711; BRONSDON MA, 1984, J CLIN MICROBIOL, V19, P952, DOI 10.1128/JCM.19.6.952-953.1984; CHOW CB, 1986, ACTA PAEDIATR SCAND, V75, P1034, DOI 10.1111/j.1651-2227.1986.tb10338.x; Dean A. G., 1990, EPI INFO VERSION 5 W; DEAN AG, 1972, J INFECT DIS, V125, P407, DOI 10.1093/infdis/125.4.407; DUPONT HL, 1973, JAMA-J AM MED ASSOC, V226, P1525, DOI 10.1001/jama.226.13.1525; DUPONT HL, 1971, NEW ENGL J MED, V285, P1, DOI 10.1056/NEJM197107012850101; ECHEVERRIA P, 1989, J INFECT DIS, V159, P543, DOI 10.1093/infdis/159.3.543; ECHEVERRIA P, 1991, REV INFECT DIS, V13, pS220; ECHEVERRIA P, 1985, AM J TROP MED HYG, V34, P547, DOI 10.4269/ajtmh.1985.34.547; ECHEVERRIA P, 1990, GENE PROBES BACTERIA; ERICSSON CD, 1990, JAMA-J AM MED ASSOC, V263, P257, DOI 10.1001/jama.263.2.257; FORMAL SB, 1963, J BACTERIOL, V85, P119, DOI 10.1128/JB.85.1.119-125.1963; HAIDER K, 1990, EPIDEMIOL INFECT, V104, P219, DOI 10.1017/S0950268800059380; HYAMS KC, 1991, NEW ENGL J MED, V325, P1423, DOI 10.1056/NEJM199111143252006; JOHNSON PC, 1986, JAMA-J AM MED ASSOC, V255, P757, DOI 10.1001/jama.255.6.757; KNISLEY CV, 1986, J CLIN MICROBIOL, V23, P897, DOI 10.1128/JCM.23.5.897-900.1986; LOLEKHA S, 1988, SCAND J INFECT DIS, P35; MAAS R, 1983, PLASMID, V10, P296, DOI 10.1016/0147-619X(83)90045-8; MELVIN DM, 1974, LABORATORY PROCEDURE; MINTON NA, 1987, BRIT MED J, V294, P1383, DOI 10.1136/bmj.294.6584.1383; ORSKOV F, 1984, METHOD MICROBIOL, V14, P43, DOI 10.1016/S0580-9517(08)70447-1; PETRUCCELLI BP, 1992, J INFECT DIS, V165, P557, DOI 10.1093/infdis/165.3.557; PICKERING LK, 1977, AM J CLIN PATHOL, V68, P562; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; SERENY B, 1955, Acta Microbiol Acad Sci Hung, V2, P293; TAYLOR DN, 1991, ANN INTERN MED, V114, P731, DOI 10.7326/0003-4819-114-9-731; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; VANLOON FPL, 1989, GUT, V30, P492, DOI 10.1136/gut.30.4.492; 1990, RATIONAL USE DRUGS M	31	68	68	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					582	586		10.7326/0003-4819-118-8-199304150-00002	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8452323				2022-12-28	WOS:A1993KW47000002
J	MCCARTHY, MP				MCCARTHY, MP			PAINFUL LESSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1872	1872						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459522				2022-12-28	WOS:A1993KW25000046
J	TANIGUCHI, T; MINAMI, Y				TANIGUCHI, T; MINAMI, Y			THE IL-2/IL-2 RECEPTOR SYSTEM - A CURRENT OVERVIEW	CELL			English	Review							INTERLEUKIN-2 RECEPTOR; SIGNAL TRANSDUCTION; FAMILY; LYMPHOCYTES; CELLS				TANIGUCHI, T (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,YAMADAOKA 1-3,SUITA,OSAKA 565,JAPAN.							ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; ASAO H, 1993, IN PRESS P NATL ACAD, V90; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GREENE WC, 1986, ANNU REV IMMUNOL, V4, P69, DOI 10.1146/annurev.iy.04.040186.000441; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOBAYASHI N, 1993, IN PRESS P NATL ACAD, V90; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PLAISANCE S, 1992, INT IMMUNOL, V4, P739, DOI 10.1093/intimm/4.7.739; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SADLACK B, 1993, J CELL BIOCH B, V17, P54; SATOH T, 1992, J BIOL CHEM, V267, P25423; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIMIZU A, 1986, IMMUNOL REV, V92, P103, DOI 10.1111/j.1600-065X.1986.tb01496.x; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOSS SD, 1993, P NATL ACAD SCI USA, V90, P2428, DOI 10.1073/pnas.90.6.2428; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	33	745	772	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					5	8		10.1016/0092-8674(93)90152-G	http://dx.doi.org/10.1016/0092-8674(93)90152-G			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462103				2022-12-28	WOS:A1993KW75300002
J	SCHEDL, A; MONTOLIU, L; KELSEY, G; SCHUTZ, G				SCHEDL, A; MONTOLIU, L; KELSEY, G; SCHUTZ, G			A YEAST ARTIFICIAL CHROMOSOME COVERING THE TYROSINASE GENE CONFERS COPY NUMBER-DEPENDENT EXPRESSION IN TRANSGENIC MICE	NATURE			English	Article							MOUSE TYROSINASE; ALBINO MUTATION; LARGE INSERTS; HUMAN DNA; LIBRARIES; CLONING; CELLS	EXPRESSION of transgenes in mice often fails to follow the normal temporal and spatial pattern and to reach the same level as the endogenous copies1,2. Only in exceptional cases has position-independent and copy number-dependent expression been reproduced3. The size constraint of standard constructs may prevent the inclusion of important remote regulatory elements. Yeast artificial chromosomes (YACs)4 provide a means of cloning large DNA fragments and the transfer of YAC DNA into somatic cells has been reported5-9. We have previously produced transgenic mice carrying a 35 kilobase YAC construct10. Here we report the transfer of a 250 kilobase YAC covering the mouse tyrosinase gene into mice by pronuclear injection of gel-purified YAC DNA. The YAC was inserted into the mouse genome without major rearrangements and expression of the YAC-borne tyrosinase gene resulted in complete rescue of the albino phenotype of the recipient mice. Expression from the transgene reached levels comparable to that of the endogenous gene and showed copy number dependence and position independence.	GERMAN CANC RES CTR,DIV MOLEC BIOL CELL 1,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Montoliu, Lluis/I-2039-2015; Schedl, Andreas/F-8823-2015; Schedl, Andreas/GOP-3427-2022	Montoliu, Lluis/0000-0003-3941-1176; Schedl, Andreas/0000-0001-9380-7396; Kelsey, Gavin/0000-0002-9762-5634				ANAND R, 1989, NUCLEIC ACIDS RES, V17, P3425, DOI 10.1093/nar/17.9.3425; BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; GAUDETTE MF, 1991, NUCLEIC ACIDS RES, V19, P1879, DOI 10.1093/nar/19.8.1879; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; GNIRKE A, 1991, SOMAT CELL MOLEC GEN, V17, P573, DOI 10.1007/BF01233622; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOGAN B, 1986, MANIPULATING MOUSE E; JACKSON IJ, 1990, P NATL ACAD SCI USA, V87, P7010, DOI 10.1073/pnas.87.18.7010; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELSEY G, 1992, GENOMICS, V14, P275, DOI 10.1016/S0888-7543(05)80217-4; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LOVELLBADGE RH, 1987, TERATOCARCINOMA EMBR; MUELLER G, 1988, EMBO (European Molecular Biology Organization) Journal, V7, P2723; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PORTER S, 1991, DEV GENET, V12, P393, DOI 10.1002/dvg.1020120604; REEVES RH, 1990, GENET ANAL TECHN APP, V5, P107; ROBINSON MO, 1991, NUCLEIC ACIDS RES, V19, P1557, DOI 10.1093/nar/19.7.1557; RUPPERT S, 1988, EMBO J, V7, P2715, DOI 10.1002/j.1460-2075.1988.tb03125.x; RUPPERT S, 1988, THESIS RUPRECHT KARL; SCHEDL A, 1992, NUCLEIC ACIDS RES, V20, P3073, DOI 10.1093/nar/20.12.3073; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; SMITH DR, 1990, P NATL ACAD SCI USA, V87, P8242, DOI 10.1073/pnas.87.21.8242; STIEF A, 1989, NATURE, V345, P341; STRAUSS WM, 1992, EMBO J, V11, P417, DOI 10.1002/j.1460-2075.1992.tb05070.x; TANAKA S, 1990, DEVELOPMENT, V108, P223; WEIS JH, 1992, TRENDS GENET, V8, P263, DOI 10.1016/0168-9525(92)90242-V; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293	31	232	270	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					258	261		10.1038/362258a0	http://dx.doi.org/10.1038/362258a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8459851				2022-12-28	WOS:A1993KT02600060
J	GERMAN, K; NUWAHID, F; MATTHEWS, P; STEPHENSON, T				GERMAN, K; NUWAHID, F; MATTHEWS, P; STEPHENSON, T			DANGERS OF LONG WAITING-TIMES FOR OUTPATIENT APPOINTMENTS AT A UROLOGY CLINIC	BRITISH MEDICAL JOURNAL			English	Article							STAGE-D1 ADENOCARCINOMA; PROSTATE; EXPERIENCE; CANCER				GERMAN, K (corresponding author), CARDIFF ROYAL INFIRM,DEPT UROL,CARDIFF CF2 1SZ,S GLAM,WALES.							GEORGE NJR, 1988, LANCET, V1, P494; PERRIN P, 1991, BRIT J UROL, V68, P263, DOI 10.1111/j.1464-410X.1991.tb15319.x; STEINBERG GD, 1990, J UROLOGY, V144, P1425, DOI 10.1016/S0022-5347(17)39759-8; ZINCKE H, 1989, UROLOGY, V33, P27, DOI 10.1016/0090-4295(89)90103-9	4	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					429	429		10.1136/bmj.306.6875.429	http://dx.doi.org/10.1136/bmj.306.6875.429			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461724	Bronze, Green Published			2022-12-28	WOS:A1993KM70000021
J	HOPE, T; SPRIGINGS, D; CRISP, R				HOPE, T; SPRIGINGS, D; CRISP, R			NOT CLINICALLY INDICATED - PATIENTS INTERESTS OR RESOURCE-ALLOCATION	BRITISH MEDICAL JOURNAL			English	Article							AORTIC-VALVE REPLACEMENT; AGED 80 YEARS; CARDIAC-SURGERY; OCTOGENARIAN; STENOSIS; VALVULOPLASTY; PREDICTORS	The decision that a particular intervention is not clinically indicated may conceal two quite different ethical assumptions. The first assumption is that the intervention is not of overall benefit to this patient. The second is that limited resources should not be used for this patient. These issues are discussed with reference to cardiac surgery in elderly patients with reference to the main theories of allocation: QALYs, needs theories, the sanctity of life theory, the lottery theory, and market forces.	UNIV OXFORD ST ANNES COLL,OXFORD OX2 6HS,ENGLAND	University of Oxford	HOPE, T (corresponding author), JOHN RADCLIFFE HOSP,OXFORD PRACTICE SKILLS PROJECT,MED SCH OFF,OXFORD OX3 9DU,ENGLAND.							Broome J, 1988, PHILOS MED WELFARE, P57; CRAVER JM, 1988, CIRCULATION, V78, P85; CULLIFORD AT, 1991, AM J CARDIOL, V67, P1256, DOI 10.1016/0002-9149(91)90937-G; EDMUNDS LH, 1988, NEW ENGL J MED, V319, P131, DOI 10.1056/NEJM198807213190302; FIORE AC, 1989, ANN THORAC SURG, V48, P104, DOI 10.1016/0003-4975(89)90189-6; FREEMAN WK, 1991, J AM COLL CARDIOL, V18, P29, DOI 10.1016/S0735-1097(10)80212-8; FREMES SE, 1989, CIRCULATION, V80, P77; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; Harris J., 1985, VALUE LIFE; KUNTZ RE, 1991, NEW ENGL J MED, V325, P17, DOI 10.1056/NEJM199107043250104; LEVINSON JR, 1989, CIRCULATION, V80, P49; Lockwood M., 1988, ROY I PHILOS S, V23, P33; MAGOVERN JA, 1987, J AM COLL CARDIOL, V9, P38, DOI 10.1016/S0735-1097(87)80079-7; MULLANY CJ, 1990, CIRCULATION, V82, P229; NORD E, 1992, BRIT MED J, V305, P875, DOI 10.1136/bmj.305.6858.875; OKEEFE JH, 1987, MAYO CLIN PROC, V62, P986, DOI 10.1016/S0025-6196(12)65068-X; RICH MW, 1985, J THORAC CARDIOV SUR, V90, P56; TSAI TP, 1986, J THORAC CARDIOV SUR, V91, P924; TURINA J, 1987, EUR HEART J, V8, P471, DOI 10.1093/oxfordjournals.eurheartj.a062307; WEINTRAUB WS, 1991, CIRCULATION, V84, P226; 1991, J R COLL PHYSICIANS, V25, P197	21	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					379	381		10.1136/bmj.306.6874.379	http://dx.doi.org/10.1136/bmj.306.6874.379			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461686	Green Published, Bronze			2022-12-28	WOS:A1993KL71500025
J	JALLEH, R; FITZPATRICK, MF; JAN, MA; MACNEE, W; DOUGLAS, NJ				JALLEH, R; FITZPATRICK, MF; JAN, MA; MACNEE, W; DOUGLAS, NJ			ALCOHOL AND COR-PULMONALE IN CHRONIC-BRONCHITIS AND EMPHYSEMA	BRITISH MEDICAL JOURNAL			English	Article									CITY HOSP EDINBURGH,DEPT MED RIE,RESP MED UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND				Douglas, Neil/B-1491-2013	MacNee, William/0000-0002-3692-1448				CHAN CS, 1990, AM REV RESPIR DIS, V141, P861, DOI 10.1164/ajrccm/141.4_Pt_1.861; CHICK J, 1986, LANCET, V2, P1380; FRANCE AJ, 1988, THORAX, V43, P621, DOI 10.1136/thx.43.8.621; MUSABAYANE CT, 1985, ACTA ENDOCRINOL-COP, V110, P214, DOI 10.1530/acta.0.1100214; 1990, SPSS ADV STATISTICS, P64	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					374	374		10.1136/bmj.306.6874.374	http://dx.doi.org/10.1136/bmj.306.6874.374			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461684	Green Published, Bronze			2022-12-28	WOS:A1993KL71500021
J	NORTH, F; SYME, SL; FEENEY, A; HEAD, J; SHIPLEY, MJ; MARMOT, MG				NORTH, F; SYME, SL; FEENEY, A; HEAD, J; SHIPLEY, MJ; MARMOT, MG			EXPLAINING SOCIOECONOMIC DIFFERENCES IN SICKNESS ABSENCE - THE WHITEHALL-II STUDY	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; CIVIL-SERVANTS; FOLLOW-UP; HEALTH; INEQUALITIES; POPULATION; MORTALITY; MEN	Objective-To describe and explain the socioeconomic gradient in sickness absence. Design-Analysis of questionnaire and sickness absence data collected from the first phase of the Whitehall II study. Grade of employment was used as a measure of socioeconomic status. Setting-20 civil service departments in London. Subjects-6900 male and 3414 female civil servants aged 35-55 years. Main outcome measures-Rates of short spells (less-than-or-equal-to 7 days) and long spells (>7 days) of sickness absence. Results-A strong inverse relation between grade of employment and sickness absence was evident. Men in the lowest grade had rates of short and long spells of absence 6.1 (95% confidence interval 5.3 to 6.9) and 6.1 (4.8 to 7.9) times higher than those in the highest grade. For women the corresponding rate ratios were 3.0 (2.3 to 3.9) and 4.2 (2.5 to 6.8) respectively. Several risk factors were identified, including health related behaviours (smoking and frequent alcohol consumption), work characteristics (low levels of control, variety and use of skills, work pace, and support at work), low levels of job satisfaction, and adverse social circumstances outside work (financial difficulties and negative support). These risk factors accounted for about one third of the grade differences in sickness absence. Conclusion-Large grade differences in sickness absence parallel socioeconomic differences in morbidity and mortality found in other studies. Identified risk factors accounted for a small proportion of the grade differences in sickness absence. More accurate measurement of the risk factors may explain some of the remaining differences in sickness absence but other factors, as yet unrecognised, are likely to be important.	UCL, UNIV COLL & MIDDLESEX SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND; UNIV OTAGO, DEPT PREVENT & SOCIAL MED, DUNEDIN, NEW ZEALAND; UNIV CALIF BERKELEY, SCH PUBL HLTH, BERKELEY, CA 94720 USA	University of London; University College London; University of Otago; University of California System; University of California Berkeley			Marmot, M G/Y-3920-2019; Head, Jenny/GYA-2625-2022	Marmot, M G/0000-0002-2431-6419; Head, Jennifer/0000-0002-6054-0872	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; AHRQ HHS [5 RO1 HS06516] Funding Source: Medline; Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 RO1 HL36310-04] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aitken M, 1989, STATISTICAL MODELLIN, P217; ALDERSON M, 1983, INTRO EPIDEMIOLOGY; ALDERSON MR, 1967, BRIT J PREV SOC MED, V21, P1; BLAXTER M, 1987, LANCET, V2, P30; Goldberg DP, 1972, DETECTION PSYCHIAT I; GREENLAND S, 1980, AM J EPIDEMIOL, V112, P564, DOI 10.1093/oxfordjournals.aje.a113025; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; Hill JMM, 1955, HUM RELAT, V8, P121, DOI 10.1177/001872675500800202; IDLER EL, 1990, AM J PUBLIC HEALTH, V80, P446, DOI 10.2105/AJPH.80.4.446; JOHNS G, 1982, RES ORGAN BEHAV, V4, P127; JOHNSON JV, 1988, AM J PUBLIC HEALTH, V78, P1336, DOI 10.2105/AJPH.78.10.1336; KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; McCullagh P, 1983, GENERALIZED LINEAR M, P127; MORRIS JN, 1965, P ROY SOC MED, V58, P821, DOI 10.1177/003591576505801028; NICHOLSON N, 1985, ACAD MANAGE REV, V10, P397, DOI 10.2307/258123; PINES A, 1985, BRIT J IND MED, V42, P326; POCOCK SJ, 1987, LANCET, V2, P197; REID DD, 1974, LANCET, V1, P469; SODERFELT B, 1987, SCAND J SOC MED, V15, P11; TAYLOR PJ, 1972, BRIT J PREV SOC MED, V26, P165; TAYLOR PJ, 1976, BRIT J IND MED, V33, P230; THOMSON D, 1972, P ROY SOC MED, V65, P572, DOI 10.1177/003591577206500633; 1978, GENERAL HOUSEHOLD SU; 1979, GENERAL HOUSEHOLD SU; 1987, ABSENCE WORK SURVEY; 1985, SAS USERS GUIDE VERS; 1985, REGIONAL TRENDS, V20; 1989, GENERAL HOUSEHOLD SU; [No title captured]; 1985, HLTH CIVIL SERVICE	33	296	301	0	17	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					361	366		10.1136/bmj.306.6874.361	http://dx.doi.org/10.1136/bmj.306.6874.361			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461681	Green Published, Bronze			2022-12-28	WOS:A1993KL71500018
J	NAYLOR, CD; SIBBALD, WJ; SPRUNG, CL; PINFOLD, SP; CALVIN, JE; CERRA, FB				NAYLOR, CD; SIBBALD, WJ; SPRUNG, CL; PINFOLD, SP; CALVIN, JE; CERRA, FB			PULMONARY-ARTERY CATHETERIZATION - CAN THERE BE AN INTEGRATED STRATEGY FOR GUIDELINE DEVELOPMENT AND RESEARCH PROMOTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CRITICALLY ILL PATIENTS; SWAN-GANZ CATHETER; FLOW CATHETERS; CLINICAL-TRIAL; BYPASS-SURGERY; HEART; HEMODYNAMICS; MORATORIUM; PHYSICIANS	Objectives.-To review the evidence regarding indications for pulmonary artery catheterization (PAC) in critically ill patients, and to propose a guideline-generating process that would encourage randomized controlled trials of PAC. Data Sources.-Computerized and manual search for randomized trials involving PAC as an integral part of the protocol, published as of October 1992. Manual search for guidelines endorsed by specialty societies and/or proposed by expert panels following an explicit group process. Data Synthesis.-Four trials suggest benefit from PAC tor pre- or perioperative management of high-risk surgical patients. Two others indicate that PAC for low-risk aortic aneurysm surgery confers no advantages. Use of PAC to guide therapy aimed at improved mixed venous oxygen saturation was beneficial compared with usual care with PAC in two small trials among patients with septic shock and severe trauma. Other PAC indications are either untested or inadequately tested by small trials. Large trials are needed, but trials to date have been impeded by clinicians' uncertainty about PAC and unwillingness to randomize critically ill patients. No published guidelines for PAC have used a formal group process and/or a hierarchical review of evidence to demarcate proven from unproven indications. Conclusions.-We propose a research-promoting expert panel on indications for PAC. Aided by a critical literature review, experts would rate case scenarios on the need for routine PAC with or without a specified intervention strategy. Future trials should test indications where there is either consensus about the uncertainty of need for PAC, or interpanelist disagreement owing to inconclusive evidence, This process could facilitate practice guideline development, utilization management, and large trials of PAC and related interventions.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, CLIN EPIDEMIOL PROGRAM, TORONTO M5S 1A1, ONTARIO, CANADA; HADASSAH HEBREW UNIV, DEPT CRIT CARE MED & ANESTHESIOL, JERUSALEM, ISRAEL; VICTORIA HOSP, DIV CRIT CARE MED, LONDON N6A 4G5, ONTARIO, CANADA; RUSH MED COLL, DEPT MED, CHICAGO, IL 60612 USA; UNIV MINNESOTA, DEPT SURG, MINNEAPOLIS, MN 55455 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Victoria; Western University (University of Western Ontario); Rush University; University of Minnesota System; University of Minnesota Twin Cities	NAYLOR, CD (corresponding author), SUNNYBROOK HLTH SCI CTR, INST CLIN EVALUAT SCI, ROOM G258, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA.							BASHEIN G, 1985, ANESTHESIOLOGY, V63, P451, DOI 10.1097/00000542-198510000-00019; BAYLISS J, 1983, BRIT MED J, V287, P187, DOI 10.1136/bmj.287.6386.187; BECKER RC, 1987, CLEV CLIN J MED, V54, P384, DOI 10.3949/ccjm.54.5.384; BENNETT D, 1991, INTENS CARE MED, V17, pR1, DOI 10.1007/BF01704735; BERLAUK JF, 1991, ANN SURG, V214, P289, DOI 10.1097/00000658-199109000-00011; BISHOP M, 1992, CRIT CARE MED, V20, pS93; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; CELORIA G, 1990, ARCH SURG-CHICAGO, V125, P1036; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; Chatterjee K, 1991, J Intensive Care Med, V6, P101; CONNORS AF, 1990, CHEST, V98, P1200, DOI 10.1378/chest.98.5.1200; CONNORS AF, 1983, NEW ENGL J MED, V308, P263, DOI 10.1056/NEJM198302033080508; DALEN JE, 1990, CHEST, V98, P1313, DOI 10.1378/chest.98.6.1313; Dzelzkalns R, 1985, J Clin Monit, V1, P197, DOI 10.1007/BF02832261; EISENBERG PR, 1984, CRIT CARE MED, V12, P549, DOI 10.1097/00003246-198407000-00001; FEIN AM, 1984, AM REV RESPIR DIS, V129, P1006; FORRESTER JS, 1977, AM J CARDIOL, V39, P137, DOI 10.1016/S0002-9149(77)80182-3; FRIESINGER GC, 1990, J AM COLL CARDIOL, V15, P1460, DOI 10.1016/0735-1097(90)92810-O; FULLER H, 1992, CRIT CARE MED, V20, P928, DOI 10.1097/00003246-199207000-00006; GORE JM, 1987, CHEST, V92, P721, DOI 10.1378/chest.92.4.721; GORE JM, 1988, CHEST, V93, P1115, DOI 10.1378/chest.93.5.1115a; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; Guyatt G, 1991, J Intensive Care Med, V6, P91; IBERTI TJ, 1990, JAMA-J AM MED ASSOC, V264, P2928, DOI 10.1001/jama.264.22.2928; ISAACSON IJ, 1990, J VASC SURG, V12, P754, DOI 10.1067/mva.1990.24456; JOHNSTON WE, 1988, COMPLICATONS CRITICA, P45; Joyce W P, 1990, Eur J Vasc Surg, V4, P633, DOI 10.1016/S0950-821X(05)80820-5; LOMAS J, 1986, CAN MED ASSOC J, V134, P1348; LOWENSTEIN E, 1980, ANESTHESIOLOGY, V53, P361, DOI 10.1097/00000542-198011000-00001; MATTHAY MA, 1988, ANN INTERN MED, V109, P826, DOI 10.7326/0003-4819-109-10-826; MERRICK NJ, 1987, AM J PUBLIC HEALTH, V77, P187, DOI 10.2105/AJPH.77.2.187; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; Norfleet E A, 1985, J Clin Monit, V1, P245, DOI 10.1007/BF02832818; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; PEARSON KS, 1989, ANESTH ANALG, V69, P336; RAJPUT MA, 1989, ARCH INTERN MED, V149, P83, DOI 10.1001/archinte.149.1.83; ROBIN ED, 1988, CHEST, V93, P1059, DOI 10.1378/chest.93.5.1059-a; ROBIN ED, 1988, ANN INTERN MED, V108, P151, DOI 10.7326/0003-4819-108-1-151_1; ROBIN ED, 1985, ANN INTERN MED, V103, P445, DOI 10.7326/0003-4819-103-3-445; ROBIN ED, 1987, CHEST, V92, P727, DOI 10.1378/chest.92.4.727; ROBIN ED, 1987, IRISH MED J, V80, P330; SCHULTZ RJ, 1985, J TRAUMA, V25, P309, DOI 10.1097/00005373-198504000-00005; SHOEMAKER WC, 1990, CRIT CARE MED, V18, P1294; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1990, ARCH SURG-CHICAGO, V125, P1332; SIBBALD WJ, 1988, CHEST, V94, P899, DOI 10.1378/chest.94.5.899; SLADEN A, 1988, CURR PROB SURG, V25, P71; SPODICK DH, 1989, JAMA-J AM MED ASSOC, V261, P1946, DOI 10.1001/jama.261.13.1946; SPODICK DH, 1989, CHEST, V95, P489, DOI 10.1378/chest.95.3.489; SPRUNG CL, 1983, PULMONARY ARTERY CAT, P73; STEINGRUB JS, 1991, CHEST, V99, P1451, DOI 10.1378/chest.99.6.1451; STEVENSON LW, 1989, JAMA-J AM MED ASSOC, V261, P884, DOI 10.1001/jama.261.6.884; Streisand J B, 1985, J Clin Monit, V1, P193, DOI 10.1007/BF02832260; SWAN HJC, 1970, NEW ENGL J MED, V283, P447, DOI 10.1056/NEJM197008272830902; TUCHSCHMIDT J, 1987, CRIT CARE MED, V15, P840, DOI 10.1097/00003246-198709000-00008; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; TUMAN KJ, 1989, ANESTHESIOLOGY, V70, P199, DOI 10.1097/00000542-198902000-00004; VOYCE SJ, 1990, J INTENSIVE CARE MED, V5, P175	58	48	48	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2407	2411		10.1001/jama.269.18.2407	http://dx.doi.org/10.1001/jama.269.18.2407			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479068				2022-12-28	WOS:A1993LA67500036
J	WIENER, C				WIENER, C			VENTILATORY MANAGEMENT OF RESPIRATORY-FAILURE IN ASTHMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							END-EXPIRATORY PRESSURE; AIR-FLOW OBSTRUCTION; MECHANICAL VENTILATION; AUTO-PEEP; EXPERIENCE				WIENER, C (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV PULM & CRIT CARE MED,720 RUTLAND AVE,ROSS 858,BALTIMORE,MD 21205, USA.							BRAMAN SS, 1990, JAMA-J AM MED ASSOC, V264, P366, DOI 10.1001/jama.264.3.366; CASSIDY SS, 1989, HEART LUNG INTERACTI, P463; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; HALL JB, 1990, MED CLIN N AM, V74, P779, DOI 10.1016/S0025-7125(16)30552-1; MANSEL JK, 1990, AM J MED, V89, P42, DOI 10.1016/0002-9343(90)90096-V; MYERBURG RJ, 1988, HEART DISEASE TXB CA, P742; PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; ROGERS PL, 1991, CHEST, V99, P492, DOI 10.1378/chest.99.2.492; SCHARF SM, 1977, AM J PHYSIOL, V232, pH35, DOI 10.1152/ajpheart.1977.232.1.H35; SCOGGIN CH, 1977, JAMA-J AM MED ASSOC, V238, P1158, DOI 10.1001/jama.238.11.1158; TUXEN DV, 1989, AM REV RESPIR DIS, V140, P5, DOI 10.1164/ajrccm/140.1.5	11	13	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2128	2131		10.1001/jama.269.16.2128	http://dx.doi.org/10.1001/jama.269.16.2128			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468769				2022-12-28	WOS:A1993KY36600037
J	FERGUSONSMITH, AC; SASAKI, H; CATTANACH, BM; SURANI, MA				FERGUSONSMITH, AC; SASAKI, H; CATTANACH, BM; SURANI, MA			PARENTAL-ORIGIN-SPECIFIC EPIGENETIC MODIFICATION OF THE MOUSE H19 GENE	NATURE			English	Article							DNA METHYLATION; X-CHROMOSOME; TRANSCRIPTION; BINDING; EXPRESSION; ISLANDS; GENOMES; PROTEIN; MICE; CPGS	THE H19 gene produces an abundant developmentally regulated transcript of unknown function in normal embryos1. In the mouse it lies on chromosome 7 and is subject to transcriptional regulation by parental imprinting, which results in the maternally inherited gene being expressed and the paternally inherited gene being repressed2. Embryos carrying maternal duplication/paternal deficiency for distal chromosome 7 (MatDi7)3 therefore express a double dose of H19. Here we examine the parental-origin-specific epigenetic modifications that may be involved in this regulation by comparing CpG methylation and nuclease sensitivity of chromatin in MatDi7 embryos with normal littermates. We show that specific sites in the CpG island promoter and 5' portion of the gene are methylated only on the paternal allele. Furthermore, active maternal alleles in chromatin of MatDi7 embryos are more sensitive and accessible to nucleases. Therefore hypermethylation and chromatin compaction in the region of the H19 promoter is associated with repression of the paternally inherited copy of the gene. Most, but not all, of these sites are unmethylated in sperm, with methylation of the paternal promoter occurring after fertilization. These results contrast with our findings for the closely linked and reciprocally imprinted gene encoding insulin-like growth factor II (ref. 4).	UNIV CAMBRIDGE,PHYSIOL LAB,CAMBRIDGE,ENGLAND; MRC,RADIOBIOL UNIT,DIDCOT OX1 3RD,OXON,ENGLAND	University of Cambridge; MRC Harwell	FERGUSONSMITH, AC (corresponding author), WELLCOME CRC INST CANC & DEV BIOL,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Ferguson-Smith, Anne C/G-7534-2011	Ferguson-Smith, Anne/0000-0002-7608-5894; Surani, Azim/0000-0002-8640-4318	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HEANDLER B, 1990, EUR J BIOCHEM, V190, P477; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; LEVINE A, 1992, P NATL ACAD SCI USA, V89, P10119, DOI 10.1073/pnas.89.21.10119; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIN D, 1988, SOMAT CELL MOLEC GEN, V14, P261, DOI 10.1007/BF01534587; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MONK M, 1986, BIOESSAYS, V4, P204, DOI 10.1002/bies.950040505; MONK M, 1990, DEVELOPMENT, P55; POIRIER F, 1991, DEVELOPMENT, V113, P1105; POURCEL C, 1990, J VIROL, V64, P931, DOI 10.1128/JVI.64.2.931-935.1990; Sasaki H., 1993, DNA methylation: molecular biology and biological significance., P469; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SEARLE AG, 1990, GENET RES, V56, P237, DOI 10.1017/S0016672300035333; SURANI MA, 1990, DEVELOPMENT, P89; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	32	378	385	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 22	1993	362	6422					751	755		10.1038/362751a0	http://dx.doi.org/10.1038/362751a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8469285				2022-12-28	WOS:A1993KY45000057
J	LINDAHL, T				LINDAHL, T			INSTABILITY AND DECAY OF THE PRIMARY STRUCTURE OF DNA	NATURE			English	Review							NON-ENZYMATIC METHYLATION; APURINIC-APYRIMIDINIC SITES; ADENOSYL-L-METHIONINE; DEOXYRIBONUCLEIC-ACID; ESCHERICHIA-COLI; SPONTANEOUS MUTATION; CYTOSINE RESIDUES; OXIDATIVE DAMAGE; HYDROGEN-PEROXIDE; EXCISION-REPAIR	Although DNA is the carrier of genetic information, it has limited chemical stability. Hydrolysis, oxidation and nonenzymatic methylation of DNA occur at significant rates in vivo, and are counteracted by specific DNA repair processes. The spontaneous decay of DNA is likely to be a major factor in mutagenesis, carcinogenesis and ageing, and also sets limits for the recovery of DNA fragments from fossils.			LINDAHL, T (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND.							AHERN TJ, 1985, SCIENCE, V228, P1280, DOI 10.1126/science.4001942; ARUOMA OI, 1989, J BIOL CHEM, V264; BAROSS JA, 1983, NATURE, V303, P423, DOI 10.1038/303423a0; BARROWS LR, 1982, CARCINOGENESIS, V3, P349, DOI 10.1093/carcin/3.3.349; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; CARMICHAEL PL, 1992, CARCINOGENESIS, V13, P1127, DOI 10.1093/carcin/13.7.1127; CHEN JD, 1991, J BACTERIOL, V173, P283, DOI 10.1128/jb.173.1.283-290.1991; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DESALLE R, 1992, SCIENCE, V257, P1933, DOI 10.1126/science.1411508; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1991, NUCLEIC ACIDS RES, V19, P3829, DOI 10.1093/nar/19.14.3829; DIRKSEN ML, 1988, INT J RADIAT BIOL, V54, P195, DOI 10.1080/09553008814551631; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; EHRLICH M, 1990, MUTAT RES, V238, P277, DOI 10.1016/0165-1110(90)90019-8; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GOLENBERG EM, 1990, NATURE, V344, P656, DOI 10.1038/344656a0; HAGELBERG E, 1991, P ROY SOC B-BIOL SCI, V244, P45, DOI 10.1098/rspb.1991.0049; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; HILLPERKINS M, 1986, MUTAT RES, V162, P153, DOI 10.1016/0027-5107(86)90081-3; IMPELLIZZERI KJ, 1991, J BACTERIOL, V173, P6807, DOI 10.1128/jb.173.21.6807-6810.1991; JOENJE H, 1989, MUTAT RES, V219, P193, DOI 10.1016/0921-8734(89)90001-5; KARRAN P, 1980, BIOCHEMISTRY-US, V19, P6005, DOI 10.1021/bi00567a010; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KLUNGLAND A, 1992, EMBO J, V11, P4439, DOI 10.1002/j.1460-2075.1992.tb05544.x; KODAMA M, 1980, CANCER LETT, V10, P319, DOI 10.1016/0304-3835(80)90048-8; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; KRICKER MC, 1990, J BACTERIOL, V172, P3037, DOI 10.1128/jb.172.6.3037-3039.1990; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LEE AT, 1987, P NATL ACAD SCI USA, V84, P8311, DOI 10.1073/pnas.84.23.8311; LINDAHL T, 1967, J BIOL CHEM, V242, P1970; LINDAHL T, 1976, NATURE, V259, P64, DOI 10.1038/259064a0; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1973, BIOCHEMISTRY-US, V12, P5151, DOI 10.1021/bi00749a020; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; LJUNGMAN M, 1992, MOL CARCINOGEN, V5, P264, DOI 10.1002/mc.2940050406; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LOEB LA, 1989, CANCER RES, V49, P5489; LUTZ WK, 1990, MUTAT RES, V238, P287, DOI 10.1016/0165-1110(90)90020-C; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MOURET JF, 1990, CHEM RES TOXICOL, V3, P102, DOI 10.1021/tx00014a004; OLLER AR, 1992, J MOL BIOL, V228, P813, DOI 10.1016/0022-2836(92)90866-I; PAABO S, 1985, NATURE, V314, P644, DOI 10.1038/314644a0; PAABO S, 1989, J BIOL CHEM, V264, P9709; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; PAIK WK, 1975, FEBS LETT, V58, P39, DOI 10.1016/0014-5793(75)80220-1; PARK JW, 1988, P NATL ACAD SCI USA, V85, P7467, DOI 10.1073/pnas.85.20.7467; PARK JW, 1988, P NATL ACAD SCI USA, V85, P9508; PERUTZ MF, 1990, J MOL BIOL, V213, P203, DOI 10.1016/S0022-2836(05)80178-0; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; RANDERATH K, 1989, MUTAT RES, V219, P121, DOI 10.1016/0921-8734(89)90023-4; REBECK GW, 1991, J BACTERIOL, V173, P2068, DOI 10.1128/jb.173.6.2068-2076.1991; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; SAPORITO SM, 1989, J BACTERIOL, V171, P2542, DOI 10.1128/jb.171.5.2542-2546.1989; SATOH MS, IN PRESS P NATN ACAD; SCHAAPER RM, 1991, GENETICS, V129, P317; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SETLOW P, 1992, J BACTERIOL, V174, P2737, DOI 10.1128/JB.174.9.2737-2741.1992; Shapiro R, 1981, CHROMOSOME DAMAGE RE, P3; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SIDOW A, 1991, PHILOS T ROY SOC B, V333, P429, DOI 10.1098/rstb.1991.0093; SMITH KC, 1992, MUTAT RES, V277, P139, DOI 10.1016/0165-1110(92)90002-Q; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TRENT JD, 1984, NATURE, V307, P737, DOI 10.1038/307737a0; VAUGHAN P, 1991, CARCINOGENESIS, V12, P263, DOI 10.1093/carcin/12.2.263; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068	85	4195	4339	15	841	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 22	1993	362	6422					709	715		10.1038/362709a0	http://dx.doi.org/10.1038/362709a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8469282				2022-12-28	WOS:A1993KY45000044
J	MOSKOPHIDIS, D; LECHNER, F; PIRCHER, H; ZINKERNAGEL, RM				MOSKOPHIDIS, D; LECHNER, F; PIRCHER, H; ZINKERNAGEL, RM			VIRUS PERSISTENCE IN ACUTELY INFECTED IMMUNOCOMPETENT MICE BY EXHAUSTION OF ANTIVIRAL CYTOTOXIC EFFECTOR T-CELLS	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NERVOUS-SYSTEM DISEASE; EXTRATHYMIC TOLERANCE; VIRAL PERSISTENCE; CLONAL ANERGY; SELECTION; INDUCTION; MECHANISM; VARIANTS; SUPPRESSION	VIRUSES that are non- or poorly cytopathic have developed various strategies to avoid elimination by the immune system and to persist in the host1-3. Acute infection of adult mice with the noncytopathic lymphocytic choriomeningitis virus (LCMV) normally induces a protective cytotoxic T-cell response that also causes immunopathology4-7. But some LCMV strains (such as DOCILE8 (LCMV-D) or Cl-13 Armstrong (Cl-13)) derived from virus carrier mice tend to persist after acute infection of adult mice without causing lethal immunopathological disease4,5. Tendency to persist correlates with tropism8,10, rapidity of virus spread8 and virus mutations11,12. We report here that these LCMV isolates may persist because they induce most of the specific antiviral CD8+ cytotoxic T cells so completely that they all disappear within a few days and therefore neither eliminate the virus nor cause lethal immunopathology. The results illustrate that partially and sequentially induced (protective) immunity or complete exhaustion of T-cell immunity (high zone tolerance) are quantitatively different points on the scale of immunity; some viruses exploit the latter possibility to persist in an immunocompetent host.			MOSKOPHIDIS, D (corresponding author), UNIV ZURICH,DEPT PATHOL,INST EXPTL IMMUNOL,STERNWARTSTR 2,CH-8091 ZURICH,SWITZERLAND.							AHMED R, 1988, J EXP MED, V167, P1719, DOI 10.1084/jem.167.5.1719; AHMED R, 1988, J VIROL, V62, P3301, DOI 10.1128/JVI.62.9.3301-3308.1988; Ahmed R., 1990, VIROLOGY, P241; AHMED R, 1984, J EXP MED, V60, P521; BORROW P, 1991, J EXP MED, V174, P203, DOI 10.1084/jem.174.1.203; CAMPBELL IL, 1992, J CELL BIOCHEM, V16, P141; CIHAK J, 1978, IMMUNOLOGY, V34, P265; CLERICI M, 1991, J IMMUNOL, V146, P2214; COLE GA, 1972, NATURE, V238, P335, DOI 10.1038/238335a0; DOHERTY PC, 1974, J IMMUNOL, V112, P1548; DUNLOP MBC, 1977, J EXP MED, V145, P1131, DOI 10.1084/jem.145.5.1131; GILDEN DH, 1972, J EXP MED, V135, P860, DOI 10.1084/jem.135.4.860; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HOTCHIN J, 1971, MONOGR VIROL, V3, P1; IGNATOWICZ L, 1992, J EXP MED, V175, P917, DOI 10.1084/jem.175.4.917; JACOBS RP, 1976, J IMMUNOL, V117, P1004; JAMIESON BD, 1991, J IMMUNOL, V147, P3521; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; MARKER O, 1973, J EXP MED, V137, P1511, DOI 10.1084/jem.137.6.1511; MILLER RG, 1980, NATURE, V287, P544, DOI 10.1038/287544a0; MIMS CA, 1987, PATHOGENESIS INFECTI; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MOSKOPHIDIS D, 1987, EUR J IMMUNOL, V17, P937, DOI 10.1002/eji.1830170707; ODERMATT B, 1991, P NATL ACAD SCI USA, V88, P8252, DOI 10.1073/pnas.88.18.8252; OLDSTONE MBA, 1989, CELL, V56, P517, DOI 10.1016/0092-8674(89)90573-4; PETERS M, 1991, HEPATOLOGY, V13, P977, DOI 10.1016/0270-9139(91)90273-X; PFAU CJ, 1982, J EXP MED, V156, P79, DOI 10.1084/jem.156.1.79; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SALVATO M, 1991, J VIROL, V65, P1863, DOI 10.1128/JVI.65.4.1863-1869.1991; SARON MF, 1990, J VIROL, V64, P4076, DOI 10.1128/JVI.64.9.4076-4083.1990; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; STITZ L, 1992, EUR J IMMUNOL, V22, P1995, DOI 10.1002/eji.1830220807; TISHON A, 1988, J IMMUNOL, V140, P1280; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; Zinkernagel R.M., 1979, ADV IMMUNOL, V27, P52; ZINKERNAGEL RM, 1985, J EXP MED, V162, P2125, DOI 10.1084/jem.162.6.2125	43	1020	1037	2	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 22	1993	362	6422					758	761		10.1038/362758a0	http://dx.doi.org/10.1038/362758a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8469287	Bronze			2022-12-28	WOS:A1993KY45000059
J	WATSON, JD; CRICK, FHC				WATSON, JD; CRICK, FHC			GENETIC-IMPLICATIONS OF THE STRUCTURE OF DEOXYRIBONUCLEIC-ACID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											WATSON, JD (corresponding author), UNIV CAMBRIDGE, CAVENDISH LAB, MED RES COUNCIL, STUDY MOLEC STRUCT BIOL SYST UNIT, CAMBRIDGE CB3 0HE, ENGLAND.		crick, francis/B-7093-2009					ASTBURY WT, 1947, SYM SOC EXP BIOL, V1, P66; FRANKLIN RE, 1953, NATURE, V171, P740, DOI 10.1038/171740a0; FRASER RSS, UNPUB; FURBERG S, 1952, ACTA CHEM SCAND, V6, P634, DOI 10.3891/acta.chem.scand.06-0634; PAULING L, 1953, P NATL ACAD SCI USA, V39, P84, DOI 10.1073/pnas.39.2.84; PAULING L, 1953, NATURE, V171, P346, DOI 10.1038/171346a0; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WILKINS MHF, 1953, NATURE, V171, P738, DOI 10.1038/171738a0; WILKINS MHF, 1953, BIOCHIM BIOPHYS ACTA, V10, P192, DOI 10.1016/0006-3002(53)90232-7; WYATT GR, 1952, J GEN PHYSIOL, V36, P201, DOI 10.1085/jgp.36.2.201; ZAMENHOF S, 1952, BIOCHIM BIOPHYS ACTA, V9, P402, DOI 10.1016/0006-3002(52)90184-4	11	14	14	2	70	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1967	1969		10.1001/jama.269.15.1967	http://dx.doi.org/10.1001/jama.269.15.1967			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464129				2022-12-28	WOS:A1993KX21500027
J	FISHELL, G; MASON, CA; HATTEN, ME				FISHELL, G; MASON, CA; HATTEN, ME			DISPERSION OF NEURAL PROGENITORS WITHIN THE GERMINAL ZONES OF THE FOREBRAIN	NATURE			English	Article							CEREBRAL-CORTEX; CELL LINEAGE; MIGRATION; INVITRO	ONE of the early events in the establishment of regional diversity in brain is the subdivision of the forebrain into the cerebral cortex1-7 and underlying basal ganglia8. This subdivision is of special interest, owing to the striking difference in cellular patterning in these two regions. Whereas the dorsal aspect of the telencephalon gives rise to the laminar, cortical regions of brain, the basal aspect gives rise to nuclear, subcortical regions. To examine early events in the regionalization of the forebrain, we visualized cell movement within the ventricular zones of the dorsal and basal regions of the E15 murine telencephalon. Over an 8-24-hour observation period, labelled cells moved extensively in the plane of the cortical ventricular zone. Cell dispersion was restricted, however, at the border between the cortical ventricular zone and the lateral ganglionic eminence, the basal telencephalic ventricular zone. We suggest that this restriction of cell movements establishes a regional pattern of neurogenesis in the developing brain.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT PATHOL,NEW YORK,NY 10032	Columbia University				Fishell, Gordon/0000-0002-9640-9278				BERRY M, 1965, J ANAT, V99, P691; Cajal S. R., 1911, HISTOLOGIE SYSTEME N, V2; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FRIEDERIKSON K, 1988, J NEUROSCI, V58, P815; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GRAY GE, 1991, NEURON, V6, P211, DOI 10.1016/0896-6273(91)90357-6; GRULER H, 1984, BLOOD CELLS, V10, P61; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Misson JP, 1991, CEREB CORTEX, V1, P221, DOI 10.1093/cercor/1.3.221; MISSON JP, 1991, GLIA, V4, P138, DOI 10.1002/glia.440040205; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; Sauer FC, 1935, J COMP NEUROL, V63, P13, DOI 10.1002/cne.900630103; SAUER ME, 1959, P SOC EXP BIOL MED, V101, P557; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SMART IHM, 1979, ONTOGENY NEOSTRIATUM, V23, P127; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Walsh C., 1992, Society for Neuroscience Abstracts, V18, P925; 1970, ANAT REC, V166, P257	29	245	249	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					636	638		10.1038/362636a0	http://dx.doi.org/10.1038/362636a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8464514				2022-12-28	WOS:A1993KX43800049
J	JIMENEZGARCIA, LF; SPECTOR, DL				JIMENEZGARCIA, LF; SPECTOR, DL			INVIVO EVIDENCE THAT TRANSCRIPTION AND SPLICING ARE COORDINATED BY A RECRUITING MECHANISM	CELL			English	Article							DNA-BINDING-PROTEIN; INFECTED HELA-CELLS; PRE-MESSENGER-RNA; NUCLEAR RIBONUCLEOPROTEIN ANTIGENS; ADENOVIRUS TYPE-5 DNA; MONOCLONAL-ANTIBODIES; INSITU HYBRIDIZATION; LOCALIZATION; MATRIX; SITES	We describe the nuclear organization of pre-mRNA processing components in HeLa cells upon adenovirus 2 infection and their relationship to the localization of viral RNA sequences. We observe a redistribution of cellular splicing factors as well as RNA polymerase II and heterogeneous nuclear ribonucleoprotein particle proteins to sites of viral RNA transcription. Similar results were obtained in cells transiently transfected with a plasmid containing a portion of the beta-tropomyosin gene. Our findings demonstrate a very close association between RNA transcripts and transcription and pre-mRNA splicing factors, suggesting that these processes are both temporally and spatially linked in the cell nucleus. Furthermore, these data suggest a recruiting mechanism that regulates the localization of transcription and splicing factors in response to the initiation of active transcription.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory					NCI NIH HHS [5P30 CA45508-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM042694, GM42694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akusjarvi G, 1986, ADENOVIRUS DNA VIRAL, P53; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P119; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BOSHER J, 1992, J VIROL, V66, P3140, DOI 10.1128/JVI.66.5.3140-3150.1992; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CIEJEK EM, 1982, BIOCHEMISTRY-US, V21, P4945, DOI 10.1021/bi00263a018; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; FAKAN S, 1976, EXP CELL RES, V99, P155, DOI 10.1016/0014-4827(76)90690-X; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; FAKAN S, 1978, EXP CELL RES, V113, P327, DOI 10.1016/0014-4827(78)90373-7; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FLINT SJ, 1986, ADV VIRUS RES, V31, P169, DOI 10.1016/S0065-3527(08)60264-X; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HABETS WJ, 1989, J IMMUNOL, V143, P2560; HUANG S, 1992, P NATL ACAD SCI USA, V89, P305, DOI 10.1073/pnas.89.1.305; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHNER RL, 1977, CELL, V12, P1007, DOI 10.1016/0092-8674(77)90165-9; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; MARIMAN ECM, 1982, J MOL BIOL, V154, P103, DOI 10.1016/0022-2836(82)90420-X; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; MARTINEZ-PALOMO A., 1967, J VIROL, V1, P817; MCGROGAN M, 1977, J VIROL, V23, P240, DOI 10.1128/JVI.23.2.240-249.1977; MCGROGAN M, 1978, P NATL ACAD SCI USA, V75, P625, DOI 10.1073/pnas.75.2.625; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Philipson L, 1979, Adv Virus Res, V25, P357, DOI 10.1016/S0065-3527(08)60573-4; PUVIONDUTILLEUL F, 1990, EUR J CELL BIOL, V52, P379; PUVIONDUTILLEUL F, 1992, J STRUCT BIOL, V108, P209, DOI 10.1016/1047-8477(92)90021-2; PUVIONDUTILLEUL F, 1990, J STRUCT BIOL, V103, P280, DOI 10.1016/1047-8477(90)90046-F; PUVIONDUTILLEUL F, 1991, BIOL CELL, V71, P135, DOI 10.1016/0248-4900(91)90060-Z; QUINLAN MP, 1984, CELL, V36, P857, DOI 10.1016/0092-8674(84)90035-7; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; REUTER R, 1984, EXP CELL RES, V154, P548, DOI 10.1016/0014-4827(84)90179-4; SASS H, 1984, J MOL BIOL, V180, P911, DOI 10.1016/0022-2836(84)90263-8; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; SMITH HC, 1986, MOL CELL BIOCHEM, V70, P151; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1984, BIOL CELL, V51, P109, DOI 10.1111/j.1768-322X.1984.tb00289.x; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; SUGAWARA K, 1977, J VIROL, V22, P527, DOI 10.1128/JVI.22.2.527-539.1977; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TOOZE J, 1982, MOL BIOL TUMOR VIRUS, V2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERHEIJEN R, 1986, J CELL SCI, V86, P173; VOELKERDING K, 1986, J VIROL, V60, P353, DOI 10.1128/JVI.60.2.353-362.1986; VOGELSTEIN B, 1982, BIOCHEM BIOPH RES CO, V105, P1224, DOI 10.1016/0006-291X(82)91099-3; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055; ZEITLIN S, 1980, NATURE, V287, P491; [No title captured]	64	240	242	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	1993	73	1					47	59		10.1016/0092-8674(93)90159-N	http://dx.doi.org/10.1016/0092-8674(93)90159-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462102				2022-12-28	WOS:A1993KW75300007
J	DVORAK, AM				DVORAK, AM			GIARDIA-LAMBLIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DVORAK, AM (corresponding author), BETH ISRAEL HOSP,BOSTON,MA 02215, USA.								0	0	0	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1010	1010						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	8450853				2022-12-28	WOS:A1993KW28200006
J	WEINZIERL, ROJ; DYNLACHT, BD; TJIAN, R				WEINZIERL, ROJ; DYNLACHT, BD; TJIAN, R			LARGEST SUBUNIT OF DROSOPHILA TRANSCRIPTION FACTOR-IID DIRECTS ASSEMBLY OF A COMPLEX CONTAINING TBP AND A COACTIVATOR	NATURE			English	Article							BINDING-PROTEIN; TFIID COMPLEX; ACTIVATION; GENE; MECHANISM; UPSTREAM	The TFIID complex consists of the TATA-binding protein (TBP) and associated factors (TAFs) serving to mediate transcriptional activation by promoter-specific regulators. Here we report the cloning of Drosophila TAF(II)250 and the assembly of a partial complex containing recombinant TBP, TAF(II)110 and the C-terminal domain of TAF(II)250. This triple complex supports Sp1 activation and reveals specific interactions between TAF(II)250, TBP and TAF(II)110.			WEINZIERL, ROJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,401 BARKER HALL,BERKELEY,CA 94720, USA.			Weinzierl, Robert/0000-0003-4095-9921				COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; Gill Grace, 1992, Current Biology, V2, P565, DOI 10.1016/0960-9822(92)90046-D; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAELIN WG, 1992, CELL, V70, P351; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	31	163	170	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					511	517		10.1038/362511a0	http://dx.doi.org/10.1038/362511a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464492				2022-12-28	WOS:A1993KW45300044
J	FAUST, BC; ANASTASIO, C; ALLEN, JM; ARAKAKI, T				FAUST, BC; ANASTASIO, C; ALLEN, JM; ARAKAKI, T			AQUEOUS-PHASE PHOTOCHEMICAL FORMATION OF PEROXIDES IN AUTHENTIC CLOUD AND FOG WATERS	SCIENCE			English	Article							STRATUS CLOUD; CHEMISTRY; MODEL	Gas-to-drop partitioning of hydrogen peroxide and its precursor, the hydroperoxyl radical (HO2.), has been considered the predominant or sole source of hydrogen peroxide in atmospheric water drops. However, atmospheric water can absorb solar ultraviolet radiation, which initiates the photoformation of peroxides (primarily hydrogen peroxide). Measurements of peroxide photoformation rates in authentic atmospheric water samples demonstrate that aqueous-phase photochemical reactions are a significant, and in some cases dominant, source of hydrogen peroxide to cloud and fog drops. This additional source could significantly change the current understanding, and hence, the models, of sulfuric acid deposition because hydrogen peroxide is the limiting reagent in the dominant pathway for the oxidation of sulfur dioxide to sulfuric acid in the troposphere over eastern North America.	DUKE UNIV,DEPT CIVIL & ENVIRONM ENGN,DURHAM,NC 27708	Duke University	FAUST, BC (corresponding author), DUKE UNIV,SCH ENVIRONM,DURHAM,NC 27708, USA.							ALLEN JM, 1992, THESIS DUKE U; AYERS GP, 1990, J ATMOS CHEM, V11, P143, DOI 10.1007/BF00053672; CHAMEIDES WL, 1984, J GEOPHYS RES-ATMOS, V89, P4739, DOI 10.1029/JD089iD03p04739; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; DAUM PH, 1987, J GEOPHYS RES-ATMOS, V92, P8426, DOI 10.1029/JD092iD07p08426; FAUST BC, 1992, J GEOPHYS RES-ATMOS, V97, P12913, DOI 10.1029/92JD00843; FAUST BC, 1990, EFFECTS SOLAR ULTRAV, P48; GRAEDEL TE, 1986, J GEOPHYS RES-ATMOS, V91, P5205, DOI 10.1029/JD091iD04p05205; GUNZ DW, 1990, ATMOS ENVIRON A-GEN, V24, P1601, DOI 10.1016/0960-1686(90)90496-A; HEWITT CN, 1991, J ATMOS CHEM, V12, P181, DOI 10.1007/BF00115779; KADLECEK J, 1985, ASRC SUNY PUBLICATIO, V1008; KOK GL, 1986, ANAL CHEM, V58, P1192, DOI 10.1021/ac00297a047; LANGNER J, 1992, NATURE, V359, P712, DOI 10.1038/359712a0; LANGNER J, 1991, J ATMOS CHEM, V13, P225, DOI 10.1007/BF00058134; LELIEVELD J, 1992, SCIENCE, V258, P117, DOI 10.1126/science.258.5079.117; LELIEVELD J, 1990, NATURE, V343, P227, DOI 10.1038/343227a0; LIN X, 1991, J ATMOS CHEM, V13, P109; MACDONALD AM, 1991, 7TH JOINT C APPL AIR; OLSZYNA KJ, 1988, ATMOS ENVIRON, V22, P1699, DOI 10.1016/0004-6981(88)90398-8	19	79	81	2	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					73	75		10.1126/science.8465202	http://dx.doi.org/10.1126/science.8465202			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8465202				2022-12-28	WOS:A1993KV42300029
J	HOLLIS, JF; LICHTENSTEIN, E; VOGT, TM; STEVENS, VJ; BIGLAN, A				HOLLIS, JF; LICHTENSTEIN, E; VOGT, TM; STEVENS, VJ; BIGLAN, A			NURSE-ASSISTED COUNSELING FOR SMOKERS IN PRIMARY CARE	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING CESSATION; NURSES; PHYSICIANS; COUNSELING	SMOKING CESSATION INTERVENTION; NICOTINE CHEWING-GUM; CONTROLLED TRIAL; GENERAL-PRACTICE; TRAINING PHYSICIANS; HEALTH PROMOTION; QUIT; PRACTITIONERS; SETTINGS; PROGRAM	Objective: Physician-delivered advice to stop smoking is effective, but time demands often reduce the number of smokers who receive assistance. We evaluated three nurse-assisted interventions designed to minimize physician burden and increase counseling in primary care settings. Design: Randomized controlled trial with a 12-month follow-up. Setting: Internal medicine and family practice offices in a health maintenance organization. Participants: Smokers (n = 3161) who were patients of participating physicians or other medical care providers (n = 60). Intervention: Medical care providers delivered a 30-second stop-smoking prompt to 2707 smokers and referred them to an on-site nurse smoking counselor. The nurse randomly provided a two-page pamphlet (advice control) or one of three nurse-assisted interventions: 1) self-quit training; 2) referral to a group cessation program; or 3) a combination of self-quit training and referral. Each nurse-delivered intervention included a 10-minute video, written materials, and a follow-up phone call. Results: Physicians delivered brief advice to 86% of identified smokers during the 1-year program. The proportion of participants reporting abstinence after both 3 and 12 months of follow-up nearly doubled (P = 0.01) for the nurse-assisted self-quit (7.1%), group-referral 7.6%), and combination (6.9%) interventions, compared to brief physician advice alone (3.9%) (P < 0.05). Saliva cotinine tests confirmed these effects (P < 0.004), although quit rates were lower (3.4%, 4.7%, 4.3%, and 2.3%, respectively) because roughly one half of quitters chose not to provide a saliva sample and were counted as smokers. Conclusion: Involving nurses in counseling smokers reduces physician burden, makes counseling more likely, and significantly increases cessation rates compared with brief physician advice alone.	KAISER PERMAMENTE CTR HLTH RES, PORTLAND, OR USA; OREGON RES INST, EUGENE, OR 97403 USA	Kaiser Permanente; Oregon Research Institute					NCI NIH HHS [1PO1-CA44648] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDA RF, 1987, JAMA-J AM MED ASSOC, V257, P1916; [Anonymous], 1990, HLTH BENEFITS SMOKIN; COHEN SJ, 1987, AM J PUBLIC HEALTH, V77, P313, DOI 10.2105/AJPH.77.3.313; CUMMINGS SR, 1989, ANN INTERN MED, V110, P640, DOI 10.7326/0003-4819-110-8-640; CUMMINGS SR, 1989, J GEN INTERN MED, V4, P482, DOI 10.1007/BF02599545; DAVIS RM, 1988, JAMA-J AM MED ASSOC, V259, P2900, DOI 10.1001/jama.259.19.2900; DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P295, DOI 10.1037/0022-006X.59.2.295; DUNCAN C, 1991, AM J PUBLIC HEALTH, V81, P899, DOI 10.2105/AJPH.81.7.899; FAGERSTROM KO, 1984, PREV MED, V13, P517, DOI 10.1016/0091-7435(84)90020-3; FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; HOLLIS JF, 1991, PREV MED, V20, P497, DOI 10.1016/0091-7435(91)90047-8; HUGHES JR, 1989, JAMA-J AM MED ASSOC, V261, P1300, DOI 10.1001/jama.261.9.1300; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; JANZ NK, 1987, AM J PUBLIC HEALTH, V77, P805, DOI 10.2105/AJPH.77.7.805; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; LAM W, 1987, LANCET, V2, P27; LEWIS CE, 1986, J GEN INTERN MED, V1, P14, DOI 10.1007/BF02596319; LICHTENSTEIN E, 1992, J FAM PRACTICE, V34, P739; OCKENE JK, 1987, PREV MED, V16, P723, DOI 10.1016/0091-7435(87)90054-5; OCKENE JK, 1988, AM J PREV MED, V4, P14, DOI 10.1016/S0749-3797(18)31214-5; OCKENE JK, 1987, AM J PUBLIC HEALTH, V77, P782, DOI 10.2105/AJPH.77.7.782; ORLANDI MA, 1987, PREV MED, V16, P119, DOI 10.1016/0091-7435(87)90011-9; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; PEDERSON LL, 1982, PREV MED, V11, P71, DOI 10.1016/0091-7435(82)90006-8; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; RIMER BK, 1986, PREV MED, V15, P92, DOI 10.1016/0091-7435(86)90039-3; SANDERS D, 1989, J ROY COLL GEN PRACT, V39, P273; SLAMA K, 1990, BRIT MED J, V300, P1707, DOI 10.1136/bmj.300.6741.1707; STEVENS VJ, 1989, J CONSULT CLIN PSYCH, V57, P420, DOI 10.1037/0022-006X.57.3.420; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; THOMPSON RS, 1988, MED CARE, V26, P62, DOI 10.1097/00005650-198801000-00007; VELICER WF, 1992, PSYCHOL BULL, V111, P23, DOI 10.1037/0033-2909.111.1.23; VOGT T M, 1989, Health Education Research, V4, P125, DOI 10.1093/her/4.1.125; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211; WELLS KB, 1986, AM J PUBLIC HEALTH, V76, P1009, DOI 10.2105/AJPH.76.8.1009; WILSON DMC, 1987, CAN MED ASSOC J, V137, P613	36	180	180	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					521	525		10.7326/0003-4819-118-7-199304010-00006	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442622				2022-12-28	WOS:A1993KU07900006
J	OGAWA, T; YU, X; SHINOHARA, A; EGELMAN, EH				OGAWA, T; YU, X; SHINOHARA, A; EGELMAN, EH			SIMILARITY OF THE YEAST RAD51 FILAMENT TO THE BACTERIAL RECA FILAMENT	SCIENCE			English	Article							CRYO-ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; STRAND EXCHANGE; DNA COMPLEXES; DUPLEX DNA; C-TERMINUS; PROTEIN; RECOMBINATION; REMOVAL; IMAGES	The RAD51 protein functions in the processes of DNA repair and in mitotic and meiotic genetic recombination in the yeast Saccharomyces cerevisiae. The protein has adenosine triphosphate-dependent DNA binding activities similar to those of the Escherichia coli RecA protein, and the two proteins have 30 percent sequence homology. RAD51 polymerized on double-stranded DNA to form a helical filament nearly identical in low-resolution, three-dimensional structure to that formed by RecA. Like RecA, RAD51 also appears to force DNA into a conformation of approximately a 5.1-angstrom rise per base pair and 18.6 base pairs per turn. As in other protein families, its structural conservation appears to be stronger than its sequence conservation. Both the structure of the protein polymer formed by RecA and the DNA conformation induced by RecA appear to be general properties of a class of recombination proteins found in prokaryotes as well as eukaryotes.	UNIV MINNESOTA, SCH MED, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA; OSAKA UNIV, DEPT BIOL, TOYONAKA, OSAKA 560, JAPAN	University of Minnesota System; University of Minnesota Twin Cities; Osaka University			Egelman, Edward H/A-2488-2009	Egelman, Edward/0000-0003-4844-5212	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035269] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35269] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; BEZZUBOVA O, IN PRESS NUCLEIC ACI; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CHANG CF, 1988, J ULTRA MOL STRUCT R, V100, P166, DOI 10.1016/0889-1605(88)90023-7; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DICAPUA E, 1990, J MOL BIOL, V214, P557, DOI 10.1016/0022-2836(90)90198-U; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; EGELMAN EH, IN PRESS MICRON; FUJISAWA H, 1985, NUCLEIC ACIDS RES, V13, P7473, DOI 10.1093/nar/13.20.7473; HORII T, 1992, J MOL BIOL, V223, P105, DOI 10.1016/0022-2836(92)90719-Z; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LARMINAT F, 1989, MOL GEN GENET, V216, P106, DOI 10.1007/BF00332237; MOREAU PL, 1989, J BIOL CHEM, V264, P2302; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; RUSCHE JR, 1985, J BIOL CHEM, V260, P949; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SHINOHARA A, UNPUB; STASIAK A, 1988, J MOL BIOL, V202, P659, DOI 10.1016/0022-2836(88)90293-8; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; STASIAK A, 1981, J MOL BIOL, V151, P557, DOI 10.1016/0022-2836(81)90010-3; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; YARRANTON GT, 1982, MOL GEN GENET, V185, P99, DOI 10.1007/BF00333797; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; YU X, 1990, BIOPHYS J, V57, P555, DOI 10.1016/S0006-3495(90)82571-6; YU X, 1991, J STRUCT BIOL, V106, P243, DOI 10.1016/1047-8477(91)90074-7; YU X, IN PRESS J MOL BIOL	34	562	574	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	1993	259	5103					1896	1899		10.1126/science.8456314	http://dx.doi.org/10.1126/science.8456314			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456314				2022-12-28	WOS:A1993KU17200031
J	PANTALEO, G; GRAZIOSI, C; DEMAREST, JF; BUTINI, L; MONTRONI, M; FOX, CH; ORENSTEIN, JM; KOTLER, DP; FAUCI, AS				PANTALEO, G; GRAZIOSI, C; DEMAREST, JF; BUTINI, L; MONTRONI, M; FOX, CH; ORENSTEIN, JM; KOTLER, DP; FAUCI, AS			HIV-INFECTION IS ACTIVE AND PROGRESSIVE IN LYMPHOID-TISSUE DURING THE CLINICALLY LATENT STAGE OF DISEASE	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELLS; AIDS; LYMPHADENOPATHY; AMPLIFICATION; RESERVOIRS; EXPRESSION; NODES; RNA	PRIMARY infection with the human immunodeficiency virus (HIV) is generally followed by a burst of viraemia with or without clinical symptoms1-3. This in turn is followed by a prolonged period of clinical latency. During this period there is little, if any, detectable viraemia, the numbers of infected cells in the blood are very low, and it is extremely difficult to demonstrate virus expression in these cells4. We have analysed viral burden and levels of virus replication simultaneously in the blood and lymphoid organs of the same individuals at various stages of HIV disease. Here we report that in early-stage disease there is a dichotomy between the levels of viral burden and virus replication in peripheral blood versus lymphoid organs. HIV disease is active in the lymphoid tissue throughout the period of clinical latency, even at times when minimal viral activity is demonstrated in blood.	UNIV ANCONA,DEPT INTERNAL MED,I-60020 ANCONA,ITALY; YALE UNIV,SCH MED,DEPT NEUROPATHOL,NEW HAVEN,CT 06510; GEORGE WASHINGTON UNIV,DEPT PATHOL,WASHINGTON,DC 20037; ST LUKES ROOSEVELT HOSP,NEW YORK,NY 10025	Marche Polytechnic University; Yale University; George Washington University; Mount Sinai St. Luke's; Mount Sinai West	PANTALEO, G (corresponding author), NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892, USA.		Pantaleo, Giuseppe/K-6163-2016; graziosi, cecilia/M-1882-2019					ARMSTRONG JA, 1985, IMMUNOL TODAY, V6, P121, DOI 10.1016/0167-5699(85)90076-3; ARMSTRONG JA, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P69; BIBERFELD P, 1987, ACTA PATH MICRO IM A, V95, P47; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLOUSE KA, 1989, J IMMUNOL, V142, P431; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMILIE D, 1990, J CLIN INVEST, V86, P148, DOI 10.1172/JCI114678; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GRAZIOSI C, IN PRESS CURR PROTOC; HAYNES BF, 1992, AIDS ETIOLOGY DIAGNO, P77; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; RACZ P, 1986, PROG ALLERGY, V37, P81; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SPIEGEL H, 1992, AM J PATHOL, V140, P15; TENNERRACZ K, 1985, LANCET, V1, P105; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401	23	1674	1705	0	70	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					355	358		10.1038/362355a0	http://dx.doi.org/10.1038/362355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455722				2022-12-28	WOS:A1993KU17600065
J	MILLER, R; DETITTA, GT; JONES, R; LANGS, DA; WEEKS, CM; HAUPTMAN, HA				MILLER, R; DETITTA, GT; JONES, R; LANGS, DA; WEEKS, CM; HAUPTMAN, HA			ON THE APPLICATION OF THE MINIMAL PRINCIPLE TO SOLVE UNKNOWN STRUCTURES	SCIENCE			English	Article							PHASE-RELATIONSHIPS; COMPLEX STRUCTURES	The Shake-and-Bake method of structure determination is a new direct methods phasing algorithm based on a minimum-variance, phase invariant residual, which is referred to as the minimal principle. Previously, the algorithm had been applied only to known structures. This algorithm has now been applied to two previously unknown structures that contain 105 and 110 non-hydrogen atoms, respectively. This report focuses on (i) algorithmic and parametric optimizations of Shake-and-Bake and (ii) the determination of two previously unknown structures. Traditional tangent formula phasing techniques were unable to unravel these two new structures.	SUNY BUFFALO,DEPT COMP SCI,BUFFALO,NY 14260; THINKING MACHINES CORP,CAMBRIDGE,MA 02142	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	MILLER, R (corresponding author), MED FDN BUFFALO INC,73 HIGH ST,BUFFALO,NY 14203, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM046733, R01GM032812] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19856] Funding Source: Medline; NIGMS NIH HHS [GM-32812, GM-46733] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarts E., 1988, SIMULATED ANNEALING; BASHIR N, 1990, 5TH P DISTR MEM COMP, P513; CHANG CS, IN PRESS INT J SUPER; DEBAERDEMAEKER T, 1988, ACTA CRYSTALLOGR A, V44, P353, DOI 10.1107/S0108767388000017; DETITTA GT, 1991, 6TH P DISTR MEM COMP, P587; HAUPTMAN HA, 1991, CRYSTALLOGRAPHIC COM, V5, P324; HAUPTMAN HA, 1988, ABSTR AM CRYST ASS, V16, P53; Holland. D.G.J., 1989, GENETIC ALGORITHMS S; Miller R, UNPUB; PLETNEV VZ, 1980, BIOPOLYMERS, V19, P1517, DOI 10.1002/bip.1980.360190808; PLETNEV VZ, 1992, BIOPOLYMERS, V32, P819, DOI 10.1002/bip.360320710; Rossmann M. G., 1972, MOL REPLACEMENT METH; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SHIONO M, 1992, ACTA CRYSTALLOGR A, V48, P451, DOI 10.1107/S010876739101471X; WEEKS CM, 1993, ACTA CRYSTALLOGR D, V49, P179, DOI 10.1107/S090744499200876X; WEEKS CM, 1976, ACTA CRYSTALLOGR B, V32, P261, DOI 10.1107/S0567740876002720; YAO JX, 1981, ACTA CRYSTALLOGR A, V37, P642, DOI 10.1107/S0567739481001460	17	159	159	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1430	1433		10.1126/science.8451639	http://dx.doi.org/10.1126/science.8451639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451639				2022-12-28	WOS:A1993KP97800029
J	XING, YG; JOHNSON, CV; DOBNER, PR; LAWRENCE, JB				XING, YG; JOHNSON, CV; DOBNER, PR; LAWRENCE, JB			HIGHER LEVEL ORGANIZATION OF INDIVIDUAL GENE-TRANSCRIPTION AND RNA SPLICING	SCIENCE			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; PRE-MESSENGER-RNA; NUCLEAR MATRIX; NEUROMEDIN-N; SEQUENCES; LOCALIZATION; NEUROTENSIN; INTERPHASE; VISUALIZATION; EXPRESSION	Visualization of fibronectin and neurotensin messenger RNAs within mammalian interphase nuclei was achieved by fluorescence hybridization with genomic, complementary DNA, and intron-specific probes. Unspliced transcripts accumulated in one or two sites per nucleus. Fibronectin RNA frequently accumulated in elongated tracks that overlapped and extended well beyond the site of transcription. Splicing appears to occur directly within this RNA track, as evidenced by an unambiguous spatial separation of intron-containing and spliced transcripts. Excised introns for neurotensin RNA appear free to diffuse. The transcription and processing site of the fibronectin gene localized to the nuclear interior and was associated with larger transcript domains in over 88 percent of the cells. These results support a view of nuclear function closely integrated with structure.	UNIV MASSACHUSETTS, MED CTR, DEPT CELL BIOL, 55 LAKE AVE N, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, MED CTR, DEPT MOLEC GENET & MICROBIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester				Lawrence, Jeanne/0000-0001-6572-3128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033307] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000251] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG00251] Funding Source: Medline; NHLBI NIH HHS [R01 HL33307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER MJ, 1989, P NATL ACAD SCI USA, V86, P5202, DOI 10.1073/pnas.86.13.5202; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BERMAN SA, 1990, SCIENCE, V247, P212, DOI 10.1126/science.1688472; Beyer A L, 1991, Semin Cell Biol, V2, P131; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BRATTLEBORO VT, 1992, METHOD CELL BIOL, V35, P73; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CIEJEK EM, 1983, NATURE, V306, P607, DOI 10.1038/306607a0; COLECLOUGH C, 1984, MOL CELL BIOL, V4, P2017, DOI 10.1128/MCB.4.10.2017; COLEMAN J, UNPUB; COMINGS DE, 1980, HUM GENET, V53, P131, DOI 10.1007/BF00273484; DOBNER PR, 1988, J BIOL CHEM, V263, P13983; Fakan S, 1980, Int Rev Cytol, V65, P255; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FEY EG, 1986, J CELL SCI, P99; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GALL JG, 1991, SCIENCE, V252, P1499, DOI 10.1126/science.1828621; GALLINARO H, 1983, EMBO J, V2, P953, DOI 10.1002/j.1460-2075.1983.tb01527.x; HUANG S, 1991, GENE DEV, V5, P2228; JACKSON DA, 1991, BIOESSAYS, V13, P1, DOI 10.1002/bies.950130102; JACKSON DA, 1988, EMBO J, V7, P3667, DOI 10.1002/j.1460-2075.1988.tb03248.x; JOHNSON CV, 1991, GENET ANAL-BIOMOL E, V8, P75, DOI 10.1016/1050-3862(91)90052-S; KISLAUSKIS E, 1988, J BIOL CHEM, V263, P4963; LAWRENCE JB, 1990, P NATL ACAD SCI USA, V87, P5420, DOI 10.1073/pnas.87.14.5420; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LAWRENCE JB, 1988, CELL, V52, P51; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LAWRENCE JH, UNPUB; MILLER OL, 1969, SCIENCE, V164, P955, DOI 10.1126/science.164.3882.955; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; Northway J.D., 1972, CLIN IMMUNOL IMMUNOP, V1, P140, DOI [10.1016/0090-1229(72)90013-X, DOI 10.1016/0090-1229(72)90013-X]; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; RAAP AK, 1991, EXP CELL RES, V197, P319, DOI 10.1016/0014-4827(91)90439-2; RINGERTZ N, 1986, J CELL SCI, P11; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SPECTOR DL, 1983, BIOL CELL, V49, P1; TKACHUK DC, 1990, SCIENCE, V250, P559, DOI 10.1126/science.2237408; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; XING Y, UNPUB; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055; ZEITLIN S, 1987, MOL CELL BIOL, V7, P111, DOI 10.1128/MCB.7.1.111	46	382	390	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1993	259	5099					1326	1330		10.1126/science.8446901	http://dx.doi.org/10.1126/science.8446901			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446901				2022-12-28	WOS:A1993KN88300032
J	CZEIZEL, AE; INTODY, Z; MODELL, B				CZEIZEL, AE; INTODY, Z; MODELL, B			WHAT PROPORTION OF CONGENITAL-ABNORMALITIES CAN BE PREVENTED	BRITISH MEDICAL JOURNAL			English	Article								Objective-To estimate the proportion of preventable congenital abnormalities i Design-Analysis of available Hungarian databases and of the effectiveness of primary, secondary, and tertiary preventive methods. Setting-Databases of ad hoc epidemiological studies and of the Hungarian congenital abnormality registry. Main outcome measures-Prevalence at birth and prevalence after prevention in 73 congenital abnormality types or groups. Results-Preventive methods are available for 51 (70%) of the 73 congenital abnormality types or groups evaluated. The birth prevalence of all congenital abnormalities could be reduced from 65 to 26 per 1000; thus 39 per 1000 (60%) are preventable. Without congenital dislocation of the hip, which is unusually common in Hungary, the preventable proportion of congenital abnormalities is 52%. Conclusion-Many congenital abnormalities can be prevented, but as they do not represent a single pathological category there is no single strategy for their prevention.	UCL, UNIV COLL & MIDDLESEX, DEPT OBSTET & GYNAECOL, WHO, LONDON WC1E 6HX, ENGLAND	University of London; University College London; World Health Organization	CZEIZEL, AE (corresponding author), WHO, COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DIS, NATL INST HYG, DEPT HUMAN GENET & TERATOL, BUDAPEST, HUNGARY.							[Anonymous], 1991, CONGENITAL MALFORMAT; BERES J, 1988, ORVOSI HETILAP, V129, P529; CZEIZEL A, 1985, Acta Paediatrica Hungarica, V26, P175; CZEIZEL A, 1988, World Health Statistics Quarterly, V41, P219; CZEIZEL A, 1981, J MED GENET, V18, P91, DOI 10.1136/jmg.18.2.91; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; CZEIZEL AE, 1984, AETIOLOGICAL STUDIES; KALMAR Z, 1980, ORVOSI HETILAP, P1205; LUCK CA, 1992, BRIT MED J, V304, P1474, DOI 10.1136/bmj.304.6840.1474; Mehes K., 1983, MINOR MALFORMATIONS; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; SMITHELLS RW, 1989, LANCET, V2, P498; WALD N, 1991, LANCET, V338, P131; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WOOLF CM, 1968, AM J HUM GENET, V20, P430	15	158	169	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					499	503		10.1136/bmj.306.6876.499	http://dx.doi.org/10.1136/bmj.306.6876.499			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448464	Green Published, Bronze			2022-12-28	WOS:A1993KN78600023
J	RANDI, ML; TISON, T; LUZZATTO, G; GIROLAMI, A				RANDI, ML; TISON, T; LUZZATTO, G; GIROLAMI, A			HEMOLYTIC UREMIC SYNDROME DURING TREATMENT WITH KETOROLAC TROMETAMOL	BRITISH MEDICAL JOURNAL			English	Letter									UNIV PADUA,SCH MED,CHAIR MED 4,I-35100 PADUA,ITALY	University of Padua	RANDI, ML (corresponding author), UNIV PADUA,SCH MED,INST MED SEMEIOT,I-35100 PADUA,ITALY.							[Anonymous], 1990, Med Lett Drugs Ther, V32, P79; BORASUBER LA, 1992, AM J MED, V92, P450, DOI 10.1016/0002-9343(92)90283-H; ENGELS S, 1990, NIEREN HOCHDRUCK, V19, P530; KINCAIDSMITH P, 1986, DRUGS, V32, P109, DOI 10.2165/00003495-198600324-00009; PATRONO C, 1987, KIDNEY INT, V32, P1, DOI 10.1038/ki.1987.164	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					186	186		10.1136/bmj.306.6871.186-b	http://dx.doi.org/10.1136/bmj.306.6871.186-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443483	Green Published, Bronze			2022-12-28	WOS:A1993KH51300026
J	ORTEGA, YR; STERLING, CR; GILMAN, RH; CAMA, VA; DIAZ, F				ORTEGA, YR; STERLING, CR; GILMAN, RH; CAMA, VA; DIAZ, F			CYCLOSPORA SPECIES - A NEW PROTOZOAN PATHOGEN OF HUMANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRYPTOSPORIDIUM OOCYSTS; DIARRHEA; APICOMPLEXA; TRAVELERS; NEPAL; MOLE	Background. Organisms referred to as ''cyanobacterium-like bodies'' have now been identified worldwide in the feces of both immunocompetent and immunocompromised patients with diarrhea. Organisms with a similar appearance have been isolated from Peruvian patients since 1985. From 1988 to 1991 we studied prospectively two cohorts of infants and young children infected with this organism. We now attempt to identify it. Methods. Fecal samples were collected weekly from the children and examined with the use of acid-fast staining and staining with a monoclonal antibody specific for cryptosporidium. Stools positive for cyanobacterium-like bodies were preserved in potassium dichromate and exposed to conditions allowing coccidian sporulation and excystation. Both unsporulated and sporulated oocysts were fixed by freeze-substitution techniques and then examined by electron microscopy. Results. Organisms isolated from the feces of Peruvian patients and two patients from the United States were identified as belonging to the coccidian genus cyclospora, after sporulation and excystation of the oocysts according to standard techniques. Complete sporulation occurred within 5 to 13 days in oocysts maintained in potassium dichromate at 25 or 32-degrees-C. Complete excystation resulted in the liberation of two sporozoites f rom the two sporocysts within each oocyst (cryptosporidia have four naked sporozoites within each oocyst). The presence of organelles characteristic of coccidian organisms was confirmed by electron microscopy. Conclusions. We have identified organisms of the genus cyclospora that are remarkably similar to cryptosporidia in their morphologic features and the diarrheal disease that they produce in humans. The complete life cycle and epidemiology of this new protozoan parasite remain to be described.	UNIV ARIZONA, DEPT VET SCI, BLDG 90, RM 201, TUCSON, AZ 85721 USA; JOHNS HOPKINS UNIV, DEPT INT HLTH, BALTIMORE, MD 21218 USA; UNIV PERUANA CAYETANO HEREDIA, DEPT PARASITOL, LIMA, PERU; ASOC BENEFICA PRISMA, LIMA, PERU	University of Arizona; Johns Hopkins University; Universidad Peruana Cayetano Heredia								ARROWOOD MJ, 1987, J PARASITOL, V73, P314, DOI 10.2307/3282084; BRIDGMAN PC, 1984, J CELL BIOL, V99, P1655, DOI 10.1083/jcb.99.5.1655; DUBEY JP, 1970, J EXP MED, V132, P636, DOI 10.1084/jem.132.4.636; DUSZYNSKI DW, 1988, J PROTOZOOL, V35, P58, DOI 10.1111/j.1550-7408.1988.tb04077.x; FORD PL, 1988, J PROTOZOOL, V35, P223, DOI 10.1111/j.1550-7408.1988.tb04328.x; FORD PL, 1989, J PARASITOL, V75, P508, DOI 10.2307/3282897; FORD PL, 1990, J PARASITOL, V76, P325, DOI 10.2307/3282659; GARCIA LS, 1987, J CLIN MICROBIOL, V25, P119, DOI 10.1128/JCM.25.1.119-121.1987; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; LEVINE ND, 1973, COCCIDIA, P1; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; MOHAMED HA, 1990, PARASITOLOGY, V101, P345, DOI 10.1017/S0031182000060534; NARANJO J, 1989, 38TH ANN M AM SOC TR; PELLERDY L, 1968, Folia Parasitologica (Ceske Budejovice), V15, P275; SCHNEIDER A, 1881, ARCH ZOOL EXP, V1, P387; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; STERLING CR, 1986, PEDIATR INFECT DIS J, V5, pS139; STERLING CR, 1991, J PROTOZOOL, V38, pS23; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; 1991, MMWR MORB MORTAL WKL, V40, P325; [No title captured]	23	316	347	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1993	328	18					1308	1312		10.1056/NEJM199305063281804	http://dx.doi.org/10.1056/NEJM199305063281804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ640	8469253	Bronze			2022-12-28	WOS:A1993KZ64000004
J	ROBERTS, CM; FOULCHER, E; ZAUNDERS, JJ; BRYANT, DH; FREUND, J; CAIRNS, D; PENNY, R; MORGAN, GW; BREIT, SN				ROBERTS, CM; FOULCHER, E; ZAUNDERS, JJ; BRYANT, DH; FREUND, J; CAIRNS, D; PENNY, R; MORGAN, GW; BREIT, SN			RADIATION PNEUMONITIS - A POSSIBLE LYMPHOCYTE-MEDIATED HYPERSENSITIVITY REACTION	ANNALS OF INTERNAL MEDICINE			English	Article						ALVEOLITIS, EXTRINSIC ALLERGIC; LYMPHOCYTES; RADIOTHERAPY; BREAST NEOPLASMS; LYMPHOCYTOSIS	BRONCHOALVEOLAR LAVAGE; LUNG-DISEASE; GA-67 UPTAKE; INJURY	Objective: To determine if unilateral thoracic irradiation results in a lymphoid alveolitis in both irradiated and unirradiated lung fields. Design: A prospective, nonrandomized study. Patients: Women receiving postoperative radiotherapy for carcinoma of the breast were evaluated both before and 4 to 6 weeks after radiotherapy. Findings after radiotherapy in 15 asymptomatic patients were compared with findings in a group of patients with clinical radiation pneumonitis. Measurements: History, physical examination, chest radiograph, quantitative gallium lung scanning, respiratory function tests, bronchoalveolar lavage, and lavage lymphocyte subset analysis. Results: After irradiation, lavage lymphocytes increased significantly (34.5% versus 46.8%; P = 0.01) in the 17 patients studied prospectively. There was an associated reduction in vital capacity (102.5% versus 95.5%; P = 0.04). Comparison of results in patients before treatment, after treatment without clinical pneumonitis, and after treatment with clinical pneumonitis showed a dramatic increase in total lymphocytes after irradiation (6.3 versus 9.4 versus 35.2 million, respectively; P = 0.005), particularly in those with clinical pneumonitis. Only in those with clinical pneumonitis was this accompanied by an increase in the gallium index (3.7 versus 3.4 versus 9.0, respectively; P < 0.001). Vital capacity was also progressively reduced (102.5% versus 96.9% versus 76.7%, respectively; P = 0.04), as was diffusing capacity (98.6% versus 91.4% versus 72.6%, respectively; P = 0.003). No statistical differences existed between irradiated and unirradiated sides of the chest in either lavage or gallium lung scan studies. Conclusion: In most patients, a lymphocytic alveolitis develops in both lung fields after strictly unilateral thoracic irradiation; this is more pronounced in patients developing clinical pneumonitis. These findings suggest that radiotherapy may cause a generalized lymphocyte-mediated hypersensitivity reaction.	ST VINCENTS HOSP, CTR IMMUNOL, SYDNEY, NSW 2010, AUSTRALIA; UNIV NEW S WALES, SYDNEY, NSW, AUSTRALIA; MACQUARIE UNIV, SCH BEHAV SCI, SYDNEY 2109, AUSTRALIA	St Vincents Hospital Sydney; University of New South Wales Sydney; Macquarie University			Zaunders, John/J-6553-2012	Zaunders, John/0000-0002-5912-5989; roberts, christopher/0000-0001-8212-1460				AKOUN GM, 1987, THORAX, V42, P652, DOI 10.1136/thx.42.9.652; BATE D, 1957, RADIOLOGY, V69, P372, DOI 10.1148/69.3.372; BENNETT DE, 1969, CANCER-AM CANCER SOC, V23, P1001, DOI 10.1002/1097-0142(196905)23:5<1001::AID-CNCR2820230505>3.0.CO;2-E; BISSON G, 1983, CHEST, V84, P513, DOI 10.1378/chest.84.5.513; CAIRNS D, 1991, AM REV RESPIR DIS, V143, P1235, DOI 10.1164/ajrccm/143.6.1235; COGGLE JE, 1986, ENVIRON HEALTH PERSP, V70, P261, DOI 10.2307/3430363; CORDIER JF, 1984, B EUR PHYSIOPATH RES, V20, P369; CORMIER Y, 1984, AM REV RESPIR DIS, V130, P1046; COSTABEL U, 1984, CHEST, V85, P514, DOI 10.1378/chest.85.4.514; COTES JE, 1979, LUNG FUNCTION ASSESS; FLEMING JAC, 1961, BRIT J RADIOL, V34, P713, DOI 10.1259/0007-1285-34-407-713; GIBSON PG, 1989, AUST NZ J MED, V19, P281, DOI 10.1111/j.1445-5994.1989.tb00263.x; GIBSON PG, 1988, ANN INTERN MED, V109, P288, DOI 10.7326/0003-4819-109-4-288; GROSS NJ, 1981, LUNG, V159, P115, DOI 10.1007/BF02713907; GROSS NJ, 1977, ANN INTERN MED, V86, P81, DOI 10.7326/0003-4819-86-1-81; Hammerschlag-Icaza B A, 1991, Bol Asoc Med P R, V83, P10; KATAOKA M, 1990, CLIN NUCL MED, V15, P707, DOI 10.1097/00003072-199015100-00012; Kataoka M, 1989, Ann Nucl Med, V3, P73; LAFITTE JJ, 1986, AM REV RESPIR DIS, V133, pA287; MARK EJ, 1984, LUNG BIOPSY INTERPRE, P73; RAMSAY SC, 1992, EUR J NUCL MED, V19, P80; ROTHWELL RI, 1985, RADIOTHER ONCOL, V4, P9, DOI 10.1016/S0167-8140(85)80056-6; SALTINI C, 1984, AM REV RESPIR DIS, V130, P650; SMITH JC, 1964, AM REV RESPIR DIS, V89, P264; WHITE DA, 1989, AM REV RESPIR DIS, V139, P18, DOI 10.1164/ajrccm/139.1.18	25	156	160	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					696	700		10.7326/0003-4819-118-9-199305010-00006	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460855				2022-12-28	WOS:A1993KY50200006
J	ANDREWS, NC; ERDJUMENTBROMAGE, H; DAVIDSON, MB; TEMPST, P; ORKIN, SH				ANDREWS, NC; ERDJUMENTBROMAGE, H; DAVIDSON, MB; TEMPST, P; ORKIN, SH			ERYTHROID TRANSCRIPTION FACTOR NF-E2 IS A HEMATOPOIETIC-SPECIFIC BASIC LEUCINE ZIPPER PROTEIN	NATURE			English	Article							BETA-GLOBIN GENE; DOMINANT CONTROL REGION; DNA-BINDING PROTEIN; PORPHOBILINOGEN DEAMINASE GENE; LOCUS-CONTROL REGION; AMINO-ACID-SEQUENCE; TRANSGENIC MICE; DEVELOPMENTAL REGULATION; FUNCTIONAL-PROPERTIES; MAMMALIAN-CELLS	Expression of globin genes in developing erythroid cells is controlled by upstream locus control regions. Activity of these regions in vivo requires an erythroid-specific nuclear factor (NF-E2) that binds AP-1-like recognition sites. Its tissue-specific component (p45 NF-E2) has been characterized by complementary DNA cloning as a new basic region-leucine zipper protein which dimerizes with a ubiquitous partner to form native NF-E2.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,DIV HEMATOL ONCOL,BOSTON,MA 02115; MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021; HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute				Andrews, Nancy/0000-0003-0243-4462; Erdjument-Bromage, Hediye/0000-0003-0224-3594				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P587; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; ERDJUMENTBROMAG.H, IN PRESS TECHNIQUES, V4; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HATTON CSR, 1990, BLOOD, V76, P221; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOON AM, 1991, BLOOD, V77, P2272; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PARK CW, 1992, J BIOL CHEM, V267, P15642; PETERS LL, 1993, NATURE, V362, P768, DOI 10.1038/362768a0; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237, DOI 10.1093/nar/20.2.237; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TAKETANI S, 1992, EUR J BIOCHEM, V205, P217, DOI 10.1111/j.1432-1033.1992.tb16771.x; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TEMPST P, 1983, EUR J BIOCHEM, V135, P321, DOI 10.1111/j.1432-1033.1983.tb07656.x; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VANDERPLOEG LHT, 1980, NATURE, V283, P637, DOI 10.1038/283637a0; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WILKINS P, 1987, MOL CELL BIOL, V7, P1751	56	579	594	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 22	1993	362	6422					722	728		10.1038/362722a0	http://dx.doi.org/10.1038/362722a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8469283				2022-12-28	WOS:A1993KY45000046
J	HERRSTEDT, J; SIGSGAARD, T; BOESGAARD, M; JENSEN, TP; DOMBERNOWSKY, P				HERRSTEDT, J; SIGSGAARD, T; BOESGAARD, M; JENSEN, TP; DOMBERNOWSKY, P			ONDANSETRON PLUS METOPIMAZINE COMPARED WITH ONDANSETRON ALONE IN PATIENTS RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CISPLATIN-INDUCED EMESIS; HIGH-DOSE METOCLOPRAMIDE; DOUBLE-BLIND; INDUCED NAUSEA; SEROTONIN ANTAGONIST; ANTIEMETIC EFFICACY; RANDOMIZED TRIAL; DEXAMETHASONE; PROPHYLAXIS; RECEPTORS	Background and Methods. The serotonin (5-hydroxytryptamine3) antagonists have improved the treatment of acute chemotherapy-induced nausea and vomiting, but their ability to prevent delayed nausea and vomiting seems less pronounced. The results of a preliminary open trial suggested that the addition of a selective dopamine D2 antagonist could improve the antiemetic efficacy of the serotonin antagonists. In a randomized, double-blind, crossover trial, we compared oral treatment with ondansetron (8 mg twice a day) and the dopamine D2 antagonist metopimazine (30 mg four times a day) with treatment with ondansetron alone for three days in 30 patients who had vomited during the previous cycle of chemotherapy. All the patients received moderately emetogenic chemotherapy. Results, Combination treatment with ondansetron and metopimazine significantly reduced the incidence of acute (P = 0.006) and delayed (P = 0.02) nausea and acute (P = 0.02) and delayed (P = 0.006) vomiting, as compared with treatment with ondansetron alone. Patients had significantly fewer days of nausea (P = 0.03) and vomiting (P = 0.003) if they received combination therapy. Sixty-seven percent of the patients preferred ondansetron and metopimazine, and 33 percent favored ondansetron alone (P = 0.10). Adverse reactions were mild with both regimens. With the exception of constipation, which was reported more frequently with combination therapy (P = 0.03), there were no significant differences in adverse reactions. Conclusions. Ondansetron plus metopimazine is a highly effective and safe antiemetic regimen that is markedly superior to treatment with ondansetron alone in patients receiving moderately emetogenic chemotherapy.			HERRSTEDT, J (corresponding author), UNIV COPENHAGEN,HERLEV HOSP,DEPT ONCOL 54B1,DK-2730 COPENHAGEN,DENMARK.		Herrstedt, Jørn/AAB-7400-2022					BATEMAN DN, 1985, BRIT MED J, V291, P930, DOI 10.1136/bmj.291.6500.930; BONNETERRE J, 1990, J CLIN ONCOL, V8, P1063, DOI 10.1200/JCO.1990.8.6.1063; BREGNI M, 1991, EUR J CANCER, V27, P561, DOI 10.1016/0277-5379(91)90217-2; CARR BI, 1985, J CLIN ONCOL, V3, P1127, DOI 10.1200/JCO.1985.3.8.1127; CLAVEL M, 1978, LYON MED, V239, P307; DELFAVERO A, 1990, EUR J CLIN PHARMACOL, V38, P115, DOI 10.1007/BF00265968; Demulder PHM, 1990, ANN INTERN MED, V113, P834, DOI 10.7326/0003-4819-113-11-834; DICATO MA, 1991, EUR J CANCER, V27, pS18; FOZARD JR, 1978, EUR J PHARMACOL, V49, P109, DOI 10.1016/0014-2999(78)90228-5; GANDARA DR, 1990, P AN M AM SOC CLIN, V9, P328; GRALLA RJ, 1987, MED CLIN N AM, V71, P289, DOI 10.1016/S0025-7125(16)30871-9; GRUNBERG SM, 1993, EUR J CANCER, V29A, pS39, DOI 10.1016/S0959-8049(05)80260-6; HAINSWORTH J, 1991, J CLIN ONCOL, V9, P721, DOI 10.1200/JCO.1991.9.5.721; HAMIK A, 1989, CANCER CHEMOTH PHARM, V24, P307, DOI 10.1007/BF00304763; HERRSTEDT J, 1990, BRIT J CLIN PHARMACO, V30, P237, DOI 10.1111/j.1365-2125.1990.tb03770.x; HERRSTEDT J, 1991, EJC SUPPL, V27, pS294; ISRAEL L, 1978, J INT MED RES, V6, P235, DOI 10.1177/030006057800600311; KAASA S, 1990, EUR J CANCER, V26, P311, DOI 10.1016/0277-5379(90)90227-K; KELLEY SL, 1986, CANCER TREAT REP, V70, P469; KILPATRICK GJ, 1987, NATURE, V330, P746, DOI 10.1038/330746a0; KRIS MG, 1989, J CLIN ONCOL, V7, P108, DOI 10.1200/JCO.1989.7.1.108; MARSCHNER NW, 1991, EUR J CANCER, V27, P1137, DOI 10.1016/0277-5379(91)90311-Z; MARSCHNER NW, 1991, EUR J CANCER, V27, P1717; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; MARTY M, 1990, EUR J CANCER, V26, pS28; MINER WD, 1986, BRIT J PHARMACOL, V88, P497, DOI 10.1111/j.1476-5381.1986.tb10228.x; MOERTEL CG, 1973, J CLIN PHARMACOL, V13, P283, DOI 10.1002/j.1552-4604.1973.tb00269.x; OLVER IN, 1986, CANCER TREAT REP, V70, P555; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P110; ROILA F, 1991, J CLIN ONCOL, V9, P675, DOI 10.1200/JCO.1991.9.4.675; Siegel S., 1956, NONPARAMETRIC STAT B; SLEDGE GW, 1990, P AN M AM SOC CLIN, V9, P323; SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4; SMYTH JF, 1991, BRIT MED J, V303, P1423, DOI 10.1136/bmj.303.6815.1423; Stroyer I, 1976, Ugeskr Laeger, V138, P1769; [No title captured]	36	77	81	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1076	1080		10.1056/NEJM199304153281502	http://dx.doi.org/10.1056/NEJM199304153281502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8455664	Bronze			2022-12-28	WOS:A1993KX17800002
J	XU, ZS; CORK, LC; GRIFFIN, JW; CLEVELAND, DW				XU, ZS; CORK, LC; GRIFFIN, JW; CLEVELAND, DW			INCREASED EXPRESSION OF NEUROFILAMENT SUBUNIT-NF-L PRODUCES MORPHOLOGICAL ALTERATIONS THAT RESEMBLE THE PATHOLOGY OF HUMAN MOTOR-NEURON DISEASE	CELL			English	Article							AMYOTROPHIC LATERAL SCLEROSIS; PHOSPHORYLATED NEUROFILAMENTS; CALIBER; MICROTUBULES; ACCUMULATION; MOTONEURONS; TRANSPORT; PROTEINS; CELLS; MICE	Excessive accumulation of neurofilaments in the cell bodies and proximal axons of motor neurons is a major pathological hallmark during the early stages of many human motor neuron diseases. To test directly the consequence of overexpression of the major neurofilament subunit NF-L, we produced transgenic mice that accumulate NF-L to approximately 4-fold the normal level in the sciatic nerve. In young animals, the motor neurons of the ventral horn of the spinal cord have massive accumulations of neurofilaments, swollen perikarya, and eccentrically localized nuclei. NF-L accumulation is accompanied by an increased frequency of axonal degeneration, proximal axon swelling, and severe skeletal muscle atrophy. These data indicate that extensive accumulation of neurofilaments in motor neurons can trigger the neurodegenerative process.	JOHNS HOPKINS UNIV, SCH MED, DEPT COMPARAT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	XU, ZS (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				BANKER BQ, 1986, MYOLOGY 2, P2031; BYERS RK, 1961, ARCH NEUROL-CHICAGO, V5, P140, DOI 10.1001/archneur.1961.00450140022003; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; CHOU SM, 1971, J NEUROPATH EXP NEUR, V30, P368, DOI 10.1097/00005072-197107000-00005; Choudhary S. R., 1979, An economic classification and segregation of farms in order to examine the effect of "group" & "time" on the value of agricultural production in Belgium.; CLEVELAND DW, 1991, J CELL SCI, P85; CORK LC, 1982, LAB INVEST, V46, P89; CORK LC, 1988, J NEUROPATH EXP NEUR, V47, P420, DOI 10.1097/00005072-198807000-00003; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; GOMEZ MR, 1986, MYOLOGY, P1993; GRIFFIN JW, 1978, SCIENCE, V202, P633, DOI 10.1126/science.81524; GRIFFIN JW, 1984, PERIPHERAL NEUROPATH, P621; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P471, DOI 10.1097/00005072-198409000-00002; HIRANO A, 1988, AMYOTROPHIC LATERAL, P193; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; Inoue K, 1979, NEUROL MED CHIR TOKY, V11, P448; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1982, J BIOL CHEM, V257, P467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; MULDER DW, 1986, MYOLOGY, P2013; MULDER DW, 1984, PERIPHERAL NEUROPATH, P1525; MUNOZ DG, 1988, J NEUROPATH EXP NEUR, V47, P9, DOI 10.1097/00005072-198801000-00002; PRICE DL, 1972, J CELL BIOL, V53, P24, DOI 10.1083/jcb.53.1.24; SCHOCHET SS, 1969, ARCH NEUROL-CHICAGO, V20, P548, DOI 10.1001/archneur.1969.00480110112012; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOBUE G, 1990, ACTA NEUROPATHOL, V79, P402, DOI 10.1007/BF00308716; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Tower SS, 1939, PHYSIOL REV, V19, P1; TRONCOSO JC, 1985, BRAIN RES, V342, P172, DOI 10.1016/0006-8993(85)91369-1; WILEY CA, 1987, ACTA NEUROPATHOL, V72, P369, DOI 10.1007/BF00687269; WONG GL, 1984, J BIOL CHEM, V259, P4019; YAMASAKI H, 1992, LAB INVEST, V66, P734	36	491	503	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	1993	73	1					23	33		10.1016/0092-8674(93)90157-L	http://dx.doi.org/10.1016/0092-8674(93)90157-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462100				2022-12-28	WOS:A1993KW75300005
J	ARMITAGE, JO				ARMITAGE, JO			DRUG-THERAPY - TREATMENT OF NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LARGE-CELL LYMPHOMA; DIFFUSE HISTIOCYTIC LYMPHOMA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; BONE-MARROW TRANSPLANTATION; FIELD RADIATION-THERAPY; HIGH-DOSE THERAPY; TERM FOLLOW-UP; B-CELL; COMBINATION CHEMOTHERAPY; LYMPHOBLASTIC LYMPHOMA				ARMITAGE, JO (corresponding author), UNIV NEBRASKA, MED CTR, DEPT INTERNAL MED, 600 S 42ND ST, OMAHA, NE 68198 USA.				NCI NIH HHS [CA 36737] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON JR, 1983, NEW ENGL J MED, V308, P559, DOI 10.1056/NEJM198303103081003; [Anonymous], 1975, BRIT J HAEMATOL, DOI DOI 10.1111/J.1365-2141.1975.TB00911.X; APPELBAUM FR, 1991, HEMATOL ONCOL CLIN N, V5, P1013, DOI 10.1016/S0889-8588(18)30398-8; ARMITAGE JO, 1986, J CLIN ONCOL, V4, P160, DOI 10.1200/JCO.1986.4.2.160; BAUER KD, 1986, CANCER RES, V46, P3173; BERMUDEZ MA, 1989, AM J MED, V86, P71, DOI 10.1016/0002-9343(89)90232-5; BERNSTEIN JI, 1986, J CLIN ONCOL, V4, P847, DOI 10.1200/JCO.1986.4.6.847; BRODER S, 1984, ANN INTERN MED, V100, P543, DOI 10.7326/0003-4819-100-4-543; BROOKS JJ, 1983, CANCER, V51, P701, DOI 10.1002/1097-0142(19830215)51:4<701::AID-CNCR2820510425>3.0.CO;2-D; BROWNE MJ, 1986, ANN INTERN MED, V104, P338, DOI 10.7326/0003-4819-104-3-338; CABANILLAS F, 1985, HEMATOL ONCOL, V3, P25, DOI 10.1002/hon.2900030104; CABANILLAS F, 1991, ANN ONCOL, V2, P31, DOI 10.1093/annonc/2.suppl_1.31; CARBONE PP, 1971, CANCER RES, V31, P1860; CARDE P, 1991, ANN ONCOL, V2, P431, DOI 10.1093/oxfordjournals.annonc.a057979; CARDE P, 1984, RADIOTHER ONCOL, V2, P301, DOI 10.1016/S0167-8140(84)80072-9; CHESON BD, 1991, HEMATOL ONCOL CLIN N, V5, P1027, DOI 10.1016/S0889-8588(18)30399-X; CHISESI T, 1991, LEUKEMIA, V5, P107; COIFFIER B, 1990, ANN ONCOL, V1, P45, DOI 10.1093/oxfordjournals.annonc.a057673; COIFFIER B, 1991, J CLIN ONCOL, V9, P211, DOI 10.1200/JCO.1991.9.2.211; COLEMAN CN, 1986, J CLIN ONCOL, V4, P1628, DOI 10.1200/JCO.1986.4.11.1628; CONLAN MG, 1990, J CLIN ONCOL, V8, P1163, DOI 10.1200/JCO.1990.8.7.1163; CONNORS JM, 1987, ANN INTERN MED, V107, P25, DOI 10.7326/0003-4819-107-1-25; COOPER IA, 1991, P AN M AM SOC CLIN, V10, P271; COX JD, 1981, CANCER, V47, P2247, DOI 10.1002/1097-0142(19810501)47:9<2247::AID-CNCR2820470924>3.0.CO;2-2; DANA BW, 1990, J CLIN ONCOL, V8, P1155, DOI 10.1200/JCO.1990.8.7.1155; DANIEU L, 1986, CANCER RES, V46, P5372; DEVITA VT, 1975, LANCET, V1, P248; DIXON DO, 1986, J CLIN ONCOL, V4, P295, DOI 10.1200/JCO.1986.4.3.295; DUPONT J, 1983, P AN M AM SOC CLIN, V2, P215; FEDERICO M, 1991, LEUKEMIA, V5, P95; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FISHER RI, 1981, CANCER, V47, P2022, DOI 10.1002/1097-0142(19810415)47:8<2022::AID-CNCR2820470820>3.0.CO;2-V; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; FREEDMAN AS, 1991, HEMATOL ONCOL CLIN N, V5, P871, DOI 10.1016/S0889-8588(18)30390-3; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; GARCIACONDE J, 1991, BLOOD S, V78, pA127; GHERLINZONI F, 1990, SEMIN ONCOL, V17, P3; GIANNI AM, 1991, P ASCO, V10, P274; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; GREER JP, 1991, J CLIN ONCOL, V9, P539, DOI 10.1200/JCO.1991.9.4.539; GRIBBEN JG, 1991, NEW ENGL J MED, V325, P1525, DOI 10.1056/NEJM199111283252201; GROGAN TM, 1988, BLOOD, V71, P1157; GULATI SC, 1988, J CLIN ONCOL, V6, P1303, DOI 10.1200/JCO.1988.6.8.1303; HAGBERG H, 1985, EUR J CANCER CLIN ON, V21, P175, DOI 10.1016/0277-5379(85)90169-5; HARDY R, 1991, HEMATOL ONCOL CLIN N, V5, P891, DOI 10.1016/S0889-8588(18)30391-5; JAGANNATH S, 1986, J CLIN ONCOL, V4, P859, DOI 10.1200/JCO.1986.4.6.859; JONES SE, 1989, J CLIN ONCOL, V7, P1186, DOI 10.1200/JCO.1989.7.9.1186; JONES SE, 1972, CANCER, V30, P31, DOI 10.1002/1097-0142(197207)30:1<31::AID-CNCR2820300106>3.0.CO;2-A; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; KARP JE, 1991, CANCER RES, V51, P4743; Kemme D J, 1992, Oncology (Williston Park), V6, P31; KEMME DJ, 1992, ONCOLOGY HUNTINGT, V6, P41; KESSINGER A, 1991, EXP HEMATOL, V19, P1013; KOPPLER H, 1991, HEMATOL ONCOL, V9, P217; KRIKORIAN JG, 1980, CANCER-AM CANCER SOC, V46, P2093, DOI 10.1002/1097-0142(19801101)46:9<2093::AID-CNCR2820460931>3.0.CO;2-4; KWAK LW, 1991, J CLIN ONCOL, V9, P1426, DOI 10.1200/JCO.1991.9.8.1426; LEVINE AM, 1990, SEMIN ONCOL, V17, P104; LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G; LEVINE AM, 1983, BLOOD, V61, P92; LEVITT M, 1972, CANCER, V29, P630, DOI 10.1002/1097-0142(197203)29:3<630::AID-CNCR2820290316>3.0.CO;2-Q; LINK MP, 1990, NEW ENGL J MED, V322, P1169, DOI 10.1056/NEJM199004263221701; LIPPMAN SM, 1988, BLOOD, V72, P436; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1989, J CLIN ONCOL, V7, P1295, DOI 10.1200/JCO.1989.7.9.1295; LONGO DL, 1991, HEMATOL ONCOL CLIN N, V5, P1067, DOI 10.1016/S0889-8588(18)30401-5; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; LOPEZ TM, 1990, J CLIN ONCOL, V8, P615, DOI 10.1200/JCO.1990.8.4.615; LUKES RJ, 1974, CANCER, V34, P1488, DOI 10.1002/1097-0142(197410)34:8+<1488::AID-CNCR2820340822>3.0.CO;2-C; MCLAUGHLIN P, 1987, J CLIN ONCOL, V5, P867, DOI 10.1200/JCO.1987.5.6.867; MCMASTER ML, 1991, J CLIN ONCOL, V9, P941, DOI 10.1200/JCO.1991.9.6.941; MILLER TP, 1988, J CLIN INVEST, V82, P370, DOI 10.1172/JCI113598; MILLER TP, 1991, J CLIN ONCOL, V9, P17, DOI 10.1200/JCO.1991.9.1.17; MURPHY SB, 1989, J CLIN ONCOL, V7, P186, DOI 10.1200/JCO.1989.7.2.186; NGAN BY, 1991, HUM PATHOL, V22, P409, DOI 10.1016/0046-8177(91)90125-9; NISSEN NI, 1983, CANCER, V52, P1, DOI 10.1002/1097-0142(19830701)52:1<1::AID-CNCR2820520102>3.0.CO;2-M; OCONNELL M, 1984, P AN M AM SOC CLIN, V3, P241; OFFIT K, 1991, HEMATOL ONCOL CLIN N, V5, P853, DOI 10.1016/S0889-8588(18)30389-7; OREILLY SE, 1991, J CLIN ONCOL, V9, P741, DOI 10.1200/JCO.1991.9.5.741; PATTE C, 1986, J CLIN ONCOL, V4, P1219, DOI 10.1200/JCO.1986.4.8.1219; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; RAPPAPORT H, 1956, CANCER-AM CANCER SOC, V9, P792, DOI 10.1002/1097-0142(195607/08)9:4<792::AID-CNCR2820090429>3.0.CO;2-B; ROHATINER AZS, 1991, HEMATOL ONCOL CLIN N, V5, P1003, DOI 10.1016/S0889-8588(18)30397-6; ROSENBERG SA, 1982, CANCER, V49, P2112; SALLOUM E, 1988, EUR J CANCER CLIN ON, V24, P1609, DOI 10.1016/0277-5379(88)90053-3; SHEIBANI K, 1986, AM J PATHOL, V124, P310; SHIPP M, 1992, P AN M AM SOC CLIN, V11, P319; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SLATER DE, 1986, J CLIN ONCOL, V4, P57, DOI 10.1200/JCO.1986.4.1.57; SMALLEY RV, 1992, NEW ENGL J MED, V327, P1336, DOI 10.1056/NEJM199211053271902; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; SWAN F, 1990, BLOOD S, V76, pA375; SWEET DL, 1981, BLOOD, V58, P1218; TIRELLI U, 1992, J CLIN ONCOL, V10, P228, DOI 10.1200/JCO.1992.10.2.228; TURA S, 1991, BLOOD S, V78, pA109; TURNER RR, 1989, ARCH PATHOL LAB MED, V113, P907; VOAKES JB, 1981, BLOOD, V57, P186; VOSE JM, 1988, J CLIN ONCOL, V6, P1838, DOI 10.1200/JCO.1988.6.12.1838; WEISENBURGER DD, 1987, BLOOD, V69, P1617; WEISENBURGER DD, 1981, CANCER, V48, P1415, DOI 10.1002/1097-0142(19810915)48:6<1415::AID-CNCR2820480625>3.0.CO;2-N; WOOLDRIDGE TN, 1988, CANCER RES, V48, P6608; YOUNG RC, 1988, SEMIN HEMATOL, V25, P11	102	342	351	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1023	1030						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	8450856				2022-12-28	WOS:A1993KW28200009
J	BRENNWALD, P; NOVICK, P				BRENNWALD, P; NOVICK, P			INTERACTIONS OF 3 DOMAINS DISTINGUISHING THE RAS-RELATED GTP-BINDING PROTEINS YPT1 AND SEC4	NATURE			English	Article							VESICULAR TRANSPORT; TERMINAL DOMAIN; YEAST; GAP; SECRETION; IDENTIFICATION; SIGNAL; P21	THE genes SEC4 and YPT1 encode Ras-related GTP-binding proteins in the yeast Saccharomyces cerevisiae. Ypt1 is necessary for vesicular transport from the endoplasmic reticulum to the Golgi1-4, whereas Sec4 is required for fusion of post-Golgi secretory vesicles to the plasma membrane5. Recently, three structural domains have been proposed to specify the stage in cellular transport at which members of the Sec4/Ypt1/Rab family act: the effector domain6, the C-terminal hypervariable region7, and a region corresponding to loop 7 in the structure of p21ras (ref. 8). Here we use Sec4/Ypt1 chimaeras to show that these three regions cooperate to specify Ypt1 function and that the C-terminal hypervariable region is needed for Ypt1 localization to the Golgi. Unexpectedly, we found that a single chimaera can function as either Ypt1 or Sec4 without missorting carboxypeptidase Y or invertase.			BRENNWALD, P (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAIR J, 1990, J CELL BIOL, V110, P1897, DOI 10.1083/jcb.110.6.1897; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1992, METHOD ENZYMOL, V219, P352; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017	27	174	175	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					560	563		10.1038/362560a0	http://dx.doi.org/10.1038/362560a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464498				2022-12-28	WOS:A1993KW45300060
J	TOMCHIK, RS; RUSSELL, MT; SZMANT, AM; BLACK, NA				TOMCHIK, RS; RUSSELL, MT; SZMANT, AM; BLACK, NA			CLINICAL PERSPECTIVES ON SEABATHERS ERUPTION, ALSO KNOWN AS SEA LICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COELENTERATE ENVENOMATION; JELLYFISH ENVENOMATION; ANAPHYLAXIS; CONTACT	Seabather's eruption is usually a benign clinical syndrome that resolves spontaneously, although severe symptoms and long-term sequelae have been identified. Recent research has implicated the larvae of a jellyfish, Linuche unguiculata, as the cause of this syndrome; confirmation by serological and experimental studies is pending. Clinical signs and symptoms are consistent with this etiology. Outbreaks occur when jellyfish larvae are transported to shore by ocean currents. Treatment is symptomatic and involves use of antihistamines and steroids.	FLORIDA DEPT HLTH & REHABIL SERV,BROWARD CTY PUBL HLTH UNIT,FT LAUDERDALE,FL; BOCA RATON COMMUNITY HOSP,DEPT EMERGENCY SERV,BOCA RATON,FL; UNIV MIAMI,ROSENSTIEL SCH MARINE & ATMOSPHER SCI,DIV MARINE BIOL & FISHERIES,MIAMI,FL 33149	Florida Department of Health; University of Miami	TOMCHIK, RS (corresponding author), UNIV MIAMI,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,POB 016069 R-669,MIAMI,FL 33101, USA.							AUERBACH PS, 1991, NEW ENGL J MED, V325, P486, DOI 10.1056/NEJM199108153250707; AUERBACH PS, 1987, MED GUIDE HAZARDOUS; BEEBE W, 1928, TROPICAL SEAS; BLACK NA, 1992, 1992 S FLOR KEYS REG; BURNETT HW, 1990, TOXICON, V28, P731, DOI 10.1016/0041-0101(90)90264-8; BURNETT JW, 1985, TOXICON, V23, P1010, DOI 10.1016/0041-0101(85)90396-4; BURNETT JW, 1977, TOXICON, V15, P177, DOI 10.1016/0041-0101(77)90044-7; BURNETT JW, 1987, J AM ACAD DERMATOL, V17, P86, DOI 10.1016/S0190-9622(87)70177-7; BURNETT JW, 1986, J AM ACAD DERMATOL, V14, P100, DOI 10.1016/S0190-9622(86)70013-3; BURNETT JW, 1981, CUTIS, V27, P50; BURNETT JW, 1986, TOXICON, V24, P104, DOI 10.1016/0041-0101(86)90171-6; BURNETT JW, 1983, SOUTHERN MED J, V76, P870, DOI 10.1097/00007611-198307000-00013; BURNETT JW, 1987, CLIN DERMATOL, V5, P14, DOI 10.1016/S0738-081X(87)80004-4; BURNETT JW, 1992, RECENT ADV TOXINOLOG, V2, P333; CONNELLY M, 1981, FORT LAUDERDALE 0506, pB1; DEOREO GA, 1946, ARCH DERMATOL SYPH, V54, P637, DOI 10.1001/archderm.1946.01510410003001; Fisher A. A., 1978, ATLAS AQUATIC DERMAT; FREUDENTAL AR, 1991, REV INT OCEANOGRAPHI, P137; GAUR PK, 1981, P SOC EXP BIOL MED, V167, P374; Halstead B.W., 1988, POISONOUS VENOMOUS M; HARTMAN KR, 1980, INT ARCH ALLER A IMM, V61, P389, DOI 10.1159/000232466; Hessinger D.A., 1988, P333; HUNTER GW, 1963, AM J PUBLIC HEALTH N, V53, P1413, DOI 10.2105/AJPH.53.9.1413; HUTTON ROBERT F., 1952, BULL MARINE SCI GULF AND CARIBBEAN, V2, P346; LARSON RJ, 1992, MAR BIOL, V112, P229; MANSSON T, 1985, ACTA DERM-VENEREOL, V65, P72; MARATEC Z, 1963, J TROP MED HYG, V32, P891; MOSCHELLA SL, 1951, AMA ARCH DERM SYPH, V64, P55, DOI 10.1001/archderm.1951.01570070058010; OHTAKI N, 1990, Journal of Dermatology (Tokyo), V17, P108; ORTIZ-CORP'S E, 1987, Caribbean Journal of Science, V23, P432; ROTHMAN S, 1981, PALM BEACH POST 0506, pC2; SAMS WM, 1949, ARCH DERMATOL SYPH, V60, P227, DOI 10.1001/archderm.1949.01530020095013; STRAUSS JS, 1956, ARCH DERMATOL, V74, P293, DOI 10.1001/archderm.1956.01550090067013; THORINGTON GU, 1988, BIOL NEMATOCYSTS, P232; TOGIAS AG, 1985, J ALLERGY CLIN IMMUN, V75, P672, DOI 10.1016/0091-6749(85)90092-2; TOMCHIK RS, 1992, OCEAN LIFEGUARD, V4, P10; WACHSMAN M, 1991, TOXICON, V29, P386, DOI 10.1016/0041-0101(91)90294-2; WALKER MJA, 1988, HDB NATURAL TOXINS, V3; 1990, UNDERCURRENT, V15, P5	39	35	36	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1669	1672		10.1001/jama.269.13.1669	http://dx.doi.org/10.1001/jama.269.13.1669			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV349	8455301				2022-12-28	WOS:A1993KV34900032
J	PALEVSKY, PM; RENDULIC, D; DIVEN, WF				PALEVSKY, PM; RENDULIC, D; DIVEN, WF			MALTOSE-INDUCED HYPONATREMIA	ANNALS OF INTERNAL MEDICINE			English	Note						MALTOSE; HYPONATREMIA; IMMUNOGLOBULINS; INTRAVENOUS; KIDNEY FAILURE, ACUTE; HYPERTONICITY	HYPERGLYCEMIA	Although hyponatremia is usually indicative of hypotonicity, the accumulation in the plasma of high concentrations of glucose, mannitol, sorbitol, glycerol, or radiocontrast agents may lead to hyponatremia with hypertonicity. We describe a patient with renal failure in whom maltose intoxication, resulting from treatment with intravenous immune globulin, produced severe hyponatremia. During repeated infusions of intravenous immune globulin, the serum sodium concentration decreased in association with an increase in serum osmolality, a rising osmolal gap, and an accumulation of maltose in the blood. Maltose-containing intravenous solutions should be used with caution in patients with renal insufficiency; the development of hyponatremia during maltose infusion should suggest hypertonicity due to the accumulation of maltose.	VET AFFAIRS MED CTR, PITTSBURGH, PA USA; UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA 15261 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Palevsky, Paul M./Q-1491-2019	Palevsky, Paul M./0000-0002-7334-5400				ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; AVIRAM A, 1967, AM J MED, V42, P648, DOI 10.1016/0002-9343(67)90066-6; DEFRONZO RA, 1980, ARCH INTERN MED, V140, P897, DOI 10.1001/archinte.140.7.897; FUNKE C, 1977, NUTR METAB, V21, P115; KATZ MA, 1973, NEW ENGL J MED, V289, P843, DOI 10.1056/NEJM197310182891607; MORAN SM, 1985, WESTERN J MED, V142, P49; OCHS HD, 1980, LANCET, V2, P1158; SCHRIER RW, 1987, CLIN DISORDERS FLUID, P461; SILVERMAN M, 1973, J CLIN INVEST, V52, P2486, DOI 10.1172/JCI107439; TAHARA Y, 1990, AM J CLIN NUTR, V52, P689, DOI 10.1093/ajcn/52.4.689	10	37	37	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					526	528		10.7326/0003-4819-118-7-199304010-00007	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442623				2022-12-28	WOS:A1993KU07900007
J	POLLOCK, DA; ONEIL, JM; PARRISH, RG; COMBS, DL; ANNEST, JL				POLLOCK, DA; ONEIL, JM; PARRISH, RG; COMBS, DL; ANNEST, JL			TEMPORAL AND GEOGRAPHIC TRENDS IN THE AUTOPSY FREQUENCY OF BLUNT AND PENETRATING TRAUMA DEATHS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY ASSURANCE	Objective.-To examine national trends in the percentage of blunt and penetrating trauma deaths autopsied. Design, Setting,and Participants.-For each year from 1980 through 1989, we used national mortality data files to determine the autopsy frequency (percentage of deaths autopsied) of all deaths in the United States. We analyzed variation in the autopsy frequency of blunt and penetrating trauma deaths by cause of injury and place of occurrence of death. Results.-The autopsy frequency of blunt and penetrating trauma deaths in the United States increased by 14.3% during the 1980s to 58.9% in 1989 (62 004 of 105 309 deaths autopsied), while the autopsy frequency of all deaths decreased by 23.6% during the same period to 11.5% in 1989 (248 272 of 2 153 859 deaths autopsied). Among trauma deaths, homicides remained far more likely to be autopsied than nonhomicides (deaths due to unintentional injuries, suicides, and injuries of undetermined intentionality). The autopsy frequency of homicidal trauma deaths in 1989 was 90.0% or higher in 44 states and ranged from 79.6% in Mississippi to 100.0% in six states. The autopsy frequency of nonhomicidal trauma deaths in 1989 was 90.0% or higher in two states and ranged from 10.3% in Oklahoma to 94.5% in Hawaii. Nationwide, we found significant differences in the autopsy frequency of trauma deaths in 1989 between metropolitan and nonmetropolitan counties, both for homicides (97.7% vs 89.3%; P<.001) and nonhomicides (58.2% vs 29.9%; P<.001). Conclusions.-The percentage of blunt and penetrating trauma deaths autopsied has increased recently in the United States, but extensive geographic variation in autopsy frequency suggests that the benefits of autopsy findings for trauma care quality improvement and public health surveillance of injuries are distributed unevenly throughout the nation.	CTR DIS CONTROL & PREVENT, NATL CTR ENVIRONM HLTH, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	POLLOCK, DA (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INJURY PREVENT & CONTROL, 4770 BUFFORD HWY NE, MAIL STOP K-59, ATLANTA, GA 30341 USA.							ANGRIST A, 1962, JAMA-J AM MED ASSOC, V182, P929; BAKER SP, 1982, ACCIDENT ANAL PREV, V14, P199, DOI 10.1016/0001-4575(82)90030-6; BAKER SP, 1970, J AMER MED ASSOC, V214, P1079, DOI 10.1001/jama.214.6.1079; Combs D, 1990, DEATH INVESTIGATION; DIMAIO DJ, 1989, FORENSIC PATHOLOGY, P1; EASTMAN AB, 1992, ARCH SURG-CHICAGO, V127, P677; Fleiss JL, 1981, STATISTICAL METHODS, P19; FROEDE RC, 1990, HDB FORENSIC PATHOLO, P1; HANZLICK R, 1993, JAMA-J AM MED ASSOC, V269, P47; HILL RB, 1991, MILBANK Q, V69, P51, DOI 10.2307/3350121; HILL RB, 1988, AUTOPSY MED PRACTICE, P108; HIRSCH CS, 1984, ARCH PATHOL LAB MED, V108, P484; Jason D, 1980, Leg Med, P137; KIRCHER T, 1990, HUM PATHOL, V21, P166, DOI 10.1016/0046-8177(90)90125-O; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; LUNDBERG GD, 1984, ARCH PATHOL LAB MED, V108, P449; LUNDBERG GD, 1988, JAMA-J AM MED ASSOC, V260, P3488; LUNDSTROM M, 1991, PUBLIC WELFARE   SUM, P18; MORITZ AR, 1956, AM J CLIN PATHOL, V26, P1383; NEMETZ PN, 1987, AM J PATHOL, V128, P362; PETTY CS, 1980, MODERN LEGAL MED PSY, P51; Reichert C M, 1985, Health Aff (Millwood), V4, P82, DOI 10.1377/hlthaff.4.2.82; RIVARA FP, 1989, PUBLIC HEALTH REP, V104, P293; ROSENBERG HM, 1990, REPORT WORKSHOP IMPR, P1; SALADINO AJ, 1984, CLIN LAB MED, V4, P165, DOI 10.1016/S0272-2712(18)30947-8; SCHMIDT S, 1983, JAMA-J AM MED ASSOC, V250, P1161, DOI 10.1001/jama.250.9.1161; STOTHERT JC, 1990, J TRAUMA, V30, P1021, DOI 10.1097/00005373-199008000-00012; SVENDSEN E, 1987, ARCH PATHOL LAB MED, V111, P846; THAL E, 1990, J TRAUMA, V30, P1021; Trunkey D D, 1990, Bull Am Coll Surg, V75, P10; Trunkey DD, 1991, CURRENT THERAPY TRAU, P3; WETLI CV, 1988, PRACTICAL FORENSIC P, P1; Wright R K, 1981, Pathol Annu, V16, P273; WRIGHT RK, 1980, AM J FOREN MED PATH, V1, P57, DOI 10.1097/00000433-198003000-00009; 1987, JAMA-J AM MED ASSOC, V258, P364; 1990, RESOURCES OPTIMAL CA, P68; 1990, STAT ABSTR US 1990; 1992, 3RD NAT INJ CONTR C, P377; [No title captured]; 1990, NATIONAL INPATIENT P, P1049; 1991, FATAL ACCIDENT REPOR; 1985, PHS851102 DEP HLTH H; 1987, MMWR, V37, P191; 1989, OTAH445 OFF TECHN AS, P45	44	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1525	1531		10.1001/jama.269.12.1525	http://dx.doi.org/10.1001/jama.269.12.1525			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445815				2022-12-28	WOS:A1993KR80300025
J	BROMHAM, DR; CARTMILL, RSV				BROMHAM, DR; CARTMILL, RSV			KNOWLEDGE AND USE OF SECONDARY CONTRACEPTION AMONG PATIENTS REQUESTING TERMINATION OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article											BROMHAM, DR (corresponding author), ST JAMES UNIV HOSP,FERTIL CONTROL UNIT,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							BROOK SJ, 1991, BR J FAMILY PLANNING, V17, P18; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; Griffiths M, 1990, BRIT J FAM PLANN, V16, P16; MELVILLE AWT, 1992, MED AUDIT NEWS, V2, P130; 1992, EMERGENCY POSTCOITAL	5	46	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					556	557		10.1136/bmj.306.6877.556	http://dx.doi.org/10.1136/bmj.306.6877.556			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461770	Bronze, Green Published			2022-12-28	WOS:A1993KP88600022
J	MOSER, E; MATHIESEN, I; ANDERSEN, P				MOSER, E; MATHIESEN, I; ANDERSEN, P			ASSOCIATION BETWEEN BRAIN TEMPERATURE AND DENTATE FIELD POTENTIALS IN EXPLORING AND SWIMMING RATS	SCIENCE			English	Article							EXPLORATION-DEPENDENT MODULATION; EVOKED-RESPONSES; FASCIA-DENTATA; SLICES; MOTOR	Attempts to correlate behavioral learning with cellular changes, such as increased synaptic efficacy, have often relied on increased extracellular potentials as an index of enhanced synaptic strength. A recent example is the enlarged excitatory field potentials in the dentate gyrus of rats that are learning spatial relations by exploration. The altered hippocampal field potentials do not reflect learning-specific cellular changes but result from a concomitant rise in brain temperature that is caused by the associated muscular effort. Enhanced dentate field excitatory potentials followed both passive and active heating and were linearly related to the brain temperature. These temperature-related effects may mask any learning-induced changes in field potential.	UNIV OSLO,INST BASIC MED SCI,DEPT NEUROPHYSIOL,POST BOX 1104 BLINDERN,N-0317 OSLO,NORWAY	University of Oslo				Mathiesen, Iacob/0000-0003-0397-0742				ABRAMS R, 1965, AM J PHYSIOL, V208, P698, DOI 10.1152/ajplegacy.1965.208.4.698; ABRAMS R, 1964, AM J PHYSIOL, V206, P641, DOI 10.1152/ajplegacy.1964.206.3.641; ABRAMS R. M., 1965, LIFE SCI, V4, P2399, DOI 10.1016/0024-3205(65)90295-X; ANDERSEN P, 1960, ACTA PHYSIOL SCAND, V48, P209, DOI 10.1111/j.1748-1716.1960.tb01857.x; BAKER MA, 1982, ANNU REV PHYSIOL, V44, P85, DOI 10.1146/annurev.ph.44.030182.000505; BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; GORDON CJ, 1990, PHYSIOL BEHAV, V47, P963, DOI 10.1016/0031-9384(90)90025-Y; GREEN EJ, 1990, J NEUROSCI, V10, P1455; HARGREAVES EL, 1990, J NEUROSCI, V10, P1472; HODGKIN AL, 1949, J PHYSIOL-LONDON, V109, P240, DOI 10.1113/jphysiol.1949.sp004388; KATZ B, 1965, J PHYSIOL-LONDON, V181, P656, DOI 10.1113/jphysiol.1965.sp007790; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS R, 1984, NEUROPSYCHOLOGY MEMO, P521; O'Keefe J, 1979, HIPPOCAMPUS COGNITIV; SCHIFF SJ, 1985, BRAIN RES, V345, P279, DOI 10.1016/0006-8993(85)91004-2; Schoepfle GM, 1941, AM J PHYSIOL, V134, P0694, DOI 10.1152/ajplegacy.1941.134.4.694; SHARP PE, 1989, PSYCHOBIOLOGY, V17, P257, DOI 10.1007/BF03337777; SHEN KF, 1988, BRAIN RES, V475, P305, DOI 10.1016/0006-8993(88)90619-1; THOMPSON SM, 1985, J NEUROSCI, V5, P817	19	205	208	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1324	1326		10.1126/science.8446900	http://dx.doi.org/10.1126/science.8446900			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446900				2022-12-28	WOS:A1993KN88300031
J	DUNAWAY, M; OSTRANDER, EA				DUNAWAY, M; OSTRANDER, EA			LOCAL DOMAINS OF SUPERCOILING ACTIVATE A EUKARYOTIC PROMOTER INVIVO	NATURE			English	Article							TRANSCRIPTION FACTOR; XENOPUS-LAEVIS; DNA; GENE; ENHANCER; POLYMERASE; TEMPLATE; OOCYTES; PROTEIN	EXPERIMENTS Correlating template topology with transcriptional activity suggest that DNA topology plays a role in eukaryotic gene expression1-4. Linear templates transfected into cultured cells produce far fewer transcripts than do circular transcription templates3, and no transcripts can be detected from linear templates injected into Xenopus oocytes1,2. Further, when transcriptionally active circular templates in Xenopus oocytes are linearized by injection of a restriction enzyme, transcription dramatically decreases. Here we show that transcription by phage T7 RNA polymerase from a divergent promoter can partially replace the requirement for circular Xenopus ribosomal RNA transcription templates in Xenopus oocytes. Supercoiled domains can apparently be generated on short pieces of DNA having no known sequences that result in association with the nuclear architecture, suggesting that localized, transient domains of supercoiling fulfil the minimum topological needs for Xenopus rRNA transcription in vivo.	LAWRENCE BERKELEY LAB,CTR HUMAN GENOME,DEPT CELLULAR & MOLEC BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	DUNAWAY, M (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.			Ostrander, Elaine/0000-0001-6075-9738				CARROLL D, 1986, MOL CELL BIOL, V6, P2053, DOI 10.1128/MCB.6.6.2053; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; DUNAWAY M, 1989, GENE DEV, V3, P1768, DOI 10.1101/gad.3.11.1768; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HARLAND R, 1983, NATURE, V301, P38; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; LABHART P, 1984, CELL, V37, P285, DOI 10.1016/0092-8674(84)90324-6; LABHART P, 1985, NUCLEIC ACIDS RES, V13, P8999, DOI 10.1093/nar/13.24.8999; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; PRUITT SC, 1984, J MOL BIOL, V174, P121, DOI 10.1016/0022-2836(84)90368-1; SCHULTZ MC, 1992, GENE DEV, V6, P1332, DOI 10.1101/gad.6.7.1332; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WEINTRAUB H, 1986, CELL, V46, P115, DOI 10.1016/0092-8674(86)90865-2	18	85	85	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					746	748		10.1038/361746a0	http://dx.doi.org/10.1038/361746a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441472				2022-12-28	WOS:A1993KN78900063
J	FEEST, TG; ROUND, A; HAMAD, S				FEEST, TG; ROUND, A; HAMAD, S			INCIDENCE OF SEVERE ACUTE-RENAL-FAILURE IN ADULTS - RESULTS OF A COMMUNITY BASED STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REFERRALS	Objective-To determine the age related incidence of severe acute renal failure Design-Prospective study of patients identified as having severe acute renal failure within a two year period; subsequent monitoring of outcome for a further two years. Setting-Two health districts in Devon. Subjects-Those adults in a population of 444971 who developed severe acute renal failure (serum creatinine concentration >500 mumol/l) for the first time during two years, with subsequent fall of the serum creatinine concentration below the index value. Main outcome measures and results-125 adults (140 per million total population yearly, 172 per million adults) developed severe acute renal failure, of whom 90 (72%) were over 70. Age related incidence rose from 17 per million yearly in adults under 50 to 949 per million yearly in the 80-89 age goups. In 31 patients (25%) the cause was prostatic disease, which was related to a good prognosis (84% (26) alive at three months). Overall survival was 54% (67) at three months and 34% (42) at two years and was not significantly age related. 18 per million total population yearly (22 per million adult population) received acute dialysis. Referral rate for specialised opinion was 51 per million total population yearly with an estimated appropriate referral rate of 70 per million per year. Conclusions-The incidence of severe acute renal failure in the community is at least twice as high as the incidence reported from renal unit based studies. Prostatic disease, a preventable and treatable problem, is the most common cause. Survival figures indicate that age alone should not be a bar to specialist referral or treatment.	PLYMOUTH HLTH AUTHOR, PLYMOUTH, ENGLAND; ROYAL DEVON & EXETER HOSP, EXETER EX2 9DW, ENGLAND	University of Exeter	FEEST, TG (corresponding author), SOUTHMEAD GEN HOSP, RICHARD BRIGHT RENAL UNIT, BRISTOL BS10 5NB, AVON, ENGLAND.							ABRAHAM G, 1989, J TROP MED HYG, V92, P325; Boardman A P, 1988, Int J Soc Psychiatry, V34, P172, DOI 10.1177/002076408803400302; BUKTUS ED, 1983, ARCH INTERN MED, V143, P209; KAUFMAN J, 1991, AM J KIDNEY DIS, V17, P191, DOI 10.1016/S0272-6386(12)81128-0; KENNEDY AC, 1973, Q J MED, V42, P73; KERSSENS JJ, 1990, SOC SCI MED, V30, P797, DOI 10.1016/0277-9536(90)90203-5; KJELLSTRAND CM, 1981, T AM SOC ART INT ORG, V27, P45; LAMIERE N, 1987, NEPHROL DIAL TRANSPL, V2, P316; LAZARUS JM, 1988, INTENSIVE CARD MED, V12, P61; LOHR JW, 1988, AM J KIDNEY DIS, V11, P254, DOI 10.1016/S0272-6386(88)80158-6; OLIVER DO, 1987, OXFORD TXB MED, P136; RASMUSSEN HH, 1982, AM J MED, V73, P211, DOI 10.1016/0002-9343(82)90181-4; REYNOLDS GA, 1991, BMJ-BRIT MED J, V302, P1250, DOI 10.1136/bmj.302.6787.1250; SACKS SH, 1989, BRIT MED J, V298, P156, DOI 10.1136/bmj.298.6667.156; SWANN RC, 1953, MEDICINE, V32, P215, DOI 10.1097/00005792-195305000-00002; TURNEY JH, 1990, Q J MED, V74, P83; 1988, REPORT	17	206	211	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 20	1993	306	6876					481	483		10.1136/bmj.306.6876.481	http://dx.doi.org/10.1136/bmj.306.6876.481			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448456	Bronze, Green Published			2022-12-28	WOS:A1993KN78600015
J	EVANS, BG; CATCHPOLE, MA; HEPTONSTALL, J; MORTIMER, JY; MCCARRIGLE, CA; NICOLL, AG; WAIGHT, P; GILL, ON; SWAN, AV				EVANS, BG; CATCHPOLE, MA; HEPTONSTALL, J; MORTIMER, JY; MCCARRIGLE, CA; NICOLL, AG; WAIGHT, P; GILL, ON; SWAN, AV			SEXUALLY-TRANSMITTED DISEASES AND HIV-1 INFECTION AMONG HOMOSEXUAL MEN IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							RESURGENT GONORRHEA; RECTAL GONORRHEA; HEPATITIS-B; UNSAFE SEX; BEHAVIOR	Objective-To examine surveillance data for evidence of changing sexual behaviour and continuing transmission of HIV-1 among men who have sex with men. Design-Analytic study of surveillance data on sexually transmitted diseases. Setting-England and Wales. Main outcome measures-Number of cases of rectal gonorrhoea and newly diagnosed HIV infection in homosexual men. Results-New cases of gonorrhoea among men attending genitourinary medicine clinics increased by 7.7% in 1989 and by 4.2% in 1990. Reports of rectal isolates of Neisseria gonorrhoeae also rose and the male to female ratio for patients with rectal gonorrhoea changed from 0.3:1 during 1988-9 to 2.6:1 in 1990-1. Although the overall number of cases of acute hepatitis B fell during 1988-91, 81 and 82 homosexual men were infected in 1990 and 1991 respectively compared with 50 and 42 in 1988 and 1989. 1526 men had HIV-1 infection diagnosed in 1991, the largest number since 1987. Twenty eight of the 97 (29%) men who seroconverted between January 1989 and December 1991 were aged less than 25. The proportion of men aged 15-19 who were found to be infected with HIV-1 at their first test increased from an average of 2.4% up to 1990 to 4.7% in the first nine months of 1991. The prevalence of HIV infection in men under 25 attending genitourinary medicine clinics in London was 17% compared with 7.8% outside London. Conclusion-Unsafe sexual behaviour and HIV transmissions have increased among homosexual men after a period of decline. Recent HIV transmissions may disproportionately affect younger men.	COMMUNICABLE DIS SURVEILLANCE CTR,PUBL HLTH LAB SERV,STAT UNIT,LONDON NW9 5EQ,ENGLAND	Public Health England	EVANS, BG (corresponding author), COMMUNICABLE DIS SURVEILLANCE CTR,SERV AIDS CTR,DIV IMMUNISAT,PUBL HLTH LAB,LONDON NW9 5EQ,ENGLAND.		McGarrigle, Christine/J-8331-2017	McGarrigle, Christine/0000-0001-5814-5673				BHATTI N, 1991, BRIT MED J, V303, P97, DOI 10.1136/bmj.303.6794.97; FORSYTH JRL, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92382-R; HANDSFIELD HH, 1989, MMWR-MORBID MORTAL W, V38, P762; HUNT AJ, 1991, BRIT MED J, V302, P505, DOI 10.1136/bmj.302.6775.505; JOHNSON AM, 1989, PHILOS T ROY SOC B, V325, P153, DOI 10.1098/rstb.1989.0080; LAWRENCE AG, 1987, LANCET, V1, P982; LOKE RHT, 1989, BRIT MED J, V298, P234, DOI 10.1136/bmj.298.6668.234; NICOLL A, 1992, 1992 P INT C AIDS II; RILEY VC, 1991, LANCET, V337, P183, DOI 10.1016/0140-6736(91)90853-H; ROSS JDC, 1991, COMMUNICABLE DISEASE, V25, P3; SINGARATNAM AE, 1991, BRIT MED J, V302, P469, DOI 10.1136/bmj.302.6774.469-b; TOMLINSON DR, 1991, LANCET, V337, P501, DOI 10.1016/0140-6736(91)93447-H; VANDELAAR MJW, 1990, GENITOURIN MED, V66, P148; VANDENHOEK JAR, 1990, LANCET, V336, P179, DOI 10.1016/0140-6736(90)91700-K; Waight P A, 1992, Commun Dis Rep CDR Rev, V2, pR85; WAIGHT PA, 1991, BMJ-BRIT MED J, V303, P311, DOI 10.1136/bmj.303.6797.311; WAUGH MA, 1991, LANCET, V337, P375, DOI 10.1016/0140-6736(91)91017-O; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V76, P685; YOUNG H, 1991, LANCET, V337, P853, DOI 10.1016/0140-6736(91)92561-F; 1993, COMMUNICABLE DISEASE, V3, pR1; 1989, BMJ, V298, P422	21	60	60	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					426	428		10.1136/bmj.306.6875.426	http://dx.doi.org/10.1136/bmj.306.6875.426			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461723	Bronze, Green Published			2022-12-28	WOS:A1993KM70000020
J	TAN, SY; CUMMING, AD				TAN, SY; CUMMING, AD			VACCINE RELATED GLOMERULONEPHRITIS	BRITISH MEDICAL JOURNAL			English	Letter											TAN, SY (corresponding author), ROYAL EDINBURGH & ASSOC HOSP,MED RENAL UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							BISHOP WB, 1966, NEW ENGL J MED, V274, P616, DOI 10.1056/NEJM196603172741107; BOULTONJONES JM, 1974, BMJ-BRIT MED J, V3, P387, DOI 10.1136/bmj.3.5927.387; GIUDICELLI CP, 1983, PRESSE MED, V12, P1587; KUZEMKO JA, 1972, BRIT MED J, V4, P665, DOI 10.1136/bmj.4.5841.665-a; ROSENFELD J, 1983, BRIT MED J, V286, P938, DOI 10.1136/bmj.286.6369.938; SINGHAL PC, 1981, ANN ALLERGY, V46, P98	6	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					248	248		10.1136/bmj.306.6872.248-b	http://dx.doi.org/10.1136/bmj.306.6872.248-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443526	Green Published, Bronze			2022-12-28	WOS:A1993KJ59100023
J	HELLER, DA; DEFAIRE, U; PEDERSEN, NL; DAHLEN, G; MCCLEARN, GE				HELLER, DA; DEFAIRE, U; PEDERSEN, NL; DAHLEN, G; MCCLEARN, GE			GENETIC AND ENVIRONMENTAL-INFLUENCES ON SERUM-LIPID LEVELS IN TWINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; HIGH-DENSITY LIPOPROTEIN; BODY-MASS INDEX; REARED APART; RISK-FACTORS; CHOLESTEROL CONCENTRATIONS; CARDIOVASCULAR-DISEASE; PLASMA-LIPIDS; A-II; DETERMINANTS	Background. The extent to which serum lipid levels are affected by genetic and environmental tactors remains a point ot controversy. We examined both genetic and environmental influences on serum lipid levels in twins reared either together or apart who participated in the Swedish Adoption/Twin Study of Aging. Methods. We studied 302 pairs ot twins (mean age, 65.6 years; range, 52 to 86); 146 pairs had been reared apart. We simultaneously compared the twins on the basis ot both zygosity and rearing status, which allowed joint estimation of genetic and environmental influences on serum lipid levels. Genetic influence was expressed in terms of heritability, the proportion of the population variation attributable to genetic variation (a value of 1.0 indicates that all of the population variation is attributable to genetic variation). The serum lipids and apolipoproteins measured included total cholesterol, high-density lipoprotein cholesterol, apolipoproteins A-I and B, and triglycerides. Results. Structural-equation analyses revealed substantial heritability for the serum levels of each lipid measured, ranging from 0.28 to 0.78. Comparisons of the twins reared together with those reared apart suggested that the environment of rearing had a substantial impact on the level of total cholesterol (accounting for 0.15 to 0.36 of the total variance). Sharing the same environment appeared to affect the other lipid measures much less, however, than did genetic factors and unique environmental factors not shared by twins. Comparisons of younger with older twins suggested that heritability for apolipoprotein B and triglyceride levels decreased with age. Conclusions. The effect of genetic factors on the serum levels of some but not all lipids appears to decrease with age. Early rearing environment appears to remain an important factor in relation to levels of total cholesterol later in life, but it has less effect on other serum lipids and apolipoproteins in the elderly.	PENN STATE UNIV,COLL HLTH & HUMAN DEV,CTR DEV & HLTH GENET,UNIV PK,PA 16802; KAROLINSKA HOSP,DEPT MED,DIV CARDIOVASC MED,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,INST ENVIRONM MED,DEPT EPIDEMIOL,S-10401 STOCKHOLM 60,SWEDEN; UMEA UNIV HOSP,DEPT AEROSP & MECH ENGN,S-90185 UMEA,SWEDEN	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Umea University	HELLER, DA (corresponding author), PENN STATE UNIV,COLL HLTH & HUMAN DEV,PROGRAM BIOBEHAV HLTH,210 E HLTH & HUMAN DEV,UNIV PK,PA 16802, USA.				NATIONAL INSTITUTE ON AGING [R01AG004563] Funding Source: NIH RePORTER; NIA NIH HHS [AG-04563] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSTIN MA, 1987, AM J EPIDEMIOL, V125, P308, DOI 10.1093/oxfordjournals.aje.a114531; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BERG K, 1989, CLIN GENET, V36, P299; BOOMSMA DI, 1989, BEHAV GENET, V19, P3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUCHER KD, 1988, GENET EPIDEMIOL, V5, P17, DOI 10.1002/gepi.1370050103; CASTELLI WP, 1989, AM J CARDIOL, V63, pH12; CEDERLOF R, 1978, BIOL EPIDEMIOLOGY, V24, P189; DAHLEN G, 1983, INT J EPIDEMIOL, V12, P32, DOI 10.1093/ije/12.1.32; DALCOLLETTO GMD, 1981, HUM HERED, V31, P232; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; Falconer D. S., 1989, Introduction to quantitative genetics.; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; HAMSTEN A, 1986, ATHEROSCLEROSIS, V60, P199, DOI 10.1016/0021-9150(86)90166-8; HASSTEDT SJ, 1984, ATHEROSCLEROSIS, V51, P21, DOI 10.1016/0021-9150(84)90141-2; HAYAKAWA K, 1987, ATHEROSCLEROSIS, V66, P1, DOI 10.1016/0021-9150(87)90173-0; HO HZ, 1989, DEV PSYCHOL, V16, P340; HOPKINS PN, 1989, ANNU REV NUTR, V9, P303; HUNT SC, 1989, AM J EPIDEMIOL, V129, P625, DOI 10.1093/oxfordjournals.aje.a115175; ISELIUS L, 1985, ACTA MED SCAND, V217, P161; JINKS JL, 1970, PSYCHOL BULL, V73, P311, DOI 10.1037/h0029135; Joreskog K. G., 1989, LISREL 7 GUIDE PROGR; KANNEL WB, 1978, B NEW YORK ACAD MED, V54, P573; KUUSI T, 1987, ARTERIOSCLEROSIS, V7, P421, DOI 10.1161/01.ATV.7.4.421; MAHLEY RW, 1991, JAMA-J AM MED ASSOC, V265, P78, DOI 10.1001/jama.265.1.78; MCDONOUGH JR, 1962, CIRCULATION, V25, P962, DOI 10.1161/01.CIR.25.6.962; MCGUE M, 1984, BEHAV GENET, V14, P325, DOI 10.1007/BF01080045; NAMBOODIRI K K, 1985, Genetic Epidemiology, V2, P227, DOI 10.1002/gepi.1370020302; NEALE MC, 1989, BEHAV GENET, V19, P63, DOI 10.1007/BF01065884; OCONNELL DL, 1988, GENET EPIDEMIOL, V5, P323, DOI 10.1002/gepi.1370050504; OSBORNE RH, 1959, AM J MED, V26, P54, DOI 10.1016/0002-9343(59)90326-2; PEDERSEN NL, 1984, ACTA GENET MED GEMEL, V33, P243, DOI 10.1017/S0001566000007285; PEDERSEN NL, 1991, ACTA GENET MED GEMEL, V40, P7, DOI 10.1017/S0001566000006681; PEDERSEN NL, 1989, PSYCHOSOM MED, V51, P428, DOI 10.1097/00006842-198907000-00006; PERUSSE L, 1989, ARTERIOSCLEROSIS, V9, P308, DOI 10.1161/01.ATV.9.3.308; PLOMIN R, 1988, PSYCHOL AGING, V3, P43, DOI 10.1037/0882-7974.3.1.43; RAO DC, 1982, AM J HUM GENET, V34, P888; RICE T, 1991, HUM HERED, V41, P107, DOI 10.1159/000153987; RIFAI N, 1988, ANN CLIN LAB SCI, V18, P429; ROBERTS WC, 1987, AM J CARDIOL, V60, pE33; ROSE RJ, 1988, J PERS SOC PSYCHOL, V54, P161, DOI 10.1037/0022-3514.54.1.161; SEIGLER L, 1981, CLIN CHEM, V27, P838; SING CF, 1989, INT J EPIDEMIOL, V18, pS183; SISTONEN P, 1989, AM J HUM GENET, V32, P1; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; VOGEL F, 1989, HUMAN GENETICS; WEIDMANN P, 1988, DRUGS, V35, P118, DOI 10.2165/00003495-198800356-00017; WHITFIELD JB, 1983, ATHEROSCLEROSIS, V48, P265, DOI 10.1016/0021-9150(83)90044-8; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416; 1989, WORLD HLTH STATISTIC, P27; 1988, ARCH INTERN MED, V148, P36	52	382	392	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1150	1156		10.1056/NEJM199304223281603	http://dx.doi.org/10.1056/NEJM199304223281603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KY447	8455681	Bronze			2022-12-28	WOS:A1993KY44700003
J	HUNT, LW; SILVERSTEIN, MD; REED, CE; OCONNELL, EJ; OFALLON, WM; YUNGINGER, JW				HUNT, LW; SILVERSTEIN, MD; REED, CE; OCONNELL, EJ; OFALLON, WM; YUNGINGER, JW			ACCURACY OF THE DEATH CERTIFICATE IN A POPULATION-BASED STUDY OF ASTHMATIC-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-ZEALAND; MORTALITY; STATISTICS; AUTOPSY; INCREASE; ENGLAND; WALES	Objective.-To quantify the reliability of death certificate data concerning asthma. Design.-The complete medical records of decedents were reviewed by a physician certified in allergy and pulmonology who determined the cause of death without having access to the original death certificate. Disagreements between the death certificate and the reviewer were adjudicated by an expert panel. Setting.-The community of Rochester, Minn. Patients.-The mortality cohort included 339 deaths from a larger cohort of 5241 Rochester residents who received medical treatment for asthma between 1964 and 1983. Main Outcome Measures.-Kappa coefficients were used to measure agreement beyond that expected by chance between the reviewer and the death certificate. The sensitivity and specificity of the death certificate diagnosis of asthma were calculated against the standard of the reviewer/panel diagnosis. Results.-Death certificates reported asthma as an immediate or underlying cause of death in 22 instances (6%), whereas the reviewer/panel identified asthma in 53 cases (16%). In four cases, the death certificate listed asthma and the panel identified another cause of death. The death certificate had a sensitivity of 42% and a specificity of 99% compared with the reviewer/panel. Agreement between death certificates and the reviewer was not influenced by whether an autopsy was performed. Conclusions.-Death certificate diagnosis of asthma as an underlying cause of death had a low sensitivity but a high specificity. Increases in mortality due to asthma are not likely caused by false-positive diagnoses of asthma as an underlying cause of death. Asthma mortality rates, determined from death certificate data, may indeed underestimate actual asthma-related mortality.	MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	HUNT, LW (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-25187] Funding Source: Medline; NIAMS NIH HHS [AR-30582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1984, Thorax, V39, P505; BARGER LW, 1988, AM REV RESPIR DIS, V137, pA147; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURNEY PGJ, 1987, J ALLERGY CLIN IMMUN, V80, P379, DOI 10.1016/0091-6749(87)90054-6; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CARTER JR, 1985, NEW ENGL J MED, V313, P1285, DOI 10.1056/NEJM198511143132009; CHAMBLEE RF, 1982, AM J PUBLIC HEALTH, V72, P1265, DOI 10.2105/AJPH.72.11.1265; CURB JD, 1983, AM J EPIDEMIOL, V118, P122, DOI 10.1093/oxfordjournals.aje.a113613; EVANS R, 1987, J ALLERGY CLIN IMMUN, V80, P377, DOI 10.1016/0091-6749(87)90053-4; Fleiss JL, 1981, STAT METHODS RATES P; GOODMAN RA, 1987, JAMA-J AM MED ASSOC, V258, P3758; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; Janssen TA, 1940, AM J PUBLIC HEALTH N, V30, P871, DOI 10.2105/AJPH.30.8.871; KIRCHER T, 1987, JAMA-J AM MED ASSOC, V258, P349, DOI 10.1001/jama.258.3.349; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEITCH DGM, 1987, AUST NZ J MED, V17, P309, DOI 10.1111/j.1445-5994.1987.tb01234.x; LINDAHL BIB, 1985, J CHRON DIS, V38, P47, DOI 10.1016/0021-9681(85)90007-4; MODELMOG D, 1992, CANCER CAUSE CONTROL, V3, P541, DOI 10.1007/BF00052751; MORIYAMA IM, 1956, AM J PUBLIC HEALTH N, V46, P436, DOI 10.2105/AJPH.46.4.436; NEMETZ PN, 1989, MAYO CLIN PROC, V64, P1055, DOI 10.1016/S0025-6196(12)64974-X; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; PAULOZZI LJ, 1986, ANN ALLERGY, V56, P392; ROBERTS WC, 1978, NEW ENGL J MED, V299, P332, DOI 10.1056/NEJM197808172990704; Schade B, 1987, Scand J Prim Health Care, V5, P109, DOI 10.3109/02813438709013985; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P383, DOI 10.1016/0091-6749(87)90055-8; SIRKEN MG, 1987, AM J PUBLIC HEALTH, V77, P137, DOI 10.2105/AJPH.77.2.137; SLY RM, 1989, J ALLERGY CLIN IMMUN, V84, P421, DOI 10.1016/0091-6749(89)90351-5; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; ZUMWALT RE, 1987, POSTGRAD MED, V81, P245, DOI 10.1080/00325481.1987.11699876; ZUMWALT RE, 1987, POSTGRAD MED, V81, P253; ZUMWALT RE, 1987, POSTGRAD MED, V81, P250; 1987, PHYSICIANS HDB MED C; 1977, INT CLASSIFICATION D, P699	37	110	113	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1947	1952		10.1001/jama.269.15.1947	http://dx.doi.org/10.1001/jama.269.15.1947			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KX215	8464126				2022-12-28	WOS:A1993KX21500023
J	FU, YH; FRIEDMAN, DL; RICHARDS, S; PEARLMAN, JA; GIBBS, RA; PIZZUTI, A; ASHIZAWA, T; PERRYMAN, MB; SCARLATO, G; FENWICK, RG; CASKEY, CT				FU, YH; FRIEDMAN, DL; RICHARDS, S; PEARLMAN, JA; GIBBS, RA; PIZZUTI, A; ASHIZAWA, T; PERRYMAN, MB; SCARLATO, G; FENWICK, RG; CASKEY, CT			DECREASED EXPRESSION OF MYOTONIN PROTEIN-KINASE MESSENGER-RNA AND PROTEIN IN ADULT FORM OF MYOTONIC-DYSTROPHY	SCIENCE			English	Article							MUTATIONS; GENE	The myotonic dystrophy mutation has recently been identified; however, the molecular mechanism of the disease is still unknown. The sequence of the myotonin-protein kinase gene was determined, and messenger RNA spliced forms were identified in various tissues. Antisera were developed for analytical studies. Quantitative reverse transcription-polymerase chain reaction and radioimmunoassay were used to demonstrate that decreased levels of the messenger RNA and protein expression are associated with the adult form of myotonic dystrophy.	BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,CARDIOL SECT,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; VET ADM MED CTR,HOUSTON,TX 77030; UNIV MILAN,CTR DINO FERRARI,IST CLIN NEUROL,I-20122 MILAN,ITALY	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Milan				PIZZUTI, Antonio/0000-0003-3245-1925	NHGRI NIH HHS [P30-HG00210] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P30HG000210] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BRINKMEIER H, 1987, BIOCHEM BIOPH RES CO, V148, P1383, DOI 10.1016/S0006-291X(87)80285-1; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YL, UNPUB; Harper P.S., 1989, MYOTONIC DYSTROPHY; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937	12	307	317	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					235	238		10.1126/science.8469976	http://dx.doi.org/10.1126/science.8469976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8469976				2022-12-28	WOS:A1993KW45200045
J	OLIVIER, JP; RAABE, T; HENKEMEYER, M; DICKSON, B; MBAMALU, G; MARGOLIS, B; SCHLESSINGER, J; HAFEN, E; PAWSON, T				OLIVIER, JP; RAABE, T; HENKEMEYER, M; DICKSON, B; MBAMALU, G; MARGOLIS, B; SCHLESSINGER, J; HAFEN, E; PAWSON, T			A DROSOPHILA SH2-SH3 ADAPTER PROTEIN IMPLICATED IN COUPLING THE SEVENLESS TYROSINE KINASE TO AN ACTIVATOR OF RAS GUANINE-NUCLEOTIDE EXCHANGE, SOS	CELL			English	Article							ELEGANS VULVAR INDUCTION; EPIDERMAL GROWTH-FACTOR; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; NEURODEVELOPMENTAL PATHWAY; FUNCTIONS DOWNSTREAM; SIGNAL TRANSDUCTION; GENETIC DISSECTION; PHOSPHOLIPASE-C; VIRAL ONCOGENE	A Drosophila gene (drk) encodes a widely expressed protein with a single SH2 domain and two flanking SH3 domains, which is homologous to the Sem-5 protein of C. elegans and mammalian GRB2. Genetic analysis suggests that drk function is essential for signaling by the sevenless receptor tyrosine kinase. Drk biological activity correlates with binding of its SH2 domain to activated receptor tyrosine kinases and concomitant localization of drk to the plasma membrane. In vitro, drk also binds directly to the C-terminal tail of Sos, a Ras guanine nucleotide-releasing protein (GNRP), which, like Ras1 and drk, is required for sevenless signaling. These results suggest that drk binds autophosphorylated receptor tyrosine kinases with its SH2 domain and the Sos GNRP through its SH3 domains, thereby coupling receptor tyrosine kinases to Ras activation. The conservation of these signaling proteins during evolution indicates that this is a general mechanism for linking tyrosine kinases to Ras.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND; NYU MED CTR,KAPLAN CANC CTR,DEPT PHARMACOL,NEW YORK,NY 10016	University of Toronto; University of Zurich; New York University	OLIVIER, JP (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ONTARIO,CANADA.		Pawson, Tony J/E-4578-2013	Dickson, Barry/0000-0003-0715-892X; Henkemeyer, Mark/0000-0002-7525-1061				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BASLER K, 1988, CELL, V54, P299; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DICKSON B, 1992, DEV DROSOPHILA; DOYLE HJ, 1993, IN PRESS GENES DEV; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROGGE R, 1992, P NATL ACAD SCI USA, V89, P5271, DOI 10.1073/pnas.89.12.5271; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	73	522	542	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					179	191		10.1016/0092-8674(93)90170-U	http://dx.doi.org/10.1016/0092-8674(93)90170-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462098	Green Submitted			2022-12-28	WOS:A1993KW75300018
J	ASHTON, CM; PETERSEN, NJ; WRAY, NP; KIEFE, CI; DUNN, JK; WU, L; THOMAS, JM				ASHTON, CM; PETERSEN, NJ; WRAY, NP; KIEFE, CI; DUNN, JK; WU, L; THOMAS, JM			THE INCIDENCE OF PERIOPERATIVE MYOCARDIAL-INFARCTION IN MEN UNDERGOING NONCARDIAC SURGERY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; CORONARY DISEASE; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; ATHEROSCLEROSIS	PERIPHERAL VASCULAR-SURGERY; MB CREATINE-PHOSPHOKINASE; CORONARY-ARTERY DISEASE; CARDIAC RISK; SURGICAL PATIENTS; DIAGNOSIS; ANESTHESIA; MORTALITY; REINFARCTION; SPECIFICITY	Objectives: To determine the incidence of and risk factors for perioperative myocardial infarction with noncardiac surgery and to test the accuracy of a risk stratification system. Design: Prospective cohort study. Setting: A large urban Veterans Affairs hospital. Participants: A total of 1487 men older than 40 years undergoing major, nonemergent, noncardiac operations. Measurements: Infarction was established by at least two of the following: development of new Q waves, typical change in creatine kinase MB, and positive technetium pyrophosphate scintigraphy. Patients were stratified preoperatively into high-, intermediate-, low-, and negligible-risk strata based on clinical markers corresponding to different levels of coronary artery disease prevalence. Main Results: Patients with coronary disease (high-risk stratum) had a 4.1 % incidence of infarction (13 of 319; 95% Cl, 1.8% to 6.4%); patients with peripheral vascular disease but no evidence of coronary disease (intermediate-risk stratum) had a 0.8% incidence (2 of 260, upper bound of Cl, 2.0%); patients with high atherogenic risk factor profiles but no clinical atherosclerosis (low-risk stratum) had a 0% incidence (0 of 256, upper bound of Cl, 1.2%). No cardiac deaths occurred in 652 men who had no atherosclerosis and low atherogenic risk factor profiles (the negligible-risk stratum). Factors independently associated with infarction included age more than 75 years (adjusted odds ratio, 4.77; Cl, 1.17 to 19.41), signs of heart failure on the preoperative examination (adjusted odds ratio, 3.31; Cl, 0.96 to 11.38), coronary disease (adjusted odds ratio, 10.39; Cl, 2.27 to 47.46), and a planned vascular operation (adjusted odds ratio, 3.72; Cl, 1.12 to 12.37). Conclusions: Coronary artery disease is the major risk factor for perioperative infarction. The stratification scheme identifies subsets of patients with different risks, and finer within-stratum distinctions can be made using additional variables.			ASHTON, CM (corresponding author), VET AFFAIRS MED CTR, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							ASHTON CM, 1989, J AM GERIATR SOC, V37, P614, DOI 10.1111/j.1532-5415.1989.tb01251.x; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; DRISCOLL AC, 1961, NEW ENGL J MED, V264, P633, DOI 10.1056/NEJM196103302641302; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GORDON T, 1983, CORONARY RISK HDB ES; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; IRVIN RG, 1980, ARCH INTERN MED, V140, P329, DOI 10.1001/archinte.140.3.329; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; Knapp RB, 1962, JAMA-J AM MED ASSOC, V182, P106; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MAUNEY FM, 1970, ANN SURG, V172, P497, DOI 10.1097/00000658-197009000-00013; MORISE AP, 1987, AM J MED SCI, V293, P150, DOI 10.1097/00000441-198703000-00002; Prineas R., 1982, MINNESOTA CODE MANUA; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; RIGHETTI A, 1977, AM J CARDIOL, V39, P43, DOI 10.1016/S0002-9149(77)80009-X; RILES TS, 1979, SURGERY, V85, P249; ROBERTS R, 1975, AM J CARDIOL, V36, P433, DOI 10.1016/0002-9149(75)90890-5; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; SALEL AF, 1977, NEW ENGL J MED, V296, P1447, DOI 10.1056/NEJM197706232962507; SECKINGER DL, 1983, AM J CLIN PATHOL, V80, P164, DOI 10.1093/ajcp/80.2.164; STEEN PA, 1978, JAMA-J AM MED ASSOC, V239, P2566, DOI 10.1001/jama.239.24.2566; TARHAN S, 1972, J AMER MED ASSOC, V220, P1451, DOI 10.1001/jama.220.11.1451; UUSITUPA M, 1983, AM HEART J, V106, P753, DOI 10.1016/0002-8703(83)90099-6; VONKNORRING J, 1981, SURGERY, V90, P55; WHITTEMORE AD, 1980, ANN SURG, V192, P414, DOI 10.1097/00000658-198009000-00017	32	225	238	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					504	510		10.7326/0003-4819-118-7-199304010-00004	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442621				2022-12-28	WOS:A1993KU07900004
J	ROBBINS, LS; NADEAU, JH; JOHNSON, KR; KELLY, MA; ROSELLIREHFUSS, L; BAACK, E; MOUNTJOY, KG; CONE, RD				ROBBINS, LS; NADEAU, JH; JOHNSON, KR; KELLY, MA; ROSELLIREHFUSS, L; BAACK, E; MOUNTJOY, KG; CONE, RD			PIGMENTATION PHENOTYPES OF VARIANT EXTENSION LOCUS ALLELES RESULT FROM POINT MUTATIONS THAT ALTER MSH RECEPTOR FUNCTION	CELL			English	Article							MELANOCYTE-STIMULATING HORMONE; TYROSINASE ACTIVITY; ALPHA-MELANOTROPIN; CELLS; MOUSE; MICE; PEPTIDES; SEQUENCE; ASSAY; SITE	Coat colors in the chestnut horse, the yellow Labrador retriever, the red fox, and one type of yellow mouse are due to recessive alleles at the extension locus. Similarly, dominant alleles at this locus are often responsible for dark coat colors in mammals, such as the melanic form of the leopard, Panthera pardus. We show here that the murine extension locus encodes the melanocyte-stimulating hormone (MSH) receptor. In mice, the recessive yellow allele (e) results from a frameshift that produces a prematurely terminated, nonfunctioning receptor. The sombre (E(so) and E(so-3J)) and tobacco darkening (E(tob)) alleles, which both have dominant melanizing effects, result from point mutations that produce hyperactive MSH receptors. The E(so-3J) receptor is constitutively activated, while the E(tob) receptor remains hormone responsive and produces a greater activation of its effector, adenylyl cyclase, than does the wild-type allele.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; JACKSON LAB,BAR HARBOR,ME 04609	Oregon Health & Science University; Jackson Laboratory	ROBBINS, LS (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED,PORTLAND,OR 97201, USA.		Mountjoy, Kathy/L-4473-2019	Kelly, Michele/0000-0003-1799-055X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239, R01DK043859] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00189] Funding Source: Medline; NIDDK NIH HHS [R01 DK43859, P01A DK44239] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADALSTEINSSON S, 1987, J HERED, V78, P235, DOI 10.1093/oxfordjournals.jhered.a110373; BATEMAN N, 1961, J HERED, V52, P186, DOI 10.1093/oxfordjournals.jhered.a107062; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; BURCHILL SA, 1986, J ENDOCRINOL, V109, P15, DOI 10.1677/joe.0.1090015; CANNON JG, 1986, J IMMUNOL, V137, P2232; Chase HB, 1939, GENETICS, V24, P610; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CONE RD, 1993, IN PRESS NY ACAD SCI; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DEWIED D, 1982, PHYSIOL REV, V62, P977; EBERLE AN, 1988, MELANOTROPINS CHEM P; ELLERKMANN E, 1992, ENDOCRINOLOGY, V130, P133, DOI 10.1210/en.130.1.133; Falconer D, 1962, MOUSE NEWS LETT, V27, P30; GERST JE, 1988, ENDOCRINOLOGY, V123, P1792, DOI 10.1210/endo-123-4-1792; Geschwind I.I., 1972, Recent Progress Hormone Res, V28, P91; GESCHWIND II, 1966, ENDOCRINOLOGY, V79, P1165, DOI 10.1210/endo-79-6-1165; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GRUBER KA, 1989, AM J PHYSIOL, V257, pR681, DOI 10.1152/ajpregu.1989.257.4.R681; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HARRISON GA, 1973, J INVEST DERMATOL, V60, P418, DOI 10.1111/1523-1747.ep12702616; HAUSCHKA TS, 1968, J HERED, V59, P339, DOI 10.1093/oxfordjournals.jhered.a107738; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HOGANSON GE, 1989, SOMAT CELL MOLEC GEN, V15, P255, DOI 10.1007/BF01534876; HRUBY VJ, 1987, J MED CHEM, V30, P2126, DOI 10.1021/jm00394a033; Ibsen HL, 1919, GENETICS, V4, P597; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; LAMOREUX ML, 1975, DEV BIOL, V46, P160, DOI 10.1016/0012-1606(75)90094-9; LERNER AB, 1961, NATURE, V189, P176, DOI 10.1038/189176a0; LIN SY, 1987, HYPERTENSION, V10, P619, DOI 10.1161/01.HYP.10.6.619; Little CC, 1957, INHERITANCE COAT COL, P49; MCGOVERN VJ, 1982, J CUTAN PATHOL, V9, P61, DOI 10.1111/j.1600-0560.1982.tb01044.x; MCGOVERN VJ, 1973, CANCER, V32, P1446, DOI 10.1002/1097-0142(197312)32:6<1446::AID-CNCR2820320623>3.0.CO;2-8; MEREDITH R, 1971, MOUSE NEWS LETT, V45, P31; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; PAWELEK JM, 1976, J INVEST DERMATOL, V66, P201, DOI 10.1111/1523-1747.ep12482134; PUNNETT RC, 1924, J GENET, V14, P230; REED TE, 1952, ANN EUGENIC, V17, P115; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Searle A.G., 1968, COMP GENETICS COAT C; SEARLE AG, 1968, J HERED, V59, P341, DOI 10.1093/oxfordjournals.jhered.a107739; SEARLE AG, 1970, MOUSE NEWS LETT, V42, P27; SELSTED ME, 1985, J BIOL CHEM, V260, P4579; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; SOLCA F, 1989, J BIOL CHEM, V264, P14277; SPONENBERG DP, 1987, J HERED, V78, P406, DOI 10.1093/oxfordjournals.jhered.a110430; STERN C, 1970, HUM HERED, V20, P165, DOI 10.1159/000152305; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRAND FL, 1980, PEPTIDES, V1, P135, DOI 10.1016/0196-9781(80)90077-7; TAKEUCHI T, 1989, SOC INVEST DERMATO S, V92, P239; TAMATE HB, 1984, SCIENCE, V224, P1241, DOI 10.1126/science.6328651; TAMATE HB, 1981, DEV GENET, V2, P349, DOI 10.1002/dvg.1020020404; TAMINAGA T, 1990, J ENDOCRINOL, V125, P287; TEMPLETON JW, 1977, J HERED, V68, P134, DOI 10.1093/oxfordjournals.jhered.a108792; VONLEHMANN E, 1973, MOUSE NEWS LETT, V48, P23; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; YASUMURA Y, 1966, SCIENCE, V154, P1186, DOI 10.1126/science.154.3753.1186; ZHU QZ, 1992, ENDOCRINOLOGY, V130, P1413, DOI 10.1210/en.130.3.1413	64	753	795	1	63	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					827	834		10.1016/0092-8674(93)90572-8	http://dx.doi.org/10.1016/0092-8674(93)90572-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458079				2022-12-28	WOS:A1993KU17500004
J	WHITEHEART, SW; GRIFF, IC; BRUNNER, M; CLARY, DO; MAYER, T; BUHROW, SA; ROTHMAN, JE				WHITEHEART, SW; GRIFF, IC; BRUNNER, M; CLARY, DO; MAYER, T; BUHROW, SA; ROTHMAN, JE			SNAP FAMILY OF NSF ATTACHMENT PROTEINS INCLUDES A BRAIN-SPECIFIC ISOFORM	NATURE			English	Article							SENSITIVE FUSION PROTEIN; VESICULAR TRANSPORT; REQUIRES; PURIFICATION; RECEPTOR	THE soluble NSF attachment proteins (SNAPs) enable N-ethyl-maleimide-sensitive fusion protein (NSF) to bind to target membranes1-3. Here we report the cloning and sequencing of complementary DNAs encoding alpha-, beta- and gamma-SNAPs. Two of these proteins, alpha and gamma, are found in a wide range of tissues, and act synergistically in intra-Golgi transport. The third, beta, is a brain-specific isoform of alpha-SNAP. Thus, NSF and SNAPs appear to be general components of the intracellular membrane fusion apparatus, and their action at specific sites of fusion must be controlled by SNAP receptors particular to the membranes being fused, as described in the accompanying article4.			WHITEHEART, SW (corresponding author), MEM SLOAN KETTERING CANC CTR,ROCKEFELLER RES LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.			Whiteheart, Sidney/0000-0001-5577-0473; Mayer, Thomas/0000-0001-6954-2287; Brunner, Michael/0000-0001-9798-3047				BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; LUPAS A, 1991, SCIENCE, V252, P1163; SMITH TF, 1981, APPL MATH, V2, P488; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SZTUL E, 1993, J BIOL CHEM, V268, P1876; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	14	236	244	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					353	355		10.1038/362353a0	http://dx.doi.org/10.1038/362353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455721				2022-12-28	WOS:A1993KU17600064
J	GALYOV, EE; HAKANSSON, S; FORSBERG, A; WOLFWATZ, H				GALYOV, EE; HAKANSSON, S; FORSBERG, A; WOLFWATZ, H			A SECRETED PROTEIN-KINASE OF YERSINIA-PSEUDOTUBERCULOSIS IS AN INDISPENSABLE VIRULENCE DETERMINANT	NATURE			English	Article							OUTER-MEMBRANE PROTEINS; YOP2B PROTEIN; CALCIUM; TRANSCRIPTION; TEMPERATURE; EXPRESSION; GENES; LEVEL	PHOSPHORYLATION of proteins catalysed by protein kinases is associated with central functions in growth and proliferation of the eukaryotic cell, and kinases are particularly important in the signal transduction pathways1,2. Enterobacterial protein kinases are structurally and functionally different from eukaryotic protein kinases3,4, and no prokaryotic kinase has so far been described implicating a direct role for this activity in virulence. Virulent Yersinia possess a common virulence plasmid that encodes a number of secreted proteins (Yops)5-7, of which YopH has protein-tyrosine phosphatase activity with a key function in the block of phagocytosis by the pathogen8-10. Here we report that the virulence plasmid of Yersinia pseudotuberculosis encodes a secreted protein kinase (YpkA) with extensive homology to eukaryotic Ser/Thr protein kinases3,11. Specific mutants of ypkA resulted in avirulent strains. Thus, YpkA is, to our knowledge, the first reported prokaryotic secreted protein kinase involved in pathogenicity, presumably by interfering with the signal transduction pathways of the target cell.	UMEA UNIV,DEPT CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN; NATL DEF RES ESTAB,DEPT MICROBIOL,S-90182 UMEA,SWEDEN	Umea University			Hakansson, Sebastian/B-1048-2008	Galyov, Edouard/0000-0003-2609-0748				BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BOLIN I, 1985, INFECT IMMUN, V48, P234; CLEMENS JC, 1991, MOL MICROBIOL, V5, P2617, DOI 10.1111/j.1365-2958.1991.tb01970.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CORNELIS G, 1987, MICROB PATHOGENESIS, V2, P367, DOI 10.1016/0882-4010(87)90078-7; COZZONE AJ, 1988, ANNU REV MICROBIOL, V42, P97, DOI 10.1146/annurev.mi.42.100188.000525; FORSBERG A, 1987, MICROB PATHOGENESIS, V2, P123, DOI 10.1016/0882-4010(87)90104-5; FORSBERG A, 1991, MOL MICROBIOL, V5, P977, DOI 10.1111/j.1365-2958.1991.tb00773.x; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; LEUNG KY, 1990, INFECT IMMUN, V58, P3262, DOI 10.1128/IAI.58.10.3262-3271.1990; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RIMPILAINEN M, 1992, J BACTERIOL, V174, P3355, DOI 10.1128/jb.174.10.3355-3363.1992; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; ROSQVIST R, 1990, MOL MICROBIOL, V4, P657, DOI 10.1111/j.1365-2958.1990.tb00635.x; STRALEY SC, 1986, INFECT IMMUN, V51, P445, DOI 10.1128/IAI.51.2.445-454.1986	20	267	271	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					730	732		10.1038/361730a0	http://dx.doi.org/10.1038/361730a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441468				2022-12-28	WOS:A1993KN78900058
J	STJOHN, DJB; MCDERMOTT, FT; HOPPER, JL; DEBNEY, EA; JOHNSON, WR; HUGHES, ESR				STJOHN, DJB; MCDERMOTT, FT; HOPPER, JL; DEBNEY, EA; JOHNSON, WR; HUGHES, ESR			CANCER RISK IN RELATIVES OF PATIENTS WITH COMMON COLORECTAL-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						COLORECTAL NEOPLASMS; OCCULT BLOOD; MASS SCREENING; HEREDITARY DISEASES; PREVENTIVE HEALTH SERVICES	LONG-TERM SURVIVAL; FAMILY HISTORY; OCCULT BLOOD; COLON CANCER; ULCERATIVE-COLITIS; LARGE BOWEL; SCREENING-PROGRAM; CONTROLLED TRIAL; ONE SURGEON; CARCINOMA	Objective: To quantify any risk for colorectal cancer in first-degree relatives of patients with common colorectal cancer and to define possible markers for increased risk. Design: Case-control family study. Patients: Relatives of colorectal cancer patients and of matched control patients from a one-surgeon practice. Methods: Family medical histories were obtained for 7493 first-degree relatives and 1015 spouses of 523 case-control pairs. Reported diagnoses of colorectal cancer in relatives were verified in 79% of instances. Results: By case-control analysis, the odds ratio was 1.8 (95% CI, 1.2 to 2.7) for one and 5.7 (CI, 1.7 to 19.3) for two affected relatives. By matched analysis of risk in relatives, the increased risk to parents and siblings was 2.1 times greater for case patients than for control patients (CI, 1.4 to 3.1); 3.7 times greater (CI, 1.5 to 9.1 ) with case patients diagnosed before 45; and 1.8 times greater (CI, 1.2 to 2.9) with case patients diagnosed at 45 years or older; and was independent of gender, type of relative, site of cancer, and type of cancer (single or multiple). The cumulative incidence, among first-degree relatives was greater for case patients than for control patients (P < 0.001), and in case patients, greater for those diagnosed before 55 years of age (P < 0.001). The cumulative incidence (+/- S.E.) to age 80 was 11.1% +/- 1.3%, 7.3% +/- 0.8%, and 4.4% +/-1.0% among relatives of case patients diagnosed before age 45 years, between 45 and 54 years, and at 55 years or older, respectively, and was 2.4% +/- 0.6% in relatives of control patients. Conclusions: First-degree relatives of patients with common colorectal cancer have an increased risk for colorectal cancer. This risk is greater if diagnosis was at an early age and is greater when other first-degree relatives are affected. This increased risk should be considered when formulating screening strategies.	ALFRED HOSP,MELBOURNE,AUSTRALIA	Florey Institute of Neuroscience & Mental Health	STJOHN, DJB (corresponding author), ROYAL MELBOURNE HOSP,DEPT GASTROENTEROL,RMH PO,PARKVILLE,VIC 3050,AUSTRALIA.							ANDERSON DE, 1974, CANCER, V34, P1090, DOI 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J; ANDERSON DE, 1977, GENETICS HUMAN CANCE, P257; BEDENNE L, 1990, GASTROEN CLIN BIOL, V14, P140; BONELLI L, 1988, INT J CANCER, V41, P513; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; BURT RW, 1990, B WORLD HEALTH ORGAN, V68, P655; CANNONALBRIGHT LA, 1989, CANCER, V64, P1971, DOI 10.1002/1097-0142(19891101)64:9<1971::AID-CNCR2820640935>3.0.CO;2-L; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; DAVIES OL, 1980, STATISTICAL METHODS, V1; DELEON MP, 1987, CANCER, V60, P2848, DOI 10.1002/1097-0142(19871201)60:11<2848::AID-CNCR2820601141>3.0.CO;2-F; DUNCAN JL, 1982, GUT, V23, P169, DOI 10.1136/gut.23.2.169; FISHER G, 1989, MED J AUSTRALIA, V150, P22, DOI 10.5694/j.1326-5377.1989.tb136314.x; FLEHINGER BJ, 1988, SCREENING GASTROINTE, P9; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GILBERTSEN VA, 1980, CANCER, V45, P2899, DOI 10.1002/1097-0142(19800601)45:11<2899::AID-CNCR2820451132>3.0.CO;2-M; GROSSMAN S, 1988, GASTROENTEROLOGY, V94, P395, DOI 10.1016/0016-5085(88)90427-1; GUILLEM JG, 1988, AM J GASTROENTEROL, V83, P271; HARDCASTLE JD, 1989, LANCET, V1, P1160; HOPPER JL, 1992, AM J EPIDEMIOL, V136, P1138, DOI 10.1093/oxfordjournals.aje.a116580; INK O, 1989, GASTROEN CLIN BIOL, V13, P1060; JARVINEN HJ, 1989, SCAND J GASTROENTERO, V24, P1153, DOI 10.3109/00365528909090780; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KRONBORG O, 1989, SCAND J GASTROENTERO, V24, P599, DOI 10.3109/00365528909093096; KUNE GA, 1989, WORLD J SURG, V13, P124, DOI 10.1007/BF01671173; LENNARDJONES JE, 1990, GUT, V31, P800, DOI 10.1136/gut.31.7.800; LIANG KY, 1986, AM J EPIDEMIOL, V124, P678, DOI 10.1093/oxfordjournals.aje.a114441; LOFBERG R, 1990, GASTROENTEROLOGY, V99, P1021; LOVE RR, 1985, J CHRON DIS, V38, P289, DOI 10.1016/0021-9681(85)90074-8; LOVETT E, 1976, BRIT J SURG, V63, P13, DOI 10.1002/bjs.1800630103; Lynch H T, 1979, Front Gastrointest Res, V4, P142; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; MACKLIN MT, 1960, J NATL CANCER I, V24, P551, DOI 10.1093/jnci/24.3.551; MAIRE P, 1984, GASTROEN CLIN BIOL, V8, P22; MCCONNELL JC, 1990, DIS COLON RECTUM, V33, P105, DOI 10.1007/BF02055536; MECKLIN JP, 1992, CANCER, V69, P1112; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; PIHL E, 1980, ANN SURG, V192, P114, DOI 10.1097/00000658-198007000-00020; PIHL E, 1980, CANCER, V45, P2902, DOI 10.1002/1097-0142(19800601)45:11<2902::AID-CNCR2820451133>3.0.CO;2-9; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; ROZEN P, 1981, CANCER, V47, P827, DOI 10.1002/1097-0142(19810215)47:4<827::AID-CNCR2820470434>3.0.CO;2-Y; ROZEN P, 1987, CANCER, V60, P248, DOI 10.1002/1097-0142(19870715)60:2<248::AID-CNCR2820600223>3.0.CO;2-G; SONDERGAARD JO, 1991, INT J CANCER, V47, P202, DOI 10.1002/ijc.2910470207; SUSSER E, 1989, AM J EPIDEMIOL, V129, P23, DOI 10.1093/oxfordjournals.aje.a115119; VOBECKY J, 1983, CANCER, V51, P1958, DOI 10.1002/1097-0142(19830515)51:10<1958::AID-CNCR2820511036>3.0.CO;2-W; WINAWER SJ, 1990, B WORLD HEALTH ORGAN, V68, P505; WINAWER SJ, 1991, CANCER, V67, P1143, DOI 10.1002/1097-0142(19910215)67:4+<1143::AID-CNCR2820671507>3.0.CO;2-D; WOOLF CM, 1958, AM J HUM GENET, V10, P42	48	300	300	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					785	790		10.7326/0003-4819-118-10-199305150-00005	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	8470852				2022-12-28	WOS:A1993LB64900005
J	MANDEL, JS; BOND, JH; CHURCH, TR; SNOVER, DC; BRADLEY, GM; SCHUMAN, LM; EDERER, F				MANDEL, JS; BOND, JH; CHURCH, TR; SNOVER, DC; BRADLEY, GM; SCHUMAN, LM; EDERER, F			REDUCING MORTALITY FROM COLORECTAL-CANCER BY SCREENING FOR FECAL OCCULT BLOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; DENMARK; FUNEN	Background. Although tests for occult blood in the feces are widely used to screen for colorectal cancers, there is no conclusive evidence that they reduce mortality from this cause. We evaluated a fecal occult-blood test in a randomized trial and documented its effectiveness. Methods. We randomly assigned 46,551 participants 50 to 80 years of age to screening for colorectal cancer once a year, to screening every two years, or to a control group. Participants who were screened submitted six guaiac-impregnated paper slides with two smears from each of three consecutive stools. About 83 percent of the slides were rehydrated. Participants who tested positive underwent a diagnostic evaluation that included colonoscopy. Vital status was ascertained for all participants over 13 years of follow-up. A committee determined causes of death. A single pathologist determined the stage of cancer for each tissue specimen. Differences in mortality from colorectal cancer, the primary study end point, were monitored with the sequential log-rank statistic. Results. The 13-year cumulative mortality per 1000 from colorectal cancer was 5.88 in the annually screened group (95 percent confidence interval, 4.61 to 7.15), 8.33 in the biennially screened group (95 percent confidence interval, 6.82 to 9.84), and 8.83 in the control group (95 percent confidence interval, 7.26 to 10.40). The rate in the annually screened group, but not in the biennially screened group, was significantly lower than that in the control group. Reduced mortality in the annually screened group was accompanied by improved survival in those with colorectal cancer and a shift to detection at an earlier stage of cancer. Conclusions. Annual fecal occult-blood testing with rehydration of the samples decreased the 13-year cumulative mortality from colorectal cancer by 33 percent.	UNIV MINNESOTA,SCH PUBL HLTH,DEPT EPIDEMIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH PUBL HLTH,DEPT BIOSTAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; EMMES CORP,POTOMAC,MD	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Emmes Corporation	MANDEL, JS (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV ENVIRONM & OCCUPAT HLTH,BOX 807 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.		Church, Timothy/AAH-7017-2020	Church, Timothy/0000-0003-3292-5035	NCI NIH HHS [N01-CB-95613, N01-CB-61005, N01-CB-53862] Funding Source: Medline; DIVISION OF CANCER BIOLOGY AND DIAGNOSIS [N01CB061005, N01CB095613, N01CB053862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER BIOLOGY AND DIAGNOSIS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1989, SAS STAT USERS GUIDE, V2; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; CHURCH TR, 1993, AM J EPIDEMIOL, V137, P797, DOI 10.1093/oxfordjournals.aje.a116740; CHURCH TR, 1991, CANC SCREENING, P83; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER S J, 1958, J Chronic Dis, V8, P699, DOI 10.1016/0021-9681(58)90126-7; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; EDERER F, 1993, AM J EPIDEMIOL, V137, P787, DOI 10.1093/oxfordjournals.aje.a116739; GILBERTSEN VA, 1980, J CHRON DIS, V33, P107, DOI 10.1016/0021-9681(80)90034-X; GILBERTSEN VA, 1979, SURG GYNECOL OBSTET, V149, P877; GILLILAND F, 1991, THESIS U MINNESOTA M; HARDCASTLE JD, 1989, LANCET, V1, P1160; HARDCASTLE JD, 1983, LANCET, V2, P1; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KEWENTER J, 1991, CANCER SCREENING, P117; KIN K, 1987, BIOMETRICS, V43, P857; KLAABORG K, 1986, SCAND J GASTROENTERO, V21, P1180, DOI 10.3109/00365528608996440; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; KRONBORG O, 1989, SCAND J GASTROENTERO, V24, P599, DOI 10.3109/00365528909093096; KRONBORG O, 1992, SCAND J GASTROENTERO, V27, P47, DOI 10.3109/00365529209011166; LAN KKG, 1988, BIOMETRICS, V44, P579, DOI 10.2307/2531870; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MANDEL JS, 1988, SCREENING GASTROINTE, P17; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; Turnbull R B Jr, 1970, Ann R Coll Surg Engl, V46, P243; WEISBURGER JH, 1991, SEMIN ONCOL, V18, P316; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243; 1967, PHS PUBLICATION, V1693	28	2600	2682	1	77	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1993	328	19					1365	1371		10.1056/NEJM199305133281901	http://dx.doi.org/10.1056/NEJM199305133281901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB495	8474513				2022-12-28	WOS:A1993LB49500001
J	FIGUEROA, M; GEHLSEN, J; HAMMOND, D; ONDREYCO, S; PIRO, L; POMEROY, T; WILLIAMS, F; MCMILLAN, R				FIGUEROA, M; GEHLSEN, J; HAMMOND, D; ONDREYCO, S; PIRO, L; POMEROY, T; WILLIAMS, F; MCMILLAN, R			COMBINATION CHEMOTHERAPY IN REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; THERAPY; LEUKEMIA; ITP	Background. Chronic idiopathic thrombocytopenic purpura is a destructive thrombocytopenia caused by an autoantibody. About 80 percent of patients with chronic idiopathic thrombocytopenic purpura have remissions after either corticosteroid therapy or splenectomy. Some patients with resistant disease respond to other agents, but a substantial group are refractory to therapy. Methods. We used combination chemotherapy to treat 10 patients with refractory immune thrombocytopenia. An average of 6.8 (range, 3 to 10) previous therapies, including corticosteroids and splenectomy, had been unsuccessful in these patients. The patients received from three to eight cycles of therapy consisting of cyclophosphamide and prednisone combined with either vincristine (one patient), vincristine and procarbazine (four patients), or etoposide (six patients, including one patient who received four cycles each containing procarbazine and etoposide) Results. Among the 10 patients, 6 had complete responses (platelet count, >180,000 per cubic millimeter); of these, 4 patients had responses that persisted for more than 11, 30, 54, or 126 months, 1 had a relapse 9 months after therapy but had a remission with further therapy and remained in remission for 48 months before dying of an unrelated illness, and another relapsed just before her fifth course of therapy. Two patients had partial responses (platelet count, >50,000 per cubic millimeter); the platelet counts in one remained stable for more than nine months after the end of therapy, and the other patient relapsed. The remaining two patients had no response. Complete responses were associated with a disappearance or marked decrease in the level of platelet-associated auto-antibody. Conclusions. Combination chemotherapy is beneficial in some patients in whom immune thrombocytopenia is refractory to corticosteroids and splenectomy.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037945] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NHLBI NIH HHS [HL37945] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN YS, 1977, ANNU REV MED, V28, P299, DOI 10.1146/annurev.me.28.020177.001503; ANDERSON T, 1977, CANCER TREAT REP, V61, P1057; BERCHTOLD P, 1989, BLOOD, V74, P2309; CHAO NJ, 1990, BLOOD, V76, P1293; COLEMAN CN, 1989, CANCER PRINCIPLES PR, V2, P2181; DENOTTOLANDER GJ, 1984, SCAND J HAEMATOL, V32, P101; DIFINO SM, 1980, AM J MED, V69, P430, DOI 10.1016/0002-9343(80)90016-9; FISHER RI, 1992, P AN M AM SOC CLIN, V11, P315; JACOBS P, 1986, Q J MED, V58, P153; JIJI RM, 1973, ARCH INTERN MED, V132, P380, DOI 10.1001/archinte.132.3.380; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KELTON JG, 1982, SEMIN THROMB HEMOST, V8, P83, DOI 10.1055/s-2007-1005045; LIGHTSEY AL, 1975, JAMA-J AM MED ASSOC, V232, P734, DOI 10.1001/jama.232.7.734; MCMILLAN R, 1981, NEW ENGL J MED, V304, P1135, DOI 10.1056/NEJM198105073041904; MCMILLAN R, 1987, BLOOD, V70, P1040; PICOZZI VJ, 1980, AM J MED, V69, P690, DOI 10.1016/0002-9343(80)90419-2; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RODGERS GM, 1980, ANN INTERN MED, V92, P713; ROSSE WF, 1983, CLIN HAEMATOL, V12, P267	20	105	108	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1226	1229		10.1056/NEJM199304293281703	http://dx.doi.org/10.1056/NEJM199304293281703			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464433				2022-12-28	WOS:A1993KZ06100003
J	NOVACK, DH; VOLK, G; DROSSMAN, DA; LIPKIN, M				NOVACK, DH; VOLK, G; DROSSMAN, DA; LIPKIN, M			MEDICAL INTERVIEWING AND INTERPERSONAL SKILLS TEACHING IN UNITED-STATES MEDICAL-SCHOOLS - PROGRESS, PROBLEMS, AND PROMISE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HISTORY-TAKING SKILLS; STUDENTS; COMMUNICATION; PHYSICIAN; FEEDBACK; DOCTORS; SYSTEM	Objective.-To assess educational practices, problems, and needs in the teaching of medical interviewing and interpersonal skills. Design.-Questionnaires sent to curricular deans and introductory course leaders at all US medical schools in 1991. Results.-Of 130 programs, 114 deans (88%) and 92 course directors (71%) responded. Respondents indicated some advances since a similar survey in 1977: Virtually all medical schools now offer teaching in medical interviewing and interpersonal skills. More faculty from a greater variety of disciplines are involved in this teaching. Most programs feature observation and feedback of students' interviews with patients, and use a variety of effective teaching methods, including simulated patients and role-playing, both little used in 1977. The majority of schools address students' personal growth through discussion or support groups. However, there are problems. Most schools lack a faculty development process. About half of the introductory courses on medical interviewing take place within physical diagnosis courses, often, it appears, without systematic observation, feedback, and evaluation of student skills. Many programs do not explicitly incorporate certain educational principles into their course designs. As in 1977, there appears to be little coordination or sequencing of teaching interpersonal skills throughout the curriculum in most medical schools. Most deans identified significant barriers to improving teaching. Conclusions.-While a number of educational advances have occurred there is still great variation in the quality and intensity of courses offered in US medical schools. However, the pace of progress bodes well for the future.	UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY 14642 USA; UNIV N CAROLINA, SCH MED, DIV DIGEST DIS & NUTR, CHAPEL HILL, NC 27514 USA; UNIV MARYLAND, MED CTR, DIV PRIMARY CARE, BALTIMORE, MD 21201 USA; AMER ACAD PHYSICIAN & PATIENT, BALTIMORE, MD USA	University of Rochester; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University System of Maryland; University of Maryland Baltimore	NOVACK, DH (corresponding author), BROWN UNIV, RHODE ISL HOSP, SCH MED, DIV GEN INTERNAL MED, 593 EDDY ST, PROVIDENCE, RI 02903 USA.		Guntinas-Lichius, Orlando/L-1871-2016	Guntinas-Lichius, Orlando/0000-0001-9671-0784				Balint M, 1972, DOCTOR HIS PATIENT I; BATES B, 1991, GUIDE PHYSICIAL EXAM; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BENSON JA, 1983, ANN INTERN MED, V99, P720, DOI 10.7326/0003-4819-99-5-720; BRANCH WT, 1991, ANN INTERN MED, V114, P482, DOI 10.7326/0003-4819-114-6-482; CARROLL G, 1980, EVAL HEALTH PROF, V3, P37; CARROLL JG, 1979, J MED EDUC, V54, P498; COHENCOLES SA, 1991, MED INTERVIEW 3 FUNC; DiMatteo M R, 1980, J Community Health, V6, P18; DiMatteo MR, 1982, ACHIEVING PATIENT CO; ENGEL GL, 1973, ANN INTERN MED, V78, P587, DOI 10.7326/0003-4819-78-4-587; ENGLER CM, 1981, J MED EDUC, V56, P572; EVANS BJ, 1989, MED EDUC, V23, P364, DOI 10.1111/j.1365-2923.1989.tb01561.x; FINE VK, 1977, J MED EDUC, V52, P752; FRANCIS V, 1969, NEW ENGL J MED, V280, P535, DOI 10.1056/NEJM196903062801004; GOLDBERG DP, 1980, LANCET, V2, P521; GREER DS, 1990, J GEN INTERN MED, V5, pS53, DOI 10.1007/BF02600438; HUTTER MJ, 1977, J MED EDUC, V52, P328; JOHNSON AH, 1979, J FAM PRACTICE, V9, P447; KAHN GS, 1979, J MED EDUC, V54, P29; Kaplan S, 1989, COMMUNICATING MED PA; KAUSS DR, 1980, J MED EDUC, V55, P595; KERN DE, 1989, J GEN INTERN MED, V4, P421, DOI 10.1007/BF02599696; KORSCH BM, 1968, PEDIATRICS, V42, P855; LIPKIN M, 1984, ANN INTERN MED, V100, P277, DOI 10.7326/0003-4819-100-2-277; LIPKIN M, 1992, MED INTERVIEW; LIPKIN M, 1987, OFFICE PRACTICE MED, P1287; MAGUIRE GP, 1977, MED EDUC, V11, P175, DOI 10.1111/j.1365-2923.1977.tb00588.x; MAGUIRE P, 1990, BRIT J HOSP MED, V43, P215; MAGUIRE P, 1986, BRIT MED J, V292, P1573, DOI 10.1136/bmj.292.6535.1573; McKegney C P, 1989, Fam Med, V21, P452; NOVACK DH, 1992, ARCH INTERN MED, V152, P1814, DOI 10.1001/archinte.152.9.1814; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; PETERSON MC, 1992, WESTERN J MED, V156, P163; PLATT FW, 1979, ANN INTERN MED, V91, P898, DOI 10.7326/0003-4819-91-6-898; REUBEN DB, 1984, PSYCHOSOMATICS, V25, P815, DOI 10.1016/S0033-3182(84)72942-2; ROST K, 1989, J GEN INTERN MED, V4, P121, DOI 10.1007/BF02602351; RUTTER DR, 1976, LANCET, V2, P558; SANSONFISHER RW, 1978, MED J AUSTRALIA, V1, P473, DOI 10.5694/j.1326-5377.1978.tb112562.x; SCHEIDT PC, 1986, J MED EDUC, V61, P585; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; SKEFF K M, 1988, Journal of General Internal Medicine, V3, pS26, DOI 10.1007/BF02600249; SMITH AC, 1989, SOC PSYCHOL QUART, V52, P56, DOI 10.2307/2786904; SOMMERS PA, 1985, J FAM PRACTICE, V20, P299; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; STILLMAN PL, 1977, PEDIATRICS, V60, P165; STOECKLE JD, 1987, J GEN INTERN MED, V2, P119, DOI 10.1007/BF02596310; VACCARINO JM, 1977, JAMA-J AM MED ASSOC, V238, P861, DOI 10.1001/jama.238.8.861; WIENER S, 1976, JAMA-J AM MED ASSOC, V236, P852, DOI 10.1001/jama.236.7.852; WILLIAMSON PR, 1991, J GEN INTERN MED, V6, P179, DOI 10.1007/BF02598321; 1979, ANN INTERN MED, V90, P402; 1987, PEDIATRICS, V79, P829; 1984, PHYSICIANS 21ST CENT; 1977, FUTURE PEDIATRIC ED	54	131	134	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2101	2105		10.1001/jama.269.16.2101	http://dx.doi.org/10.1001/jama.269.16.2101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468764				2022-12-28	WOS:A1993KY36600031
J	HILL, CS; MARAIS, R; JOHN, S; WYNNE, J; DALTON, S; TREISMAN, R				HILL, CS; MARAIS, R; JOHN, S; WYNNE, J; DALTON, S; TREISMAN, R			FUNCTIONAL-ANALYSIS OF A GROWTH FACTOR-RESPONSIVE TRANSCRIPTION FACTOR COMPLEX	CELL			English	Article							C-FOS PROMOTER; SIGNAL TRANSDUCTION; PROTEIN COMPLEX; TERNARY COMPLEX; BINDING-FACTOR; DNA-BINDING; YEAST; ELEMENT; GENES; CARG	Serum response factor (SRF) forms a ternary complex at the c-fos serum response element (SRE) with an accessory factor, Elk-1. We constructed altered-binding specificity derivatives of SRF and Elk-1 that form a ternary complex at a mutated, inactive SRE; like Elk-1, the Elk-1 variant only binds its target as part of a ternary complex with SRF. Simultaneous expression of these SRF and Elk-1 derivatives restores serum-regulated activity to the mutated SRE in transfected cells. Efficient transcriptional activation is dependent on the regulated phosphorylation of Elk-1 C-terminal MAP kinase sites and requires the C-terminal sequences of SRF as well as SRF sequences that mediate ternary complex formation. These experiments provide direct evidence that SRF and Elk-1 functionally cooperate in the ternary complex at the SRE to regulate transcription.			HILL, CS (corresponding author), IMPERIAL CANC RES FUND,TRANSCRIPT LAB,LONDON WC2A 3PX,ENGLAND.			Hill, Caroline/0000-0002-8632-0480; Treisman, Richard/0000-0002-9658-0067; Marais, Richard/0000-0001-7484-4183; John, Susan/0000-0002-5620-1982				BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; Miller J.H., 1972, EXPT MOL GENETICS; MOHUN TJ, 1991, EMBO J, V10, P933, DOI 10.1002/j.1460-2075.1991.tb08027.x; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1992, ONCOGENE, V11, P2335; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SENGUPTA P, 1991, GENE DEV, V5, P1924, DOI 10.1101/gad.5.10.1924; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; SPRAGUE GF, 1991, TRENDS GENET, V7, P393, DOI 10.1016/0168-9525(91)90262-O; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WYNNE J, 1992, NUCLEIC ACIDS RES, V20, P3297, DOI 10.1093/nar/20.13.3297	49	379	384	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					395	406		10.1016/0092-8674(93)90238-L	http://dx.doi.org/10.1016/0092-8674(93)90238-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8477450				2022-12-28	WOS:A1993KY50500019
J	WAINRIGHT, PO; HINKLE, G; SOGIN, ML; STICKEL, SK				WAINRIGHT, PO; HINKLE, G; SOGIN, ML; STICKEL, SK			MONOPHYLETIC ORIGINS OF THE METAZOA - AN EVOLUTIONARY LINK WITH FUNGI	SCIENCE			English	Article							SEPTATE JUNCTIONS; RIBOSOMAL-RNA; SEQUENCES; ULTRASTRUCTURE; PHYLOGENY; MEMBRANES; PORIFERA; TREES	A phylogenetic framework inferred from comparisons of small subunit ribosomal RNA sequences describes the evolutionary origin and early branching patterns of the kingdom Animalia. Maximum likelihood analyses show the animal lineage is monophyletic and includes choanoflagellates. Within the metazoan assemblage, the divergence of sponges is followed by the Ctenophora, the Cnidaria plus the placozoan Trichoplax adhaerens, and finally by an unresolved polychotomy of bilateral animal phyla. From these data, it was inferred that animals and fungi share a unique evolutionary history and that their last common ancestor was a flagellated protist similar to extant choanoflagellates.	MARINE BIOL LAB, CTR MOLEC EVOLUT, WOODS HOLE, MA 02543 USA; RUTGERS STATE UNIV, INST MARINE & COASTAL SCI, NEW BRUNSWICK, NJ 08903 USA	Marine Biological Laboratory - Woods Hole; Rutgers State University New Brunswick			Sogin, Mitchell/AAE-7186-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032964] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32964] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergstrom J., 1990, Ichnos, V1, P3; Bruns TD, 1992, MOL PHYLOGENET EVOL, V1, P231, DOI 10.1016/1055-7903(92)90020-H; CAVALIERSMITH T, 1987, T BRIT MYCOL SOC, V12, P339; CHRISTEN R, 1991, EMBO J, V10, P499, DOI 10.1002/j.1460-2075.1991.tb07975.x; CLARK AG, 1992, MOL BIOL EVOL, V9, P744; DECECCATTY MP, 1986, J MORPHOL, V189, P45, DOI 10.1002/jmor.1051890105; DESAEDELEER H, 1930, ANN SOC R ZOOL BELG, V60, P16; ELWOOD HJ, 1985, MOL BIOL EVOL, V2, P399; EXPOSITO JY, 1990, EUR J BIOCHEM, V190, P401, DOI 10.1111/j.1432-1033.1990.tb15589.x; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; FILAHIE BK, 1977, J CELL SCI, V23, P151; Garrone R, 1985, BIOL INVERTEBRATE LO, P157; GREEN CR, 1982, J CELL SCI, V53, P279; HADZI J, 1953, SYST ZOOL, V2, P145, DOI 10.2307/2411558; HAECKEL E, 1874, Q J MICROSC SCI, V14, P142; Harbison G. R., 1985, ORIGINS RELATIONSHIP, P78; Harrison F.W., 1990, P223; HASEGAWA M, 1993, J MOL EVOL, V36, P380, DOI 10.1007/BF00182185; HEDGES SB, 1992, MOL BIOL EVOL, V9, P366; HERNANDEZNICAIS.ML, 1991, MICROSCOPIC ANATOMY, V2, P364; HIBBERD DJ, 1975, J CELL SCI, V17, P191; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; HYMAN LH, 1940, INVERTEBRATES PROTOZ, P365; James-Clark H., 1868, BOWERBANK ANN MAG NA, V1, P133; James-Clark H, 1868, ANN MAG NAT HIST, V1, P250; James-Clark H, 1868, ANN MAG NAT HIST, V1, P188; James-Clark J., 1867, ANN MAG NAT HIST, V19, P13; KING MG, 1979, J CELL SCI, V36, P391; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; LABATROBERT J, 1981, P NATL ACAD SCI-BIOL, V78, P6261, DOI 10.1073/pnas.78.10.6261; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; LAVAL M, 1971, Protistologica, V7, P325; LEADBEATER BS, 1974, J MAR BIOL ASSOC UK, V54, P269, DOI 10.1017/S0025315400058537; LEADBEATER BSC, 1983, J MAR BIOL ASSOC UK, V63, P135, DOI 10.1017/S0025315400049857; LEIPE D, IN PRESS MOL BIOCH P; LETHIAS C, 1983, TISSUE CELL, V15, P523, DOI 10.1016/0040-8166(83)90004-6; LI WH, 1990, METHOD ENZYMOL, V183, P645; MACKIE GO, 1983, PHILOS T ROY SOC B, V301, P365, DOI 10.1098/rstb.1983.0028; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; NEI M, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P90; NEI M, 1991, EVOLUTION MHC GENES, P13; NIELSEN C, 1985, BIOL J LINN SOC, V25, P243, DOI 10.1111/j.1095-8312.1985.tb00396.x; OLSEN G, UNPUB; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; PATTERSON DJ, IN PRESS ORIGIN EVOL; PEDERSEN KJ, 1991, ACTA ZOOL-STOCKHOLM, V72, P181, DOI 10.1111/j.1463-6395.1991.tb01196.x; RUTHMANN A, 1986, ZOOMORPHOLOGY, V106, P115, DOI 10.1007/BF00312113; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAVILLEKENT W, 1880, MANUAL INFUSORIA, V1, P363; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; SWOFFORD D, ILLINOIS NATURAL HIS; Towe K.M., 1981, NASA C PUBL, V2156, P297; West Lani, 1993, Molecular Marine Biology and Biotechnology, V2, P71; WHITTAKER RH, 1959, Q REV BIOL, V34, P210, DOI 10.1086/402733; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	59	513	525	3	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1993	260	5106					340	342		10.1126/science.8469985	http://dx.doi.org/10.1126/science.8469985			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8469985				2022-12-28	WOS:A1993KX80000034
J	BULPITT, KJ; CLEMENTS, PJ; LACHENBRUCH, PA; PAULUS, HE; PETER, JB; AGOPIAN, MS; SINGER, JZ; STEEN, VD; CLEGG, DO; ZIMINSKI, CM; ALARCON, GS; LUGGEN, ME; POLISSON, RP; WILLKENS, RF; READING, JC; WILLIAMS, HJ; WARD, JR				BULPITT, KJ; CLEMENTS, PJ; LACHENBRUCH, PA; PAULUS, HE; PETER, JB; AGOPIAN, MS; SINGER, JZ; STEEN, VD; CLEGG, DO; ZIMINSKI, CM; ALARCON, GS; LUGGEN, ME; POLISSON, RP; WILLKENS, RF; READING, JC; WILLIAMS, HJ; WARD, JR			EARLY UNDIFFERENTIATED CONNECTIVE-TISSUE DISEASE .3. OUTCOME AND PROGNOSTIC INDICATORS IN EARLY SCLERODERMA (SYSTEMIC-SCLEROSIS)	ANNALS OF INTERNAL MEDICINE			English	Article						CONNECTIVE TISSUE DISEASES; SCLERODERMA, SYSTEMIC; CARDIOPULMONARY SYSTEM; KIDNEY DISEASES; INFLAMMATION	SOLUBLE INTERLEUKIN-2 RECEPTORS; LIFE-TABLE ANALYSIS; DEMOGRAPHIC FACTORS; SURVIVAL; CLASSIFICATION; ANTINUCLEAR; ANTIBODIES	Objective: To characterize the course of early scleroderma and to delineate prognostic factors present within 1 year of disease onset that might identify patients at high risk. Design: Inception cohort study. Setting: Ten university-based rheumatology clinics participating in the Cooperative Systematic Studies of Rheumatic Diseases Program. Patients: Forty-eight patients who had had scleroderma for less than 1 year. Measurements: Fifteen patients with early scleroderma who died were compared with those still living during the initial study period (1982 to 1992). Kaplan-Meier survival estimation and Cox proportional hazards analysis were used to analyze baseline variables for their ability to predict survival duration. Results: Eight of 15 deaths were due to cardiac or pulmonary system failure. The estimated 5-year survival rate was 68%. Baseline factors that were the most predictive of a poor outcome included the presence of abnormal cardiopulmonary signs and abnormal urine sediment (pyuria, hematuria). Conclusion: Evidence of early cardiopulmonary disease, renal disease, inflammation, or immune activation may identify a subset of patients with scleroderma who will experience rapidly progressive disease and early death.	UNIV CALIF LOS ANGELES, DIV BIOSTAT, LOS ANGELES, CA 90024 USA; SPECIALTY LABS INC, SANTA MONICA, CA 90404 USA; SUNY HLTH SCI CTR, BROOKLYN, NY 11203 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15261 USA; UNIV UTAH, MED CTR, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, CTR COORDINATING COOPERAT SYSTEMAT STUDIES RHEUMAT, SALT LAKE CITY, UT 84112 USA; JOHNS HOPKINS UNIV, DIV RHEUMATOL, BALTIMORE, MD 21239 USA; UNIV ALABAMA, DEPT MED, DIV RHEUMATOL, BIRMINGHAM, AL 35294 USA; UNIV CINCINNATI, MED CTR, DIV IMMUNOL, CINCINNATI, OH 45267 USA; DUKE UNIV, DURHAM, NC 27706 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; NIH, BETHESDA, MD 20892 USA	University of California System; University of California Los Angeles; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; University System of Ohio; University of Cincinnati; Duke University; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA	BULPITT, KJ (corresponding author), UNIV CALIF LOS ANGELES, DIV RHEUMATOL, 1000 VET AVE, 32-47, LOS ANGELES, CA 90024 USA.				NIADDK NIH HHS [1-AM6-2228] Funding Source: Medline; NIAMS NIH HHS [AR3-6834-05] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036834] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCON GS, 1991, J RHEUMATOL, V18, P1332; ALTMAN RD, 1991, ARTHRITIS RHEUM, V34, P403, DOI 10.1002/art.1780340405; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; BARNETT AJ, 1988, J RHEUMATOL, V15, P276; BENNETT R, 1971, ANN RHEUM DIS, V30, P581, DOI 10.1136/ard.30.6.581; BERNSTEIN RM, 1982, CLIN EXP IMMUNOL, V48, P43; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; CANNON PJ, 1974, MEDICINE, V53, P1, DOI 10.1097/00005792-197401000-00001; CLEGG DO, 1991, J RHEUMATOL, V18, P1340; CLEMENTS PJ, 1990, J RHEUMATOL, V17, P908; COX DR, 1972, J R STAT SOC B, V34, P187; DEGIANNIS D, 1990, ARTHRITIS RHEUM, V33, P375, DOI 10.1002/art.1780330310; ENGEL E E, 1989, Arthritis and Rheumatism, V32, pS42; FARMER RG, 1960, CIRCULATION, V21, P1088, DOI 10.1161/01.CIR.21.6.1088; JIMENEZ SA, 1991, J RHEUMATOL, V18, P1496; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOSTIS JB, 1988, AM J MED, V84, P1007, DOI 10.1016/0002-9343(88)90305-1; LALLY EV, 1988, SEMIN ARTHRITIS RHEU, V18, P1, DOI 10.1016/0049-0172(88)90030-3; LEROY EC, 1988, J RHEUMATOL, V15, P202; LEROY EC, 1978, AM J MED, V64, P974, DOI 10.1016/0002-9343(78)90452-7; MANTEL N, 1959, J NATL CANCER I, V22, P719; MEDSGER T A JR, 1979, Clinics in Rheumatic Diseases, V5, P15; MEDSGER TA, 1971, ANN INTERN MED, V75, P369, DOI 10.7326/0003-4819-75-3-369; MEDSGER TA, 1973, J CHRON DIS, V26, P647, DOI 10.1016/0021-9681(73)90054-4; PETERSGOLDEN M, 1984, AM J MED, V77, P1027, DOI 10.1016/0002-9343(84)90183-9; ROPES M W, 1958, Bull Rheum Dis, V9, P175; ROWELL NR, 1976, BRIT J DERMATOL, V95, P57, DOI 10.1111/j.1365-2133.1976.tb15535.x; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SEIBOLD JR, 1992, J RHEUMATOL, V19, P673; STEEN VD, 1988, ARTHRITIS RHEUM, V31, P196, DOI 10.1002/art.1780310207; STEEN VD, 1990, ANN INTERN MED, V113, P352, DOI 10.7326/0003-4819-113-5-352; STEEN VD, 1984, AM J MED, V76, P779, DOI 10.1016/0002-9343(84)90986-0; STEEN VD, 1984, ARTHRITIS RHEUM, V27, P125, DOI 10.1002/art.1780270202; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TUFFANELLI D, 1961, ARCH DERMATOL, V84, P359, DOI 10.1001/archderm.1961.01580150005001; WYNN J, 1985, AM HEART J, V110, P123, DOI 10.1016/0002-8703(85)90525-3; YOUNG E A, 1986, Arthritis and Rheumatism, V29, pS51	37	80	81	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					602	609		10.7326/0003-4819-118-8-199304150-00005	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8452326				2022-12-28	WOS:A1993KW47000005
J	TAN, SS; BREEN, S				TAN, SS; BREEN, S			RADIAL MOSAICISM AND TANGENTIAL CELL DISPERSION BOTH CONTRIBUTE TO MOUSE NEOCORTICAL DEVELOPMENT	NATURE			English	Article							CEREBRAL-CORTEX; SOMATOSENSORY CORTEX; MIGRATION PATTERNS; VISUAL-CORTEX; THALAMUS; PROJECTIONS; NEURONS; LINEAGE; RHESUS	THE mammalian neocortex is generated by waves of migrating cells originating from the ventricular Zone1,2. Radial migration3 along radial glia4,5 has been proposed as the dominant mechanism for this process. The radial unit hypothesis3 is poorly supported by retroviral lineage studies, however, and although some clones show limited radial organization6, the emphasis appears to be on widespread tangential dispersion7-10. Here we investigate the pattern of cortical cell dispersion using transgenic mice in which roughly half of the brain cells are coloured by a transgene11. We find that the neocortex is randomly divided into diffused bands, the majority of cells within each band have the same colour, and their radial orientation suggests radial dispersion. Superimposed upon this was a significant contribution by tangentially dispersed cells that did not respect clonal borders. These observations indicate that cortical specification is not dependent upon a single mechanism of cell allocation, but that both radial mosaicism and tangential cell migration are involved.			TAN, SS (corresponding author), UNIV MELBOURNE,DEPT ANAT & CELL BIOL,EMBRYOL LAB,PARKVILLE,VIC 3052,AUSTRALIA.							ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; GADISSEUX JF, 1989, DEV BRAIN RES, V50, P55, DOI 10.1016/0165-3806(89)90126-0; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; METIN C, 1989, P NATL ACAD SCI USA, V86, P357, DOI 10.1073/pnas.86.1.357; MOLNAR Z, 1991, NATURE, V351, P475, DOI 10.1038/351475a0; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PRICE J, 1988, DEVELOPMENT, V104, P473; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SUR M, 1988, SCIENCE, V242, P1437, DOI 10.1126/science.2462279; TAN SS, 1993, NAT GENET, V3, P170, DOI 10.1038/ng0293-170; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520	18	173	174	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					638	640		10.1038/362638a0	http://dx.doi.org/10.1038/362638a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8464515				2022-12-28	WOS:A1993KX43800050
J	WALSH, C; CEPKO, CL				WALSH, C; CEPKO, CL			CLONAL DISPERSION IN PROLIFERATIVE LAYERS OF DEVELOPING CEREBRAL-CORTEX	NATURE			English	Article							MIGRATION PATTERNS	IN the adult cerebral cortex, many retrovirally labelled clones are widely dispersed1, though the mechanisms of this dispersion are not well understood. Here we investigate the temporal sequence of clonal dispersion after labelling progenitors of rat cortical cells with replication-incompetent retroviruses at early stages of cortical neurogenesis, 14-15 days after conception (E14/15). The location of labelled daughter cells was determined 3, 6 or 10 days later. Labelled sibling cells were radially arrayed three days after infection (E18). In contrast, by six days after infection (E20/21), 43% of cortical clones were dispersed non-radially by at least 500 mum. Four of these widespread clones were dispersed longitudinally by greater-than-or-equal-to 2 mm, implying sustained rates of dispersion of > 15 mum per hour. Dispersed sibling cells occurred within proliferative zones of the forebrain in 35% of widely dispersed clones, suggesting that some dispersion reflects movement of dividing cells. Some clones dispersed beyond the neocortex into the olfactory bulb. Progenitor cell dispersion represents a previously unrecognized mode of migration by which sibling cells become widely dispersed in the developing forebrain.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								ALTMAN J, 1991, NEOCORT DEV; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; BAYER SA, 1983, EXP BRAIN RES, V50, P329; FINLAY BL, 1983, SCIENCE, V219, P1349, DOI 10.1126/science.6828866; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; GROVE EA, 1992, NEURON, V8, P217, DOI 10.1016/0896-6273(92)90289-P; KIRKWOOD TBL, 1992, SCIENCE, V258, P317, DOI 10.1126/science.1411530; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MCCONNELL SK, 1989, SCIENCE, V245, P978, DOI 10.1126/science.2475909; Misson JP, 1991, CEREB CORTEX, V1, P221, DOI 10.1093/cercor/1.3.221; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; WALSH C, 1992, SCIENCE, V258, P317, DOI 10.1126/science.258.5080.317-a; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; 1970, ANAT REC, V1666, P257	17	201	202	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					632	635		10.1038/362632a0	http://dx.doi.org/10.1038/362632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8464513				2022-12-28	WOS:A1993KX43800048
J	COHEN, J				COHEN, J			AIDS THERAPIES - EARLY AZT TAKES A POUNDING IN FRENCH-BRITISH CONCORDE TRIAL	SCIENCE			English	Editorial Material																			0	14	15	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					157	157		10.1126/science.8469966	http://dx.doi.org/10.1126/science.8469966			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8469966				2022-12-28	WOS:A1993KW45200016
J	MIZUKAMI, T; CHANG, WI; GARKAVTSEV, I; KAPLAN, N; LOMBARDI, D; MATSUMOTO, T; NIWA, O; KOUNOSU, A; YANAGIDA, M; MARR, TG; BEACH, D				MIZUKAMI, T; CHANG, WI; GARKAVTSEV, I; KAPLAN, N; LOMBARDI, D; MATSUMOTO, T; NIWA, O; KOUNOSU, A; YANAGIDA, M; MARR, TG; BEACH, D			A 13-KB RESOLUTION COSMID MAP OF THE 14-MB FISSION YEAST GENOME BY NONRANDOM SEQUENCE-TAGGED SITE MAPPING	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; GENE; IDENTIFICATION; INTEGRATION; CHROMOSOMES; FRAGMENTS	We present the application of a nonrandom sequence-tagged site (STS) content detection method in mapping an entire genome, that of fission yeast. The novelty of our strategy is in the use of STS probes made from both ends of cosmid clones, selected on the basis of ''sample without replacement'' (only library clones that show no previous positive hybridization are selected and made into probes). We developed powerful techniques, based on consistency analysis, for error detection and contig assembly. In addition, we probed our library with genetically mapped markers and NotI or SfiI linking clones, thereby anchoring contigs onto chromosomes. Our map contains more than 1000 sites, including genes (most were previously unmapped), occurrences of known repetitive elements, and NotI-SfiI restriction sites.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; HOWARD HUGHES MED INST,COCONUT GROVE,FL 33133; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Kyoto University					NHGRI NIH HHS [5201 HG00017-02, 1R01 HG0020301A1] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000203] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ARRATIA R, 1991, GENOMICS, V11, P806, DOI 10.1016/0888-7543(91)90004-X; BARILLOT E, 1991, P NATL ACAD SCI USA, V88, P3917, DOI 10.1073/pnas.88.9.3917; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; CAERANOANOLLIS G, 1991, BIOTECHNOLOGY, V9, P553; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7826; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; EVANS GA, 1989, GENE, V79, P9, DOI 10.1016/0378-1119(89)90088-7; FAN JB, 1991, NUCLEIC ACIDS RES, V19, P6289, DOI 10.1093/nar/19.22.6289; FAN JB, 1988, NUCLEIC ACIDS RES, V17, P2801; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUI Y, 1985, EMBO J, V4, P687, DOI 10.1002/j.1460-2075.1985.tb03684.x; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEVIN HL, 1990, MOL CELL BIOL, V10, P6791, DOI 10.1128/MCB.10.12.6791; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MARR TG, 1992, MAMM GENOME, V3, P644, DOI 10.1007/BF00352482; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MATSUMOTO T, 1990, CURR GENET, V18, P323, DOI 10.1007/BF00318213; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; OLSON M, 1986, P NATL ACAD SCI USA, V83, P7821; PALAZZOLO MJ, 1991, P NATL ACAD SCI USA, V88, P8034, DOI 10.1073/pnas.88.18.8034; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; TODA T, 1984, CURR GENET, V8, P93, DOI 10.1007/BF00420224; YANAGIDA M, 1991, CONTROL CELL GROWTH, P255; ZHANG MQ, 1993, IN PRESS P NATL ACAD, V90	28	120	120	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					121	132		10.1016/0092-8674(93)90165-M	http://dx.doi.org/10.1016/0092-8674(93)90165-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462095				2022-12-28	WOS:A1993KW75300013
J	ZAKANY, J; DUBOULE, D				ZAKANY, J; DUBOULE, D			CORRELATION OF EXPRESSION OF WNT-1 IN DEVELOPING LIMBS WITH ABNORMALITIES IN GROWTH AND SKELETAL PATTERNING	NATURE			English	Article							INT-1 PROTOONCOGENE; TRANSGENIC MICE; GENE; ORGANIZATION	THE Wnt genes are members of a family of vertebrate genes related to the Drosophila gene wingless (wg)1,2. They encode secreted molecules3,4 that are thought to be important in patterning and growth control during ontogenesis5-7. Several such genes are transcribed in localized domains during limb budding and morphogenesis2,8. We report here a congenital limb malformation in a mouse transgenic line that ectopically expresses Wnt-1 in the developing limbs. The hemizygote phenotype, which is inherited as an autosomal dominant trait, presents extensive distal truncations of skeletal elements, skeletal fusions and interdigital webbing. The data shown here demonstrate that abnormal Wnt-1 expression is correlated with retarded mesenchymal condensations replaced by highly proliferative cells in the limb bud. This seems to lead to an inability of the affected cells to participate in normal skeletal development leading to the adult defects.			ZAKANY, J (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,POSTFACH 10-2209,W-6900 HEIDELBERG,GERMANY.			duboule, denis/0000-0001-9961-2960				DELOIA JA, 1990, DEVELOPMENT S, V110, P73; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HAYASHI Y, 1988, J HISTOCHEM CYTOCHEM, V36, P511, DOI 10.1177/36.5.3282006; HERKEN R, 1980, TERATOLOGY LIMBS, P163; HOGAN B, 1986, MANIPULATING MOUSE E; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEISLER MH, 1992, TRENDS GENET, V8, P341, DOI 10.1016/0168-9525(92)90278-C; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; POHL TM, 1990, DEVELOPMENT, V110, P1153; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS JW, 1971, VERTEBRATE LIMB SOMI, P1; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; ZAKANY J, 1988, NEURON, V1, P679, DOI 10.1016/0896-6273(88)90167-5	23	55	59	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					546	549		10.1038/362546a0	http://dx.doi.org/10.1038/362546a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464495				2022-12-28	WOS:A1993KW45300056
J	SELBY, CP; SANCAR, A				SELBY, CP; SANCAR, A			MOLECULAR MECHANISM OF TRANSCRIPTION-REPAIR COUPLING	SCIENCE			English	Article							MUTATION FREQUENCY DECLINE; STRAND-SPECIFIC REPAIR; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; DNA DAMAGE; PYRIMIDINE DIMERS; DHFR GENE; RECOMBINATION; INVITRO; SITE	Lesions in the transcribed strand block transcription and are repaired more rapidly than lesions in the nontranscribed (coding) strand which do not block RNA polymerase (RNAP). It has been shown previously that in Escherichia coli the mfd (mutation frequency decline) gene is necessary for strand-specific repair. The mfd gene was cloned and sequenced and the Mfd protein was purified and used to reconstitute strand-specific repair in a completely defined system. The mfd gene encodes a protein of 130 kilodaltons and contains the so-called ''helicase motifs,'' a leucine zipper motif, and regions of sequence similarity to UvrB and RecG proteins. The Mfd protein was shown to (i) displace RNAP stalled at a lesion in an adenosine triphosphate-dependent reaction, (ii) bind to the damage recognition subunit (UvrA) of the excision nuclease, and (iii) stimulate the repair of the transcribed strand only when transcription is taking place. Thus, Mfd appears to target the transcribed strand for repair by recognizing a stalled RNAP and actively recruiting the repair enzyme to the transcription blocking lesion as it dissociates the stalled RNAP.			SELBY, CP (corresponding author), UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA.							ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BOCKRATH R, 1987, MUTAT RES, V183, P241, DOI 10.1016/0167-8817(87)90006-X; BOCKRATH RC, 1977, MOL GEN GENET, V156, P133, DOI 10.1007/BF00283485; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUNALA S, 1992, P NATL ACAD SCI USA, V89, P11031, DOI 10.1073/pnas.89.22.11031; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LOMMEL L, 1991, MUTAT RES, V255, P183, DOI 10.1016/0921-8777(91)90052-Q; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; ORREN DK, 1992, J BIOL CHEM, V267, P780; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; REINES D, 1992, J BIOL CHEM, V267, P3795; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SELBY CP, 1990, J BIOL CHEM, V267, P17688; SHI YB, 1987, NUCLEIC ACIDS RES, V15, P6843, DOI 10.1093/nar/15.17.6843; SHI YB, 1988, J BIOL CHEM, V263, P527; SICARD N, 1992, J BACTERIOL, V174, P2412, DOI 10.1128/JB.174.7.2412-2415.1992; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VOS JMH, 1991, MOL CELL BIOL, V11, P2245, DOI 10.1128/MCB.11.4.2245; WITKIN EM, 1969, ANNU REV MICROBIOL, V23, P487, DOI 10.1146/annurev.mi.23.100169.002415; WITKIN EM, 1966, SCIENCE, V152, P1345, DOI 10.1126/science.152.3727.1345; WITKIN EM, 1992, COMMUNICATION	39	570	574	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	1993	260	5104					53	58		10.1126/science.8465200	http://dx.doi.org/10.1126/science.8465200			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8465200				2022-12-28	WOS:A1993KV42300023
J	WINSTON, DJ; CHANDRASEKAR, PH; LAZARUS, HM; GOODMAN, JL; SILBER, JL; HOROWITZ, H; SHADDUCK, RK; ROSENFELD, CS; HO, WG; ISLAM, MZ; BUELL, DN				WINSTON, DJ; CHANDRASEKAR, PH; LAZARUS, HM; GOODMAN, JL; SILBER, JL; HOROWITZ, H; SHADDUCK, RK; ROSENFELD, CS; HO, WG; ISLAM, MZ; BUELL, DN			FLUCONAZOLE PROPHYLAXIS OF FUNGAL-INFECTIONS IN PATIENTS WITH ACUTE-LEUKEMIA - RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						FLUCONAZOLE; AMPHOTERICIN-B; CANDIDIASIS; LEUKEMIA; ASPERGILLOSIS	FEBRILE GRANULOCYTOPENIC PATIENTS; CANDIDA-KRUSEI; IMMUNOCOMPROMISED PATIENTS; ASPERGILLUS INFECTIONS; MARROW TRANSPLANTATION; CANCER-PATIENTS; AMPHOTERICIN-B; THERAPY; NEUTROPENIA; PREVENTION	Objective: To evaluate the efficacy and safety of fluconazole for prevention of fungal infections. Design: A randomized, placebo-controlled, double-blind, multicenter trial. Patients: Adults (257) undergoing chemotherapy for acute leukemia. Intervention: Patients were randomly assigned to receive either fluconazole (400 mg orally once daily or 200 mg intravenously every 12 hours) or placebo. The study drug was started at initiation of chemotherapy and continued until recovery of neutrophil count, development of proven or suspected invasive fungal infection, or the occurrence of a drug-related toxicity. Measurements: Fungal colonization, proven superficial or invasive fungal infection, empiric antifungal therapy with amphotericin B, drug-related side effects, and mortality. Main Results: Fluconazole decreased fungal colonization (83 of 122 [68%] placebo patients compared with 34 of 119 [29%] fluconazole patients colonized at end of prophylaxis, P < 0.001) and proven fungal infections (27 of 132 [21%] placebo patients compared with 11 of 123 [9%] fluconazole patients infected, P = 0.02). Superficial fungal infections occurred in 20 of 132 (15%) placebo patients but in only 7 of 123 (6%) fluconazole patients (P = 0.01), whereas invasive fungal infections developed in 10 of 132 (8%) placebo patients and in 5 of 123 (4%) fluconazole patients (P = 0.3). Fluconazole was especially effective in eliminating colonization and infection by Candida species other than Candida krusei (66 of 122 [64%] placebo patients colonized at end of prophylaxis compared with 11 of 119 [9%] fluconazole patients, P < 0.001; 22 of 132 [17%] placebo patients infected compared with 7 of 123 16%] fluconazole patients, P = 0.005). Aspergillus infections were infrequent in both fluconazole (3 cases) and placebo groups (3 cases). The use of amphotericin B, the incidence of drug-related side effects, and overall mortality were similar in both study groups. Conclusion: Prophylactic fluconazole prevents colonization and superficial infections by Candida species other than Candida krusei in patients undergoing chemotherapy for acute leukemia and is well tolerated. Fluconazole could not be clearly shown to be effective for preventing invasive fungal infections, reducing the use of amphotericin B, or decreasing the number of deaths.	UNIV HOSP CLEVELAND, IRELAND CANC CTR, CLEVELAND, OH 44106 USA; UNIV MINNESOTA, SCH MED, DEPT MED, MINNEAPOLIS, MN 55455 USA; WESTCHESTER CTY MED CTR, DEPT MED, VALHALLA, NY 10595 USA; WESTERN PENN HOSP, WESTERN PENN CANC INST, PITTSBURGH, PA 15224 USA; ST JOSEPH HOSP, REG CANC CTR, ORANGE, CA 92668 USA; FUJISAWA CO, DEERFIELD, IL 60015 USA; PFIZER INC, CENT RES, GROTON, CT 06340 USA	University Hospitals of Cleveland; University of Minnesota System; University of Minnesota Twin Cities; Westchester Medical Center; West Penn Hospital; Pfizer	WINSTON, DJ (corresponding author), UNIV CALIF LOS ANGELES, MED CTR, DEPT MED, CHS, ROOM 42-121, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA-23175, P30CA43703, CA-14548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA014548, P01CA023175, P30CA043703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anaissie E, 1989, Infect Dis Clin North Am, V3, P867; ANAISSIE E, 1987, P INTERSCIENCE C ANT, P265; BODEY GP, 1990, SEMIN ONCOL, V17, P24; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BODEY GP, 1990, FUNGAL INFECTIONS CA, P2; BRAMMER KW, 1990, REV INFECT DIS, V12, pS318; Breslow N, 1980, STATISTICAL METHODS, V32; CHAMPLIN R, 1987, BLOOD, V69, P1551; CHAMPLIN R, 1989, BLOOD, V73, P2051; FAINSTEIN V, 1980, ANN INTERN MED, V93, P432, DOI 10.7326/0003-4819-93-3-432; GALGIANI JN, 1987, ANTIMICROB AGENTS CH, V31, P1867, DOI 10.1128/AAC.31.12.1867; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GERSON SL, 1984, ANN INTERN MED, V100, P345, DOI 10.7326/0003-4819-100-3-345; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GRANT SM, 1990, DRUGS, V39, P877, DOI 10.2165/00003495-199039060-00006; HO WG, 1986, CLIN HAEMATOL, V15, P873; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEE ET, 1980, STATISTICAL METHODS; LEWIS JH, 1984, GASTROENTEROLOGY, V86, P503; MCQUILLEN DP, 1992, CLIN INFECT DIS, V14, P472, DOI 10.1093/clinids/14.2.472; MERZ WG, 1986, J CLIN MICROBIOL, V24, P581, DOI 10.1128/JCM.24.4.581-584.1986; MEUNIER F, 1987, REV INFECT DIS, V9, P408; MEUNIER F, 1989, AM J MED, V86, P668; OPAL SM, 1986, J INFECT DIS, V153, P634, DOI 10.1093/infdis/153.3.634; PATTERSON TF, 1990, REV INFECT DIS, V12, pS281; PERSONS DA, 1991, NEW ENGL J MED, V325, P1315; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; RINALDI MG, 1991, REV INFECT DIS, V13, P493; ROBERTSON MJ, 1988, AM J MED, V84, P233, DOI 10.1016/0002-9343(88)90419-6; ROUSEY SR, 1991, AM J MED, V91, P484, DOI 10.1016/0002-9343(91)90184-Y; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; SAMONIS G, 1990, REV INFECT DIS, V12, pS369; SARAL R, 1991, REV INFECT DIS, V13, P487; WALSH TJ, 1990, REV INFECT DIS, V12, pS307; WALSH TJ, 1991, REV INFECT DIS, V13, P496; WINGARD JR, 1987, AM J MED, V83, P1103, DOI 10.1016/0002-9343(87)90949-1; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; WINSTON DJ, 1991, ANN INTERN MED, V115, P849, DOI 10.7326/0003-4819-115-11-849	39	329	332	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					495	503		10.7326/0003-4819-118-7-199304010-00003	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442620				2022-12-28	WOS:A1993KU07900003
J	BOELENS, WC; JANSEN, EJR; VANVENROOIJ, WJ; STRIPECKE, R; MATTAJ, IW; GUNDERSON, SI				BOELENS, WC; JANSEN, EJR; VANVENROOIJ, WJ; STRIPECKE, R; MATTAJ, IW; GUNDERSON, SI			THE HUMAN U1 SNRNP-SPECIFIC U1A PROTEIN INHIBITS POLYADENYLATION OF ITS OWN PREMESSENGER RNA	CELL			English	Article							5' SPLICE SITE; A-PROTEIN; THYMIDYLATE SYNTHASE; BINDING DOMAIN; CHROMOSOMAL LOCALIZATION; RIBOSOMAL-PROTEINS; ESCHERICHIA-COLI; RIBONUCLEOPROTEIN; INVITRO; EXPRESSION	Human, mouse, and Xenopus mRNAs encoding the U1 snRNP-specific U1A protein contain a conserved 47 nt region in their 3' untranslated regions (UTRs). In vitro studies show that human U1A protein binds to two sites within the conserved region that resemble, in part, the previously characterized U1A-binding site on U1 snRNA. Overexpression of human U1A protein in mouse cells results in down-regulation of endogenous mouse U1A mRNA accumulation. In vitro and in vivo experiments demonstrate that excess U1A protein specifically inhibits polyadenylation of pre-mRNAs that contain the conserved 3' UTR from human U1A mRNA. Thus, U1A protein regulates the production of its own mRNA via a mechanism that involves pre-mRNA binding and inhibition of polyadenylation.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	BOELENS, WC (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT BIOCHEM,6500 HB NIJMEGEN,NETHERLANDS.		Boelens, Wilbert/D-8877-2012; Jansen, Eric J.R./A-3158-2013	Mattaj, Iain/0000-0002-5537-8284				AMALDI F, 1989, TRENDS BIOCHEM SCI, V14, P175, DOI 10.1016/0968-0004(89)90269-7; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P4611, DOI 10.1093/nar/19.17.4611; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P455, DOI 10.1093/nar/19.3.455; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DRAPER DE, 1989, TRENDS BIOCHEM SCI, V14, P335, DOI 10.1016/0968-0004(89)90167-9; FEENEY RJ, 1989, J BIOL CHEM, V264, P5776; GALLI G, 1987, GENE DEV, V1, P471, DOI 10.1101/gad.1.5.471; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUNDERSON SI, 1990, GENE DEV, V4, P2048, DOI 10.1101/gad.4.12a.2048; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; HAMM J, 1990, EMBO J, V9, P1237, DOI 10.1002/j.1460-2075.1990.tb08231.x; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; HENTZE MW, 1986, P NATL ACAD SCI USA, V83, P7226, DOI 10.1073/pnas.83.19.7226; HODGKIN J, 1989, CELL, V56, P905, DOI 10.1016/0092-8674(89)90619-3; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HSIEH SY, 1991, J VIROL, V65, P6438, DOI 10.1128/JVI.65.12.6438-6446.1991; HUMPHREY T, 1987, EMBO J, V6, P4159, DOI 10.1002/j.1460-2075.1987.tb02762.x; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KANEDA S, 1987, NUCLEIC ACIDS RES, V15, P1259, DOI 10.1093/nar/15.3.1259; KANEDA S, 1990, J BIOL CHEM, V265, P20277; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; LUTZREYERMUTH C, 1989, MOL CELL BIOL, V9, P2975, DOI 10.1128/MCB.9.7.2975; MATTAJ IW, 1989, DEVELOPMENT, V105, P183; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MCCUE PA, 1984, J CELL BIOL, V98, P602, DOI 10.1083/jcb.98.2.602; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5931, DOI 10.1093/nar/8.24.5931; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NELISSEN RLH, 1991, GENE, V102, P189, DOI 10.1016/0378-1119(91)90077-O; PAPAVASSILIOU AG, 1992, P NATL ACAD SCI USA, V89, P11562, DOI 10.1073/pnas.89.23.11562; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1991, J MOL BIOL, V219, P577, DOI 10.1016/0022-2836(91)90651-L; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; SIMMEN KA, 1992, J MOL BIOL, V223, P873, DOI 10.1016/0022-2836(92)90249-J; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WELLINGTON C L, 1992, Current Biology, V2, P216, DOI 10.1016/0960-9822(92)90544-K; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	62	185	189	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					881	892		10.1016/0092-8674(93)90577-D	http://dx.doi.org/10.1016/0092-8674(93)90577-D			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458082				2022-12-28	WOS:A1993KU17500009
J	PULLEN, I				PULLEN, I			COUNTDOWN TO COMMUNITY CARE - HUNTING THE GOWK - PSYCHIATRIC COMMUNITY CARE IN SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article								The implementation of the community care changes throughout the United Kingdom from 1 April will mark the culmination of a series of major health and social care reforms. The avowed aims of achieving value for money and improved consumer choice through the introduction of competitive internal markets have yet to be tested. The political complexion of Scotland means that any proposed change to the NHS has tended to be greeted with a mixture of suspicion and resistance. As a result very few self governing trusts and fundholding general practices exist north of the border. And although Scotland has not had a wide reaching policy of moving psychiatric patients out of hospitals, community care for mentally ill people has advanced spontaneously.			PULLEN, I (corresponding author), ROYAL EDINBURGH & ASSOCIATED HOSP,EDINBURGH EH10 5HF,SCOTLAND.							BLUGLASS R, 1993, COMMUNITY SUPERVISIO; Dean R M, 1972, J R Coll Gen Pract, V22, P161; Goldberg D., 1983, INT J REHABIL RES, V6, P127, DOI [10.1097/00004356-198303000-00021, DOI 10.1097/00004356-198303000-00021]; JONES D, 1987, CREATING COMMUNITY M, V2; JONES K, 1985, BRIT J PSYCHIAT, V146, P341, DOI 10.1192/bjp.146.4.341; JONES M, 1982, PROCESS CHANGE CLOSE; MORGAN DH, IN PRESS BR J PSYCHI; PULLEN IM, 1988, BRIT J PSYCHIAT, V153, P663, DOI 10.1192/bjp.153.5.663; STRATHDEE G, 1984, J ROY COLL GEN PRACT, V34, P615; 1992, COMMUNITY CARE RESOU; 1993, GENERAL PRACTITIONER; 1980, PRIORITIES 80S; 1990, INPATIENT DATA 1987; 1985, MENTAL HLTH FOCUS; 1975, CMND6233; 1992, SCOTLANDS HLTH POLIC; 1989, MENTAL HOSPITALS FOC	17	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					710	712		10.1136/bmj.306.6879.710	http://dx.doi.org/10.1136/bmj.306.6879.710			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KT216	8471932	Green Published, Bronze			2022-12-28	WOS:A1993KT21600033
J	STAREY, N; BOSANQUET, N; GRIFFITHS, J				STAREY, N; BOSANQUET, N; GRIFFITHS, J			GENERAL-PRACTITIONERS IN PARTNERSHIP WITH MANAGEMENT - AN ORGANIZATIONAL MODEL FOR DEBATE	BRITISH MEDICAL JOURNAL			English	Article							CARE	The role of general practitioners is changing and expanding. Doctors have more control over the treatment received by their patients but remain largely unaccountable to the public and management. This article proposes an organisational model for integrating primary and secondary care which retains the advantages of fundholding while giving management control over overall strategy. It proposes that general practitioners control funds for all primary and secondary care. Secondary care will be contracted through a joint team of managers and an elected general practice executive committee. A new health care purchasing authority will contract for primary services with individual practices or primary care provider units. General practitioners will have local contracts reflecting their desire to provide an expanded range of services and the needs of the community.	UNIV LONDON,LONDON,ENGLAND; OXFORDSHIRE FAMILY HLTH SERV AUTHOR,OXFORD,ENGLAND	University of London	STAREY, N (corresponding author), BURNHAM SURG,BURNHAM CROUCH CM0 8SJ,ESSEX,ENGLAND.							BOSANQUET N, 1991, BRIT MED J, V303, P233, DOI 10.1136/bmj.303.6796.233; FOSTER A, 1991, FHSAS TODAYS TOMORRO; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; IRVINE D, 1990, MANAGING QUALITY GEN; ODOWD TC, 1991, BRIT MED J, V303, P450, DOI 10.1136/bmj.303.6800.450; ROLAND M, 1991, BRIT MED J, V303, P171, DOI 10.1136/bmj.303.6795.171; TAYLOR D, 1991, DEV PRIMARY CARE OPP; 1989, CMND849; 1991, PRIMARY HLTH CARE 90	10	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					308	310		10.1136/bmj.306.6873.308	http://dx.doi.org/10.1136/bmj.306.6873.308			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461651	Green Published, Bronze			2022-12-28	WOS:A1993KK71800023
J	WEINBERGER, SE				WEINBERGER, SE			MEDICAL PROGRESS .1. RECENT ADVANCES IN PULMONARY MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CYSTIC-FIBROSIS GENE; ALTERNATE-DAY PREDNISONE; LOWER RESPIRATORY-TRACT; AIR-FLOW LIMITATION; HOME OXYGEN-THERAPY; HIGH-RESOLUTION CT; ALPHA-1-ANTITRYPSIN DEFICIENCY; LUNG-DISEASE; PULSE OXIMETRY; DOUBLE-BLIND				WEINBERGER, SE (corresponding author), BETH ISRAEL HOSP,DIV PULM & CRIT CARE,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753; ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; [Anonymous], 1981, LANCET, V1, P681; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14, DOI 10.1164/arrd.1986.133.1.14; ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; AUERBACH HS, 1985, LANCET, V2, P686; AUFFARTH B, 1991, THORAX, V46, P372, DOI 10.1136/thx.46.5.372; BARKER SJ, 1987, ANESTHESIOLOGY, V66, P677, DOI 10.1097/00000542-198705000-00014; BARKER SJ, 1989, ANESTHESIOLOGY, V70, P112, DOI 10.1097/00000542-198901000-00021; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BOSKEN CH, 1990, AM REV RESPIR DIS, V142, P563, DOI 10.1164/ajrccm/142.3.563; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRAUN SR, 1990, ARCH INTERN MED, V150, P1242; BRAUN SR, 1989, ARCH INTERN MED, V149, P544, DOI 10.1001/archinte.149.3.544; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1992, NEW ENGL J MED, V326, P560, DOI 10.1056/NEJM199202203260809; CABANES LR, 1989, NEW ENGL J MED, V320, P1317, DOI 10.1056/NEJM198905183202005; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; CHRETIEN J, 1989, CHEST, V96, pS316, DOI 10.1378/chest.96.3_Supplement.316S; CHRISTOPHER KL, 1987, ANN INTERN MED, V107, P802, DOI 10.7326/0003-4819-107-6-802; CLARK JS, 1992, AM REV RESPIR DIS, V145, P220, DOI 10.1164/ajrccm/145.1.220; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; COOKE JC, 1987, THORAX, V42, P272, DOI 10.1136/thx.42.4.272; COOKSON WOCM, 1989, LANCET, V1, P1292; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CRYSTAL RG, 1989, CHEST, V95, P196, DOI 10.1378/chest.95.1.196; DAVIES RJ, 1992, BRIT MED BULL, V48, P85, DOI 10.1093/oxfordjournals.bmb.a072544; DAVIS PB, 1991, NEW ENGL J MED, V325, P575, DOI 10.1056/NEJM199108223250809; EDELMAN NH, 1992, CHEST, V102, pS243, DOI 10.1378/chest.102.3.243S; ELIAS S, 1991, AM J OBSTET GYNECOL, V164, P1077, DOI 10.1016/0002-9378(91)90589-J; EMERMAN CL, 1989, CHEST, V95, P563, DOI 10.1378/chest.95.3.563; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; FEINLEIB M, 1989, AM REV RESPIR DIS, V140, pS9, DOI 10.1164/ajrccm/140.3_Pt_2.S9; FINDLAY SR, 1992, J ALLERGY CLIN IMMUN, V89, P1040, DOI 10.1016/0091-6749(92)90227-S; FUJITA J, 1990, AM REV RESPIR DIS, V142, P57, DOI 10.1164/ajrccm/142.1.57; GADEK JE, 1990, LUNG, V168, P552, DOI 10.1007/BF02718178; GAMSU G, 1989, AM REV RESPIR DIS, V139, P254, DOI 10.1164/ajrccm/139.1.254; GLENNY RW, 1987, CHEST, V91, P289, DOI 10.1378/chest.91.2.289-c; GRENIER P, 1986, RADIOLOGY, V161, P95, DOI 10.1148/radiology.161.1.3763889; GRENIER P, 1991, RADIOLOGY, V179, P123, DOI 10.1148/radiology.179.1.2006262; GROSS NJ, 1984, AM REV RESPIR DIS, V129, P856, DOI 10.1164/arrd.1984.129.5.856; GURNEY JW, 1992, RADIOLOGY, V183, P457, DOI 10.1148/radiology.183.2.1561350; GUYATT GH, 1988, ARCH INTERN MED, V148, P1949, DOI 10.1001/archinte.148.9.1949; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HODGKIN JE, 1990, CLIN CHEST MED, V11, P447; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; HUBBARD RC, 1989, ANN INTERN MED, V111, P206, DOI 10.7326/0003-4819-111-3-206; HUBBARD RC, 1989, J CLIN INVEST, V84, P1349, DOI 10.1172/JCI114305; HUBBARD RC, 1988, JAMA-J AM MED ASSOC, V260, P1259, DOI 10.1001/jama.260.9.1259; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JEFFERY PK, 1991, AM REV RESPIR DIS, V143, P1152, DOI 10.1164/ajrccm/143.5_Pt_1.1152; JUBRAN A, 1991, CONT MANAGEMENT CRIT, P79; KAUFFMANN F, 1983, AM REV RESPIR DIS, V127, P263; KAY AB, 1992, AM REV RESPIR DIS, V145, pS22, DOI 10.1164/ajrccm/145.2_Pt_2.S22; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; KLEIN JS, 1992, RADIOLOGY, V182, P817, DOI 10.1148/radiology.182.3.1535900; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KUWANO K, 1990, AM REV RESPIR DIS, V141, P169, DOI 10.1164/ajrccm/141.1.169; LEMANSKE RF, 1992, CHEST, V101, pS372, DOI 10.1378/chest.101.6.372S; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; LEUNG AN, 1991, AM J ROENTGENOL, V157, P693, DOI 10.2214/ajr.157.4.1892019; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MCELVANEY NG, 1991, LANCET, V337, P392, DOI 10.1016/0140-6736(91)91167-S; MULLARKEY MF, 1990, ANN INTERN MED, V112, P577, DOI 10.7326/0003-4819-112-8-577; MULLER NL, 1991, AM J ROENTGENOL, V157, P1163; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; MURPHY TF, 1992, AM REV RESPIR DIS, V146, P1067, DOI 10.1164/ajrccm/146.4.1067; NADEL JA, 1990, LUNG, V168, P123, DOI 10.1007/BF02718124; Naidich D., 1991, COMPUTED TOMOGRAPHY; NEFF TA, 1988, CHEST, V94, P227, DOI 10.1378/chest.94.2.227a; NIEDERMAN MS, 1991, CHEST, V99, P798, DOI 10.1378/chest.99.4.798; Nocturnal Oxygen Therapy Trial Group, 1980, ANN INTERN MED, V93, P391; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; OGUSHI F, 1987, J CLIN INVEST, V80, P1366, DOI 10.1172/JCI113214; OLOPADE CO, 1992, MAYO CLIN PROC, V67, P144, DOI 10.1016/S0025-6196(12)61316-0; PAGE CP, 1992, AM REV RESPIR DIS, V145, pS31, DOI 10.1164/ajrccm/145.2_Pt_2.S31; PANG J, 1989, THORAX, V44, P948, DOI 10.1136/thx.44.11.948; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; PERLMUTTER DH, 1991, HEPATOLOGY, V13, P172, DOI 10.1002/hep.1840130125; PETTY TL, 1987, MAYO CLIN PROC, V62, P841, DOI 10.1016/S0025-6196(12)62339-8; PETTY TL, 1990, CHEST, V97, P75, DOI 10.1378/chest.97.1.75; PRIDE NB, 1992, BRIT MED BULL, V48, P1; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; ROSENSTEIN BJ, 1991, PEDIATRICS, V87, P245; SALMERON S, 1989, AM REV RESPIR DIS, V140, P167, DOI 10.1164/ajrccm/140.1.167; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; SCHAAD UB, 1991, LANCET, V338, P1236, DOI 10.1016/0140-6736(91)92103-9; SCHNAPP LM, 1990, CHEST, V98, P1244, DOI 10.1378/chest.98.5.1244; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; SILVERMAN EK, 1989, ANN INTERN MED, V111, P982, DOI 10.7326/0003-4819-111-12-982; SMITH LJ, 1991, AM REV RESPIR DIS, V143, pS100, DOI 10.1164/ajrccm/143.5_Pt_2.S100; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STOLLER JK, 1989, CLEV CLIN J MED, V56, P683, DOI 10.3949/ccjm.56.7.683; SWENSEN SJ, 1992, AM J ROENTGENOL, V158, P971, DOI 10.2214/ajr.158.5.1566699; TAGER IB, 1989, CHEST, V96, P1161, DOI 10.1378/chest.96.5.1161; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; THOMPSON AB, 1992, AM REV RESPIR DIS, V146, P389, DOI 10.1164/ajrccm/146.2.389; THURLBECK WM, 1990, CLIN CHEST MED, V11, P389; TIEP BL, 1990, CLIN CHEST MED, V11, P505; TREMPER KK, 1989, ANESTHESIOLOGY, V70, P98, DOI 10.1097/00000542-198901000-00019; VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2; WATSON A, 1992, CHEST, V101, P350, DOI 10.1378/chest.101.2.350; WEBB WR, 1992, RADIOLOGY, V182, P621, DOI 10.1148/radiology.182.3.1311115; WEST WW, 1987, AM REV RESPIR DIS, V135, P123; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; 1990, NEW ENGL J MED, V323, P70; 1989, AM REV RESPIR DIS, V140, P1494; 1991, DHMS NIH913042 PUBL	126	33	33	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1993	328	19					1389	1397		10.1056/NEJM199305133281906	http://dx.doi.org/10.1056/NEJM199305133281906			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB495	8474515				2022-12-28	WOS:A1993LB49500006
J	KOFF, A; OHTSUKI, M; POLYAK, K; ROBERTS, JM; MASSAGUE, J				KOFF, A; OHTSUKI, M; POLYAK, K; ROBERTS, JM; MASSAGUE, J			NEGATIVE REGULATION OF G1 IN MAMMALIAN-CELLS - INHIBITION OF CYCLIN-E-DEPENDENT KINASE BY TGF-BETA	SCIENCE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; SV40 LARGE-T; PROTEIN-KINASE; FISSION YEAST; M-PHASE; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; MESSENGER-RNA; HISTONE-H1 KINASE; DIVISION CYCLE	Transforming growth factor-beta (TGF-beta) is a naturally occurring growth inhibitory polypeptide that arrests the cell cycle in middle to late G1 phase. Cells treated with TGF-beta contained normal amounts of cyclin E and cyclin-dependent protein kinase 2 (Cdk2) but failed to stably assemble cyclin E-Cdk2 complexes or accumulate cyclin E-associated kinase activity. Moreover, G1 phase extracts from TGF-beta-treated cells did not support activation of endogenous cyclin-dependent protein kinases by exogenous cyclins. These effects of TGF-beta, which correlated with the inhibition of retinoblastoma protein phosphorylation, suggest that mammalian G1 cyclin-dependent kinases, like their counterparts in yeast, are targets for negative regulators of the cell cycle.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T., 1983, CELL, V33, P289; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1991, GENETICS, V129, P975; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS S, 1991, P NATL ACAD SCI USA, V88, P1029; PICKHAM KM, 1992, MOL CELL BIOL, V12, P3192, DOI 10.1128/MCB.12.7.3192; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON KJ, 1991, CELL, V63, P1013; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	71	563	588	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					536	539		10.1126/science.8475385	http://dx.doi.org/10.1126/science.8475385			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	8475385				2022-12-28	WOS:A1993KY50400032
J	NANDABALAN, K; PRICE, L; ROEDER, GS				NANDABALAN, K; PRICE, L; ROEDER, GS			MUTATIONS IN U1 SNRNA BYPASS THE REQUIREMENT FOR A CELL TYPE-SPECIFIC RNA SPLICING FACTOR	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; GENE-EXPRESSION; SITE SELECTION; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SYNAPSIS; YEAST; RECOMBINATION; SEQUENCE; DNA	Previous studies have demonstrated that efficient splicing of the primary transcript of the yeast MER2 gene requires the MER1 protein, which is produced only in meiotic cells. A genetic selection was devised to recover second-site mutations that bypass the requirement for MER1 in MER2 RNA splicing. This selection identified a mutation in SNR19, the gene for U1 snRNA. The suppressor mutation affects the first residue in U1 snRNA, allowing this nucleotide to base pair with the eighth nucleotide in the MER2 intron. This base in MER2 lies outside the conserved hexanucleotide that defines the 5' splice site in yeast. The MER2 5' splice site (GUUCGU) differs from the consensus in yeast (GUAYGU) at the third position. When this nucleotide is mutated to restore the consensus, base pairing with U1 snRNA is increased and the requirement for MER1 is alleviated.			NANDABALAN, K (corresponding author), YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA.				NICHD NIH HHS [5-T32-HD07180] Funding Source: Medline; NIGMS NIH HHS [GM-28904, GM-47342] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904, R01GM047342] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V117, P5; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONEY LR, 1988, MOL CELL BIOL, V8, P4009, DOI 10.1128/MCB.8.10.4009; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; GOGUEL V, 1991, GENE DEV, V5, P1430, DOI 10.1101/gad.5.8.1430; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KRETZNER L, 1987, CELL, V50, P593, DOI 10.1016/0092-8674(87)90032-8; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LATCHMAN D S, 1990, New Biologist, V2, P297; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; Parent S A, 1985, Yeast, V1, P83, DOI 10.1002/yea.320010202; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; Parker R, 1987, MOL BIOL RNA NEW PER, P133; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RYMOND RC, 1992, MOL BIOL YEAST SACCH, P143; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAPHIN B, 1989, GENE, V82, P145, DOI 10.1016/0378-1119(89)90039-5; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; Sherman F., 1986, METHODS YEAST GENETI; SILICIANO PG, 1987, SCIENCE, V237, P1484, DOI 10.1126/science.3306922; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STEITZ JA, 1988, STRUCTURE FUNCTION M, P71; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; VOELKELMEIMAN K, 1987, CELL, V48, P1071, DOI 10.1016/0092-8674(87)90714-8; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; YUAN ZA, 1987, MOL CELL BIOL, V7, P3018, DOI 10.1128/MCB.7.8.3018; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; [No title captured]	46	49	51	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					407	415		10.1016/0092-8674(93)90239-M	http://dx.doi.org/10.1016/0092-8674(93)90239-M			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8477451	hybrid			2022-12-28	WOS:A1993KY50500020
J	HONIGMAN, B; THEIS, MK; KOZIOLMCLAIN, J; ROACH, R; YIP, R; HOUSTON, C; MOORE, LG				HONIGMAN, B; THEIS, MK; KOZIOLMCLAIN, J; ROACH, R; YIP, R; HOUSTON, C; MOORE, LG			ACUTE MOUNTAIN-SICKNESS IN A GENERAL TOURIST POPULATION AT MODERATE ALTITUDES	ANNALS OF INTERNAL MEDICINE			English	Article						ALTITUDE SICKNESS; LUNG DISEASES; ACETAZOLAMIDE; HEADACHE; PHYSICAL FITNESS	VENTILATION; DEXAMETHASONE; ACETAZOLAMIDE; PROPHYLAXIS; HYPOXIA	Objective: To determine the incidence of acute mountain sickness in a general population of visitors to moderate elevations, the characteristics associated with it, and its effect on physical activity. Design: A cross-sectional study. Setting: Resort communities located at 6300 to 9700 feet elevation in the Rocky Mountains of Colorado. Participants: Convenience sample of 3158 adult travelers, 16 to 87 years old (mean age [+/- SD], 43.8 +/- 11.8 years). Results: Twenty-five percent of the travelers to moderate elevations developed acute mountain sickness, which occurred in 65% of travelers within the first 12 hours of arrival. Fifty-six percent of those with symptoms reduced their physical activity. The odds favoring acute mountain sickness were 3.5 times as large for visitors whose permanent residence was below 3000 feet elevation as for those whose residence was above 3000 feet; 2.8 times as large for visitors with previous symptoms of acute mountain sickness; and twice as large in travelers younger than 60 years. Women, obese persons, those in poor or average physical condition, and those with underlying lung disease also had a higher occurrence of acute mountain sickness (P < 0.05). Conclusions: Acute mountain sickness occurs in 25% of visitors to moderate altitudes and affects activity in most symptomatic visitors. Persons who are younger, less physically fit, live at sea level, have a history of acute mountain sickness, or have underlying lung problems more often develop these symptoms.	CTR DIS CONTROL, DIV NUTR, ATLANTA, GA 30333 USA; UNIV COLORADO, DEPT ANTHROPOL, DENVER, CO 80202 USA; COLORADO ALTITUDE RES INST, KEYSTONE, CO USA; LOVELACE FDN MED EDUC & RES, ALBUQUERQUE, NM USA	Centers for Disease Control & Prevention - USA; University of Colorado System; University of Colorado Denver; Lovelace Respiratory Research Institute	HONIGMAN, B (corresponding author), UNIV COLORADO, HLTH SCI CTR, 4200 E 9TH AVE, B-215, DENVER, CO 80262 USA.		; Roach, Robert/F-4729-2011	Koziol-McLain, Jane/0000-0003-3453-023X; Roach, Robert/0000-0002-7998-8976				ANHOLM JD, 1979, CHEST, V75, P33, DOI 10.1378/chest.75.1.33; CYMERMAN A, 1979, 1979 P HYP S CALG, P66; DAVIES CTM, 1972, CLIN SCI, V42, P1; DEAN AG, 1990, J WILDERNESS MED, V1, P86, DOI 10.1580/0953-9859-1.2.86; DILL DB, 1980, J APPL PHYSIOL, V48, P6, DOI 10.1152/jappl.1980.48.1.6; ELLSWORTH AJ, 1987, AM J MED, V83, P1024, DOI 10.1016/0002-9343(87)90937-5; EVANS WO, 1976, AVIAT SPACE ENVIR MD, V47, P512; FERRAZZINI G, 1987, BRIT MED J, V294, P1380, DOI 10.1136/bmj.294.6584.1380; GONG H, 1984, AM REV RESPIR DIS, V130, P980; HACKETT PH, 1982, RESPIRATION, V43, P321, DOI 10.1159/000194501; HACKETT PH, 1979, AM J MED, V67, P214, DOI 10.1016/0002-9343(79)90393-0; HACKETT PH, 1976, LANCET, V2, P1149; HACKETT PH, 1983, SEMIN RESPIR MED, V5, P132, DOI 10.1055/s-2007-1011443; Hackett PH, 1989, MANAGEMENT WILDERNES, P1; HARBER MJ, 1981, AVIAT SPACE ENVIR MD, V52, P38; HARRIS CW, 1966, AEROSPACE MED, V37, P1163; HEYES MP, 1983, SEMIN RESPIR MED, V5, P207, DOI 10.1055/s-2007-1011454; HOUSTON CS, 1985, AM ALPINE J, V59, P162; HOUSTON CS, 1987, GOING HIGHER STORY M; JOHNSON TS, 1988, NEW ENGL J MED, V319, P841, DOI 10.1056/NEJM198809293191306; KING AB, 1972, AEROSPACE MED, V43, P419; LARSON EB, 1982, JAMA-J AM MED ASSOC, V248, P328, DOI 10.1001/jama.248.3.328; LUPIHERRERA E, 1982, AM REV RESPIR DIS, V126, P509; MONTGOMERY AB, 1989, JAMA-J AM MED ASSOC, V261, P732, DOI 10.1001/jama.261.5.732; MOORE LG, 1986, J APPL PHYSIOL, V60, P1407, DOI 10.1152/jappl.1986.60.4.1407; MOORE LG, 1987, ANN EMERG MED, V16, P965, DOI 10.1016/S0196-0644(87)80742-4; ROBINSON SM, 1971, AEROSPACE MED, V42, P706; SINGH I, 1969, NEW ENGL J MED, V280, P175, DOI 10.1056/NEJM196901232800402; STAMPER DA, 1980, AVIAT SPACE ENVIR MD, V51, P379; Sutton J., 1992, HYPOXIA MOUNTAIN MED, P327; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; STATISTICAL ANAL SYS; 1991, COLORADO BOARD TOURI	33	327	335	2	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					587	592		10.7326/0003-4819-118-8-199304150-00003	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8452324				2022-12-28	WOS:A1993KW47000003
J	LUBITZ, JD; RILEY, GF				LUBITZ, JD; RILEY, GF			TRENDS IN MEDICARE PAYMENTS IN THE LAST YEAR OF LIFE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OLDER PERSONS; CARE; DEATH; ILL	Background. Increased attention is being paid to the amount and types of medical services rendered in the period before death. There is a popular impression that a greater share of resources is being devoted to dying patients than in the past. We examined trends in the proportion of Medicare expenditures for persons 65 years old or older in their last year of life to determine whether there were any changes from 1976 to 1988. Methods. Using Medicare program data for 1976, 1980, 1985, and 1988, we classified Medicare payments according to whether they were made for people in their last year of life (decedents) or for survivors. We also assigned expenses for care in the last year of life according to intervals of 30 days before the person's death and examined trends according to age. Results. Reflecting the large overall increase in Medicare spending, Medicare costs for decedents rose from $3,488 per person-year in 1976 to $13,316 in 1988. However, Medicare payments for decedents as a percentage of the total Medicare budget changed little, fluctuating between 27.2 and 30.6 percent during the study period. Payments for care during the last 60 days of life expressed as a percentage of payments for the last year also held steady at about 52 percent. Furthermore, the pattern of lower payments for older as compared with younger decedents also prevailed throughout the study period. Conclusions. The same forces that have acted to increase overall Medicare expenditures have affected care for both decedents and survivors. There is no evidence that persons in the last year of life account for a larger share of Medicare expenditures than in earlier years.			LUBITZ, JD (corresponding author), HLTH CARE FINANCING ADM,6325 SECUR BLVD,RM 2504,OAK MEADOWS BLDG,BALTIMORE,MD 21207, USA.							ANDERSON K, 1991, US TODAY        0311, pB3; BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; Brock Dwight B., 1992, P315; CLARK N, 1992, WALL STREET J   0226, pA12; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FORSTER LE, 1988, ARCH INTERN MED, V148, P2540, DOI 10.1001/archinte.148.12.2540; FREUDENHEIM M, 1990, NY TIMES        0205, pA1; GURALNIK JM, 1991, AM J PUBLIC HEALTH, V81, P443, DOI 10.2105/AJPH.81.4.443; KIDDER D, 1992, HEALTH SERV RES, V27, P195; LAWTON MP, 1990, MILBANK Q, V68, P1, DOI 10.2307/3350075; Levit K R, 1991, Health Care Financ Rev, V13, P29; Lubitz J, 1984, Health Care Financ Rev, V5, P117; McMillan A, 1990, Health Care Financ Rev, V12, P1; MORALES P, 1990, COTTAGE GROVE S 1107, pA4; OLESKER M, 1992, BALTIMORE SUN   0114, pD1; ROOS NP, 1987, MILBANK Q, V65, P231, DOI 10.2307/3350021; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; Tukey J. W., 1977, EXPLORATORY DATA ANA; 1991, IMPACT MEDICARE HOSP; 1991, MEDICARE AM HLTH CAR; 1990, MON VITAL STAT REP S, V39	24	498	503	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1092	1096		10.1056/NEJM199304153281506	http://dx.doi.org/10.1056/NEJM199304153281506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KX178	8455667				2022-12-28	WOS:A1993KX17800006
J	MULLERHILL, B				MULLERHILL, B			THE SHADOW OF GENETIC INJUSTICE	NATURE			English	Editorial Material											MULLERHILL, B (corresponding author), UNIV COLOGNE,INST GENET,WEYERTAL 121,W-5000 COLOGNE 41,GERMANY.							HALDANE JBS, 1924, SCI FUTURE	1	12	12	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					491	492		10.1038/362491a0	http://dx.doi.org/10.1038/362491a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464485				2022-12-28	WOS:A1993KW45300022
J	GEORGOPOULOS, AP; TAIRA, M; LUKASHIN, A				GEORGOPOULOS, AP; TAIRA, M; LUKASHIN, A			COGNITIVE NEUROPHYSIOLOGY OF THE MOTOR CORTEX	SCIENCE			English	Article							DIMENSIONAL ARM MOVEMENTS; NEURONAL POPULATION VECTOR; CROSS-CORRELATION ANALYSIS; VISUAL TARGETS; 3-DIMENSIONAL SPACE; STIMULUS DIRECTION; FUNCTIONAL-PROPERTIES; MENTAL ROTATION; DIFFERENT PARTS; CELL DISCHARGE	A major challenge of current neuroscience is to elucidate the brain mechanisms that underlie cognitive function. There is no doubt that cognitive processing in the brain engages large populations of cells. This article explores the logic of investigating these problems by combining psychological studies in human subjects and neurophysiological studies of neuronal populations in the motor cortex of behaving monkeys. The results obtained show that time-varying psychological processes can be visualized in the time-varying activity of neuronal populations. Moreover, the functional interactions between cells in the motor cortex are very similar to those observed in a massively interconnected artificial network performing the same computation.	UNIV MINNESOTA,SCH MED,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT NEUROL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	GEORGOPOULOS, AP (corresponding author), DEPT VET AFFAIRS MED CTR,CTR BRAIN SCI,MINNEAPOLIS,MN 55417, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017413] Funding Source: NIH RePORTER; NINDS NIH HHS [NS17413] Funding Source: Medline; NCHHSTP CDC HHS [PSMH48185] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCHHSTP CDC HHS		ALLUM JHJ, 1982, BRAIN RES, V231, P325, DOI 10.1016/0006-8993(82)90369-9; Armitage P., 1975, SEQUENTIAL MED TRIAL; ASANUMA H, 1973, EXP BRAIN RES, V16, P507, DOI 10.1007/BF00234477; Atiya A., 1989, International Journal of Neural Systems, V1, P103, DOI 10.1142/S0129065789000025; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BROOKS VB, 1965, ARCH ITAL BIOL, V103, P247; Cajal SR, 1955, HISTOLOGIE SYSTEME N, V2; CAMINITI R, 1990, J NEUROSCI, V10, P2039; CAMINITI R, 1991, J NEUROSCI, V11, P1182; CAMINITI R, 1992, CEREB CORTEX, V2, P269, DOI 10.1093/cercor/2.4.269-a; CHENEY PD, 1980, J NEUROPHYSIOL, V44, P773, DOI 10.1152/jn.1980.44.4.773; CONRAD B, 1977, EXP BRAIN RES, V29, P85; Cox D. R., 1962, RENEWAL THEORY; COX DR, 1966, STATISTICAL ANAL SER; DEFELIPE J, 1986, J NEUROSCI, V6, P3749, DOI 10.1523/jneurosci.06-12-03749.1986; EISENMAN LN, 1991, ANAL MODELLING NEURA, P371; EVARTS EV, 1964, J NEUROPHYSIOL, V27, P152, DOI 10.1152/jn.1964.27.2.152; EVARTS EV, 1983, J NEUROPHYSIOL, V49, P1199, DOI 10.1152/jn.1983.49.5.1199; EVARTS EV, 1969, J NEUROPHYSIOL, V32, P375, DOI 10.1152/jn.1969.32.3.375; FORTIER PA, 1989, J NEUROPHYSIOL, V62, P198, DOI 10.1152/jn.1989.62.1.198; FREYD JJ, 1987, PSYCHOL REV, V94, P427, DOI 10.1037/0033-295X.94.4.427; Georgopoulos A. P., 1984, DYNAMIC ASPECTS NEOC, P501; GEORGOPOULOS AP, 1987, EXP BRAIN RES, V65, P361; GEORGOPOULOS AP, 1988, EXP BRAIN RES, V69, P315; GEORGOPOULOS AP, 1992, SCIENCE, V256, P1692, DOI 10.1126/science.256.5064.1692; GEORGOPOULOS AP, 1989, EXP BRAIN RES, V75, P183; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GEORGOPOULOS AP, 1990, ATTENTION PERFORM, V13, P227; GEORGOPOULOS AP, 1985, EXP BRAIN RES S, V10, P176; GROSSBERG S, 1983, IEEE T SYST MAN CYB, V13, P815; HEPPREYMOND MC, 1978, J PHYSIOL-PARIS, V74, P287; HOPFIELD JJ, 1984, P NATL ACAD SCI-BIOL, V81, P3088, DOI 10.1073/pnas.81.10.3088; Humphrey D R, 1983, Adv Neurol, V39, P347; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; KALASKA JF, 1989, J NEUROSCI, V9, P2080; KALASKA JF, 1983, EXP BRAIN RES, V51, P247; KALASKA JF, 1991, MOTOR CONTROL CONCEP, P307; KETTNER RE, 1988, J NEUROSCI, V8, P2938; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KWAN HC, 1987, BRAIN RES, V400, P259, DOI 10.1016/0006-8993(87)90625-1; LEMON R, 1988, TRENDS NEUROSCI, V11, P501, DOI 10.1016/0166-2236(88)90012-4; Lemon RN, 1984, METHODS NEURONAL REC; LUKASHIN AV, 1990, BIOL CYBERN, V63, P377, DOI 10.1007/BF00202754; LUKASHIN AV, UNPUB; LURITO J T, 1988, Society for Neuroscience Abstracts, V14, P342; LURITO JT, 1991, EXP BRAIN RES, V87, P562; MARTIN JH, 1985, EXP BRAIN RES, V57, P427; MARTIN KAC, 1988, Q J EXP PHYSIOL CMS, V73, P637, DOI 10.1113/expphysiol.1988.sp003190; MARTIN KAC, 1991, J PHYSIOL-LONDON, V440, P735; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; MURRAY GM, 1992, J NEUROPHYSIOL, V67, P775, DOI 10.1152/jn.1992.67.3.775; NURNOD Y, 1992, J NEUROSCI, V12, P1435; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OGAWA S, 1990, MAGNET RESON MED, V16, P9, DOI 10.1002/mrm.1910160103; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; OSBORN CE, 1988, J NEUROSCI METH, V24, P125, DOI 10.1016/0165-0270(88)90055-6; PELLIZZER G, IN PRESS EXP BRAIN R; PORTER R, 1981, HDB PHYSL 1, V2, P1063; RICCI G, 1957, 4E C INT EEG NEUR CL, P401; SCHOR RH, 1984, J NEUROPHYSIOL, V51, P136, DOI 10.1152/jn.1984.51.1.136; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; SCHWARTZ AB, 1992, J NEUROPHYSIOL, V68, P528, DOI 10.1152/jn.1992.68.2.528; SCHWARTZ AB, 1989, SOC NEUR ABSTR, V15, P788; SEJNOWSKI TJ, 1976, BIOL CYBERN, V22, P203, DOI 10.1007/BF00365086; SHEPARD RN, 1971, SCIENCE, V171, P701, DOI 10.1126/science.171.3972.701; Shepard RN., 1982, J HIST BEHAV SCI, V19, P301, DOI 10.2307/1422825; SMITH AM, 1975, EXP BRAIN RES, V23, P315; SMITH W S, 1986, Society for Neuroscience Abstracts, V12, P256; SMYRNIS N, 1992, EXP BRAIN RES, V92, P139; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; STEFANIS C, 1964, J NEUROPHYSIOL, V27, P828, DOI 10.1152/jn.1964.27.5.828; STEFANIS C, 1964, J NEUROPHYSIOL, V27, P855, DOI 10.1152/jn.1964.27.5.855; STEINMETZ MA, 1987, J NEUROSCI, V7, P177; SUZUKI I, 1985, J NEUROPHYSIOL, V54, P123, DOI 10.1152/jn.1985.54.1.123; TAKAHASHI K, 1967, J NEUROPHYSIOL, V30, P22, DOI 10.1152/jn.1967.30.1.22; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; TSO DY, 1986, J NEUROSCI, V6, P1160; WILSON VJ, 1984, J NEUROPHYSIOL, V51, P567, DOI 10.1152/jn.1984.51.3.567; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; [No title captured]; NS17413 US PUBL HLTH	86	220	222	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					47	52		10.1126/science.8465199	http://dx.doi.org/10.1126/science.8465199			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8465199				2022-12-28	WOS:A1993KV42300022
J	PARTRIDGE, L; BARTON, NH				PARTRIDGE, L; BARTON, NH			OPTIMALITY, MUTATION AND THE EVOLUTION OF AGING	NATURE			English	Review							LIFE-HISTORY EVOLUTION; DROSOPHILA-MELANOGASTER; QUANTITATIVE GENETICS; ANTAGONISTIC PLEIOTROPY; SENESCENCE; REPRODUCTION; SELECTION; COVARIATION; DOMINANCE; TRAITS	Evolutionary explanations of ageing fall into two classes. Organisms might have evolved the optimal life history, in which survival and fertility late in life are sacrificed for the sake of early reproduction and survival. Alternatively, the life history might be depressed below this optimal compromise by deleterious mutations: because selection against late-acting mutations is weaker, these will impose a greater load on late life. Evidence for the importance of both is emerging, and unravelling their relative importance presents experimentalists with a major challenge.			PARTRIDGE, L (corresponding author), UNIV EDINBURGH, DIV BIOL SCI, ICAPB, W MAINS RD, EDINBURGH EH9 3JT, MIDLOTHIAN, SCOTLAND.		Partridge, Linda/A-5501-2010	Partridge, Linda/0000-0001-9615-0094				[Anonymous], 1988, SEX DEATH PROTOZOA H; AUSTAD SN, 1991, J GERONTOL, V46, pB47, DOI 10.1093/geronj/46.2.B47; BARRETT SCH, 1989, EVOLUTION, V43, P1398, DOI 10.1111/j.1558-5646.1989.tb02591.x; BARTON NH, 1990, GENETICS, V124, P773; BARTON NH, 1989, ANNU REV GENET, V23, P337, DOI 10.1146/annurev.ge.23.120189.002005; Bell G., 1986, Oxford Surveys in Evolutionary Biology, V3, P83; BELL G, 1988, J EVOLUTION BIOL, V1, P67, DOI 10.1046/j.1420-9101.1988.1010067.x; BERNSTEIN C, 1991, AGEING SEX DNA REPAI; BULMER M, 1991, GENETICS, V129, P897; CHARLESWORTH B, 1979, NATURE, V278, P848, DOI 10.1038/278848a0; Charlesworth B., 1994, EVOLUTION AGE STRUCT, V2nd ed, edited by C. Cannings, F. C. Hoppensteadt, and L. A. Segel.; Charlesworth B., 1984, EVOLUTIONARY ECOLOGY, P117; CHARLESWORTH D, 1990, EVOLUTION, V44, P1469, DOI 10.1111/j.1558-5646.1990.tb03839.x; CHARNOV EL, 1989, HEREDITY, V62, P113, DOI 10.1038/hdy.1989.15; CLARK A G, 1987, American Naturalist, V129, P932, DOI 10.1086/284686; Comfort A., 1979, BIOL SENESCENCE; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; EDNEY EB, 1968, NATURE, V220, P281, DOI 10.1038/220281a0; Finch CE, 1990, LONGEVITY SENESCENCE; Fisher RA, 1928, AM NAT, V62, P571, DOI 10.1086/280234; GIESEL JT, 1986, AM NAT, V128, P593, DOI 10.1086/284590; GIESEL JT, 1982, AM NAT, V119, P464, DOI 10.1086/283926; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; Haldane JBS, 1937, AM NAT, V71, P337, DOI 10.1086/280722; HAMILTON WD, 1966, J THEOR BIOL, V12, P12, DOI 10.1016/0022-5193(66)90184-6; HEDGES SB, 1992, NATURE, V356, P708, DOI 10.1038/356708a0; HOULE D, 1991, EVOLUTION, V45, P630, DOI 10.1111/j.1558-5646.1991.tb04334.x; HOULE D, 1992, NATURE, V359, P58, DOI 10.1038/359058a0; HOULE D, 1992, GENETICS, V130, P195; HUGHES DM, 1988, EVOLUTION, V42, P1309, DOI 10.1111/j.1558-5646.1988.tb04190.x; HUTCHINSON EW, 1991, GENETICS, V127, P729; HUTCHINSON EW, 1991, GENETICS, V127, P719; KIMURA M, 1966, GENETICS, V54, P1337; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; KIRKWOOD TBL, 1988, MUTAT RES, P7; KIRKWOOD TBL, 1981, PHYSL ECOLOGY EVOLUT; KONDRASHOV AS, 1992, GENETICS, V132, P603; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; LAMB MJ, 1964, J INSECT PHYSIOL, V10, P487, DOI 10.1016/0022-1910(64)90072-1; LANDE R, 1980, GENETICS, V94, P203; Lessells C.M., 1991, P32; Luckinbill LS, 1988, EVOL ECOL, V2, P85, DOI 10.1007/BF02071591; LUCKINBILL LS, 1988, HEREDITY, V60, P367, DOI 10.1038/hdy.1988.54; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; MARTINEZ DE, 1992, P NATL ACAD SCI USA, V89, P9920, DOI 10.1073/pnas.89.20.9920; MAYNARDSMITH J, 1976, AM NAT, V110, P331, DOI 10.1086/283071; Medawar P., 1952, UNSOLVED PROBLEM BIO; Medawar P. B., 1946, MODERN Q, V2, P30, DOI DOI 10.1111/J.1540-4781.1946.TB04867.X; MUELLER LD, 1987, P NATL ACAD SCI USA, V84, P1974, DOI 10.1073/pnas.84.7.1974; MULLER H, AM J HUM GENET, V2, P111; NESSE RM, 1988, EXP GERONTOL, V23, P445, DOI 10.1016/0531-5565(88)90056-3; ORGEL LE, 1963, P NATL ACAD SCI USA, V49, P517, DOI 10.1073/pnas.49.4.517; ORR HA, 1991, P NATL ACAD SCI USA, V88, P11413, DOI 10.1073/pnas.88.24.11413; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; PARTRIDGE L, 1988, SCIENCE, V241, P1449, DOI 10.1126/science.241.4872.1449; PARTRIDGE L, 1991, PHILOS T R SOC B, V332, P3, DOI 10.1098/rstb.1991.0027; Partridge L., 1989, P421; PARTRIDGE L, 1992, EVOLUTION, V46, P76, DOI [10.2307/2409806, 10.1111/j.1558-5646.1992.tb01986.x]; PARTRIDGE L, 1985, NATURE, V316, P20, DOI 10.1038/316020a0; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; PEASE CM, 1988, J EVOLUTION BIOL, V1, P293, DOI 10.1046/j.1420-9101.1988.1040293.x; POMEROY D, 1990, BIOL J LINN SOC, V40, P53, DOI 10.1111/j.1095-8312.1990.tb00534.x; PROMISLOW DEL, 1991, EVOLUTION, V45, P1869, DOI 10.1111/j.1558-5646.1991.tb02693.x; QUATTRO JM, 1992, P NATL ACAD SCI USA, V89, P348, DOI 10.1073/pnas.89.1.348; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REZNICK D, 1985, OIKOS, V44, P257, DOI 10.2307/3544698; ROPER C, IN PRESS EVOLUTION; ROSE M, 1980, NATURE, V287, P141, DOI 10.1038/287141a0; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; ROSE MR, 1982, HEREDITY, V48, P63, DOI 10.1038/hdy.1982.7; ROSE MR, 1984, AM NAT, V123, P565, DOI 10.1086/284222; ROSE MR, 1985, THEOR POPUL BIOL, V28, P342, DOI 10.1016/0040-5809(85)90034-6; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; ROSE MR, 1987, GENETIC CONSTRAINTS; SCHEINER SM, 1989, EVOL ECOL, V3, P51, DOI 10.1007/BF02147931; SERVICE PM, 1985, EVOLUTION, V39, P943, DOI [10.2307/2408694, 10.1111/j.1558-5646.1985.tb00436.x]; SERVICE PM, 1988, EVOLUTION, V42, P708, DOI 10.1111/j.1558-5646.1988.tb02489.x; SERVICE PM, 1989, J INSECT PHYSIOL, V35, P447, DOI 10.1016/0022-1910(89)90120-0; SHAW RG, 1987, EVOLUTION, V41, P812, DOI 10.1111/j.1558-5646.1987.tb05855.x; SMITH JM, 1978, ANNU REV ECOL SYST, V9, P31, DOI 10.1146/annurev.es.09.110178.000335; SMITH JM, 1958, J EXP BIOL, V35, P832; SPOLSKY CM, 1992, NATURE, V356, P706, DOI 10.1038/356706a0; Stearns S.C., 1992, pi; STEARNS SC, 1976, Q REV BIOL, V51, P3, DOI 10.1086/409052; STENSETH NC, 1984, EVOLUTION, V38, P870, DOI 10.1111/j.1558-5646.1984.tb00358.x; TUCIC N, 1988, HEREDITY, V60, P55, DOI 10.1038/hdy.1988.9; TURELLI M, 1985, GENETICS, V111, P165; TURNER JRG, 1981, ANNU REV ECOL SYST, V12, P99, DOI 10.1146/annurev.es.12.110181.000531; TYNDALEBISCOE M, 1984, B ENTOMOL RES, V74, P341, DOI 10.1017/S0007485300015637; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; WAGNER G, 1987, GENETICS, V122, P223; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461	95	487	497	1	124	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 25	1993	362	6418					305	311		10.1038/362305a0	http://dx.doi.org/10.1038/362305a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455716				2022-12-28	WOS:A1993KU17600049
J	ARTWOHL, RR				ARTWOHL, RR			JFK ASSASSINATION - CONSPIRACY, FORENSIC-SCIENCE, AND COMMON-SENSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											ARTWOHL, RR (corresponding author), UNION MEM HOSP,DEPT EMERGENCY MED,201 E UNIV PKWY,BALTIMORE,MD 21218, USA.							AGUILAR GL, 1992, JAMA-J AM MED ASSOC, V268, P1681, DOI 10.1001/jama.1992.03490130069018; ALVAREZ LW, 1976, AM J PHYS, V44, P813, DOI 10.1119/1.10297; BREO DL, 1992, JAMA-J AM MED ASSOC, V268, P1748, DOI 10.1001/jama.268.13.1748; BREO DL, 1992, JAMA-J AM MED ASSOC, V267, P2804, DOI 10.1001/jama.267.20.2804; BREO DL, 1992, JAMA-J AM MED ASSOC, V267, P2794, DOI 10.1001/jama.267.20.2794; DIMAIO VJM, 1985, GUNSHOT WOUNDS, P42; Lattimer J K, 1968, Int Surg, V50, P524; LATTIMER JK, 1976, SURG GYNECOL OBSTET, V142, P246; LATTIMER JK, 1972, B NEW YORK ACAD MED, V48, P513; LIVINGSTONE HE, 1992, HIGH TREASON 2, P432; MANTIK DW, 1992, JAMA-J AM MED ASSOC, V268, P1684; MARRS J, 1990, CROSSFIRE PLOT KILLE, P39; MICOZZI MS, 1992, JAMA-J AM MED ASSOC, V268, P1684; SMITH WS, 1992, JAMA-J AM MED ASSOC, V268, P1684; SUMMERS A, 1989, CONSPIRACY, P485; WHITE A, 1992, JAMA-J AM MED ASSOC, V268, P1683, DOI 10.1001/jama.1992.03490130069022	16	4	4	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1540	1543		10.1001/jama.269.12.1540	http://dx.doi.org/10.1001/jama.269.12.1540			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445818				2022-12-28	WOS:A1993KR80300028
J	HURWITZ, B; GOODMAN, C; YUDKIN, J				HURWITZ, B; GOODMAN, C; YUDKIN, J			PROMPTING THE CLINICAL CARE OF NON-INSULIN-DEPENDENT (TYPE-II) DIABETIC-PATIENTS IN AN INNER-CITY AREA - ONE MODEL OF COMMUNITY CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; RETINOPATHY	Objective-To evaluate the effectiveness and acceptability of centrally organised prompting for coordinating community care of non-insulin dependent diabetic patients. Design-Randomised single centre trial. Patients allocated to prompted care in the community or to, continued attendance at hospital diabetic clinic (controls). Median follow up two years. Setting-Two hospital outpatient clinics, 38 general practices, and 11 optometrists in the catchment area of a district general hospital in Islington. Patients-181 patients attending hospital outpatient clinics. Null hypothesis-There is no difference in process of medical care measures and medical outcome between prompted community care and hospital clinic care. Results-14 hospital patients failed to receive a single review in the clinic as compared with three patients in the prompted group (chi2=6.1, df=1; p=0.013). Follow up for retinal screening was better in prompted patients than in controls; two prompted patients defaulted as against 12 controls (chi2=6.9, df=1; p=0.008). Three measures per patient yearly were more frequent in prompted patients: tests for albuminuria (median 3.0 v 2.3; p=0.03), plasma glucose estimations (3.1 v 2.5; p=0.003), and glycated haemoglobin estimations (2-4 v 0-9; p<0.001). Continuity of care was better in the prompted group (3.2 v 2.2 reviews by each doctor seen; p<0.001). The study ended with no significant differences between the groups in last recorded random plasma glucose concentration, glycated haemoglobin value, numbers admitted to hospital for a diabetes related reason, and number of deaths. Questionnaires revealed a high level of patient, general practitioner, and optometrist satisfaction. Conclusions-Six monthly prompting of non-insulin treated diabetic patients for care by inner city general practitioners and by optometrists is effective and acceptable.			HURWITZ, B (corresponding author), UCL, WHITTINGTON HOSP, SCH MED, DEPT MED, GREAT NO BLDG, LONDON N19 5NF, ENGLAND.		Yudkin, John S/C-1988-2008					BURNSCOX CJ, 1985, BMJ-BRIT MED J, V290, P1052, DOI 10.1136/bmj.290.6474.1052; BUXTON MJ, 1991, DIABETIC MED, V8, P371, DOI 10.1111/j.1464-5491.1991.tb01612.x; DAY JL, 1987, BRIT MED J, V294, P1590, DOI 10.1136/bmj.294.6587.1590; Doney B J, 1976, J R Coll Gen Pract, V26, P734; DORNAN C, 1983, J ROY COLL GEN PRACT, V33, P151; FINLAY R, 1991, HLTH TRENDS, V23, P104; FOULKES A, 1989, J ROY COLL GEN PRACT, V39, P444; HAINES A, 1992, BMJ-BRIT MED J, V305, P785, DOI 10.1136/bmj.305.6857.785; HAMMERSLEY MS, 1985, BRIT MED J, V291, P1330, DOI 10.1136/bmj.291.6505.1330; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; HILL RD, 1981, DIABETOLOGIA, V20, P670; HILL RD, 1976, BRIT MED J, V1, P1137, DOI 10.1136/bmj.1.6018.1137; IRVING J, 1988, PRACTICAL DIABETES, V51, P215; KEMPLE TJ, 1991, BRIT MED J, V302, P451, DOI 10.1136/bmj.302.6774.451; KOPELMAN P, 1990, DIABETIC MED, V8, P558; KRITZINGER EE, 1984, DIABETIC EYE DISEASE; LINDLEY DV, 1984, NEW CAMBRIDGE ELEMEN; MALINS JM, 1971, BRIT MED J, V4, P161, DOI 10.1136/bmj.4.5780.161; PORTER AMD, 1979, KIRKCALDY COMMUNITY, P75; ROHAN TE, 1989, BMJ-BRIT MED J, V299, P1198, DOI 10.1136/bmj.299.6709.1198; SCULPHER MJ, 1991, DIABETIC MED, V8, P644, DOI 10.1111/j.1464-5491.1991.tb01671.x; SINGH BM, 1984, BRIT MED J, V289, P726, DOI 10.1136/bmj.289.6447.726; TASKER PRW, 1984, PRACTICAL DIABETES, V1, P21; THORN PA, 1973, BRIT MED J, V2, P534, DOI 10.1136/bmj.2.5865.534; WAINE C, 1986, WHY NOT CARE YOUR DI; Wilkes E, 1980, J R Coll Gen Pract, V30, P199; WILLIAMS DRR, 1990, DIABETIC MED, V7, P74, DOI 10.1111/j.1464-5491.1990.tb01312.x; YIANNAKI A, 1989, THESIS CITY U; YUDKIN JS, 1980, J EPIDEMIOL COMMUN H, V34, P277, DOI 10.1136/jech.34.4.277	29	73	73	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					624	630		10.1136/bmj.306.6878.624	http://dx.doi.org/10.1136/bmj.306.6878.624			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461815	Green Published, Bronze			2022-12-28	WOS:A1993KQ85900023
J	SMITH, J				SMITH, J			COUNTDOWN TO COMMUNITY CARE - NEWCASTLE - IF IT DOESNT WORK HERE, IT CANT WORK ANYWHERE	BRITISH MEDICAL JOURNAL			English	Article																		1989, CARING PEOPLE COMMUN; 1989, PARTNERSHIP ACTION S	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					566	569		10.1136/bmj.306.6877.566	http://dx.doi.org/10.1136/bmj.306.6877.566			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461775	Green Published, Bronze			2022-12-28	WOS:A1993KP88600028
J	COOK, JTE; LEVY, JC; PAGE, RCL; SHAW, JAG; HATTERSLEY, AT; TURNER, RC				COOK, JTE; LEVY, JC; PAGE, RCL; SHAW, JAG; HATTERSLEY, AT; TURNER, RC			ASSOCIATION OF LOW-BIRTH-WEIGHT WITH BETA-CELL FUNCTION IN THE ADULT 1ST DEGREE RELATIVES OF NON-INSULIN-DEPENDENT DIABETIC SUBJECTS	BRITISH MEDICAL JOURNAL			English	Article							MODEL ASSESSMENT; GLUCOSE; RESISTANCE; INFUSION; FETAL	Objective-To examine the relation between birth weight and beta cell function in the first degree relatives of non-insulin dependent diabetic subjects. Design-Cross sectional study of 101 adults of known birth weight from 47 families which had at least one member with non-insulin dependent diabetes. Subjects-101 white adults aged mean 43 (SD 7) years. Setting-Oxfordshire, England. Main outcome measures-Glucose tolerance was measured by continuous infusion glucose tolerance test. Beta cell function and insulin sensitivity were calculated from the fasting plasma glucose and insulin concentrations with homeostasis model assessment. Beta cell function was standardised to allow for the confounding effects of age and obesity. Results-Twenty seven subjects had non-insulin dependent diabetes, 32 had impaired glucose tolerance, and 42 were normoglycaemic. Birth weight correlated with the beta cell function of the complete cohort (r(s)=0.29, p=0.005), the non-insulin dependent diabetic subjects (r(s)=0.50, p=0.023), and the non-diabetic subjects (r(s)=0.29, p=0.013). The non-insulin dependent diabetic (n=27) and the non-diabetic (n=74) subjects had similar mean (inter-quartile range) centile birth weight 50% (19%-91%), and 53% (30%-75%) respectively. Non-insulin dependent diabetic subjects had significantly lower beta function than the non-diabetic subjects: 69% (48%-83%) v 97% (86%-120%), p<0.001. Conclusions-The cause of the association between low birth weight and reduced beta cell function in adult life is uncertain. Impaired beta cell function in non-insulin dependent diabetic subjects was not accounted for by low birth weight, and genetic or environmental factors are likely to be necessary for development of diabetes.			COOK, JTE (corresponding author), RADCLIFFE INFIRM,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND.			Hattersley, Andrew/0000-0001-5620-473X; Levy, Jonathan/0000-0002-9486-1885				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HAMMERSLEY MS, 1992, DIABETIC MED S1, V9, P17; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; Hellerstrom C, 1988, PATHOLOGY ENDOCRINE, P141; HOSKER JP, 1985, DIABETOLOGIA, V28, P401, DOI 10.1007/BF00280882; HOSKER JP, 1985, DIABETOLOGIA, V28, P809, DOI 10.1007/BF00291069; LEVY JC, 1991, DIABETOLOGIA, V34, P488, DOI 10.1007/BF00403285; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; ORAHILLY SP, 1986, LANCET, V2, P360; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; SAAD MF, 1990, J CLIN ENDOCR METAB, V70, P1247, DOI 10.1210/jcem-70-5-1247; TANNER JM, 1970, ARCH DIS CHILD, V45, P566, DOI 10.1136/adc.45.242.566; TEMPLE RC, 1989, LANCET, V1, P293, DOI 10.1016/S0140-6736(89)91306-8; THOMSON A M, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P903; van Assche F A, 1979, Contrib Gynecol Obstet, V5, P44; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; WEIR GC, 1982, DIABETOLOGIA, V30, P123; 1985, WHO TECH REP SER, V727	21	79	81	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					302	306		10.1136/bmj.306.6873.302	http://dx.doi.org/10.1136/bmj.306.6873.302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461648	Green Published, Bronze			2022-12-28	WOS:A1993KK71800020
J	FAIRLEY, CK; MCNEIL, JJ; DESMOND, P; SMALLWOOD, R; YOUNG, H; FORBES, A; PURCELL, P; BOYD, I				FAIRLEY, CK; MCNEIL, JJ; DESMOND, P; SMALLWOOD, R; YOUNG, H; FORBES, A; PURCELL, P; BOYD, I			RISK-FACTORS FOR DEVELOPMENT OF FLUCLOXACILLIN ASSOCIATED JAUNDICE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To identify risk factors predisposing to the development of flucloxacillin associated jaundice. Design-Case-control study. Medical records of cases and controls were reviewed and information recorded on standard data collection forms. Setting-Alfred Hospital recruiting subjects from Melbourne, Sydney, and Brisbane. Subjects-Cases were defined as patients who had developed jaundice within eight weeks of stopping flucloxacillin, biochemical test results suggesting cholestasis, normal calibre bile ducts, and not been taking recognised hepatotoxic drugs. 51 of the 53 patients referred were included in the study. Four controls for each case were randomly selected from the patient register of the prescribing doctor. These were defined as patients who had been prescribed flucloxacillin without developing jaundice. Main outcome measures-Demographic characteristics, medical history, indication for flucloxacillin, dose, route and duration of treatment, other drugs, smoking, and previous drug allergies or use of flucloxacillin. Results-Increasing age and a prolonged duration of flucloxacillin treatment were found to be risk factors for the development of jaundice. Patients aged over 55 years had an odds ratio of 18.61 (95% confidence interval 5.16-67.17) compared with patients under 30. The odds ratio for patients prescribed flucloxacillin for over 14 days was 7.13 (2.90 to 17.58) compared with patients treated for 14 days or less. Dose and route of administration were not related to the risk of jaundice. Conclusions-Older patients and those receiving flucloxacillin for longer than two weeks are at a substantially greater risk of jaundice. Careful consideration of the risk-benefit ratio is required when flucloxacillin is used in these settings.	ST VINCENTS HOSP,DEPT GASTROENTEROL,MELBOURNE,VIC,AUSTRALIA; REPATRIAT GEN HOSP,DEPT MED,MELBOURNE,AUSTRALIA; THERAPEUT GOODS ADM,DRUG EVALUAT BRANCH,ADVERSE DRUG REACT SECT,CANBERRA,ACT 2601,AUSTRALIA	St Vincent's Hospital Melbourne	FAIRLEY, CK (corresponding author), MONASH UNIV,ALFRED HOSP,DEPT SOCIAL & PREVENT MED,MELBOURNE,VIC 3181,AUSTRALIA.		McNeil, John/L-6440-2019	McNeil, John/0000-0002-1049-5129; Forbes, Andrew/0000-0003-4269-914X; Christopher, Fairley/0000-0001-9081-1664				COULTER DM, 1990, LANCET, V336, P785, DOI 10.1016/0140-6736(90)93248-N; FAIRLEY CK, 1992, LANCET, V339, P679, DOI 10.1016/0140-6736(92)90837-S; LOBATTO S, 1982, NETH J MED, V25, P47; MIROS M, 1990, AUST NZ J MED, V20, P251, DOI 10.1111/j.1445-5994.1990.tb01032.x; OLSSON R, 1992, J HEPATOL, V15, P154, DOI 10.1016/0168-8278(92)90029-O; SUTHERLAND R, 1970, BMJ-BRIT MED J, V4, P455, DOI 10.1136/bmj.4.5733.455; TURNER IB, 1989, MED J AUSTRALIA, V151, P701, DOI 10.5694/j.1326-5377.1989.tb139652.x	7	68	68	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					233	235		10.1136/bmj.306.6872.233	http://dx.doi.org/10.1136/bmj.306.6872.233			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443520	Bronze, Green Published			2022-12-28	WOS:A1993KJ59100016
J	PIENTA, KJ; ESPER, PS				PIENTA, KJ; ESPER, PS			RISK-FACTORS FOR PROSTATE-CANCER	ANNALS OF INTERNAL MEDICINE			English	Review						PROSTATIC NEOPLASMS; AGE FACTORS; VASECTOMY; DIETARY FATS; RACIAL STOCKS	SERUM SEX-HORMONES; UNITED-STATES; VITAMIN-A; ENVIRONMENTAL-FACTORS; SOCIOECONOMIC-STATUS; CIGARETTE-SMOKING; FREE TESTOSTERONE; LATENT CARCINOMA; FOOD-CONSUMPTION; STEROID-HORMONES	Purpose: To review the current state of knowledge regarding risk factors for prostate cancer. Data Sources: Analysis of the literature through the use of MEDLINE as well as identification of papers through review of article bibliographies and the authors' personal files. Current data were also extracted from the Surveillance, Epidemiology, and End Results Program (SEER) database. Data Selection: A review of risk factors for the development of prostate cancer. Emphasis was placed on identifying larger, controlled studies. Data Synthesis: The clinical incidence of prostate cancer is increasing. Risk factors for prostate cancer appear to include age, race, positive family history, vasectomy, and dietary fat intake. Conclusions: It appears that prostate cancer results from an interplay between endogenous hormones and environmental influences that include, most prominently, dietary fat.	WAYNE STATE UNIV, SCH MED, MEYER L PRENTIS COMPREHENS CANC CTR METROPOLITAN D, DETROIT, MI 48201 USA	Wayne State University			Pienta, Kenneth/E-7679-2015	Pienta, Kenneth/0000-0002-4138-2186	DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005225] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K11CA060156] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CN-05225, CA 60156] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLERCREUTZ H, 1990, SCAND J CLIN LAB INV, V50, P3, DOI 10.3109/00365519009085798; AHLUWALIA B, 1981, CANCER, V48, P2267, DOI 10.1002/1097-0142(19811115)48:10<2267::AID-CNCR2820481023>3.0.CO;2-R; AKAZAKI K, 1973, J NATL CANCER I, V50, P1137, DOI 10.1093/jnci/50.5.1137; ANDREWS GS, 1949, J CLIN PATHOL, V2, P197, DOI 10.1136/jcp.2.3.197; ARMENIAN HK, 1974, LANCET, V2, P115; ARMENIAN HK, 1975, AM J EPIDEMIOL, V102, P47, DOI 10.1093/oxfordjournals.aje.a112133; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; ARMSTRONG BG, 1985, BRIT J IND MED, V42, P540; BAQUET CR, 1991, J NATL CANCER I, V83, P551, DOI 10.1093/jnci/83.8.551; BARNETSON J, 1954, SEM HOP PARIS, V30, P129; Baron E, 1941, ARCH PATHOL, V32, P787; BARTSCH W, 1977, EUR UROL, V3, P47; BERG JW, 1975, CANCER RES, V35, P3345; BLAIR A, 1978, J NATL CANCER I, V61, P1379; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BORING CC, 1992, CA-CANCER J CLIN, V42, P7, DOI 10.3322/canjclin.42.1.7; BOYD AS, 1989, AM J MED, V86, P568, DOI 10.1016/0002-9343(89)90386-0; BRAWER MK, 1990, UROL CLIN N AM, V17, P759; BRESLOW N, 1977, INT J CANCER, V20, P680, DOI 10.1002/ijc.2910200506; Buell P, 1960, J CHRONIC DIS, V12, P600, DOI [10.1016/0021-9681(60)90004-7, DOI 10.1016/0021-9681(60)90004-7]; Cannon L., 1982, CANCER SURV, V1, P47; CARTER BS, 1990, PROSTATE, V16, P187, DOI 10.1002/pros.2990160302; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CARTER BS, 1992, AM ASS CANCER RES P, V33, P240; CARTER HB, 1990, PROSTATE, V16, P39; CARTER HB, 1990, J UROLOGY, V143, P742, DOI 10.1016/S0022-5347(17)40078-4; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CENTIFANTO YM, 1973, J VIROL, V12, P1608, DOI 10.1128/JVI.12.6.1608-1611.1973; CHECKOWAY H, 1987, PROSTATE, V10, P79, DOI 10.1002/pros.2990100111; CLEMMESEN J, 1951, BRIT J CANCER, V5, P159, DOI 10.1038/bjc.1951.17; COFFEY D S, 1987, P1; COFFEY DS, 1979, UICC TECH REP SER, V48, P4; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; DAI WS, 1988, AM J EPIDEMIOL, V128, P796, DOI 10.1093/oxfordjournals.aje.a115033; DECOUFLE P, 1977, DHEW NIOSH77178 PUBL; DHOM G, 1983, J CANCER RES CLIN, V106, P210, DOI 10.1007/BF00402610; DISHI K, 1990, PROSTATE, V17, P269; DRAFTA D, 1982, J STEROID BIOCHEM, V17, P689, DOI 10.1016/0022-4731(82)90572-6; DUNN JE, 1975, CANCER RES, V35, P3240; EDWARDS CN, 1953, CANCER, V6, P531, DOI 10.1002/1097-0142(195305)6:3<531::AID-CNCR2820060311>3.0.CO;2-9; Elghany N A, 1990, Epidemiology, V1, P107, DOI 10.1097/00001648-199003000-00005; ERNSTER VL, 1978, AM J EPIDEMIOL, V107, P311, DOI 10.1093/oxfordjournals.aje.a112546; ERNSTER VL, 1979, J OCCUP ENVIRON MED, V21, P175; ERNSTER VL, 1977, CANCER TREAT REP, V61, P187; FEINBERG AP, 1982, TUMOR CELL HETEROGEN, P469; FINCHAM SM, 1990, PROSTATE, V17, P189, DOI 10.1002/pros.2990170303; FLANDERS WD, 1984, PROSTATE, V5, P621, DOI 10.1002/pros.2990050608; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; FRANKS LM, 1956, LANCET, V271, P1037; GELLER J, 1978, J CLIN ENDOCR METAB, V46, P440; GHANADIAN R, 1979, BRIT J CANCER, V39, P696, DOI 10.1038/bjc.1979.122; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P878, DOI 10.1001/jama.269.7.878; GLANTZ GM, 1964, J UROLOGY, V91, P291, DOI 10.1016/S0022-5347(17)64110-7; GOLDIN BR, 1982, NEW ENGL J MED, V307, P1542, DOI 10.1056/NEJM198212163072502; GRAHAM S, 1983, JNCI-J NATL CANCER I, V70, P687; GRAHAM S, 1960, CANCER, V13, P180, DOI 10.1002/1097-0142(196001/02)13:1<180::AID-CNCR2820130129>3.0.CO;2-6; GREENWALD P, 1974, JNCI-J NATL CANCER I, V53, P335, DOI 10.1093/jnci/53.2.335; GREENWALD P, 1974, JNCI-J NATL CANCER I, V53, P341, DOI 10.1093/jnci/53.2.341; GUILEYARDO JM, 1980, J NATL CANCER I, V65, P311; GYORKEY F, 1967, CANCER RES, V27, P1348; HAAS GP, 1992, J UROLOGY, V147, P290; HABIB FK, 1980, PREV MED, V9, P650, DOI 10.1016/0091-7435(80)90036-5; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; HAKKY SI, 1979, BRIT J UROL, V51, P393, DOI 10.1111/j.1464-410X.1979.tb02893.x; HALPERT B, 1963, CANCER-AM CANCER SOC, V16, P737, DOI 10.1002/1097-0142(196306)16:6<737::AID-CNCR2820160608>3.0.CO;2-Z; HAMALAINEN E, 1984, J STEROID BIOCHEM, V20, P459, DOI 10.1016/0022-4731(84)90254-1; HAMALAINEN EK, 1983, J STEROID BIOCHEM, V18, P369, DOI 10.1016/0022-4731(83)90117-6; HAMMOND GL, 1978, CLIN ENDOCRINOL, V9, P113, DOI 10.1111/j.1365-2265.1978.tb02189.x; HARBITZ TB, 1972, ACTA PATH MICRO IM A, VA 80, P756; HARPER ME, 1976, ACTA ENDOCRINOL-COP, V81, P409, DOI 10.1530/acta.0.0810409; HENDERSON BE, 1982, CANCER RES, V42, P3232; HESHMAT MY, 1985, PROSTATE, V6, P7, DOI 10.1002/pros.2990060103; HESHMAT MY, 1973, MED ANN DIST COLUMBI, V42, P373; HILL P, 1980, PREV MED, V9, P657, DOI 10.1016/0091-7435(80)90037-7; HILL P, 1979, CANCER RES, V39, P5101; HILL PB, 1979, CANCER LETT, V7, P273, DOI 10.1016/S0304-3835(79)80054-3; Hirayama T, 1979, Natl Cancer Inst Monogr, P149; HOLUND B, 1980, SCAND J UROL NEPHROL, V14, P29, DOI 10.3109/00365598009181186; HONDA GD, 1988, BRIT J CANCER, V57, P326, DOI 10.1038/bjc.1988.74; HOOVER R, 1975, PERSONS HIGH RISK CA; HOVENANIAN MS, 1948, SURG GYNECOL OBSTET, V86, P29; HOWIE BJ, 1985, AM J CLIN NUTR, V42, P127, DOI 10.1093/ajcn/42.1.127; HSING AW, 1990, CANCER RES, V50, P6836; Huggins C, 1941, CANCER RES, V1, P293; Hutchison G B, 1976, Semin Oncol, V3, P151; Jackson M A, 1981, Prog Clin Biol Res, V53, P111; KARUBE K, 1961, TOHOKU J EXP MED, V74, P265, DOI 10.1620/tjem.74.265; KAUL L, 1987, Nutrition and Cancer, V9, P123; KERR WK, 1960, CANCER, V13, P550, DOI 10.1002/1097-0142(196005/06)13:3<550::AID-CNCR2820130320>3.0.CO;2-X; KING H, 1963, J CHRON DIS, V16, P117, DOI 10.1016/0021-9681(63)90091-2; KIPLING MD, 1967, LANCET, V730; KOLONEL L, 1977, LANCET, V566; Kolonel L N, 1985, Natl Cancer Inst Monogr, V69, P137; KOLONEL LN, 1987, CANCER RES, V47, P2982; KOLONEL LN, 1988, AM J EPIDEMIOL, V127, P999, DOI 10.1093/oxfordjournals.aje.a114903; KOLONEL LN, 1983, CANCER RES, V43, P2397; KRAIN LS, 1974, PREV MED, V3, P154, DOI 10.1016/0091-7435(74)90070-X; LANCASTER H O, 1952, Med J Aust, V2, P41; LEMEN RA, 1976, ANN NY ACAD SCI, V271, P273, DOI 10.1111/j.1749-6632.1976.tb23122.x; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LIAVAG I, 1968, ACTA PATHOL MIC SC, V73, P338; LLOYD JW, 1970, JOM-J OCCUP MED, V12, P151, DOI 10.1097/00043764-197005000-00002; LUNDBERG S, 1970, Scandinavian Journal of Urology and Nephrology, V4, P93, DOI 10.3109/00365597009137581; MAWSON CA, 1952, CAN J MED SCI, V30, P336, DOI 10.1139/cjms52-043; MCWHORTER WP, 1989, CANCER, V63, P982, DOI 10.1002/1097-0142(19890301)63:5<982::AID-CNCR2820630533>3.0.CO;2-I; MEIKLE AW, 1990, UROL CLIN N AM, V17, P709; MEIKLE AW, 1982, J CLIN ENDOCR METAB, V54, P1104, DOI 10.1210/jcem-54-6-1104; MEIKLE AW, 1985, PROSTATE, V6, P121; MEIKLE AW, 1987, PROSTATE, V10, P25, DOI 10.1002/pros.2990100106; METTLIN C, 1990, AM J EPIDEMIOL, V132, P1056, DOI 10.1093/oxfordjournals.aje.a115747; METTLIN C, 1989, CANCER, V64, P605, DOI 10.1002/1097-0142(19890801)64:3&lt;605::AID-CNCR2820640307&gt;3.0.CO;2-I; MILLS PK, 1989, CANCER, V64, P598, DOI 10.1002/1097-0142(19890801)64:3&lt;598::AID-CNCR2820640306&gt;3.0.CO;2-6; MISHINA T, 1985, PROSTATE, V6, P423, DOI 10.1002/pros.2990060411; MORGANTI G, 1956, Acta Genet Stat Med, V6, P304; MUIR CS, 1991, ACTA ONCOL, V30, P133, DOI 10.3109/02841869109092336; NEWELL GR, 1987, J NATL CANCER I, V79, P259; NEWELL GR, 1989, AM J EPIDEMIOL, V130, P395, DOI 10.1093/oxfordjournals.aje.a115346; NOBLE RL, 1959, CANCER RES, V19, P1125; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; OHNO Y, 1988, CANCER RES, V48, P1331; OOTA K, 1961, ACTA UNION INT CONTR, V17, P952; OWEN WL, 1976, J CHRON DIS, V29, P89, DOI 10.1016/0021-9681(76)90009-6; PIENTA KJ, 1989, CANCER RES, V49, P2525; POTTS CL, 1976, ANN NY ACAD SCI, V271, P273; RANNIKKO S, 1983, PROSTATE, V4, P223, DOI 10.1002/pros.2990040302; REDMOND CK, 1975, COMP CAUSE SPECIFIC; RICHARDSON IM, 1965, BRIT J PREV SOC MED, V19, P140; ROSE DP, 1986, CANCER-AM CANCER SOC, V58, P2363, DOI 10.1002/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-#; ROSS JK, 1990, AM J CLIN NUTR, V51, P365, DOI 10.1093/ajcn/51.3.365; ROSS R, 1986, JNCI-J NATL CANCER I, V76, P45; ROSS RK, 1992, LANCET, V339, P887, DOI 10.1016/0140-6736(92)90927-U; ROSS RK, 1987, JNCI-J NATL CANCER I, V78, P869; ROSS RK, 1981, BRIT J CANCER, V43, P233, DOI 10.1038/bjc.1981.34; ROSS RK, 1983, PROSTATE, V4, P333, DOI 10.1002/pros.2990040403; ROTKIN ID, 1977, CANCER TREAT REP, V61, P173; SANDBERG AA, 1957, J CLIN INVEST, V36, P1266, DOI 10.1172/JCI103524; SANFORD EJ, 1977, J UROLOGY, V118, P789, DOI 10.1016/S0022-5347(17)58194-X; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; SCHRODT GR, 1964, CANCER, V17, P1555, DOI 10.1002/1097-0142(196412)17:12<1555::AID-CNCR2820171207>3.0.CO;2-U; SCHUMAN LM, 1980, PREV MED, V9, P630, DOI 10.1016/0091-7435(80)90035-3; SCHUMAN LM, 1977, CANCER TREAT REP, V61, P181; SCHWARTZ GG, 1990, ANTICANCER RES, V10, P1307; SEIDMAN H, 1970, ENVIRON RES, V3, P234, DOI 10.1016/0013-9351(70)90019-8; SEVERSON RK, 1988, BRIT MED J, V297, P713, DOI 10.1136/bmj.297.6650.713; SEVERSON RK, 1989, CANCER RES, V49, P1857; SHEKELLE RB, 1981, LANCET, V2, P1185; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; SIDNEY S, 1987, J UROLOGY, V138, P795, DOI 10.1016/S0022-5347(17)43377-5; SILVERBERG E, 1988, CA, V38, P14; SLATTERY ML, 1990, AM J CLIN NUTR, V52, P752, DOI 10.1093/ajcn/52.4.752; SNOWDON DA, 1984, AM J EPIDEMIOL, V120, P244, DOI 10.1093/oxfordjournals.aje.a113886; SPITZ MR, 1991, J UROLOGY, V146, P1305, DOI 10.1016/S0022-5347(17)38074-6; SPORN MB, 1976, FED PROC, V35, P1332; STEELE R, 1971, J CHRON DIS, V24, P29, DOI 10.1016/0021-9681(71)90056-7; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; TALAMINI R, 1986, BRIT J CANCER, V53, P817, DOI 10.1038/bjc.1986.138; THIESSEN EU, 1974, CANCER, V34, P1102, DOI 10.1002/1097-0142(197410)34:4<1102::AID-CNCR2820340421>3.0.CO;2-5; VIITANEN I, 1958, Acta Pathol Microbiol Scand, V44, P64; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WATANABE H, 1984, PROSTATE, V5, P559, DOI 10.1002/pros.2990050511; WATERHOUSE J, 1982, 42 INT AG RES CANC P, V6; WEST DW, 1991, CANCER CAUSE CONTROL, V2, P85, DOI 10.1007/BF00053126; WHELAN P, 1983, BRIT J UROL, V55, P525, DOI 10.1111/j.1464-410X.1983.tb03362.x; WHITTEMORE AS, 1991, J NATL CANCER I, V83, P1231, DOI 10.1093/jnci/83.17.1231; WHITTEN CG, 1988, NUTR RES, V8, P1223, DOI 10.1016/S0271-5317(05)80085-5; WILLDEN EG, 1975, BRIT J UROL, V47, P295, DOI 10.1111/j.1464-410X.1975.tb03968.x; WILLIAMS RR, 1977, J NATL CANCER I, V59, P1147, DOI 10.1093/jnci/59.4.1147; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; WOOLF CM, 1960, CANCER, V13, P739, DOI 10.1002/1097-0142(196007/08)13:4<739::AID-CNCR2820130414>3.0.CO;2-E; WYNDER EL, 1971, CANCER, V28, P344, DOI 10.1002/1097-0142(197108)28:2<344::AID-CNCR2820280214>3.0.CO;2-#; WYNDER EL, 1984, PROSTATE, V5, P47, DOI 10.1002/pros.2990050105; YAMABE H, 1986, WORLD J UROL, V4, P136, DOI 10.1007/BF00327009; YATANI R, 1982, INT J CANCER, V29, P611, DOI 10.1002/ijc.2910290602; YATANI R, 1988, J NATL CANCER I, V80, P683, DOI 10.1093/jnci/80.9.683; YU H, 1991, INT J EPIDEMIOL, V20, P76, DOI 10.1093/ije/20.1.76; 1957, OCCUP MORT 2	178	355	358	1	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					793	803		10.7326/0003-4819-118-10-199305150-00007	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	8470854				2022-12-28	WOS:A1993LB64900007
J	HODES, RM				HODES, RM			A BIRTH IN TEDDA	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ATTITUDE TO DEATH; MIDWIFERY; DEVELOPING COUNTRIES; ETHIOPIA; PHYSICIANS ROLE		A Western physician in rural Ethiopia finds himself helpless when a local woman insists on delivering a baby her own way. A chicken and frankincense are used to ward off an evil spirit, and the woman delivers a discourse on her delivery techniques.			HODES, RM (corresponding author), AMER JOINT DISTRIBUT COMM, POB 7600, ADDIS ABABA, ETHIOPIA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					738	740		10.7326/0003-4819-118-9-199305010-00013	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460862				2022-12-28	WOS:A1993KY50200012
J	BELL, MR; HOLMES, DR; BERGER, PB; GARRATT, KN; BAILEY, KR; GERSH, BJ				BELL, MR; HOLMES, DR; BERGER, PB; GARRATT, KN; BAILEY, KR; GERSH, BJ			THE CHANGING IN-HOSPITAL MORTALITY OF WOMEN UNDERGOING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; BYPASS-SURGERY; SEX-DIFFERENCES; ARTERY DISEASE; EXPERIENCE; REGISTRY; CATHETER; MEN; OCCLUSION; EFFICACY	Objective.-To compare in-hospital mortality among women and men undergoing percutaneous transluminal coronary angioplasty (PTCA) and determine whether mortality differences have changed recently. Design.-A retrospective cohort study. Setting.-Tertiary referral institution. Patients.-Consecutive series of 3557 patients (27% women) who underwent 4071 PTCA procedures. Two cohorts were analyzed: patients treated between 1979 and 1987 (n=1970) and those treated between 1988 and 1990 (n=2101). Main Outcome Measures.-In-hospital and periprocedural mortality. Results.-Women were older than men (P<.001) and more had class III or IV angina (P<.001), unstable angina (P<.001), angina at rest (P<.001), cardiac failure (P<.001), and diabetes mellitus, hypertension, and hypercholesterolemia (P<.001). The PTCA was successful in 85% of women and 86% of men with an in-hospital mortality rate of 4.2% and 2.7%, respectively (P=.005). No significant change in mortality occurred in men between the early (2.2%) and late (3.1%) eras in contrast to a significant increase among women, 2.9% to 5.4% (P=.04). Periprocedural mortalities for women and men between 1979 and 1987 were 1.0% and 1.2% (P=not significant) and between 1988 and 1990 were 2.9% and 1.4% (P=.02), respectively. The multivariate odds ratio of in-hospital mortality for women vs men was 1.51 (95% confidence interval, 1.00 to 2.29; P=.05), although six other baseline variables were more powerful predictors of in-hospital mortality. Accounting for body surface area resulted in no significant association between gender and in-hospital mortality. Periprocedural mortality was not independently associated with gender. Conclusions.-In-hospital mortality among women has increased in recent years, but their higher mortality compared with men is related more to the severity of their underlying disease rather than gender alone.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI STAT, ROCHESTER, MN 55905 USA	Mayo Clinic	BELL, MR (corresponding author), MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BELL MR, 1990, J AM COLL CARDIOL, V16, P553, DOI 10.1016/0735-1097(90)90342-M; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; COWLEY MJ, 1985, CIRCULATION, V72, P1314, DOI 10.1161/01.CIR.72.6.1314; DELIGONUL U, 1988, J AM COLL CARDIOL, V11, P1173, DOI 10.1016/0735-1097(88)90278-1; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DOUGLAS JS, 1981, CIRCULATION, V64, P11; ELLIS SG, 1988, J AM COLL CARDIOL, V11, P211, DOI 10.1016/0735-1097(88)90082-4; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; GRUENTZIG AR, 1987, NEW ENGL J MED, V316, P1127, DOI 10.1056/NEJM198704303161805; HOLMES DR, 1988, J AM COLL CARDIOL, V12, P1149, DOI 10.1016/0735-1097(88)92593-4; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MCENIERY PT, 1987, CATHETER CARDIO DIAG, V13, P364, DOI 10.1002/ccd.1810130602; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; QUIGLEY PJ, 1988, CIRCULATION, V78, P1128, DOI 10.1161/01.CIR.78.5.1128; ROTHBAUM DA, 1987, J AM COLL CARDIOL, V10, P264, DOI 10.1016/S0735-1097(87)80006-2; SIGWART U, 1988, CIRCULATION, V78, P1121, DOI 10.1161/01.CIR.78.5.1121; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; SIMOONS ML, 1988, LANCET, V1, P199; SIMPSON JB, 1982, AM J CARDIOL, V49, P1216, DOI 10.1016/0002-9149(82)90047-9; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; TURI ZG, 1987, CIRCULATION, V75, P1273, DOI 10.1161/01.CIR.75.6.1273; VLIETSTRA RE, 1981, MAYO CLIN PROC, V56, P287; VLIETSTRA RE, 1989, INTERVENTIONAL CARDI, P64; 1990, PHS901102 NAT CTR HL, V2	31	106	108	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2091	2095		10.1001/jama.269.16.2091	http://dx.doi.org/10.1001/jama.269.16.2091			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468762				2022-12-28	WOS:A1993KY36600029
J	HOLLSBERG, P; HAFLER, DA				HOLLSBERG, P; HAFLER, DA			PATHOGENESIS OF DISEASES INDUCED BY HUMAN LYMPHOTROPIC VIRUS TYPE-I INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							T-CELL LEUKEMIA; TROPICAL SPASTIC PARAPARESIS; TUMOR-NECROSIS-FACTOR; CHRONIC PROGRESSIVE MYELOPATHY; CHRONIC INFLAMMATORY ARTHROPATHY; FACTOR-BETA-1 TGF-BETA-1 GENE; COMPLETE NUCLEOTIDE-SEQUENCE; CYTOTOXIC LYMPHOCYTES-T; HUMAN-ENDOTHELIAL CELLS; HTLV-I		BRIGHAM & WOMENS HOSP, CTR NEUROL DIS,DEPT MED,DIV NEUROL, 221 LONGWOOD AVE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								AKAGI T, 1988, JPN J CANCER RES, V79, P836, DOI 10.1111/j.1349-7006.1988.tb00045.x; ARAI N, 1989, J IMMUNOL, V142, P274; ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; AZUMA C, 1986, NUCLEIC ACIDS RES, V14, P9149, DOI 10.1093/nar/14.22.9149; BARTHOLOMEW C, 1987, JAMA-J AM MED ASSOC, V257, P2604, DOI 10.1001/jama.257.19.2604; BARTHOLOMEW C, 1986, LANCET, V2, P99; BHAGAVATI S, 1988, NEW ENGL J MED, V318, P1141, DOI 10.1056/NEJM198805053181801; BHIGJEE AI, 1991, NEUROLOGY, V41, P1990, DOI 10.1212/WNL.41.12.1990; BLATTNER WA, 1982, INT J CANCER, V30, P257, DOI 10.1002/ijc.2910300302; BLATTNER WA, 1983, J INFECT DIS, V147, P406, DOI 10.1093/infdis/147.3.406; BROD SA, 1990, EUR J IMMUNOL, V20, P2259, DOI 10.1002/eji.1830201015; BROSNAN CF, 1988, J NEUROIMMUNOL, V18, P87, DOI 10.1016/0165-5728(88)90137-3; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; CANN AJ, 1990, FIELDS VIROLOGY, P150; CERONI M, 1988, ANN NEUROL, V23, pS188, DOI 10.1002/ana.410230742; CHEN YMA, 1990, HUMAN RETROVIROLOGY : HTLV, P447; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; CLAPHAM P, 1983, SCIENCE, V222, P1125, DOI 10.1126/science.6316502; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; CRUICKSHANK E K, 1956, West Indian Med J, V5, P147; CRUICKSHANK JK, 1989, BRAIN, V112, P1057, DOI 10.1093/brain/112.4.1057; CRUICKSHANK JK, 1992, NEUROLOGICAL ASPECTS, V1, P61; DAENEN S, 1984, BRIT J HAEMATOL, V58, P723, DOI 10.1111/j.1365-2141.1984.tb06119.x; DAENKE S, 1990, J VIROL, V64, P1278, DOI 10.1128/JVI.64.3.1278-1282.1990; DALGLEISH A, 1988, AIDS RES HUM RETROV, V4, P475, DOI 10.1089/aid.1988.4.475; DALGLEISH AG, 1990, HUMAN RETROVIROLOGY : HTLV, P45; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DETHE G, 1990, HUMAN RETROVIROLOGY : HTLV, P333; DETHE G, 1989, J ACQ IMMUN DEF SYND, V2, P550; DUNCAN J, 1990, J NEUROL NEUROSUR PS, V53, P173, DOI 10.1136/jnnp.53.2.173-a; Ellerman V., 1908, ZBL BAKT, V46, P595; GESSAIN A, 1985, LANCET, V2, P407; GESSAIN A, 1986, LANCET, V2, P698; GOEBELS N, 1988, J IMMUNOL, V141, P1231; GOUT O, 1990, NEW ENGL J MED, V322, P383, DOI 10.1056/NEJM199002083220607; GREENBERG SJ, 1989, J INFECT DIS, V159, P741, DOI 10.1093/infdis/159.4.741; HARPER ME, 1986, NEW ENGL J MED, V315, P1073, DOI 10.1056/NEJM198610233151707; HIGUCHI I, 1992, MUSCLE NERVE, V15, P43, DOI 10.1002/mus.880150108; HINO S, 1985, JPN J CANCER RES, V76, P474; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAMATSU K, 1986, INT J CANCER, V37, P601, DOI 10.1002/ijc.2910370420; HIROSE S, 1986, LANCET, V2, P397; HO DD, 1984, P NATL ACAD SCI-BIOL, V81, P7588, DOI 10.1073/pnas.81.23.7588; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HOSHINO H, 1984, NATURE, V310, P324, DOI 10.1038/310324a0; HOXIE JA, 1984, P NATL ACAD SCI-BIOL, V81, P7591, DOI 10.1073/pnas.81.23.7591; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; IJICHI S, 1990, ANN RHEUM DIS, V49, P718, DOI 10.1136/ard.49.9.718; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITOYAMA Y, 1988, NEUROLOGY, V38, P1302, DOI 10.1212/WNL.38.8.1302; ITOYAMA Y, 1989, ANN NEUROL, V26, P257, DOI 10.1002/ana.410260212; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; JACOBSON S, 1990, ANN NEUROL, V27, P149, DOI 10.1002/ana.410270209; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JACOBSON S, 1988, ANN NEUROL, V23, pS196, DOI 10.1002/ana.410230744; JACOBSON S, 1991, J IMMUNOL, V146, P1155; JACOBSON S, 1992, ANN NEUROL, V32, P651, DOI 10.1002/ana.410320508; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JARRETT RF, 1986, J EXP MED, V163, P383, DOI 10.1084/jem.163.2.383; KANAMORI H, 1990, EMBO J, V9, P4161, DOI 10.1002/j.1460-2075.1990.tb07639.x; KANNAGI M, 1984, J IMMUNOL, V133, P1037; KANNAGI M, 1983, J IMMUNOL, V130, P2942; KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096; KAWANO F, 1985, CANCER-AM CANCER SOC, V55, P851, DOI 10.1002/1097-0142(19850215)55:4<851::AID-CNCR2820550424>3.0.CO;2-J; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KINOSHITA K, 1985, BLOOD, V66, P120; KITAJIMA I, 1991, J CLIN INVEST, V88, P1315, DOI 10.1172/JCI115436; Kitajima I, 1988, Autoimmunity, V1, P125, DOI 10.3109/08916938809001925; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; LAGRENADE L, 1990, LANCET, V336, P1345; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P3856, DOI 10.1073/pnas.81.12.3856; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; LINK H, 1989, NEUROLOGY, V39, P1566, DOI 10.1212/WNL.39.12.1566; LOFTERS W, 1987, CANCER, V60, P2605, DOI 10.1002/1097-0142(19871201)60:11<2605::AID-CNCR2820601104>3.0.CO;2-T; MACATONIA SE, 1992, AIDS RES HUM RETROV, V8, P1699, DOI 10.1089/aid.1992.8.1699; MALONEY EM, 1989, INT J CANCER, V44, P419, DOI 10.1002/ijc.2910440307; MALONEY EM, 1992, ENDEMIC HUMAN T CELL, V166, P100; MITSUYA H, 1983, J EXP MED, V158, P994, DOI 10.1084/jem.158.3.994; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MOCHIZUKI M, 1992, JPN J CANCER RES, V83, P236, DOI 10.1111/j.1349-7006.1992.tb00092.x; MONTGOMERY RD, 1964, BRAIN, V87, P425, DOI 10.1093/brain/87.3.425; MOORE GRW, 1989, ANN NEUROL, V26, P523, DOI 10.1002/ana.410260405; MORGAN OS, 1989, LANCET, V2, P1184; MORIMOTO C, 1985, J CLIN INVEST, V75, P836, DOI 10.1172/JCI111780; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; MURPHY EL, 1989, ANN INTERN MED, V111, P555, DOI 10.7326/0003-4819-111-7-555; NAGASATO K, 1991, J NEUROL SCI, V103, P203, DOI 10.1016/0022-510X(91)90165-4; NEWTON M, 1987, LANCET, V1, P415; NIITSU Y, 1988, BLOOD, V71, P263; NISHIOKA K, 1989, LANCET, V1, P441; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OSAME M, 1987, ANN NEUROL, V22, P116; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; OSAME M, 1986, LANCET, V1, P1031; OSAME M, 1986, LANCET, V2, P104; PALKER TJ, 1989, J IMMUNOL, V142, P971; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; POPOVIC M, 1982, NATURE, V300, P63, DOI 10.1038/300063a0; REEVES WC, 1988, AM J EPIDEMIOL, V127, P532, DOI 10.1093/oxfordjournals.aje.a114828; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; ROBERTS AB, 1983, FED PROC, V42, P2621; RODGERSJOHNSON P, 1985, LANCET, V2, P1247; ROMAN GC, 1987, NEW ENGL J MED, V316, P51; ROMAN GC, 1988, LANCET, V1, P651; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; RUDGE P, 1991, J NEUROL NEUROSUR PS, V54, P689, DOI 10.1136/jnnp.54.8.689; RUSCETTI FW, 1986, J IMMUNOL, V136, P3619; SALAHUDDIN SZ, 1984, SCIENCE, V223, P703, DOI 10.1126/science.6320367; SALAZARGRUESO EF, 1990, NEW ENGL J MED, V323, P732, DOI 10.1056/NEJM199009133231107; SARIN PS, 1989, P NATL ACAD SCI USA, V86, P2021, DOI 10.1073/pnas.86.6.2021; SAXINGER W, 1984, SCIENCE, V225, P1473, DOI 10.1126/science.6089348; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SHIBASAKI H, 1988, J NEUROL SCI, V87, P15, DOI 10.1016/0022-510X(88)90050-0; SHIMIZU K, 1985, J IMMUNOL, V134, P1728; SHIRAKAWA F, 1986, CANCER RES, V46, P4458; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SOMMERFELT MA, 1988, SCIENCE, V242, P1557, DOI 10.1126/science.3201246; SUEHARA M, 1989, HTLVI NERVOUS SYSTEM, V51, P203; SUGAMURA K, 1983, J IMMUNOL, V131, P1611; TAGAWA S, 1985, SCAND J HAEMATOL, V34, P360; TAJIMA K, 1990, HUMAN RETROVIROLOGY : HTLV, P267; TAKATSUKI K, 1985, CANCER RES, V45, P4644; TANAKA Y, 1991, J IMMUNOL, V147, P354; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; TOKUDOME S, 1989, CANCER RES, V49, P226; TSCHACHLER E, 1990, HUMAN RETROVIROLOGY : HTLV, P105; TSCHACHLER E, 1989, BLOOD, V73, P194; TSUJIMOTO A, 1988, MOL BIOL MED, V5, P29; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; USUKU K, 1988, ANN NEUROL, V23, pS143, DOI 10.1002/ana.410230733; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; VERNANT JC, 1987, ANN NEUROL, V21, P123, DOI 10.1002/ana.410210204; WALDMANN TA, 1990, JAMA-J AM MED ASSOC, V263, P272, DOI 10.1001/jama.263.2.272; WALDMANN TA, 1984, J CLIN INVEST, V73, P1711, DOI 10.1172/JCI111379; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; WATABE K, 1989, J NEUROPATH EXP NEUR, V48, P610, DOI 10.1097/00005072-198911000-00003; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; WEISS RA, 1985, CURR TOP MICROBIOL, V115, P235; WILEY CA, 1989, NEW ENGL J MED, V320, P992, DOI 10.1056/NEJM198904133201507; WILLIAMS AE, 1988, SCIENCE, V240, P643, DOI 10.1126/science.2896386; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P2110, DOI 10.1073/pnas.89.6.2110; YAMAGUCHI K, 1990, HUMAN RETROVIROLOGY : HTLV, P163; YAMAMOTO N, 1982, NATURE, V299, P367, DOI 10.1038/299367a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; YOSHIDA M, 1987, LANCET, V1, P1085; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1989, ANN NEUROL, V26, P331, DOI 10.1002/ana.410260304; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; 1989, WEEKLY EPIDEMIOLOGIC, V382, P3	159	291	297	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1173	1182						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY447	8455685				2022-12-28	WOS:A1993KY44700008
J	BEESE, LS; DERBYSHIRE, V; STEITZ, TA				BEESE, LS; DERBYSHIRE, V; STEITZ, TA			STRUCTURE OF DNA-POLYMERASE-I KLENOW FRAGMENT BOUND TO DUPLEX DNA	SCIENCE			English	Article							ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; 3'-5' EXONUCLEASE; CRYSTAL-STRUCTURE; IDENTIFICATION; INACTIVATION; COMPLEX; ENZYME; SITES; ACID	Klenow fragment of Escherichia coli DNA polymerase I, which was cocrystallized with duplex DNA, positioned 11 base pairs of DNA in a groove that lies at right angles to the cleft that contains the polymerase active site and is adjacent to the 3' to 5' exonuclease domain. When the fragment bound DNA, a region previously referred to as the ''disordered domain'' became more ordered and moved along with two helices toward the 3' to 5' exonuclease domain to form the binding groove. A single-stranded, 3' extension of three nucleotides bound to the 3' to 5' exonuclease active site. Although this cocrystal structure appears to be an editing complex, it suggests that the primer strand approaches the catalytic site of the polymerase from the direction of the 3' to 5' exonuclease domain and that the duplex DNA product may bend to enter the cleft that contains the polymerase catalytic site.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511; YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511	Yale University; Howard Hughes Medical Institute; Yale University; Yale University			Steitz, Thomas A./C-6559-2009; beese, lorena/G-4993-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BASU S, 1988, BIOCHEMISTRY-US, V27, P6710, DOI 10.1021/bi00418a011; BEESE L, UNPUB; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BRUNGER AT, 1990, X PLOR MANUAL; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; CATALANO CE, 1989, BIOCHEMISTRY-US, V28, P4374, DOI 10.1021/bi00436a038; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREIDMAN JM, UNPUB; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P8759, DOI 10.1021/bi00100a007; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CR, UNPUB; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOLOCHEVA TI, 1989, FEBS LETT, V248, P97, DOI 10.1016/0014-5793(89)80439-9; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OLLIS DL, 1985, NATURE, V313, P818, DOI 10.1038/313818a0; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; STEITZ TA, 1987, COLD SPRING HARB SYM, V52, P465, DOI 10.1101/SQB.1987.052.01.053; TENHEGGELERBORDIER B, 1992, EMBO J, V11, P667, DOI 10.1002/j.1460-2075.1992.tb05098.x; WARWICKER J, 1985, J MOL BIOL, V186, P645, DOI 10.1016/0022-2836(85)90136-6; XUONG NH, 1978, ACTA CRYSTALLOGR A, V34, P289, DOI 10.1107/S0567739478000546	32	463	490	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					352	355		10.1126/science.8469987	http://dx.doi.org/10.1126/science.8469987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8469987				2022-12-28	WOS:A1993KX80000038
J	SIMON, MA; DODSON, GS; RUBIN, GM				SIMON, MA; DODSON, GS; RUBIN, GM			AN SH3-SH2-SH3 PROTEIN IS REQUIRED FOR P21(RAS1) ACTIVATION AND BINDS TO SEVENLESS AND SOS PROTEINS INVITRO	CELL			English	Article							DEVELOPING DROSOPHILA EYE; GLUTATHIONE-S-TRANSFERASE; ELEGANS VULVAR INDUCTION; SIGNAL TRANSDUCTION; TYROSINE KINASE; CELL FATES; CAENORHABDITIS-ELEGANS; ESCHERICHIA-COLI; GENE; PHOTORECEPTOR	Activation of the sevenless protein-tyrosine kinase is required for the proper specification of R7 photoreceptors in the Drosophila eye. The activation of a Ras protein, p21Ras1, is a crucial early event in the signaling pathway, and constitutive activation of p21Ras1 is sufficient to induce all of the effects of sevenless action. Here we report that another gene, E(sev)2B, required for proper signaling by sevenless encodes a protein of the structure SH3-SH2-SH3. We further provide evidence that the E(sev)2B protein is required for activation of p21Ras1 but not for any subsequent events, and that this protein can bind in vitro to sevenless and to Son of sevenless (Sos), a putative guanine nucleotide exchange factor for p21Ras1. These results suggest that the E(sev)2B protein may act to stimulate the ability of Sos to catalyze p21Ras1 activation by linking sevenless and Sos in a signaling complex. We have renamed the E(sev)2B locus downstream of receptor kinases (drk).	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	SIMON, MA (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Rubin, Gerald/0000-0001-8762-8703	NATIONAL EYE INSTITUTE [R01EY009845] Funding Source: NIH RePORTER; NEI NIH HHS [1RO1EY9845-01] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; KARPEN GH, 1992, GENETICS, V132, P737; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; LI BQ, 1992, SCIENCE, V256, P1546; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OLIVIER JP, 1993, IN PRESS CELL, V73; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; SZEBERENYI J, 1992, MOL CELL BIOL, V7, P2105; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; XU T, 1993, IN PRESS DEVELOPMENT	35	443	452	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					169	177		10.1016/0092-8674(93)90169-Q	http://dx.doi.org/10.1016/0092-8674(93)90169-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462097				2022-12-28	WOS:A1993KW75300017
J	GRAHAM, GG				GRAHAM, GG			STARVATION IN THE MODERN WORLD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTEIN-CALORIE MALNUTRITION; CHILDREN		JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21205 USA; INST INVEST NUTR, LIMA, PERU	Johns Hopkins University								APPLETON J, 1987, DROUGHT RELIEF ETHIO, P48; AYKROYD WR, 1974, FAMINE IRELAND, P34; BRUNSER O, 1966, PEDIATRICS, V38, P605; CAHILL GF, 1978, ECOL FOOD NUTR, V6, P221, DOI 10.1080/03670244.1978.9990501; CHEEK DB, 1970, PEDIATR RES, V4, P135, DOI 10.1203/00006450-197003000-00004; DRENICK EJ, 1964, JAMA-J AM MED ASSOC, V187, P100; GRAHAM GG, 1986, J NUTR, V116, P978, DOI 10.1093/jn/116.6.978; GRAHAM GG, 1969, JOHNS HOPKINS MED J, V124, P139; GRAHAM GG, 1971, AM J CLIN NUTR, V24, P416; GRAHAM GG, 1973, AM J CLIN NUTR, V26, P491, DOI 10.1093/ajcn/26.5.491; HANSEN JDL, 1954, LANCET, V2, P477; HINTZ RL, 1978, J PEDIATR-US, V92, P153, DOI 10.1016/S0022-3476(78)80099-7; IFEKWUNIGWE AE, 1975, AM J CLIN NUTR, V28, P79, DOI 10.1093/ajcn/28.1.79; KEYS A, 1950, BIOL HUMAN STARVATIO, V2, P769; MAYER J, 1971, FAMINE S DEALING NUT, P178; MCLAREN DS, 1974, LANCET, V2, P93; RAMALINGASWAMI V, 1971, FAMINE S DEALING NUT, P94; SCRIMSHAW NS, 1972, P NUTR SOC, V31, P219; Stein Z., 1975, FAMINE HUM DEV DUTCH; TEPLY LJ, 1971, FAMINE S DEALING NUT, P165; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; Viteri F E, 1968, Vitam Horm, V26, P573; VITERI FE, 1971, FAMINE S DEALING NUT, P25	24	15	15	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1058	1061		10.1056/NEJM199304083281429	http://dx.doi.org/10.1056/NEJM199304083281429			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	8450873				2022-12-28	WOS:A1993KW28200038
J	WINAWER, SJ; ZAUBER, AG; OBRIEN, MJ; HO, MN; GOTTLIEB, L; STERNBERG, SS; WAYE, JD; BOND, J; SCHAPIRO, M; STEWART, ET; PANISH, J; ACKROYD, F; KURTZ, RC; SHIKE, M				WINAWER, SJ; ZAUBER, AG; OBRIEN, MJ; HO, MN; GOTTLIEB, L; STERNBERG, SS; WAYE, JD; BOND, J; SCHAPIRO, M; STEWART, ET; PANISH, J; ACKROYD, F; KURTZ, RC; SHIKE, M			RANDOMIZED COMPARISON OF SURVEILLANCE INTERVALS AFTER COLONOSCOPIC REMOVAL OF NEWLY DIAGNOSED ADENOMATOUS POLYPS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLORECTAL ADENOMAS; SUBSEQUENT CARCINOMA; FOLLOW-UP; RISK; CANCER; INDIVIDUALS; POLYPECTOMY; POPULATION; COLON	Background. The identification and removal of adenomatous polyps and post-polypectomy surveillance are considered to be important for the control of colorectal cancer. In current practice, the intervals between colonoscopies after polypectomy are variable, often a year long, and not based on data from randomized clinical trials. We sought to determine whether follow-up colonoscopy at three years would detect important colonic lesions as well as follow-up colonoscopy at both one and three years. Methods. Patients were eligible if they had one or more adenomas, no previous polypectomy, and a complete colonoscopy and if all their polyps had been removed. They were randomly assigned to have follow-up colonoscopy at one and three years or at three years only. The two study end points were the detection of any adenoma, and the detection of adenomas with advanced pathological features (defined as those >1 cm in diameter and those with high-grade dysplasia or invasive cancer). Results. Of 2632 eligible patients, 1418 were randomly assigned to the two follow-up groups, 699 to the two-examination group and 719 to the one-examination group. The percentage of patients with adenomas in the group examined at one and three years was 41.7 percent, as compared with 32.0 percent in the group examined at three years (P = 0.006). The percentage of patients with adenomas with advanced pathological features was the same in both groups (3.3 percent). Conclusions. Colonoscopy performed three years after colonoscopic removal of adenomatous polyps detects important colonic lesions as effectively as follow-up colonoscopy after both one and three years. An interval of at least three years is recommended before follow-up examination after colonoscopic removal of newly diagnosed adenomatous polyps. Adoption of this recommendation nationally should reduce the cost of post-polypectomy surveillance and screening.	MEM SLOAN KETTERING CANC CTR,NATL POLYP STUDY HEADQUARTERS,NEW YORK,NY 10021; MT SINAI HOSP,NEW YORK,NY; VET AFFAIRS MED CTR,MINNEAPOLIS,MN; VALLEY PRESBYTERIAN HOSP,VAN NUYS,CA; CEDARS SINAI MED CTR,LOS ANGELES,CA 90048; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; BOSTON CITY HOSP,MALLORY INST PATHOL,BOSTON,MA 02118; MILWAUKEE CTY MED CTR,MILWAUKEE,WI	Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Cedars Sinai Medical Center; Harvard University; Massachusetts General Hospital; Boston Medical Center			O'Brien, Michael J/R-7179-2019	O'Brien, Michael J/0000-0003-1124-3537	NCI NIH HHS [CA-26852] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026852] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1989, SAS STAT USERS GUIDE, V2; ARMITAGE P, 1987, STATISTICAL METHODS, P411; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; AUBERT H, 1982, GASTROEN CLIN BIOL, V6, P183; EIDE TJ, 1986, INT J CANCER, V38, P173, DOI 10.1002/ijc.2910380205; FOWLER DL, 1980, GASTROINTEST ENDOSC, V26, P67; HENRY LG, 1975, ANN SURG, V182, P511, DOI 10.1097/00000658-197510000-00017; HIXSON LJ, 1990, JNCI-J NATL CANCER I, V82, P1769, DOI 10.1093/jnci/82.22.1769; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KIRSNER JB, 1960, GASTROENTEROLOGY, V39, P178; KRONBORG O, 1987, INT J COLORECTAL DIS, V2, P203, DOI 10.1007/BF01649506; LOTFI AM, 1986, MAYO CLIN PROC, V61, P337, DOI 10.1016/S0025-6196(12)61950-8; MACRAE FA, 1982, GASTROINTEST ENDOSC, V28, P138; MATEK W, 1985, ENDOSCOPY, V17, P175, DOI 10.1055/s-2007-1018494; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; WAYE JD, 1982, ENDOSCOPY, V14, P79, DOI 10.1055/s-2007-1021585; WINAWER S J, 1991, Gastroenterology, V100, pA410; WINAWER S J, 1992, Gastroenterology, V102, pA409; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243; WINAWER SJ, 1990, B WORLD HEALTH ORGAN, V68, P789; WINAWER SJ, 1992, CANCER, V70, P1236, DOI 10.1002/1097-0142(19920901)70:3+<1236::AID-CNCR2820701508>3.0.CO;2-4; 1989, SAS STAT USERS GUIDE, V1; 1987, GASTROINTEST ENDOSC, V33, P167; 1990, BMDP STATISTICAL SOF, V2, P1013	28	820	839	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 1	1993	328	13					901	906		10.1056/NEJM199304013281301	http://dx.doi.org/10.1056/NEJM199304013281301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU177	8446136				2022-12-28	WOS:A1993KU17700001
J	LEMASSON, G; MARDER, E; ABBOTT, LF				LEMASSON, G; MARDER, E; ABBOTT, LF			ACTIVITY-DEPENDENT REGULATION OF CONDUCTANCES IN MODEL NEURONS	SCIENCE			English	Article							IMMEDIATE EARLY GENES; CALCIUM; CHANNELS; SYSTEM	Neurons maintain their electrical activity patterns despite channel turnover, cell growth, and variable extracellular conditions. A model is presented in which maximal conductances of ionic currents depend on the intracellular concentration of calcium ions and so, indirectly, on activity. Model neurons with activity-dependent maximal conductances modify their conductances to maintain a given behavior when perturbed. Moreover, neurons that are described by identical sets of equations can develop different properties in response to different patterns of presynaptic activity.	BRANDEIS UNIV,DEPT PHYS,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University; Brandeis University; Brandeis University					NIMH NIH HHS [MH46742] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH046742, R01MH046742] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABBOTT LF, IN PRESS NEURAL COMP; BUCHHOLTZ F, 1992, J NEUROPHYSIOL, V67, P332, DOI 10.1152/jn.1992.67.2.332; Byrne J. H., 1989, NEURAL MODELS PLASTI; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; EPSTEIN IR, 1990, BIOL CYBERN, V63, P25, DOI 10.1007/BF00202450; FRANKLIN JL, 1992, J NEUROSCI, V12, P1726; Gluck M. A., 1990, NEUROSCIENCE CONNECT; GOLOWASCH J, 1992, J NEUROPHYSIOL, V67, P318, DOI 10.1152/jn.1992.67.2.318; GOLOWASCH J, 1992, J NEUROPHYSIOL, V67, P341, DOI 10.1152/jn.1992.67.2.341; HEMMICK LM, 1992, J NEUROSCI, V12, P2007; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORRIS C, 1981, BIOPHYS J, V35, P193, DOI 10.1016/S0006-3495(81)84782-0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; PLANT RE, 1976, BIOPHYS J, V16, P227, DOI 10.1016/S0006-3495(76)85683-4; RASMUSSEN H, 1984, PHYSIOL REV, V64, P938, DOI 10.1152/physrev.1984.64.3.938; RINZEL J, 1987, J MATH BIOL, V25, P653, DOI 10.1007/BF00275501; ROSS WN, 1989, ANNU REV PHYSIOL, V51, P491, DOI 10.1146/annurev.physiol.51.1.491; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; TURRIGIANO GG, UNPUB	23	240	245	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1915	1917		10.1126/science.8456317	http://dx.doi.org/10.1126/science.8456317			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456317				2022-12-28	WOS:A1993KU17200037
J	GRIFFIN, S; PETERS, A; REID, M				GRIFFIN, S; PETERS, A; REID, M			DRUG MISUSERS IN LOTHIAN - CHANGES IN INJECTING HABITS 1988-90	BRITISH MEDICAL JOURNAL			English	Article											GRIFFIN, S (corresponding author), ROYAL EDINBURGH & ASSOCIATED HOSP,COMMUNITY DRUG PROBLEM SERV,EDINBURGH EH10 5BT,SCOTLAND.							GREENWOOD J, 1990, BRIT MED J, V300, P587, DOI 10.1136/bmj.300.6724.587; 1992, AIDS WEEKLY NEW S, V272	2	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					693	693		10.1136/bmj.306.6879.693	http://dx.doi.org/10.1136/bmj.306.6879.693			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT216	8471923	Bronze, Green Published			2022-12-28	WOS:A1993KT21600023
J	FALLS, DL; ROSEN, KM; CORFAS, G; LANE, WS; FISCHBACH, GD				FALLS, DL; ROSEN, KM; CORFAS, G; LANE, WS; FISCHBACH, GD			ARIA, A PROTEIN THAT STIMULATES ACETYLCHOLINE-RECEPTOR SYNTHESIS, IS A MEMBER OF THE NEU LIGAND FAMILY	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; SUBUNIT GENE-EXPRESSION; CULTURED MUSCLE-CELLS; AMINO-ACID-SEQUENCE; MESSENGER-RNA; NEUROMUSCULAR SYNAPSES; CHICK MYOTUBES; SPINAL-CORD; IMMUNOGLOBULIN SUPERFAMILY; DEVELOPMENTAL REGULATION	Motor neurons stimulate their postsynaptic muscle targets to synthesize neurotransmitter receptors. Polypeptide signaling molecules may mediate this inductive interaction. Here we report the purification of ARIA, a protein that stimulates the synthesis of muscle acetylcholine receptors, and the isolation of ARIA cDNA. Recombinant ARIA increases acetylcholine receptor synthesis greater than 3-fold, and it induces tyrosine phosphorylation of a 185 kd muscle protein. The ARIA cDNA hybridizes with mRNAs that are expressed in the spinal cord f rom E4, a time prior to the onset of neuromuscular synapse formation, through adulthood. By E7, hybridizing mRNAs are concentrated in motor neurons. Chicken ARIA is homologous to the rat Neu differentiation factor and human heregulin, ligands for the receptor tyrosine kinase encoded by the neu (c-erbB2, HER2) proto-oncogene. Our data suggest that members of the ARIA protein family promote the formation and maintenance of chemical synapses and, furthermore, that receptor tyrosine kinases play important roles in this process.	HARVARD UNIV, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02138 USA	Harvard University	FALLS, DL (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA.		Corfas, Gabriel/AAH-2378-2020	Corfas, Gabriel/0000-0001-5412-9473				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER LP, 1992, J CELL SCI, V102, P543; BAKER LP, 1993, J CELL BIOL, V120, P185, DOI 10.1083/jcb.120.1.185; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRENNER HR, 1992, P ROY SOC B-BIOL SCI, V250, P151, DOI 10.1098/rspb.1992.0143; BRENNER HR, 1978, NATURE, V271, P366, DOI 10.1038/271366a0; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; BUCCARON MH, 1983, DEV BIOL, V95, P378, DOI 10.1016/0012-1606(83)90039-8; BURSZTAJN S, 1990, J NEUROBIOL, V21, P387, DOI 10.1002/neu.480210302; CAGAN RL, 1992, CELL, V69, P393, DOI 10.1016/0092-8674(92)90442-F; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; CHANGEUX JP, 1991, NEW BIOL, V3, P413; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; COHEN SA, 1977, DEV BIOL, V59, P24, DOI 10.1016/0012-1606(77)90237-8; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; CORFAS G, 1993, IN PRESS J NEUROSCI, V13; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAHM LM, 1991, J NEUROSCI, V11, P238; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DEVREOTES PN, 1975, J CELL BIOL, V65, P335, DOI 10.1083/jcb.65.2.335; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1990, COLD SPRING HARB SYM, V55, P397; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FONTAINE B, 1989, J CELL BIOL, V108, P1025, DOI 10.1083/jcb.108.3.1025; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HARRIS DA, 1989, NATURE, V337, P173, DOI 10.1038/337173a0; HARRIS DA, 1988, P NATL ACAD SCI USA, V85, P1983, DOI 10.1073/pnas.85.6.1983; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOROVITZ O, 1989, J CELL BIOL, V108, P1823, DOI 10.1083/jcb.108.5.1823; HOROVITZ O, 1989, J CELL BIOL, V108, P1817, DOI 10.1083/jcb.108.5.1817; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JO SA, 1992, DEVELOPMENT, V115, P673; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIRILOVSKY J, 1989, NEUROSCIENCE, V32, P289, DOI 10.1016/0306-4522(89)90079-1; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEEK RL, 1982, J BIOL CHEM, V257, P2245; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MORGAN MM, 1990, THESIS WASHINGTON U; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PENG HB, 1991, NEURON, V6, P237; PENG HB, 1993, J CELL BIOL, V120, P197, DOI 10.1083/jcb.120.1.197; PERIN MS, 1991, J BIOL CHEM, V266, P623; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; ROLE LW, 1985, J NEUROSCI, V5, P2197; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; SALPETER M, 1987, VERTEBRATE NEUROMUSC; SANES JR, 1991, DEVELOPMENT, V113, P1181; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TAKAHASHI T, 1987, J NEUROSCI, V7, P473; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; TUSZYNSKI GP, 1980, ANAL BIOCHEM, V106, P118, DOI 10.1016/0003-2697(80)90126-8; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1992, J NEUROBIOL, V23, P592, DOI 10.1002/neu.480230512; WANG GK, 1980, J BIOL CHEM, V255, P1156; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WITZEMANN V, 1989, FEBS LETT, V242, P419, DOI 10.1016/0014-5793(89)80514-9; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	104	584	626	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 12	1993	72	5					801	815		10.1016/0092-8674(93)90407-H	http://dx.doi.org/10.1016/0092-8674(93)90407-H			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453670				2022-12-28	WOS:A1993KR43600015
J	PONGUBALA, JMR; VANBEVEREN, C; NAGULAPALLI, S; KLEMSZ, MJ; MCKERCHER, SR; MAKI, RA; ATCHISON, ML				PONGUBALA, JMR; VANBEVEREN, C; NAGULAPALLI, S; KLEMSZ, MJ; MCKERCHER, SR; MAKI, RA; ATCHISON, ML			EFFECT OF PU.1 PHOSPHORYLATION ON INTERACTION WITH NF-EM5 AND TRANSCRIPTIONAL ACTIVATION	SCIENCE			English	Article							DNA-BINDING ACTIVITY; CASEIN KINASE-II; SERUM RESPONSE FACTOR; NF-KAPPA-B; PUTATIVE ONCOGENE; NUCLEAR FACTOR; FACTOR CREB; C-JUN; SEQUENCE; ERYTHROLEUKEMIAS	PU.1 recruits the binding of a second B cell-restricted nuclear factor, NF-EM5, to a DNA site in the immunoglobulin kappa 3' enhancer. DNA binding by NF-EM5 requires a protein-protein interaction with PU.1 'and specific DNA contacts. Dephosphorylated PU.1 bound to DNA but did not interact with NF-EM5. Analysis of serine-to-alanine mutations in PU.1 indicated that serine 148 (Ser148) is required for protein-protein interaction. PU.1 produced in bacteria did not interact with NF-EM5. Phosphorylation of bacterially produced PU.1 by purified casein kinase II modified it to a form that interacted with NF-EM5 and that recruited NF-EM5 to bind to DNA. Phosphopeptide analysis of bacterially produced PU.1 suggested that Ser148 is phosphorylated by casein kinase II. This site is also phosphorylated in vivo. Expression of wild-type PU.1 increased expression of a reporter construct containing the PU.1 and NF-EM5 binding sites nearly sixfold, whereas the Ser148 mutant form only weakly activated transcription. These results demonstrate that phosphorylation of PU.1 at Ser148 is necessary for interaction with NF-EM5 and suggest that this phosphorylation can regulate transcriptional activity.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,PHILADELPHIA,PA 19104; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	University of Pennsylvania; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA042909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042415] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42909] Funding Source: Medline; NIAID NIH HHS [AI 30656] Funding Source: Medline; NIGMS NIH HHS [GM 42415] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KLEMSZ M, UNPUB; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, UNPUB; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Van Beveren C., UNPUB; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	28	264	264	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 12	1993	259	5101					1622	1625		10.1126/science.8456286	http://dx.doi.org/10.1126/science.8456286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8456286				2022-12-28	WOS:A1993KR54300043
J	HOLE, DJ; HAWTHORNE, VM; ISLES, CG; MCGHEE, SM; ROBERTSON, JWK; GILLIS, CR; WAPSHAW, JA; LEVER, AF				HOLE, DJ; HAWTHORNE, VM; ISLES, CG; MCGHEE, SM; ROBERTSON, JWK; GILLIS, CR; WAPSHAW, JA; LEVER, AF			INCIDENCE OF AND MORTALITY FROM CANCER IN HYPERTENSIVE PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE	Objectives-To assess incidence of and mortality from cancer in hypertensive patients taking atenolol, comparing the findings with two control populations and with hypertensive patients taking other drugs. Design-Retrospective analysis of patients first seen in the Glasgow Blood Pressure Clinic between 1972 and 1990. Patients' records were linked with the registrar general's data for information on mortality and with the West of Scotland Cancer Registry for information on incident and fatal cancers. Cancers were compared in patients and controls and in patients taking atenolol, beta blockers other than atenolol, and hypotensive drugs other than beta blockers. Subjects-6528 male and female patients providing 54 355 years of follow up. Setting-Hypertension clinic in Glasgow. Main outcome measures-Observed numbers of cancers in clinic patients were compared with expected numbers derived from cancer rates in two control populations adjusted for age, sex, and time period of data collection. Results-Cancer mortality was not significantly different in clinic patients as a whole and controls. Incident and fatal cancers were not significantly increased in male or female patients taking atenolol. Cancer incidence did not rise in the clinic after a large increase in prescriptions for atenolol after 1976. Conclusion-This analysis does not suggest a link between atenolol and cancer.	WESTERN INFIRM & ASSOCIATED HOSP,MRC,BLOOD PRESSURE UNIT,GLASGOW G11 6NT,SCOTLAND; RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,SCOTLAND; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109; DUMFRIES & GALLOWAY ROYAL INFIRM,DUMFRIES DG1 4AP,SCOTLAND; GREATER GLASGOW HLTH BOARD,DIV MANAGEMENT SERV,GLASGOW G1 1PT,SCOTLAND	University of Glasgow; University of Michigan System; University of Michigan			McGhee, Sarah M/A-6460-2013	McGhee, Sarah M/0000-0003-1025-5915				COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; FLETCHER AE, 1993, BRIT MED J, V306, P622, DOI 10.1136/bmj.306.6878.622; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P44, DOI 10.1136/jech.42.1.44; GILLIS CR, 1987, CANC INCIDENCE 5 CON, V5, P704; HAWTHORNE VM, 1974, BMJ-BRIT MED J, V3, P600, DOI 10.1136/bmj.3.5931.600; HOLE DJ, 1981, J CHRON DIS, V34, P291, DOI 10.1016/0021-9681(81)90034-5; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; NEILSEN HO, 1973, SCAND J NEPHROL, V9, P293; RAM MD, 1969, BRIT MED J, V4, P87, DOI 10.1136/bmj.4.5675.87; 1992, BMJ, V304, P405	10	66	66	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					609	611		10.1136/bmj.306.6878.609	http://dx.doi.org/10.1136/bmj.306.6878.609			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461810	Bronze, Green Published			2022-12-28	WOS:A1993KQ85900017
J	SANCAR, A; HEARST, JE				SANCAR, A; HEARST, JE			MOLECULAR MATCHMAKERS	SCIENCE			English	Article							POLYMERASE ACCESSORY PROTEINS; EARLY TRANSCRIPTION FACTOR; CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; DNA-POLYMERASE; ATP HYDROLYSIS; REPLICATION; INITIATION; REPAIR; BACTERIOPHAGE-T4	Molecular matchmakers are a class of proteins that use the energy released from the hydrolysis of adenosine triphosphate to cause a conformational change in one or both components of a DNA binding protein pair to promote formation of a metastable DNA-protein complex. After matchmaking the matchmaker dissociates from the complex, permitting the matched protein to engage in other protein-protein interactions to bring about the effector function. Matchmaking is most commonly used under circumstances that require targeted, high-avidity DNA binding without relying solely on sequence specificity. Molecular matchmaking is an extensively used mechanism in repair, replication, and transcription and most likely in recombination and transposition reactions, too.	LAWRENCE BERKELEY LAB,DIV CHEM BIODYNAM,BERKELEY,CA 94720; LAWRENCE BERKELEY LAB,DEPT CHEM,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	SANCAR, A (corresponding author), UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NIGMS NIH HHS [GM32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AU KG, 1992, J BIOL CHEM, V267, P12142; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; BROYLES SS, 1991, J BIOL CHEM, V266, P15539; BROYLES SS, 1991, J BIOL CHEM, V266, P15545; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY RC, 1991, J BIOL CHEM, V266, P6205; CONOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476; ELLIS RJ, 1991, ANN REV BIOCH, V60, P427; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; GAMAS P, 1992, NUCLEIC ACIDS RES, V20, P2525, DOI 10.1093/nar/20.10.2525; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GEIDUSCHEK EP, 1991, ANNU REV GENET, V25, P437; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HUANG CC, 1981, J BIOL CHEM, V256, P4087; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1991, DNA REPLICATION; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; MASAI H, 1990, J BIOL CHEM, V265, P15134; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MODRICH P, 1989, J BIOL CHEM, V264, P6597; ORREN DK, 1992, J BIOL CHEM, V267, P780; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P53237; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PINSINCE JM, UNPUB; RADDING CM, 1991, ANN REV BIOPHYS CHEM, V20, P539; REDDY MK, 1992, J BIOL CHEM, V267, P14157; Ringe Dagmar, 1992, Current Biology, V2, P545; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; YARUS M, 1969, ANNU REV BIOCHEM, V38, P841, DOI 10.1146/annurev.bi.38.070169.004205; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	60	168	170	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1415	1420		10.1126/science.8451638	http://dx.doi.org/10.1126/science.8451638			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451638				2022-12-28	WOS:A1993KP97800025
J	STONE, R				STONE, R			OLDEN,KEN HEALS NIEHSS SPLIT BRAIN	SCIENCE			English	Article																		OLDEN K, IN PRESS REGULATORY	1	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1398	1399		10.1126/science.8451636	http://dx.doi.org/10.1126/science.8451636			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451636				2022-12-28	WOS:A1993KP97800018
J	FIDLER, HM; ROOK, GA; JOHNSON, NM; MCFADDEN, J				FIDLER, HM; ROOK, GA; JOHNSON, NM; MCFADDEN, J			MYCOBACTERIUM-TUBERCULOSIS DNA IN TISSUE AFFECTED BY SARCOIDOSIS	BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGY; DIAGNOSIS; ANTIGEN; TOOL	Objective-To investigate the prevalence of Mycobacterium tuberculosis DNA in granulomatous tissues from patients with sarcoidosis and from controls matched for age, sex, and tissue by using the polymerase chain reaction. Design-Single blind control trial. Subjects-16 patients with sarcoidosis who had undergone diagnostic biopsy of lung, skin, or lymph node and 16 patients with squamous cell carcinoma or Hodgkin's disease to act as controls. In addition, four lung specimens infected with M tuberculosis were included as positive controls. Results-M tuberculosis DNA was present in sarcoid tissues containing granulomas from seven of the 16 patients and one of the 16 matched controls. Two of the four specimens known to be infected with M tuberculosis were positive in the controlled experiment. Conclusion-These figures suggest that M tuberculosis DNA is detected as readily in patients with sarcoidosis as in patients with frankly tuberculous tissues and imply that M tuberculosis may be linked to the cause of sarcoidosis.	WHITTINGTON HOSP, UNIV COLL & MIDDLESEX SCH MED, LONDON N19 5NF, ENGLAND; UNIV SURREY, SCH BIOL SCI, MOLEC BIOL GRP, GUILDFORD GU2 5XH, SURREY, ENGLAND	University of London; University College London; University of Surrey	FIDLER, HM (corresponding author), UCL, SCH MED, DEPT MED MICROBIOL, DIV BACTERIOL, LONDON W1P 7PP, ENGLAND.			Rook, Graham/0000-0002-8041-8110; McFadden, Johnjoe/0000-0003-2145-0046				BALBI B, 1990, J CLIN INVEST, V85, P1353, DOI 10.1172/JCI114579; BOCART D, 1992, AM REV RESPIR DIS, V145, P1142, DOI 10.1164/ajrccm/145.5.1142; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRETT G. Z., 1965, Tubercle, V46, P412, DOI 10.1016/S0041-3879(65)80007-1; BRISSONNOEL A, 1991, LANCET, V338, P364, DOI 10.1016/0140-6736(91)90492-8; CALMETTE A., 1926, ANN MID, V19, P553; DEWIT D, 1990, J CLIN MICROBIOL, V28, P2347; FIDLER H, IN PRESS AM REV RESP; FOLEY N, 1988, CLIN SCI         S19, V75, pP2; GRAHAM DY, 1992, LANCET, V340, P52, DOI 10.1016/0140-6736(92)92465-R; GRAHAM DY, 1988, EXCERPTA MED SARCOID, V756, P16; Greer C E, 1991, PCR Methods Appl, V1, P46; Hanngren A, 1987, Sarcoidosis, V4, P101; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; JAMES DG, 1959, LANCET, V1, P1057; KENT DC, 1970, AM REV RESPIR DIS, V101, P721; KHOMENKO AG, 1980, PROBL TUBERK, V2, P18; MANJUNATH N, 1991, TUBERCLE, V72, P21, DOI 10.1016/0041-3879(91)90020-S; MCFADDEN JJ, 1991, METHODS GENE TECHNOL, V1, P1; MCFADDEN JJ, 1991, GENETIC MANIPULATION, P97; MITCHELL DN, 1983, 9TH INT C SARC OTH G, P132; MITCHELL IC, 1992, LANCET, V339, P1015, DOI 10.1016/0140-6736(92)90536-C; PARKES SA, 1987, THORAX, V42, P420, DOI 10.1136/thx.42.6.420; ROOK GAW, 1992, IMMUNOL TODAY, V13, P160, DOI 10.1016/0167-5699(92)90119-R; SABOOR SA, 1992, LANCET, V339, P12; SCADDING JG, 1961, BRIT MED J, V2, P1165, DOI 10.1136/bmj.2.5261.1165; SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987; SIEGELE DA, 1992, J BACTERIOL, V174, P345, DOI 10.1128/jb.174.2.345-348.1992; VANEK J, 1970, AM REV RESPIR DIS, V101, P395; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991	30	108	110	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					546	549		10.1136/bmj.306.6877.546	http://dx.doi.org/10.1136/bmj.306.6877.546			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461766	Green Published, Bronze			2022-12-28	WOS:A1993KP88600018
J	STRADLING, JR				STRADLING, JR			ABC OF SLEEP DISORDERS - RECREATIONAL DRUGS AND SLEEP	BRITISH MEDICAL JOURNAL			English	Article											STRADLING, JR (corresponding author), CHURCHILL HOSP,OXFORD OX3 7LJ,ENGLAND.							DEWS PB, 1984, CAFFEINE, P61; ISSA FG, 1982, J NEUROL NEUROSUR PS, V45, P353, DOI 10.1136/jnnp.45.4.353	2	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					573	575		10.1136/bmj.306.6877.573	http://dx.doi.org/10.1136/bmj.306.6877.573			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461777	Bronze, Green Published			2022-12-28	WOS:A1993KP88600030
J	COLLINGE, J; PALMER, MS; CAMPBELL, T; SIDLE, KCL; CARROLL, D; HARDING, A				COLLINGE, J; PALMER, MS; CAMPBELL, T; SIDLE, KCL; CARROLL, D; HARDING, A			INHERITED PRION DISEASE (PRP LYSINE-200) IN BRITAIN - 2 CASE-REPORTS	BRITISH MEDICAL JOURNAL			English	Article							CREUTZFELDT-JAKOB DISEASE; PROTEIN GENE; MUTATION	Objective-To identify cases of inherited prion diseases in Britain and to assess their phenotypic features. Design-Screening study of patients suspected clinically to have Creutzfeldt-Jakob disease and other neurodegenerative diseases by prion protein gene analysis. Setting-Biochemical research department. Subjects-Patients suspected to have Creutzfeldt-Jakob disease and other neurodegenerative diseases. Results-Two patients with symptoms characteristic of sporadic Creutzfeldt-Jakob disease were found to have inherited prion protein disease (PrP lysine 200), with a mutation at codon 200 of the prion protein gene. Both were homozygous at codon 129 of the gene. One patient was a man aged 58 of British descent while the other was of Libyan Jewish origin. Conclusion-Two foci of inherited prion disease are known, among Libyan Jews and in Slovakia. A separate British focus of the disease may also exist. Heterozygosity at codon 129 may lead to reduced penetrance of the mutation.	ROYAL SURREY CTY HOSP,GUILDFORD GU2 5XX,ENGLAND; INST NEUROL,LONDON WC1N 3BG,ENGLAND	Royal Surrey County Hospital; University of London; University College London	COLLINGE, J (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,PRION DIS GRP,LONDON W2 1PG,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; COLLINGE J, 1991, AM J HUM GENET, V49, P1351; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; COLLINGE J, 1991, NATURE, V353, P802, DOI 10.1038/353802a0; COLLINGE J, 1992, PRION DIS HUMANS ANI, P5; Collinge J, 1992, CURR OPIN GENET DEV, V2, P448, DOI 10.1016/S0959-437X(05)80156-X; GOLDFARB LG, 1990, LANCET, V336, P514, DOI 10.1016/0140-6736(90)92073-Q; HERZBERG L, 1974, SCIENCE, V186, P848, DOI 10.1126/science.186.4166.848; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1991, NEW ENGL J MED, V324, P1091, DOI 10.1056/NEJM199104183241604; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0	13	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					301	302		10.1136/bmj.306.6873.301	http://dx.doi.org/10.1136/bmj.306.6873.301			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461647	Green Published, Bronze			2022-12-28	WOS:A1993KK71800019
J	ROSENGREN, A; TIBBLIN, G; WILHELMSEN, L				ROSENGREN, A; TIBBLIN, G; WILHELMSEN, L			LOW SYSTOLIC BLOOD-PRESSURE AND SELF PERCEIVED WELLBEING IN MIDDLE-AGED MEN	BRITISH MEDICAL JOURNAL			English	Article							POPULATION; DISEASE	Objective-To examine the relation between systolic blood pressure and self perceived wellbeing in 50 year old men. Design-Cross sectional population study of data derived from questionnaires and physical examination as a part of a cardiovascular risk factor survey. Setting-City of Gothenburg, Sweden. Study population-776 men from a random population sample of 1016 men aged 50. Methods-Self perceived wellbeing according to the Gothenburg quality of life questionnaire, which is an assessment of social, physical, and mental wellbeing in 15 different areas. Main results-Low systolic blood pressure was significantly (p < 0.05) related to impaired social wellbeing in four areas: work, home and family, financial situation, and housing. Of the items dealing with physical wellbeing, health, memory, and appetite were significantly related to blood pressure. As regards mental wellbeing, energy and self confidence were significantly related to systolic blood pressure. Diastolic blood pressure was significantly related to housing, memory, energy, patience, and self confidence. In multiple regression analyses that controlled for smoking, stress, physical activity, social activity, and emotional support, poor social, physical, and mental wellbeing were all significantly related to low systolic blood pressure independently of other factors. Low diastolic blood pressure was independently associated with poor physical and mental, but not social, wellbeing. Conclusion-Low systolic blood pressure was associated with poor perception of wellbeing in several areas. The cause is unclear.	UNIV UPPSALA,DEPT FAMILY MED,S-75105 UPPSALA,SWEDEN	Uppsala University	ROSENGREN, A (corresponding author), GOTHENBURG UNIV,OSTRA HOSP,DEPT MED,PREVENT CARDIOL SECT,S-41685 GOTHENBURG,SWEDEN.							Bengtsson C, 1987, Scand J Prim Health Care, V5, P155, DOI 10.3109/02813438709013997; COTTINGTON EM, 1985, AM J EPIDEMIOL, V121, P515, DOI 10.1093/oxfordjournals.aje.a114029; GOODCHILD ME, 1985, BRIT J PSYCHIAT, V146, P55, DOI 10.1192/bjp.146.1.55; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; PEMBERTON J, 1989, BRIT MED J, V298, P660, DOI 10.1136/bmj.298.6674.660; PILGRIM JA, 1992, BRIT MED J, V304, P75, DOI 10.1136/bmj.304.6819.75; Rose G, 1982, CARDIOVASCULAR SURVE; ROSENGREN A, 1991, AM J CARDIOL, V68, P1171, DOI 10.1016/0002-9149(91)90189-R; Tibblin G, 1990, Scand J Prim Health Care Suppl, V1, P39; Tibblin G, 1990, Scand J Prim Health Care Suppl, V1, P33; TIBBLIN G, 1967, THESIS U GOTHENBURG; UNDEN AL, 1989, SOC SCI MED, V29, P1387, DOI 10.1016/0277-9536(89)90240-2; WELIN L, 1985, LANCET, V1, P915; WESSELY S, 1990, BRIT MED J, V301, P362, DOI 10.1136/bmj.301.6748.362	14	66	66	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					243	246		10.1136/bmj.306.6872.243	http://dx.doi.org/10.1136/bmj.306.6872.243			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443523	Bronze, Green Published			2022-12-28	WOS:A1993KJ59100019
J	CRUM, RM; ANTHONY, JC; BASSETT, SS; FOLSTEIN, MF				CRUM, RM; ANTHONY, JC; BASSETT, SS; FOLSTEIN, MF			POPULATION-BASED NORMS FOR THE MINI-MENTAL-STATE-EXAMINATION BY AGE AND EDUCATIONAL-LEVEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSTIC INTERVIEW SCHEDULE; ALZHEIMERS-DISEASE; NURSING-HOME; DOUBLE-BLIND; PSYCHIATRIC-DIAGNOSIS; COGNITIVE IMPAIRMENT; MEDICAL PATIENTS; SENILE DEMENTIA; AREA; PERFORMANCE	Objective.-To report the distribution of Mini-Mental State Examination (MMSE) scores by age and educational level. Design.-National Institute of Mental Health Epidemiologic Catchment Area Program surveys conducted between 1980 and 1984. Setting.-Community populations in New Haven, Conn; Baltimore, Md; St Louis, Mo; Durham, NC; and Los Angeles, Calif. Participants.-A total of 18 056 adult participants selected by probability sampling within census tracts and households. Main Outcome Measures.-Summary scores for the MMSE are given in the form of mean, median, and percentile distributions specific for age and educational level. Results.-The MMSE scores were related to both age and educational level. There was an inverse relationship between MMSE scores and age, ranging from a median of 29 for those 18 to 24 years of age, to 25 for individuals 80 years of age and older. The median MMSE score was 29 for individuals with at least 9 years of schooling, 26 for those with 5 to 8 years of schooling, and 22 for those with 0 to 4 years of schooling. Conclusions.-Cognitive performance as measured by the MMSE varies within the population by age and education. The cause of this variation has yet to be determined. Mini-Mental State Examination scores should be used to identify current cognitive difficulties and not to make formal diagnoses. The results presented should prove to be useful to clinicians who wish to compare an individual patient's MMSE scores with a population reference group and to researchers making plans for new studies in which cognitive status is a variable of interest.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT MENTAL HLTH, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	CRUM, RM (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA.		Anthony, Jim/H-3637-2011; Fahimifar, Sepideh/M-5303-2019	Anthony, Jim/0000-0001-7176-0929; 	NIA NIH HHS [AG00149] Funding Source: Medline; NIMH NIH HHS [MH46290, MH47447] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH046290, R01MH047447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000149] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANTHONY JC, 1985, ARCH GEN PSYCHIAT, V42, P667; ANTHONY JC, 1982, PSYCHOL MED, V12, P397, DOI 10.1017/S0033291700046730; ARMITAGE P, 1987, STATISTICAL METHODS; BALESTRERI R, 1987, J AM GERIATR SOC, V35, P425, DOI 10.1111/j.1532-5415.1987.tb04664.x; BASSETT SS, 1991, PSYCHOL MED, V21, P77, DOI 10.1017/S0033291700014677; BERKMAN LF, 1986, J CHRON DIS, V39, P171, DOI 10.1016/0021-9681(86)90020-2; BIRD HR, 1987, J NERV MENT DIS, V175, P731, DOI 10.1097/00005053-198712000-00005; BLEECKER ML, 1988, NEUROLOGY, V38, P1565, DOI 10.1212/WNL.38.10.1565; CHATELLIER G, 1990, BRIT MED J, V300, P495, DOI 10.1136/bmj.300.6723.495; COLOHAN H, 1989, IRISH J MED SCI, V158, P178, DOI 10.1007/BF02984635; DEKOSKY S T, 1990, Alzheimer Disease and Associated Disorders, V4, P14, DOI 10.1097/00002093-199040100-00002; DEVANAND DP, 1989, ARCH NEUROL-CHICAGO, V46, P854, DOI 10.1001/archneur.1989.00520440036018; Eaton W.M., 1985, EPIDEMIOLOGIC FIELD; EATON WW, 1989, ACTA PSYCHIAT SCAND, V79, P163, DOI 10.1111/j.1600-0447.1989.tb08584.x; EATON WW, 1989, EPIDEMIOLOGY AND THE PREVENTION OF MENTAL DISORDERS, P108; ELVEBACK LR, 1970, J AMER MED ASSOC, V211, P69, DOI 10.1001/jama.211.1.69; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FARBER JF, 1988, J AM GERIATR SOC, V36, P509, DOI 10.1111/j.1532-5415.1988.tb04020.x; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; FEINSTEIN AR, 1974, CLIN PHARMACOL THER, V15, P97; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS; FILLENBAUM GG, 1987, ARCH NEUROL-CHICAGO, V44, P924, DOI 10.1001/archneur.1987.00520210026014; FINLEY WW, 1985, NEUROLOGY, V35, P323, DOI 10.1212/WNL.35.3.323; FOLSTEIN M, 1985, J AM GERIATR SOC, V33, P228, DOI 10.1111/j.1532-5415.1985.tb07109.x; FOLSTEIN MF, 1991, J GERONTOL, V46, pM132, DOI 10.1093/geronj/46.4.M132; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; George L, 1991, PSYCHIAT DISORDERS A, P291; HOLZER CE, 1984, RES COMMUNITY MENTAL, V0004; HORTON AM, 1987, PERCEPT MOTOR SKILL, V65, P64, DOI 10.2466/pms.1987.65.1.64; INDACO A, 1988, NEUROLOGY, V38, P1720, DOI 10.1212/WNL.38.11.1720; JORM AF, 1988, PSYCHOL MED, V18, P727, DOI 10.1017/S0033291700008424; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; KNIGHTS EB, 1977, ANN INTERN MED, V87, P723, DOI 10.7326/0003-4819-87-6-723; Leaf P.J., 1991, PSYCHIAT DISORDERS A, P11; LI G, 1989, ACTA PSYCHIAT SCAND, V79, P557, DOI 10.1111/j.1600-0447.1989.tb10303.x; LIU IY, 1989, AM J EPIDEMIOL, V130, P416, DOI 10.1093/oxfordjournals.aje.a115350; MAGAZINER J, 1987, J AM GERIATR SOC, V35, P996, DOI 10.1111/j.1532-5415.1987.tb04002.x; MURPHY EA, 1981, BIOSTATISTICS MED, V38, P381; OCONNOR DW, 1989, PSYCHOL MED, V19, P771, DOI 10.1017/S0033291700024375; PEARLSON GD, 1986, PSYCHIAT RES, V17, P23, DOI 10.1016/0165-1781(86)90038-7; REGIER D A, 1990, Journal of the American Medical Association, V264, P2511, DOI 10.1001/jama.264.19.2511; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROCA RP, 1984, ARCH INTERN MED, V144, P73, DOI 10.1001/archinte.144.1.73; ROVNER BW, 1986, AM J PSYCHIAT, V143, P1446; SALMON DP, 1989, ARCH NEUROL-CHICAGO, V46, P769, DOI 10.1001/archneur.1989.00520430063019; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; TENG EL, 1987, J CONSULT CLIN PSYCH, V55, P96, DOI 10.1037/0022-006X.55.1.96; TSAI L, 1979, AM J PSYCHIAT, V136, P436; UHLMANN RF, 1989, JAMA-J AM MED ASSOC, V261, P1916, DOI 10.1001/jama.261.13.1916; ZILLMER EA, 1990, J GERONTOL, V45, pP69, DOI 10.1093/geronj/45.2.P69; 1985, SAS USERS GUIDES STA	54	2027	2079	7	185	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2386	2391		10.1001/jama.269.18.2386	http://dx.doi.org/10.1001/jama.269.18.2386			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479064				2022-12-28	WOS:A1993LA67500032
J	CAMERINIOTERO, RD; HSIEH, P				CAMERINIOTERO, RD; HSIEH, P			PARALLEL DNA TRIPLEXES, HOMOLOGOUS RECOMBINATION, AND OTHER HOMOLOGY-DEPENDENT DNA INTERACTIONS	CELL			English	Review							DOUBLE-STRAND BREAKS; COLI RECA PROTEIN; GENETIC-RECOMBINATION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; 3-STRANDED DNA; ATP HYDROLYSIS; HUMAN-CELLS; EXCHANGE; SITE				CAMERINIOTERO, RD (corresponding author), NIDDKD,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892, USA.							ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; Bartolomei M.S., 1992, SEMIN DEV BIOL, V3, P107; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRINK RA, 1973, ANNU REV GENET, V7, P129, DOI 10.1146/annurev.ge.07.120173.001021; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; COUROT M, 1970, TESTIS, P339; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; CRAIG NL, 1988, ANNU REV GENET, V22, P77; EISEN A, 1988, P NATL ACAD SCI USA, V85, P7481, DOI 10.1073/pnas.85.20.7481; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P293; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; HABER J E, 1992, Current Biology, V2, P483, DOI 10.1016/0960-9822(92)90669-2; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; HSIEH P, 1989, J BIOL CHEM, V264, P5089; HSIEH P, 1986, CELL, V44, P885, DOI 10.1016/0092-8674(86)90011-5; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; JUDD BH, 1988, CELL, V53, P841, DOI 10.1016/S0092-8674(88)90209-7; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KLECKNER N, 1991, COLD SH Q B, V56, P729; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LACKS S, 1966, GENETICS, V53, P207; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; RADDING CM, 1981, CELL, V25, P3, DOI 10.1016/0092-8674(81)90224-5; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RAO BJ, 1993, J MOL BIOL, V229, P328, DOI 10.1006/jmbi.1993.1038; RAO BJ, 1990, J MOL BIOL, V213, P789, DOI 10.1016/S0022-2836(05)80264-5; REGISTER JC, 1987, J BIOL CHEM, V262, P12812; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; STASIAK A, 1992, MOL MICROBIOL, V6, P3267, DOI 10.1111/j.1365-2958.1992.tb02194.x; STASIAK A, 1984, COLD SPRING HARB SYM, V49, P561, DOI 10.1101/SQB.1984.049.01.063; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Whitehouse H. L. K., 1982, GENETIC RECOMBINATIO	60	109	114	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					217	223		10.1016/0092-8674(93)90224-E	http://dx.doi.org/10.1016/0092-8674(93)90224-E			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8477443				2022-12-28	WOS:A1993KY50500005
J	ERNST, CB				ERNST, CB			ABDOMINAL AORTIC-ANEURYSM	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY-ARTERY DISEASE; FACTORS AFFECTING SURVIVAL; WEST-VIRGINIA COMMUNITY; COMPUTED-TOMOGRAPHY; VASCULAR-SURGERY; EXPANSION RATE; ELECTIVE RESECTION; NATURAL-HISTORY; MORTALITY; MANAGEMENT		UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan	ERNST, CB (corresponding author), HENRY FORD HOSP, DIV VASC SURG, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.							ABURAHMA AF, 1991, SURGERY, V109, P244; ABURAHMA AF, 1991, SURG GYNECOL OBSTET, V172, P377; ALLEN PIM, 1987, LANCET, V2, P736; AMPARO EG, 1985, RADIOLOGY, V154, P451, DOI 10.1148/radiology.154.2.3880912; BAUR GM, 1978, AM J SURG, V136, P184, DOI 10.1016/0002-9610(78)90223-4; BENGTSSON H, 1989, WORLD J SURG, V13, P266, DOI 10.1007/BF01659032; BENGTSSON H, 1992, EUR J SURG, V158, P19; BERNSTEIN EF, 1984, ANN SURG, V200, P255, DOI 10.1097/00000658-198409000-00003; BERNSTEIN EF, 1990, J VASC SURG, V11, P268; Berridge D C, 1989, Eur J Vasc Surg, V3, P421, DOI 10.1016/S0950-821X(89)80049-0; BICKERSTAFF LK, 1984, J VASC SURG, V1, P6, DOI 10.1067/mva.1984.avs0010006; BRECKWOLDT WL, 1991, J VASC SURG, V13, P798, DOI 10.1016/0741-5214(91)90044-U; BROPHY CM, 1991, J SURG RES, V50, P653, DOI 10.1016/0022-4804(91)90058-T; BROWN PM, 1992, J VASC SURG, V15, P21, DOI 10.1016/0741-5214(92)70009-A; CAMBRIA RP, 1992, J VASC SURG, V15, P43, DOI 10.1016/0741-5214(92)70012-A; CAMPA JS, 1987, ATHEROSCLEROSIS, V65, P13, DOI 10.1016/0021-9150(87)90003-7; Campbell J J, 1990, Ann Vasc Surg, V4, P419, DOI 10.1016/S0890-5096(07)60063-6; CHANG BB, 1990, J VASC SURG, V11, P326, DOI 10.1067/mva.1990.17036; COHEN JR, 1988, J VASC SURG, V7, P210; COHEN JR, 1987, SURG GYNECOL OBSTET, V164, P355; Collin J, 1989, Eur J Vasc Surg, V3, P15, DOI 10.1016/S0950-821X(89)80102-1; CRAWFORD ES, 1991, J VASC SURG, V13, P348; CRAWFORD ES, 1989, NEW ENGL J MED, V321, P1040, DOI 10.1056/NEJM198910123211509; CRONENWETT JL, 1990, J VASC SURG, V11, P260, DOI 10.1067/mva.1990.16697; CRONENWETT JL, 1985, SURGERY, V98, P472; DARLING RC, 1989, J VASC SURG, V10, P39, DOI 10.1067/mva.1989.vs0100039; DELIN A, 1985, BRIT J SURG, V72, P530, DOI 10.1002/bjs.1800720709; DIEHL JT, 1983, ANN SURG, V197, P49, DOI 10.1097/00000658-198301001-00008; DOBRIN PB, 1984, ARCH SURG-CHICAGO, V119, P405; DONALDSON MC, 1985, J VASC SURG, V2, P564, DOI 10.1067/mva.1985.avs0020564; DUBOST C, 1952, AMA ARCH SURG, V64, P405, DOI 10.1001/archsurg.1952.01260010419018; ELLIS M, 1990, CAUSE MANAGEMENT ANE, P117; ESTES JE, 1950, CIRCULATION, V2, P258, DOI 10.1161/01.CIR.2.2.258; Glimaker H, 1991, Eur J Vasc Surg, V5, P125, DOI 10.1016/S0950-821X(05)80675-9; GLOVICZKI P, 1992, J VASC SURG, V15, P851, DOI 10.1016/0741-5214(92)90720-S; GOLDEN MA, 1990, ANN SURG, V212, P415, DOI 10.1097/00000658-199010000-00004; GOMES MN, 1987, J VASC SURG, V6, P262, DOI 10.1067/mva.1987.avs0060262; GREEN RM, 1989, J VASC SURG, V9, P124, DOI 10.1067/mva.1989.vs0090124; GUIRGUIS EM, 1991, AM J SURG, V162, P481, DOI 10.1016/0002-9610(91)90266-G; HARRIS LM, 1991, J VASC SURG, V14, P812, DOI 10.1067/mva.1991.33494; HERTZER NR, 1984, J VASC SURG, V1, P13; HERTZER NR, 1980, ANN SURG, V192, P667; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HOFFMAN M, 1982, SURGERY, V91, P597; HOLLIER LH, 1984, J VASC SURG, V1, P290, DOI 10.1067/mva.1984.avs0010290; HOLLIER LH, 1992, J VASC SURG, V15, P1046, DOI 10.1016/0741-5214(92)90462-H; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; JOHANSEN K, 1991, J VASC SURG, V13, P240, DOI 10.1016/0741-5214(91)90216-H; JOHANSEN K, 1986, JAMA-J AM MED ASSOC, V256, P1934, DOI 10.1001/jama.256.14.1934; Johansson G, 1990, Eur J Vasc Surg, V4, P497, DOI 10.1016/S0950-821X(05)80791-1; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; JOHNSTON KW, 1989, J VASC SURG, V9, P437, DOI 10.1067/mva.1989.vs0090437; JOHNSTON KW, 1991, J VASC SURG, V13, P452, DOI 10.1067/mva.1991.26737; KATZ DA, 1992, JAMA-J AM MED ASSOC, V268, P2678, DOI 10.1001/jama.268.19.2678; KELLY TF, 1981, ANN SURG, V193, P686, DOI 10.1097/00000658-198106000-00003; KONTUSAARI S, 1990, J CLIN INVEST, V86, P1465, DOI 10.1172/JCI114863; KVILEKVAL KHV, 1990, J VASC SURG, V12, P28, DOI 10.1067/mva.1990.19859; LAROY LL, 1989, AM J ROENTGENOL, V152, P785, DOI 10.2214/ajr.152.4.785; LEATHER RP, 1989, SURG GYNECOL OBSTET, V168, P387; LEDERLE FA, 1990, ANN INTERN MED, V113, P731, DOI 10.7326/0003-4819-113-10-731; LIMET R, 1991, J VASC SURG, V14, P540, DOI 10.1016/0741-5214(91)90249-T; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; MARSTON WA, 1992, J VASC SURG, V16, P17, DOI 10.1016/0741-5214(92)90412-2; MCCABE CJ, 1981, ARCH SURG-CHICAGO, V116, P1025; MCENROE CS, 1990, J VASC SURG, V11, P497, DOI 10.1067/mva.1990.18756; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; MENASHI S, 1987, J VASC SURG, V6, P578, DOI 10.1067/mva.1987.avs0060578; MEYER AA, 1986, AM J SURG, V152, P27, DOI 10.1016/0002-9610(86)90132-7; NEVITT MP, 1989, NEW ENGL J MED, V321, P1009, DOI 10.1056/NEJM198910123211504; NORRGARD O, 1984, SURGERY, V95, P650; OURIEL K, 1990, J VASC SURG, V11, P493, DOI 10.1067/mva.1990.18639; OURIEL K, 1992, J VASC SURG, V15, P12, DOI 10.1016/0741-5214(92)70008-9; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; PASCH AR, 1984, CIRCULATION, V70, P1; POWELL JT, 1990, CLIN SCI, V78, P13, DOI 10.1042/cs0780013; QUILL DS, 1989, SURG CLIN N AM, V69, P713; REIGEL MM, 1987, J VASC SURG, V5, P222, DOI 10.1067/mva.1987.avs0050222; ROHRER MJ, 1988, ARCH SURG-CHICAGO, V123, P1213; ROWE DW, 1977, J BIOL CHEM, V252, P939; RUFF SJ, 1988, AM J SURG, V155, P651, DOI 10.1016/S0002-9610(88)80136-3; SHACKLETON CR, 1987, J VASC SURG, V6, P583, DOI 10.1067/mva.1987.avs0060583; SICARD GA, 1989, SURG CLIN N AM, V69, P795; SULLIVAN CA, 1990, J VASC SURG, V11, P799, DOI 10.1067/mva.1990.19420; SUMNER DS, 1970, SURG GYNECOL OBSTETR, V131, P417; SZILAGYI DE, 1966, ANN SURG, V164, P678, DOI 10.1097/00000658-196610000-00014; THOMAS PRS, 1988, BRIT J SURG, V75, P733, DOI 10.1002/bjs.1800750804; TILSON MD, 1984, AM J SURG, V147, P551, DOI 10.1016/0002-9610(84)90020-5; TILSON MD, 1989, J VASC SURG, V9, P367; TODD GJ, 1991, J VASC SURG, V13, P302, DOI 10.1016/0741-5214(91)90223-H; VEITH FJ, 1991, J VASC SURG, V13, P523, DOI 10.1016/0741-5214(91)90313-J; WAKEFIELD TW, 1982, SURGERY, V91, P586; WEBSTER MW, 1991, J VASC SURG, V13, P9; WEBSTER MW, 1991, J VASC SURG, V13, P366, DOI 10.1067/mva.1991.26359; ZARINS CK, 1986, J VASC SURG, V3, P238, DOI 10.1067/mva.1986.avs0030238; 1991, VITAL HLTH STATISTIC, V13; 1991, VITAL STATISTICS US, V2	96	563	584	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1167	1172						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY447	8455684				2022-12-28	WOS:A1993KY44700007
J	WATSON, JD; CRICK, FHC				WATSON, JD; CRICK, FHC			MOLECULAR-STRUCTURE OF NUCLEIC-ACIDS - A STRUCTURE FOR DEOXYRIBOSE NUCLEIC-ACID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											WATSON, JD (corresponding author), UNIV CAMBRIDGE,CAVENDISH LAB,MED RES COUNCIL,STUDY MOLEC STRUCT BIOL SYST UNIT,CAMBRIDGE CB3 0HE,ENGLAND.		crick, francis/B-7093-2009					ASTBURY WT, 1947, SYM SOC EXP BIOL, V1, P66; CHARGAFF E, 1952, BIOCHIM BIOPHYS ACTA, V9, P402; FURBERG S, 1952, ACTA CHEM SCAND, V6, P634, DOI 10.3891/acta.chem.scand.06-0634; PAULING L, 1953, P NATL ACAD SCI USA, V39, P84, DOI 10.1073/pnas.39.2.84; PAULING L, 1953, NATURE, V171, P346, DOI 10.1038/171346a0; WILKINS MHF, 1953, BIOCHIM BIOPHYS ACTA, V10, P192, DOI 10.1016/0006-3002(53)90232-7; WYATT GR, 1952, J GEN PHYSIOL, V36, P201, DOI 10.1085/jgp.36.2.201	7	19	19	22	199	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1966	1967		10.1001/jama.269.15.1966	http://dx.doi.org/10.1001/jama.269.15.1966			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464128				2022-12-28	WOS:A1993KX21500026
J	ITO, E; TOKI, T; ISHIHARA, H; OHTANI, H; GU, L; YOKOYAMA, M; ENGEL, JD; YAMAMOTO, M				ITO, E; TOKI, T; ISHIHARA, H; OHTANI, H; GU, L; YOKOYAMA, M; ENGEL, JD; YAMAMOTO, M			ERYTHROID TRANSCRIPTION FACTOR GATA-1 IS ABUNDANTLY TRANSCRIBED IN MOUSE TESTIS	NATURE			English	Article							RESTRICTION ENDONUCLEASE FRAGMENTS; TARGETED MUTATION; BINDING PROTEIN; GENE; EXPRESSION; PROMOTER; DIFFERENTIATION; ENHANCER; LINEAGES; CELLS	THE transcription factor GATA-1 is a fundamental regulator of genes in haematopoietic cell lineages1,2 and belongs to a family of factors that bind to the consensus sequence WGATAR3-5. The GATA motif was originally identified in cis-regulatory regions of globin and other erythroid-specific genes6,7, but the range of genes controlled by the GATA factors has since expanded1,7-10. Members of the GATA transcription factor family share a conserved zinc-finger DNA-binding domain, but the expression profile of each GATA factor is distinct11-13 . Here we show that a testis form of murine (m)GATA-1 messenger RNA is transcribed from a promoter located 5' to the erythroid first exon, and the remaining exons (which encode the mGATA-1 protein) are used in common by both testis and erythroid transcripts. We use an anti-mGATA-1 monoclonal antibody to show that the factor expressed in erythroid cells is the same as that found in the seminiferous tubules of murine testis. The GATA-1-expressing cells in 10-week-old testis were found only in contact with the basement membrane of seminiferous tubules, suggesting that GATA-1 regulates genes during the earliest stages of spermatogenesis.	TOHOKU UNIV,SCH MED,DEPT BIOCHEM,SEIRYOMACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,SCH MED,DEPT PATHOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN; HIROSAKI UNIV,SCH MED,DEPT PEDIAT,HIROSAKI,AOMORI 036,JAPAN; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Tohoku University; Tohoku University; Hirosaki University; Northwestern University			Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Ito, Etsuro/0000-0002-0168-2475				EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Fawcett DW, 1986, TXB HISTOLOGY, P796; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PLUMP M, 1989, NUCLEIC ACIDS RES, V47, P73; REDONDO JM, 1991, MOL CELL BIOL, V11, P5671, DOI 10.1128/MCB.11.11.5671; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHICKLER M, 1992, MOL CELL BIOL, V12, P120, DOI 10.1128/MCB.12.1.120; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG Z, 1991, REGULATION HEMOGLOBI, P249	23	270	272	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					466	468		10.1038/362466a0	http://dx.doi.org/10.1038/362466a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8464479				2022-12-28	WOS:A1993KV42400089
J	KUNIN, CM				KUNIN, CM			RESISTANCE TO ANTIMICROBIAL DRUGS - A WORLDWIDE CALAMITY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						DRUG RESISTANCE, MICROBIAL; DEVELOPING COUNTRIES; GOVERNMENT; HEALTH PERSONNEL; DRUG INDUSTRY	ANTIBIOTIC USE; SELF-MEDICATION; DEVELOPING-COUNTRIES; THIRD-WORLD; AGENTS; PRESCRIPTION; PHARMACEUTICALS; PHARMACIES; TRAVELERS; CHILDREN	The introduction of penicillin 50 years ago was followed by an extraordinary period of discovery, exuberant use, and predictable obsolescence. Resistant bacterial strains have emerged and have spread throughout the world because of the remarkable genetic plasticity of the microorganisms, heavy selective pressures of use, and the mobility of the world population. New and more expensive drugs have appeared almost in the nick of time, but it is doubtful that they will keep pace. The problem of resistance to antimicrobial drugs is particularly troublesome in developing countries. The underlying problems are largely economic and societal, and no ready solutions are available. An urgent need exists for more appropriate selection and use of antimicrobial drugs in the developed as well as in developing countries. The focus in developing countries should be on the availability of safe and effective drugs and on the enforcement of more responsible national drug policies. These issues must be addressed by the collective action of governments, the pharmaceutical industry, health care providers, and consumers. The developed countries have an important stake in the ways in which antibiotics are used in developing countries because resistant microorganisms do not recognize national boundaries.			KUNIN, CM (corresponding author), OHIO STATE UNIV, DEPT INTERNAL MED, STARLING LOVING HALL, ROOM M110, 320 W 10TH AVE, COLUMBUS, OH 43210 USA.							[Anonymous], 1983, B WORLD HEALTH ORGAN, V61, P423; ANTEZANA FS, 1981, J ROY SOC MED, V74, P175, DOI 10.1177/014107688107400301; APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; BEAM TR, 1992, CLIN INFECT DIS, V15, pS1, DOI 10.1093/clind/15.Supplement_1.S1; BROWN S, 1982, LANCET, V2, P1366; BURKE JP, 1985, REV INFECT DIS, V7, P560; Castelo A, 1991, J Clin Epidemiol, V44 Suppl 2, p21S; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; CONE M, 1991, J CLIN EPIDEMIOL, V44, pS45; DANTES RB, 1991, J CLIN EPIDEMIOL, V44, pS29; DARMANSJAH I, 1991, J CLIN EPIDEMIOL, V44, pS39; FERGUSON AE, 1981, CULT MED PSYCHIAT, V5, P105, DOI 10.1007/BF00055416; FINLAND M, 1959, JAMA-J AM MED ASSOC, V170, P2188, DOI 10.1001/jama.1959.63010180008012; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; GRANT JP, 1983, STATE WORLDS CHILDRE; GREENHALGH T, 1986, LANCET, V1, P1318; GREENHALGH T, 1987, SOC SCI MED, V25, P307, DOI 10.1016/0277-9536(87)90233-4; GUSTAFSSON LL, 1981, LANCET, V1, P31; HAAK H, 1988, LANCET, V2, P620; HARDON AP, 1987, SOC SCI MED, V25, P277, DOI 10.1016/0277-9536(87)90231-0; HOGERZEIL HV, 1989, LANCET, V1, P141; HOSSAIN MM, 1982, INT J EPIDEMIOL, V11, P402, DOI 10.1093/ije/11.4.402; JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906; Kanji N, 1992, DRUGS POLICY DEV COU; KUNIN CM, 1983, ANN INTERN MED, V99, P859, DOI 10.7326/0003-4819-99-6-859; KUNIN CM, 1969, NEW ENGL J MED, V280, P1442, DOI 10.1056/NEJM196906262802605; KUNIN CM, 1987, REV INFECT DIS, V9, pS270; KUNIN CM, 1991, J CLIN EPIDEMIOL, V44, pS1; LANSANG MA, 1990, J CLIN EPIDEMIOL, V43, P61, DOI 10.1016/0895-4356(90)90057-V; LEE D, 1991, J CLIN EPIDEMIOL, V44, pS31; LERMAN SJ, 1985, LANCET, V2, P651; LEVY SB, 1991, J CLIN EPIDEMIOL, V44, pS83; Mansfield P R, 1991, Int J Risk Saf Med, V2, P171, DOI 10.3233/JRS-1991-2401; MAPLE PAC, 1989, LANCET, V1, P537; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MELROSE D, 1982, BITTER PILLS MED 3RD; MICHEL JM, 1985, LANCET, V1, P210; MUNISHI GK, 1991, J CLIN EPIDEMIOL, V44, pS7; MURRAY BE, 1990, ANTIMICROB AGENTS CH, V34, P515, DOI 10.1128/AAC.34.4.515; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OBASEIKIEBOR EE, 1987, J ANTIMICROB CHEMOTH, V20, P759, DOI 10.1093/jac/20.5.759; OBRIEN TF, 1992, NEW ENGL J MED, V326, P339, DOI 10.1056/NEJM199201303260510; OLARTE J, 1973, ANTIMICROB AGENTS CH, V4, P597, DOI 10.1128/AAC.4.6.597; PAINE TF, 1947, NEW ENGL J MED, V236, P748, DOI 10.1056/NEJM194705152362004; QUICK JD, 1991, J CLIN EPIDEMIOL, V44, pS57; SANZ EJ, 1989, EUR J CLIN PHARMACOL, V37, P65; Schatz A, 1944, P SOC EXP BIOL MED, V57, P244, DOI 10.3181/00379727-57-14769; SCHORLING JB, 1991, INT J EPIDEMIOL, V20, P293, DOI 10.1093/ije/20.1.293; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; Silverman M, 1992, BAD MED PRESCRIPTION; STEIN CM, 1984, J ANTIMICROB CHEMOTH, V14, P149, DOI 10.1093/jac/14.2.149; STERKY G, 1991, J CLIN EPIDEMIOL, V44, pS67; TAUXE RV, 1990, J INFECT DIS, V162, P1107, DOI 10.1093/infdis/162.5.1107; THAMLIKITKUL V, 1988, J ANTIMICROB CHEMOTH, V21, P125, DOI 10.1093/jac/21.1.125; TOMSON G, 1986, LANCET, V2, P620; WALLMARK G, 1961, JAMA-J AM MED ASSOC, V175, P886, DOI 10.1001/jama.1961.63040100007012; WALSH JA, 1989, ANN NY ACAD SCI, V569, P1, DOI 10.1111/j.1749-6632.1989.tb27354.x; WILSON D, 1976, SEARCH PENICILLIN, P171; WOLFFERS I, 1987, SOC SCI MED, V25, P319, DOI 10.1016/0277-9536(87)90234-6; 1988, WORLD DRUG SITUATION; 1991, MMWR, V40, P685	61	370	385	0	36	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					557	561		10.7326/0003-4819-118-7-199304010-00011	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442626				2022-12-28	WOS:A1993KU07900011
J	PANDIT, MK; BURKE, J; GUSTAFSON, AB; MINOCHA, A; PEIRIS, AN				PANDIT, MK; BURKE, J; GUSTAFSON, AB; MINOCHA, A; PEIRIS, AN			DRUG-INDUCED DISORDERS OF GLUCOSE-TOLERANCE	ANNALS OF INTERNAL MEDICINE			English	Review						BLOOD GLUCOSE; HYPERINSULINISM; INSULIN RESISTANCE; DRUG TOXICITY; DIABETES-MELLITUS	DEPENDENT DIABETES-MELLITUS; PENTAMIDINE-INDUCED HYPOGLYCEMIA; INDUCED INSULIN RESISTANCE; SYMPATHOMIMETIC TOCOLYTIC THERAPY; CORONARY-HEART-DISEASE; CHRONIC-RENAL-FAILURE; B-CELL FUNCTION; NICOTINIC-ACID; CARBOHYDRATE-METABOLISM; NEONATAL HYPOGLYCEMIA	Purpose: To review the medications that influence glucose metabolism and to examine the mechanisms of these medications on glucose metabolism. Data Sources: Data were obtained from a MEDLINE search back to 1966 and included animal and human studies published in the English language. Study Selection:Approximately 80% of original publications were included after review by the authors. Case reports were included if they provided additional information. Date Extraction: The original data from the literature were included on the basis of independent extraction by the authors. Data Synthesis: Many common therapeutic agents influence glucose metabolism. Multiple mechanisms of action on glucose metabolism exist through pancreatic, hepatic, and peripheral effects. Based on circumstances at the time of use, a drug may cause both hyper- and hypoglycemia in a patient. The patient's previous pancreatic reserve, nutritional state, use of other medication, or exposure to alcohol may influence the direction of the plasma glucose alterations. Conclusion: Hyperinsulinemia and insulin resistance form an intrinsic component of diabetes, hyperlipidemia, and atherosclerotic vascular disease (syndrome X). The induction of hyperinsulinemia and insulin resistance by medication may therefore counteract intended benefits. An extensive review of recent medication in patients with disorders of glucose tolerance and the avoidance of polypharmacy are recommended. It is prudent to monitor plasma glucose values when it is not possible to avoid prescription of medication with known effects on carbohydrate metabolism.	FARGO VET AFFAIRS MED CTR, FARGO, ND 58102 USA; UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA; UNIV N DAKOTA, GRAND FORKS, ND 58201 USA	University of Louisville; University of North Dakota Grand Forks	PANDIT, MK (corresponding author), VAMC, 800 ZORN AVE, LOUISVILLE, KY 40206 USA.			Peiris, Alan/0000-0001-9323-7557				ADNITT PI, 1968, DIABETES, V17, P628, DOI 10.2337/diab.17.10.628; AGBAYEWA MO, 1986, PSYCHIAT J U OTTAWA, V11, P153; ALMIRALL J, 1989, NEPHRON, V53, P273, DOI 10.1159/000185757; AMES RP, 1983, AM J CARDIOL, V51, P632, DOI 10.1016/S0002-9149(83)80200-8; ANDERSSON DEH, 1981, ACTA MED SCAND, V210, P27; ANGELONIELSEN K, 1980, JAMA-J AM MED ASSOC, V244, P2263, DOI 10.1001/jama.1980.03310200015012; AREM R, 1983, ARCH INTERN MED, V143, P827, DOI 10.1001/archinte.143.4.827; ARKY RA, 1989, ENDOCRIN METAB CLIN, V18, P75, DOI 10.1016/S0889-8529(18)30389-X; ARNESON GA, 1964, J NEUROPSYCHIATRY, V5, P181; ASENSIO AS, 1987, INT J LEPROSY, V55, P357; BARNETT AH, 1980, BRIT MED J, V280, P976, DOI 10.1136/bmj.280.6219.976; BEARDWOO.DM, 1965, METABOLIS, V14, P561, DOI 10.1016/S0026-0495(65)80016-6; BELEHU A, 1982, LANCET, V1, P1463; BELLEJO G, 1983, CONTRACEPTION, P28; BENDING JJ, 1987, BRIT MED J, V294, P401, DOI 10.1136/bmj.294.6569.401; BHATNAGAR SK, 1984, BRIT MED J, V289, P19, DOI 10.1136/bmj.289.6436.19; BLANE GF, 1987, AM J MED, V83, P26, DOI 10.1016/0002-9343(87)90868-0; BLAZAR BR, 1984, DIABETES, V33, P1133, DOI 10.2337/diabetes.33.12.1133; BOUCHARD P, 1982, DIABETES, V31, P40, DOI 10.2337/diabetes.31.1.40; BRASS EP, 1984, DRUGS, V27, P447, DOI 10.2165/00003495-198427050-00004; BRATUSCHMARRAIN PR, 1985, DIABETOLOGIA, V28, P671, DOI 10.1007/BF00291974; BRATUSCHMARRAIN PR, 1984, AM J PHYSIOL, V247, pE681, DOI 10.1152/ajpendo.1984.247.5.E681; BRAZY JE, 1979, J PEDIATR-US, V94, P444, DOI 10.1016/S0022-3476(79)80599-5; BRECKENR.A, 1967, LANCET, V1, P61; BROADSTONE VL, 1987, DIABETES, V36, P932, DOI 10.2337/diabetes.36.8.932; BUFFINGTON CK, 1991, DIABETES, V40, P693, DOI 10.2337/diabetes.40.6.693; CAGNACCI A, 1992, J CLIN ENDOCR METAB, V74, P1396, DOI 10.1210/jc.74.6.1396; CALDWELL G, 1987, OBSTET GYNECOL, V70, P478; CALLAGHAN N, 1977, ACTA NEUROL SCAND, V56, P563; CAMPBELL DB, 1981, POSTGRAD MED J, V57, P7; CAPRIO S, 1984, DIABETOLOGIA, V27, P52, DOI 10.1007/BF00253502; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; CARRINGTON LJ, 1984, GEN PHARMACOL, V15, P415, DOI 10.1016/0306-3623(84)90041-7; CAVALLOPERIN P, 1988, J ENDOCRINOL INVEST, V11, P795, DOI 10.1007/BF03350228; CERASI E, 1972, ACTA ENDOCRINOL-COP, V69, P335, DOI 10.1530/acta.0.0690335; CHAN JCN, 1991, ADVERSE DRUG REACT T, V10, P1; Collard K.J., 1986, ENDOCRINE METABOLIC; COLLINS RJ, 1989, AM J MED SCI, V297, P174; Connor H, 1985, Diabet Med, V2, P413; COOPER AJ, 1966, LANCET, V1, P407; Corcoran F H, 1971, J Fla Med Assoc, V58, P38; CORNELL RC, 1984, DERMATOL CLIN, V2, P397, DOI 10.1016/S0733-8635(18)30955-0; CORNISH AL, 1961, NEW ENGL J MED, V265, P673, DOI 10.1056/NEJM196110052651403; COTTON EK, 1964, AM J DIS CHILD, V108, P171, DOI 10.1001/archpedi.1964.02090010173009; COTTRILL CM, 1977, J PEDIATR-US, V91, P812, DOI 10.1016/S0022-3476(77)81049-4; COWLEY AJ, 1977, LANCET, V1, P154; CROXSON MS, 1987, NEW ZEAL MED J, V100, P407; DANTE A, 1986, ANN INTERN MED, V104, P125, DOI 10.7326/0003-4819-104-1-125_3; DAVIES DM, 1985, TXB ADVERSE DRUG REA, P352; DEPIRRO R, 1981, J CLIN ENDOCR METAB, V52, P29, DOI 10.1210/jcem-52-1-29; DICKSON I, 1962, MED J AUSTRALIA, V1, P325, DOI 10.5694/j.1326-5377.1962.tb25948.x; ELLING P, 1985, ANN INTERN MED, V103, P644, DOI 10.7326/0003-4819-103-4-644; ELLIS ME, 1986, AM J CLIN ONCOL-CANC, V9, P533, DOI 10.1097/00000421-198612000-00013; EPSTEIN MF, 1979, J PEDIATR-US, V94, P449, DOI 10.1016/S0022-3476(79)80600-9; ERLE G, 1977, EUR J CLIN PHARMACOL, V11, P15, DOI 10.1007/BF00561782; FARISS BL, 1971, DIABETES, V20, P177, DOI 10.2337/diab.20.3.177; FENDERSON RW, 1982, ANGIOLOGY, V33, P581, DOI 10.1177/000331978203300904; FERRERO E, 1985, IMMUNOL LETT, V10, P183, DOI 10.1016/0165-2478(85)90075-6; FERRIERE M, 1985, ANN INTERN MED, V102, P134, DOI 10.7326/0003-4819-102-1-134_3; Fioretti P, 1975, Acta Eur Fertil, V6, P63; FITZGERALD DB, 1984, J TROP MED HYG, V87, P15; FLAMENBAUM W, 1983, ANN INTERN MED, V98, P875, DOI 10.7326/0003-4819-98-5-875; FLOHR K, 1983, CLIN EXP IMMUNOL, V53, P605; FRANKEL MC, 1984, NEW YORK STATE J MED, V84, P30; FRASER AG, 1977, BRIT MED J, V2, P1518, DOI 10.1136/bmj.2.6101.1518; FRIEDL KE, 1989, J CLIN ENDOCR METAB, V68, P971, DOI 10.1210/jcem-68-5-971; FULCHER GR, 1988, DIABETES NEWS, V9, P4; FULLER JH, 1980, LANCET, V1, P1373; GANDA OP, 1984, ANN INTERN MED, V100, P464, DOI 10.7326/0003-4819-100-3-464_2; GARBITELLI VP, 1987, NEW YORK STATE J MED, V87, P576; GARG A, 1990, JAMA-J AM MED ASSOC, V264, P723, DOI 10.1001/jama.264.6.723; GILGORE SG, 1960, DIABETES, V9, P392, DOI 10.2337/diab.9.5.392; GIUGLIANO D, 1979, DIABETES, V28, P841, DOI 10.2337/diabetes.28.9.841; GIUGLIANO D, 1985, J CLIN ENDOCR METAB, V61, P160, DOI 10.1210/jcem-61-1-160; GOLDBERG IJ, 1980, AM J MED, V69, P463, DOI 10.1016/0002-9343(80)90020-0; GOLDZIEHER JW, 1978, FERTIL STERIL, V30, P146; GRAJOWER MM, 1980, NEPHRON, V26, P126, DOI 10.1159/000181967; GREENSTONE MA, 1987, POSTGRAD MED J, V63, P761, DOI 10.1136/pgmj.63.743.761; HALE PJ, 1991, ANN CLIN BIOCHEM, V28, P39, DOI 10.1177/000456329102800106; HALL KW, 1984, ANN INTERN MED, V101, P457, DOI 10.7326/0003-4819-101-4-457; HALLAM NF, 1980, SCOT MED J, V25, P287, DOI 10.1177/003693308002500408; HAYAKAWA F, 1986, J PEDIATR-US, V109, P138, DOI 10.1016/S0022-3476(86)80594-7; HECHT A, 1959, METABOLISM, V8, P418; HELDERMAN JH, 1983, DIABETES, V32, P106, DOI 10.2337/diabetes.32.2.106; HENKIN Y, 1991, AM J MED, V91, P239, DOI 10.1016/0002-9343(91)90122-E; HERMANSEN K, 1985, METABOLISM, V34, P784, DOI 10.1016/0026-0495(85)90031-9; HEYMAN SN, 1989, DICP ANN PHARMAC, V23, P236, DOI 10.1177/106002808902300309; HILLEMAN DE, 1987, DRUG INTEL CLIN PHAR, V21, P38, DOI 10.1177/10600280870211P104; HUNT NJ, 1987, BIOL PSYCHIAT, V22, P798, DOI 10.1016/0006-3223(87)90219-8; IWAKIRI R, 1987, EXPERIENTIA, V43, P324, DOI 10.1007/BF01945570; JANDA A, 1986, Regional-Anaesthesie, V9, P88; JAUCH KW, 1986, BIOL CHEM H-S, V367, P207, DOI 10.1515/bchm3.1986.367.1.207; JAVIER Z, 1968, METABOLISM, V17, P443, DOI 10.1016/0026-0495(68)90067-X; JEUNEMAITRE X, 1987, AM J CARDIOL, V60, P820, DOI 10.1016/0002-9149(87)91030-7; JHA TK, 1984, T ROY SOC TROP MED H, V78, P252, DOI 10.1016/0035-9203(84)90289-X; JONES BJ, 1988, CLIN PHARMACY, V7, P235; KAHN SE, 1989, DIABETES, V38, P562, DOI 10.2337/diabetes.38.5.562; KAPLAN NM, 1985, ANN INTERN MED, V102, P359, DOI 10.7326/0003-4819-102-3-359; KAPLAN SM, 1960, JAMA-J AM MED ASSOC, V174, P511, DOI 10.1001/jama.1960.63030050009013; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; KARLANDER SG, 1989, J CLIN ENDOCR METAB, V68, P780, DOI 10.1210/jcem-68-4-780; KASDORF G, 1988, J CLIN ENDOCR METAB, V66, P846, DOI 10.1210/jcem-66-4-846; KORENYI C, 1968, DIS NERV SYST, V29, P827; KOTLER MN, 1966, LANCET, V2, P1389; KRAUSZ Y, 1987, ACTA ENDOCRINOL-COP, V116, P241, DOI 10.1530/acta.0.1160241; Kurz M, 1968, Wien Med Wochenschr, V118, P239; LAKSHMANAN MC, 1986, ARCH INTERN MED, V146, P1931, DOI 10.1001/archinte.146.10.1931; LEDERLE RM, 1985, J CARDIOVASC PHARM, V7, pS63, DOI 10.1097/00005344-198507001-00013; LENZEN S, 1984, ENDOCR REV, V5, P411, DOI 10.1210/edrv-5-3-411; LESLIE D, 1977, BRIT MED J, V2, P768, DOI 10.1136/bmj.2.6089.768-b; LEVIN SR, 1973, DIABETES, V22, P194, DOI 10.2337/diab.22.3.194; LEWIS PJ, 1976, LANCET, V1, P564; Long CNH, 1940, ENDOCRINOLOGY, V26, P309, DOI 10.1210/endo-26-2-309; LUNDJOHANSEN P, 1987, J CARDIOVASC PHARM, V10, pS29, DOI 10.1097/00005344-198706110-00009; LURIA MH, 1988, ARCH INTERN MED, V148, P2493, DOI 10.1001/archinte.148.11.2493; Madison L L, 1968, Adv Metab Disord, V3, P85; MAIN DM, 1985, AM J OBSTET GYNECOL, V152, P1031, DOI 10.1016/0002-9378(85)90553-8; MAIN EK, 1987, AM J OBSTET GYNECOL, V157, P644, DOI 10.1016/S0002-9378(87)80021-2; MCCULLOCH DK, 1991, J CLIN INVEST, V87, P1395, DOI 10.1172/JCI115145; MCMURRAY J, 1986, LANCET, V1, P1035; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; METZ SA, 1978, DIABETES, V27, P554, DOI 10.2337/diab.27.5.554; MICOSSI P, 1984, HORM METAB RES, V16, P59, DOI 10.1055/s-2007-1014697; MILLER RR, 1973, AM J HOSP PHARM, V30, P584, DOI 10.1093/ajhp/30.7.584; MINAKER KL, 1989, ARCH NEUROL-CHICAGO, V46, P981, DOI 10.1001/archneur.1989.00520450051018; MORTIMER EA, 1962, AM J DIS CHILD, V103, P583, DOI 10.1001/archpedi.1962.02080020596008; MUELLER PS, 1969, ARCH GEN PSYCHIAT, V21, P587; MUGGEO M, 1986, 6TH P INT M ATH CARD; MULLEROERLINGHAUSEN B, 1979, INT PHARMACOPSYCHIAT, V14, P350; NAPPI JM, 1983, WESTERN J MED, V138, P95; NEWMAN WP, 1983, J CLIN ENDOCR METAB, V57, P1102, DOI 10.1210/jcem-57-6-1102; OBYRNE S, 1990, DRUGS, V40, P6, DOI 10.2165/00003495-199040010-00002; OLEFSKY JM, 1976, AM J MED SCI, V271, P202, DOI 10.1097/00000441-197603000-00009; OSEI K, 1986, ARCH INTERN MED, V146, P1973, DOI 10.1001/archinte.146.10.1973; OST L, 1988, TRANSPLANTATION, V46, P370; PAGANO G, 1983, J CLIN INVEST, V72, P1814, DOI 10.1172/JCI111141; PEDERSEN OL, 1977, ACTA CARDIOL, V32, P283; PEIRIS AN, 1989, ANN INTERN MED, V110, P867, DOI 10.7326/0003-4819-110-11-867; PEIRIS AN, 1993, J CLIN ENDOCR METAB, V76, P279, DOI 10.1210/jc.76.2.279; PEIRIS AN, 1992, J CLIN ENDOCR METAB, V75, P290, DOI 10.1210/jc.75.1.290; PELUFFO E, 1958, Arch Pediatr Urug, V29, P94; PERLMAN JA, 1985, J CHRON DIS, V38, P857, DOI 10.1016/0021-9681(85)90110-9; PERRYKEENE DA, 1980, CLIN ENDOCRINOL, V12, P575, DOI 10.1111/j.1365-2265.1980.tb01378.x; PERSHADSINGH HA, 1987, JAMA-J AM MED ASSOC, V257, P930; PETERS BH, 1969, NEW ENGL J MED, V281, P91, DOI 10.1056/NEJM196907102810208; PHILLIPS RE, 1986, LANCET, V1, P713; PHILLIPS RE, 1986, BRIT MED J, V292, P1319, DOI 10.1136/bmj.292.6531.1319; POLITI A, 1984, BRIT MED J, V288, P285, DOI 10.1136/bmj.288.6413.285; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; POLLOCK SH, 1991, J PHARMACOL EXP THER, V258, P8; PORETSKY L, 1984, DIABETES CARE, V7, P508, DOI 10.2337/diacare.7.5.508; QUEVEDO SF, 1981, JAMA-J AM MED ASSOC, V245, P2424, DOI 10.1001/jama.245.23.2424; RAIA JI, 1983, CLIN PHARMACY, V2, P505; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REGAL H, 1984, DRUG EXP CLIN RES, V10, P621; ROSATI G, 1976, EUR NEUROL, V14, P229, DOI 10.1159/000114744; ROTH A, 1989, ANN INTERN MED, V110, P171, DOI 10.7326/0003-4819-110-2-171_2; RUBIN M, 1983, NEW YORK STATE J MED, V83, P1057; RUSSELL JD, 1981, AUST NZ J PSYCHIAT, V15, P349, DOI 10.3109/00048678109159459; RYAN EA, 1985, DIABETES, V34, P380, DOI 10.2337/diabetes.34.4.380; SAI P, 1983, DIABETOLOGIA, V25, P418, DOI 10.1007/BF00282521; Said D M, 1968, Med Ann Dist Columbia, V37, P170; SAITO T, 1982, ENDOCRINOL JAPON, V29, P137; SALERNO DM, 1988, AM J MED, V84, P39, DOI 10.1016/0002-9343(88)90006-X; SALMERON S, 1986, ANN INTERN MED, V105, P140, DOI 10.7326/0003-4819-105-1-140_2; SATO S, 1988, J PHARMACOBIO-DYNAM, V11, P492, DOI 10.1248/bpb1978.11.492; SELTZER HS, 1989, ENDOCRIN METAB CLIN, V18, P163, DOI 10.1016/S0889-8529(18)30395-5; SESTIER C, 1985, IMMUNOL LETT, V10, P57, DOI 10.1016/0165-2478(85)90051-3; SEVIOUR PW, 1988, DIABETIC MED, V5, P166, DOI 10.1111/j.1464-5491.1988.tb00965.x; SHAH JH, 1986, METABOLISM, V35, P634, DOI 10.1016/0026-0495(86)90170-8; SHEN M, 1989, AM J MED, V86, P726, DOI 10.1016/0002-9343(89)90457-9; SKOUBY SO, 1985, CONTRACEPTION, V32, P23, DOI 10.1016/0010-7824(85)90113-1; SMALL M, 1986, HORM METAB RES, V18, P647, DOI 10.1055/s-2007-1012395; SMITH GD, 1987, BRIT MED J, V294, P465, DOI 10.1136/bmj.294.6570.465; SPELLACY WN, 1991, INT J GYNECOL OBSTET, V35, P69, DOI 10.1016/0020-7292(91)90066-E; SPELLACY WN, 1970, J REPROD MED, V5, P40; SPELLACY WN, 1979, FERTIL STERIL, V31, P381; SPELLACY WN, 1982, AM J OBSTET GYNECOL, V142, P732; STAHLBAYLISS CM, 1986, CLIN PHARMACOL THER, V39, P271, DOI 10.1038/clpt.1986.38; STAPLETON JT, 1983, SOUTH MED J, V76, P1453, DOI 10.1097/00007611-198311000-00037; SUNG PK, 1971, CURR THER RES CLIN E, V13, P280; TAKASU N, 1982, AM REV RESPIR DIS, V125, P23; TAYLOR R, 1985, ACTA ENDOCRINOL-COP, V109, P96, DOI 10.1530/acta.0.1090096; TKACH JR, 1982, J AM ACAD DERMATOL, V7, P802, DOI 10.1016/S0190-9622(82)80165-5; TOLLEFSON G, 1983, J CLIN PSYCHIAT, V44, P347; TORNVALL P, 1991, J INTERN MED, V230, P415, DOI 10.1111/j.1365-2796.1991.tb00466.x; TOTTERMAN K, 1984, EUR J CLIN PHARMACOL, V26, P13, DOI 10.1007/BF00546701; TOURNIAIRE J, 1988, DIABETES METAB, V14, P717; VALDES CT, 1991, J CLIN ENDOCR METAB, V72, P642, DOI 10.1210/jcem-72-3-642; VANDERVELDE CD, 1969, ARCH GEN PSYCHIAT, V21, P478; VANPRAAG HM, 1965, PSYCHOPHARMACOLOGIA, V8, P67, DOI 10.1007/BF00405362; VESTER JW, 1970, CLIN PHARMACOL THER, V11, P689; VESTERGAARD P, 1987, NEUROPSYCHOBIOLOGY, V17, P130, DOI 10.1159/000118351; WASKIN H, 1988, JAMA-J AM MED ASSOC, V260, P345, DOI 10.1001/jama.260.3.345; WHITCROFT I, 1985, BRIT MED J, V290, P322, DOI 10.1136/bmj.290.6464.322-b; WHITCROFT I, 1986, BRIT J CLIN PHARMACO, V22, pP236; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201; WOLLHEIM CB, 1978, J CLIN INVEST, V62, P451, DOI 10.1172/JCI109146; WYNN V, 1969, LANCET, V2, P761; WYNN V, 1979, LANCET, V1, P1045; YASUDA K, 1980, DIABETES, V29, P811, DOI 10.2337/diabetes.29.10.811; YASUDA K, 1981, TOHOKU J EXP MED, V134, P411, DOI 10.1620/tjem.134.411; YASUDA K, 1982, J CLIN ENDOCR METAB, V55, P910, DOI 10.1210/jcem-55-5-910; YOSHIMURA N, 1988, AM J KIDNEY DIS, V12, P11, DOI 10.1016/S0272-6386(88)80065-9; ZOFKOVA I, 1990, EXP CLIN ENDOCRINOL, V96, P185; ZUGER A, 1986, JAMA-J AM MED ASSOC, V256, P2383, DOI 10.1001/jama.256.17.2383; ZUMOFF B, 1977, JAMA-J AM MED ASSOC, V237, P1960, DOI 10.1001/jama.237.18.1960	207	146	150	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					529	539		10.7326/0003-4819-118-7-199304010-00008	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442624				2022-12-28	WOS:A1993KU07900008
J	JIANG, J; LEVINE, M				JIANG, J; LEVINE, M			BINDING AFFINITIES AND COOPERATIVE INTERACTIONS WITH BHLH ACTIVATORS DELIMIT THRESHOLD RESPONSES TO THE DORSAL GRADIENT MORPHOGEN	CELL			English	Article							NF-KAPPA-B; DROSOPHILA EMBRYO; DNA-BINDING; DORSOVENTRAL PATTERN; GENE-EXPRESSION; SYNERGISTIC ACTIVATION; SEGMENTATION GENE; PROTEIN; MESODERM; SEQUENCE	The dorsal (dl) morphogen gradient initiates the formation of the mesoderm, neuroectoderm, and dorsal ectoderm by setting different limits of regulatory gene expression along the dorsoventral axis of the early Drosophila embryo. In this paper, we show that low affinity dl-binding sites restrict target gene expression to the ventralmost regions (presumptive mesoderm), where there are peak levels of dl, while high affinity sites permit expression in ventrolateral regions (mesoderm and mesectoderm) containing intermediate levels of the morphogen. Activation by low levels of dl in lateral regions (the presumptive neuroectoderm) depends on cooperative DNA binding interactions between dl and bHLH proteins. The snail repressor blocks this interaction and restricts expression to the neuroectoderm. We discuss how enhancers serve as templates to bring weakly interacting regulatory factors into close proximity so that they can function combinatorially to activate and repress transcription.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				Levine, Michael/0000-0001-7629-0081	NIGMS NIH HHS [GM46638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046638, R01GM046638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERGA A, 1991, DEVELOPMENT, V111, P983; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1991, CELL, V64, P439; IP YT, 1992, SEM DEV BIOL, V3, P15; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1992, EMBO J, V11, P3147, DOI 10.1002/j.1460-2075.1992.tb05387.x; JIANG J, 1991, GENE DEV, V5, P265, DOI 10.1101/gad.5.2.265; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KASAI Y, 1992, P NATL ACAD SCI USA, V89, P3414, DOI 10.1073/pnas.89.8.3414; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PAN D, 1992, EMBO J, V11, P1837, DOI 10.1002/j.1460-2075.1992.tb05235.x; PAN D, 1991, GENE DEV, V5, P1592; RAO Y, 1991, GENE DEV, V5, P1577, DOI 10.1101/gad.5.9.1577; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sander K, 1975, Ciba Found Symp, V0, P241; SIMPSON P, 1983, GENETICS, V105, P615; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDOREN M, 1991, DEVELOPMENT, V113, P245	57	273	281	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					741	752		10.1016/0092-8674(93)90402-C	http://dx.doi.org/10.1016/0092-8674(93)90402-C			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453668	Bronze			2022-12-28	WOS:A1993KR43600010
J	XUE, FY; COOLEY, L				XUE, FY; COOLEY, L			KELCH ENCODES A COMPONENT OF INTERCELLULAR BRIDGES IN DROSOPHILA EGG CHAMBERS	CELL			English	Article							SHOPE FIBROMA VIRUS; VACCINIA VIRUS; ESCHERICHIA-COLI; STRUCTURAL PROTEINS; ZINC FINGERS; UGA CODON; GENE; SELENOCYSTEINE; SEQUENCE; REGION	Oocyte maturation in Drosophila is supported by a cluster of 15 germline-derived nurse cells whose cytoplasm is transported into the oocyte through intercellular bridges called ring canals. kelch was isolated as a female sterile mutation affecting cytoplasm transport. We have cloned the kelch gene and found that it encodes an unusual transcript containing two open reading frames (ORF1 and ORF2) separated by a single UGA stop codon. At least two protein products are made from the kelch mRNA: a short protein from ORF1 and a longer protein from both ORF1 and ORF2 as a result of partial suppression of the UGA codon. The kelch ORF1 product is conserved, and antibodies directed against it are localized specifically to ring canals. Our results suggest that kelch produces a component of ring canals that regulates the flow of cytoplasm between cells.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University					NIGMS NIH HHS [GM43301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENYAJATI C, 1992, NUCLEIC ACIDS RES, V20, P4481, DOI 10.1093/nar/20.17.4481; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BROWN EH, 1964, GROWTH, V28, P41; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BURGOS MH, 1955, J BIOPHYS BIOCHEM CY, V1, P287, DOI 10.1083/jcb.1.4.287; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIBELLO PR, 1991, GENETICS, V129, P385; FAWCETT DW, 1959, J BIOPHYS BIOCHEM CY, V5, P453, DOI 10.1083/jcb.5.3.453; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG YX, 1989, J VIROL, V63, P2870, DOI 10.1128/JVI.63.6.2870-2873.1989; FORCHHAMMER K, 1990, J BIOL CHEM, V265, P9346; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GONDOS B, 1987, INT J GYNECOL PATHOL, V6, P114, DOI 10.1097/00004347-198706000-00003; GUTZEIT HO, 1986, J CELL SCI, V80, P159; GUTZEIT HO, 1989, ROUX ARCH DEV BIOL, V198, P185, DOI 10.1007/BF00375904; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HOFSTETTER H, 1974, BIOCHIM BIOPHYS ACTA, V374, P238, DOI 10.1016/0005-2787(74)90366-9; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; ITO S, 1960, J BIOPHYS BIOCHEM CY, V7, P433, DOI 10.1083/jcb.7.3.433; JALAJAKUMARI MB, 1989, MOL MICROBIOL, V3, P1685, DOI 10.1111/j.1365-2958.1989.tb00154.x; JONES DS, 1989, NUCLEIC ACIDS RES, V15, P5933; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; King R. C., 1970, OVARIAN DEV DROSOPHI; KOTWAL GJ, 1988, VIROLOGY, V167, P524, DOI 10.1016/S0042-6822(88)90115-8; KOZAK M, 1986, ADV VIRUS RES, V31, P229, DOI 10.1016/S0065-3527(08)60265-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKUS ME, 1991, VIROLOGY, V180, P406, DOI 10.1016/0042-6822(91)90047-F; QIAN S, 1987, NUCLEIC ACIDS RES, V15, P987, DOI 10.1093/nar/15.3.987; RUBY JR, 1969, J MORPHOL, V127, P307, DOI 10.1002/jmor.1051270304; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHON A, 1989, NUCLEIC ACIDS RES, V17, P7159, DOI 10.1093/nar/17.18.7159; SCHUPBACH T, 1991, GENETICS, V129, P1119; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling Allan C., 1993, P1; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STEWARD R, 1986, GENETICS, V113, P665; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRAUSS EG, 1983, P NATL ACAD SCI-BIOL, V80, P5271, DOI 10.1073/pnas.80.17.5271; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; UPTON C, 1990, VIROLOGY, V179, P618, DOI 10.1016/0042-6822(90)90129-F; UPTON C, 1986, VIROLOGY, V152, P308, DOI 10.1016/0042-6822(86)90134-0; WARN RM, 1985, EXP CELL RES, V157, P355, DOI 10.1016/0014-4827(85)90120-X; WEINER AM, 1973, J MOL BIOL, V80, P837, DOI 10.1016/0022-2836(73)90213-1; WRIGHT TRF, 1976, GENETICS, V84, P267; YUE L, 1992, GENE DEV, V6, P2443, DOI 10.1101/gad.6.12b.2443; ZAMBONI L, 1968, J CELL BIOL, V36, P276, DOI 10.1083/jcb.36.1.276; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	59	377	395	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					681	693		10.1016/0092-8674(93)90397-9	http://dx.doi.org/10.1016/0092-8674(93)90397-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453663	Bronze			2022-12-28	WOS:A1993KR43600005
J	BUEKENS, P; BOUTSEN, M; KITTEL, F; VANDENBUSSCHE, P; DRAMAIX, M				BUEKENS, P; BOUTSEN, M; KITTEL, F; VANDENBUSSCHE, P; DRAMAIX, M			DOES AWARENESS OF RATES OF OBSTETRIC INTERVENTIONS CHANGE PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							FEEDBACK				BUEKENS, P (corresponding author), SCH PUBL HEALTH,DEPT EPIDEMIOL & SOCIAL MED,B-1070 BRUSSELS,BELGIUM.							Hemminki E, 1992, Qual Assur Health Care, V4, P133; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; SZCEPURA A, 1987, BMJ, V294, P875; WINER BJ, 1971, STATISTICAL PRINCIPL, P205	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					623	623		10.1136/bmj.306.6878.623	http://dx.doi.org/10.1136/bmj.306.6878.623			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461814	Green Published, Bronze			2022-12-28	WOS:A1993KQ85900022
J	ANDERSON, G; JENKINSON, EJ; MOORE, NC; OWEN, JJT				ANDERSON, G; JENKINSON, EJ; MOORE, NC; OWEN, JJT			MHC CLASS-II-POSITIVE EPITHELIUM AND MESENCHYME CELLS ARE BOTH REQUIRED FOR T-CELL DEVELOPMENT IN THE THYMUS	NATURE			English	Article							LYMPHOCYTE-T; DIFFERENTIATION; MICE	T LYMPHOCYTES are produced in the thymus from precursors originating in the haemopoietic tissues. On entering the thymus, they undergo a programme of proliferation, T-cell receptor (TCR) gene rearrangement, differentiation and repertoire selection1. Although the thymus provides a unique environment for these events, the role of the thymic stroma in regulating specific developmental stages is not well understood2. We therefore devised an in vitro system to study the role of individual thymic stromal components in T-cell development. We report here that the development of TCR-CD4-CD8- T-cell precursors into TCR+ cells expressing CD4 and/or CD8 requires the presence of both major histocompatibility complex class II+ epithelial cells and fetal mesenchyme. The requirement for mesenchymal support can be mapped to the initial stages of intrathymic development because the later stages of maturation, from double-positive CD4+CD8+ thymocytes into single-positive CD4+ or CD8+ cells, can be supported by epithelial cells alone. We also show that the requirement for mesenchymal cells can be met by cells of the fibroblast line 3T3 (but not by supernatants from these cells). To our knowledge, these findings provide the first direct evidence that mesenchymal as well as epithelial cells are involved in T-cell development, and suggest that their involvement is stage-specific and likely to be dependent on short-range or contact-mediated interactions.			ANDERSON, G (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT ANAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			anderson, graham/0000-0002-2917-4085	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUERBACH R, 1960, DEV BIOL, V2, P271, DOI 10.1016/0012-1606(60)90009-9; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; HAYNES BF, 1983, J CLIN INVEST, V71, P9, DOI 10.1172/JCI110755; Jenkinson E J, 1990, Semin Immunol, V2, P51; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; JENKINSON EJ, 1982, EUR J IMMUNOL, V12, P583, DOI 10.1002/eji.1830120710; KANARIOU M, 1989, CLIN EXP IMMUNOL, V78, P263; KINGSTON R, 1984, EUR J IMMUNOL, V14, P1052, DOI 10.1002/eji.1830141117; LARSSON L, 1991, INT IMMUN, V1, P279; MIZUTANI S, 1987, P NATL ACAD SCI USA, V84, P4999, DOI 10.1073/pnas.84.14.4999; MOORE NC, IN PRESS EUR J IMMUN; MURDOCH A, 1990, J IMMUNOL METHODS, V132, P45, DOI 10.1016/0022-1759(90)90396-D; NAGAMINE J, 1991, J IMMUNOL, V147, P1147; Shortman K, 1990, Semin Immunol, V2, P3; SIDERAS P, 1987, EUR J IMMUNOL, V17, P217, DOI 10.1002/eji.1830170211; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	20	288	297	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					70	73		10.1038/362070a0	http://dx.doi.org/10.1038/362070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8446171	Bronze			2022-12-28	WOS:A1993KP97600063
J	DAVIES, K				DAVIES, K			PERIPHERIN AND THE VISION THING	NATURE			English	Editorial Material							RETINITIS-PIGMENTOSA; GENE; FAMILY											AHMAD NN, 1991, P NATL ACAD SCI USA, V88, P6624, DOI 10.1073/pnas.88.15.6624; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FORSMAN K, 1992, CLIN GENET, V42, P156; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KAJIWARA K, 1993, NAT GENET, V3, P208, DOI 10.1038/ng0393-208; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; MCINNES RR, 1992, NAT GENET, V1, P155, DOI 10.1038/ng0692-155; NICHOLS BE, 1993, NAT GENET, V3, P202, DOI 10.1038/ng0393-202; SMALL KW, 1992, GENOMICS, V13, P681, DOI 10.1016/0888-7543(92)90141-E; STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246; WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213	12	9	10	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					92	92						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8446174				2022-12-28	WOS:A1993KP97600070
J	LOWRY, S				LOWRY, S			MEDICAL-EDUCATION .9. MAKING CHANGE HAPPEN	BRITISH MEDICAL JOURNAL			English	Article							STUDENTS											Coles C., 1991, CHALLENGE PROBLEM BA; COLES CR, 1985, MED EDUC, V19, P308, DOI 10.1111/j.1365-2923.1985.tb01327.x; COLES CR, 1990, MED EDUC, V24, P14, DOI 10.1111/j.1365-2923.1990.tb02431.x; COLES CR, 1987, ASSESS EVAL HIGH EDU, V12, P209; MOORE GT, 1991, MED EDUC, V25, P140, DOI 10.1111/j.1365-2923.1991.tb00040.x; NEUFELD VR, 1989, ACAD MED, V64, P423, DOI 10.1097/00001888-198908000-00001; RAMOS M, 1987, INNOVATIVE TRACKS ES; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405; TOWLE A, 1991, CRITICAL THINKING FU; 1991, UNDERGRADUATE MED ED	10	18	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					320	322		10.1136/bmj.306.6873.320	http://dx.doi.org/10.1136/bmj.306.6873.320			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461653	Green Published, Bronze			2022-12-28	WOS:A1993KK71800027
J	BERRILL, WT				BERRILL, WT			FOR DEBATE - IS THE DEATH RATE FROM ASTHMA EXAGGERATED - EVIDENCE FROM WEST CUMBRIA	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; INCREASE; ENGLAND; WALES	Although the death rate from asthma in England and Wales is reported to be about 2000 a year, clinical experience suggests that it is much rarer. Doctors in West Cumbria health district could recall only seven cases in 14 years. Examination of case notes of patients officially recorded as dying of asthma showed that many were aged over 60 and cigarette smokers. An alternative cause of death was evident in over half the patients. If the picture is representative of that in the whole of Britain the reported mortality from asthma may be much too high.			BERRILL, WT (corresponding author), W CUMBERLAND DIST GEN HOSP,WHITEHAVEN CA28 8JG,CUMBRIA,ENGLAND.							[Anonymous], 1984, Thorax, V39, P505; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURNEY PGJ, 1986, LANCET, V2, P323; COCHRANE AL, 1981, LANCET, V2, P742; EASON J, 1987, BRIT MED J, V294, P1255, DOI 10.1136/bmj.294.6582.1255; REA HH, 1986, THORAX, V41, P83; 1982, BMJ, V285, P1251	7	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					193	194		10.1136/bmj.306.6871.193	http://dx.doi.org/10.1136/bmj.306.6871.193			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443487	Bronze, Green Published			2022-12-28	WOS:A1993KH51300029
J	LOWRY, S				LOWRY, S			MEDICAL-EDUCATION .7. THE PREREGISTRATION YEAR	BRITISH MEDICAL JOURNAL			English	Article							HOUSE OFFICERS											BAHRAMI J, 1992, BRIT MED J, V304, P981, DOI 10.1136/bmj.304.6832.981-b; DOWLING S, 1992, DOCTORS MAKING EXPER; FIRTHCOZENS J, 1989, BRIT J HOSP MED, V41, P161; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; FLEMING C, 1992, BRIT MED J, V305, P210; LESLIE PJ, 1990, BRIT MED J, V300, P1038, DOI 10.1136/bmj.300.6731.1038; REES G, 1992, BRIT MED J, V304, P981, DOI 10.1136/bmj.304.6832.981; RICHARDS P, 1992, BRIT MED J, V304, P625, DOI 10.1136/bmj.304.6827.625; WILSON DH, 1993, BRIT MED J, V306, P194, DOI 10.1136/bmj.306.6871.194; 1992, STRESS MED PROFESSIO; 1992, RECOMMENDATIONS GENE; 1988, DOCTORS THEIR CAREER	12	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					196	198		10.1136/bmj.306.6871.196	http://dx.doi.org/10.1136/bmj.306.6871.196			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443489	Bronze, Green Published			2022-12-28	WOS:A1993KH51300031
J	PIZZO, PA				PIZZO, PA			MANAGEMENT OF FEVER IN PATIENTS WITH CANCER AND TREATMENT-INDUCED NEUTROPENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; FEBRILE GRANULOCYTOPENIC PATIENTS; GRAM-NEGATIVE BACTEREMIA; INTRAVENOUS IMMUNE GLOBULIN; PEDIATRIC ONCOLOGY PATIENTS; CYTOMEGALO-VIRUS PNEUMONIA; PLACEBO-CONTROLLED TRIAL; ACUTE-LEUKEMIA; DOUBLE-BLIND				PIZZO, PA (corresponding author), NCI, PEDIAT BRANCH, BLDG 10, RM 13N240, BETHESDA, MD 20892 USA.							ANAISSIE E, 1991, AM J MED, V91, P142, DOI 10.1016/0002-9343(91)90006-J; [Anonymous], 1991, J Infect Dis, V163, P951; ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; BARLOON TJ, 1991, CHEST, V99, P928, DOI 10.1378/chest.99.4.928; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BODEY GP, 1985, ARCH INTERN MED, V145, P1621, DOI 10.1001/archinte.145.9.1621; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; BURCH PA, 1987, J CLIN ONCOL, V5, P1985, DOI 10.1200/JCO.1987.5.12.1985; CALANDRA T, 1987, NEW ENGL J MED, V317, P1692; CALANDRA T, 1991, J INFECT DIS, V164, P832; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; COTTON D, 1984, 24TH INT C ANT AG CH; COTTON DJ, 1987, J CLIN MICROBIOL, V25, P672, DOI 10.1128/JCM.25.4.672-674.1987; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DEKKER AW, 1987, ANN INTERN MED, V106, P7, DOI 10.7326/0003-4819-106-1-7; DINARELLO CA, 1991, J INFECT DIS, V163, P1177, DOI 10.1093/infdis/163.6.1177; DINARELLO CA, 1991, BLOOD, V77, P1627; DUHRSEN U, 1988, BLOOD, V72, P2074; DWYER JM, 1992, NEW ENGL J MED, V326, P107; DYBEDAL I, 1989, EUR J HAEMATOL, V42, P405; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; FEUSNER J, 1988, J CLIN ONCOL, V6, P1699, DOI 10.1200/JCO.1988.6.11.1699; FLYNN PM, 1988, PEDIATR INFECT DIS J, V7, P510, DOI 10.1097/00006454-198807000-00014; FREIFELD A, 1991, PRINCIPLES PRACTICE, V5, P1; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GLENN J, 1988, REV INFECT DIS, V10, P42; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; HAAS R, 1990, EXP HEMATOL, V18, P94; HARON E, 1987, AM J MED, V83, P17, DOI 10.1016/0002-9343(87)90492-X; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; HUGHES WT, 1990, J INFECT DIS, V161, P1316; HUIJGENS PC, 1991, EUR J HAEMATOL, V46, P42; INGRAM J, 1991, AM J PEDIAT HEMATOL, V13, P130; JONES PG, 1986, AM J MED, V81, P243, DOI 10.1016/0002-9343(86)90258-5; KARP JE, 1987, ANN INTERN MED, V106, P1, DOI 10.7326/0003-4819-106-1-1; KARP JE, 1986, AM J MED, V81, P237, DOI 10.1016/0002-9343(86)90257-3; KAUFFMAN CA, 1991, AM J MED, V91, P137, DOI 10.1016/0002-9343(91)90005-I; KLASTERSKY J, 1982, REV INFECT DIS, V4, P294; KOTILAINEN P, 1990, J INFECT DIS, V161, P41, DOI 10.1093/infdis/161.1.41; KRAMER BS, 1982, AM J MED, V72, P561, DOI 10.1016/0002-9343(82)90449-1; LADISCH S, 1978, PEDIATRICS, V61, P231; LECCIONES JA, 1992, CLIN INFECT DIS, V14, P875, DOI 10.1093/clinids/14.4.875; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; LOPEZBERESTEIN G, 1989, ARCH INTERN MED, V149, P2533, DOI 10.1001/archinte.149.11.2533; LOVE LJ, 1980, AM J MED, V68, P643, DOI 10.1016/0002-9343(80)90243-0; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; MEUNIER F, 1989, AM J MED, V86, P668; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MIRRO J, 1989, J CLIN ONCOL, V7, P214, DOI 10.1200/JCO.1989.7.2.214; MUELLER BU, 1992, J CLIN ONCOL, V10, P1943, DOI 10.1200/JCO.1992.10.12.1943; MULLEN CA, 1990, J CLIN ONCOL, V8, P1998, DOI 10.1200/JCO.1990.8.12.1998; NAVARRO E, IN PRESS AM J MED; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NEMUNAITIS J, 1991, BLOOD, V78, P907; Neu H C, 1989, Infect Dis Clin North Am, V3, P625; NOVAKOVA I, 1991, ANTIMICROB AGENTS CH, V35, P672, DOI 10.1128/AAC.35.4.672; PATTON WN, 1985, J ANTIMICROB CHEMOTH, V16, P667, DOI 10.1093/jac/16.5.667; PETER JB, 1991, REV INFECT DIS, V13, P166; PETERS WP, 1989, BLOOD S, V74, pA50; Pizzo P A, 1984, Cancer, V54, P2649, DOI 10.1002/1097-0142(19841201)54:2+<2649::AID-CNCR2820541409>3.0.CO;2-6; PIZZO PA, 1985, AM J MED, V79, P75, DOI 10.1016/0002-9343(85)90265-7; PIZZO PA, 1984, AM J MED, V76, P436, DOI 10.1016/0002-9343(84)90663-6; PIZZO PA, 1979, AM J MED, V67, P194, DOI 10.1016/0002-9343(79)90390-5; PIZZO PA, 1978, MED PEDIATR ONCOL, V5, P241, DOI 10.1002/mpo.2950050133; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; PIZZO PA, 1991, J PEDIATR-US, V119, P845, DOI 10.1016/S0022-3476(05)83032-X; PIZZO PA, 1991, J PEDIATR-US, V119, P679, DOI 10.1016/S0022-3476(05)80281-1; PIZZO PA, 1989, EUR J CANCER CLIN ON, V25, pS9; PIZZO PA, 1987, REV INFECT DIS, V9, P214; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; PIZZO PA, 1982, MEDICINE, V61, P153, DOI 10.1097/00005792-198205000-00003; Pizzo PA, 1989, REV INFECT DIS    S7, V11, pS1551; PIZZO PA, 1983, CURRENT CLIN TOPICS, V4, P153; Pizzo PA, 1990, PRINCIPLES PRACTICE, P2303; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; ROILIDES E, 1992, J INFECT DIS, V166, P668, DOI 10.1093/infdis/166.3.668; ROILIDES E, 1992, PEDIATR INFECT DIS J, V11, P547, DOI 10.1097/00006454-199207000-00008; ROILIDES E, 1991, J INFECT DIS, V163, P579, DOI 10.1093/infdis/163.3.579; ROLIDES E, 1992, CLIN INFECT DIS, V15, P508, DOI 10.1093/clind/15.3.508; RUBIN M, 1988, ANN INTERN MED, V108, P30, DOI 10.7326/0003-4819-108-1-30; Rubin M, 1991, HEMATOLOGY BASIC PRI, P1063; RUBIN M, 1988, 28TH INT C ANT AG CH; RUBIN RH, 1989, NEW ENGL J MED, V321, P935, DOI 10.1056/NEJM198910053211404; SANDERS JW, 1991, J INFECT DIS, V164, P907, DOI 10.1093/infdis/164.5.907; SARAL R, 1981, NEW ENGL J MED, V305, P63, DOI 10.1056/NEJM198107093050202; SCHIFFER CA, 1979, BLOOD, V54, P766; SCHIFFER CA, 1984, CURRENT CLIN TOPICS, V5, P189; SCHIMPFF SC, 1985, REV INFECT DIS, V7, pS734; SCHIMPFF SC, 1972, ANN INTERN MED, V77, P707, DOI 10.7326/0003-4819-77-5-707; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SCHWARTZ C, 1990, J CLIN ONCOL, V8, P1591, DOI 10.1200/JCO.1990.8.9.1591; SHENEP JL, 1988, NEW ENGL J MED, V319, P1053, DOI 10.1056/NEJM198810203191604; SICKLES EA, 1975, ARCH INTERN MED, V135, P715, DOI 10.1001/archinte.135.5.715; SOCINSKI MA, 1988, LANCET, V1, P1194; TALCOTT JA, 1992, J CLIN ONCOL, V10, P316, DOI 10.1200/JCO.1992.10.2.316; THALER M, 1988, J INFECT DIS, V158, P80, DOI 10.1093/infdis/158.1.80; THALER M, 1988, ANN INTERN MED, V108, P88, DOI 10.7326/0003-4819-108-1-88; THALER M, 1986, AM J MED, V81, P596, DOI 10.1016/0002-9343(86)90543-7; TRUCKSIS M, 1991, ANN INTERN MED, V114, P424, DOI 10.7326/0003-4819-114-5-424; VADHANRAJ S, 1992, J CLIN ONCOL, V10, P1266, DOI 10.1200/JCO.1992.10.8.1266; Walsh T. J., 1989, Diagnosis and therapy of systemic fungal infections., P47; WALSH TJ, 1991, REV INFECT DIS, V13, P496; WALSH TJ, 1991, NEW ENGL J MED, V324, P1026, DOI 10.1056/NEJM199104113241504; WEEKS JC, 1991, NEW ENGL J MED, V325, P81, DOI 10.1056/NEJM199107113250202; WEINBERGER M, 1992, MEDICINE, V71, P24, DOI 10.1097/00005792-199201000-00003; WEINBERGER M, 1991, REV INFECT DIS, V13, P201; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; WINSTON DJ, 1991, ANN INTERN MED, V115, P849, DOI 10.7326/0003-4819-115-11-849; WINSTON DJ, 1980, ANN INTERN MED, V93, P671, DOI 10.7326/0003-4819-93-5-671; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; [No title captured]; 1990, J INFECT DIS, V61, P397	120	684	698	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1993	328	18					1323	1332						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ640	8469254				2022-12-28	WOS:A1993KZ64000008
J	RIMMER, JM; GENNARI, FJ				RIMMER, JM; GENNARI, FJ			ATHEROSCLEROTIC RENOVASCULAR DISEASE AND PROGRESSIVE RENAL-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Review						ATHEROSCLEROSIS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; KIDNEY FAILURE, CHRONIC; RENAL ARTERY OBSTRUCTION; ANGIOPLASTY	ANGIOTENSIN-CONVERTING-ENZYME; ARTERY STENOSIS; OPERATIVE MORBIDITY; NATURAL-HISTORY; 2 KIDNEY; ONE-CLIP; HYPERTENSION; REVASCULARIZATION; INSUFFICIENCY; ANGIOPLASTY	Purpose: To evaluate information on the prevalence and rate of progression of atherosclerotic renovascular disease and the effect of angiotensin-converting enzyme inhibition on this process, with the goal of developing a rational approach to the diagnosis and management of this disorder. Data Sources: Relevant articles were identified from the authors' files and from MEDLINE searches. Additional references were obtained from the bibliographies of identified articles. Study Selection: Virtually no controlled prospective studies have been reported. The articles presented are primarily retrospective analyses and include those that provide sufficient information about the incidence or progression of renovascular disease and about the outcome and mortality rate associated with various treatments, to allow evaluation. Data Extraction: For the outcomes of interest, data from individual reports are presented in tabular form, the results summed, and averages obtained. Results: Atherosclerotic renovascular disease, in many cases involving both renal arteries, is a common finding in patients older than 50 years, particularly those with diffuse atherosclerotic vascular disease. Hypertension is not a particularly sensitive indicator of this disease (almost one half are not hypertensive). The disease progresses and may account for 5% to 15% of all patients developing end-stage renal disease each year. Angiotensin-converting enzyme inhibition may damage ischemic renal tissue, but this is counterbalanced by beneficial effects of this therapy. Once endstage renal disease is present, mortality rates are high despite dialysis support (> 50% over 3 years). Both surgery and angioplasty can preserve or improve renal function and may delay or prevent the need for dialysis therapy. These invasive procedures may have lower rates of morbidity and mortality than the so-called ''conservative'' approach of dialysis therapy when renal failure develops. Conclusions: Given available information, diagnosis and intervention should be considered seriously in patients at high risk for renovascular disease who have clearly progressing renal insufficiency. Prospective trials are needed, however, to determine the costs and benefits of each approach to treatment in all patients with renovascular disease and renal insufficiency.			RIMMER, JM (corresponding author), UNIV VERMONT, COLL MED, D305 GIVEN BLDG, BURLINGTON, VT 05405 USA.							BELL GM, 1987, Q J MED, V63, P393; BERK BC, 1990, J BIOL CHEM, V265, P19632; BERNS JS, 1992, KIDNEY, V24, P1; BREDENBERG CE, 1992, J VASC SURG, V15, P1018, DOI 10.1016/0741-5214(92)90458-K; CANZANELLO VJ, 1989, HYPERTENSION, V13, P163, DOI 10.1161/01.HYP.13.2.163; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DAVIDSON RA, 1992, JAMA-J AM MED ASSOC, V268, P3353, DOI 10.1001/jama.268.23.3353; DEAN RH, 1981, ARCH SURG-CHICAGO, V116, P1408; DONDI M, 1991, J NUCL MED, V32, P424; DUSTAN HP, 1966, ANTIHYPERTENSIVE THE, P544; ERBSLOHMOLLER B, 1991, AM J MED, V90, P23, DOI 10.1016/0002-9343(91)90502-O; EYLER WR, 1962, RADIOLOGY, V78, P879, DOI 10.1148/78.6.879; FRANKLIN SS, 1975, JAMA-J AM MED ASSOC, V231, P1148, DOI 10.1001/jama.231.11.1148; GRONE HJ, 1986, LAB INVEST, V54, P645; GRUNTZIG A, 1978, LANCET, V1, P801; HALLETT JW, 1987, J VASC SURG, V5, P622, DOI 10.1067/mva.1987.avs0050622; HANSEN KJ, 1990, J VASC SURG, V12, P227, DOI 10.1067/mva.1990.22791; HANSEN KJ, 1989, J VASC SURG, V10, P266; HARDING MB, 1992, J AM SOC NEPHROL, V2, P1608; HOLLEY KE, 1964, AM J MED, V37, P14, DOI 10.1016/0002-9343(64)90208-6; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; HRICIK DE, 1990, J AM SOC NEPHROL, V1, P845; JACKSON B, 1990, J LAB CLIN MED, V115, P21; JACOBSON HR, 1988, KIDNEY INT, V34, P729, DOI 10.1038/ki.1988.240; JAMIESON GG, 1984, BRIT J SURG, V71, P338, DOI 10.1002/bjs.1800710506; KAKINUMA Y, 1991, Journal of the American Society of Nephrology, V2, P682; KAUFMAN SL, 1984, RADIOLOGY, V151, P323, DOI 10.1148/radiology.151.2.6369390; KENT KC, 1991, J VASC SURG, V13, P311, DOI 10.1016/0741-5214(91)90224-I; LIBERTINO JA, 1992, J UROLOGY, V147, P1485, DOI 10.1016/S0022-5347(17)37603-6; LIBERTINO JA, 1980, JAMA-J AM MED ASSOC, V244, P1340, DOI 10.1001/jama.244.12.1340; LUFT FC, 1983, J UROLOGY, V130, P654, DOI 10.1016/S0022-5347(17)51386-5; MAILLOUX LU, 1988, AM J MED, V84, P855, DOI 10.1016/0002-9343(88)90063-0; MANN SJ, 1992, ANN INTERN MED, V117, P845, DOI 10.7326/0003-4819-117-10-845; MANN SJ, 1991, AM J MED, V90, P30, DOI 10.1016/0002-9343(91)90503-P; MARTIN LG, 1988, AM J ROENTGENOL, V150, P839, DOI 10.2214/ajr.150.4.839; MEANEY TF, 1968, RADIOLOGY, V91, P881, DOI 10.1148/91.5.881; MESSINA LM, 1992, J VASC SURG, V15, P73, DOI 10.1016/0741-5214(92)70015-D; MICHEL JB, 1986, KIDNEY INT, V29, P1011, DOI 10.1038/ki.1986.101; MORRIS GC, 1962, JAMA-J AM MED ASSOC, V182, P609, DOI 10.1001/jama.1962.03050450009002; NOVICK AC, 1984, UROL CLIN N AM, V11, P477; NOVICK AC, 1981, JAMA-J AM MED ASSOC, V246, P749, DOI 10.1001/jama.246.7.749; NOVICK AC, 1987, JAMA-J AM MED ASSOC, V257, P498, DOI 10.1001/jama.257.4.498; ODONOVAN RM, 1992, NEPHRON, V60, P187, DOI 10.1159/000186737; Pickering T, 1990, HYPERTENSION PATHOPH, P1539; PICKERING TG, 1986, J HYPERTENS, V4, pS667; POHL M A, 1991, Journal of the American Society of Nephrology, V2, P242; RUDNICK M, 1991, Journal of the American Society of Nephrology, V2, P668; SCHREIBER MJ, 1984, UROL CLIN N AM, V11, P383; SCOBLE JE, 1989, CLIN NEPHROL, V31, P119; TOLLEFSON DFJ, 1991, J VASC SURG, V14, P327; WEAVER FA, 1991, J VASC SURG, V13, P266, DOI 10.1016/0741-5214(91)90219-K; WOLLENWEBER J, 1968, AM J CARDIOL, V21, P60, DOI 10.1016/0002-9149(68)90014-3; ZAMBETISBELLESIS M, 1991, CLIN EXP PHARMACOL P, V18, P337, DOI 10.1111/j.1440-1681.1991.tb01458.x; 1991, PREVALENCE COST ESRD, P10; 1991, INCIDENCE CAUSES TRE, P13; 1991, INCIDENCE REPORTED E, pA1; 1991, SURVIVAL PROBABILITI, P31	57	342	350	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					712	719		10.7326/0003-4819-118-9-199305010-00010	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460859				2022-12-28	WOS:A1993KY50200010
J	KING, MC; ROWELL, S; LOVE, SM				KING, MC; ROWELL, S; LOVE, SM			INHERITED BREAST AND OVARIAN-CANCER - WHAT ARE THE RISKS - WHAT ARE THE CHOICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROPHYLACTIC MASTECTOMY; P53 MUTATIONS; ONCOGENE; PREVENTION; LINKAGE		UNIV CALIF BERKELEY, SCH PUBL HLTH, BERKELEY, CA 94720 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT SURG, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, CTR BREAST, LOS ANGELES, CA USA	University of California System; University of California Berkeley; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	KING, MC (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 140 WARREN HALL, BERKELEY, CA 94720 USA.			King, Mary-Claire/0000-0001-9426-1743	NCI NIH HHS [R01 CA27632] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON LA, IN PRESS GENOMICS; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOICE JD, 1977, J NATL CANCER I, V59, P823, DOI 10.1093/jnci/59.3.823; BOWCOCK AM, IN PRESS AM J HUM GE; Broca P., 1866, TRAITE TUMERURS; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLAUS EB, IN PRESS AM J HUM GE; COLES C, 1992, CANCER RES, V52, P5291; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CRUICKSHANK DJ, 1992, BRIT J OBSTET GYNAEC, V99, P226, DOI 10.1111/j.1471-0528.1992.tb14504.x; EASTON DF, IN PRESS AM J HUM GE; GOODNIGHT JE, 1984, J SURG ONCOL, V26, P198, DOI 10.1002/jso.2930260313; HALL JM, 1992, AM J HUM GENET, V50, P1235; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IRWIN KL, 1988, AM J EPIDEMIOL, V127, P1192, DOI 10.1093/oxfordjournals.aje.a114912; KING MC, 1992, NAT GENET, V2, P89, DOI 10.1038/ng1092-89; KING MC, 1990, CANCER SURV, V9, P417; La Francis I E, 1992, Conn Med, V56, P411; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCGREGOR DH, 1977, J NATL CANCER I, V59, P799, DOI 10.1093/jnci/59.3.799; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NELSON H, 1989, PLAST RECONSTR SURG, V83, P662, DOI 10.1097/00006534-198904000-00011; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; RIES LA, 1990, CANCER STATISTICS RE; RUNOWICZ CD, 1992, CA-CANCER J CLIN, V42, P327, DOI 10.3322/canjclin.42.6.327; SCHILDKRAUT JM, 1988, AM J EPIDEMIOL, V128, P456, DOI 10.1093/oxfordjournals.aje.a114994; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; TEMPLE WJ, 1991, AM J SURG, V161, P413, DOI 10.1016/0002-9610(91)91100-W; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WEBER AM, 1992, OBSTET GYNECOL, V80, P558; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZIEGLER LD, 1991, AM J CLIN ONCOL-CANC, V14, P451, DOI 10.1097/00000421-199110000-00018; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	44	227	228	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1975	1980		10.1001/jama.269.15.1975	http://dx.doi.org/10.1001/jama.269.15.1975			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464130				2022-12-28	WOS:A1993KX21500029
J	SPARANO, JA; BRANDT, LJ; DUTCHER, JP; DUBOIS, JS; ATKINS, MB				SPARANO, JA; BRANDT, LJ; DUTCHER, JP; DUBOIS, JS; ATKINS, MB			SYMPTOMATIC EXACERBATION OF CROHN DISEASE AFTER TREATMENT WITH HIGH-DOSE INTERLEUKIN-2	ANNALS OF INTERNAL MEDICINE			English	Note						CROHN DISEASE; INTERLEUKIN-2; DOSE-RESPONSE RELATIONSHIP, DRUG; CARCINOMA, RENAL CELL; RECURRENCE	CELLS	Two patients treated with high-dose interleukin-2 (IL-2), who had a history of Crohn disease that was clinically quiescent for 4 and 9 years before therapy, developed symptomatic reactivation of Crohn disease requiring surgical intervention. At laparotomy, both patients had histologic evidence of active Crohn disease. One patient had previously received another cytokine, alpha-interferon-alpha, without disease reactivation, suggesting that this effect was specific for IL-2. The striking temporal relation between the administration of IL-2 and the symptomatic reactivation of previously quiescent Crohn disease suggests the need to carefully evaluate patients with a history of inflammatory bowel disease who are considered for IL-2 therapy and provides evidence supporting an important role for IL-2 in the pathogenesis of Crohn disease.	NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	Tufts Medical Center	SPARANO, JA (corresponding author), MONTEFIORE MED CTR, ALBERT EINSTEIN CANC CTR, 111 E 210TH ST, BRONX, NY 10467 USA.				NATIONAL CANCER INSTITUTE [K08CA001130] Funding Source: NIH RePORTER; NCI NIH HHS [CA P30CA1130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINS MB, 1991, P AN M AM SOC CLIN, V10, P166; BRYNSKOV J, 1990, GUT, V31, P795, DOI 10.1136/gut.31.7.795; FISHER RI, 1988, ANN INTERN MED, V108, P518, DOI 10.7326/0003-4819-108-4-518; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; JAMES SP, 1988, GASTROENTEROLOGY, V95, P1667, DOI 10.1016/S0016-5085(88)80094-5; KUSUGAMI K, 1989, GASTROENTEROLOGY, V97, P1; ROSENSTEIN M, 1986, J IMMUNOL, V137, P1735; SCHWARTZENTRUBER D, 1988, CANCER, V62, P2350, DOI 10.1002/1097-0142(19881201)62:11<2350::AID-CNCR2820621116>3.0.CO;2-S; SPARANO JA, 1991, CANCER, V68, P1538, DOI 10.1002/1097-0142(19911001)68:7<1538::AID-CNCR2820680714>3.0.CO;2-2	9	33	33	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					617	618		10.7326/0003-4819-118-8-199304150-00007	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8452327				2022-12-28	WOS:A1993KW47000007
J	DINARELLO, CA; GELFAND, JA; WOLFF, SM				DINARELLO, CA; GELFAND, JA; WOLFF, SM			ANTICYTOKINE STRATEGIES IN THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; SEPTIC SHOCK; ENDOGENOUS PYROGEN; FACTOR CACHECTIN; SOLUBLE FORM; HUMAN-URINE; CELLS; ENDOTOXIN; MICE	The systemic inflammatory response syndrome (SIRS) is an acute illness characterized by generalized activation of the endothelium. The most severe form of the syndrome is found in patients with shock due to gram-negative sepsis. We examined both animal and limited human data for the contribution of cytokines to this syndrome. Cytokines are endogenously produced proteins of small molecular weight and multiple biological effects. The cytokines interleukin 1 (IL-1) and tumor necrosis factor (TNF), as well as interferon-gamma and interleukin 8, are discussed. Laboratory investigations suggest that these cytokines play a critical role in SIRS by promoting the biochemical and clinical characteristics of SIRS. The biochemical changes induced by TNF and IL-1 include increased synthesis of nitric oxide, prostaglandins, platelet-activating factor, and endothelial cell adhesion molecules. Specific blockade of TNF using neutralizing antibodies or soluble receptors to TNF in animal models of SIRS reduces mortality and severity of disease. Similar results have been observed blocking IL-1 using soluble IL-1 receptors or IL-1 receptor antagonists. Preliminary clinical studies suggest that blockade may be useful in treating human SIRS. The various strategies for blocking IL-1 and TNF are presented; in addition, their mechanism(s) of action and safety in humans are discussed. We conclude that based on animal studies and preliminary clinical trials, strategies to block IL-1 or TNF may benefit patients with the syndrome, although thorough clinical trials have not been completed.	TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts University	DINARELLO, CA (corresponding author), NEW ENGLAND MED CTR, DEPT MED, BOSTON, MA 02111 USA.		Gelfand, Jeffrey A/G-1885-2018	Gelfand, Jeffrey A/0000-0002-4118-5676	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700, T32GM007035] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15614] Funding Source: Medline; NIGMS NIH HHS [GM 07035, GM 21700] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADERKA D, 1991, CANCER RES, V51, P5602; AIURA K, 1991, Cytokine, V3, P498; ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; BAGGIOLINI M, 1992, INFLAMMATION BASIC P, P247; BARAK V, 1991, LYMPHOKINE CYTOK RES, V10, P437; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BIANCONE L, 1992, J AM SOC NEPHROL, V2, P1251; BILLIAU A, 1991, EUR J CLIN INVEST, V21, P559, DOI 10.1111/j.1365-2362.1991.tb01410.x; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; BROMBERG JS, 1992, J IMMUNOL, V148, P3412; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; CANNON JG, 1992, CRIT CARE MED, V20, P1414, DOI 10.1097/00003246-199210000-00009; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHAPMAN PB, 1987, J CLIN ONCOL, V5, P1942, DOI 10.1200/JCO.1987.5.12.1942; CHRISTMAN JW, 1992, CHEST, V102, P613, DOI 10.1378/chest.102.2.613; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DEJANA E, 1987, BLOOD, V69, P695; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; DINARELLO CA, 1992, IMMUNOL REV, V127, P119, DOI 10.1111/j.1600-065X.1992.tb01411.x; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESKANDARI MK, 1992, J IMMUNOL, V148, P2724; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FISCHER E, 1992, BLOOD, V79, P2196; FISCHER E, 1991, AM J PHYSIOL, V261, pR442, DOI 10.1152/ajpregu.1991.261.2.R442; FISCHER E, 1992, J CLIN INVEST, V89, P1551, DOI 10.1172/JCI115748; FISHER CJ, 1993, 13TH INT S INT CAR E; FISHER CJJ, 1991, 4TH ANN M AM COLL CH; GERSHENWALD JE, 1990, P NATL ACAD SCI USA, V87, P4966, DOI 10.1073/pnas.87.13.4966; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GRANOWTIZ EV, 1992, CYTOKINE, V4, P353, DOI 10.1016/1043-4666(92)90078-6; HACK CE, 1989, BLOOD, V74, P1704; HACKETT SP, 1992, J INFECT DIS, V165, P879, DOI 10.1093/infdis/165.5.879; HAVELL EA, 1992, J IMMUNOL, V148, P1486; HENRICSON BE, 1991, INFECT IMMUN, V59, P1188, DOI 10.1128/IAI.59.3.1188-1191.1991; HERVE P, 1992, BLOOD, V79, P3362; HOWARD M, 1992, J CLIN IMMUNOL, V12, P239, DOI 10.1007/BF00918147; IKEJIMA T, 1988, J INFECT DIS, V158, P1017, DOI 10.1093/infdis/158.5.1017; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; LESSLAUER W, 1991, Cytokine, V3, P497; MANCILLA J, IN PRESS INFECT IMMU; MANDRUPPOULSEN T, 1987, J IMMUNOL, V139, P4077; MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540; MCCARTHY PL, 1991, BLOOD, V78, P1915; McCartney-Francis N, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011007; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MILLER LC, 1993, LANCET, V341, P146, DOI 10.1016/0140-6736(93)90006-3; MIZOGUCHI Y, 1991, J GASTROEN HEPATOL, V6, P283, DOI 10.1111/j.1440-1746.1991.tb01479.x; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; PERMUTTER DH, 1986, J CLIN INVEST, V78, P1349; PORAT R, 1992, FASEB J, V6, P2482, DOI 10.1096/fasebj.6.7.1532945; RAMBALDI A, 1991, BLOOD, V78, P3248; RAZ A, 1988, J BIOL CHEM, V263, P3022; SECKINGER P, 1987, J IMMUNOL, V139, P1546; SHAPIRO L, IN PRESS J INFECT DI; SMITH JW, 1992, J CLIN ONCOL, V10, P1141, DOI 10.1200/JCO.1992.10.7.1141; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; STRIETER RM, 1988, BIOCHEM BIOPH RES CO, V155, P1230, DOI 10.1016/S0006-291X(88)81271-3; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; TEWARI A, 1990, LANCET, V336, P712, DOI 10.1016/0140-6736(90)92206-W; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; ULICH TR, 1991, AM J PATHOL, V138, P521; VANDAMME J, 1985, NATURE, V314, P266, DOI 10.1038/314266a0; VANDERMEER JWM, 1988, P NATL ACAD SCI USA, V85, P1620; VANDERPOLL T, 1992, BLOOD, V79, P693; VANDERPOLL T, 1990, J CLIN ENDOCR METAB, V71, P1567; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; VANNIER E, 1992, P NATL ACAD SCI USA, V89, P4076, DOI 10.1073/pnas.89.9.4076; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WALLACH D, 1988, J IMMUNOL, V140, P2994; WALSH CE, 1992, BRIT J HAEMATOL, V80, P106, DOI 10.1111/j.1365-2141.1992.tb06408.x	84	364	396	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1829	1835		10.1001/jama.269.14.1829	http://dx.doi.org/10.1001/jama.269.14.1829			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459516				2022-12-28	WOS:A1993KW25000039
J	COTE, F; COLLARD, JF; JULIEN, JP				COTE, F; COLLARD, JF; JULIEN, JP			PROGRESSIVE NEURONOPATHY IN TRANSGENIC MICE EXPRESSING THE HUMAN NEUROFILAMENT HEAVY GENE - A MOUSE MODEL OF AMYOTROPHIC-LATERAL-SCLEROSIS	CELL			English	Article							SLOW AXONAL-TRANSPORT; MOTOR-NEURON; MAMMALIAN NEUROFILAMENTS; INTERMEDIATE FILAMENTS; PHOSPHORYLATION SITES; NEUROLOGICAL DISEASE; TRIPLET PROTEINS; NF-H; INVITRO; POLYPEPTIDES	We generated four transgenic mice with a 34 kb genomic fragment including the complete human neurofilament heavy (NF-H) gene. This human NF-H fragment contained all regulatory elements for tissue-specific expression, and in two transgenic lines, human NF-H proteins were produced at levels up to 2-fold the levels of endogenous mouse NF-H protein. By 3-4 months of age, these NF-H transgenics progressively develop neurological defects and abnormal neurofilamentous swellings that are highly reminiscent of those found in amyotrophic lateral sclerosis (ALS). We propose that a modest up-regulation of NF-H cross-linkers can result in an impairment of neurofilament transport, causing neuronal swellings with ensuing axonopathy and muscle atrophy, a mechanism of pathogenesis pertinent to the possible etiology of ALS.			COTE, F (corresponding author), MCGILL UNIV,MONTREAL GEN HOSP,RES INST,CTR RES NEUROSCI,MONTREAL H3G 1A4,QUEBEC,CANADA.							ANDREWS JM, 1975, J NEUROPATH EXP NEUR, V34, P12, DOI 10.1097/00005072-197501000-00002; ARMON C, 1992, HDB AMYOTROPHIC LATE, P93; ASBURY AK, 1978, PATHOLOGY PERIPHERAL, V9; AUBRY M, 1992, GENOMICS, V13, P641, DOI 10.1016/0888-7543(92)90135-F; AVERBACK P, 1982, ARCH NEUROL-CHICAGO, V39, P155, DOI 10.1001/archneur.1982.00510150025006; BIZZI A, 1984, J NEUROSCI, V4, P722; BREUER AC, 1992, HDB AMYOTROPHIC LATE, P503; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; CALLAHAN LM, 1991, J NEUROPATH EXP NEUR, V50, P491, DOI 10.1097/00005072-199107000-00009; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CARPENTE.S, 1974, ARCH NEUROL-CHICAGO, V31, P312, DOI 10.1001/archneur.1974.00490410060005; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chou SM., 1992, HDB AMYOTROPHIC LATE, P133; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; FIGLEWICZ DA, 1992, HDB AMYOTROPHIC LATE, P687; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GAJDUSEK DC, 1985, NEW ENGL J MED, V312, P714, DOI 10.1056/NEJM198503143121110; GARDNER EE, 1984, J NEUROSCI RES, V11, P145, DOI 10.1002/jnr.490110204; GEISLER N, 1984, EMBO J, V3, P2701, DOI 10.1002/j.1460-2075.1984.tb02196.x; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; GOLDMAN JE, 1986, ANN NEUROL, V19, P209, DOI 10.1002/ana.410190302; GRAHAM DG, 1984, P NATL ACAD SCI-BIOL, V81, P4979, DOI 10.1073/pnas.81.15.4979; GRIFFIN JW, 1978, SCIENCE, V202, P633, DOI 10.1126/science.81524; GRIFFIN JW, 1988, ANN NEUROL, V23, P3, DOI 10.1002/ana.410230103; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; HIRANO A, 1992, HDB AMYOTROPHIC LATE, P183; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J CELL BIOL, V101, P1332, DOI 10.1083/jcb.101.4.1332; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; Julien JP, 1991, NEURONAL CYTOSKELETO, P215; KAUPMANN K, 1992, GENOMICS, V13, P39, DOI 10.1016/0888-7543(92)90199-3; KAWAMURA Y, 1981, J NEUROPATH EXP NEUR, V40, P667, DOI 10.1097/00005072-198111000-00008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LIEM RKH, 1978, J CELL BIOL, V79, P637, DOI 10.1083/jcb.79.3.637; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; LUTSEP HL, 1989, J NEUROPATH EXP NEUR, V48, P519, DOI 10.1097/00005072-198909000-00003; MACK K, 1988, J NEUROSCI RES, V20, P129, DOI 10.1002/jnr.490200118; MESSER A, 1992, HDB AMYOTROPHIC LATE, P433; MITSUMOTO H, 1982, BRAIN, V105, P811, DOI 10.1093/brain/105.4.811; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; NORRIS FH, 1992, HDB AMYOTROPHIC LATE, P3; RADTKE RA, 1986, NEUROLOGY, V36, P796, DOI 10.1212/WNL.36.6.796; SACHER MG, 1992, BIOCHEM BIOPH RES CO, V186, P524, DOI 10.1016/S0006-291X(05)80839-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASAKI S, 1989, ANN NEUROL, V25, P520, DOI 10.1002/ana.410250520; SCHMIDT ML, 1987, LAB INVEST, V56, P282; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SHAW G, 1982, NATURE, V298, P277, DOI 10.1038/298277a0; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TRONCOSO JC, 1990, J STRUCT BIOL, V103, P2, DOI 10.1016/1047-8477(90)90080-V; TRONCOSO JC, 1985, BRAIN RES, V342, P172, DOI 10.1016/0006-8993(85)91369-1; TRONCOSO JC, 1992, HDB AMYOTROPHIC LATE, P543; WILLARD M, 1983, CELL, V35, P551, DOI 10.1016/0092-8674(83)90189-7; ZIMMERMAN UJP, 1986, BIOCHEMISTRY-US, V25, P3533, DOI 10.1021/bi00360a009	69	496	509	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					35	46		10.1016/0092-8674(93)90158-M	http://dx.doi.org/10.1016/0092-8674(93)90158-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462101				2022-12-28	WOS:A1993KW75300006
J	RUFF, HA; BIJUR, PE; MARKOWITZ, M; MA, YC; ROSEN, JF				RUFF, HA; BIJUR, PE; MARKOWITZ, M; MA, YC; ROSEN, JF			DECLINING BLOOD LEAD LEVELS AND COGNITIVE CHANGES IN MODERATELY LEAD-POISONED CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PORT-PIRIE COHORT; EXPOSURE; MONKEYS; DEFICITS; REVERSAL; CHILDHOOD; INFANCY; BIRTH; IRON	Objective.-To determine whether chelation therapy or biochemical changes during a lead-lowering intervention was associated with changes in cognitive functioning of moderately lead-poisoned children. It was hypothesized that cognitive performance would improve as blood lead level declined over time. Design.-Short-term intervention study with measures obtained before and after intervention. Setting.-Hospital specialty clinic and university research center. Patients.-A total of 154 previously untreated children referred to clinic with blood lead levels between 1.21 and 2.66 mumol/L (25 and 55 mug/dL) at time of enrollment. Ages ranged from 13 to 87 months. Intervention.-Enrolled children were treated with edetate calcium disodium (EDTA) if eligible and/or with orally administered iron supplement if iron deficient. For all children, housing inspections and abatement procedures were performed as necessary. Main Outcome Measures.-Score on Bayley Mental Development Scale or Stanford-Binet Intelligence Scale (4th edition). Results.-There was no effect of edetate calcium disodium treatment per se. In the short term (7 weeks), changes in blood lead levels were not related to changes in cognitive scores. In the long term (6 months), however, changes in performance were significantly related to changes in blood lead level, even after controlling for confounding variables. The standardized score increased 1 point for every decrease of 0.14 mumol/L (3 mug/dL) in blood lead level. Conclusion.-The results suggest an association between decreases in blood lead level and cognitive improvements in moderately lead-poisoned children.			RUFF, HA (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT PEDIAT, ROOM 222, KENNEDY CTR, BRONX, NY 10461 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000652] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07199] Funding Source: Medline; NIEHS NIH HHS [ES04039] Funding Source: Medline; NIMH NIH HHS [MH00652] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAGHURST PA, 1987, NEUROTOXICOLOGY, V8, P395; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BUSHNELL PJ, 1979, PHARMACOL BIOCHEM BE, V10, P733, DOI 10.1016/0091-3057(79)90326-5; BUSHNELL PJ, 1979, J TOXICOL ENV HEALTH, V5, P1015, DOI 10.1080/15287397909529810; COHEN J, 1983, APPLIED MULTIPLE REG, P145; DAVID OJ, 1985, ARCH ENVIRON HEALTH, V40, P109, DOI 10.1080/00039896.1985.10545899; DAVID OJ, 1976, AM J PSYCHIAT, V133, P1155; DIETRICH KN, 1990, ENVIRON HEALTH PERSP, V89, P13, DOI 10.2307/3430891; DIETRICH KN, 1987, PEDIATRICS, V80, P721; ERNHART CB, 1987, NEUROTOXICOL TERATOL, V9, P259, DOI 10.1016/0892-0362(87)90011-0; ESCALONA SK, 1982, PEDIATRICS, V70, P670; FULTON M, 1987, LANCET, V1, P1221; LEVIN ED, 1983, NEUROBEH TOXICOL TER, V5, P391; LOZOFF B, 1989, B NEW YORK ACAD MED, V65, P1050; MARKOWITZ ME, 1984, J PEDIATR-US, V104, P337, DOI 10.1016/S0022-3476(84)81091-4; MARKOWITZ ME, 1990, J PEDIATR-US, V116, P360, DOI 10.1016/S0022-3476(05)82821-5; MARKOWITZ ME, 1991, J PEDIATR-US, V119, P305, DOI 10.1016/S0022-3476(05)80750-4; MARKOWITZ ME, IN PRESS PEDIATRICS; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; PIOMELLI S, 1977, CLIN CHEM, V23, P264; RICE DC, 1985, TOXICOL APPL PHARM, V77, P201, DOI 10.1016/0041-008X(85)90319-9; RICE DC, 1984, TOXICOL APPL PHARM, V75, P337, DOI 10.1016/0041-008X(84)90216-3; RUFF HA, 1989, J DEV BEHAV PEDIATR, V10, P103; SCHWARTZ J, IN PRESS NEUROTOXICO; SILVERSTEIN AB, 1982, J CONSULT CLIN PSYCH, V50, P415, DOI 10.1037/0022-006X.50.3.415; THORNDIKE RL, 1986, STANFORDBINET INTELL	30	90	91	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1641	1646		10.1001/jama.269.13.1641	http://dx.doi.org/10.1001/jama.269.13.1641			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV349	8455297				2022-12-28	WOS:A1993KV34900027
J	SPRADLING, AC				SPRADLING, AC			GERMLINE CYSTS - COMMUNES THAT WORK	CELL			English	Review							DROSOPHILA-MELANOGASTER; OOGENESIS				SPRADLING, AC (corresponding author), CARNEGIE INST WASHINGTON,HOWARD HUGHES MED INST,BALTIMORE,MD 21210, USA.				Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		AMBROSIO L, 1985, DEV BIOL, V111, P220, DOI 10.1016/0012-1606(85)90447-6; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; FAWCETT DW, 1959, J BIOPHYS BIOCH CYTO, V5, P543; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; LANTZ V, 1992, DEVELOPMENT, V115, P75; MAHOWALD AP, 1970, J CELL BIOL, V45, P306, DOI 10.1083/jcb.45.2.306; MCKEARIN DM, 1990, GENE DEV, V4, P2242, DOI 10.1101/gad.4.12b.2242; PATTERSON J, 1991, GENETICS, V129, P1073; SCHUPBACH T, 1991, GENETICS, V129, P1119; STEINHAUER WR, 1992, GENE DEV, V6, P233, DOI 10.1101/gad.6.2.233; STORTO PD, 1989, DEV GENET, V10, P70, DOI 10.1002/dvg.1020100203; STORTO PD, 1988, DEV GENET, V9, P91, DOI 10.1002/dvg.1020090203; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; XUE F, 1993, CELL, V72; YUE L, 1992, GENE DEV, V6, P2443, DOI 10.1101/gad.6.12b.2443; ZAMBONI L, 1968, J CELL BIOL, V36, P276, DOI 10.1083/jcb.36.1.276	17	81	82	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					649	651		10.1016/0092-8674(93)90393-5	http://dx.doi.org/10.1016/0092-8674(93)90393-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453660	Bronze			2022-12-28	WOS:A1993KR43600001
J	ROMAN, E; WATSON, A; BERAL, V; BUCKLE, S; BULL, D; BAKER, K; RYDER, H; BARTON, C				ROMAN, E; WATSON, A; BERAL, V; BUCKLE, S; BULL, D; BAKER, K; RYDER, H; BARTON, C			CASE-CONTROL STUDY OF LEUKEMIA AND NON-HODGKINS-LYMPHOMA AMONG CHILDREN AGED 0-4 YEARS LIVING IN WEST-BERKSHIRE AND NORTH-HAMPSHIRE HEALTH DISTRICTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD LEUKEMIA; OCCUPATIONS; AUTHORITY; MORTALITY; CUMBRIA; CANCER	Objective-To investigate the relation between parental employment in the nuclear industry and childhood leukaemia and non-Hodgkin's lymphoma. Design-Case-control study. Setting-West Berkshire and Basingstoke and North Hampshire District Health Authorities. Subjects-54 children aged 0-4 years who had leukaemia or non-Hodgkin's lymphoma diagnosed during 1972-89, who were born in the study area and were resident there when cancer was diagnosed. Six controls were selected for each case: four from hospital delivery registers and two from livebirth registers maintained by the NHS central register. Controls were matched for sex, date of birth (within six months), and area of residence at birth and time of diagnosis. Main outcome measures-Parents' employment by the nuclear industry and exposure to ionising radiation at work. Results-Five (9%) of the 54 cases and 14 (4%) of the 324 controls had fathers or mothers, or both, who had been employed by the nuclear industry (relative risk 2.2, 95% confidence interval 0.6 to 6.9). Nuclear industry employees who work in areas where exposure to radiation is possible are given film badges to monitor their exposure to external penetrating ionising radiation. Three fathers of cases and two fathers of controls (and no mothers of either) had been monitored in this way before their child was conceived (relative risk 9.0, 95% confidence interval 1.0 to 107.8). No father (of a case or control) had accumulated a recorded dose of more than 5 mSv before his child was conceived, and no father had been monitored at any time in the four years before his child was conceived. A dose-response relation was not evident among fathers who had been monitored. Conclusions-These results suggest that the children of fathers who had been monitored for exposure to external penetrating ionising radiation in the nuclear industry may be at increased risk of developing leukaemia before their fifth birthday. The finding is based on small numbers and could be due to chance. If the relationship is real the mechanisms are far from clear, except that the effect is unlikely to be due to external radiation; the possibility that it could be due to internal contamination by radioactive substances or some other exposure at work should be pursued. The above average rates of leukaemia in the study area cannot be accounted for by these findings.	STOKE MANDEVILLE HOSP, AYLESBURY HP21 8AL, BUCKS, ENGLAND; ROYAL BERKSHIRE HOSP, READING RG1 5AN, BERKS, ENGLAND	Royal Berkshire Hospital	ROMAN, E (corresponding author), RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT, GIBSON UNIT, OXFORD OX2 6HE, ENGLAND.			Roman, Eve/0000-0001-7603-3704				[Anonymous], 1980, CLASSIFICATION OCCUP; BERAL V, 1990, BRIT MED J, V300, P411, DOI 10.1136/bmj.300.6722.411; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; Breslow N, 1980, STATISTICAL METHODS, V32; DOLL R, 1989, J R STAT SOC A STAT, V152, P1; FRASER P, 1985, BRIT MED J, V291, P435, DOI 10.1136/bmj.291.6493.435; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GREAVES MF, 1988, LEUKEMIA, V2, P120; KAYE SA, 1991, CANCER-AM CANCER SOC, V68, P1351, DOI 10.1002/1097-0142(19910915)68:6<1351::AID-CNCR2820680627>3.0.CO;2-J; KENDALL GM, 1992, BRIT MED J, V304, P220, DOI 10.1136/bmj.304.6821.220; MCKINNEY PA, 1991, BRIT MED J, V302, P681, DOI 10.1136/bmj.302.6778.681; MCLAUGHLIN JR, 1992, OCCUPATIONAL EXPOSUR; NAROD SA, 1991, BRIT J CANCER, V63, P993, DOI 10.1038/bjc.1991.216; OLEARY LM, 1991, AM J IND MED, V20, P17, DOI 10.1002/ajim.4700200103; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; SANDERS BM, 1981, J EPIDEMIOL COMMUN H, V35, P245, DOI 10.1136/jech.35.4.245; STILLER CA, 1991, STUDIES MED POPULATI, V53, P7; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; VANSTEENSELMOLL HA, 1985, INT J EPIDEMIOL, V14, P555, DOI 10.1093/ije/14.4.555; YOSHIMOTO Y, 1991, J RADIAT RES, P294; 1989, EGRET USERS GUIDE; 1989, STATISTICAL PACKAGE; 1988, 2ND COMM MED ASP RAD; 1989, 3RD COMM MED ASP RAD; 1991, FOXPRO USERS GUIDE	26	86	86	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	1993	306	6878					615	621		10.1136/bmj.306.6878.615	http://dx.doi.org/10.1136/bmj.306.6878.615			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461811	Bronze, Green Published			2022-12-28	WOS:A1993KQ85900019
J	YOSHIHISA, T; BARLOWE, C; SCHEKMAN, R				YOSHIHISA, T; BARLOWE, C; SCHEKMAN, R			REQUIREMENT FOR A GTPASE-ACTIVATING PROTEIN IN VESICLE BUDDING FROM THE ENDOPLASMIC-RETICULUM	SCIENCE			English	Article							ADP-RIBOSYLATION FACTOR; TRANSPORT VESICLES; BINDING PROTEIN; RAS PROTEINS; FUSION; YEAST; ER; CYTOPLASM; MECHANISM; CLONING	The binding and hydrolysis of guanosine triphosphate (GTP) by the small GTP-binding protein Sar1p is required to form transport vesicles from the endoplasmic reticulum (ER) in Saccharomyces cerevisiae. Experiments revealed that an interaction between Sar1p and the Sec23p subunit of an oligomeric protein is also required for vesicle budding. The isolated Sec23p subunit and the oligomeric complex stimulated guanosine triphosphatase (GTPase) activity of Sar1p 10- to 15-fold but did not activate two other small GTP-binding proteins involved in vesicle traffic (Ypt1p and ARF). Activation of GTPase was inhibited by an antibody to Sec23p but not by an antibody that inhibits the budding activity of the other subunit of the Sec23p complex. Also, activation was thermolabile in pure samples of Sec23p that were isolated from two independent sec23 mutant strains. It appears that Sec23p represents a new class of GTPase-activating protein because its sequence shows no similarity to any known member of this family.			YOSHIHISA, T (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BARKER HALL,BERKELEY,CA 94720, USA.							BARLOWE C, 1993, J BIOL CHEM, V268, P873; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WEISS O, 1989, J BIOL CHEM, V264, P21066; YOSHIHISA T, UNPUB; YU G, 1990, CELL, V62, P599	27	285	289	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1466	1468		10.1126/science.8451644	http://dx.doi.org/10.1126/science.8451644			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451644				2022-12-28	WOS:A1993KP97800040
J	TAFT, KL; PAPAEFTHYMIOU, GC; LIPPARD, SJ				TAFT, KL; PAPAEFTHYMIOU, GC; LIPPARD, SJ			A MIXED-VALENT POLYIRON OXO COMPLEX THAT MODELS THE BIOMINERALIZATION OF THE FERRITIN CORE	SCIENCE			English	Article							HORSE SPLEEN APOFERRITIN; MAMMALIAN FERRITIN; IRON-OXO; CHEMISTRY; BIOLOGY	A novel polyiron oxo complex, [FeIII4FeII8(O)2(OCH3)18(O2CCH3)6(CH3OH)4.67] (1), has been prepared from ferrous acetate and lithium methoxide in methanol by slow addition of dioxygen. The three-dimensional close-packed layered structure found in 1 closely mimics that proposed for the inorganic core in the iron storage protein ferritin. The Mossbauer spectra of 1 reveal superparamagnetic relaxation at temperatures below 15 K, a property characteristic of the ferritin core. The small size and mixed-valent nature of 1 suggest that it is a reasonable model for intermediates formed in the biomineralization of iron during ferritin core formation. A related compound, with the same iron-oxygen framework found in 1 but containing only two ferric ions, has also been structurally characterized. Because the clusters exhibit properties of both discrete molecules and extended solids, they are representative of a new class of nanometer-sized compounds that bridge the molecular solid-state boundary.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; MIT, FRANCIS BITTER NATL MAGNET LAB, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)								ARTYMIUK PJ, 1991, IRON BIOMINERALS, P269; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; BURNS RG, 1991, NATO ADV SCI I C-MAT, V343, P175; Crichton R. R., 1991, INORGANIC BIOCH IRON; DAY VW, 1985, SCIENCE, V228, P533, DOI 10.1126/science.228.4699.533; FISCHER RX, 1985, J APPL CRYSTALLOGR, V18, P258, DOI 10.1107/S002188988501024X; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; GORUN SM, 1987, J AM CHEM SOC, V109, P3337, DOI 10.1021/ja00245a025; HAGEN SL, 1992, ANGEW CHEM INT ED EN, V31; HANNA PM, 1991, J BIOL CHEM, V266, P886; HARRISON PM, 1991, ADV INORG CHEM, V36, P449; HEATH SL, 1992, ANGEW CHEM INT EDIT, V31, P191, DOI 10.1002/anie.199201911; HEGETSCHWEILER K, 1992, INORG CHEM, V31, P1299, DOI 10.1021/ic00033a032; HEGETSCHWEILER K, 1990, INORG CHEM, V29, P3625, DOI 10.1021/ic00343a066; JACOBS D, 1989, BIOCHEMISTRY-US, V28, P9216, DOI 10.1021/bi00449a038; KURTZ DM, 1990, CHEM REV, V90, P585, DOI 10.1021/cr00102a002; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LIPPARD SJ, 1988, ANGEW CHEM INT EDIT, V27, P344, DOI 10.1002/anie.198803441; Mann S., 1989, BIOMINERALIZATION CH; MELDRUM FC, 1992, SCIENCE, V257, P522, DOI 10.1126/science.1636086; MICKLITZ W, 1989, J AM CHEM SOC, V111, P6856, DOI 10.1021/ja00199a064; MICKLITZ W, UNPUB; Murad E., 1987, MOSSBAUER SPECTROSCO, V2, P507; PAPAEFTHYMIOU GC, 1992, PHYS REV B, V46, P10366, DOI 10.1103/PhysRevB.46.10366; Pope M. T., 1983, HETEROPOLY ISOPOLY O; QUE L, 1990, PROG INORG CHEM, V38, P97; Robinson M.B., 1967, ADV INORG CHEM, V10, P247, DOI [10.1016/S0065-2792(08)60179-X, DOI 10.1016/S0065-2792(08)60179-X]; STPIERRE TG, 1986, BIOCHIM BIOPHYS ACTA, V870, P127, DOI 10.1016/0167-4838(86)90015-4; TAFT KL, UNPUB; TOWE KM, 1967, J COLLOID INTERF SCI, V24, P384, DOI 10.1016/0021-9797(67)90266-4; TREFFRY A, 1992, FEBS LETT, V302, P108, DOI 10.1016/0014-5793(92)80417-F; WADE VJ, 1991, J MOL BIOL, V221, P1443, DOI 10.1016/0022-2836(91)80137-J; WATT GD, 1985, P NATL ACAD SCI USA, V82, P3640, DOI 10.1073/pnas.82.11.3640; YANG CY, 1987, BIOCHEMISTRY-US, V26, P497, DOI 10.1021/bi00376a023; YOU JF, 1992, J AM CHEM SOC, V114, P2697, DOI 10.1021/ja00033a050; ZIOLO RF, 1992, SCIENCE, V257, P219, DOI 10.1126/science.257.5067.219; [No title captured]	37	173	174	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1993	259	5099					1302	1305		10.1126/science.8446898	http://dx.doi.org/10.1126/science.8446898			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446898				2022-12-28	WOS:A1993KN88300024
J	HAINES, A				HAINES, A			HEALTH-CARE IN BRAZIL	BRITISH MEDICAL JOURNAL			English	Article							BRASILIA	Brazil has great geopolitical importance because of its size, environmental resources, and potential economic power. The organisation of its health care system reflects the schisms within Brazilian society. High technology private care is available to the rich and inadequate public care to the poor. Limited financial resources have been overconcentrated on health care in the hospital sector and health professionals are generally inappropriately trained to meet the needs of the community. However, recent changes in the organisation of health care are taking power away from federal government to state and local authorities. This should help the process of reform, but many vested interests remain to be overcome. A link programme between Britain and Brazil focusing on primary care has resulted in exchange of ideas and staff between the two countries. If primary care in Brazil can be improved it could help to narrow the health divide between rich and poor.			HAINES, A (corresponding author), UCL, WHITTINGTON HOSP, SCH MED, LONDON N19 5NF, ENGLAND.			Haines, Andy/0000-0002-8053-4605				CORTES E, 1989, NEW ENGL J MED, V320, P953, DOI 10.1056/NEJM198904133201501; DEOLIVEIRA M, 1992, 9 C NAC SAUD CAD NON, V2; LOGIE D, 1992, BRIT MED J, V304, P1423, DOI 10.1136/bmj.304.6839.1423; MARSDEN PD, 1990, BRIT MED J, V300, P666, DOI 10.1136/bmj.300.6725.666; MARSDEN PD, 1990, BRIT MED J, V300, P311, DOI 10.1136/bmj.300.6720.311; MARSDEN PD, 1989, BRIT MED J, V299, P1328, DOI 10.1136/bmj.299.6711.1328; MENDES C, 1989, FIGHT FOREST; ROCHA J, 1991, GUARDIAN        0914, P7; RUSETTI MC, 1987, MOMENTO PERPSECTIVA, V1, P65; STEIN A, 1987, MOMENTO PERSPECTIVA, V1, P60; VIANNA SM, 1992, 9 C NAC SAUD CAD NON, V1; 1992, BMJ, V305, P909; 1989, 7807BR WORLD BANK RE; 1992, 1992 UN DEV PROGR HU; 1992, STATE WORLDS POPULAT	15	15	16	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					503	506		10.1136/bmj.306.6876.503	http://dx.doi.org/10.1136/bmj.306.6876.503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448465	Bronze, Green Published			2022-12-28	WOS:A1993KN78600024
J	JOHNSTON, J; PATERSON, KR; OREILLY, DS				JOHNSTON, J; PATERSON, KR; OREILLY, DS			ESTIMATING URINARY ALBUMIN EXCRETION RATE OF DIABETIC-PATIENTS IN CLINICAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							SLIGHT ALBUMINURIA		GLASGOW ROYAL INFIRM,CTR DIABET,GLASGOW G4 0SF,SCOTLAND	University of Glasgow	JOHNSTON, J (corresponding author), GLASGOW ROYAL INFIRM,DEPT PATHOL BIOCHEM,GLASGOW G4 0SF,SCOTLAND.							COHEN DL, 1987, DIABETIC MED, V4, P437, DOI 10.1111/j.1464-5491.1987.tb00905.x; HOWEY JEA, 1987, CLIN CHEM, V33, P2034; HUTCHISON AS, 1988, CLIN CHEM, V34, P2019; WINOCOUR PH, 1992, BRIT MED J, V304, P1196, DOI 10.1136/bmj.304.6836.1196; WOOD P, 1985, ANN CLIN BIOCHEM, V22, P1	5	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					493	494		10.1136/bmj.306.6876.493-a	http://dx.doi.org/10.1136/bmj.306.6876.493-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448461	Green Published, Bronze			2022-12-28	WOS:A1993KN78600020
J	CAGLIOTI, A; ESPOSITO, C; FUIANO, G; BUZIO, C; POSTORINO, M; RAMPINO, T; CONTE, G; DALCANTON, A				CAGLIOTI, A; ESPOSITO, C; FUIANO, G; BUZIO, C; POSTORINO, M; RAMPINO, T; CONTE, G; DALCANTON, A			PREVALENCE OF SYMPTOMS IN PATIENTS WITH SIMPLE RENAL CYSTS	BRITISH MEDICAL JOURNAL			English	Article							KIDNEYS		UNIV CATANZARO, CATTEDRA NEFROL, CATANZARO, ITALY; UNIV PARMA, IST MED INTERNA & NEFROL, I-43100 PARMA, ITALY; CNR, CTR FISIOL CLIN, REGGIO DI CALALBRIA, ITALY; UNITA DIALISI, SANT ANGELO LOMBARDI, ITALY; UNIV NAPLES, PRIMA FAC, CATTEDRA NEFROL, I-80138 NAPLES, ITALY; UNIV PAVIA, CATTEDRA NEFROL, I-27100 PAVIA, ITALY	Magna Graecia University of Catanzaro; University of Parma; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Pavia			dal canton, antonio/G-4388-2013; esposito, ciro/AAC-8023-2020; Rampino, Teresa/AAF-3988-2022; Rampino, Teresa/AFI-8315-2022	esposito, ciro/0000-0002-7906-1097; Rampino, Teresa/0000-0002-5311-9174; Rampino, Teresa/0000-0002-5311-9174; DAL CANTON, ANTONIO/0000-0002-2189-6315				DALTON D, 1986, J UROLOGY, V135, P905, DOI 10.1016/S0022-5347(17)45919-2; GARDNER KD, 1984, AM J KIDNEY DIS, V3, P403, DOI 10.1016/S0272-6386(84)80002-5; GARDNER KD, 1988, KIDNEY INT, V33, P610, DOI 10.1038/ki.1988.41; LUSCHER TF, 1986, CLIN NEPHROL, V26, P91; NORUSIS MJ, 1986, STATISTICAL PACKAGE	5	30	31	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					430	431		10.1136/bmj.306.6875.430	http://dx.doi.org/10.1136/bmj.306.6875.430			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461726	Bronze, Green Published			2022-12-28	WOS:A1993KM70000023
J	WRIGHT, CDP; MANSELL, RE; GAZET, JC; COMPSTON, JE				WRIGHT, CDP; MANSELL, RE; GAZET, JC; COMPSTON, JE			EFFECT OF LONG-TERM TAMOXIFEN TREATMENT ON BONE TURNOVER IN WOMEN WITH BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV WALES COLL MED,DEPT SURG,CARDIFF CF4 4XN,S GLAM,WALES; ST GEORGE HOSP,DEPT SURG,LONDON SW17,ENGLAND	Addenbrooke's Hospital; University of Cambridge; Cardiff University; St Georges University London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		FORNANDER T, 1989, LANCET, V1, P117; GOTFREDSEN A, 1984, CANCER, V53, P853, DOI 10.1002/1097-0142(19840215)53:4<853::AID-CNCR2820530406>3.0.CO;2-M; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; RECKER RR, 1988, J BONE MINER RES, V3, P133	5	31	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					429	430		10.1136/bmj.306.6875.429-a	http://dx.doi.org/10.1136/bmj.306.6875.429-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461725	Green Published, Bronze			2022-12-28	WOS:A1993KM70000022
J	KERRIGAN, DD; THEVASAGAYAM, RS; WOODS, TO; MCWELCH, I; THOMAS, WEG; SHORTHOUSE, AJ; DENNISON, AR				KERRIGAN, DD; THEVASAGAYAM, RS; WOODS, TO; MCWELCH, I; THOMAS, WEG; SHORTHOUSE, AJ; DENNISON, AR			WHOS AFRAID OF INFORMED CONSENT	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; LITIGATION; QUALITY	Objective-To test the assumption that patients will become unduly anxious if they are given detailed information about the risks of surgery in an attempt to obtain fully informed consent. Design-Preoperative anxiety assessed before and after patients were randomly allocated an information sheet containing either simple or detailed descriptions of possible postoperative complications. Setting-Four surgical wards at two Sheffield hospitals. Subjects-96 men undergoing elective inguinal hernia repair under general anaesthesia. Main outcome measure-Change in anxiety level observed after receiving information about potential complications. Results-Detailed information did not increase patient anxiety (mean Spielberger score at baseline 33.7 (95% confidence interval 31.3 to 36.2), after information 34.8 (32.1 to 37.5); p=0.20, paired t test). A simple explanation of the facts provided a statistically significant degree of reassurance (mean score at baseline 34.6 (31.5 to 37.6), after information 32.3 (29.8 to 34.9); p=0.012), although this small effect is likely to be clinically important only in those whose baseline anxiety was high (r=0.27, p=0.05). Conclusions-In men undergoing elective inguinal hernia repair a very detailed account of what might go wrong does not increase patient anxiety significantly and has the advantage of allowing patients a fully informed choice before they consent to surgery, thus reducing the potential for subsequent litigation.	BOOTH HALL CHILDRENS HOSP,DEPT CHILD & ADOLESCENT PSYCHIAT,MANCHESTER M9 2AA,ENGLAND; ROYAL HALLAMSHIRE HOSP,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	Royal Manchester Children's Hospital; University of Sheffield				Dennison, Ashley/0000-0003-0090-503X				BLACK N, 1990, LANCET, V335, P35, DOI 10.1016/0140-6736(90)90151-T; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BUNKER TD, 1983, ANN ROY COLL SURG, V65, P242; DELAMOTHE T, 1990, BRIT MED J, V301, P510; EDEN OB, 1990, BRIT MED J, V301, P1334, DOI 10.1136/bmj.301.6764.1334-a; EDWARDS MH, 1990, BRIT J SURG, V77, P463, DOI 10.1002/bjs.1800770431; LYNOE N, 1991, BRIT MED J, V303, P610, DOI 10.1136/bmj.303.6803.610; ORR CJB, 1989, BRIT J HOSP MED, V42, P439; SMITH R, 1990, BRIT MED J, V301, P621, DOI 10.1136/bmj.301.6753.621; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; TRIBE DMR, 1990, BRIT J HOSP MED, V43, P217; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	12	116	118	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					298	300		10.1136/bmj.306.6873.298	http://dx.doi.org/10.1136/bmj.306.6873.298			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461646	Bronze, Green Published			2022-12-28	WOS:A1993KK71800018
J	FRANK, A				FRANK, A			FUTILITY AND AVOIDANCE - MEDICAL PROFESSIONALS IN THE TREATMENT OF OBESITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ENERGY-EXPENDITURE; BODY-WEIGHT				FRANK, A (corresponding author), GEORGE WASHINGTON UNIV, MED CTR, OBES MANAGEMENT PROGRAM, SUITE 208, 3 WASHINGTON CIRCLE NW, WASHINGTON, DC 20037 USA.							[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; [Anonymous], 1992, Ann Intern Med, V116, P942; Colditz G A, 1992, Am J Clin Nutr, V55, p503S, DOI 10.1093/ajcn/55.2.503s; DALLMAN M, 1986, FASEB J, V45, P1383; FLEMYNG M, 1990, INT J OBESITY, V14, P909; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; HIMMSHAGEN J, 1984, NEW ENGL J MED, V311, P1549, DOI 10.1056/NEJM198412133112407; LEVINE AS, 1987, FASEB J, V46, P159; MORLEY JE, 1982, AM J CLIN NUTR, V35, P757, DOI 10.1093/ajcn/35.4.757; PETTIGREW J, 1981, R BROWNING POEMS, V1, P643; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; REID LD, 1985, AM J CLIN NUTR, V42, P1099, DOI 10.1093/ajcn/42.5.1099; ROBERTS SB, 1988, NEW ENGL J MED, V318, P461, DOI 10.1056/NEJM198802253180801; ROTHWELL NJ, 1981, ANNU REV NUTR, V1, P235, DOI 10.1146/annurev.nu.01.070181.001315; Stunkard AJ, 1993, OBESITY THEORY THERA; STUNKARD AJ, 1958, NY STATE J MED, V58, P78	16	86	88	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2132	2133		10.1001/jama.269.16.2132	http://dx.doi.org/10.1001/jama.269.16.2132			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468770				2022-12-28	WOS:A1993KY36600038
J	ARDAVIN, C; WU, L; LI, CL; SHORTMAN, K				ARDAVIN, C; WU, L; LI, CL; SHORTMAN, K			THYMIC DENDRITIC CELLS AND T-CELLS DEVELOP SIMULTANEOUSLY IN THE THYMUS FROM A COMMON PRECURSOR POPULATION	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; LANGERHANS CELLS; BONE-MARROW; MOUSE	DENDRITIC cells, a minor cell population in lymphoid tissues, are specialized for presentation of antigenic peptides to T lymphocytes1. Thymic dendritic cells are involved in the deletion of self-reactive T lymphocytes2,3. Although all dendritic cells are ultimately of bone-marrow origin4-7, it has not been clear whether thymic dendritic cells are produced in the adult thymus from a precursor cell or whether they migrate there preformed from the periphery. Recently we isolated from adult mouse thymus a population of early T precursors that could still form B lymphocytes, but not erythroid or myeloid cells, when transferred intravenously8,9. Here we show that these thymic lymphoid precursor cells, as well as bone-marrow haematopoietic stem cells, are able to form both dendritic cells and T-cell progeny when transferred into an irradiated thymus. Such linked development may ensure that developing T cells are negatively selected predominantly by self antigens presented on newly formed thymic dendritic cells.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute				Shortman, Ken/0000-0002-9107-3007				BARCLAY AN, 1981, J EXP MED, V153, P1666, DOI 10.1084/jem.153.6.1666; FAIRCHILD P J, 1990, International Reviews of Immunology, V6, P187, DOI 10.3109/08830189009056629; KAMPINGA J, 1990, J IMMUNOL, V145, P1659; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981; LI CL, 1992, J EXP MED, V175, P1443, DOI 10.1084/jem.175.6.1443; MILLER JFA, 1992, REV IMMUNOL, V10, P51; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; PUGH CW, 1983, J EXP MED, V157, P1758, DOI 10.1084/jem.157.6.1758; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1990, J IMMUNOL, V145, P3661; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; STEINMAN RM, 1974, J EXP MED, V139, P1431, DOI 10.1084/jem.139.6.1431; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; THAN S, 1992, EUR J IMMUNOL, V22, P1299, DOI 10.1002/eji.1830220527; VREMEC D, 1992, J EXP MED, V176, P47, DOI 10.1084/jem.176.1.47; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0	18	562	577	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 22	1993	362	6422					761	763		10.1038/362761a0	http://dx.doi.org/10.1038/362761a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8469288				2022-12-28	WOS:A1993KY45000060
J	BRAVERMAN, AS				BRAVERMAN, AS			CHEMOTHERAPEUTIC FAILURE - RESISTANCE OR INSENSITIVITY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						CELL TRANSFORMATION, NEOPLASTIC; BIOLOGICAL THERAPY; ANTINEOPLASTIC AGENTS; IMMUNOTHERAPY; ONCOGENES	ONCOGENES; LEUKEMIA; PROTEIN; CANCER; GENE	Immunocyte and germ cell neoplasms, often curable by chemotherapy, arise from normal tissues most vulnerable to the effects of cytotoxic drugs; generalizing from these results to treating other tumors with such agents may not be entirely valid. Our limited success in treating epithelial neoplasms may be due to insensitivity rather than to drug resistance. Well-designed attempts to overcome resistance have been unsuccessful. The acquired immunodeficiency syndrome has not confirmed the putative role of immune surveillance in the pathogenesis of most neoplasms. The limited success of the most elaborate immunotherapies suggests that they, too, are nonspecific cell-killing techniques. Immunologic and cytotoxic drug therapies deserve further investigation but on a smaller scale. Neoplastic cell molecular biology, unknown when these therapies were developed, is being rapidly elucidated and may make it possible to treat malignancies by modulating cell physiology. Success of therapies based on the advances, in molecular biology, is not more uncertain than that of traditional treatments. Differentiation-induction techniques have already induced remissions in patients with acute promyelocytic leukemia and squamous cell carcinomas.			BRAVERMAN, AS (corresponding author), SUNY HLTH SCI CTR, DIV HEMATOL ONCOL, BOX 55, 450 CLARKSON AVE, BROOKLYN, NY 11203 USA.							ABEL U, 1991, CHEMOTHERAPY ADV EPI; ARMITAGE JO, 1992, ANN INTERN MED, V116, P771, DOI 10.7326/0003-4819-116-9-771; BALTIMORE D, 1987, CANCER, V59, P1985, DOI 10.1002/1097-0142(19870615)59:12<1985::AID-CNCR2820591202>3.0.CO;2-T; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLMAN RO, 1989, ANN INTERN MED, V111, P592, DOI 10.7326/0003-4819-111-7-592; DIVERIO D, 1992, BLOOD, V79, P3331; ELLIOTT S, 1992, BLOOD, V79, P1916; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GUTIERREZ AA, 1992, LANCET, V339, P715, DOI 10.1016/0140-6736(92)90606-4; HERTLER AA, 1989, J CLIN ONCOL, V7, P1932, DOI 10.1200/JCO.1989.7.12.1932; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MYERS C, 1992, J CLIN ONCOL, V10, P881, DOI 10.1200/JCO.1992.10.6.881; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; QUIRT IC, 1990, J CLIN ONCOL, V8, P1125, DOI 10.1200/JCO.1990.8.7.1125; ROSENBERG SA, 1992, J CLIN ONCOL, V10, P180, DOI 10.1200/JCO.1992.10.2.180; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	23	10	10	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					630	632		10.7326/0003-4819-118-8-199304150-00010	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8452329				2022-12-28	WOS:A1993KW47000010
J	BRADY, ST				BRADY, ST			MOTOR NEURONS AND NEUROFILAMENTS IN SICKNESS AND IN HEALTH	CELL			English	Review							AXONAL-TRANSPORT; NERVOUS-SYSTEM; PROTEINS; IDENTIFICATION; TERMINALS				BRADY, ST (corresponding author), UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA.							BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BRADY ST, 1992, NEUROREGENERATION, P7; Brown A., 1990, SQUID EXPT ANIMALS, P235; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; GARNER JA, 1988, BRAIN RES, V458, P309, DOI 10.1016/0006-8993(88)90473-8; GOLDMAN JE, 1986, ANN NEUROL, V19, P209, DOI 10.1002/ana.410190302; GRIFFIN JW, 1988, ANN NEUROL, V23, P3, DOI 10.1002/ana.410230103; HIRANO A, 1991, ADV NEUROL, V56, P91; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Lasec R, 1988, INTRINSIC DETERMINAN, P1; LASEK RJ, 1992, J CELL BIOL, V117, P607, DOI 10.1083/jcb.117.3.607; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; NORRIS FH, 1992, HDB AMYOTROPHIC LATE, P3; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PAGGI P, 1987, J NEUROSCI, V7, P2397; PRICE RL, 1988, J NEUROCYTOL, V17, P55, DOI 10.1007/BF01735377; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; ROOTS B, 1983, SCIENCE, V21, P971; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROWLAND LP, 1991, ADV NEUROL, V56, P3; SCHLAEPFER WW, 1978, J CELL BIOL, V78, P653, DOI 10.1083/jcb.78.3.653; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; [No title captured]	27	58	59	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 9	1993	73	1					1	3		10.1016/0092-8674(93)90151-F	http://dx.doi.org/10.1016/0092-8674(93)90151-F			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462093				2022-12-28	WOS:A1993KW75300001
J	BLENDON, RJ; DONELAN, K; LEITMAN, R; EPSTEIN, A; CANTOR, JC; COHEN, AB; MORRISON, I; MOLONEY, T; KOECK, C; LEVITT, SW				BLENDON, RJ; DONELAN, K; LEITMAN, R; EPSTEIN, A; CANTOR, JC; COHEN, AB; MORRISON, I; MOLONEY, T; KOECK, C; LEVITT, SW			PHYSICIANS PERSPECTIVES ON CARING FOR PATIENTS IN THE UNITED-STATES, CANADA, AND WEST-GERMANY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE SYSTEM	Background. The United States is considering enacting a national health plan and global health care budget similar to those in other countries. There are few data on the effects of such policies on physicians and patients. Methods. We conducted a telephone survey of 602 physicians in the United States, 507 physicians in Canada, and 519 physicians in the former West Germany from February through May 1991; the response rates were 44 percent, 49 percent, and 41 percent, respectively. Among other topics, the questionnaire included measures of satisfaction with the health care system and with medical practice. Results. In the United States, 23 percent of the physicians surveyed thought the health care system worked well, as compared with 33 percent in Canada and 48 percent in West Germany. Seventy-three percent of U.S. physicians reported that patients' inability to afford necessary treatment was a serious problem, as compared with 25 percent in Canada and 15 percent in West Germany. Seventy-seven percent of West German physicians, 56 percent of Canadian physicians, and 54 percent of U.S. physicians said the shortage of competent nurses was a serious problem. In Canada, 50 percent of the respondents cited the lack of well-equipped medical facilities as a problem, as compared with 14 percent in the United States and 20 percent in West Germany. Conclusions. Programs of universal coverage and cost containment necessitate important trade-offs. In Canada and West Germany, physicians do not report serious problems of access to care for the poor and uninsured. In the United States, doctors do not face the limited access to sophisticated forms of medical technology that was reported in Canada or the diminished quality of some services reported in West Germany.	LOUIS HARRIS & ASSOCIATES,NEW YORK,NY; HARVARD UNIV,SCH MED,DEPT MED CARE POLICY,BOSTON,MA 02115; ROBERT WOOD JOHNSON FDN,PRINCETON,NJ 08540; INST FUTURE,MENLO PK,CA 94025; BRANDEIS UNIV,FLORENCE HELLER GRAD SCH ADV STUDIES SOCIAL WELF,INST HLTH POLICY,WALTHAM,MA 02254	Harvard University; Harvard Medical School; Robert Wood Johnson Foundation (RWJF); Brandeis University	BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019	Cohen, Alan B./0000-0002-5232-8927				EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; GLASER W, 1991, HLTH INSURANCE PRACT; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; IGLEHART JK, 1989, NEW ENGL J MED, V321, P1767, DOI 10.1056/NEJM198912213212527; IGLEHART JK, 1991, NEW ENGL J MED, V324, P503, DOI 10.1056/NEJM199102143240725; IGLEHART JK, 1986, NEW ENGL J MED, V315, P202, DOI 10.1056/NEJM198607173150330; KIRKMANLIFF BL, 1990, J HEALTH POLIT POLIC, V15, P69, DOI 10.1215/03616878-15-1-69; REINHARDT UE, 1990, BIPARTISAN COMMISS S, P3; Schieber G J, 1992, Health Care Financ Rev, V13, P1; 1991, CANADIAN MED DIRECTO; 1991, CANADIAN HLTH INSURA; 1991, GAOHRD929 GEN ACCT O	12	46	46	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1011	1016		10.1056/NEJM199304083281407	http://dx.doi.org/10.1056/NEJM199304083281407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	8450854	Bronze			2022-12-28	WOS:A1993KW28200007
J	WEITZMAN, M; ASCHENGRAU, A; BELLINGER, D; JONES, R; HAMLIN, JS; BEISER, A				WEITZMAN, M; ASCHENGRAU, A; BELLINGER, D; JONES, R; HAMLIN, JS; BEISER, A			LEAD-CONTAMINATED SOIL ABATEMENT AND URBAN CHILDRENS BLOOD LEAD LEVELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL LEAD; ABSORPTION; EXPOSURE; CHILDHOOD; DUST	Objective.-To test the hypothesis that a reduction of 1 000 ppm or more of lead in soil accessible to children would result in a decrease of at least 0.14 mumol/L (3 mug/dL) in blood lead levels. Setting.-Urban neighborhoods with a high incidence of childhood lead poisoning and high soil lead levels. Design.-Randomized controlled trial of the effects of lead-contaminated soil abatement on blood lead levels of children followed up for approximately 1 year after the intervention. Patients.-A total of 152 children less than 4 years of age with venous blood lead levels of 0.34 to 1.16 mumol/L (7 to 24 mug/dL). Children were largely poor and had a mean age at baseline of 32 months, a mean blood lead level of 0.60 mumol/L (12.5 mug/dL), and a median surface soil lead level of 2075 ppm. Interventions.-Children were randomized to one of three groups: the study group, whose homes received soil and interior dust abatement and loose paint removal; comparison group A, whose homes received interior dust abatement and loose paint removal; and comparison group B, whose homes received only interior loose paint removal. Main Outcome Measures.-Change in children's blood lead levels from preabatement levels to levels approximately 6 and 11 months after abatement. Results.-The mean decline in blood lead level between preabatement and 11 months after abatement was 0.12 mumol/L (2.44 mug/dL) in the study group (P=.001), 0.04 mumol/L (0.91 mug/dL) in group A (P=.04), and 0.02 mumol/L (0.52 mug/mL) in group B (P=.31). The mean blood lead level of the study group declined 0.07 mumol/L (1.53 mug/dL) more than that of group A (95% confidence interval [CI], -0.14 to -0.01 mumol/L [-2.87 to -0.19 mug/dL]) and 0.09 mumol/L (1.92 mug/dL) more than group B (95% CI, -0.16 to -0.03 mumol/L [-3.28 to -0.56 mug/dL]). When adjusted for preabatement lead level, the 11-month mean blood lead level was 0.06 mumol/L (1.28 mug/dL) lower in the study group as compared with group A (P=.02) and 0.07 mumol/L (1.49 mug/dL) lower than in group B (P=.01). The magnitude of th decline independently associated with soil abatement ranged from 0.04 to 0.08 mumol/L (0.8 to 1.6 mug/dL) when the impact of potential confounders, such as water, dust, and paint lead levels, children's mouthing behaviors, and other characteristics, was controlled for. Conclusions.-These results demonstrate that lead-contaminated soil contributes to the lead burden of urban children and that abatement of lead-contaminated soil around homes results in a modest decline in blood lead levels. The magnitude of reduction in blood lead level observed, however, suggests that lead-contaminated soil abatement is not likely to be a useful clinical intervention for the majority of urban children in the United States with low-level lead exposure.	UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; DEPT PUBL HLTH,CLEVELAND,OH; CEDARS SINAI MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90048	University of Rochester; Boston University; Harvard University; Harvard Medical School; Cedars Sinai Medical Center				Beiser, Alexa/0000-0001-8551-7778; Aschengrau, Ann/0000-0001-8153-7712				ANGLE CR, 1984, ENVIRON RES, V35, P160, DOI 10.1016/0013-9351(84)90123-3; [Anonymous], 1988, NATURE EXTENT LEAD P; [Anonymous], 1991, PREVENTING LEAD POIS; BARLTROP D, 1979, ARCH ENVIRON HEALTH, V34, P280, DOI 10.1080/00039896.1979.10667414; BARLTROP D, 1975, POSTGRAD MED J, V51, P801, DOI 10.1136/pgmj.51.601.801; BORNSCHEIN RL, 1985, ENVIRON RES, V38, P4, DOI 10.1016/0013-9351(85)90067-2; BORNSCHEIN RL, 1987, TRACE SUBSTANCES ENV, V20, P322; CHARNEY E, 1983, NEW ENGL J MED, V309, P1089, DOI 10.1056/NEJM198311033091804; CHARNEY E, 1980, PEDIATRICS, V65, P226, DOI 10.1542/peds.65.2.226; CHISOLM JJ, 1986, AM J PUBLIC HEALTH, V26, P236; CLARK CS, 1985, ENVIRON RES, V38, P46, DOI 10.1016/0013-9351(85)90071-4; CLARK CS, 1987, INT C HEAVY METALS E, P159; COLTON TC, 1974, STAT MED, P122; DUGGAN M J, 1985, Public Health Reviews, V13, P1; JONES RR, 1989, MONITORING MASSACHUS, P121; LANDRIGAN PJ, 1975, NEW ENGL J MED, V292, P123, DOI 10.1056/NEJM197501162920302; MCMICHAEL AJ, 1985, MED J AUSTRALIA, V143, P499, DOI 10.5694/j.1326-5377.1985.tb119911.x; MIELKE HW, 1983, AM J PUBLIC HEALTH, V73, P1366, DOI 10.2105/AJPH.73.12.1366; MIELKE HW, 1984, ENVIRON RES, V34, P64, DOI 10.1016/0013-9351(84)90076-8; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; RABIN R, 1989, AM J PUBLIC HEALTH, V79, P1668, DOI 10.2105/AJPH.79.12.1668; RABINOWITZ M, 1985, ENVIRON RES, V38, P96, DOI 10.1016/0013-9351(85)90075-1; RABINOWITZ M, 1988, B ENVIRON CONTAM TOX, V44, P791; ROELS HA, 1980, ENVIRON RES, V22, P81, DOI 10.1016/0013-9351(80)90121-8; SAYRE JW, 1974, AM J DIS CHILD, V127, P167, DOI 10.1001/archpedi.1974.02110210017002; SCHNEIDER DJ, 1986, AM J PUBLIC HEALTH, V76, P242, DOI 10.2105/AJPH.76.3.242; Weitzman M, 1992, Pediatr Rev, V13, P461; YAFFE Y, 1983, ARCH ENVIRON HEALTH, V38, P237, DOI 10.1080/00039896.1983.10545809; 1990, LEGACY LEAD AM CONTI; EPA600877017 PUBL, pCH12	31	115	116	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1647	1654		10.1001/jama.269.13.1647	http://dx.doi.org/10.1001/jama.269.13.1647			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KV349	8455298				2022-12-28	WOS:A1993KV34900028
J	ABRAMS, FR				ABRAMS, FR			THE DOCTOR WITH 2 HEADS - THE PATIENT VERSUS THE COSTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ABRAMS, FR (corresponding author), UNIV COLORADO,DENVER,CO 80262, USA.								0	18	18	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 1	1993	328	13					975	976		10.1056/NEJM199304013281320	http://dx.doi.org/10.1056/NEJM199304013281320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU177	8446161				2022-12-28	WOS:A1993KU17700038
J	COHEN, J				COHEN, J			AIDS VACCINES - MICROGENESYS WITHDRAWS FROM TRIAL	SCIENCE			English	Editorial Material																		MOORE J, 1993, NATURE          0211; 1993, SCIENCE, V259, P752; 1992, SCIENCE, V258, P536	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1821	1822		10.1126/science.8456308	http://dx.doi.org/10.1126/science.8456308			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456308				2022-12-28	WOS:A1993KU17200016
J	LANDRY, DW; ZHAO, K; YANG, GXQ; GLICKMAN, M; GEORGIADIS, TM				LANDRY, DW; ZHAO, K; YANG, GXQ; GLICKMAN, M; GEORGIADIS, TM			ANTIBODY-CATALYZED DEGRADATION OF COCAINE	SCIENCE			English	Article							DOPAMINE TRANSPORTER; NONHUMAN-PRIMATES; EXPRESSION; HYDROLYSIS; CHEMISTRY; SUBSTRATE; CLONING; PLASMA; DRUGS	Immunization with a phosphonate monoester transition-state analog of cocaine provided monoclonal antibodies capable of catalyzing the hydrolysis of the cocaine benzoyl ester group. An assay for the degradation of radiolabeled cocaine identified active enzymes. Benzoyl esterolysis yields ecgonine methyl ester and benzoic acid, fragments devoid of cocaine's stimulant activity. Passive immunization with such an artificial enzyme could provide a treatment for dependence by blunting reinforcement.			LANDRY, DW (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.		Zhao, Kang/K-3777-2015	Zhao, Kang/0000-0002-0213-2854	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007258] Funding Source: NIH RePORTER; NINDS NIH HHS [T32 NS07258] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENDER ML, 1960, CHEM REV, V60, P53, DOI 10.1021/cr60203a005; BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; BONESE KF, 1974, NATURE, V252, P708, DOI 10.1038/252708a0; CORRIU RJP, 1980, TETRAHEDRON, V36, P1617, DOI 10.1016/S0040-4020(01)83131-8; FISCHMAN MW, 1990, J PHARMACOL EXP THER, V253, P760; FISCHMAN MW, 1988, J CLIN PSYCHIAT, V49, P7; FOWLER JS, 1989, SYNAPSE, V4, P371, DOI 10.1002/syn.890040412; FUJII I, 1991, J AM CHEM SOC, V113, P8528, DOI 10.1021/ja00022a054; GATLEY SJ, 1991, BIOCHEM PHARMACOL, V41, P1249, DOI 10.1016/0006-2952(91)90665-R; GAWIN FH, 1989, ARCH GEN PSYCHIAT, V46, P117; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; IKEDA S, 1991, J AM CHEM SOC, V113, P7763, DOI 10.1021/ja00020a049; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1991, J AM CHEM SOC, V113, P5427, DOI 10.1021/ja00014a039; JANDA KD, 1991, TETRAHEDRON, V47, P2503, DOI 10.1016/S0040-4020(01)81784-1; Johanson C E, 1984, NIDA Res Monogr, V50, P54; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LANDRY D, UNPUB; LERNER RA, 1992, SCIENCE, V258, P1313, DOI 10.1126/science.1455226; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SCHULTZ PG, 1988, SCIENCE, V240, P426, DOI 10.1126/science.2833815; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SPEALMAN RD, 1989, J PHARMACOL EXP THER, V251, P142; STEWART DJ, 1977, LIFE SCI, V20, P1557, DOI 10.1016/0024-3205(77)90448-9; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; ZHAO K, 1993, TETRAHEDRON, V49, P363, DOI 10.1016/S0040-4020(01)80305-7	35	224	236	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1899	1901		10.1126/science.8456315	http://dx.doi.org/10.1126/science.8456315			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456315				2022-12-28	WOS:A1993KU17200032
J	STORY, RM; BISHOP, DK; KLECKNER, N; STEITZ, TA				STORY, RM; BISHOP, DK; KLECKNER, N; STEITZ, TA			STRUCTURAL RELATIONSHIP OF BACTERIAL RECA PROTEINS TO RECOMBINATION PROTEINS FROM BACTERIOPHAGE-T4 AND YEAST	SCIENCE			English	Article							AMINO-ACID SEQUENCES; DNA STRAND EXCHANGE; GENETIC-RECOMBINATION; UVSX; MECHANISM; FILAMENTS; ENZYMES; FOLD	RecA protein is essential in eubacteria for homologous recombination and promotes the homologous pairing and strand exchange of DNA molecules in vitro. Recombination proteins with weak sequence similarity to bacterial RecA proteins have been identified in bacteriophage T4, yeast, and other higher organisms. Analysis of the primary sequence relationships of DMC1 from Saccharomyces cerevisiae and UvsX of T4 relative to the three-dimensional structure of RecA from Escherichia coli suggests that both proteins are structural homologs of bacterial RecA proteins. This analysis argues that proteins in this group are members of a single family that diverged from a common ancestor that existed prior to the divergence of prokaryotes and eukaryotes.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; Harvard University			Steitz, Thomas A./C-6559-2009		NIGMS NIH HHS [GM22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BENEDICT RC, 1991, J BIOL CHEM, V263, P5450; BEZZUGOVA O, IN PRESS NUCLEIC ACI; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1181; CHENG R, IN PRESS MUTAT RES; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DELBAERE LTJ, 1975, NATURE, V257, P758, DOI 10.1038/257758a0; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FUJISAWA H, 1985, NUCLEIC ACIDS RES, V13, P7473, DOI 10.1093/nar/13.20.7473; GRIFFITH J, 1985, J BIOL CHEM, V260, P4484; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; KOBAYASHI T, IN PRESS MOL GEN GEN; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; MCLACHLAN AD, 1971, J MOL BIOL, V61, P409, DOI 10.1016/0022-2836(71)90390-1; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RESNICK M A, 1987, P157; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SHINOHARA A, COMMUNICATION; STORY RM, 1992, NATURE, V355, P567, DOI 10.1038/355567a0; STORY RM, 1992, J MOL BIOL, V355, P374; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	34	149	168	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1892	1896		10.1126/science.8456313	http://dx.doi.org/10.1126/science.8456313			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456313				2022-12-28	WOS:A1993KU17200030
J	GREEN, P; LIPMAN, D; HILLIER, L; WATERSTON, R; STATES, D; CLAVERIE, JM				GREEN, P; LIPMAN, D; HILLIER, L; WATERSTON, R; STATES, D; CLAVERIE, JM			ANCIENT CONSERVED REGIONS IN NEW GENE-SEQUENCES AND THE PROTEIN DATABASES	SCIENCE			English	Article							MOTIFS	Sets of new gene sequences from human, nematode, and yeast were compared with each other and with a set of Escherichia coli genes in order to detect ancient evolutionarily conserved regions (ACRs) in the encoded proteins. Nearly all of the ACRs so identified were found to be homologous to sequences in the protein databases. This suggests that currently known proteins may already include representatives of most ACRs and that new sequences not similar to any database sequence are unlikely to contain ACRs. Preliminary analyses indicate that moderately expressed genes may be more likely to contain ACRs than rarely expressed genes. It is estimated that there are fewer than 900 ACRs in all.	NIH, NATL CTR BIOTECHNOL INFORMAT, NATL LIB MED, BETHESDA, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	GREEN, P (corresponding author), WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA.		Claverie, Jean-Michel/AAG-4889-2019; Claverie, Jean Michel/Z-2183-2019	Claverie, Jean-Michel/0000-0003-1424-0315; 				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALTSCHUL SF, 1991, GENOMICS, V11, P408; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BARTON GJ, 1990, J MOL BIOL, V212, P389, DOI 10.1016/0022-2836(90)90133-7; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CLAVERIE JM, IN PRESS COMPUT CHEM; CLAVERIE JM, UNPUB; DANCKAERT A, 1991, COMPUT APPL BIOSCI, V7, P509; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P191; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PEARSON WR, 1991, GENOMICS, V11, P635, DOI 10.1016/0888-7543(91)90071-L; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POSFAI J, 1988, GENE, V74, P261, DOI 10.1016/0378-1119(88)90299-5; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STATES DJ, UNPUB; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SUTCLIFFE JG, 1988, ANNU REV NEUROSCI, V11, P157, DOI 10.1146/annurev.ne.11.030188.001105; WATERSTON R, 1992, NAT GENET, V1, P79; WOESE CR, 1982, ARCHAEBACTERIA, P1	31	152	160	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1993	259	5102					1711	1716		10.1126/science.8456298	http://dx.doi.org/10.1126/science.8456298			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456298				2022-12-28	WOS:A1993KT81000026
J	LOVEJOY, B; CHOE, S; CASCIO, D; MCRORIE, DK; DEGRADO, WF; EISENBERG, D				LOVEJOY, B; CHOE, S; CASCIO, D; MCRORIE, DK; DEGRADO, WF; EISENBERG, D			CRYSTAL-STRUCTURE OF A SYNTHETIC TRIPLE-STRANDED ALPHA-HELICAL BUNDLE	SCIENCE			English	Article							COILED-COILS; SECONDARY-STRUCTURE; PROTEIN; DESIGN; REFINEMENT; TROPOMYOSIN; REPEATS; MODEL; STABILIZATION; PREDICTION	The x-ray crystal structure of a peptide designed to form a double-stranded parallel coiled coil shows that it is actually a triple-stranded coiled coil formed by three alpha-helices. Unlike the designed parallel coiled coil, the helices run up-up-down. The structure is stabilized by a distinctive hydrophobic interface consisting of eight layers. As in the design, each alpha-helix in the coiled coil contributes one leucine side chain to each layer. The structure suggests that hydrophobic interactions are a dominant factor in the stabilization of coiled coils. The stoichiometry and geometry of coiled coils are primarily determined by side chain packing in the solvent-inaccessible interior, but electrostatic interactions also contribute.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; BECKMAN INSTRUMENTS INC,DEPT RES & APPLICAT,PALO ALTO,CA 94304; DUPONT MERCK PHARMACEUT CO,DEPT BIOTECHNOL,WILMINGTON,DE 19880; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; DuPont; University of California System; University of California Los Angeles					PHS HHS [31299] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P15; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DEGRADO WF, 1987, COLD SPRING HARB SYM, V52, P521, DOI 10.1101/SQB.1987.052.01.059; DEGRADO WF, UNPUB; DEISENHOFER J, 1978, H-S Z PHYSIOL CHEM, V359, P975, DOI 10.1515/bchm2.1978.359.2.975; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; EISENBERG D, 1986, Proteins Structure Function and Genetics, V1, P16, DOI 10.1002/prot.340010105; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; EISENBERG D, 1989, CHEM SCRIPTA, V29A, P217; ELLENBERGER TE, 1993, CELL, V71, P1224; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LOVEJOY B, 1992, PROTEIN SCI, V1, P956, DOI 10.1002/pro.5560010714; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; POLLET RJ, 1979, J BIOL CHEM, V254, P30; SKOLNICK J, 1985, MACROMOLECULES, V18, P1549, DOI 10.1021/ma00150a005; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WEBER PC, 1980, NATURE, V287, P81; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	43	275	297	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1288	1293		10.1126/science.8446897	http://dx.doi.org/10.1126/science.8446897			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446897				2022-12-28	WOS:A1993KN88300020
J	ZAADSTRA, BM; SEIDELL, JC; VANNOORD, PAH; TEVELDE, ER; HABBEMA, JDF; VRIESWIJK, B; KARBAAT, J				ZAADSTRA, BM; SEIDELL, JC; VANNOORD, PAH; TEVELDE, ER; HABBEMA, JDF; VRIESWIJK, B; KARBAAT, J			FAT AND FEMALE FECUNDITY - PROSPECTIVE-STUDY OF EFFECT OF BODY-FAT DISTRIBUTION ON CONCEPTION RATES	BRITISH MEDICAL JOURNAL			English	Article							WOMEN; ASSOCIATION; INFERTILITY; OBESITY; WEIGHT	Objectives-To study the effect of body fat distribution in women of reproducti Design-Prospective cohort study of all women who had entered a donor insemination programme. Setting-One fertility clinic serving a large part of the midwest of the Netherlands. Subjects-Of 542 women attending the clinic for artificial insemination for the first time, 500 women were eligible for study. Main outcome measures-Probability of conception per cycle and number of insemination cycles before pregnancy or stopping treatment. Results-A 0.1 unit increase in waist-hip ratio led to a 30% decrease in probability of conception per cycle (hazard ratio 0.706; 95% confidence interval 0.562 to 0.887) after adjustment for age, fatness, reasons for artificial insemination, cycle length and regularity, smoking, and parity. Increasing age was significantly related to lower fecundity (p<0.05); very lean and obese women were less likely to conceive (p<0.10) as were women with subfertile partners (p<0.10). All other exposure variables were not significantly related to fecundity. Conclusions-Increasing waist-hip ratio is negatively associated with the probability of conception per cycle, before and after adjustment for confounding factors. Body fat distribution in women of reproductive age seems to have more impact on fertility than age or obesity.	AGR UNIV WAGENINGEN, DEPT HUMAN NUTR, 6700 HB WAGENINGEN, NETHERLANDS; UNIV UTRECHT, SCH MED, DEPT EPIDEMIOL, UTRECHT, NETHERLANDS; UNIV HOSP UTRECHT, DEPT OBSTET & GYNAECOL, UTRECHT, NETHERLANDS; ERASMUS UNIV, SCH MED, DEPT PUBL HLTH & SOCIAL MED, 3000 DR ROTTERDAM, NETHERLANDS; CRYO BIOL LABS BIJDORP, BARENDRECHT, NETHERLANDS	Wageningen University & Research; Utrecht University; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam	ZAADSTRA, BM (corresponding author), TNO, INST PREVENT HLTH CARE, DIV CHILD HLTH, POSTBOX 124, 2300 AC LEIDEN, NETHERLANDS.		seidell, jacob/AAF-5362-2019; seidell, jacob c/N-7427-2013	seidell, jacob/0000-0002-9262-9062; 				AITKIN M, 1989, STATISTICAL MODELLIN; BAIRD DD, 1985, JAMA-J AM MED ASSOC, V253, P2979, DOI 10.1001/jama.253.20.2979; COX DR, 1972, J R STAT SOC B, V34, P187; EMPERAIRE JC, 1982, FERTIL STERIL, V37, P90; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; FRIEDL KE, 1985, J OBESITY WEIGHT REG, V4, P129; FRISCH RE, 1988, SCI AM, V3, P70; GRENMAN S, 1986, J CLIN ENDOCR METAB, V63, P1257, DOI 10.1210/jcem-63-6-1257; HARTZ AJ, 1979, INT J OBESITY, V3, P57; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MITCHELL GW, 1953, NEW ENGL J MED, V249, P835, DOI 10.1056/NEJM195311192492102; NEWCOMBE RG, 1982, J EPIDEMIOL COMMUN H, V36, P306, DOI 10.1136/jech.36.4.306; PASQUALI R, 1987, J ENDOCRINOL INVEST, V10, P575, DOI 10.1007/BF03346997; REGAN L, 1990, LANCET, V336, P1141, DOI 10.1016/0140-6736(90)92765-A; ROGERS J, 1952, NEW ENGL J MED, V247, P53, DOI 10.1056/NEJM195207102470204; ROOKUS MA, 1987, HUM BIOL, V59, P617; SEIDELL JC, 1990, J CLIN EPIDEMIOL, V43, P21, DOI 10.1016/0895-4356(90)90052-Q; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SHIMOKATA H, 1989, INT J OBESITY, V13, P455; van Noord-Zaadstra B M, 1980, Ned Tijdschr Geneeskd, V124, P581; van Noord-Zaadstra B M, 1989, Paediatr Perinat Epidemiol, V3, P11; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361	23	402	405	0	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					484	487		10.1136/bmj.306.6876.484	http://dx.doi.org/10.1136/bmj.306.6876.484			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448457	Green Accepted, Bronze, Green Published			2022-12-28	WOS:A1993KN78600016
J	ALLSOPP, TE; WYATT, S; PATERSON, HF; DAVIES, AM				ALLSOPP, TE; WYATT, S; PATERSON, HF; DAVIES, AM			THE PROTOONCOGENE BCL-2 CAN SELECTIVELY RESCUE NEUROTROPHIC FACTOR-DEPENDENT NEURONS FROM APOPTOSIS	CELL			English	Article							PROGRAMMED CELL-DEATH; NERVE GROWTH-FACTOR; CHROMOSOMAL BREAKPOINT; MOLECULAR-CLONING; MEMBRANE PROTEIN; SENSORY NEURONS; B-CELLS; SURVIVAL; EXPRESSION; PURIFICATION	Apoptosis plays an important role in regulating cell numbers in a wide variety of tissues during development. The product of the bcl-2 gene inhibits apoptosis in certain cells of the myeloid and lymphoid lineages and is expressed in many cells that have an extended life span. To assess the role of bcl-2 in neuronal apoptosis, we microinjected a bcl-2 expression vector into neurotrophic factor-deprived embryonic neurons. Sensory neurons that depend for survival on one or more members of the nerve growth factor family of neurotrophic factors (nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3) were rescued by bcl-2, whereas ciliary neurotrophic factor (CNTF)-dependent ciliary neurons were not. Sensory neurons, however, became refractory to bcl-2 after exposure to CNTF. These findings indicate that at least two death pathways operate in neurons that are distinguished by their susceptibility to bcl-2. Neurons may die by either pathway, depending on the factors to which they have been exposed.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	ALLSOPP, TE (corresponding author), SCH BIOL & MED SCI,BUTE MED BLDG,ST ANDREWS KY16 9TS,FIFE,SCOTLAND.		Davies, Alun M/A-4334-2010; Wyatt, Sean/A-5266-2010	Davies, Alun M/0000-0001-5841-8176; Wyatt, Sean/0000-0002-0572-234X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BLOMGREN H, 1971, CELL IMMUNOL, V1, P545; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHEN JJ, 1984, J IMMUNOL, V132, P38; Davies A, 1983, Int J Dev Neurosci, V1, P171, DOI 10.1016/0736-5748(83)90211-3; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DAVIES AM, 1986, NATURE, V319, P497, DOI 10.1038/319497a0; DAVIES AM, 1985, DEV BIOL, V111, P62, DOI 10.1016/0012-1606(85)90435-X; DAVIES AM, 1987, DEVELOPMENT, V101, P185; DAVIES AM, 1988, TRENDS GENET, V4, P139, DOI 10.1016/0168-9525(88)90137-0; DAVIES AM, 1986, DEV BIOL, V115, P56, DOI 10.1016/0012-1606(86)90227-7; DAVIES AM, 1989, NERVE GROWTH FACTORS, P95; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ECKENSTEIN FP, 1990, NEURON, V4, P623, DOI 10.1016/0896-6273(90)90120-5; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IP NY, 1991, J NEUROSCI, V11, P3124; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KALOUSEK F, 1980, J BIOL CHEM, V255, P60; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; Lockshin R. A, 1981, CELL DEATH BIOL PATH, P79; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; PEZZELLA F, 1990, AM J PATHOL, V137, P225; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCOTT SA, 1990, J NEUROBIOL, V21, P630, DOI 10.1002/neu.480210410; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	59	565	579	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					295	307		10.1016/0092-8674(93)90230-N	http://dx.doi.org/10.1016/0092-8674(93)90230-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8477446				2022-12-28	WOS:A1993KY50500011
J	ZHOU, YH; BUSBY, S; EBRIGHT, RH				ZHOU, YH; BUSBY, S; EBRIGHT, RH			IDENTIFICATION OF THE FUNCTIONAL SUBUNIT OF A DIMERIC TRANSCRIPTION ACTIVATOR PROTEIN BY USE OF ORIENTED HETERODIMERS	CELL			English	Article							AMP RECEPTOR PROTEIN; LAC OPERON TRANSCRIPTION; CAP-DNA COMPLEX; ESCHERICHIA-COLI; MUTATIONS; SPECIFICITY; RECOGNITION; RESOLUTION; PROMOTER; ALTER	We have constructed heterodimers consisting of two subunits: one CAP subunit that has a nonfunctional activating region but wild-type DNA binding specificity, and one CAP subunit that has a functional activating region but non-wild-type DNA binding specificity. We have oriented the heterodimers on lac promoter DNA by use of promoter derivatives that have DNA sites for CAP consisting of one wild-type half site and one non-wild-type half site, and we have analyzed the abilities of the oriented heterodimers to activate transcription. Our results indicate that transcription activation requires the activating region of only one subunit of CAP: the promoter-proximal subunit. The oriented heterodimers method of this report should be generalizable to other dimeric transcription activator proteins.	RUTGERS STATE UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855; UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	Rutgers State University New Brunswick; University of Birmingham	ZHOU, YH (corresponding author), RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855, USA.		Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; BRENNAN R, 1992, CURR OPIN STRUC BIOL, V2, P100; Brennan RG, 1991, CURR OPIN STRUC BIOL, V1, P80, DOI 10.1016/0959-440X(91)90015-L; BROWN AM, 1989, P NATL ACAD SCI USA, V86, P7387, DOI 10.1073/pnas.86.19.7387; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DICKSON RC, 1977, J MOL BIOL, V111, P65, DOI 10.1016/S0022-2836(77)80132-0; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; EBRIGHT RH, 1984, NATURE, V311, P232, DOI 10.1038/311232a0; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GUNASEKERA A, 1992, J BIOL CHEM, V267, P14713; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; IPPEN K, 1968, NATURE, V217, P825, DOI 10.1038/217825a0; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; Miller J.H., 1972, EXPT MOL GENETICS; PASTAN I, 1976, BACTERIOL REV, V40, P527, DOI 10.1128/MMBR.40.3.527-551.1976; REZNIKOFF WS, 1992, J BACTERIOL, V174, P655, DOI 10.1128/jb.174.3.655-658.1992; SCAIFE J, 1966, COLD SPRING HARB SYM, V31, P403, DOI 10.1101/SQB.1966.031.01.052; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WILLIAMS R, 1991, NUCLEIC ACIDS RES, V19, P6705, DOI 10.1093/nar/19.24.6705; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929; ZHANG XP, 1992, J BIOL CHEM, V267, P8136; ZHANG XP, 1990, P NATL ACAD SCI USA, V87, P4717, DOI 10.1073/pnas.87.12.4717; ZHOU Y, 1993, IN PRESS P NATL ACAD	26	70	71	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					375	379		10.1016/0092-8674(93)90236-J	http://dx.doi.org/10.1016/0092-8674(93)90236-J			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8477449				2022-12-28	WOS:A1993KY50500017
J	GUYATT, GH; FEENY, DH; PATRICK, DL				GUYATT, GH; FEENY, DH; PATRICK, DL			MEASURING HEALTH-RELATED QUALITY-OF-LIFE	ANNALS OF INTERNAL MEDICINE			English	Review						QUALITY OF LIFE; HEALTH POLICY; HEALTH STATUS INDICATORS; QUESTIONNAIRES; HEALTH STATUS	SICKNESS IMPACT PROFILE; OBSTRUCTIVE PULMONARY-DISEASE; RHEUMATOID-ARTHRITIS; CLINICAL-TRIALS; LUNG-DISEASE; THERAPY; AURANOFIN; OUTCOMES; CAPACITY; VALIDITY	Clinicians and policymakers are recognizing the importance of measuring health-related quality of life (HRQL) to inform patient management and policy decisions. Self- or interviewer-administered questionnaires can be used to measure cross-sectional differences in quality of life between patients at a point in time (discriminative instruments) or longitudinal changes in HRQL within patients during a period of time (evaluative instruments). Both discriminative and evaluative instruments must be valid (really measuring what they are supposed to measure) and have a high ratio of signal to noise (reliability and responsiveness, respectively). Reliable discriminative instruments are able to reproducibly differentiate between persons. Responsive evaluative measures are able to detect important changes in HRQL during a period of time, even if those changes are small. Health-related quality of life measures should also be interpretable-that is, clinicians and policymakers must be able to identify differences in scores that correspond to trivial, small, moderate, and large differences. Two basic approaches to quality-of-life measurement are available: generic instruments that provide a summary of HRQL; and specific instruments that focus on problems associated with single disease states, patient groups, or areas of function. Generic instruments include health profiles and instruments that generate health utilities. The approaches are not mutually exclusive. Each approach has its strengths and weaknesses and may be suitable for different circumstances. Investigations in HRQL have led to instruments suitable for detecting minimally important effects in clinical trials, for measuring the health of populations, and for providing information for policy decisions.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT HLTH SERV, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	GUYATT, GH (corresponding author), MCMASTER UNIV, HLTH SCI CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, 1200 MAIN ST W, ROOM 2C12, HAMILTON L8N 3Z5, ONTARIO, CANADA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492				APTRICK DL, 1993, HLTH STATUS HLTH POL; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERKANOVIC E, 1980, AM J PUBLIC HEALTH, V70, P1273, DOI 10.2105/AJPH.70.12.1273; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DEYO RA, 1984, AM J PUBLIC HEALTH, V74, P569, DOI 10.2105/AJPH.74.6.569; DEYO RA, 1983, MED CARE, V21, P180, DOI 10.1097/00005650-198302000-00006; FEENY D, 1991, CONTROL CLIN TRIALS, V12, pS79, DOI 10.1016/S0197-2456(05)80013-3; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; Feinstein AR, 1987, CLINIMETRICS, P141, DOI DOI 10.2307/J.CTT1XP3VBC.13; FLETCHER A, 1988, LANCET, V2, P4; GANIATS TG, 1992, MED CARE, V30, P958, DOI 10.1097/00005650-199210000-00008; GELBER RD, 1992, ANN INTERN MED, V116, P961, DOI 10.7326/0003-4819-116-12-961; GINDMAN AB, 1990, MED CARE, V28, P1142; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; GUYATT GH, 1987, AM REV RESPIR DIS, V135, P1069; GUYATT GH, 1985, J CHRON DIS, V38, P517, DOI 10.1016/0021-9681(85)90035-9; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; Guyatt GH, 1991, CONTROLLED CLIN TRIA, V12, p266S; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; LAUPACIS A, 1990, SEMIN NEPHROL, V10, P11; MCCUSKER J, 1984, MED CARE, V22, P789, DOI 10.1097/00005650-198409000-00002; MCDOWELL I, 1987, MEASURING HLTH; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; NORD E, 1991, HEALTH POLICY, V18, P25, DOI 10.1016/0168-8510(91)90141-J; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; Patrick D L, 1992, Pharmacoeconomics, V1, P76, DOI 10.2165/00019053-199201020-00002; PATRICK DL, 1990, ANNU REV PUBL HEALTH, V11, P165; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; PATRICK DL, 1992, HLTH STATUS HLTH POL; ROTHMAN ML, 1991, MED CARE, V29, P115, DOI 10.1097/00005650-199102000-00004; Spilker B., 1990, QUALITY LIFE ASSESSM; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; THOMPSON MS, 1988, J RHEUMATOL, V15, P35; TOEVS CD, 1984, MED CARE, V22, P1088, DOI 10.1097/00005650-198412000-00004; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710	40	2541	2642	4	214	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					622	629		10.7326/0003-4819-118-8-199304150-00009	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8452328				2022-12-28	WOS:A1993KW47000009
J	BAYER, SR; DECHERNEY, AH				BAYER, SR; DECHERNEY, AH			CLINICAL MANIFESTATIONS AND TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-ENDOMETRIUM; BLOOD-LOSS; ESTROGEN; PROGESTERONE; INSULIN; HYPERANDROGENISM; RECEPTOR; WOMEN	Dysfunctional uterine bleeding is a common gynecologic disorder that can affect any woman during her reproductive years. It is a diagnosis of exclusion, and the clinician must proceed through a logical stepwise evaluation to rule out all other causes of the abnormal bleeding. In most cases dysfunctional uterine bleeding is associated with anovulation. During the pubertal and perimenopausal periods, anovulatory bleeding is a common occurrence. During these transitional states, the abnormal bleeding has a physiological basis and is secondary to an estrogen withdrawal. Anovulatory bleeding can also be associated with chronic anovulation. The chronic unopposed estrogen that characterizes this disorder causes a continuous proliferation of the endometrium; this can result in abnormal bleeding and place the patient at risk for endometrial cancer. The goals of treatment for anovulatory bleeding are to stop the acute bleeding, avert future episodes, and prevent long-term complications. In some cases surgical intervention is indicated, but the foundation of treatment has been a medical approach. Several progestational agents have demonstrated effectiveness and can be administered either orally or by intramuscular injection. If the patient fails to have resolution of the bleeding with medical therapy, another cause of the bleeding must be suspected, and reevaluation is necessary.	TUFTS UNIV,SCH MED,DEPT OBSTET & GYNECOL,750 WASHINGTON ST,BOX 36,BOSTON,MA 02111; NEW ENGLAND MEM HOSP,DEPT OBSTET & GYNECOL,STONEHAM,MA	Tufts University			DeCherney, Alan H/AAS-2944-2020					AMBRUS JL, 1971, J MED, V2, P65; BARBIERI RL, 1983, AM J OBSTET GYNECOL, V147, P90, DOI 10.1016/0002-9378(83)90091-1; BARBIERI RL, 1988, FERTIL STERIL, V50, P197; Barer AP, 1936, AM J OBSTET GYNECOL, V31, P979, DOI 10.1016/S0002-9378(36)90820-7; COULAM CB, 1983, OBSTET GYNECOL, V61, P403; DEVORE GR, 1982, OBSTET GYNECOL, V59, P285; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DISAIA PJ, 1989, CLIN GYNECOLOGIC ONC, P162; ELKELES RS, 1968, LANCET, V2, P315; FARHI DC, 1986, OBSTET GYNECOL, V68, P741; FLOWERS CE, 1983, OBSTET GYNECOL, V61, P135; FRASER IS, 1984, AM J OBSTET GYNECOL, V149, P788, DOI 10.1016/0002-9378(84)90123-6; GIVENS JR, 1977, GYNECOLOGIC ENDOCRIN, P127; GRAY N, 1979, J INT MED RES, V7, P96, DOI 10.1177/030006057900700115; GURPIDE E, 1976, J STEROID BIOCHEM, V7, P891, DOI 10.1016/0022-4731(76)90007-8; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HSUEH AJW, 1975, NATURE, V254, P337, DOI 10.1038/254337a0; JOHNSON JF, 1957, P SOC EXP BIOL MED, V94, P92, DOI 10.3181/00379727-94-22864; LEAVITT WW, 1977, ANN NY ACAD SCI, V286, P210, DOI 10.1111/j.1749-6632.1977.tb29418.x; MAKI M, 1969, TOHOKU J EXP MED, V97, P63, DOI 10.1620/tjem.97.63; Mishell D R Jr, 1990, J Reprod Med, V35, P447; NAVOT D, 1986, NEW ENGL J MED, V314, P806, DOI 10.1056/NEJM198603273141302; NOYES RW, 1950, FERTIL STERIL, V1, P3, DOI 10.1016/s0015-0282(16)30062-0; OTTOSSON UB, 1986, AM J OBSTET GYNECOL, V151, P456; PADWICK ML, 1986, FERTIL STERIL, V46, P402; PAVLIK EJ, 1976, J STEROID BIOCHEM, V7, P369, DOI 10.1016/0022-4731(76)90096-0; PORETSKY L, 1987, ENDOCR REV, V8, P132, DOI 10.1210/edrv-8-2-132; SHERMAN BM, 1975, J CLIN INVEST, V55, P699, DOI 10.1172/JCI107979; SMITH S, 1987, FERTIL STERIL, V48, P72; TSENG L, 1979, ENDOCRINOLOGY, V104, P1745, DOI 10.1210/endo-104-6-1745; TSENG L, 1982, J CLIN ENDOCR METAB, V55, P1029, DOI 10.1210/jcem-55-5-1029; Vollman RF., 1977, MENSTRUAL CYCLE; WHITEHEAD MI, 1982, J REPROD MED, V27, P539	33	54	58	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1823	1828						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459515				2022-12-28	WOS:A1993KW25000038
J	VALE, RD				VALE, RD			MEASURING SINGLE PROTEIN MOTORS AT WORK	SCIENCE			English	Article							KINESIN MOLECULES; MOVEMENT; INVITRO; ASSAY				VALE, RD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.							BLOCK SM, 1992, NATURE, V360, P493, DOI 10.1038/360493a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CORDOVA NJ, 1992, P NATL ACAD SCI USA, V89, P339, DOI 10.1073/pnas.89.1.339; DENK W, 1990, APPL OPTICS, V29, P2382, DOI 10.1364/AO.29.002382; FINER J, COMMUNICATION; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I	17	10	10	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					169	170		10.1126/science.8469971	http://dx.doi.org/10.1126/science.8469971			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8469971				2022-12-28	WOS:A1993KW45200025
J	MIKI, T; SMITH, CL; LONG, JE; EVA, A; FLEMING, TP				MIKI, T; SMITH, CL; LONG, JE; EVA, A; FLEMING, TP			ONCOGENE ECT2 IS RELATED TO REGULATORS OF SMALL GTP-BINDING PROTEINS	NATURE			English	Article							EXPRESSION CDNA CLONING; CELL-DIVISION-CYCLE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; HUMAN HOMOLOG; ABL-ONCOGENE; GENE; YEAST; BCR	WE have developed an efficient expression cloning system that allows rapid isolation of complementary DNAs able to induce the transformed phenotype1,2. We searched for molecules expressed in epithelial cells and possessing transforming potential to fibroblasts, and cloned a cDNA for the normal receptor of a growth factor secreted by NIH/3T3 cells3,4. Here we report a second novel transforming gene, ect2. The isolated cDNA is activated by amino-terminal truncation of the normal product. The Ect2 protein has sequence similarity within a central core of 255 amino acids with the products of the breakpoint cluster gene, bcr (ref. 5), the yeast cell cycle gene, CDC24 (ref. 6), and the dbl oncogene7. Each of these genes encodes regulatory molecules or effectors for Rho-like small GTP-binding proteins8-10. The baculovirus-expressed Ect2 protein could bind highly specifically to Rho and Rac proteins, whereas the dbl product showed broader binding specificity to Rho family proteins. Thus ect2 is a new member of an expanding family, whose products have transforming properties and interact with Rho-like proteins of the Ras superfamily.			MIKI, T (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37-1E24,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X; Smith, Cheryl/0000-0003-4323-6382				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS JM, 1992, ONCOGENE, V7, P611; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1991, NATURE, V3546, P3116; HARTWELL LH, 1973, GENETICS, V74, P267; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MIYAMOTO S, 1991, BIOCHEM BIOPH RES CO, V181, P604, DOI 10.1016/0006-291X(91)91233-3; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; RON D, 1991, NEW BIOL, V3, P372; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUMMERS MD, 1987, TEX AGR EXP STN B, P1555; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	27	255	274	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					462	465		10.1038/362462a0	http://dx.doi.org/10.1038/362462a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8464478	Green Published			2022-12-28	WOS:A1993KV42400088
J	PESSI, A; BIANCHI, E; CRAMERI, A; VENTURINI, S; TRAMONTANO, A; SOLLAZZO, M				PESSI, A; BIANCHI, E; CRAMERI, A; VENTURINI, S; TRAMONTANO, A; SOLLAZZO, M			A DESIGNED METAL-BINDING PROTEIN WITH A NOVEL FOLD	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; DENOVO DESIGN; LIGHT CHAIN; SITE; CONFORMATION; EXPRESSION	A MAJOR challenge in protein design is to create stable scaffolds into which tailored functions can be introduced. Here we present the design, synthesis and characterization of a 61-residue all-beta protein: the minibody. We used a portion of the heavy chain variable domain of an immunoglobulin as a template, obtaining a molecule with a novel beta-sheet scaffold and two regions corresponding to the hypervariable loops H1 and H2. To exploit the potential for creating functional centres in the minibody, we engineered a metal-binding site into it. This site is formed by one histidine in H1 and two in H2. The protein is folded, compact and able to bind metal, thus representing the first designed beta-protein with a novel fold and a tailored function. By randomizing the sequence of the hypervariable loops, we are using the minibody scaffold to construct a conformationally constrained peptide library displayed on phage.	IST RIC BIOL MOLEC P ANGELETTI, DEPT GENET, VIA PONTINA KM 306, I-00040 POMEZIA, ITALY; IST RIC BIOL MOLEC P ANGELETTI, DEPT BIOCHEM, I-00040 POMEZIA, ITALY; IST RIC BIOL MOLEC P ANGELETTI, DEPT BIOCOMP, I-00040 POMEZIA, ITALY				Tramontano, anna/D-5378-2009	Tramontano, anna/0000-0002-5610-3338; Bianchi, Elisabetta/0000-0002-5302-6912				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; BIANCHI E, IN PRESS INT J PEPTI; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; FEDOROV AN, 1992, J MOL BIOL, V225, P927, DOI 10.1016/0022-2836(92)90092-X; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; IVERSON BL, 1990, SCIENCE, V249, P659, DOI 10.1126/science.2116666; KANNAN KK, 1975, P NATL ACAD SCI USA, V72, P51, DOI 10.1073/pnas.72.1.51; KUBIAK T, 1987, BIOCHEMISTRY-US, V26, P7849, DOI 10.1021/bi00398a047; LEVITT M, 1977, J MOL BIOL, V114, P181, DOI 10.1016/0022-2836(77)90207-8; LINDSKOG S, 1964, BIOCHIM BIOPHYS ACTA, V85, P462, DOI 10.1016/0926-6569(64)90310-4; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; Pace C N, 1986, Methods Enzymol, V131, P266; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; SARAGOVI HU, 1992, BIO-TECHNOL, V10, P773, DOI 10.1038/nbt0792-773; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; Smith G P, 1991, Curr Opin Biotechnol, V2, P668, DOI 10.1016/0958-1669(91)90032-Z; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001	24	190	212	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	1993	362	6418					367	369		10.1038/362367a0	http://dx.doi.org/10.1038/362367a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455724				2022-12-28	WOS:A1993KU17600069
J	TSAY, YF; SCHROEDER, JI; FELDMANN, KA; CRAWFORD, NM				TSAY, YF; SCHROEDER, JI; FELDMANN, KA; CRAWFORD, NM			THE HERBICIDE SENSITIVITY GENE CHL1 OF ARABIDOPSIS ENCODES A NITRATE-INDUCIBLE NITRATE TRANSPORTER	CELL			English	Article							MAIZE ROOTS; H+-ATPASE; THALIANA; REDUCTASE; SEEDLINGS; SEQUENCE; KINETICS; EXPRESSION; INDUCTION; MUTANTS	This paper reports the identification and functional expression of a gene that is involved in nitrate uptake in plants, a process essential for the assimilation of nitrate and the biological removal of nitrate from the soil solution. The CHL1 gene of Arabidopsis, which when mutated confers resistance to the herbicide chlorate and a decrease in nitrate uptake, was isolated and found to encode a protein with 12 putative membrane-spanning segments. Injection of CHL1 mRNA into Xenopus oocytes produces a nitrate- and pH-dependent membrane depolarization, inward current, and nitrate uptake. These data show that the CHL1 gene encodes an electrogenic nitrate transporter. CHL1 mRNA is found predominantly in roots and displays nitrate- and pH-dependent regulation.	UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; UNIV ARIZONA, DEPT PLANT SCI, TUCSON, AZ 85721 USA	University of California System; University of California San Diego; University of Arizona	TSAY, YF (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.		Geenen, Rinie/G-3408-2012; Tsay, Yi-Fang/ABB-3662-2021	Tsay, Yi-Fang/0000-0003-4271-0687	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040672, R29GM040672] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40672] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERG B, 1947, ANN R AGR COLL SWEDE, V15, P37; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BRAAKSMA FJ, 1982, THEOR APPL GENET, V64, P83, DOI 10.1007/BF00303657; CABOCHE M, 1990, TRENDS GENET, V6, P187, DOI 10.1016/0168-9525(90)90175-6; CAO YW, 1992, PLANT CELL, V4, P961, DOI 10.1105/tpc.4.8.961; CHASAN R, 1992, PLANT CELL, V4, P1180; Crawford N. M., 1992, Genetic engineering: principles and methods. Volume 14., P89; CRAWFORD NM, 1990, PLANT CELL, V2, P829; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DEWITT ND, 1991, PLANT J, V1, P121, DOI 10.1111/j.1365-313X.1991.00121.x; DODDEMA H, 1979, PHYSIOL PLANTARUM, V45, P332, DOI 10.1111/j.1399-3054.1979.tb02593.x; DODDEMA H, 1978, PHYSIOL PLANTARUM, V43, P343, DOI 10.1111/j.1399-3054.1978.tb01592.x; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FELDMANN KA, 1989, SCIENCE, V243, P1351, DOI 10.1126/science.243.4896.1351; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; GLASS ADM, 1992, PLANT PHYSIOL, V99, P456, DOI 10.1104/pp.99.2.456; GOYAL SS, 1986, PLANT CELL ENVIRON, V9, P209, DOI 10.1111/1365-3040.ep11611654; HARPER JF, 1990, J BIOL CHEM, V265, P13601; HARPER JF, 1989, P NATL ACAD SCI USA, V86, P1234, DOI 10.1073/pnas.86.4.1234; Haynes R., 1986, MINERAL NITROGEN PLA; HOLE DJ, 1990, PLANT PHYSIOL, V93, P642, DOI 10.1104/pp.93.2.642; HUMBURG NE, 1909, HERBICIDE HDB WEED S; JACKSON WA, 1973, PLANT PHYSIOL, V51, P120, DOI 10.1104/pp.51.1.120; Kleinhofs A., 1990, BIOCH PLANTS, P89, DOI [DOI 10.1016/B978-0-08-092616-2.50009-7, 10.1016/B978-0-08-092616-2.50009-7]; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABRIE ST, 1992, MOL GEN GENET, V233, P169, DOI 10.1007/BF00587576; Larsson C. M., 1989, Molecular and genetic aspects of nitrate assimilation., P3; MACKOWN CT, 1988, PLANT PHYSIOL, V87, P162, DOI 10.1104/pp.87.1.162; MARKS MD, 1987, PLANT MOL BIOL, V10, P91, DOI 10.1007/BF00016147; MCCLURE PR, 1990, PLANT PHYSIOL, V93, P281, DOI 10.1104/pp.93.1.281; NEHER E, 1992, SCIENCE, V256, P498, DOI 10.1126/science.1373906; NOJI S, 1989, FEBS LETT, V252, P139, DOI 10.1016/0014-5793(89)80906-8; OOSTINDI.FJ, 1973, MUTAT RES, V19, P175, DOI 10.1016/0027-5107(73)90076-6; REDINBAUGH MG, 1991, PHYSIOL PLANTARUM, V82, P640, DOI 10.1111/j.1399-3054.1991.tb02958.x; Saier MH, 1991, CURR OPIN STRUC BIOL, V1, P362, DOI 10.1016/0959-440X(91)90034-Q; SAKMANN B, 1992, SCIENCE, V256, P503, DOI 10.1126/science.1373907; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; SCHACHTMAN DP, 1992, IN PRESS SCIENCE; SCHOLTEN HJ, 1986, PHYSIOL PLANTARUM, V66, P265, DOI 10.1111/j.1399-3054.1986.tb02418.x; SCHROEDER JI, 1989, TRENDS BIOCHEM SCI, V14, P187, DOI 10.1016/0968-0004(89)90272-7; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; SHEPHERD GM, 1991, CELL, V67, P845, DOI 10.1016/0092-8674(91)90358-6; SIDDIQI MY, 1990, PLANT PHYSIOL, V93, P1426, DOI 10.1104/pp.93.4.1426; SIDDIQI MY, 1989, PLANT PHYSIOL, V90, P806, DOI 10.1104/pp.90.3.806; STIMMANN M W, 1990, California Agriculture, V44, P12; SUSSMAN MR, 1992, SCIENCE, V256, P619, DOI 10.1126/science.256.5057.619; TEYKER RH, 1988, PLANT PHYSIOL, V86, P778, DOI 10.1104/pp.86.3.778; THAYER JR, 1980, ANAL BIOCHEM, V102, P110, DOI 10.1016/0003-2697(80)90325-5; THOMAS RC, 1989, NATURE, V337, P601, DOI 10.1038/337601a0; ULLRICH WR, 1981, PLANT SCI LETT, V22, P211, DOI 10.1016/0304-4211(81)90233-9; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WILKINSON JQ, 1991, PLANT CELL, V3, P461, DOI 10.1105/tpc.3.5.461; Wray J.L., 1989, MOL GENETIC ASPECTS; WRIGHT EM, 1991, J CLIN INVEST, V88, P1435, DOI 10.1172/JCI115451	60	573	627	8	131	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 12	1993	72	5					705	713		10.1016/0092-8674(93)90399-B	http://dx.doi.org/10.1016/0092-8674(93)90399-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453665	Bronze			2022-12-28	WOS:A1993KR43600007
J	ROSEN, DR; SIDDIQUE, T; PATTERSON, D; FIGLEWICZ, DA; SAPP, P; HENTATI, A; DONALDSON, D; GOTO, J; OREGAN, JP; DENG, HX; RAHMANI, Z; KRIZUS, A; MCKENNAYASEK, D; CAYABYAB, A; GASTON, SM; BERGER, R; TANZI, RE; HALPERIN, JJ; HERZFELDT, B; VANDENBERGH, R; HUNG, WY; BIRD, T; DENG, G; MULDER, DW; SMYTH, C; LAING, NG; SORIANO, E; PERICAKVANCE, MA; HAINES, J; ROULEAU, GA; GUSELLA, JS; HORVITZ, HR; BROWN, RH				ROSEN, DR; SIDDIQUE, T; PATTERSON, D; FIGLEWICZ, DA; SAPP, P; HENTATI, A; DONALDSON, D; GOTO, J; OREGAN, JP; DENG, HX; RAHMANI, Z; KRIZUS, A; MCKENNAYASEK, D; CAYABYAB, A; GASTON, SM; BERGER, R; TANZI, RE; HALPERIN, JJ; HERZFELDT, B; VANDENBERGH, R; HUNG, WY; BIRD, T; DENG, G; MULDER, DW; SMYTH, C; LAING, NG; SORIANO, E; PERICAKVANCE, MA; HAINES, J; ROULEAU, GA; GUSELLA, JS; HORVITZ, HR; BROWN, RH			MUTATIONS IN CU/ZN SUPEROXIDE-DISMUTASE GENE ARE ASSOCIATED WITH FAMILIAL AMYOTROPHIC-LATERAL-SCLEROSIS	NATURE			English	Article							MOTOR NEURON DISEASE; DOWNS-SYNDROME; SACCHAROMYCES-CEREVISIAE; NEUROMUSCULAR-JUNCTION; ESCHERICHIA-COLI; LINKAGE ANALYSIS; TRANSGENIC MICE; MONOSOMY-21; RESOLUTION; PATHOLOGY	AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3. About 10% of cases are inherited as an autosomal dominant trait, with high penetrance after the sixth decade4,5. In most instances, sporadic and autosomal dominant familial ALS (FALS) are clinically similar4,6,7. We have previously shown that in some but not all FALS pedigrees the disease is linked to a genetic defect on chromosome 21q (refs 8, 9). Here we report tight genetic linkage between FALS and a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion O2.- to O2 and H2O2 (ref. 10). Given this linkage and the potential role of free radical toxicity in other neurodenegerative disorders11, we investigated SOD1 as a candidate gene in FALS. We identified 11 different SOD1 missense mutations in 13 different FALS families.	MASSACHUSETTS GEN HOSP, DAY NEUROMUSCULAR RES LAB,ROOM 6627,MGH-E, BLDG 149,13TH ST, BOSTON, MA 02129 USA; NORTHWESTERN UNIV, SCH MED, DEPT NEUROL, CHICAGO, IL 60611 USA; ELEANOR ROOSEVELT INST CANC RES, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80206 USA; MCGILL UNIV, CTR RES NEUROSCI, MONTREAL H3A 2T5, QUEBEC, CANADA; MONTREAL GEN HOSP, RES INST, MONTREAL H3G 1A4, QUEBEC, CANADA; MIT, DEPT BIOL, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; MASSACHUSETTS GEN HOSP, CTR NEUROSCI, GENET & AGING LAB, BOSTON, MA 02129 USA; NORTHSHORE UNIV HOSP, DEPT NEUROL, MANHASSET, NY 11030 USA; UNIV ZIEKENHUIZEN, DEPT NEUROL, B-3000 LOUVAIN, BELGIUM; UNIV WASHINGTON, SCH MED, DEPT NEUROL, SEATTLE, WA 98195 USA; MAYO CLIN & MAYO FDN, DEPT NEUROL, ROCHESTER, MN 55905 USA; AUSTRALIAN NEUROMUSCULAR RES INST, NEDLANDS, WA, AUSTRALIA; DUKE UNIV, MED CTR, DEPT MED NEUROL, DURHAM, NC 27710 USA; MASSACHUSETTS GEN HOSP, CTR NEUROSCI, MOLEC NEUROGENET LAB, BOSTON, MA 02129 USA	Harvard University; Massachusetts General Hospital; Northwestern University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; McGill University; McGill University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; University of Washington; University of Washington Seattle; Mayo Clinic; University of Western Australia; Duke University; Harvard University; Massachusetts General Hospital			Tanzi, Rudolph/AAE-9622-2019; Gaston, Sandra/AAN-4088-2021; Haines, Jonathan/C-3374-2012; Siddique, Teepu/AAT-8166-2021; halperin, john/X-6433-2019	Tanzi, Rudolph/0000-0002-7032-1454; Haines, Jonathan/0000-0002-4351-4728; halperin, john/0000-0003-1170-1710; Deng, Han-Xiang/0000-0002-0030-8465; Laing, Nigel/0000-0001-5111-3732; Siddique, Teepu/0000-0001-7293-9146				ACKERMAN AD, 1988, NEW ENGL J MED, V318, P1666, DOI 10.1056/NEJM198806233182506; AVRAHAM KB, 1991, J NEUROCYTOL, V20, P208, DOI 10.1007/BF01186993; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BEWLEY GC, 1988, NUCLEIC ACIDS RES, V16, P2728, DOI 10.1093/nar/16.6.2728; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHANG EC, 1991, J BIOL CHEM, V266, P4417; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; CREAGAN R, 1973, HUMANGENETIK, V20, P203, DOI 10.1007/BF00385731; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DRYJA TP, 1989, NATURE, V339, P556, DOI 10.1038/339556a0; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; HALLEWELL RA, 1986, SUPEROXIDE DISMUTASE, P249; HENDRICKSON DJ, 1990, GENOMICS, V8, P736, DOI 10.1016/0888-7543(90)90264-U; HENKLE KJ, 1991, INFECT IMMUN, V59, P2063, DOI 10.1128/IAI.59.6.2063-2069.1991; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; HORTON WA, 1976, NEUROLOGY, V26, P460, DOI 10.1212/WNL.26.5.460; HUSQUINET H, 1980, CLIN GENET, V18, P109; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; KITAGAWA Y, 1991, J BIOCHEM-TOKYO, V109, P477, DOI 10.1093/oxfordjournals.jbchem.a123407; KURLAND LT, 1957, P STAFF M MAYO CLIN, V32, P449; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; MINOTTI G, 1987, CHEM PHYS LIPIDS, V44, P191, DOI 10.1016/0009-3084(87)90050-8; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; Muller H.J, 1932, P 6 INT C GEN, V1, P213; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OTT J, 1976, AM J HUM GENET, V28, P528; OTT J, 1991, ANAL HUMAN GENETIC L, P203; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; PARK EC, 1986, GENETICS, V113, P821; PERLTREVES R, 1988, PLANT MOL BIOL, V11, P609, DOI 10.1007/BF00017461; PHILLIPS JP, 1989, P NATL ACAD SCI USA, V86, P2761, DOI 10.1073/pnas.86.8.2761; REYNOLDS JF, 1985, AM J MED GENET, V20, P173, DOI 10.1002/ajmg.1320200121; RICHARDSON JS, 1975, P NATL ACAD SCI USA, V72, P1349, DOI 10.1073/pnas.72.4.1349; ROSEN DR, 1992, HUM MOL GENET, V1, P547, DOI 10.1093/hmg/1.7.547; SHOULSON I, 1992, ANN NY ACAD SCI, V648, P37, DOI 10.1111/j.1749-6632.1992.tb24522.x; SIDDIQUE T, 1989, NEUROLOGY, V39, P919, DOI 10.1212/WNL.39.7.919; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; SWERTS L, 1976, J GENET HUM, V24, P247; TANDAN R, 1985, ANN NEUROL, V18, P419, DOI 10.1002/ana.410180402; TANDAN R, 1985, ANN NEUROL, V18, P271, DOI 10.1002/ana.410180302; WISNIEWSKI K, 1983, CLIN GENET, V23, P102; YAROM R, 1988, J NEUROL SCI, V88, P41, DOI 10.1016/0022-510X(88)90204-3	47	5239	5395	14	698	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	1993	362	6415					59	62		10.1038/362059a0	http://dx.doi.org/10.1038/362059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8446170				2022-12-28	WOS:A1993KP97600059
J	WATERHOUSE, J				WATERHOUSE, J			ABC OF SLEEP DISORDERS - CIRCADIAN-RHYTHMS	BRITISH MEDICAL JOURNAL			English	Article											WATERHOUSE, J (corresponding author), UNIV MANCHESTER,DEPT PHYSIOL SCI,MANCHESTER M13 9PL,LANCS,ENGLAND.							AKERSTEDT T, 1981, SLEEP, V4, P159, DOI 10.1093/sleep/4.2.159; ARENDT J, 1986, BRIT MED J, V292, P1170, DOI 10.1136/bmj.292.6529.1170; CZEISLER CA, 1980, SCIENCE, V210, P1264, DOI 10.1126/science.7434029; CZEISLER CA, 1981, PHOTOCHEM PHOTOBIOL, V34, P239; FROBERG JE, 1975, BIOL PSYCHOL, V2, P175, DOI 10.1016/0301-0511(75)90018-6; KLEIN, 1976, AVIATION SPACE ENV M, V47, P221; MORGAN BB, 1974, 742 INT TECHN REP, P21; Rutenfranz J., 1975, EXPT STUDIES SHIFTWO, P20; WATERHOUSE JM, 1990, YOUR BODY CLOCK	9	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					448	451		10.1136/bmj.306.6875.448	http://dx.doi.org/10.1136/bmj.306.6875.448			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461731	Green Published, Bronze			2022-12-28	WOS:A1993KM70000030
J	CHEUNG, NT; COLEY, S; SHEERAN, T; SITUNAYAKE, RD				CHEUNG, NT; COLEY, S; SHEERAN, T; SITUNAYAKE, RD			SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC-HORMONE INDUCED BY DICLOFENAC	BRITISH MEDICAL JOURNAL			English	Letter											CHEUNG, NT (corresponding author), DUDLEY RD GEN HOSP,DEPT RHEUMATOL,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							BLUM M, 1980, RHEUMATOL REHABIL, V19, P258, DOI 10.1093/rheumatology/19.4.258; DUNN AM, 1986, BRIT MED J, V293, P202, DOI 10.1136/bmj.293.6540.202-c; PETERSSON I, 1987, ACTA MED SCAND, V221, P221	3	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					186	186		10.1136/bmj.306.6871.186-a	http://dx.doi.org/10.1136/bmj.306.6871.186-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443484	Green Published, Bronze			2022-12-28	WOS:A1993KH51300025
J	KINMOND, S; AITCHISON, TC; HOLLAND, BM; JONES, JG; TURNER, TL; WARDROP, CAJ				KINMOND, S; AITCHISON, TC; HOLLAND, BM; JONES, JG; TURNER, TL; WARDROP, CAJ			UMBILICAL-CORD CLAMPING AND PRETERM INFANTS - A RANDOMIZED TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-DISTRESS; PLACENTAL TRANSFUSION; PREMATURE-INFANTS; NEWBORN-INFANTS; CELL VOLUME; BLOOD	Objective-To investigate the clinical effects of regulating umbilical cord clamping in preterm infants. Design-A prospective randomised study. Setting-The Queen Mother's Hospital, Glasgow. Subjects-36 vaginally delivered infants over 27 and under 33 weeks' gestation. Intervention-Holding the infant 20 cm below the introitus for 30 seconds before clamping the umbilical cord (''regulated'' group, 17 patients), or conventional management (''random'' group, 19 patients). Main outcome measures-Initial packed cell volume, peak serum bilirubin concentrations, red cell transfusion requirements, and respiratory impairment (assessed by ventilatory requirements, arterial-alveolar oxygen tension ratio over the first day in ventilated infants, and duration of dependence on supplemental oxygen). Results-There were statistically significant differences between the two groups in mean initial packed cell volume (regulated group 0.564, random group 0.509) and median red cell transfusion requirements (regulated group zero, random group 23 ml/kg). 13 infants from each group underwent mechanical ventilation and showed significant differences in mean minimum arterial-alveolar oxygen tension ratio on the first day (regulated group 0.42, random group 0.22) and in median duration of dependence on supplemental oxygen (regulated group three days, random group 10 days). Differences in final outcome measures such as duration of supplemental oxygen dependence and red cell transfusion requirements were mediated primarily through arterial-alveolar oxygen tension ratio and also packed cell volume. Conclusions-This intervention at preterm deliveries produces clinical and economic benefits.	UNIV GLASGOW, QUEEN MOTHERS HOSP, DEPT CHILD HLTH, GLASGOW G12 8QQ, SCOTLAND; UNIV GLASGOW, DEPT STAT, GLASGOW G12 8QQ, SCOTLAND; UNIV WALES COLL CARDIFF, DEPT BIOCHEM, CARDIFF CF1 3NS, S GLAM, WALES; UNIV WALES COLL MED, DEPT HAEMATOL, CARDIFF CF4 4XN, S GLAM, WALES	University of Glasgow; University of Glasgow; Cardiff University; Cardiff University			Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713				BOUND JP, 1962, LANCET, V1, P1200; BROWN EG, 1975, J PEDIATR-US, V87, P1133, DOI 10.1016/S0022-3476(75)80127-2; BUCKELS LJ, 1965, J PEDIATR-US, V67, P239, DOI 10.1016/S0022-3476(65)80246-3; CLAPP DW, 1989, J LAB CLIN MED, V113, P422; DUNN PM, 1985, PERINATAL MED, P47; DUNN PM, 1973, PERINATAL MED, P138; FANAROFF AA, 1990, YB NEONATAL PERINATA, P234; FAXELIUS G, 1977, J PEDIATR-US, V90, P273, DOI 10.1016/S0022-3476(77)80650-1; FRANK DJ, 1967, AM J OBSTET GYNECOL, V97, P1142, DOI 10.1016/0002-9378(67)90479-6; GILBERT R, 1974, AM REV RESPIR DIS, V109, P142; GUNTHER M, 1957, LANCET, V1, P1277, DOI 10.1016/S0140-6736(57)92302-4; HOFMEYR GJ, 1988, S AFR MED J, V73, P104; Holland BM, 1991, PERINATAL HAEMATOLOG, P121; HUDSON IR, 1990, PEDIATR RES, V27, pA209; INALL JA, 1965, ARCH DIS CHILD, V40, P480, DOI 10.1136/adc.40.213.480; JAYKKA S, 1958, Acta Paediatr, V47, P484; JONES JG, 1990, BRIT J HAEMATOL, V76, P288, DOI 10.1111/j.1365-2141.1990.tb07886.x; LINDERKAMP O, 1978, EUR J PEDIATR, V129, P167, DOI 10.1007/BF00442160; LINDERKAMP O, 1982, CLIN PERINATOL, V9, P559, DOI 10.1016/S0095-5108(18)31013-3; MOSS AJ, 1963, JAMA-J AM MED ASSOC, V184, P48, DOI 10.1001/jama.1963.73700140001016; MOSS AJ, 1967, PEDIATRICS, V40, P109; PELTONEN T, 1981, EUR J PEDIATR, V137, P141; PRENDIVILLE W, 1989, EFFECTIVE CARE PREGN, P1145; SAIGAL S, 1972, PEDIATRICS, V49, P406; SAIGAL S, 1977, BIOL NEONATE, V32, P62; SOLA A, 1992, LANCET, V340, P1363; TARNOWMORDI W, 1990, BRIT MED J, V300, P1611, DOI 10.1136/bmj.300.6740.1611; TAYLOR PM, 1963, AM J OBSTET GYNECOL, V86, P893; USHER RH, 1975, BIOL NEONATE, V26, P241; VONENGEL G, 1885, ZNETRALBLATT GYNAKOL, V9, P721; YAO AC, 1969, ACTA PAEDIATR SCAND, V58, P561, DOI 10.1111/j.1651-2227.1969.tb04762.x; 1990, PROTOCOL; 1989, REFERENCE MANUAL, P6	33	131	133	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	1993	306	6871					172	175		10.1136/bmj.306.6871.172	http://dx.doi.org/10.1136/bmj.306.6871.172			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443480	Bronze, Green Published			2022-12-28	WOS:A1993KH51300020
J	WILSON, DH				WILSON, DH			EDUCATION AND TRAINING OF PREREGISTRATION HOUSE OFFICERS - THE CONSULTANTS VIEWPOINT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the opinions, attitudes, and requirements of consultants responsible for preregistration house officers in the light of the General Medical Council's Recommendations on General Clinical Training. Design-A questionnaire was piloted asking 28 questions under the headings professional details, present training arrangements, effectiveness of current training, and perceived help required for implementing the recommendations. Setting-Two teaching hospitals and nine district general hospitals in the Yorkshire region. Subjects-33 consultants (19 physicians, 14 surgeons) responded to an hour long interview. Results-The traditional teaching ward round, with clinical meetings, was the main educational provision for house officers. Under a quarter of respondents provided specific teaching, which rarely exceeded 30 minutes weekly. Many delegated teaching to other junior or non-medical staff. Few consultants assessed the effectiveness of teaching, and feedback to juniors was rudimentary. There was strong support for the apprenticeship system and concern that it should not be downgraded. Appointing educational supervisors and introducing a structured educational programme were approved theoretically. Pressure on consultants to work faster, participate in audit and management, and accept financial responsibility for their clinical work, coupled with the reduction in junior doctors' hours, were considered to militate against educational developments. Many respondents felt frustrated and powerless. They would welcome an increased educational role but considered there must be conceptual, contractual, and financial changes. Conclusions-Fundamental changes are required by both consultants and management before the preregistration year can have proper educational value. Training in educational methods for consultants and a structured curriculum and formative assessment for trainees require recognition and financial support.	UNIV LEEDS,DEPT POSTGRAD MED EDUC,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds								1992, RECOMMENDATIONS GENE	1	13	13	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					194	196		10.1136/bmj.306.6871.194	http://dx.doi.org/10.1136/bmj.306.6871.194			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443488	Green Published, Bronze			2022-12-28	WOS:A1993KH51300030
J	BURRIS, JF				BURRIS, JF			AIDS AND THE COMMON MAN	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											BURRIS, JF (corresponding author), GEORGETOWN UNIV, MED CTR, NE 120 MED DENT, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					819	819		10.7326/0003-4819-118-10-199305150-00009	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	8470855				2022-12-28	WOS:A1993LB64900009
J	ORCI, L; PALMER, DJ; RAVAZZOLA, M; PERRELET, A; AMHERDT, M; ROTHMAN, JE				ORCI, L; PALMER, DJ; RAVAZZOLA, M; PERRELET, A; AMHERDT, M; ROTHMAN, JE			BUDDING FROM GOLGI MEMBRANES REQUIRES THE COATOMER COMPLEX OF NON-CLATHRIN COAT PROTEINS	NATURE			English	Article							BREFELDIN-A; BINDING PROTEIN; BETA-COP; TRANSPORT; VESICLES; STACK; APPARATUS; CELLS; PITS	DO the coats on vesicles budded from the Golgi apparatus actually cause the budding, or do they simply coat buds (Fig. 1)? One view (the membrane-mediated budding hypothesis1) is that budding is an intrinsic property of Golgi membranes not requiring extrinsic coat proteins. Assembly of coats from dispersed subunits is superimposed upon the intrinsic budding process and is proposed to convert the tips of tubules into vesicles. The alternative view (the coat-mediated budding hypothesis1) is that coat formation provides the essential driving force for budding. The membrane-mediated budding hypothesis was inspired by the microtubule-dependent extension of apparently uncoated, 90-nm-diameter membrane tubules from the Golgi apparatus2 and other organelles3-5 in vivo after treatment with brefeldin A, a drug that inhibits the assembly of coat proteins onto Golgi membranes6-9. This hypothesis predicts that tubules will be extended when coat proteins are unavailable to convert tubule-derived membrane into vesicles. Here we use a cell-free system in which coated vesicles are formed from Golgi cisternae to show that, on the contrary, when budding diminishes as a result of immunodepletion of coat protein pools, tubules are not formed at the expense of vesicles. We conclude that coat proteins are required for budding from Golgi membranes.	SLOAN KETTERING INST CANC RES, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	ORCI, L (corresponding author), UNIV GENEVA, SCH MED, INST HISTOL & EMBRYOL, 1 RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND.							ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; CLUETT EB, 1993, J CELL BIOL, V120, P15, DOI 10.1083/jcb.120.1.15; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PALMER DJ, IN PRESS J BIOL CHEM; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SMYTHE E, 1989, J CELL BIOL, V108, P843, DOI 10.1083/jcb.108.3.843; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	30	147	148	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 15	1993	362	6421					648	652		10.1038/362648a0	http://dx.doi.org/10.1038/362648a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8464517				2022-12-28	WOS:A1993KX43800054
J	ARSUAGA, JL; MARTINEZ, I; GRACIA, A; CARRETERO, JM; CARBONELL, E				ARSUAGA, JL; MARTINEZ, I; GRACIA, A; CARRETERO, JM; CARBONELL, E			3 NEW HUMAN SKULLS FROM THE SIMA-DE-LOS-HUESOS MIDDLE-PLEISTOCENE SITE IN SIERRA-DE-ATAPUERCA, SPAIN	NATURE			English	Article							DENTAL REMAINS; IBEAS SPAIN; EVOLUTION; REGION; SAMPLE; HOMO	THREE important fossil hominids were found in July 1992 in the Middle Pleistocene cave site called Sima de los Huesos (Sierra de Atapuerca, Burgos, Northern Spain). One is a complete calvaria (cranium 4), the second a virtually complete cranium (cranium 5), the third represents a more fragmentary cranium of an immature individual (cranium 6). There is a large difference in size between the two adult specimens (for example endocranial volume 1,125 cm3 versus 1,390 cm3). The Atapuerca human remains are dated to >300,000 years. The Atapuerca cranial sample fits within the 'archaic Homo sapiens' group, but is well differentiated from the Asian Homo erectus group. The extensive Atapuerca human collection is the most complete sample of Middle Pleistocene humans yet discovered from one site, and appears to document an early stage in Neanderthal evolution.	UNIV ROVIRA & VIRGILI,ARQUEOL LAB,TARRAGONA,SPAIN	Universitat Rovira i Virgili	ARSUAGA, JL (corresponding author), UNIV COMPLUTENSE MADRID,DEPT PALEONTOL,E-28040 MADRID,SPAIN.		Carretero, José-Miguel/AAN-1926-2020; Díaz, José-Miguel Carretero/L-1703-2018; Klein, Richard G/B-5910-2009; Carbonell, Eudald/G-3003-2015	Carretero, José-Miguel/0000-0003-0409-8087; Díaz, José-Miguel Carretero/0000-0003-0409-8087; Arsuaga, Juan Luis/0000-0001-5361-2295; martinez, ignacio/0000-0002-1835-9199				AGUIRRE E, 1991, J HUM ECOL, V2, P227; Andrews P., 1984, Courier Forschungsinstitut Senckenberg, V69, P167; ARSUAGA JL, 1991, J HUM EVOL, V20, P191, DOI 10.1016/0047-2484(91)90073-5; ARSUAGA JL, 1990, HUM EVOL, V5, P505; BRAUER G, 1992, J HUM EVOL, V22, P79, DOI 10.1016/0047-2484(92)90032-5; Cervera J., 1992, Revista Espanola de Paleontologia, P21; DECASTRO JMB, 1986, J HUM EVOL, V15, P265; DECASTRO JMB, 1988, J HUM EVOL, V17, P279; Heim J.-L., 1976, HOMMES FOSSILES FERR; HEIM J-L, 1989, Bulletins et Memoires de la Societe d'Anthropologie de Paris, V1, P95, DOI 10.3406/bmsap.1989.1702; HOWELL FC, 1960, CURR ANTHROPOL, V1, P195, DOI 10.1086/200100; Howells W. W., 1973, PAPERS PEABODY MUSEU; HUBLIN JJ, 1982, GEOBIOS MEM SPEC, V6, P345; KENNEDY GE, 1991, J HUM EVOL, V20, P375, DOI 10.1016/0047-2484(91)90006-H; KENNEDY KAR, 1991, AM J PHYS ANTHROPOL, V86, P175; PEREZ PJ, 1989, PALEOPATH, V3, P15; POPE GG, 1991, J HUM EVOL, V21, P189, DOI 10.1016/0047-2484(91)90061-Y; POPE GG, 1992, YEARB PHYS ANTHROPOL, V35, P243; ROSAS A, 1991, ANTHROPOLOGIE, V95, P89; ROSAS A, 1987, J HUM EVOL, V16, P417, DOI 10.1016/0047-2484(87)90070-4; SMITH FH, 1980, AM J PHYS ANTHROPOL, V53, P589, DOI 10.1002/ajpa.1330530414; Stringer C.B., 1991, ORIGINES HOMO SAPIEN, P49; STRINGER CB, 1979, J ARCHAEOL SCI, V6, P235, DOI 10.1016/0305-4403(79)90002-5; TIANYUAN L, 1992, Nature (London), V357, P404, DOI 10.1038/357404a0; TORRES T, 1988, B GEOL MIN S, V99; Trinkaus, 2014, SHANIDAR NEANDERTALS	26	193	197	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					534	537		10.1038/362534a0	http://dx.doi.org/10.1038/362534a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KW453	8464493				2022-12-28	WOS:A1993KW45300051
J	FUCHS, VR				FUCHS, VR			DEAR CLINTON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									STANFORD UNIV,DEPT ECON,STANFORD,CA 94305; STANFORD UNIV,DEPT HLTH RES & POLICY,STANFORD,CA 94305	Stanford University; Stanford University	FUCHS, VR (corresponding author), NATL BUR ECON RES,204 JUNIPERO SERRA BLVD,STANFORD,CA 94305, USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1678	1679		10.1001/jama.269.13.1678	http://dx.doi.org/10.1001/jama.269.13.1678			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV349	8455302				2022-12-28	WOS:A1993KV34900034
J	DURANT, RH; RICKERT, VI; ASHWORTH, CS; NEWMAN, C; SLAVENS, G				DURANT, RH; RICKERT, VI; ASHWORTH, CS; NEWMAN, C; SLAVENS, G			USE OF MULTIPLE-DRUGS AMONG ADOLESCENTS WHO USE ANABOLIC-STEROIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-SCHOOL-STUDENTS; SEXUAL-BEHAVIOR; FEMALE ADOLESCENTS; KNOWLEDGE; PREVALENCE; PREDICTORS; EDUCATION	Background. Because adolescent users of anabolic steroids are concerned with increasing muscle size and strength, they may be unique among substance users and unlikely to use other drugs. Alternatively, if the factors that cause the use of anabolic steroids are similar to those associated with the use of other substances, adolescents who use anabolic steroids would be expected to report use of other drugs as well. Methods. We administered a questionnaire based on the 1989 Secondary School Health Risk Survey and the 1990 Youth Risk Behavior Survey of the Centers for Disease Control and Prevention to 1881 students enrolled in compulsory health-science classes (mean [+/-SD] age, 14.9 +/- 1.0 years) in the Richmond County, Georgia, school system. Results. A higher percentage of boys (6.5 percent) than girls (1.9 percent, P less-than-or-equal-to 0.001) reported using anabolic steroids without a doctor's prescription. Among ninth-grade students, 5.4 percent of boys and 1.5 percent of girls reported using anabolic steroids (P less-than-or-equal-to 0.001). Among users of anabolic steroids, 25 percent reported sharing needles to inject drugs. The frequency of anabolic-steroid use was significantly (P<0.001) associated with the frequency of use in the previous 30 days of cocaine (r = 0.44), injectable drugs, alcohol (r = 0.23), marijuana (r = 0.42), cigarettes (r = 0.25), and smokeless tobacco (r = 0.40). On the basis of multiple regression analysis, the use of marijuana, shared needles, smokeless tobacco, and cocaine accounted for 33 percent of the variation in anabolic-steroid use among the ninth-grade students. Conclusions. In our study, adolescent users of anabolic steroids were likely to use other drugs as well, and many were sharing needles.	MED COLL GEORGIA, DEPT INTERNAL MED, AUGUSTA, GA 30912 USA; UNIV ALABAMA, DEPT PEDIAT, BIRMINGHAM, AL 35294 USA; UNIV ARKANSAS MED SCI HOSP, ARKANSAS CHILDRENS HOSP, DEPT PEDIAT, LITTLE ROCK, AR 72205 USA	University System of Georgia; Augusta University; University of Alabama System; University of Alabama Birmingham; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	DURANT, RH (corresponding author), MED COLL GEORGIA, DEPT PEDIAT, GEN PEDIAT & ADOLESCENT MED SECT, CE-112, AUGUSTA, GA 30912 USA.							ANDERSON JE, 1990, FAM PLANN PERSPECT, V22, P252, DOI 10.2307/2135681; [Anonymous], 1984, BEHAV HLTH HDB HLTH; ASHWORTH CS, 1992, J ADOLESCENT HEALTH, V13, P582, DOI 10.1016/1054-139X(92)90372-I; BOTVIN GJ, 1989, J DEV BEHAV PEDIATR, V10, P181; BUCKLEY W E, 1988, Journal of the American Medical Association, V260, P3441, DOI 10.1001/jama.260.23.3441; BURKETT LN, 1984, PHYSICIAN SPORTSMED, V12, P69; DICLEMENTE RJ, 1991, J ADOLESCENT HEALTH, V12, P385, DOI 10.1016/0197-0070(91)90052-N; DURANT RH, 1992, J ADOLESCENT HEALTH, V13, P499, DOI 10.1016/1054-139X(92)90014-3; DURANT RH, 1992, J SCHOOL HEALTH, V62, P59, DOI 10.1111/j.1746-1561.1992.tb07886.x; DURANT RH, 1990, PEDIATRICS, V85, P1051; GIANNINI AJ, 1991, CLIN PEDIATR, V30, P538, DOI 10.1177/000992289103000903; GOLDBERG L, 1990, NEW ENGL J MED, V322, P775; GOLDBERG L, 1991, PEDIATRICS, V87, P283; GOLDBERG L, 1990, J ADOLESCENT HEALTH, V11, P210, DOI 10.1016/0197-0070(90)90350-B; HALLAGAN JB, 1990, NEW ENGL J MED, V322, P776; HALLAGAN JB, 1989, NEW ENGL J MED, V321, P1042, DOI 10.1056/NEJM198910123211510; JOHNSON MD, 1990, PEDIATR CLIN N AM, V37, P1111; JOHNSON MD, 1989, PEDIATRICS, V83, P921; KANN L, 1989, J SCHOOL HEALTH, V59, P55, DOI 10.1111/j.1746-1561.1989.tb05392.x; KASHKIN KB, 1989, JAMA-J AM MED ASSOC, V262, P3166, DOI 10.1001/jama.262.22.3166; KOLBE LJ, 1990, HLTH ED, V21, P44; KOMOROSKI EM, 1992, AM J DIS CHILD, V146, P823, DOI 10.1001/archpedi.1992.02160190055019; NEMECHEK PM, 1991, NEW ENGL J MED, V325, P357; NEWMAN C, IN PRESS J AIDS ED; PENDERGRAST RA, 1992, J ADOLESCENT HEALTH, V13, P133, DOI 10.1016/1054-139X(92)90080-U; POPE HG, 1988, PHYSICIAN SPORTSMED, V16, P75, DOI 10.1080/00913847.1988.11709554; RICKERT VI, 1990, MED CLIN N AM, V74, P1135, DOI 10.1016/S0025-7125(16)30507-7; SKLAREK HM, 1984, NEW ENGL J MED, V311, P1701; TAYLOR W N, 1987, Annals of Sports Medicine, V3, P155; TERNEY R, 1990, AM J DIS CHILD, V144, P99, DOI 10.1001/archpedi.1990.02150250111046; WINDSOR R, 1989, MED SCI SPORT EXER, V21, P494; YESALIS CE, 1989, J DRUG EDUC, V19, P103, DOI 10.2190/NG9C-0WEA-8AU8-GUA4; 1989, GAOHRD89109 PUBL; 1986, SPSSX USERS GUIDE, P663	34	197	199	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 1	1993	328	13					922	926		10.1056/NEJM199304013281304	http://dx.doi.org/10.1056/NEJM199304013281304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU177	8446139	Bronze			2022-12-28	WOS:A1993KU17700004
J	WEISS, DS; THAUER, RK				WEISS, DS; THAUER, RK			METHANOGENESIS AND THE UNITY OF BIOCHEMISTRY	CELL			English	Article							BACTERIA; COENZYMES; REDUCTION		MAX PLANCK INST TERRESTR MIKROBIOL,W-3550 MARBURG,GERMANY	Max Planck Society	WEISS, DS (corresponding author), UNIV MARBURG,MIKROBIOL LAB,W-3550 MARBURG,GERMANY.			Weiss, David/0000-0003-2217-0070				BECHER B, 1992, J BACTERIOL, V174, P7656, DOI 10.1128/JB.174.23.7656-7660.1992; BLAUT M, 1992, J BIOENERG BIOMEMBR, V24, P529, DOI 10.1007/BF00762346; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; FARBER G, 1991, HELV CHIM ACTA, V74, P697, DOI 10.1002/hlca.19910740404; Friedmann H. C., 1991, BIOSYNTHESIS TETRAPY, P139; GARTNER P, 1993, IN PRESS EUR J BIOCH; GLOSS LM, 1987, FEMS MICROBIOL LETT, V48, P143; HEDDERICH R, 1990, EUR J BIOCHEM, V193, P255, DOI 10.1111/j.1432-1033.1990.tb19331.x; HOGAN KB, 1991, NATURE, V354, P181, DOI 10.1038/354181a0; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KAESLER B, 1989, EUR J BIOCHEM, V186, P309, DOI 10.1111/j.1432-1033.1989.tb15210.x; KELTJENS J T, 1988, Biofactors, V1, P95; LIN SK, 1991, HELV CHIM ACTA, V74, P1725, DOI 10.1002/hlca.19910740814; MORPETH FF, 1984, BIOCHEM J, V220, P235, DOI 10.1042/bj2200235; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; ROSPERT S, 1992, EUR J BIOCHEM, V210, P101, DOI 10.1111/j.1432-1033.1992.tb17396.x; SCHLEUCHER J, 1992, FEBS LETT, V3, P440; SCHMITZ RA, 1992, EUR J BIOCHEM, V209, P1013, DOI 10.1111/j.1432-1033.1992.tb17376.x; SCHWORER B, 1993, IN PRESS ARCH MICROB; THAUER RK, 1990, BIOCHIM BIOPHYS ACTA, V1018, P256, DOI 10.1016/0005-2728(90)90261-2; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; WALSH C, 1986, ACCOUNTS CHEM RES, V19, P216, DOI 10.1021/ar00127a004; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOLFE RS, 1991, ANNU REV MICROBIOL, V45, P1, DOI 10.1146/annurev.mi.45.100191.000245; ZIRNGIBL C, 1992, EUR J BIOCHEM, V208, P511, DOI 10.1111/j.1432-1033.1992.tb17215.x	25	57	57	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					819	822		10.1016/0092-8674(93)90570-G	http://dx.doi.org/10.1016/0092-8674(93)90570-G			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458077				2022-12-28	WOS:A1993KU17500002
J	BEINBORN, M; LEE, YM; MCBRIDE, EW; QUINN, SM; KOPIN, AS				BEINBORN, M; LEE, YM; MCBRIDE, EW; QUINN, SM; KOPIN, AS			A SINGLE AMINO-ACID OF THE CHOLECYSTOKININ-B GASTRIN RECEPTOR DETERMINES SPECIFICITY FOR NONPEPTIDE ANTAGONISTS	NATURE			English	Article							ANALGESIA; L-365,260; POTENT	THE brain cholecystokinin-B/gastrin receptor (CCK-B/gastrin) has been implicated in mediating anxiety, panic attacks, satiety, and the perception of pain1-5. The canine and human CCK-B/gastrin receptors share 90% amino-acid identity6,7 and have similar agonist affinities. These receptors can be selectively blocked by the non-peptide benzodiazepine-based antagonists L365260 (ref. 8) and L364718 (ref. 9); however, the binding of these antagonists to the human and canine receptors differs by up to 20-fold, resulting in a reversal of affinity rank order. Here we report the identification of a single amino acid in the sixth transmembrane domain of the CCK-B/gastrin receptor that corresponds to valine 319 in the human homologue and which is critical in determining the binding affinity for these non-peptide antagonists. We show that it is the variability in the aliphatic side chain of the amino acid in position 319 that confers antagonist specificity. Substitution of valine 319 with a leucine residue decreases the affinity for L365260 20-fold while concomitantly increasing the affinity for L364718. An isoleucine in the same position of the human receptor selectively increases affinity for L364718. Interspecies differences in the aliphatic amino acid occupying this single position selectively affect antagonist affinities without altering the agonist binding profile6,7,10. We therefore conclude that the residues underlying non-peptide antagonist affinity must differ from those that confer agonist specificity. To our knowledge, these findings are the first example in which a critical antagonist binding determinant for a seven-transmembrane-domain peptide hormone receptor has been identified.	TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GASTROENTEROL,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,GRASP,CTR DIGEST DIS,BOSTON,MA 02111; MED SCH HANNOVER,DEPT GEN PHARMACOL,W-3000 HANNOVER 61,GERMANY	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Hannover Medical School								CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; DOURISH CT, 1989, SCIENCE, V245, P1509, DOI 10.1126/science.2781294; DOURISH CT, 1990, EUR J PHARMACOL, V176, P35, DOI 10.1016/0014-2999(90)90129-T; EGHTEDARZADEH MK, 1986, NUCLEIC ACIDS RES, V14, P5115, DOI 10.1093/nar/14.12.5115; FARIS PL, 1983, SCIENCE, V219, P310, DOI 10.1126/science.6294831; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE YM, IN PRESS J BIOL CHEM; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; RAVARD S, 1990, TRENDS PHARMACOL SCI, V11, P271, DOI 10.1016/0165-6147(90)90004-R; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WIERTELAK EP, 1992, SCIENCE, V256, P830, DOI 10.1126/science.1589765	15	228	237	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					348	350		10.1038/362348a0	http://dx.doi.org/10.1038/362348a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455720				2022-12-28	WOS:A1993KU17600062
J	HONIG, PK; WORTHAM, DC; ZAMANI, K; CONNER, DP; MULLIN, JC; CANTILENA, LR				HONIG, PK; WORTHAM, DC; ZAMANI, K; CONNER, DP; MULLIN, JC; CANTILENA, LR			TERFENADINE-KETOCONAZOLE INTERACTION - PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC CONSEQUENCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ERYTHROMYCIN; METABOLITE	Objective.-To examine prospectively the effects of ketoconazole on the pharmacokinetics and electrocardiographic repolarization pharmacodynamics (corrected QT intervals) of terfenadine in men and women. Design.-Prospective cohort study with each subject serving as his or her own control. Setting.-Outpatient cardiology clinic and inpatient telemetry unit for monitoring period. Participants.-Six healthy volunteers (four men and two women, aged 24 to 35 years) not taking any prescription or over-the-counter medications. Intervention.-After achieving a steady state while taking terfenadine (60 mg every 12 hours for 7 days), daily concomitant oral ketoconazole (200 mg every 12 hours) was added to the subjects' regimen. Pharmacokinetic profiles were obtained while subjects were taking terfenadine alone and after the addition of ketoconazole. Electrocardiograms were obtained at baseline, after 1 week of taking terfenadine alone, and at the time of the second pharmacokinetic profile after the addition of ketoconazole to the regimen. Main Outcome Measures.-Terfenadine and its acid metabolite serum concentrations and corrected QT intervals. Results.-All subjects had detectable levels of unmetabolized terfenadine after the addition of ketoconazole, which was associated with QT prolongation. Only two of the six subjects could complete the entire course of ketoconazole coadministration. Four subjects received a shortened duration of ketoconazole therapy because of significant electrocardiographic repolarization abnormalities. There was a significant change in the area under the curve of the acid metabolite of terfenadine after the addition of ketoconazole administration. Conclusions.-Ketoconazole alters the metabolism of terfenadine in normal men and women and results in the accumulation of unmetabolized parent drug, which is associated with significant prolongation of the corrected QT interval. This drug combination should be avoided.	UNIFORMED SERV UNIV HLTH SCI,DEPT PHARMACOL,DIV CLIN PHARMACOL,4301 JONES BRIDGE RD,BETHESDA,MD 20814; WALTER REED ARMY MED CTR,DIV CARDIOL,WASHINGTON,DC 20307; US FDA,ROCKVILLE,MD 20857	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; US Food & Drug Administration (FDA)			Zamani, Kaveh/A-9182-2011					ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; [Anonymous], 1992, Med Lett Drugs Ther, V34, P9; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BENNETT JE, 1990, GOODMAN GILMANS PHAR; BETHEA RM, 1985, STATISTICAL METHODS; CHEN Y, 1991, J AM COLL CARDIOL, V17, P140; COUTANT JE, 1991, J CHROMATOGR-BIOMED, V570, P139, DOI 10.1016/0378-4347(91)80208-T; DANAN G, 1981, J PHARMACOL EXP THER, V218, P509; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; GUTTENDORF RJ, 1992, J CLIN PHARMACOL, V32, P107, DOI 10.1002/j.1552-4604.1992.tb03814.x; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HUME AL, 1983, DRUG INTEL CLIN PHAR, V17, P169, DOI 10.1177/106002808301700301; HUNT CM, 1992, CLIN PHARMACOL THER, V51, P18, DOI 10.1038/clpt.1992.3; LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903; MCBRIDE G, 1991, JAMA-J AM MED ASSOC, V266, P2375; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; NATTEL S, 1990, AM J MED, V89, P235, DOI 10.1016/0002-9343(90)90305-W; SANFORD JP, 1992, J CRIT ILLNESS, V7, P605; SIMONSEN L, 1991, PHARM TIMES      APR, P57; 1992, IMPORTANT DRUG WARNI; 1992, 1992 NATIONAL PRESCR; 1984, FDA DRUG B, V14, P2; 1992, HLTH INFORMATION DES; 1990, IMPORTANT DRUG WARNI; 1992, ADVERSE REACTION REP; 1992, MED GRAM IMPORTANT D; 1990, P PULMONARY ALLERGY	28	606	623	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1513	1518		10.1001/jama.269.12.1513	http://dx.doi.org/10.1001/jama.269.12.1513			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445813				2022-12-28	WOS:A1993KR80300023
J	LI, CQ; WINDSOR, RA; PERKINS, L; GOLDENBERG, RL; LOWE, JB				LI, CQ; WINDSOR, RA; PERKINS, L; GOLDENBERG, RL; LOWE, JB			THE IMPACT ON INFANT BIRTH-WEIGHT AND GESTATIONAL-AGE OF COTININE-VALIDATED SMOKING REDUCTION DURING PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MATERNAL SMOKING; CESSATION PROGRAM; CIGARETTE-SMOKING; RANDOMIZED TRIAL; CLINICAL-TRIAL; SERUM COTININE; SMOKERS; WOMEN; INTERVENTION; CONSUMPTION	Objective.-To evaluate the impact of cotinine-confirmed smoking reduction during pregnancy on infant birth weight and gestational age at birth. Design.-Group analyses from a prospective, randomized smoking-cessation intervention trial using cotinine levels to assess smoking cessation and reduction. Setting.-Four maternity clinics of Jefferson County Health Department in Birmingham, Ala. Patients.-A total of 803 pregnant smokers and 474 never smokers with a fetal gestational age of 32 weeks or less at the first prenatal visit to a clinic. Main Outcome Measures.-Infant birth weight and gestational age at birth. Results.-Infants who were born to women who quit smoking (quitters) had the highest mean birth weight (3371+/-581 g), followed by infants who were born to women who reduced smoking (reducers) (3120+/-651 g), and infants who were born to women who did not change smoking behavior (no changers) (3043+/-587 g). The mean infant birth weight of infants born to the quitters, adjusted by mothers age, race, height, weight at baseline, and gestational age at delivery was 241 g heavier than that among the no changers (P=.0008) and 167 g heavier than the reducers (P=.04). The adjusted mean infant birth weight of infants born to the reducers was 92 g heavier than that among the no changers (P=.08). White reducers with baseline cotinine levels greater than 100 ng/mL had infants who were 241 g heavier than did white no changers. A 220-g difference was also seen in black reducers with a baseline cotinine level of 100 ng/mL or less. Although smoking cessation increased infant gestational age at delivery by 1 week, smoking reduction had little effect. Conclusion.-Cotinine-validated smoking reduction rates were positively associated with an increase in infant birth weight. While smoking cessation must continue to be the primary objective for pregnant smokers, specific intervention methods should also be directed toward smoking reduction for women who cannot quit.	UNIV ALABAMA, SCH MED, DEPT OBSTET & GYNECOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH PUBL HLTH, DEPT HLTH BEHAV, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH PUBL HLTH, DEPT BIOSTAT, BIRMINGHAM, AL 35294 USA; UNIV QUEENSLAND, CANC PREVENT RES CTR, BRISBANE, QLD 4000, AUSTRALIA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Queensland	LI, CQ (corresponding author), UNIV ALABAMA, SCH MED, OFF EDUC RES & DEV, 401 CH19 UAB STN, BIRMINGHAM, AL 35294 USA.			Lowe, John/0000-0003-1222-2295	NCI NIH HHS [5R01CA41648-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS J, 1972, J OBSTET GYN BR COMM, V79, P1057; BENOWITZ N L, 1986, Journal of the American Medical Association, V256, P241, DOI 10.1001/jama.256.2.241; BERKOWITZ GS, 1982, EARLY HUM DEV, V7, P239, DOI 10.1016/0378-3782(82)90086-X; BINKIN N J, 1985, Journal of the American Medical Association, V253, P372, DOI 10.1001/jama.253.3.372; ERSHOFF DH, 1989, AM J PUBLIC HEALTH, V79, P182, DOI 10.2105/AJPH.79.2.182; ERSHOFF DH, 1990, PUBLIC HEALTH REP, V105, P340; ETZEL RA, 1990, PREV MED, V19, P190, DOI 10.1016/0091-7435(90)90020-K; GRITZ ER, 1980, ADV SUBSTANC ABUSE, V1, P91; HADDOW JE, 1991, BRIT J OBSTET GYNAEC, V98, P859, DOI 10.1111/j.1471-0528.1991.tb13506.x; HADDOW JE, 1987, BRIT J OBSTET GYNAEC, V94, P678, DOI 10.1111/j.1471-0528.1987.tb03174.x; HALCY NJ, 1983, AM J PUBLIC HEALTH, V73, P1204; HEBEL JR, 1988, J CLIN EPIDEMIOL, V41, P483, DOI 10.1016/0895-4356(88)90050-9; JENSEN OH, 1981, ACTA OBSTET GYN SCAN, V60, P177; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P271; KLIEGMAN RM, 1990, AM J OBSTET GYNECOL, V162, P1073, DOI 10.1016/0002-9378(90)91320-C; LANGONE JJ, 1973, BIOCHEMISTRY-US, V12, P5025, DOI 10.1021/bi00748a032; LI CQ, 1992, AM J PREV MED, V8, P171, DOI 10.1016/S0749-3797(18)30827-4; MACARTHUR C, 1987, BRIT J OBSTET GYNAEC, V94, P295, DOI 10.1111/j.1471-0528.1987.tb03094.x; MATSUKURA S, 1979, CLIN PHARMACOL THER, V25, P555; MCDONALD RL, 1965, OBSTET GYNECOL, V26, P470; MEYER MB, 1976, AM J EPIDEMIOL, V103, P464, DOI 10.1093/oxfordjournals.aje.a112248; OVERPECK MD, 1992, AM J PUBLIC HEALTH, V82, P441, DOI 10.2105/AJPH.82.3.441; PERMUTT T, 1989, BIOMETRICS, V45, P619, DOI 10.2307/2531503; PIERCE JP, 1987, J CHRON DIS, V40, P689, DOI 10.1016/0021-9681(87)90105-6; PRAGER K, 1984, PUBLIC HEALTH REP, V99, P117; PRAGER K, 1989, MAY INT HLTH FOR SCH; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; UNDERWOO.PB, 1967, OBSTET GYNECOL, V29, P1; VANDENBERG BJ, 1977, EPIDEMIOLOGY PREMATU, P00157; WAGENKNECHT LE, 1990, AM J PUBLIC HEALTH, V80, P1053, DOI 10.2105/AJPH.80.9.1053; WINDSOR R, 1989, ADDICT BEHAV, V14, P447, DOI 10.1016/0306-4603(89)90032-4; WINDSOR RA, 1985, AM J PUBLIC HEALTH, V75, P1389, DOI 10.2105/AJPH.75.12.1389; WINDSOR RA, 1986, HEALTH EDUC QUART, V13, P131, DOI 10.1177/109019818601300203; WINDSOR RA, 1993, AM J PUBLIC HEALTH, V83, P201, DOI 10.2105/AJPH.83.2.201; WINDSOR RA, 1993, AM J PUBLIC HEALTH, V83, P173, DOI 10.2105/AJPH.83.2.173; WINDSOR RA, 1991, PREGNANT WOMANS GUID; WINDSOR RA, IN PRESS HLTH ED Q; WIRTSHAFTER DD, 1982, J MED SCI, V6, P227; 1985, SAS USERS GUIDE STAT; 1988, OTAH345 OFF TECHN AS; 1991, PHS9150213 DEP HLTH; 1990, CDC908416 HEP HLTH H; 1988, CDC888406 DEP HLTH H; 1989, CDC898411 DEP HLTH H; 1986, MMWR, V35, P188; 1988, VITAL HLTH STAT, V10, P163; 1987, MMWR, V36, P1; [No title captured]; 1992, MONTHLY VITAL STAT R, V40, P12	49	158	162	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1519	1524		10.1001/jama.269.12.1519	http://dx.doi.org/10.1001/jama.269.12.1519			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445814				2022-12-28	WOS:A1993KR80300024
J	GARROD, DR				GARROD, DR			BASIC MOLECULAR AND CELL BIOLOGY - CELL TO CELL AND CELL TO MATRIX ADHESION	BRITISH MEDICAL JOURNAL			English	Article							INTEGRIN				GARROD, DR (corresponding author), UNIV MANCHESTER,DEPT CELL & STRUCT BIOL,CANC RES CAMPAIGN,MANCHESTER M13 9PT,LANCS,ENGLAND.							BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; EDELMAN GM, 1990, MORPHOREGULATORY MOL; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1991, THROMB HAEMOSTASIS, V66, P40; LEGAN PK, IN PRESS BIOESSAYS; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237	11	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					703	705		10.1136/bmj.306.6879.703	http://dx.doi.org/10.1136/bmj.306.6879.703			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT216	8471929	Green Published, Bronze			2022-12-28	WOS:A1993KT21600030
J	NEVILLE, RG; CLARK, RC; HOSKINS, G; SMITH, B				NEVILLE, RG; CLARK, RC; HOSKINS, G; SMITH, B			NATIONAL ASTHMA ATTACK AUDIT 1991-2	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; HOSPITAL-CARE; MANAGEMENT	Objective-To describe the frequency and characteristics of asthma attacks in the United Kingdom and to compare actual management with recommended guidelines for the management of attacks. Design-Correspondence survey. Setting-218 general practices in the United Kingdom. Subjects-1775 patients of all ages who had a total of 1805 asthma attacks over three months. Main outcome measures-Patient characteristics, place of management of attacks, comparison of actual management with recommended guidelines. Results-Of the 1805 attacks, 300 occurred in boys aged 0-9, 144 in girls aged 0-9, and 118 in women aged 20-29. The estimated frequency of attacks in the community was 14.3 per 1000 patients per year. 1546 (86%) patients with attacks were managed within general practice, 225 (12%) were admitted to hospital, and 34 (2%) were discharged from an accident and emergency department. Two patients died. On initial presentation, 248 (14%) patients were ''not breathless,'' 900 (50%) were ''moderately breathless,'' 535 (30%) were ''breathless and distressed,'' 68 (4%) were ''too breathless to talk,'' and 2 were ''moribund.'' Recording of clinical data was variable. Underuse of nebulised bronchodilators and systemic steroids was apparent in all grades of clinical severity. Contrary to current guidelines for asthma management, ''step up'' in maintainance therapy after an attack was often not practised. Conclusion-Reported management was at variance with recommended guidelines. This has major implications for the design and distribution of future guidelines.			NEVILLE, RG (corresponding author), UNIV DUNDEE,WESTGATE HLTH CTR,DEPT GEN PRACTICE,GEN PRACTITIONERS ASTHMA GRP,RES UNIT,DUNDEE DD2 4AD,SCOTLAND.							ALDERSON M, 1987, TRENDS MORBIDITY MOR; ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; [Anonymous], 1990, BMJ, V301, P651; ARNOLD AG, 1983, BRIT J DIS CHEST, V77, P51, DOI 10.1016/0007-0971(83)90005-0; BELL D, 1991, BRIT MED J, V302, P1440, DOI 10.1136/bmj.302.6790.1440; BUCKNALL CE, 1988, BRIT MED J, V296, P1637, DOI 10.1136/bmj.296.6637.1637; CHIDLEY KE, 1991, RESP MED, V85, P373, DOI 10.1016/S0954-6111(06)80180-0; HAINES A, 1992, BMJ, V305, P705; JOBANPUTRA P, 1991, BRIT J GEN PRACT, V41, P410; JONES K, 1991, BRIT J GEN PRACT, V41, P224; LIM KL, 1991, THORAX, V46, P316; STRACHAN DP, 1992, BRIT MED J, V304, P819, DOI 10.1136/bmj.304.6830.819; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; 1986, 3RD ANN STUDY MORBID; 1982, BMJ, V285, P1251; 1990, OCCURRENCE COST ASTH; 1990, BMJ, V301, P797	18	64	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					559	562		10.1136/bmj.306.6877.559	http://dx.doi.org/10.1136/bmj.306.6877.559			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461773	Green Published, Bronze			2022-12-28	WOS:A1993KP88600025
J	BOSLEY, ARJ; BLUETT, NH; SOWDEN, G				BOSLEY, ARJ; BLUETT, NH; SOWDEN, G			LESSON OF THE WEEK - TOXIC SHOCK SYNDROME AFTER ELECTIVE MINOR DERMATOLOGICAL SURGERY	BRITISH MEDICAL JOURNAL			English	Article											BOSLEY, ARJ (corresponding author), NO DEVON HEALTHCARE TRUST,BARNSTAPLE EX31 4JB,DEVON,ENGLAND.							DAVIS JP, 1980, NEW ENGL J MED, V303, P1429, DOI 10.1056/NEJM198012183032501; DESAXE MJ, 1986, POSTGRAD MED J S, V61, P5; FRAME JD, 1985, BURNS, V11, P234, DOI 10.1016/0305-4179(85)90117-2; FRAME JD, 1988, LANCET, V1, P1330; HUNTLEY AC, 1987, J AM ACAD DERMATOL, V16, P227, DOI 10.1016/S0190-9622(87)80068-3; KNUDSEN F, 1981, BRIT MED J, V282, P399, DOI 10.1136/bmj.282.6261.399-b; MANSFIELD CJ, 1989, CLIN PEDIATR, V28, P443, DOI 10.1177/000992288902801002; REINGOLD AL, 1982, ANN INTERN MED, V96, P871, DOI 10.7326/0003-4819-96-6-871; RESNICK SD, 1990, J PEDIATR-US, V116, P321, DOI 10.1016/S0022-3476(05)82815-X; TODD J, 1978, LANCET, V2, P1116; WILLIAMS GR, 1990, BRIT MED J, V300, P960, DOI 10.1136/bmj.300.6730.960	11	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					386	387		10.1136/bmj.306.6874.386	http://dx.doi.org/10.1136/bmj.306.6874.386			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461689	Bronze, Green Published			2022-12-28	WOS:A1993KL71500028
J	MAXWELL, R				MAXWELL, R			LONDON AFTER TOMLINSON .9. OTHER CITIES, SAME PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article								London's health care problems, particularly under-funding, are mirrored in other major cities in the United Kingdom and abroad. None has found the perfect solution, but the debates on the Tomlinson report provide an opportunity to review how to manage the three major areas of service provision, medical education, and research in London. Mr Robert Maxwell suggests that some aspects of the successful ambulatory care initiative in New York could be adapted by the capital's primary care providers while the secondary services might learn from the rationalisation of specialist services in Paris.			MAXWELL, R (corresponding author), KINGS FUND,LONDON W2 4HT,ENGLAND.							RODWIN VG, 1992, PUBLIC HOSPITAL SYST	1	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					199	201		10.1136/bmj.306.6871.199	http://dx.doi.org/10.1136/bmj.306.6871.199			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443490	Bronze, Green Published			2022-12-28	WOS:A1993KH51300033
J	CRIQUI, MH; HEISS, G; COHN, R; COWAN, LD; SUCHINDRAN, CM; BANGDIWALA, S; KRITCHEVSKY, S; JACOBS, DR; OGRADY, HK; DAVIS, CE				CRIQUI, MH; HEISS, G; COHN, R; COWAN, LD; SUCHINDRAN, CM; BANGDIWALA, S; KRITCHEVSKY, S; JACOBS, DR; OGRADY, HK; DAVIS, CE			PLASMA TRIGLYCERIDE LEVEL AND MORTALITY FROM CORONARY HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; CLINICS PROGRAM PREVALENCE; INDEPENDENT RISK FACTOR; MYOCARDIAL-INFARCTION; FOLLOW-UP; CARDIOVASCULAR MORTALITY; PLASMINOGEN-ACTIVATOR; SERUM TRIGLYCERIDES; MEN; DEATH	Background. Whether the plasma triglyceride level is a risk factor for coronary heart disease has been controversial, and evaluation of the triglyceride level as a risk factor is fraught with methodologic difficulties. Methods. We studied the association between plasma triglyceride levels and the 12-year incidence of death from coronary heart disease in 10 North American populations participating in the Lipid Research Clinics Follow-up Study, while adjusting for the potential confounding effects of other risk factors for cardiovascular disease, including the level of high-density lipoprotein (HDL) cholesterol. All analyses were sex-specific, and separate analyses were performed in high and low strata of HDL cholesterol, low-density lipoprotein (LDL) cholesterol, fasting plasma glucose, and age. Results. The rates of coronary death in both men and women increased with the triglyceride level. In Cox proportional-hazards models adjusted for age, in which the natural log of the triglyceride levels was used to give a normal distribution, the relative risk per natural-log unit of triglyceride (e.g., a triglyceride level of 150 mg per deciliter vs. a level of 55 mg per deciliter) was 1.54 (95 percent confidence interval, 1.19 to 1.98; P<0.001) in men and 1.88 (95 percent confidence interval, 1.19 to 2.98; P = 0.007) in women. After an adjustment for potential covariates, however, these relative risks were not statistically significant. Analyses based on lipoprotein cholesterol levels revealed a positive association between the triglyceride level and coronary mortality in the lower stratum of both HDL and LDL cholesterol, but not in the higher stratum. Conversely, the HDL cholesterol level was unrelated to coronary mortality in the lower stratum of LDL cholesterol, but was strongly inversely associated with coronary death in the higher stratum of LDL cholesterol. The relative risk of coronary death associated with triglyceride level was higher at younger ages. The associations between the triglyceride level and coronary mortality in the lower HDL cholesterol, LDL cholesterol, and age strata were small and were further reduced by an adjustment for the fasting plasma glucose level. Conclusions. Overall, the plasma triglyceride level showed no independent association with coronary mortality. However, in subgroups of subjects with lower HDL and LDL cholesterol levels and in younger subjects, defined a priori, an association between the triglyceride level and coronary mortality was observed, although this association was small and was not statistically significant after an adjustment for the plasma glucose level.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT COMMUNITY & FAMILY MED, LA JOLLA, CA 92093 USA; UNIV OKLAHOMA HLTH SCI CTR, COLL PUBL HLTH, DEPT BIOSTAT & EPIDEMIOL, OKLAHOMA CITY, OK USA; UNIV MINNESOTA, SCH PUBL HLTH, DEPT EPIDEMIOL, MINNEAPOLIS, MN 55455 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT BIOSTAT & EPIDEMIOL, MEMPHIS, TN 38163 USA; UNIV N CAROLINA, DEPT EPIDEMIOL, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, DEPT BIOSTAT, CHAPEL HILL, NC 27514 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Minnesota System; University of Minnesota Twin Cities; University of Tennessee System; University of Tennessee Health Science Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Jacobs, David/0000-0002-7232-0543	NHLBI NIH HHS [N01-HV32961, N01-HV12156, N01-HV12159] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV012156] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT RD, 1988, ARTERIOSCLEROSIS, V8, P207, DOI 10.1161/01.ATV.8.3.207; ABERG H, 1985, ATHEROSCLEROSIS, V54, P89, DOI 10.1016/0021-9150(85)90156-X; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1989, AM J EPIDEMIOL, V129, P249, DOI 10.1093/oxfordjournals.aje.a115130; AVINS AL, 1993, CIRCULATION, V87, P300, DOI 10.1161/circ.87.1.8419022; BAINTON D, 1992, BRIT HEART J, V68, P60; BENFANTE RJ, 1989, J CLIN EPIDEMIOL, V42, P95, DOI 10.1016/0895-4356(89)90082-6; CAMBIEN F, 1986, AM J EPIDEMIOL, V124, P624, DOI 10.1093/oxfordjournals.aje.a114435; CARLSON LA, 1985, ACTA MED SCAND, V218, P207; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CASTELLI WP, 1986, AM HEART J, V112, P432, DOI 10.1016/0002-8703(86)90296-6; COWAN LD, 1985, ARTERIOSCLEROSIS, V5, P466, DOI 10.1161/01.ATV.5.5.466; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1986, CIRCULATION, V73, P40; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1990, PROG CARDIOL, V3, P3; DAVIS CE, 1990, CIRCULATION, V81, P725; DAVIS CE, 1980, CIRCULATION, V62, P24; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; GLYNN RJ, 1982, CIRCULATION, V66, P724, DOI 10.1161/01.CIR.66.4.724; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEYDEN S, 1980, J CHRON DIS, V33, P275, DOI 10.1016/0021-9681(80)90022-3; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; JANKA HU, 1985, HORM METAB RES, V15, P15; LAMONFAVA S, 1988, CLIN RES, V36, pA787; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; LAROSA JC, 1986, CIRCULATION, V73, P12; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; NESTEL PJ, 1987, PRACT CARDIOL, V13, P96; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PELKONEN R, 1977, BRIT MED J, V2, P1185, DOI 10.1136/bmj.2.6096.1185; PETERSSON B, 1984, AM J MED, V77, P418, DOI 10.1016/0002-9343(84)90096-2; POCOCK SJ, 1989, BMJ-BRIT MED J, V298, P998, DOI 10.1136/bmj.298.6679.998; SALONEN JT, 1983, INT J EPIDEMIOL, V12, P26, DOI 10.1093/ije/12.1.26; SIMPSON HCR, 1983, LANCET, V1, P786; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; TVERDAL A, 1989, AM J EPIDEMIOL, V129, P458, DOI 10.1093/oxfordjournals.aje.a115157; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; WILHELMSEN L, 1973, CIRCULATION, V48, P950, DOI 10.1161/01.CIR.48.5.950; WILLIAMS OD, 1986, CIRCULATION, V73, P4; WU LL, 1988, CIRCULATION S2, V78, P481; 1974, DHEW NIH75628 PUBL	47	316	326	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1220	1225		10.1056/NEJM199304293281702	http://dx.doi.org/10.1056/NEJM199304293281702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464432				2022-12-28	WOS:A1993KZ06100002
J	SHAW, SY; WANG, JC				SHAW, SY; WANG, JC			KNOTTING OF A DNA CHAIN DURING RING-CLOSURE	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; SINGLE-STRANDED-DNA; CIRCULAR DNA; TOPOLOGY; KNOTS; TOPOISOMERASE; DEPENDENCE; TRANSITION; MOLECULES; WALKS	The formation of knotted species on random ring closure of two DNAs that are 5.6 kilobase pairs (kbp) and 8.6 kbp in length was measured, and these data were used to calculate the effective DNA helix diameter as a function of sodium ion and magnesium ion concentration. In the presence of more than 50 mM magnesium ion, interactions between DNA segments appear to be attractive rather than repulsive. The free energy of formation of relaxed trefoil and figure-eight DNA knots and of supercoiled trefoil DNA knots was also evaluated.			SHAW, SY (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVINITY AVE,CAMBRIDGE,MA 02138, USA.							ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; ANNAN NK, 1992, NUCLEIC ACIDS RES, V20, P983, DOI 10.1093/nar/20.5.983; BRIAN AA, 1981, BIOPOLYMERS, V20, P1305, DOI 10.1002/bip.1981.360200615; DEGENNES PG, 1984, MACROMOLECULES, V18, P2445; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DIETRICHBUCHECK.CO, 1990, ANGEW CHEM INT EDIT, V29, P556; DIETRICHBUCHECKER CO, 1989, ANGEW CHEM INT EDIT, V28, P189, DOI 10.1002/anie.198901891; EDWARDS SF, 1967, P PHYS SOC LOND, V91, P513, DOI 10.1088/0370-1328/91/3/301; FRANKKAMENETSKII MD, 1981, USP FIZ NAUK+, V134, P641, DOI 10.3367/UFNr.0134.198108c.0641; FRANKKAMENETSKII MD, 1975, NATURE, V258, P398, DOI 10.1038/258398a0; FRISCH HL, 1961, J AM CHEM SOC, V83, P3789, DOI 10.1021/ja01479a015; GELLERT M, 1987, NATURE, V325, P401, DOI 10.1038/325401a0; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1503, DOI 10.1002/bip.1981.360200710; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; HSIEH T, 1983, J BIOL CHEM, V258, P8413; JONES VFR, 1985, B AM MATH SOC, V12, P103, DOI 10.1090/S0273-0979-1985-15304-2; KAM Z, 1981, BIOPOLYMERS, V20, P2671, DOI 10.1002/bip.1981.360201213; Kauffman, 1991, KNOTS TOPOLOGY QUANT; KLENIN KV, 1988, J BIOMOL STRUCT DYN, V5, P1173, DOI 10.1080/07391102.1988.10506462; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P5498, DOI 10.1073/pnas.78.9.5498; LIU LF, 1976, J MOL BIOL, V106, P439, DOI 10.1016/0022-2836(76)90095-4; MICHELS JPJ, 1986, P ROY SOC LOND A MAT, V403, P269, DOI 10.1098/rspa.1986.0012; MUELLER JE, 1991, J AM CHEM SOC, V113, P6306, DOI 10.1021/ja00016a077; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; PIPPENGER N, 1989, DISCRETE APPL MATH, V25, P273, DOI 10.1016/0166-218X(89)90005-X; POLLOCK TJ, 1983, J MOL BIOL, V170, P1, DOI 10.1016/S0022-2836(83)80224-1; PORSCHKE D, 1986, J BIOMOL STRUCT DYN, V4, P373, DOI 10.1080/07391102.1986.10506356; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; RYBENKOV VV, IN PRESS P NATL ACAD; Schill G., 1971, CATENANES ROTAXANES; SCHLICK T, 1992, J MOL BIOL, V223, P1089, DOI 10.1016/0022-2836(92)90263-J; SCHLICK T, 1992, SCIENCE, V257, P1110, DOI 10.1126/science.257.5073.1110; SHORTLE D, 1982, P NATL ACAD SCI-BIOL, V79, P1588, DOI 10.1073/pnas.79.5.1588; STIGTER D, 1977, BIOPOLYMERS, V16, P1435, DOI 10.1002/bip.1977.360160705; SUMNERS DW, 1988, J PHYS A-MATH GEN, V21, P1689, DOI 10.1088/0305-4470/21/7/030; Tait P. G., 1898, SCI PAPERS, V1, P273; Thomson W., 1867, PHILOS MAG, V34, P15, DOI DOI 10.1080/14786446708639836; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; VANRENSBURG EJJ, 1990, J PHYS A-MATH GEN, V23, P3573, DOI 10.1088/0305-4470/23/15/028; VOLOGODSKII AV, 1974, ZH EKSP TEOR FIZ, V39, P1059; WALBA DM, 1985, TETRAHEDRON, V41, P3161, DOI 10.1016/S0040-4020(01)96671-2; WANG JC, 1966, J MOL BIOL, V15, P111, DOI 10.1016/S0022-2836(66)80213-9; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WASSERMAN E, 1960, J AM CHEM SOC, V82, P4433, DOI 10.1021/ja01501a082; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WU FY, 1992, REV MOD PHYS, V64, P1099, DOI 10.1103/RevModPhys.64.1099	49	243	270	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					533	536		10.1126/science.8475384	http://dx.doi.org/10.1126/science.8475384			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	8475384				2022-12-28	WOS:A1993KY50400031
J	TAO, MH; LEVY, R				TAO, MH; LEVY, R			IDIOTYPE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FUSION PROTEIN AS A VACCINE FOR B-CELL LYMPHOMA	NATURE			English	Article							GENE-TRANSFER; IMMUNITY; ANTIGEN; POTENT; ANTIBODIES; MOLECULES; RECEPTORS; INVIVO	To produce a vaccine against cancer, antigens must be found that are preferentially expressed by tumour cells and can induce an immune response against the tumour. The variable regions of the immunoglobulin molecules expressed on malignant B cells (idiotypes) are tumour-specific, but are weak immunogens. To induce an immune response in animals or humans, the idiotypic protein has therefore to be chemically coupled to a strongly immunogenic protein and mixed with an adjuvant1-8. The resulting response can protect animals from subsequent tumour challenge, and cure animals with established tumours in combination with chemotherapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) augments antigen presentation in a variety of cells9-12. Here we show that by fusing a tumour-derived idiotype to GM-CSF, it can be converted into a strong immunogen capable of inducing idiotype-specific antibodies without other carrier proteins or adjuvants and of protecting recipient animals from challenge with an otherwise lethal dose of tumour cells. This approach may be applicable to the design of vaccines for a variety of other diseases.	STANFORD UNIV, MED CTR, SCH MED, DEPT MED, DIV ONCOL, STANFORD, CA 94305 USA	Stanford University				Tao, Mi-Hua/0000-0002-4307-5729; Levy, Ronald/0000-0003-2061-0650				ALLISON AC, 1986, J IMMUNOL METHODS, V95, P157, DOI 10.1016/0022-1759(86)90402-3; BERGMAN Y, 1977, EUR J IMMUNOL, V7, P413, DOI 10.1002/eji.1830070702; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; CAMPBELL MJ, 1988, J IMMUNOL, V141, P3227; CAMPBELL MJ, 1987, J IMMUNOL, V139, P2825; CARROLL WL, 1988, J EXP MED, V168, P1607, DOI 10.1084/jem.168.5.1607; CURTIS BM, 1991, P NATL ACAD SCI USA, V88, P5809, DOI 10.1073/pnas.88.13.5809; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FISCHER HG, 1988, J IMMUNOL, V141, P3882; FREEDMAN PM, 1976, J NATL CANCER I, V56, P735, DOI 10.1093/jnci/56.4.735; GANSBACHER B, 1990, CANCER RES, V50, P7820; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700; HINUMA S, 1991, FEBS LETT, V288, P138, DOI 10.1016/0014-5793(91)81020-9; HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LUSIS AJ, 1981, BLOOD, V57, P13; LYNCH RG, 1972, P NATL ACAD SCI USA, V69, P1540, DOI 10.1073/pnas.69.6.1540; MALONEY DG, 1985, HYBRIDOMA, V4, P191, DOI 10.1089/hyb.1985.4.191; MORRISSEY PJ, 1987, J IMMUNOL, V139, P1113; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; SHIN SU, 1989, METHOD ENZYMOL, V178, P459; SMITH PD, 1990, J IMMUNOL, V144, P3829; STARNES CO, 1988, J IMMUNOL, V141, P333; SUGAI S, 1974, Journal of Experimental Medicine, V140, P1547, DOI 10.1084/jem.140.6.1547; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	30	280	326	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 22	1993	362	6422					755	758		10.1038/362755a0	http://dx.doi.org/10.1038/362755a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8469286				2022-12-28	WOS:A1993KY45000058
J	FERGUSON, GT; CHERNIACK, RM				FERGUSON, GT; CHERNIACK, RM			CURRENT CONCEPTS - MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AIR-FLOW OBSTRUCTION; NEGATIVE-PRESSURE VENTILATION; ALPHA-1-ANTITRYPSIN DEFICIENCY; NICOTINE-REPLACEMENT; IPRATROPIUM BROMIDE; CHRONIC HYPERCAPNIA; EXERCISE TOLERANCE; MUSCLE FUNCTION; LUNG-DISEASE; DOUBLE-BLIND		UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV PULM SCI, DENVER, CO 80262 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DENVER, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health								AMBROSINO N, 1992, CHEST, V101, P385, DOI 10.1378/chest.101.2.385; ANGELILLO VA, 1985, ANN INTERN MED, V103, P883, DOI 10.7326/0003-4819-103-6-883; [Anonymous], 1980, Ann Intern Med, V93, P391; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; BEGIN P, 1991, AM REV RESPIR DIS, V143, P905, DOI 10.1164/ajrccm/143.5_Pt_1.905; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BOMAN G, 1983, EUR J RESPIR DIS, V64, P405; BRAUN NMT, 1984, CHEST S, V85, P59; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; BYE PTP, 1985, AM REV RESPIR DIS, V132, P236; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; CASABURI R, 1991, AM REV RESPIR DIS, V143, P9, DOI 10.1164/ajrccm/143.1.9; CHETTY KG, 1983, AM J MED, V74, P415, DOI 10.1016/0002-9343(83)90960-9; COUSER JI, 1989, AM REV RESPIR DIS, V139, P627, DOI 10.1164/ajrccm/139.3.627; CRINER GJ, 1988, AM REV RESPIR DIS, V138, P856, DOI 10.1164/ajrccm/138.4.856; CROPP A, 1987, AM REV RESPIR DIS, V135, P1056; DOCKERY DW, 1988, AM REV RESPIR DIS, V137, P286, DOI 10.1164/ajrccm/137.2.286; EASTON PA, 1986, NEW ENGL J MED, V315, P735, DOI 10.1056/NEJM198609183151205; FERNANDEZ E, 1991, AM REV RESPIR DIS, V144, P390, DOI 10.1164/ajrccm/144.2.390; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER EC, 1987, CHEST, V92, P604, DOI 10.1378/chest.92.4.604; GHAFOURI MA, 1984, CHEST, V86, P387, DOI 10.1378/chest.86.3.387; HIGGINS M, 1991, ANN NY ACAD SCI, V624, P7; HUBBARD RC, 1988, JAMA-J AM MED ASSOC, V260, P1259, DOI 10.1001/jama.260.9.1259; HURT RD, 1990, MAYO CLIN PROC, V65, P1529, DOI 10.1016/S0025-6196(12)62186-7; KARPEL JP, 1991, CHEST, V99, P871, DOI 10.1378/chest.99.4.871; LARSON JL, 1988, AM REV RESPIR DIS, V138, P689, DOI 10.1164/ajrccm/138.3.689; LIGHT RW, 1989, AM REV RESPIR DIS, V139, P126, DOI 10.1164/ajrccm/139.1.126; MAL H, 1989, AM REV RESPIR DIS, V140, P797, DOI 10.1164/ajrccm/140.3.797; MAN GCW, 1986, CHEST, V90, P832, DOI 10.1378/chest.90.6.832; MARTIN JG, 1990, CHEST, V97, pS105; MARTIN RJ, 1992, AM REV RESPIR DIS, V145, P540, DOI 10.1164/ajrccm/145.3.540; MATHUR PN, 1981, ANN INTERN MED, V95, P283, DOI 10.7326/0003-4819-95-3-283; MATTHAY RA, 1982, AM HEART J, V104, P1022, DOI 10.1016/0002-8703(82)90435-5; MOSER KM, 1980, ARCH INTERN MED, V140, P1596, DOI 10.1001/archinte.140.12.1596; MURATA GH, 1990, CHEST, V98, P845, DOI 10.1378/chest.98.4.845; NICKOLADZE GD, 1992, CHEST, V101, P119, DOI 10.1378/chest.101.1.119; ODONNELL DE, 1988, AM REV RESPIR DIS, V138, P1510, DOI 10.1164/ajrccm/138.6.1510; PETTY TL, 1990, CHEST, V97, P75, DOI 10.1378/chest.97.1.75; POSTMA DS, 1988, EUR RESPIR J, V1, P22; REDLINE S, 1991, CHRONIC OBSTRUCTIVE, P225; SEES KL, 1989, J PSYCHOACTIVE DRUGS, V21, P355, DOI 10.1080/02791072.1989.10472177; SMITH K, 1992, AM REV RESPIR DIS, V145, P533, DOI 10.1164/ajrccm/145.3.533; SPEIZER FE, 1991, HARRISONS PRINCIPLES, P1056; Spika J S, 1990, Infect Dis Clin North Am, V4, P11; TAGER IB, 1988, AM REV RESPIR DIS, V138, P837, DOI 10.1164/ajrccm/138.4.837; WAKABAYASHI A, 1991, LANCET, V337, P881, DOI 10.1016/0140-6736(91)90206-5; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; WILSON DO, 1989, AM REV RESPIR DIS, V139, P1435, DOI 10.1164/ajrccm/139.6.1435; ZIMENT I, 1990, CLIN CHEST MED, V11, P461	50	183	187	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1017	1022						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	8450855				2022-12-28	WOS:A1993KW28200008
J	HOFER, M; HIRSCHEL, B; KIRSCHNER, P; BEGHETTI, M; KAELIN, A; SIEGRIST, CA; SUTER, S; TESKE, A; BOTTGER, EC				HOFER, M; HIRSCHEL, B; KIRSCHNER, P; BEGHETTI, M; KAELIN, A; SIEGRIST, CA; SUTER, S; TESKE, A; BOTTGER, EC			DISSEMINATED OSTEOMYELITIS FROM MYCOBACTERIUM-ULCERANS AFTER A SNAKEBITE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							IDENTIFICATION; INFECTION		HOP CANTONAL UNIV,DIV INFECT DIS,CH-1211 GENEVA 4,SWITZERLAND; HOP CANTONAL UNIV,UNITE ORTHOPEDIE PEDIAT,CH-1211 GENEVA 4,SWITZERLAND; HOP CANTONAL UNIV,DEPT PEDIAT,CH-1211 GENEVA 4,SWITZERLAND; HANNOVER MED SCH,INST MED MIKROBIOL,W-3000 HANNOVER 61,GERMANY	University of Geneva; University of Geneva; University of Geneva; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf			Teske, Andreas/AAQ-9577-2021; Böttger, Erik C./F-6175-2011					BODDINGHAUS B, 1990, J CLIN MICROBIOL, V28, P1751; BOTTGER EC, 1992, LANCET, V340, P76, DOI 10.1016/0140-6736(92)90397-L; DAFFE M, 1992, J GEN MICROBIOL, V138, P131, DOI 10.1099/00221287-138-1-131; DAUTZENBERG B, 1991, AM REV RESPIR DIS, V144, P564, DOI 10.1164/ajrccm/144.3_Pt_1.564; HAYMAN J, 1991, LANCET, V337, P124, DOI 10.1016/0140-6736(91)90791-M; KWONG JS, 1991, SKELETAL RADIOL, V20, P458; MUELDER K, 1990, LANCET, V336, P1109, DOI 10.1016/0140-6736(90)92581-2; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; Roberts GD, 1991, MANUAL CLIN MICROBIO, P304; ROGALL T, 1990, INT J SYST BACTERIOL, V40, P323, DOI 10.1099/00207713-40-4-323; ROGALL T, 1990, J GEN MICROBIOL, V136, P1915, DOI 10.1099/00221287-136-9-1915; ROUGRAFF BT, 1989, CLIN ORTHOPAEDICS, V238, P308; VANDERHOEVEN LH, 1958, AM J CLIN PATHOL, V29, P433, DOI 10.1093/ajcp/29.5.433; 1990, AM REV RESPIR DIS, V142, P940	15	48	49	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1007	1009		10.1056/NEJM199304083281405	http://dx.doi.org/10.1056/NEJM199304083281405			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	8450852				2022-12-28	WOS:A1993KW28200005
J	WATSON, A; SMALDON, N; LUCKE, R; HAWKINS, T				WATSON, A; SMALDON, N; LUCKE, R; HAWKINS, T			THE CAENORHABDITIS-ELEGANS GENOME SEQUENCING PROJECT - 1ST STEPS IN AUTOMATION	NATURE			English	Editorial Material									MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; PROMEGA CORP,MADISON,WI	MRC Laboratory Molecular Biology; Promega Corporation	WATSON, A (corresponding author), SANGER CTR,HINXTON PK,CAMBRIDGE CB10 1RQ,ENGLAND.							ANSORGE W, 1992, ELECTROPHORESIS, V13, P616, DOI 10.1002/elps.11501301125; BANKIER A, 1988, METHOD ENZYMOL, V155, P52; BRUMLEY RL, 1991, NUCLEIC ACIDS RES, V19, P4121, DOI 10.1093/nar/19.15.4121; DU ZJ, 1993, METHOD ENZYMOL, V218, P104; HAWKINS TL, 1992, J DNA SEQ MAPPING, V3, P65; JONES P, 1992, NUCLEIC ACIDS RES, V17, P4599; MATHIES RA, 1992, NATURE, V359, P167, DOI 10.1038/359167a0; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; UBER DC, 1991, BIOTECHNIQUES, V11, P642	9	12	12	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					569	570		10.1038/362569a0	http://dx.doi.org/10.1038/362569a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464500				2022-12-28	WOS:A1993KW45300063
J	SHIN, J; LEE, S; STROMINGER, JL				SHIN, J; LEE, S; STROMINGER, JL			TRANSLOCATION OF TCR-ALPHA CHAINS INTO THE LUMEN OF THE ENDOPLASMIC-RETICULUM AND THEIR DEGRADATION	SCIENCE			English	Article							CELL RECEPTOR COMPLEX; PROTEINS; RETENTION; MEMBRANE; CD4; ER	After synthesis, the alpha chain of the T cell antigen receptor (TCRalpha) can form a complex with other TCR chains and move to the cell surface, or TCRalpha can undergo degradation in the endoplasmic reticulum (ER) if it remains unassembled. The mechanism of translocation and degradation in the ER is unclear. It was found that the putative transmembrane region of TCRalpha (alpha(tm)) was incompetent on its own to act as a transmembrane region. Molecules that contained alpha(tm) were translocated into the ER lumen and then underwent either rapid degradation or secretion, depending on the sequence of the cytoplasmic domain. A specific signal for ER degradation within alpha(tm) does not appear to be present.			SHIN, J (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048961] Funding Source: NIH RePORTER; NCI NIH HHS [CA47554] Funding Source: Medline; NIAID NIH HHS [AI20182] Funding Source: Medline; NIGMS NIH HHS [GM48961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALARCON B, 1988, J BIOL CHEM, V263, P2953; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P142; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; KUCHROO VK, 1991, P NATL ACAD SCI USA, V88, P8700, DOI 10.1073/pnas.88.19.8700; LEIDEN JM, 1986, IMMUNOGENETICS, V24, P17, DOI 10.1007/BF00372293; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; Shin J., UNPUB; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	23	73	75	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1901	1904		10.1126/science.8456316	http://dx.doi.org/10.1126/science.8456316			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456316				2022-12-28	WOS:A1993KU17200033
J	GIRLING, R; PARTRIDGE, JF; BANDARA, LR; BURDEN, N; TOTTY, NF; HSUAN, JJ; LATHANGUE, NB				GIRLING, R; PARTRIDGE, JF; BANDARA, LR; BURDEN, N; TOTTY, NF; HSUAN, JJ; LATHANGUE, NB			A NEW COMPONENT OF THE TRANSCRIPTION FACTOR-DRTF1/E2F	NATURE			English	Article							RETINOBLASTOMA GENE-PRODUCT; CARCINOMA STEM-CELLS; T-ANTIGEN; CYCLIN-A; PROTEIN; DIFFERENTIATION; BINDING; TRANSACTIVATION; ADENOVIRUS-E1A; REGIONS	TRANSCRIPTION factor DRTF1/E2F coordinates events in the cell cycle with transcription by its cyclical interactions with important regulators of cellular proliferation like the retinoblastoma tumour-suppressor gene product (Rb) and the Rb-related protein, p107 (refs 1-8). DRTF1/E2F binding sites occur in the control regions of genes involved in proliferation9,10, and both Rb and p107 repress the capacity of DRTF1/E2F to activate transcription (refs 11, 12; M. Zamanian and N.B.L.T., manuscript submitted). Mutant Rb proteins isolated from tumour cells are unable to bind DRTF1/E2F (refs 11-13), and certain viral oncoproteins, such as adenovirus E1A, sequester Rb and p107 in order to free active DRTF1/E2F (refs 5, 11, 12, 14, 15). Here we report the isolation of a complementary DNA encoding DRTF1-polypeptide-1 (DP-1), a major sequence-specific binding protein that is present in DRTF1/E2F, including Rb- and p107-associated DRTF1/E2F. The DNA-binding domain of DP-1 contains a region that resembles that of E2F-1 (refs 16, 17), and recognizes the same sequence. DRTF1/E2F thus appears to contain at least two sequence-specific DNA-binding proteins.	MRC,NATL INST MED RES,EUKARYOT MOLEC GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; MIDDLESEX HOSP,LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	MRC National Institute for Medical Research; Ludwig Institute for Cancer Research; University of London; University College London			Hsuan, Justin/C-8825-2009; Partridge, Janet/M-9352-2018	Hsuan, Justin/0000-0001-6083-7564; Partridge, Janet/0000-0003-1102-6305				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, IN PRESS J CELL SCI; BARTEK J, 1992, ONCOGENE, V7, P101; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HEIN K, 1992, CELL, V70, P337; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, IN PRESS TRENDS CELL; MORRIS JDH, IN PRESS ONCOGENE; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	33	245	261	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					83	87		10.1038/362083a0	http://dx.doi.org/10.1038/362083a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8446173				2022-12-28	WOS:A1993KP97600067
J	MACDESSI, J; OATES, RK				MACDESSI, J; OATES, RK			CLINICAL-DIAGNOSIS OF PYLORIC-STENOSIS - A DECLINING ART	BRITISH MEDICAL JOURNAL			English	Article							ULTRASOUND	Objective-To assess whether diagnostic imaging of pyloric stenosis has made a difference in rapidity of diagnosis, duration of pre-operative hydration, and length of stay in hospital. Design-Chart review of infants with confirmed diagnosis of pyloric stenosis. Setting-Paediatric teaching hospital. Subjects-215 infants with a confirmed diagnosis of pyloric stenosis seen during 1974-7 and 187 infants with pyloric stenosis seen during 1988-91. Main outcome measures-State of hydration on admission, time between presentation to hospital and a definite diagnosis, techniques used to make the diagnosis, whether a pyloric mass was felt before or after an imaging procedure, time between presentation and surgery, and length of stay in hospital. Results-The average age at presentation was 40 days in both groups. A pyloric mass was palpated either without or before an imaging study in 87% (187/215) of cases during 1974-7 but in only 49% (91/187) during 1988-91. The use of barium meal examination and ultrasonography increased from 20% (42/215) of cases during 1974-7 to 61% (114/187) during 1988-91. There were no significant differences between the two groups in the time taken to establish a diagnosis, the mean duration of preoperative treatment, or the length of stay in hospital (after allowance for the decline in average length of stay of all hospital patients between the two periods). Conclusions-An increased use of diagnostic imaging for pyloric stenosis did not lead to earlier diagnosis or better management. While imaging is important in identifying pyloric stenosis in difficult cases, increasing reliance on imaging has reduced doctors' skills in diagnosing pyloric stenosis clinically.	SYDNEY UNIV,CHILDRENS HOSP,DEPT PAEDIAT & CHILD HLTH,CAMPERDOWN,NSW 2050,AUSTRALIA	University of Sydney								BEASELY S, 1991, J PAEDIATR CHILD HLT, V27, P231; BREAUX CW, 1988, PEDIATRICS, V81, P213; FORMAN HP, 1990, J PEDIATR SURG, V25, P262, DOI 10.1016/0022-3468(90)90436-D; Garcia V F, 1990, Pediatr Rev, V11, P292, DOI 10.1542/pir.11-10-292; LEAHY PF, 1986, IRISH MED J, V79, P114; MENUSSEN T, 1934, AM J DIS CHILD, V48, P1304; PERRY EP, 1988, LANCET, V2, P391; SCHARLI A, 1969, J PEDIATR SURG, V4, P108, DOI 10.1016/0022-3468(69)90190-0; SCHUMAN FL, 1967, J PEDIATR, V71, P70; STUNDEN RJ, 1986, PEDIATR RADIOL, V16, P200, DOI 10.1007/BF02456287; TEELE RL, 1977, NEW ENGL J MED, V296, P1149, DOI 10.1056/NEJM197705192962006; 1984, LANCET, V1, P888; 1988, LANCET, V1, P1146	13	61	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					553	555		10.1136/bmj.306.6877.553	http://dx.doi.org/10.1136/bmj.306.6877.553			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461768	Bronze, Green Published			2022-12-28	WOS:A1993KP88600020
J	WEIJLAND, A; PARMEGGIANI, A				WEIJLAND, A; PARMEGGIANI, A			TOWARD A MODEL FOR THE INTERACTION BETWEEN ELONGATION FACTOR-TU AND THE RIBOSOME	SCIENCE			English	Article							AMINOACYL-TRANSFER-RNA; EF-TU; MOLECULES PARTICIPATE; ESCHERICHIA-COLI; BINDING DOMAIN; MUTATION; SPECIFICITY; P21	In the elongation cycle of bacterial protein synthesis the interaction between elongation factor-Tu (EF-Tu).guanosine triphosphate (GTP), aminoacyl-transfer RNA (aa-tRNA), and messenger RNA-programmed ribosomes is associated with the hydrolysis of GTP. This interaction determines the selection of the proper aa-tRNA for incorporation into the polypeptide. In the canonical scheme, one molecule of GTP is hydrolyzed in the EF-Tu-dependent binding of aa-tRNA to the ribosome, and a second molecule is hydrolyzed in the elongation factor-G (EF-G)-mediated translocation of the polypeptide from the ribosomal A site to the P site. Substitution of Asp138 with Asn in EF-Tu changed the substrate specificity from GTP to xanthosine triphosphate and demonstrated that the EF-Tu-mediated reactions involved the hydrolysis of two nucleotide triphosphates for each Phe incorporated. This stoichiometry of two is associated with the binding of the correct aa-tRNA to the ribosome.			WEIJLAND, A (corresponding author), ECOLE POLYTECH,BIOCHIM LAB,CNRS,SDI 61840,F-91128 PALAISEAU,FRANCE.							ANBORGH PH, 1991, FEBS LETT, V292, P232, DOI 10.1016/0014-5793(91)80874-3; BENSCH K, 1991, BIOCHIMIE, V73, P1045, DOI 10.1016/0300-9084(91)90146-R; BILGIN N, 1992, J MOL BIOL, V224, P1011, DOI 10.1016/0022-2836(92)90466-W; CABRER B, 1976, J BIOL CHEM, V251, P1718; CHINALI G, 1980, J BIOL CHEM, V255, P7455; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HUGHES D, 1987, EMBO J, V6, P4235, DOI 10.1002/j.1460-2075.1987.tb02772.x; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAKHNIASHVILI DG, 1986, FEBS LETT, V196, P103, DOI 10.1016/0014-5793(86)80222-8; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NISHIZUKA Y, 1966, ARCH BIOCHEM BIOPHYS, V116, P344, DOI 10.1016/0003-9861(66)90040-3; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; RICHTER AA, 1990, J MOL BIOL, V216, P311; RUUSALA T, 1982, EMBO J, V1, P741, DOI 10.1002/j.1460-2075.1982.tb01240.x; SWART GWM, 1987, BIOCHEMISTRY-US, V26, P2047, DOI 10.1021/bi00381a038; THOMAS LK, 1988, P NATL ACAD SCI USA, V85, P4242, DOI 10.1073/pnas.85.12.4242; THOMAS LK, 1989, P NATL ACAD SCI USA, V86, P6888; THOMPSON RC, 1981, J BIOL CHEM, V256, P81; THOMPSON RC, 1981, ARCH BIOCHEM BIOPHYS, V258, P6676; UHLENBECK OC, 1971, J MOL BIOL, V57, P221; VIGENBOOM E, 1989, J BIOL CHEM, V264, P1302; VIGENBOOM E, 1985, EMBO J, V4, P1049; WEIJLAND A, 1992, MOL MICROBIOL, V6, P683, DOI 10.1111/j.1365-2958.1992.tb01516.x; WEIJLAND A, UNPUB	33	114	117	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1311	1314		10.1126/science.8446899	http://dx.doi.org/10.1126/science.8446899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446899				2022-12-28	WOS:A1993KN88300027
J	LEVINE, B; HUANG, Q; ISAACS, JT; REED, JC; GRIFFIN, DE; HARDWICK, JM				LEVINE, B; HUANG, Q; ISAACS, JT; REED, JC; GRIFFIN, DE; HARDWICK, JM			CONVERSION OF LYTIC TO PERSISTENT ALPHAVIRUS INFECTION BY THE BCL-2 CELLULAR ONCOGENE	NATURE			English	Article							FOLLICULAR LYMPHOMA; B-CELLS; DEATH; APOPTOSIS; GENE; EXPRESSION; VIRUS; PROTEIN; LINES	LITTLE is known about virus-host cell interactions that regulate the lytic potential of viruses during productive replication. Sindbis virus (SV), a single-stranded positive-sense RNA virus in the alphavirus genus (family Togaviridae), results in lytic infection in most vertebrate cell lines, but persistent productive infection in post-mitotic neurons1. The cellular oncogene bcl-2, which encodes an inner mitochondrial membrane protein of M(r) 26,000 (ref. 2), blocks programmed cell death (apoptosis) in neurons3. We therefore investigated whether SV infection induces programmed cell death in non-neuronal cells, and if so, whether virus-induced programmed cell death can be blocked by transfection with bcl-2. We demonstrate that SV infection of baby hamster kidney (BHK-2), mouse neuroblastoma (N18), and rat prostatic adenocarcinoma (AT-3) cells results in programmed cell death, whereas SV infection of bcl-2-transfected AT-3 cells results in long-term persistent productive infection. Thus cellular bcl-2 oncogene expression plays a role in the establishment of persistent viral infection by blocking virus-induced programmed cell death.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT UROL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21287 USA; LA JOLLA CANC RES FDN, CANC RES INST, LA JOLLA, CA 92037 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Sanford Burnham Prebys Medical Discovery Institute								ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JOHNSON RT, 1972, J INFECT DIS, V125, P257, DOI 10.1093/infdis/125.3.257; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEVINE B, 1992, J VIROL, V66, P6429, DOI 10.1128/JVI.66.11.6429-6435.1992; LEVINE B, 1991, SCIENCE, V254, P856, DOI 10.1126/science.1658936; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TREIGER B, 1988, J UROLOGY, V140, P1580, DOI 10.1016/S0022-5347(17)42131-8; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wyllie A H, 1980, Int Rev Cytol, V68, P251; [No title captured]; [No title captured]	28	447	470	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1993	361	6414					739	742		10.1038/361739a0	http://dx.doi.org/10.1038/361739a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441470				2022-12-28	WOS:A1993KN78900061
J	JONES, RVH; HANSFORD, J; FISKE, J				JONES, RVH; HANSFORD, J; FISKE, J			DEATH FROM CANCER AT HOME - THE CARERS PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To collect information from principal carers of people who had died at home with cancer; to identify areas of support which need improvement. Design-Semistructured interviews with carers two to four months after the death. Setting-38 general practices in the Exeter, Torbay, and Plymouth health districts. Subjects-207 carers. Main outcome measures-Services received by carers and quality of support. Results-161 of 207 patients were aged 60 or over. 88 carers were aged under 60, 110 were 60-80, and 9 were > 80. Carers had difficulty in getting urgent professional help in only 15 out of 177 cases. 124 carers were not given advice on financial help and 174 were not told of support available from local charities. Although pain was well controlled, 25% of patients had no relief of other symptoms. Overall, 150 carers considered the support excellent, 45 good, 8 moderate, 2 poor, and 2 had no comment. Conclusions-Although care has improved in recent years, health professionals need to give carers more advice about help available outside health services. Domestic help was often needed earlier. Better appreciation of carers' problems is needed.			JONES, RVH (corresponding author), UNIV EXETER,POSTGRAD MED SCH,DEPT GEN PRACTICE,EXETER EX2 5DW,ENGLAND.							CARTWRIGHT A, 1973, LIFE DEATH; HERD EB, 1990, BRIT J GEN PRACT, V40, P248; HIGGINSON I, 1990, BRIT MED J, V301, P277, DOI 10.1136/bmj.301.6746.277; HIGGINSON I, 1989, J R SOC MED, V82, P2264; JONES R, 1992, EUR J CANCER CARE, V1, P9; JONES RVH, 1992, BRIT J GEN PRACT, V42, P419; Parkes C M, 1978, J R Coll Gen Pract, V28, P19; SYKES N P, 1992, Palliative Medicine, V6, P227, DOI 10.1177/026921639200600307; WILKES E, 1984, LANCET, V1, P950; 1987, CARE DYING GUIDE HLT; 1989, MORTALITY UK; 1980, TERMINAL CARE REPORT	12	86	87	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					249	251		10.1136/bmj.306.6872.249	http://dx.doi.org/10.1136/bmj.306.6872.249			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443527	Green Published, Bronze			2022-12-28	WOS:A1993KJ59100024
J	SNELLER, MC; STROBER, W; EISENSTEIN, E; JAFFE, JS; CUNNINGHAMRUNDLES, C				SNELLER, MC; STROBER, W; EISENSTEIN, E; JAFFE, JS; CUNNINGHAMRUNDLES, C			NEW INSIGHTS INTO COMMON VARIABLE IMMUNODEFICIENCY	ANNALS OF INTERNAL MEDICINE			English	Article						COMMON VARIABLE IMMUNODEFICIENCY; AGAMMAGLOBULINEMIA; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; LYMPHOPROLIFERATIVE DISORDERS	EPSTEIN-BARR VIRUS; LINKED LYMPHOPROLIFERATIVE SYNDROME; PERIPHERAL-BLOOD LYMPHOCYTES; INTRAVENOUS GAMMA-GLOBULIN; T-CELL; VARIED IMMUNODEFICIENCY; HYPOGAMMAGLOBULINEMIA; DEFICIENCY; INFECTION; IMMUNOGLOBULIN	Common variable immunodeficiency (CVI) is a heterogenous immunodeficiency syndrome characterized by hypogammaglobulinemia, recurrent bacterial infections, and various immunologic abnormalities. In addition to recurrent infections, patients with this syndrome also have an increased incidence of autoimmune disease and malignancy. Because the spectrum of associated diseases is broad, patients with CVI are seen by various medical specialists. This review discusses the pathogenesis, clinical manifestations, diagnosis, and treatment of CVI.	NIAID, IMMUNOREGULAT LAB,BLDG 10,ROOM 11N250, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA; NIAID, CLIN INVEST LAB, BETHESDA, MD 20892 USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA; MT SINAI MED CTR, DEPT MED, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT PEDIAT, NEW YORK, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Drexel University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai								AMBROSINO DM, 1987, NEW ENGL J MED, V316, P790, DOI 10.1056/NEJM198703263161306; AMMANN AJ, 1982, CLIN IMMUNOL IMMUNOP, V22, P60, DOI 10.1016/0090-1229(82)90022-8; ASHERSON GL, 1980, DIAGNOSIS TREATMENT, P37; ASHMAN RF, 1980, J ALLERGY CLIN IMMUN, V65, P242, DOI 10.1016/0091-6749(80)90151-7; BRUTON OC, 1952, PEDIATRICS, V9, P722; BRYANT A, 1990, CLIN IMMUNOL IMMUNOP, V56, P239, DOI 10.1016/0090-1229(90)90145-G; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; CARNEY WP, 1983, J IMMUNOL, V130, P390; CHOI YS, 1972, LANCET, V1, P1149; CLEMENT LT, 1984, J IMMUNOL, V133, P2461; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUNNINGHAMRUNDLES C, 1987, J CLIN IMMUNOL, V7, P294, DOI 10.1007/BF00915550; CUNNINGHAMRUNDLES C, 1984, ANN INTERN MED, V101, P435, DOI 10.7326/0003-4819-101-4-435; CUNNINGHAMRUNDLES C, 1992, CLIN IMMUNOL IMMUNOP, V64, P46, DOI 10.1016/0090-1229(92)90058-V; CUNNINGHAMRUNDLES C, 1988, IMMUNOL ALLERGY CLIN, V8, P17; DEGAST GC, 1980, CLIN EXP IMMUNOL, V42, P535; DELACONCHA EG, 1977, CLIN EXP IMMUNOL, V27, P208; EISENSTEIN EM, 1992, J ALLERGY CLIN IMMUN, V89, P167; FASTH A, 1982, J CLIN IMMUNOL, V2, P86, DOI 10.1007/BF00916891; FREEMAN HJ, 1977, GASTROENTEROLOGY, V73, P1397; FRIEDMAN JM, 1977, CLIN EXP IMMUNOL, V28, P375; GRABSTEIN K, 1986, J IMMUNOL, V136, P4503; GRIERSON H, 1987, ANN INTERN MED, V106, P538, DOI 10.7326/0003-4819-106-4-538; GUPTA S, 1986, J CLIN IMMUNOL, V6, P502, DOI 10.1007/BF00915256; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P3189; HERMANS PE, 1976, AM J MED, V61, P221, DOI 10.1016/0002-9343(76)90173-X; HILL LE, 1971, MED RES COUNCIL SPEC, V310; JAFFE JS, 1992, FASEB J, V6, pA1120; JANEWAY CA, 1966, NEW ENGL J MED, V275, P826, DOI 10.1056/NEJM196610132751508; JEFFERIS R, 1990, CLIN EXP IMMUNOL, V81, P357; JOHNSTON CLW, 1983, ANN RHEUM DIS, V42, P108, DOI 10.1136/ard.42.1.108; KINLEN LJ, 1985, LANCET, V1, P263; KRUGER G, 1984, J CLIN IMMUNOL, V4, P295, DOI 10.1007/BF00915297; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; LEICKLY FE, 1987, AM J MED, V82, P159, DOI 10.1016/0002-9343(87)90398-6; MAHER P, 1985, CLIN EXP IMMUNOL, V62, P515; McCluskey DR, 1989, P R COLL PHYSICIANS, V19, P191; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; NOLTE MT, 1979, CLIN EXP IMMUNOL, V36, P237; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PHILLIPS JH, 1986, J IMMUNOL, V136, P1579; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROIFMAN CM, 1985, AM J MED, V79, P171, DOI 10.1016/0002-9343(85)90006-3; SAIKI O, 1982, P NATL ACAD SCI-BIOL, V79, P6008, DOI 10.1073/pnas.79.19.6008; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANDER CA, 1992, AM J SURG PATHOL, V16, P1170, DOI 10.1097/00000478-199212000-00004; SCHAFFER FM, 1989, P NATL ACAD SCI USA, V86, P8015, DOI 10.1073/pnas.86.20.8015; SNELLER MC, 1990, J IMMUNOL, V144, P3762; SPERBER KE, 1988, IMMUNOL ALLERGY CLIN, V8, P423; STRAUS SE, 1984, ANN INTERN MED, V100, P522, DOI 10.7326/0003-4819-100-4-522; SULLIVAN JL, 1988, SEMIN HEMATOL, V25, P269; SULLIVAN JL, 1983, J CLIN INVEST, V71, P1765, DOI 10.1172/JCI110932; TOMKINSON BE, 1987, J IMMUNOL, V139, P3802; TWOMEY JJ, 1969, AM J MED, V47, P340, DOI 10.1016/0002-9343(69)90218-6; WAGNER DK, 1988, AM J MED, V84, P315, DOI 10.1016/0002-9343(88)90432-9; WEBSTER ADB, 1981, J CLIN IMMUNOL, V1, P113, DOI 10.1007/BF00915388; WHITE WB, 1985, NEW ENGL J MED, V312, P198, DOI 10.1056/NEJM198501243120402; WRIGHT JJ, 1990, BLOOD, V76, P2046; WRIGHT JJ, 1987, NEW ENGL J MED, V317, P1516, DOI 10.1056/NEJM198712103172406; WU LYE, 1973, J CLIN INVEST, V52, P3180, DOI 10.1172/JCI107518	60	191	193	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					720	730		10.7326/0003-4819-118-9-199305010-00011	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00011			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460860				2022-12-28	WOS:A1993KY50200011
J	FERGUSON, JH; DUBINSKY, M; KIRSCH, PJ				FERGUSON, JH; DUBINSKY, M; KIRSCH, PJ			COURT-ORDERED REIMBURSEMENT FOR UNPROVED MEDICAL TECHNOLOGY - CIRCUMVENTING TECHNOLOGY-ASSESSMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							AMYGDALIN	Objective.-Because we found examples where courts ot law ruled against insurance carriers that had been sued for reimbursement for unproven medical procedures, we conducted a case study to determine the reasoning behind these decisions that run counter to accepted medical science. Such actions circumvent health technology assessment and could contribute to escalating health care costs and poorer quality health care. Data Sources.-A literature search identified 17 cases between 1980 and 1989 in which an insurance company was sued to reimburse a patient who had received an unproven or questionable health technology; 14 of these suits were decided in favor of the plaintiff, and the insurance company was ordered to pay. Discussed in this article are six of these cases, two involving Laetrile (amygdalin), two involving immunoaugmentative therapy, and two involving thermography, technologies that had previously been assessed as not safe, not effective, or inadequately evaluated. Data Synthesis and Conclusions.-The circumstances determining how the courts arrive at these ''unscientific'' decisions fall into three general categories: (1) for legal reasons, the insurance contract is interpreted in favor of the insured; (2) the reluctance and/or inability, legal or otherwise, of the courts to use published scientific literature; and (3) the use of adversarial ''expert'' witnesses with potential conflicts of interest. To address this situation, we first urge the legal and insurance industries to cooperate in improving the contract language and process in a way that would be both legally and scientifically appropriate. Second, we encourage the courts to use and foster the use of published peer-reviewed scientific material as evidence whenever possible. Third, we recommend that the courts choose their own unbiased expert witnesses to interpret scientific material.	ADM CHILDREN & FAMILIES, WASHINGTON, DC USA; CUTLER & STANFIELD, WASHINGTON, DC USA		FERGUSON, JH (corresponding author), NIH, OFF MED APPLICAT RES, FED BLDG, RM 618, BETHESDA, MD 20892 USA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; BAILAR JC, 1992, MED USES STATISTICS; CLINE JS, 1985, TORT INSUR LAW J, V21, P120; CURT GA, 1986, JAMA-J AM MED ASSOC, V255, P505, DOI 10.1001/jama.255.4.505; ELLISON NM, 1978, NEW ENGL J MED, V299, P549, DOI 10.1056/NEJM197809072991013; HUBER PW, 1991, GALILEOS REVENGE JUN, P206; Larson E B, 1989, Int J Technol Assess Health Care, V5, P195; MOERTEL CG, 1982, NEW ENGL J MED, V306, P201, DOI 10.1056/NEJM198201283060403; MOERTEL CG, 1981, JAMA-J AM MED ASSOC, V245, P591, DOI 10.1001/jama.245.6.591; MONACO GP, 1985, FORUM, V20, P400; 1990, OTAH4045 PUBL; 1979, CAN MED ASS J, V121, P1193; 1983, NCHSR HLTH TECHNOL A, V22, P1; 1989, NCHSR HLTH TECHNOL A, V2, P1	14	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2116	2121		10.1001/jama.269.16.2116	http://dx.doi.org/10.1001/jama.269.16.2116			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468767				2022-12-28	WOS:A1993KY36600035
J	GATTINONI, L; DANDREA, L; PELOSI, P; VITALE, G; PESENTI, A; FUMAGALLI, R				GATTINONI, L; DANDREA, L; PELOSI, P; VITALE, G; PESENTI, A; FUMAGALLI, R			REGIONAL EFFECTS AND MECHANISM OF POSITIVE END-EXPIRATORY PRESSURE IN EARLY ADULT RESPIRATORY-DISTRESS SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAILURE; VENTILATION; SCAN	Objective.-To test the hypothesis that positive end-expiratory pressure (PEEP) prevents the collapse of a given lung region when it is equal to or greater than the hydrostatic pressure superimposed (SPL) to that region. Design.-Intervention study with sequential levels of PEEP applied in random order to a cohort of patients with adult respiratory distress syndrome (ARDS). Setting.-Referral center for ARDS in a university hospital. Patients.-Ten ARDS patients (with Murray scores >2.5). Intervention.-Basal computed tomographic (CT) section taken at 0, 2, 4, 5, 6, 8, 10, 12, 14, 15, and 20 cm H2O PEEP. Main Outcome Measures.-Basal lung CT sections were divided into 1 0 equal levels from the ventral to dorsal surfaces. In each level SPL was measured from density and height. The inflation of the level was measured as the gas/tissue ratio (g/t); g/t changes with PEEP were defined as the g/t-P curve. The slope of the g/t-P curve was defined as level compliance (ie, the ratio of change in the g/t of the level to the change in pressure). A linear g/t-P curve was the criterion to detect inflation without recruitment (ie, new pulmonary units opening at a given pressure). A biphasic g/t-P curve (change of compliance after an inflection point) was the criterion to detect recruitment. Pflex was defined as the pressure at which the inflection point occurred. Results.-The SPL increased from level 1 (ventral) to level 10 (dorsal) (r=.91; P<.01). The number of linear g/t-P curves decreased from level 1 to level 10 (r=.98; P<.01), while the number of biphasic g/t-P curves increased (r=.95; P<.01). The Pflex increased from level 1 to 10 (r=.97; P<.01) and Pflex was similar to SPL (Pflex=1.05+0.9 SPL; r=.75; P<0.01). Conclusions.-The increased SPL causes compression atelectasis; this is prevented when PEEP to a given lung region is equal to or greater than the SPL.	UNIV MILAN,OSPED S GERARDO MONZA,IST ANESTESIA & RIANIMAZIONE,I-20122 MILAN,ITALY	University of Milan			Rocco, Patricia/I-7460-2012; Fumagalli, Roberto/AAB-9746-2019; Pesenti, Antonio/H-7483-2012	Rocco, Patricia/0000-0003-1412-7136; Fumagalli, Roberto/0000-0003-0398-1329; Pesenti, Antonio/0000-0003-2593-729X; Gattinoni, Luciano/0000-0001-5380-2494; Pelosi, Paolo/0000-0001-5055-3023				ASHBAUGH DG, 1967, LANCET, V2, P319; Beydon L, 1991, ADULT RESP DISTRESS, P139; BRISMAR B, 1985, ANESTHESIOLOGY, V62, P422, DOI 10.1097/00000542-198504000-00009; DANTZKER DR, 1980, CHEST, V77, P636, DOI 10.1378/chest.77.5.636; DEMEDTS M, 1975, J APPL PHYSIOL, V38, P228, DOI 10.1152/jappl.1975.38.2.228; FALKE KJ, 1972, J CLIN INVEST, V51, P2315, DOI 10.1172/JCI107042; GATTINONI L, 1987, AM REV RESPIR DIS, V136, P730, DOI 10.1164/ajrccm/136.3.730; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; Gattinoni L, 1988, J Thorac Imaging, V3, P59, DOI 10.1097/00005382-198807000-00013; GATTINONI L, 1991, ACTA ANAESTH SCAND, V35, P87, DOI 10.1111/j.1399-6576.1991.tb03404.x; GATTINONI L, 1986, J THORAC IMAG, V3, P25; INGRAM RH, 1974, J APPL PHYSIOL, V36, P135, DOI 10.1152/jappl.1974.36.2.135; KRUGGER JJ, 1961, J APPL PHYSIOL, V16, P465; LAMY M, 1976, AM REV RESPIR DIS, V114, P267; MATAMIS D, 1984, CHEST, V86, P58, DOI 10.1378/chest.86.1.58; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; PESENTI A, 1985, CRIT CARE MED, V13, P34, DOI 10.1097/00003246-198501000-00009; SALMON RB, 1981, J APPL PHYSIOL, V51, P353, DOI 10.1152/jappl.1981.51.2.353; Snedecor G.W., 1980, STAT METHODS, V7; ZAPOL WM, 1979, AM REV RESPIR DIS, V119, P547	22	301	310	2	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2122	2127		10.1001/jama.269.16.2122	http://dx.doi.org/10.1001/jama.269.16.2122			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468768				2022-12-28	WOS:A1993KY36600036
J	SCHERTLER, GFX; VILLA, C; HENDERSON, R				SCHERTLER, GFX; VILLA, C; HENDERSON, R			PROJECTION STRUCTURE OF RHODOPSIN	NATURE			English	Article							BOVINE RHODOPSIN; CYSTEINE RESIDUE-110; PURPLE MEMBRANE; RESOLUTION; BACTERIORHODOPSIN; TRANSDUCIN; SEQUENCE	LIGHT absorption by the visual pigment rhodopsin1,2 triggers, through G-protein coupling, a cascade of events in the outer segment of the rod cell of the vertebrate retina that results in membrane hyperpolarization and nerve excitation3-5. Rhodopsin, which contains 348 amino acids6-8, has seven helices that cross the disk membrane 69 and its amino terminus is extracellular. A wealth of biochemical data is available for rhodopsin: 11-cis retinal is bound10 to lysine 296 in helix VII; glutamic acid 113 on helix III is the counterion to the protonated Schiffs base11,12; a disulphide bridge, cystine 110-187, connects helix III to the second extracellular loop e2 (refs 13, 14); the carboxy terminus has two palmitoylated cysteines forming a cytoplasmic loop i4 (ref. 15); three intracellular loops i2, i3 and i4 mediate activation of the heterotrimeric G protein transducin16,17; glutamic acid 135 and arginine 136 at the cytoplasmic end of helix III affect binding of transducin18. But to provide a framework to interpret these data, not only for rhodopsin but for other G-protein-coupled receptors, requires the structure to be determined. Here we present a projection map of rhodopsin showing the configuration of the helices.			SCHERTLER, GFX (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		Schertler, Gebhard/M-9512-2014	Schertler, Gebhard F.X./0000-0002-5846-6810				BALDWIN JM, IN PRESS EMBO J; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; CESKA TA, 1990, J MOL BIOL, V213, P539, DOI 10.1016/S0022-2836(05)80214-1; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CORLESS JM, 1982, P NATL ACAD SCI-BIOL, V79, P1116, DOI 10.1073/pnas.79.4.1116; DEGRIP WJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P799, DOI 10.1111/j.1751-1097.1988.tb02895.x; DEGRIP WJ, 1982, METHOD ENZYMOL, V81, P197; DEMIN VV, 1987, RETINAL PROTEINS, P519; DRATZ EA, 1985, BIOCHIM BIOPHYS ACTA, V832, P337, DOI 10.1016/0167-4838(85)90268-7; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HARGRAVE PA, IN PRESS BIOESSAYS; Hargrave PA, 1991, CURR OPIN STRUC BIOL, V1, P575, DOI 10.1016/S0959-440X(05)80080-6; HENDERSON R, 1990, PHILOS T ROY SOC B, V326, P379, DOI 10.1098/rstb.1990.0019; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHLBRANDT W, 1992, Q REV BIOPHYS, V25, P1; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1424; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; STRYER L, 1991, J BIOL CHEM, V266, P10711; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	27	696	704	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 22	1993	362	6422					770	772		10.1038/362770a0	http://dx.doi.org/10.1038/362770a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8469290				2022-12-28	WOS:A1993KY45000063
J	BRANCH, P; AQUILINA, G; BIGNAMI, M; KARRAN, P				BRANCH, P; AQUILINA, G; BIGNAMI, M; KARRAN, P			DEFECTIVE MISMATCH BINDING AND A MUTATOR PHENOTYPE IN CELLS TOLERANT TO DNA DAMAGE	NATURE			English	Article							ESCHERICHIA-COLI DNA; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; CHO CELLS; REPAIR; GENE; METHYLNITROSOUREA; RESISTANCE; LOCUS	ACQUIRED resistance to alkylating agents such as N-methyl-N-nitrosourea or N-methyl-N'-nitro-N-nitrosoguanidine results from the ability to tolerate the potentially cytotoxic methylated base O6-methylguanine (m6-G) in DNA. In the absence of repair by demethylation in situ, m6-G is probably lethal through its inappropriate processing by the cell1. DNA mismatch correction is an attractive candidate for the processing function because although it is replicated, m6-G has no perfect complementary base. Thus, m6-G in DNA might provoke abortive mismatch repair and tolerance could subsequently arise through loss of a mismatch repair pathway2-3. Mismatch correction helps maintain genomic fidelity by removing misincorporated bases and deaminated 5-methylcytosine from DNA, and its loss by mutation confers a mutator phenotype on Escherichia coli4,5. Here we describe human and hamster cell lines that are tolerant to N-methyl-N-nitrosourea and are defective in a DNA mismatch binding activity. The loss of this activity, which acts on G.T mispairs, confers a mutator phenotype.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; IST SUPER SANITA,I-00161 ROME,ITALY	Istituto Superiore di Sanita (ISS)			Aquilina, Gabriele/AAI-7978-2021	Aquilina, Gabriele/0000-0002-3280-7883				AQUILINA G, 1988, CARCINOGENESIS, V9, P1217, DOI 10.1093/carcin/9.7.1217; AQUILINA G, 1989, CARCINOGENESIS, V10, P1219, DOI 10.1093/carcin/10.7.1219; BORTS RH, 1990, GENETICS, V124, P573; COX EC, 1976, ANNU REV GENET, V10, P135, DOI 10.1146/annurev.ge.10.120176.001031; FLECK O, 1992, NUCLEIC ACIDS RES, V20, P2271, DOI 10.1093/nar/20.9.2271; FUJII H, 1989, J BIOL CHEM, V264, P10057; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; KARRAN P, 1990, CANCER RES, V50, P1532; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LIEB M, 1991, GENETICS, V128, P23; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; Luria SE, 1943, GENETICS, V28, P491; MCGREGOR WG, 1991, SOMAT CELL MOLEC GEN, V17, P463, DOI 10.1007/BF01233170; MODRICH P, 1989, J BIOL CHEM, V264, P6597; PHEAR G, 1989, J MOL BIOL, V209, P577, DOI 10.1016/0022-2836(89)90595-0; REWINSKI C, 1987, NUCLEIC ACIDS RES, V15, P8205, DOI 10.1093/nar/15.20.8205; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177	21	345	354	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					652	654		10.1038/362652a0	http://dx.doi.org/10.1038/362652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8464518				2022-12-28	WOS:A1993KX43800055
J	LEVY, SB				LEVY, SB			CONFRONTING MULTIDRUG RESISTANCE - A ROLE FOR EACH OF US	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ANTIMICROBIAL RESISTANCE; ESCHERICHIA-COLI; ENTEROCOCCUS		TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112; NEW ENGLAND MED CTR,BOSTON,MA 02111	Tulane University; Tufts Medical Center	LEVY, SB (corresponding author), TULANE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,CTR ADAPTAT GENET & DRUG RESISTANCE,NEW ORLEANS,LA 70112, USA.							BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BLUMBERG HM, 1991, J INFECT DIS, V163, P1279, DOI 10.1093/infdis/163.6.1279; DATTA N, 1971, LANCET, V1, P312; DOVER MJ, 1986, BIOSCIENCE, V36, P78, DOI 10.2307/1310107; FORNASINI M, 1992, J INFECT DIS, V166, P326, DOI 10.1093/infdis/166.2.326; HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065; KLOOS WE, 1986, MICROBIOLOGY 1986, P132; KUNIN CM, 1990, PRINCIPLES PRACTICE, P427; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; Lederberg J., 1992, EMERGING INFECTIONS; Levy S. B., 1986, BANBURY REPORT, P17; Levy Stuart B., 1992, ANTIBIOTIC PARADOX M; MOELLERING RC, 1991, J ANTIMICROB CHEMOTH, V28, P1, DOI 10.1093/jac/28.1.1; MORTON A, 1991, J INFECT DIS, V163, P542; MURRAY BE, 1982, NEW ENGL J MED, V306, P130, DOI 10.1056/NEJM198201213060302; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; Shlaes D, 1991, ASM NEWS, V57, P455; STAMM WE, 1992, INFECT DIS, P792; TAUXE RV, 1990, J INFECT DIS, V162, P1107, DOI 10.1093/infdis/162.5.1107; WONGSRICHANALAI C, 1992, AM J TROP MED HYG, V47, P112, DOI 10.4269/ajtmh.1992.47.112	22	47	47	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1840	1842		10.1001/jama.269.14.1840	http://dx.doi.org/10.1001/jama.269.14.1840			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459518				2022-12-28	WOS:A1993KW25000041
J	HOHEISEL, JD; MAIER, E; MOTT, R; MCCARTHY, L; GRIGORIEV, AV; SCHALKWYK, LC; NIZETIC, D; FRANCIS, F; LEHRACH, H				HOHEISEL, JD; MAIER, E; MOTT, R; MCCARTHY, L; GRIGORIEV, AV; SCHALKWYK, LC; NIZETIC, D; FRANCIS, F; LEHRACH, H			HIGH-RESOLUTION COSMID AND P1-MAPS SPANNING THE 14-MB GENOME OF THE FISSION YEAST S-POMBE	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; REFERENCE LIBRARIES; DNA; CONSTRUCTION; PHOSPHATASE; CHROMOSOMES; DEPENDENCE; ELEGANS; TYPE-1; REPEAT	Gridded on high density filters, a P1 genomic library of 17-fold coverage and a cosmid library of 8 genome equivalents, both made from S. pombe strain 972h-, were ordered by hybridizing genetic markers and individual clones from the two libraries. Yeast artificial chromosome (YAC) clones covering the entire genome were used to subdivide the libraries, and hybridization of short oligonucleotides and DNA pools made from randomly selected cosmids provided further mapping information. Restriction digests were generated as an independent confirmation of the clone order. The high resolution clone map was aligned to the genetic map and the physical NotI and YAC maps. The usefulness of the various mapping techniques and cloning procedures could be assessed upon the different data sets.			HOHEISEL, JD (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Nizetic, Dean/F-9509-2015; Schalkwyk, Leonard C/A-2150-2010; Francis, Fiona/B-5854-2016	Schalkwyk, Leonard C/0000-0001-7030-5756; Mott, Richard/0000-0002-1022-9330; Nizetic, Dean/0000-0001-5486-5761; Francis, Fiona/0000-0001-8542-7537; Grigoriev, Andrey/0000-0002-3227-532X				BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; CRAIG AG, 1990, NUCLEIC ACIDS RES, V18, P2653; ELLIOTT S, 1986, J BIOL CHEM, V261, P2936; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; EVANS GA, 1989, P NATL ACAD SCI USA, V86, P5030, DOI 10.1073/pnas.86.13.5030; FAN JB, 1988, NUCLEIC ACIDS RES, V17, P2801; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; HAYLES J, 1992, ANNU REV GENET, V26, P373, DOI 10.1146/annurev.ge.26.120192.002105; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HOHEISEL JD, 1990, J BIOL CHEM, V265, P16656; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LARIN Z, 1990, GENET RES, V56, P203, DOI 10.1017/S0016672300035308; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LEHRACH H., 1990, GENOME ANAL, P39; LENNON GG, 1992, CURR GENET, V21, P1, DOI 10.1007/BF00318646; LEVIN HL, 1990, MOL CELL BIOL, V10, P6791, DOI 10.1128/MCB.10.12.6791; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MEIEREWERT S, 1993, NATURE, V361, P375, DOI 10.1038/361375a0; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; POHL FM, 1982, EUR J BIOCHEM, V123, P141, DOI 10.1111/j.1432-1033.1982.tb06510.x; Ross M. T., 1992, Techniques for the analysis of complex genomes., P137; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAK J, 1982, NUCLEIC ACIDS RES, V10, P2851, DOI 10.1093/nar/10.9.2851; STERNBERG N, 1990, New Biologist, V2, P151; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0	35	236	239	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					109	120		10.1016/0092-8674(93)90164-L	http://dx.doi.org/10.1016/0092-8674(93)90164-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462094				2022-12-28	WOS:A1993KW75300012
J	LOCKHART, DJ; KIM, PS				LOCKHART, DJ; KIM, PS			ELECTROSTATIC SCREENING OF CHARGE AND DIPOLE INTERACTIONS WITH THE HELIX BACKBONE	SCIENCE			English	Article							ALPHA-HELIX; PROTEINS; MODEL; STABILIZATION; RESONANCE; STABILITY; PEPTIDES; ALANINE	Electrostatic interactions in proteins are potentially quite strong, but these interactions are mitigated by the screening effects of water, ions, and nearby protein atoms. The early work of Kirkwood and Westheimer on small organic molecules showed that the extent of the screening may depend on whether charged or dipolar groups are involved. The dielectric and ionic screening of the interactions between the dipolar backbone amide groups of monomeric a helices and either (i) solvent-exposed charges or (ii) solvent-exposed dipoles at the amino terminus was measured. The dielectric screening effects are an order of magnitude greater for the backbone-charge interactions than for the backbone-dipole interactions, and the ionic strength dependence is substantially different in the two cases. These results suggest that interactions that involve the dipolar groups of proteins may be relatively more important for stability and function than is generally thought.			LOCKHART, DJ (corresponding author), MIT,DEPT BIOL,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; BAKER FW, 1967, J AM CHEM SOC, V89, P5677, DOI 10.1021/ja00998a032; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Cantor C.R., 1980, BIOPHYS CHEM; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; EHRENSON S, 1976, J AM CHEM SOC, V98, P7510, DOI 10.1021/ja00440a009; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; GILSON MK, 1985, J MOL BIOL, V183, P503; HILL TL, 1956, J PHYS CHEM-US, V60, P253, DOI 10.1021/j150536a029; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; Kirkwood JG, 1938, J CHEM PHYS, V6, P506, DOI 10.1063/1.1750302; Kirkwood JG, 1934, J CHEM PHYS, V2, DOI 10.1063/1.1749489; LIFF MI, 1991, J AM CHEM SOC, V113, P1014, DOI 10.1021/ja00003a041; LOCKHART DJ, 1992, SCIENCE, V257, P947, DOI 10.1126/science.1502559; LOCKHART DJ, UNPUB; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MIICK SM, 1991, BIOCHEMISTRY-US, V30, P9498, DOI 10.1021/bi00103a016; MIICK SM, 1992, NATURE, V359, P653, DOI 10.1038/359653a0; NICHOLSON H, 1991, BIOCHEMISTRY-US, V30, P9816, DOI 10.1021/bi00105a002; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; REES DC, 1980, J MOL BIOL, V141, P323, DOI 10.1016/0022-2836(80)90184-9; ROHL CA, 1992, BIOCHEMISTRY-US, V31, P1263, DOI 10.1021/bi00120a001; SAKAMOTO T, 1989, J PHYS CHEM-US, V93, P357, DOI 10.1021/j100338a069; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SCHOLTZ JM, 1991, J AM CHEM SOC, V113, P5102, DOI 10.1021/ja00013a079; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SHAKA AJ, 1983, J MAGN RESON, V53, P313, DOI 10.1016/0022-2364(83)90035-5; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; TAKAHASHI T, 1992, BIOPOLYMERS, V32, P897, DOI 10.1002/bip.360320802; TANFORD C, 1957, J AM CHEM SOC, V79, P5333, DOI 10.1021/ja01577a001; THOMAS PG, 1985, NATURE, V318, P375, DOI 10.1038/318375a0; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; Wada A, 1976, Adv Biophys, P1; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P1219, DOI 10.1073/pnas.84.5.1219; Westneimer FH, 1938, J CHEM PHYS, V6, P513, DOI 10.1063/1.1750303; Wuthrich K., 1986, NMR PROTEINS NUCL AC	41	158	159	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					198	202		10.1126/science.8469972	http://dx.doi.org/10.1126/science.8469972			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8469972				2022-12-28	WOS:A1993KW45200033
J	MAURICE, J				MAURICE, J			CONTROVERSIAL VACCINE SHOWS PROMISE	SCIENCE			English	Editorial Material																		1992, SCIENCE, V258, P207	1	2	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1689	1690		10.1126/science.8456292	http://dx.doi.org/10.1126/science.8456292			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456292				2022-12-28	WOS:A1993KT81000015
J	KIM, CWA; BERG, JM				KIM, CWA; BERG, JM			THERMODYNAMIC BETA-SHEET PROPENSITIES MEASURED USING A ZINC-FINGER HOST PEPTIDE	NATURE			English	Article							HELIX-FORMING TENDENCIES; OCCURRING AMINO-ACIDS; GLOBULAR-PROTEINS; SECONDARY STRUCTURE; DEPENDENT STRUCTURE; PREFERENCES; STABILITY	THE three-dimensional structures of proteins reveal that the distribution of amino acids within the major classes of secondary structure is not random but that each amino acid has its own preferred secondary structural arrangements1-5. Propensity scales for residues in alpha-helices have been generated through the use of various host-guest systems6-9. Here we measure the thermodynamic beta-sheet propensities of each of the twenty commonly occurring amino acids. A previously studied zinc-finger peptide10 was used as the host system in which amino acids were substituted into a guest site, a solvent-exposed position in an antiparallel beta-sheet. As these peptides are unfolded in the absence of bound metal but are folded in their presence, it is assumed that the thermodynamics of metal binding fully reflect peptide-folding energy. A competitive cobalt(II)-binding assay was used to determine these energies with high precision. The relative free energies correlate well with previously derived potential values based on statistical analysis of protein structures. We are therefore able to present a thermodynamic beta-sheet propensity scale for all the commonly occurring amino acids in aqueous solution.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205	Johns Hopkins University	KIM, CWA (corresponding author), JOHNS HOPKINS UNIV,DEPT CHEM,34TH & CHARLES ST,BALTIMORE,MD 21218, USA.		Berg, Jeremy/GRY-6706-2022	Berg, Jeremy/0000-0002-2444-8139; Berg, Jeremy/0000-0003-3022-0963				CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CREAMER TP, 1992, P NATL ACAD SCI USA, V89, P5937, DOI 10.1073/pnas.89.13.5937; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARPER LV, IN PRESS J AM CHEM S; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; KRIZEK BA, IN PRESS INORG CHEM; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LIFSON S, 1979, NATURE, V282, P109, DOI 10.1038/282109a0; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; ZAWADZKE LE, 1992, J AM CHEM SOC, V114, P4002, DOI 10.1021/ja00036a073	19	334	349	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					267	270		10.1038/362267a0	http://dx.doi.org/10.1038/362267a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8459852				2022-12-28	WOS:A1993KT02600063
J	OLSSON, T; BAKHIET, M; HOJEBERG, B; LJUNGDAHL, A; EDLUND, C; ANDERSSON, G; EKRE, HP; FUNGLEUNG, WP; MAK, T; WIGZELL, H; FISZER, U; KRISTENSSON, K				OLSSON, T; BAKHIET, M; HOJEBERG, B; LJUNGDAHL, A; EDLUND, C; ANDERSSON, G; EKRE, HP; FUNGLEUNG, WP; MAK, T; WIGZELL, H; FISZER, U; KRISTENSSON, K			CD8 IS CRITICALLY INVOLVED IN LYMPHOCYTE-ACTIVATION BY A TRYPANOSOMA-BRUCEI BRUCEI-RELEASED MOLECULE	CELL			English	Article							GROWTH-FACTOR-BETA; TRYPANOSOMA-CRUZI INFECTIONS; ATHYMIC NUDE-MICE; INTERFERON-GAMMA; MONOCLONAL-ANTIBODIES; RAT LYMPHOCYTES; IFN-GAMMA; CYTOKINE PRODUCTION; INVIVO TREATMENT; ALPHA-3 DOMAIN	T. brucei brucei released a lymphocyte triggering factor (TLTF), which triggered purified CD8+, but not CD4+, T cells to interferon gamma (IFN-gamma) mRNA expression and secretion and to [H-3]thymidine incorporation. TLTF also induced mRNA for transforming growth factor beta, but not for interleukin-4. The action of this TLTF on mononuclear cell (MNC) cultures was blocked by anti-CD8 antibodies and by soluble CD8. MNCs from a mutant mouse strain lacking CD8 expression were not triggered by TLTF. IFN-gamma provides a growth stimulus for T. brucei brucei, and infected CD8- mice had much lower parasitemia and survived longer than CD8+ mice. The host-parasite interaction in experimental African trypanosomiasis thus involves parasite release of TLTF, which by binding to CD8 triggers CD8+ cells to produce the parasite growth-promoting cytokine IFN-gamma.	KAROLINSKA INST,HUDDINGE HOSP,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN; UNIV LUND,DEPT MED MICROBIOL & CLIN IMMUNOL,S-22007 LUND 7,SWEDEN; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO M4X 1K9,ONTARIO,CANADA; KAROLINSKA INST,DEPT IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Lund University; University of Toronto; University of Toronto; Karolinska Institutet	OLSSON, T (corresponding author), KAROLINSKA INST,HUDDINGE HOSP,DEPT NEUROL,S-14186 HUDDINGE,SWEDEN.			Fiszer, Urszula/0000-0002-9286-2454; Fung-Leung, Wai-Ping/0000-0001-7013-8855				AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; ANDERSSON G, 1989, J IMMUNOL METHODS, V125, P89, DOI 10.1016/0022-1759(89)90081-1; ANDERSSON U, 1988, EUR J IMMUNOL, V18, P2081, DOI 10.1002/eji.1830181232; ASKONAS BA, 1984, PARASITOLOGY, V88, P633, DOI 10.1017/S0031182000085553; BAKHIET M, 1990, CLIN EXP IMMUNOL, V81, P195, DOI 10.1111/j.1365-2249.1990.tb03317.x; BAKHIET M, 1993, IN PRESS SCAND J IMM; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BARCLAY AN, 1981, IMMUNOLOGY, V42, P593; BLACK SJ, 1985, CURR TOP MICROBIOL, V117, P93; BRIDEAU RJ, 1980, EUR J IMMUNOL, V10, P609, DOI 10.1002/eji.1830100807; CARDELL S, 1991, EUR J IMMUNOL, V21, P2495, DOI 10.1002/eji.1830211028; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; CZERKINSKY C, 1988, J IMMUNOL METHODS, V110, P29, DOI 10.1016/0022-1759(88)90079-8; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; DALLMAN MJ, 1984, EUR J IMMUNOL, V14, P260, DOI 10.1002/eji.1830140311; DOHLSTEN M, 1991, IMMUNOL TODAY, V12, P147, DOI 10.1016/0167-5699(91)90078-8; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; ENEROTH A, 1992, J NEUROCYTOL, V21, P846, DOI 10.1007/BF01191682; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GOLDSTEIN SAN, 1988, J IMMUNOL, V140, P3707; HECHT TT, 1983, J IMMUNOL, V131, P1049; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HIDE G, 1989, MOL BIOCHEM PARASIT, V36, P51, DOI 10.1016/0166-6851(89)90199-0; HOLMDAHL R, 1985, SCAND J IMMUNOL, V22, P157, DOI 10.1111/j.1365-3083.1985.tb01868.x; JACOB CO, 1987, J EXP MED, V166, P798, DOI 10.1084/jem.166.3.798; JOHNSON P, 1985, EMBO J, V4, P2539, DOI 10.1002/j.1460-2075.1985.tb03968.x; KABILAN L, 1990, EUR J IMMUNOL, V20, P1085, DOI 10.1002/eji.1830200521; KANE KP, 1989, J IMMUNOL, V142, P4153; KAPLOW LS, 1974, AM J CLIN PATHOL, V63, P451; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KARUPIAH G, 1990, J EXP MED, V172, P1495, DOI 10.1084/jem.172.5.1495; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LAKE JP, 1991, J IMMUNOL, V147, P1121; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LJUNGDAHL A, 1989, J NEUROSCI RES, V24, P451, DOI 10.1002/jnr.490240316; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MIX E, 1990, SCAND J IMMUNOL, V31, P493, DOI 10.1111/j.1365-3083.1990.tb02797.x; MIZUOCHI T, 1988, J IMMUNOL, V141, P1571; MOLLER G, 1989, IMMUNOL REV, V112; MUSTAFA MI, 1991, J NEUROIMMUNOL, V31, P165, DOI 10.1016/0165-5728(91)90022-Y; OLSSON T, 1989, J NEUROSCI, V9, P3870; OLSSON T, 1991, EUR J IMMUNOL, V21, P2447, DOI 10.1002/eji.1830211022; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; PALIARD X, 1988, J IMMUNOL, V141, P849; PORAT R, 1991, SCIENCE, V254, P430, DOI 10.1126/science.1833820; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; REED SG, 1988, J IMMUNOL, V140, P4342; ROOSNEK EE, 1985, EUR J IMMUNOL, V15, P652, DOI 10.1002/eji.1830150703; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SANDVIG S, 1987, IMMUNOL REV, V97, P51, DOI 10.1111/j.1600-065X.1987.tb00516.x; SCHLUESENER HJ, 1989, J NEUROIMMUNOL, V24, P249, DOI 10.1016/0165-5728(89)90123-9; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; TERRY LA, 1990, TISSUE ANTIGENS, V35, P82, DOI 10.1111/j.1399-0039.1990.tb01761.x; TODD RF, 1984, LEUCOCYTE TYPING, P424; VANDERMEIDE PH, 1986, J GEN VIROL, V67, P1059, DOI 10.1099/0022-1317-67-6-1059; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VYAKARNAM A, 1990, AIDS, V4, P21, DOI 10.1097/00002030-199001000-00003; WILLIAMS AF, 1977, CELL, V12, P663, DOI 10.1016/0092-8674(77)90266-5	63	127	129	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					715	727		10.1016/0092-8674(93)90400-K	http://dx.doi.org/10.1016/0092-8674(93)90400-K			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453666	Bronze			2022-12-28	WOS:A1993KR43600008
J	TROFATTER, JA; MACCOLLIN, MM; RUTTER, JL; MURRELL, JR; DUYAO, MP; PARRY, DM; ELDRIDGE, R; KLEY, N; MENON, AG; PULASKI, K; HAASE, VH; AMBROSE, CM; MUNROE, D; BOVE, C; HAINES, JL; MARTUZA, RL; MACDONALD, ME; SEIZINGER, BR; SHORT, MP; BUCKLER, AJ; GUSELLA, JF				TROFATTER, JA; MACCOLLIN, MM; RUTTER, JL; MURRELL, JR; DUYAO, MP; PARRY, DM; ELDRIDGE, R; KLEY, N; MENON, AG; PULASKI, K; HAASE, VH; AMBROSE, CM; MUNROE, D; BOVE, C; HAINES, JL; MARTUZA, RL; MACDONALD, ME; SEIZINGER, BR; SHORT, MP; BUCKLER, AJ; GUSELLA, JF			A NOVEL MOESIN-LIKE, EZRIN-LIKE, RADIXIN-LIKE GENE IS A CANDIDATE FOR THE NEUROFIBROMATOSIS-2 TUMOR SUPPRESSOR	CELL			English	Article							BILATERAL ACOUSTIC NEUROFIBROMATOSIS; PROTEIN-TYROSINE-PHOSPHATASE; TYPE-1 GENE; SEQUENCE HOMOLOGY; CDNA SEQUENCE; DNA MARKER; CHROMOSOME-22; CELLS; ASSOCIATION; CLONING	Neurofibromatosis 2 (NF2) is a dominantly inherited disorder characterized by the occurrence of bilateral vestibular schwannomas and other central nervous system tumors including multiple meningiomas. Genetic linkage studies and investigations of both sporadic and familial tumors suggest that NF2 is caused by inactivation of a tumor suppressor gene in chromosome 22q12. We have identified a candidate gene for the NF2 tumor suppressor that has suffered nonoverlapping deletions in DNA from two independent NF2 families and alterations in meningiomas from two unrelated NF2 patients. The candidate gene encodes a 587 amino acid protein with striking similarity to several members of a family of proteins proposed to link cytoskeletal components with proteins in the cell membrane. The NF2 gene may therefore constitute a novel class of tumor suppressor gene.	HARVARD UNIV,SCH MED,BOSTON,MA 02129; NCI,CLIN EPIDEMIOL BRANCH,BETHESDA,MD 20892; US PHS,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,ONCOL DRUG DISCOVERY,PRINCETON,NJ 08543; UNIV CINCINNATI,MED CTR,DEPT MOLEC GENET,CINCINNATI,OH 45267; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; GEORGETOWN UNIV,MED CTR,DEPT NEUROSURG,WASHINGTON,DC 20007	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Public Health Service; Bristol-Myers Squibb; University System of Ohio; University of Cincinnati; Massachusetts Institute of Technology (MIT); Georgetown University	TROFATTER, JA (corresponding author), MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129, USA.		Haines, Jonathan/C-3374-2012; Haase, Volker Hans/A-6758-2013; Haase, Volker Hans/AAJ-5061-2021	Haines, Jonathan/0000-0002-4351-4728; Haase, Volker Hans/0000-0002-7051-8994; Rutter, Joni/0000-0002-6502-2361	NHGRI NIH HHS [HG00317, HG00672] Funding Source: Medline; NINDS NIH HHS [NS24279] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000317, R01HG000672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; ATHWAL RS, 1977, P NATL ACAD SCI USA, V74, P2943, DOI 10.1073/pnas.74.7.2943; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BERNAL SD, 1985, CRC CR REV ONCOL-HEM, V3, P191, DOI 10.1016/S1040-8428(85)80026-3; BIJLSMA EK, 1992, GENE CHROMOSOME CANC, V5, P201, DOI 10.1002/gcc.2870050305; BIRGBAUER E, 1991, J NEUROSCI RES, V30, P232; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BUCAN M, 1990, GENOMICS, V6, P1; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; CORREAS I, 1986, J BIOL CHEM, V261, P3310; COUTURIER J, 1990, CANCER GENET CYTOGEN, V45, P55, DOI 10.1016/0165-4608(90)90066-J; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DELAUNAY J, 1991, NOUV REV FR HEMATOL, V33, P63; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FIEDLER W, 1991, GENOMICS, V10, P786, DOI 10.1016/0888-7543(91)90464-P; FONTAINE B, 1991, ANN NEUROL, V29, P183, DOI 10.1002/ana.410290211; FONTAINE B, 1991, GENOMICS, V10, P280, DOI 10.1016/0888-7543(91)90513-E; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FRAZER KA, 1992, GENOMICS, V14, P574, DOI 10.1016/S0888-7543(05)80154-5; FROSCH PM, 1991, MOL BIOCHEM PARASIT, V48, P121, DOI 10.1016/0166-6851(91)90108-I; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; FURTHMAYR H, 1992, KIDNEY INT, V41, P665, DOI 10.1038/ki.1992.102; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; KAISERKUPFER MI, 1989, ARCH OPHTHALMOL-CHIC, V107, P541, DOI 10.1001/archopht.1989.01070010555030; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P5297; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LETO TL, 1984, J BIOL CHEM, V259, P4603; LETO TL, 1986, MEMBRANE SKELETONS C, P201; LOGAN JA, 1990, CANCER GENET CYTOGEN, V45, P41, DOI 10.1016/0165-4608(90)90064-H; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MULVIHILL JJ, 1990, ANN INTERN MED, V113, P39, DOI 10.7326/0003-4819-113-1-39; NAROD SA, 1992, AM J HUM GENET, V51, P486; PAKKANEN R, 1988, J CELL BIOCHEM, V38, P65, DOI 10.1002/jcb.240380107; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; ROULEAU GA, 1990, AM J HUM GENET, V46, P323; ROULEAU GA, 1987, NATURE, V329, P246, DOI 10.1038/329246a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SATO N, 1992, J CELL SCI, V103, P131; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; Trofatter J. A., 1992, Human Molecular Genetics, V1, P455, DOI 10.1093/hmg/1.6.455-a; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WERTELECKI W, 1988, NEW ENGL J MED, V319, P278, DOI 10.1056/NEJM198808043190505; WOLFF RK, 1992, AM J HUM GENET, V51, P478; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	73	1089	1126	0	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					791	800		10.1016/0092-8674(93)90406-G	http://dx.doi.org/10.1016/0092-8674(93)90406-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453669	Bronze			2022-12-28	WOS:A1993KR43600014
J	MORRIS, R				MORRIS, R			COUNTDOWN TO COMMUNITY CARE .1. COMMUNITY CARE AND THE FUNDHOLDER	BRITISH MEDICAL JOURNAL			English	Article								According to the government, clearly agreed local arrangements should enable individual general practitioners to make their full contribution to the new system of community care without getting involved in extra bureaucracy.1 From 1 April the main part of that contribution will be to refer to social services those patients who seem to need social care. Many general practitioners are worried that such referrals will be complex and time consuming and will generate too much extra work. Moreover, general practitioners may also be asked to see patients specifically to help social workers' assessment procedures, and many fear that such consultations will overwork and underpay them. General practitioner fundholders already use contracts to spell out what they expect from hospital services. From 1 April they will be able to set up contracts for community health services such as district nursing and chiropody, and possibly this might be extended to social aspects of community care. Over the past 14 months Dr Rhidian Morris and his partners in a fundholding practice in Devon have piloted contracts for all aspects of community care. In this article Dr Morris explains how the most radical part of the pilot project-the contract for social care-was set up. He argues that the lessons on communication that came from what was essentially a fundholding project could apply also to non-fundholding practices.			MORRIS, R (corresponding author), IVYBRIDGE HEALTH CTR,IVYBRIDGE PL21 0AB,DEVON,ENGLAND.							1992, CARING PEOPLE	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					635	637		10.1136/bmj.306.6878.635	http://dx.doi.org/10.1136/bmj.306.6878.635			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461817	Bronze, Green Published			2022-12-28	WOS:A1993KQ85900025
J	STEWART, MW; LAKER, MF; ALBERTI, KGMM				STEWART, MW; LAKER, MF; ALBERTI, KGMM			EFFECTS OF SELF MONITORING OF TRIGLYCERIDE CONCENTRATIONS IN NON-INSULIN-DEPENDENT DIABETES	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CLIN BIOCHEM & METAB MED,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK	STEWART, MW (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,ENGLAND.							BARRETTCONNOR E, 1984, NIH851468 PUBLICATIO, P1; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; Hanefeld M, 1985, Monogr Atheroscler, V13, P98; HOWARD BV, 1987, J LIPID RES, V28, P613; 1992, DIABETIC MED, V9, P189	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					493	493		10.1136/bmj.306.6876.493	http://dx.doi.org/10.1136/bmj.306.6876.493			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448460	Green Published, Bronze			2022-12-28	WOS:A1993KN78600019
J	GAMBLE, AR; BELL, JA; RONAN, JE; PEARSON, D; ELLIS, IO				GAMBLE, AR; BELL, JA; RONAN, JE; PEARSON, D; ELLIS, IO			USE OF TUMOR-MARKER IMMUNOREACTIVITY TO IDENTIFY PRIMARY SITE OF METASTATIC CANCER	BRITISH MEDICAL JOURNAL			English	Article							UNKNOWN PRIMARY SITE; MONOCLONAL-ANTIBODIES; CARCINOMA; ADENOCARCINOMA; ANTIGEN; BREAST; CA-125	Objectives-To determine whether variations in the expression of tumour related antigens can predict the origin of tumours. Design-Immunohistological study of tumour marker expression in primary adenocarcinomas and respective metastatic deposits. Antibodies to the following tumour markers were used: polymorphic epithelial mucin (NCRC-11 and SM3), carcinoembryonic antigen, carcinoembryonic antigen with non-specific antigen cospecificity, CA125, CA19.9, prostate specific antigens, and thyroglobulin. Setting-Histopathology department of teaching hospital. Subjects-100 pathology sections of metastatic adenocarcinoma and their related primary tumours. Main outcome measures-Concordance of reactivity between primary and metastatic tumours. Reactivity profiles of tumour sites. Results-The correct primary site of origin was predicted in 70% (33/47) of tumours in men and 54% (27/43) tumours in women with antibodies SM3, 288, CA19.9, CA125, and PSA (men only). Specificities ranged from 68% for breast tumour to 98% for prostate tumour. Conclusion-Use of tumour markers in patients presenting with metastatic adenocarcinoma of unknown origin can help localise the probable primary sites and reduce the need for extensive and expensive imaging techniques.	CITY HOSP NOTTINGHAM,DEPT HISTOPATHOL,NOTTINGHAM NG5 1PB,ENGLAND; CITY HOSP NOTTINGHAM,DEPT MED PHYS,NOTTINGHAM NG5 1PB,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital				Ellis, Ian/0000-0001-5292-8474				BERCHUCK A, 1989, CANCER RES, V49, P2091; COGGI G, 1966, IMMUNOHISTOCHEMISTRY; ELLIS IO, 1984, HISTOPATHOLOGY, V8, P501, DOI 10.1111/j.1365-2559.1984.tb02360.x; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Gorich J, 1988, Rofo, V149, P277, DOI 10.1055/s-2008-1048341; GRECO FA, 1989, SEMIN ONCOL, V16, P116; Hamaya K, 1988, Gan No Rinsho, V34, P1956; HAMMOND ME, 1989, CANCER-AM CANCER SOC, V63, P461, DOI 10.1002/1097-0142(19890201)63:3<461::AID-CNCR2820630312>3.0.CO;2-J; HEYDERMAN E, 1990, J CLIN PATHOL, V43, P448, DOI 10.1136/jcp.43.6.448; HITCHCOCK A, 1987, J OBSTET GYNAECOL, V8, P173, DOI 10.3109/01443618709008792; KEEP JC, 1989, TUMOR BIOL, V10, P153, DOI 10.1159/000217612; MA WX, 1989, CHUNG HUA PING LI HS, V18, P37; NYSTROM JS, 1979, JAMA-J AM MED ASSOC, V241, P381, DOI 10.1001/jama.241.4.381; REID WA, 1990, J PATHOL, V160, P203, DOI 10.1002/path.1711600304; ROSEN A, 1990, ARCH GYNECOL OBSTET, V247, P125, DOI 10.1007/BF02390860; SHEAHAN K, 1990, LAB INVEST, V62, pA112; STERNS EE, 1989, SURG GYNECOL OBSTET, V169, P81; STURM U, 1989, Zentralblatt fuer Allgemeine Pathologie und Pathologische Anatomie, V135, P281	18	39	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					295	298		10.1136/bmj.306.6873.295	http://dx.doi.org/10.1136/bmj.306.6873.295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461645	Bronze, Green Published			2022-12-28	WOS:A1993KK71800017
J	KNAUS, WA; WAGNER, DP; ZIMMERMAN, JE; DRAPER, EA				KNAUS, WA; WAGNER, DP; ZIMMERMAN, JE; DRAPER, EA			VARIATIONS IN MORTALITY AND LENGTH OF STAY IN INTENSIVE-CARE UNITS	ANNALS OF INTERNAL MEDICINE			English	Article						HOSPITALIZATION; LENGTH OF STAY; INTENSIVE CARE UNITS; PATIENT ADMISSION; RISK MANAGEMENT	ACUTE MYOCARDIAL-INFARCTION; ILL HOSPITALIZED ADULTS; CASE-MIX; SURGERY; SYSTEM; ADJUSTMENT; PREDICTION; SEVERITY; OUTCOMES; SERVICES	Objective: To evaluate the amount of variation in in-hospital mortality and length of intensive care unit (ICU) stay that can be accounted for by clinical data available at ICU admission. Design: Inception cohort study. Setting: Forty-two ICUs in 40 hospitals, including 26 hospitals that were randomly selected and 14 large tertiary care hospitals that volunteered for the study. Participants: A consecutive sample of 16 622 patients and 17 440 ICU admissions. Measurements and Main Outcomes: Data on selected demographic characteristics, comorbidity, and specific physiologic variables were recorded during the first ICU day for an average of 415 admissions at each ICU; hospital discharge status (dead or alive) and length of ICU stay were recorded for individual patients; and the ratio of actual to predicted in-hospital mortality, standardized mortality ratios, and the ratio of actual to predicted length of ICU stay were recorded for individual ICUs. Results: Unadjusted in-hospital mortality rates for the 42 units varied from 6.4% to 40%, and 90% (R2 = 0.90) of this variation was attributable to patient characteristics at admission. The standard mortality ratio varied from 0.67 to 1.25. The mean unadjusted length of ICU stay varied from 3.3 to 7.3 days, and 78% of the variation (R2 = 0.78) was attributed to patient and selected institutional characteristics. The best performing unit had a length of stay ratio of 0.88, whereas the poorest performing unit had a ratio of 1.21. Conclusions: Clinicians can use readily available admission data to adjust for considerable variations in patient severity and type in different ICUs. Such data should permit precise evaluation and comparison of ICU effectiveness and efficiency, which varied substantially in this study, and result in improved methods of risk prediction and evaluation of new medical practices.	APACHE MED SYST INC, WASHINGTON, DC 20006 USA		KNAUS, WA (corresponding author), GEORGE WASHINGTON UNIV, MED CTR, ICU RES UNIT, 2300 K ST NW, WASHINGTON, DC 20037 USA.		Knaus, William/AAX-2138-2020		AHRQ HHS [HS 5787] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS005787] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Berenson RA., 1984, INTENSIVE CARE UNITS; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DAMIANO AM, 1992, J CLIN EPIDEMIOL, V45, P93, DOI 10.1016/0895-4356(92)90001-4; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; EAGLE KA, 1990, JAMA-J AM MED ASSOC, V264, P992, DOI 10.1001/jama.264.8.992; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; ESCARCE JJ, 1990, JAMA-J AM MED ASSOC, V264, P2389, DOI 10.1001/jama.264.18.2389; FARLEY DE, 1992, MED CARE, V30, P77, DOI 10.1097/00005650-199201000-00009; Fetter RB, 1980, MED CARE S, V18, P1; GARBER AM, 1984, NEW ENGL J MED, V310, P1231, DOI 10.1056/NEJM198405103101906; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; JENCKS SF, 1987, NEW ENGL J MED, V317, P679, DOI 10.1056/NEJM198709103171106; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KRAKAUER H, 1992, HEALTH SERV RES, V27, P317; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2689; LOOP FD, 1983, JAMA-J AM MED ASSOC, V250, P63, DOI 10.1001/jama.250.1.63; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; MILLER RG, 1974, BIOMETRIKA, V61, P1; MULLEY AG, 1980, NEW ENGL J MED, V302, P943, DOI 10.1056/NEJM198004243021704; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; Pettengill J, 1982, Health Care Financ Rev, V4, P101; POLLACK MM, 1987, NEW ENGL J MED, V316, P134, DOI 10.1056/NEJM198701153160304; POLLACK MM, 1987, JAMA-J AM MED ASSOC, V258, P1481, DOI 10.1001/jama.258.11.1481; SAX FL, 1987, ARCH INTERN MED, V147, P929, DOI 10.1001/archinte.147.5.929; Seneff M, 1990, J INTENSIVE CARE MED, V5, P33, DOI DOI 10.1177/088506669000500107; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; STEVENS R, 1989, SICKNESS WEALTH AM H, P228; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143; WILLIAMS SV, 1991, JAMA-J AM MED ASSOC, V266, P810, DOI 10.1001/jama.266.6.810; YOUNG WW, 1982, MED CARE, V20, P501, DOI 10.1097/00005650-198205000-00006; ZIMMERMAN JE, 1989, CRIT CARE MED S, V17, pS169; 1991, HOSPITAL STATISTICS; 1992, MEDICARE HOSPITAL MO	46	429	442	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					753	761		10.7326/0003-4819-118-10-199305150-00001	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	8470850				2022-12-28	WOS:A1993LB64900001
J	ORENCIA, A; BAILEY, K; YAWN, BP; KOTTKE, TE				ORENCIA, A; BAILEY, K; YAWN, BP; KOTTKE, TE			EFFECT OF GENDER ON LONG-TERM OUTCOME OF ANGINA-PECTORIS AND MYOCARDIAL-INFARCTION SUDDEN UNEXPECTED DEATH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; RESIDENTS; ROCHESTER; MINNESOTA	Objective.-To determine the effects of female gender on long-term survival and subsequent coronary heart disease events in a population developing first clinical manifestations of coronary artery disease. Design.-Follow-up of all Rochester, Minn, residents first diagnosed with either angina pectoris or myocardial infarction/sudden unexpected death between January 1, 1960, and December 31, 1979. Main Outcome Measures.-Patients with angina pectoris were followed up through 1982 for survival and time to initial myocardial infarction/cardiac death. Patients with myocardial infarction were followed up through 1982 for survival and time to recurrent myocardial infarction/cardiac death. Results.-Angina pectoris was the initial diagnosis for 529 women and 504 men. Myocardial infarction or sudden unexpected death was the initial diagnosis for 611 women and 997 men. The average age of patients diagnosed with angina pectoris was 67.0 years (SE, 0.5 years) for women and 60.0 years (SE, 0.5 years) for men. The average age of patients diagnosed with myocardial infarction/sudden unexpected death was 71.9 years (SE, 0.5 years) for women and 62.0 years (SE, 0.4 years) for men. Women presenting with angina pectoris survived significantly longer and had a lower incidence of subsequent myocardial infarction/cardiac death compared with men of similar age (P<.01). When rates of myocardial infarction and sudden unexpected death were combined to assess all cardiac endpoints with objective criteria (''hard'' endpoints), women presenting with myocardial infarction/sudden unexpected death had survival rates and risk of subsequent myocardial infarction/coronary death that were similar to men of the same age. When survival following myocardial infarction Was analyzed separately, survival also did not vary by gender. Conclusion.-In this population, women with angina pectoris as an initial diagnosis, but not those with myocardial infarction or sudden unexpected death, have longer survival and lower risk of subsequent myocardial infarction/cardiac death than do men with the same presentation and of a similar age.	MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,DIV BIOSTAT,HARWICK BLDG,ROOM 669,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV CARDIOVASC DIS,ROCHESTER,MN 55905; OLMSTED MED GRP,ROCHESTER,MN	Mayo Clinic; Mayo Clinic; Olmsted Medical Center					NHLBI NIH HHS [HL 24326] Funding Source: Medline; NIAMS NIH HHS [AR 30582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; CONNOLLY DC, 1981, MAYO CLIN PROC, V56, P661; COX DR, 1972, J R STAT SOC B, V34, P187; ELVEBACK LR, 1986, MAYO CLIN PROC, V61, P896, DOI 10.1016/S0025-6196(12)62612-3; ELVEBACK LR, 1981, MAYO CLIN PROC, V56, P665; FLEMING JR, 1986, SUGI SUPPLEMENTAL LI, P535; GARBER CE, 1992, J CLIN EPIDEMIOL, V45, P715, DOI 10.1016/0895-4356(92)90048-R; GOVE WR, 1979, AM SOCIOL REV, V44, P126, DOI 10.2307/2094822; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; Heston T F, 1992, Fam Pract Res J, V12, P383; KANNEL WB, 1972, AM J CARDIOL, V29, P154, DOI 10.1016/0002-9149(72)90624-8; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; KURLAND LT, 1984, EPIDEMIOLOGY RHEUMAT; OFFORD K, 1986, SUGI SUPPLEMENTARY L, P554; PACKARD B, 1984, REHABILITATION CORON, P217; PHILLIPS SJ, 1990, MAYO CLIN PROC, V65, P344, DOI 10.1016/S0025-6196(12)62535-X; SELVIN S, 1991, STATISTICAL ANAL EPI, P316; 1991, JAMA-J AM MED ASSOC, V266, P559	19	89	91	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2392	2397		10.1001/jama.269.18.2392	http://dx.doi.org/10.1001/jama.269.18.2392			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479065				2022-12-28	WOS:A1993LA67500033
J	QUEZADO, ZMN; NATANSON, C; ALLING, DW; BANKS, SM; KOEV, CA; ELIN, RJ; HOSSEINI, JM; BACHER, JD; DANNER, RL; HOFFMAN, WD				QUEZADO, ZMN; NATANSON, C; ALLING, DW; BANKS, SM; KOEV, CA; ELIN, RJ; HOSSEINI, JM; BACHER, JD; DANNER, RL; HOFFMAN, WD			A CONTROLLED TRIAL OF HA-1A IN A CANINE MODEL OF GRAM-NEGATIVE SEPTIC SHOCK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MONOCLONAL ANTIENDOTOXIN ANTIBODIES; CARDIOVASCULAR DYSFUNCTION; ESCHERICHIA-COLI; INITIAL EVALUATION; IGM ANTIBODY; LIPID-A; BACTEREMIA; ENDOTOXEMIA; MORTALITY; THERAPY	Objective.-To investigate the therapeutic efficacy and microbiological and physiological effects of a human IgM monoclonal antibody (HA-1A) directed against the lipid A component of endotoxin in a canine model of sepsis that simulates the cardiovascular abnormalities of human septic shock. Design.-Blinded, placebo-controlled 28-day trial. Interventions.-Purpose-bred beagles were implanted with an intraperitoneal clot infected with Escherichia coli O111:B4. At clot placement, animals received HA-1A (10 mg.kg-1), control human IgM antibody (10 mg.kg-1), or control human serum albumin intravenously. All animals were given antibiotic and fluid therapy. Measures.-Survival and microbiological and physiological events. Results.-Only two (15%) of 13 animals in the HA-1A group, compared with eight (57%) of 14 control animals (combined control human IgM antibody and control human serum albumin groups) (P=.05), survived 28 days. At 24 hours, the HA-1A group had lower mean arterial pressure (P=.04) and cardiac index (P=.004) and higher lactate levels (P=.05) compared with the combined-controls group. In addition, these parameters in the HA-1A group were significantly more predictive of death. The HA-1A and combined-controls groups had similar significant increases in the level of endotoxemia and bacteremia. Studies of toxic effects showed no harmful effects of control human IgM antibody in infected animals or HA-1A in non-infected animals. Conclusion.-In a canine model of E coli sepsis, HA-1 A did not alter levels of bacteremia or endotoxemia and actually decreased survival. If these data are relevant to human septic shock, HA-1A therapy should be limited until the conditions under which this monoclonal antibody has beneficial or deleterious effects are more completely defined.	NIH,DEPT CLIN PATHOL,BETHESDA,MD 20892; NIH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	QUEZADO, ZMN (corresponding author), NIH,DEPT CRIT CARE MED,BLDG 10,ROOM 7D43,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Quezado, Zenaide/O-4860-2016	Quezado, Zenaide/0000-0001-9793-4368				ALLING DW, 1963, J AM STAT ASSOC, V58, P713, DOI 10.2307/2282719; Baumgartner J D, 1991, Infect Dis Clin North Am, V5, P915; BAUMGARTNER JD, 1990, EUR J CLIN MICROBIOL, V9, P711, DOI 10.1007/BF02184682; BAUMGARTNER JD, 1991, NEW ENGL J MED, V325, P281; BAUMGARTNER JD, 1990, J EXP MED, V171, P889, DOI 10.1084/jem.171.3.889; BOGARD WC, 1991, CIRC SHOCK, V34, P119; BOGARD WC, 1990, 1990 INT C ANT AG CH, P166; BRANDTZAEG P, 1989, J INFECT DIS, V160, P58, DOI 10.1093/infdis/160.1.58; COX DR, 1972, J R STAT SOC B, V34, P187; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DANNER RL, 1990, CHEST, V98, P1480, DOI 10.1378/chest.98.6.1480; FISHER CJ, 1990, CRIT CARE MED, V18, P1311, DOI 10.1097/00003246-199012000-00001; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HOFFMAN WD, 1990, CLIN RES, V38, pA454; HOFFMAN WD, 1991, CLIN RES, V39, pA164; HOFFMAN WD, 1991, CRIT CARE MED, V19, pS67; KHAZAELI MB, 1990, J BIOL RESP MODIF, V9, P178; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; NATANSON C, 1986, J CLIN INVEST, V78, P259, DOI 10.1172/JCI112559; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; NATANSON C, 1990, AM J PHYSIOL, V259, pH1440, DOI 10.1152/ajpheart.1990.259.5.H1440; OISHI K, 1992, J INFECT DIS, V165, P34, DOI 10.1093/infdis/165.1.34; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; POLLACK M, 1990, ADV EXP MED BIOL, V256, P331; Scheffe H, 1959, ANAL VARIANCE; SIEGEL JP, 1992, NEW ENGL J MED, V327, P890; Siegel S., 1956, NONPARAMETRIC STAT B; TENG NNH, 1985, P NATL ACAD SCI USA, V82, P1790, DOI 10.1073/pnas.82.6.1790; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; ZIEGLER EJ, 1987, CLIN RES, V35, pA619; ZIEGLER EJ, 1988, J INFECT DIS, V158, P286, DOI 10.1093/infdis/158.2.286; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1990, MMWR, V39, P31	33	97	100	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1993	269	17					2221	2227		10.1001/jama.269.17.2221	http://dx.doi.org/10.1001/jama.269.17.2221			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ406	8474201				2022-12-28	WOS:A1993KZ40600029
J	YOUNG, T; PALTA, M; DEMPSEY, J; SKATRUD, J; WEBER, S; BADR, S				YOUNG, T; PALTA, M; DEMPSEY, J; SKATRUD, J; WEBER, S; BADR, S			THE OCCURRENCE OF SLEEP-DISORDERED BREATHING AMONG MIDDLE-AGED ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DAYTIME SLEEPINESS; MYOCARDIAL-INFARCTION; APNEA SYNDROME; RISK FACTOR; NIGHT; MEN; ASSOCIATION; POPULATION; PREVALENCE; MORBIDITY	Background. Limited data have suggested that sleep-disordered breathing, a condition of repeated episodes of apnea and hypopnea during sleep, is prevalent among adults. Data from the Wisconsin Sleep Cohort Study, a longitudinal study of the natural history of cardiopulmonary disorders of sleep, were used to estimate the prevalence of undiagnosed sleep-disordered breathing among adults and address its importance to the public health. Methods. A random sample of 602 employed men and women 30 to 60 years old were studied by overnight polysomnography to determine the frequency of episodes of apnea and hypopnea per hour of sleep (the apnea-hypopnea score). We measured the age- and sex-specific prevalence of sleep-disordered breathing in this group using three cutoff points for the apnea-hypopnea score (greater-than-or-equal-to 5, greater-than-or-equal-to 10, and greater-than-or-equal-to 15); we used logistic regression to investigate risk factors. Results. The estimated prevalence of sleep-disordered breathing, defined as an apnea-hypopnea score of 5 or higher, was 9 percent for women and 24 percent for men We estimated that 2 percent of women and 4 percent of men in the middle-aged work force meet the minimal diagnostic criteria for the sleep apnea syndrome (an apnea-hypopnea score of 5 or higher and daytime hypersomnolence). Male sex and obesity were strongly associated with the presence of sleep-disordered breathing. Habitual snorers, both men and women, tended to have a higher prevalence of apnea-hypopnea scores of 15 or higher. Conclusions. The prevalence of undiagnosed sleep-disordered breathing is high among men and is much higher than previously suspected among women. Undiagnosed sleep-disordered breathing is associated with daytime hypersomnolence.	UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53705; UNIV WISCONSIN,SCH MED,DEPT NEUROL,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	YOUNG, T (corresponding author), UNIV WISCONSIN,SCH MED,DEPT PREVENT MED,504 N WALNUT ST,MADISON,WI 53705, USA.				NCRR NIH HHS [RR 03186] Funding Source: Medline; NHLBI NIH HHS [HL 02588, P01 HL 42242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042242, K08HL002588] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agnew H W Jr, 1966, Psychophysiology, V2, P263, DOI 10.1111/j.1469-8986.1966.tb02650.x; ANCOLIISRAEL S, 1991, SLEEP, V14, P486, DOI 10.1093/sleep/14.6.486; BLOCK AJ, 1979, NEW ENGL J MED, V300, P513, DOI 10.1056/NEJM197903083001001; CARSKADON MA, 1989, PRINCIPLES PRACTICE, P3; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P107; DALESSANDRO R, 1990, BRIT MED J, V300, P1557, DOI 10.1136/bmj.300.6739.1557-a; DEMPSEY JA, 1991, LUNG SCI F, V2, P1615; GISLASON T, 1988, J CLIN EPIDEMIOL, V41, P571, DOI 10.1016/0895-4356(88)90061-3; GOULD GA, 1988, AM REV RESPIR DIS, V137, P895, DOI 10.1164/ajrccm/137.4.895; GUILLEMINAULT C, 1991, CHEST, V99, P40, DOI 10.1378/chest.99.1.40; GUILLEMINAULT C, 1988, CHEST, V93, P104, DOI 10.1378/chest.93.1.104; Guilleminault C., 1989, PRINCIPLES PRACTICE, P552; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HUNG J, 1990, LANCET, V336, P261, DOI 10.1016/0140-6736(90)91799-G; IBER C, 1991, SLEEP, V14, P383; KNIGHT H, 1987, AM REV RESPIR DIS, V136, P845, DOI 10.1164/ajrccm/136.4.845; KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16; LAVIE P, 1983, SLEEP, V6, P312, DOI 10.1093/sleep/6.4.312; LORD S, 1991, SLEEP, V14, P252; LUGARESI E, 1990, OBSTRUCTIVE SLEEP APNEA SYNDROME : CLINICAL RESEARCH AND TREATMENT, P25; MARTIN RJ, 1985, SLEEP, V8, P371, DOI 10.1093/sleep/8.4.371; PARTINEN M, 1990, CHEST, V97, P27, DOI 10.1378/chest.97.1.27; PHILLIPS BA, 1992, CHEST, V101, P345, DOI 10.1378/chest.101.2.345; RECHTSCHAFFEN A, 1968, NIH204 PUBL; REDLINE S, 1991, CHEST, V100, P1281, DOI 10.1378/chest.100.5.1281; SANDERS MH, 1991, AM REV RESPIR DIS, V144, P1256, DOI 10.1164/ajrccm/144.6.1256; SCHMIDTNOWARA WW, 1990, OBSTRUCTIVE SLEEP APNEA SYNDROME : CLINICAL RESEARCH AND TREATMENT, P1; SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597; SEPPALA T, 1991, J INTERN MED, V229, P23, DOI 10.1111/j.1365-2796.1991.tb00301.x; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; SULLIVAN CE, 1981, LANCET, V1, P862; THORPY MJ, 1992, SLEEP, V15, P268; THORPY MJ, 1992, SLEEP, V15, P381; Thorpy MJ, 1990, DIAGNOSTIC CODING MA; VINER S, 1991, ANN INTERN MED, V115, P356, DOI 10.7326/0003-4819-115-5-356; WITTIG RM, 1984, AM REV RESPIR DIS, V129, P244; 1985, SAS USERS GUIDE STAT; 1988, ANTHROPOMETRIC STAND, P1; 1993, NATIONAL COMMISSION, V1; 1989, AM REV RESPIR DIS, V139, P559; 1991, SLEEP, V14, P169	41	7173	7556	12	527	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1230	1235		10.1056/NEJM199304293281704	http://dx.doi.org/10.1056/NEJM199304293281704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464434	Bronze			2022-12-28	WOS:A1993KZ06100004
J	KRA, SJ				KRA, SJ			THE CAPTAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1934	1934		10.1001/jama.269.15.1934	http://dx.doi.org/10.1001/jama.269.15.1934			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464116				2022-12-28	WOS:A1993KX21500008
J	STEERE, AC; TAYLOR, E; MCHUGH, GL; LOGIGIAN, EL				STEERE, AC; TAYLOR, E; MCHUGH, GL; LOGIGIAN, EL			THE OVERDIAGNOSIS OF LYME-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED IMMUNOSORBENT-ASSAY; BORRELIA-BURGDORFERI; NEUROLOGIC MANIFESTATIONS; FIBROMYALGIA; ANTIBODY; NEUROBORRELIOSIS; ABNORMALITIES; PENICILLIN; DIAGNOSIS	Objective.-To analyze the diagnoses, serological test results, and treatment results of the patients evaluated in a Lyme disease clinic, both prior to referral and from current evaluation. Design.-Retrospective case survey of prescreened patients. Setting.-Research and diagnostic Lyme disease clinic in a university hospital. Patients.-All 788 patients referred to the clinic during a 4.5-year period who were thought by the referring physician or the patient to have a diagnosis of Lyme disease. Main Outcome Measurements.-Symptoms and signs of disease, immunodiagnostic tests of Lyme disease, and tests of neurological function. Results.-Of the 788 patients, 180 (23%) had active Lyme disease, usually arthritis, encephalopathy, or polyneuropathy. One hundred fifty-six patients (20%) had previous Lyme disease and another current illness, most commonly chronic fatigue syndrome or fibromyalgia; and in 49 patients, these symptoms began soon after objective manifestations of Lyme disease. The remaining 452 patients (57%) did not have Lyme disease. The majority of these patients also had the chronic fatigue syndrome or fibromyalgia; the others usually had rheumatic or neurological diseases. Of the patients who did not have Lyme disease, 45% had had positive serological test results for Lyme disease in other laboratories, but all were seronegative in our laboratory. Prior to referral, 409 of the 788 patients had been treated with antibiotic therapy. In 322 (79%) of these patients, the reason for lack of response was incorrect diagnosis. Conclusions.-Only a minority of the patients referred to the clinic met diagnostic criteria for Lyme disease. The most common reason for lack of response to antibiotic therapy was misdiagnosis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School	STEERE, AC (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV RHEUMATOL IMMUNOL,BOX 406,750 WASHINGTON AVE,BOSTON,MA 02111, USA.			Steere, Allen/0000-0002-5268-9853	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020358] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20358] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BUCHWALD D, 1991, REV INFECT DIS, V13, pS12; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1988, LANCET, V1, P1191; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; GOLDENBERG DL, 1986, ARTHRITIS RHEUM, V29, P1371, DOI 10.1002/art.1780291110; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; HALPERIN JJ, 1989, NEUROLOGY, V39, P753, DOI 10.1212/WNL.39.6.753; HALPERIN JJ, 1987, NEUROLOGY, V37, P1700, DOI 10.1212/WNL.37.11.1700; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KALISH RA, IN PRESS INFECT IMMU; KAPLAN RF, 1992, NEUROLOGY, V42, P1263, DOI 10.1212/WNL.42.7.1263; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; LANE TJ, 1991, AM J MED, V91, P334; LIU N Y, 1989, Arthritis and Rheumatism, V32, pS46; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; MCCAIN GA, 1988, ARTHRITIS RHEUM, V31, P1135, DOI 10.1002/art.1780310908; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; REILLY P A, 1990, Current Opinion in Rheumatology, V2, P282; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEER AC, 1983, ANN INTERN MED, V99, P767, DOI 10.7326/0003-4819-99-6-767; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1990, J INFECT DIS, V161, P1203, DOI 10.1093/infdis/161.6.1203; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; 1992, MED LETT, V34, P95	40	300	304	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1812	1816		10.1001/jama.269.14.1812	http://dx.doi.org/10.1001/jama.269.14.1812			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459513				2022-12-28	WOS:A1993KW25000036
J	BLOCK, BA; FINNERTY, JR; STEWART, AFR; KIDD, J				BLOCK, BA; FINNERTY, JR; STEWART, AFR; KIDD, J			EVOLUTION OF ENDOTHERMY IN FISH - MAPPING PHYSIOLOGICAL TRAITS ON A MOLECULAR PHYLOGENY	SCIENCE			English	Article							BODY SIZE; MUSCLE; HEATER; DNA; BRAIN; AMPLIFICATION; POLYMERASE; SKIPJACK; EXCHANGE; CAPACITY	Mackerels, tunas, and billfishes (suborder Scombroidei and Teleostei) provide an ideal taxonomic context in which to examine the evolution of endothermy. Multiple origins and diverse strategies for endothermy exist among these fish. Here a molecular phylogeny of the Scombroidei has been determined by direct sequencing of a portion of the mitochondrial cytochrome b gene. The distribution of endothermic species within this proposed genealogy indicates that the ability to warm the brain and retina arose independently in three lineages, each time in association with a movement into colder water. This suggests that the evolution of cranial endothermy in fish was selected in order to permit thermal niche expansion and not selected for increased aerobic capacity.			BLOCK, BA (corresponding author), UNIV CHICAGO,DEPT ORGANISMAL BIOL & ANAT,CHICAGO,IL 60637, USA.		Stewart, Alexandre F.R./A-5677-2011; Finnerty, John R/B-6564-2011	Stewart, Alexandre/0000-0003-2673-9164	NIAMS NIH HHS [AR40246] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040246] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARETT I, 1964, NATURE, V203, P96; BECKETT JS, 1974, NOAA NMFS SSRF675 US, P103; BENNETT AF, 1991, J EXP BIOL, V160, P1; BENNETT AF, 1979, SCIENCE, V206, P649, DOI 10.1126/science.493968; BLOCK BA, 1986, J MORPHOL, V190, P169, DOI 10.1002/jmor.1051900203; BLOCK BA, 1991, AM ZOOL, V31, P726; BLOCK BA, 1988, J CELL BIOL, V107, P1099, DOI 10.1083/jcb.107.3.1099; BLOCK BA, 1991, BIOCH MOL BIOL FISHE, P269; BLOCK BA, UNPUB; BRILL RW, 1987, FISH B-NOAA, V85, P25; Brooks DR, 1991, PHYLOGENY ECOLOGY BE; CAREY FG, 1966, P NATL ACAD SCI USA, V56, P1464, DOI 10.1073/pnas.56.5.1464; CAREY FG, 1990, MAR BIOL, V106, P329, DOI 10.1007/BF01344309; CAREY FG, 1969, COMP BIOCHEM PHYSIOL, V28, P199, DOI 10.1016/0010-406X(69)91335-8; CAREY FG, 1982, SCIENCE, V216, P1327, DOI 10.1126/science.7079766; CAREY FG, 1982, COMPANION ANIMAL PHY, P216; Carey FG, 1990, PLANNING FUTURE BILL, P103; CAREY FG, 1973, SCI AM, V238, P36; CASANOVA L, 1991, NUCLEIC ACIDS RES, V18, P4028; COLELTTE BB, 1978, PHYSL ECOLOGY TUNAS, P1; CROMPTON AW, 1978, NATURE, V272, P333, DOI 10.1038/272333a0; DEAN J, 1976, T AM FISH SOC, P709; Fierstine H.L., 1968, MEM STH CALIF ACAD S, V6, P1, DOI DOI 10.5962/BHL.TITLE.146943; FINNERTY J, UNPUB; Finnerty John R., 1992, Molecular Marine Biology and Biotechnology, V1, P206; GOODING RM, 1981, FISH B-NOAA, V79, P31; GRAHAM JB, 1973, P NATL ACAD SCI USA, V70, P1964, DOI 10.1073/pnas.70.7.1964; GRAHAM JB, 1975, FISH B-NOAA, V73, P219; GRAHAM JB, 1983, CAN J ZOOL, V61, P2087, DOI 10.1139/z83-274; GRAHAM JB, 1982, MAR BIOL, V72, P1, DOI 10.1007/BF00393941; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HEBRANK JH, 1990, J EXP BIOL, V148, P449; HOLLAND KN, 1992, NATURE, V358, P410, DOI 10.1038/358410a0; JOHNSON GD, 1986, B MAR SCI, V39, P1; Kafuku T., 1950, Japanese Journal of Ichthyology, V1, P89; Kishinouye K., 1923, Journal of the College of Agriculture Tokyo, V8, P293; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KOHNO H, 1984, JPN J ICHTHYOL, V31, P268; LINDSEY CC, 1978, FISH PHYSIOL, P1; NEILL WH, 1974, SCIENCE, V184, P1008, DOI 10.1126/science.184.4140.1008; POTTHOFF T, 1984, SPEC PUBLI AM SOC S, V1, P591; RUBEN J, 1991, EVOLUTION, V45, P1, DOI 10.1111/j.1558-5646.1991.tb05261.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sharp G.D., 1978, P41; SHUBNIKOV DA, 1974, J ICHTHYOL, V14, P633; STEVENS ED, 1971, COMP BIOCHEM PHYSIOL, V38, P203; STEVENS ED, 1970, CAN J ZOOLOG, V48, P221, DOI 10.1139/z70-036; TULLIS A, 1991, J EXP BIOL, V161, P383; WESTNEAT MW, UNPUB	51	207	211	2	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					210	214		10.1126/science.8469974	http://dx.doi.org/10.1126/science.8469974			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8469974				2022-12-28	WOS:A1993KW45200037
J	KATES, RW				KATES, RW			ENDING DEATHS FROM FAMINE - THE OPPORTUNITY IN SOMALIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									BROWN UNIV,ALAN SHAWN FEINSTEIN WORLD HUNGER PROGRAM,PROVIDENCE,RI 02912	Brown University								Carl Riskin, 1990, HUNGER HIST FOOD SHO, P331; COHEN MN, 1990, HUNGER HIST FOOD SHO, P56; DERIA A, 1980, B WORLD HEALTH ORGAN, V58, P279; DREZE J, 1989, HUNGER PUBLIC ACTION, P122; KATES RW, 1988, HUNGER REPORT 1988, P5; MACRAE J, 1992, DISASTERS, V16, P299, DOI 10.1111/j.1467-7717.1992.tb00412.x; MESSER E, 1990, HUNGER REPORT 1990, P27; MILLMAN SR, 1991, HUNGER REPORT UPDATE, P10; MINEAR L, 1992, 13 I INT STUD OCC PA; Minear Larry, 1991, HUMANITARIANISM SIEG; Post John D., 1977, LAST GREAT SUBSISTEN; ROUX G, 1980, ANCIENT IRAQ, P168; Sen A, 1981, POVERTY FAMINES; THOMAS J, 1992, PROVIDENCE PRINCIPLE; 1990, FOOD POLICY, V15, P286; 1990, FOOD POLICY, V15, P352; 1992, WORLD FOOD SUPPLIES; [No title captured]; 1992, FAO WHO JOINT SECRET, P1	19	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1055	1057		10.1056/NEJM199304083281428	http://dx.doi.org/10.1056/NEJM199304083281428			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KW282	8450872				2022-12-28	WOS:A1993KW28200037
J	ANDERSON, GM; GRUMBACH, K; LUFT, HS; ROOS, LL; MUSTARD, C; BROOK, R				ANDERSON, GM; GRUMBACH, K; LUFT, HS; ROOS, LL; MUSTARD, C; BROOK, R			USE OF CORONARY-ARTERY BYPASS-SURGERY IN THE UNITED-STATES AND CANADA - INFLUENCE OF AGE AND INCOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To compare overall rates of coronary artery bypass surgery (CABS) in several Canadian and US jurisdictions and to compare use by age and income groups in the two countries. Design.-Survey, using computerized hospital discharge abstracts. Setting.-All nonfederal hospitals in New York, California, Ontario, Manitoba, and British Columbia between 1983 and 1989. Patients.-All adult residents of the five jurisdictions who underwent CABS in a hospital in their jurisdiction. Results.-Between 1983 and 1989, the CABS rates were consistently highest in California and lowest in the Canadian jurisdictions. In 1989, the age-adjusted rate of CABS in California (1 12.5/1 00 000 adults) was 27% higher than in New York (88.4/100 000) and 80% higher than in the three Canadian provinces combined (62.4/100 000). The CABS rates increased for those aged 65 years and older and decreased for those aged 20 to 54 years in all five jurisdictions. In 1989, CABS rates were three times higher in California than in Canada for those aged 75 years and older, and the higher rates for those aged 65 years and older accounted for 75% of the overall difference in rates between California and Canada. In Canada, CABS rates for the nonelderly varied little by income of area of residence, but in New York and California, rates increased steadily with the income of area of residence. Conclusion.-Control over the supply of resources in Canada is associated with markedly lower CABS rates for the elderly than found in the United States. While overall rates are lower in Canada, the Canadian universal health insurance system reduces the influence of income on access to CABS found in the United States. However, even without universal health insurance, CABS rates for the nonelderly living in the poorest areas in California are similar to the rates for those living in the poorest parts of Canada.	UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV MANITOBA,MANITOBA CTR HLTH POLICY & EVALUAT,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Toronto; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Manitoba	ANDERSON, GM (corresponding author), SUNNYBROOK HLTH SCI CTR,INST CLIN EVALUAT SCI,ROOM 231,2075 BAYVIEW AVE,N YORK M4N 3M5,ON,CANADA.		Grumbach, Kevin/L-9222-2016	Roos, Leslie L./0000-0002-4215-8346	AHRQ HHS [HS06503-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON GM, 1989, NEW ENGL J MED, V321, P1443, DOI 10.1056/NEJM198911233212105; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; NAYLOR CD, 1991, HEALTH AFFAIR, V10, P110, DOI 10.1377/hlthaff.10.3.110; NICHOLLS E, 1986, 82544 STAT CAN HLTH; ROOS LL, 1989, SOC SCI MED, V28, P175, DOI 10.1016/0277-9536(89)90145-7; ROOS LL, 1992, HEALTH AFFAIR, V11, P56, DOI 10.1377/hlthaff.11.2.56; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; Wilkins R, 1989, Health Rep, V1, P137; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; 1990, DHHS PUBLICATION 10, V176	12	103	103	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1661	1666						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KV349	8455299				2022-12-28	WOS:A1993KV34900030
J	HEALY, B				HEALY, B			MUCOSAL IMMUNITY, VACCINE DEVELOPMENTS NEW FRONTIER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA								LAMM M, 1991, P NATL ACAD SCI USA, V88, P8796; LAMM M, 1992, P NATL ACAD SCI USA, V89, P6901	2	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1612	1612						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV349	8455284				2022-12-28	WOS:A1993KV34900006
J	MICHISHITA, M; VIDEM, V; ARNAOUT, MA				MICHISHITA, M; VIDEM, V; ARNAOUT, MA			A NOVEL DIVALENT CATION-BINDING SITE IN THE A-DOMAIN OF THE BETA-2-INTEGRIN-CR3 (CD11B/CD18) IS ESSENTIAL FOR LIGAND-BINDING	CELL			English	Article							COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID-SEQUENCE; COMMON BETA-SUBUNIT; LEUKOCYTE ADHESION GLYCOPROTEIN; LEU-CAM DEFICIENCY; VONWILLEBRAND-FACTOR; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; POLYMORPHONUCLEAR LEUKOCYTES	A recombinant peptide encoding the CD11b A domain bound Mn-54(2+), with a high affinity. Other divalent cations, including Mg2+, Zn2+, Ni2+, Co2+, and Cd2+, but not Ca2+ or Ba2+, competed effectively for Mn2+ binding. Amino acid substitutions within two conserved and noncontiguous regions in the recombinant peptide abolished Mn-54(2+) binding. When these substitutions were introduced independently in complement receptor type 3 (CR3), each abolished the metal-dependent binding of the receptor to the major C3 opsonin iC3b, without impairing subunit association or surface expression of the receptor. These findings identify an unsuspected and novel metal-binding site within the A domain of CR3 that is required for metal-dependent ligand binding and also identify a good target for designing drugs aimed at countering the inflammatory potential of this key receptor.	HARVARD UNIV,SCH MED,BOSTON,MA 02129	Harvard University; Harvard Medical School	MICHISHITA, M (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MED,LEUKOCYTE BIOL & INFLAMMAT PROGRAM,BOSTON,MA 02129, USA.				NIAID NIH HHS [AI-28465, AI-21964] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028465, R01AI021964] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; ARNAOUT MA, 1988, J CELL PHYSIOL, V137, P305, DOI 10.1002/jcp.1041370214; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1985, NEW ENGL J MED, V312, P457, DOI 10.1056/NEJM198502213120801; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; ARNAOUT MA, 1987, METHOD ENZYMOL, V150, P602; ARNAOUT MA, 1983, IMMUNOLOGY, V48, P229; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; ARNAOUT MA, 1993, IN PRESS CONCEPTS IM; ARNAOUT MA, 1993, SAMTERS IMMUNOLOGIC; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; CAMPBELL RD, 1983, P NATL ACAD SCI-BIOL, V80, P4464, DOI 10.1073/pnas.80.14.4464; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; CORBI AL, 1990, J BIOL CHEM, V265, P2782; DANA N, 1987, J CLIN INVEST, V79, P1010, DOI 10.1172/JCI112868; DANA N, 1984, J CLIN INVEST, V73, P153, DOI 10.1172/JCI111186; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; DANA N, 1986, J IMMUNOL, V137, P3259; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GIRMA JP, 1987, BLOOD, V70, P605; GULINO D, 1992, J BIOL CHEM, V267, P1001; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; JONES DH, 1990, BIOTECHNIQUES, V8, P178; JUST M, 1991, J BIOL CHEM, V266, P17326; KAWASAKI H, 1985, ANAL BIOCHEM, V148, P297, DOI 10.1016/0003-2697(85)90232-5; KLEBANOFF SJ, 1985, J IMMUNOL, V134, P1153; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER LL, 1985, EUR J IMMUNOL, V15, P713, DOI 10.1002/eji.1830150714; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEBIEN TW, 1980, J IMMUNOL, V125, P2208; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NELSON C, 1992, J BIOL CHEM, V267, P3351; PARKOS CA, 1992, J CELL BIOL, V117, P757, DOI 10.1083/jcb.117.4.757; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH JW, 1991, J BIOL CHEM, V266, P11429; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TEVELDE AA, 1987, IMMUNOLOGY, V61, P261; TROWBRIDGE IS, 1981, J EXP MED, V154, P1517, DOI 10.1084/jem.154.5.1517; TURNER DC, 1989, J NEUROSCI, V9, P3287; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	74	352	372	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					857	867		10.1016/0092-8674(93)90575-B	http://dx.doi.org/10.1016/0092-8674(93)90575-B			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458080				2022-12-28	WOS:A1993KU17500007
J	HUANG, S; HENDRIKS, W; ALTHAGE, A; HEMMI, S; BLUETHMANN, H; KAMIJO, R; VILCEK, J; ZINKERNAGEL, RM; AGUET, M				HUANG, S; HENDRIKS, W; ALTHAGE, A; HEMMI, S; BLUETHMANN, H; KAMIJO, R; VILCEK, J; ZINKERNAGEL, RM; AGUET, M			IMMUNE-RESPONSE IN MICE THAT LACK THE INTERFERON-GAMMA RECEPTOR	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CD4+ T-CELLS; MONOCLONAL-ANTIBODY; EXPRESSION; INVIVO; CD8+; INFECTION; CLONING; BINDING; DISEASE	Interferon-gamma (IFN-gamma) exerts pleiotropic effects, including antiviral activity, stimulation of macrophages and natural killer cells, and increased expression of major histocompatibility complex antigens. Mice without the IFN-gamma receptor had no overt anomalies, and their immune system appeared to develop normally. However, mutant mice had a defective natural resistance; they had increased susceptibility to infection by Listeria monocytogenes and vaccinia virus despite normal cytotoxic and T helper cell responses. Immunoglobulin isotype analysis revealed that IFN-gamma is necessary for a normal antigen-specific immunoglobulin G2a response. These mutant mice offer the possibility for the further elucidation of IFN-gamma-mediated functions by transgenic cell- or tissue-specific reconstitution of a functional receptor.	UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,DEPT PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; UNIV ZURICH,INST EXPTL IMMUNOL,CH-8057 ZURICH,SWITZERLAND; NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016	University of Zurich; Roche Holding; University of Zurich; New York University			Hendriks, Wiljan/Q-4325-2019; Hendriks, Wiljan J.A.J./A-5214-2013	Hendriks, Wiljan/0000-0001-9481-8281; Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Lee-Huang, Sylvia/0000-0003-3302-241X	NCI NIH HHS [CA 49731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BAENZIGER J, 1986, EUR J IMMUNOL, V16, P387, DOI 10.1002/eji.1830160413; BINDER D, 1991, J IMMUNOL, V146, P4301; Blanden R V, 1972, Scand J Immunol, V1, P379, DOI 10.1111/j.1365-3083.1972.tb03304.x; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7407; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; DING AH, 1988, J IMMUNOL, V141, P2407; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FOUNTOULAKIS M, 1991, J BIOL CHEM, V266, P14970; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; Huang S. H., UNPUB; JACOB CO, 1987, J EXP MED, V166, P798, DOI 10.1084/jem.166.3.798; KLAVINSKIS LS, 1989, J GEN VIROL, V70, P3317, DOI 10.1099/0022-1317-70-12-3317; LEFEVRE F, 1990, EUR J IMMUNOL, V20, P2485, DOI 10.1002/eji.1830201119; LEIST TP, 1989, J VIROL, V63, P2813, DOI 10.1128/JVI.63.6.2813-2819.1989; LEIST TP, 1987, J IMMUNOL, V138, P2278; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LOH JE, 1992, EMBO J, V11, P1351, DOI 10.1002/j.1460-2075.1992.tb05180.x; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; PORTNOY DA, 1992, CURR OPIN IMMUNOL, V4, P20, DOI 10.1016/0952-7915(92)90118-X; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SCHIJNS V, COMMUNICATION; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VALENTE G, 1992, EUR J IMMUNOL, V22, P2403, DOI 10.1002/eji.1830220933; WILLE A, 1989, EUR J IMMUNOL, V19, P1283, DOI 10.1002/eji.1830190720; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928	34	1423	1447	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1742	1745		10.1126/science.8456301	http://dx.doi.org/10.1126/science.8456301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456301				2022-12-28	WOS:A1993KT81000034
J	WALD, N				WALD, N			ETHICAL ISSUES IN RANDOMIZED PREVENTION TRIALS	BRITISH MEDICAL JOURNAL			English	Article											WALD, N (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					HOLLAND WW, 1990, SCREENING HLTH CARE, P140; Silverman W. A., 1980, RETROLENTAL FIBROPLA; WALD N, 1991, EUR J PEDIATR SURG, V1, P41, DOI 10.1055/s-2008-1042539; 1991, LANCET, V338, P132	4	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					563	565		10.1136/bmj.306.6877.563	http://dx.doi.org/10.1136/bmj.306.6877.563			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KP886	8461774	Bronze, Green Published			2022-12-28	WOS:A1993KP88600027
J	ESPIE, CA				ESPIE, CA			ABC OF SLEEP DISORDERS - PRACTICAL MANAGEMENT OF INSOMNIA - BEHAVIORAL AND COGNITIVE TECHNIQUES	BRITISH MEDICAL JOURNAL			English	Article											ESPIE, CA (corresponding author), COMMUNITY HLTH CARE UNIT,AYR,SCOTLAND.			Espie, Colin/0000-0002-1294-8734					0	12	12	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					509	511		10.1136/bmj.306.6876.509	http://dx.doi.org/10.1136/bmj.306.6876.509			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448467	Green Published, Bronze			2022-12-28	WOS:A1993KN78600028
J	BHOPAL, RS				BHOPAL, RS			PUBLIC-HEALTH MEDICINE AND PURCHASING HEALTH-CARE	BRITISH MEDICAL JOURNAL			English	Article											BHOPAL, RS (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.							Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; COCHRANE AL, 1989, ONE MANS MED AUTOBIO, P283; DOWNIE RS, 1990, HLTH PROMOTION MODEL, P9; ESKIN F, 1992, BRIT MED J, V304, P1307, DOI 10.1136/bmj.304.6837.1307-b; LEWIS J, 1991, OXFORD TXB PUBLIC HL, V1, P23; MACKENBACH JP, 1990, J EPIDEMIOL COMMUN H, V44, P106, DOI 10.1136/jech.44.2.106; Mckeown T, 1974, INTRO SOCIAL MED; OPIT LJ, 1991, OXFORD TXB PUBLIC HL, V3, pCH10; ROBINSON D, 1992, BRIT MED J, V304, P1307, DOI 10.1136/bmj.304.6837.1307-a; SZRETER S, 1986, IMPORTANCE SOCIAL IN; WHITTY P, 1992, BRIT MED J, V304, P1039, DOI 10.1136/bmj.304.6833.1039; [No title captured]; 1989, CMND555	13	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					381	382		10.1136/bmj.306.6874.381	http://dx.doi.org/10.1136/bmj.306.6874.381			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461687	Bronze, Green Published			2022-12-28	WOS:A1993KL71500026
J	DOMPELING, E; VANSCHAYCK, CP; VANGRUNSVEN, PM; VANHERWAARDEN, CLA; AKKERMANS, R; MOLEMA, J; FOLGERING, H; VANWEEL, C				DOMPELING, E; VANSCHAYCK, CP; VANGRUNSVEN, PM; VANHERWAARDEN, CLA; AKKERMANS, R; MOLEMA, J; FOLGERING, H; VANWEEL, C			SLOWING THE DETERIORATION OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY-DISEASE OBSERVED DURING BRONCHODILATOR THERAPY BY ADDING INHALED CORTICOSTEROIDS - A 4-YEAR PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ASTHMA; LUNG DISEASES, OBSTRUCTIVE; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; BECLOMETHASONE	AIR-FLOW OBSTRUCTION; LUNG-FUNCTION; CHRONIC-BRONCHITIS; DEPENDENT ASTHMATICS; EXACERBATION RATE; CLINICAL ASTHMA; DECLINE; RESPONSIVENESS; BUDESONIDE; MORTALITY	Objective: To determine if deterioration in patients with asthma or chronic obstructive pulmonary disease (COPD) during bronchodilator therapy could be slowed by additional treatment with an inhaled corticosteroid. Design: A 4-year prospective study. Setting: Twenty-nine general practices in the catchment area of the University of Nijmegen, Nijmegen, the Netherlands. Patients: The study included 56 patients (28 with asthma and 28 with COPD) who showed an annual decrease in the forced expiratory volume in 1 second (FEV1) of at least 80 mL in combination with at least two exacerbations per year during bronchodilator therapy alone. Forty-eight patients completed the study. Intervention: During the first 2 years of treatment, patients received only bronchodilator therapy (salbutamol, 400 mug, or ipratropium bromide, 40 mug). During years 3 and 4, they received additional treatment with beclomethasone dipropionate, 400 mug two times daily. Results: Prebronchodilator FEV1 increased 458 mL/y (95% CI, 233 to 683 mL/y) during the first 6 months of beclomethasone treatment; FEV1 then decreased 102 mL/y (CI, 57 to 147 mL/y) during months 7 to 24. The annual decline in FEV1 during beclomethasone treatment was less than the decline of 160 mL/y seen before beclomethasone therapy (difference, 58 mL/y; 95% CI, 2 to 87 mL/y). Only in patients with asthma did beclomethasone treatment improve bronchial hyperresponsiveness (assessed by determining the concentration of histamine that provoked a 20% decrease in FEV1 [PC20]) by 3.0 doubling doses per year (95% CI, 0.8 to 5.2 doses per year). Beclomethasone treatment was associated with improvement in peak expiratory flow rate, alleviation of symptoms, and a decrease in the number of exacerbations in both patient groups. Conclusion: Adding beclomethasone, 800 mug daily, slowed the unfavorable course of asthma or COPD seen with bronchodilator therapy alone. This effect was most evident in asthmatic patients.			DOMPELING, E (corresponding author), CATHOLIC UNIV NIJMEGEN, DEPT FAMILY MED, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1990, BMJ, V301, P651; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BOMAN G, 1983, EUR J RESPIR DIS, V64, P405; BURNEY PGJ, 1986, LANCET, V2, P323; BURROWS B, 1986, AM REV RESPIR DIS, V133, P974; CAMPBELL AH, 1985, THORAX, V40, P741, DOI 10.1136/thx.40.10.741; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V143, P1165, DOI 10.1164/ajrccm/143.5_Pt_1.1165; Das P, 1983, STAT NEERL, V37, P15; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DOMPELING E, 1991, EUR RESPIR J, V4, P612; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; JUNIPER EF, 1990, EUR RESPIR J, V3, P1122; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KAUFFMANN F, 1979, INT J EPIDEMIOL, V8, P201, DOI 10.1093/ije/8.3.201; LOUIS TA, 1984, NEW ENGL J MED, V310, P24, DOI 10.1056/NEJM198401053100106; MITCHELL EA, 1989, THORAX, V44, P81, DOI 10.1136/thx.44.2.81; PARKER DR, 1990, AM REV RESPIR DIS, V141, P589, DOI 10.1164/ajrccm/141.3.589; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; POSTMA DS, 1985, EUR J RESPIR DIS, V67, P56; POSTMA DS, 1988, EUR RESPIR J, V1, P22; POSTMA DS, 1986, AM REV RESPIR DIS, V134, P276; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; SANJAR S, 1988, LANCET, V2, P160; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; STEAD RJ, 1989, BRIT MED J, V298, P403, DOI 10.1136/bmj.298.6671.403; STOLLER JK, 1987, CHEST, V91, P155, DOI 10.1378/chest.91.2.155; THOM TJ, 1989, AM REV RESPIR DIS, V140, pS27, DOI 10.1164/ajrccm/140.3_Pt_2.S27; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; VANSCHAYCK CP, 1990, EUR RESPIR J, V3, P338; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V144, P1297, DOI 10.1164/ajrccm/144.6.1297; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426	38	175	184	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					770	778		10.7326/0003-4819-118-10-199305150-00003	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	8470851				2022-12-28	WOS:A1993LB64900003
J	BESSER, RE; LETT, SM; WEBER, JT; DOYLE, MP; BARRETT, TJ; WELLS, JG; GRIFFIN, PM				BESSER, RE; LETT, SM; WEBER, JT; DOYLE, MP; BARRETT, TJ; WELLS, JG; GRIFFIN, PM			AN OUTBREAK OF DIARRHEA AND HEMOLYTIC UREMIC SYNDROME FROM ESCHERICHIA-COLI O157-H7 IN FRESH-PRESSED APPLE CIDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMORRHAGIC COLITIS; SEROTYPE; 0157-H7	Objective.-Escherichia coli O157:H7 causes hemorrhagic colitis and the hemolytic uremic syndrome. In the fall of 1991, an outbreak of E coli O157:H7 infections in southeastern Massachusetts provided an opportunity to identify transmission by a seemingly unlikely vehicle. Design.-Case-control study to determine the vehicle of infection. New England cider producers were surveyed to assess production practices and determined the survival time of E coli O157:H7 organisms in apple cider. Results.-Illness was significantly associated with drinking one brand of apple cider. Thirteen (72%) of 18 patients but only 16 (33%) of 49 controls reported drinking apple cider in the week before illness began (odds ratio [OR], 8.3; 95% confidence interval [CI], 1.8 to 39.7). Among those who drank cider, 12 (92%) of 13 patients compared with two (13%) of 16 controls drank cider from cider mill A (lower 95% CI, 2.9; P<.01). This mill pressed cider in a manner similar to that used by other small cider producers: apples were not washed, cider was not pasteurized, and no preservatives were added. In the laboratory, E coli O157:H7 organisms survived for 20 days in unpreserved refrigerated apple cider. Addition of sodium benzoate 0.1% reduced survival to less than 7 days. Conclusions.-Fresh-pressed, unpreserved apple cider can transmit E coli O157:H7 organisms, which cause severe infections. Risk of transmission can be reduced by washing and brushing apples before pressing, and preserving cider with sodium benzoate. Consumers can reduce their risk by only drinking cider made from apples that have been washed and brushed	MASSACHUSETTS DEPT PUBL HLTH,DIV EPIDEMIOL,BOSTON,MA 02130; UNIV GEORGIA,DEPT FOOD SCI & TECHNOL,FOOD SAFETY & QUAL ENHANCEMENT LAB,GRIFFIN,GA 30223; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30333	Massachusetts Department of Public Health; University System of Georgia; University of Georgia; Centers for Disease Control & Prevention - USA	BESSER, RE (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ENTER DIS BRANCH,ATLANTA,GA 30333, USA.							BARRETT TJ, 1991, CURR MICROBIOL, V23, P189, DOI 10.1007/BF02092278; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; DEAN AG, 1990, EPI INFO VERSION 5; GOVERD KA, 1979, J APPL BACTERIOL, V46, P521, DOI 10.1111/j.1365-2672.1979.tb00851.x; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; MEYERS JA, 1976, J BACTERIOL, V127, P1529, DOI 10.1128/JB.127.3.1529-1537.1976; PADHYE NV, 1991, APPL ENVIRON MICROB, V57, P2693, DOI 10.1128/AEM.57.9.2693-2698.1991; PADHYE NV, 1991, J CLIN MICROBIOL, V29, P99, DOI 10.1128/JCM.29.1.99-103.1991; REMIS RS, 1984, ANN INTERN MED, V101, P624, DOI 10.7326/0003-4819-101-5-624; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; Shamody H. J., 1991, MANUAL CLIN MICROBIO, V5, P1117; STEELE BT, 1982, J PEDIATR-US, V101, P963, DOI 10.1016/S0022-3476(82)80021-8; STROCKBINE NA, 1992, MOL CELL PROBE, V6, P93, DOI 10.1016/0890-8508(92)90052-Y; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; THOMAS DG, 1992, COMPUT BIOMED RES, V25, P75, DOI 10.1016/0010-4809(92)90036-A; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983; 1975, MMWR, V24, P87; [No title captured]; 1993, MMWR, V42, P85; 1982, RETAIL FOOD STORE SA, P9	24	732	748	1	95	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1993	269	17					2217	2220		10.1001/jama.269.17.2217	http://dx.doi.org/10.1001/jama.269.17.2217			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ406	8474200				2022-12-28	WOS:A1993KZ40600028
J	KAHN, JK; BERNSTEIN, M; BENGTSON, JR				KAHN, JK; BERNSTEIN, M; BENGTSON, JR			ISOLATED RIGHT VENTRICULAR MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Note						MYOCARDIAL INFARCTION; VENTRICULAR FUNCTION, RIGHT HEART CATHETERIZATION; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE	RIGHT CORONARY-ARTERY; OCCLUSION	Infarction of the right ventricle can be detected in as many as 30% to 40% of patients with inferior myocardial infarction. Infarction involving only the right ventricle is unusual, and the diagnosis has rarely been made early in presentation. We report two patients with myocardial infarction isolated to the right ventricle. Both patients had prolonged chest pain and normal electrocardiograms in the first patient, urgent cardiac catheterization showed an occluded, nondominant right coronary artery that was reperfused using emergency angioplasty. In the second patient, a subtotally occluded nondominant right coronary artery caused postinfarction angina and was treated successfully with angioplasty. Patients with prolonged chest pain and nondiagnostic electrocardiograms should be assessed for this rarely reported syndrome.	ST JOSEPH MERCY HOSP, MICHIGAN HEART & VASC INST, ANN ARBOR, MI 48104 USA	Saint Joseph Mercy Health System (SJMHS)								DELLITALIA LJ, 1983, ANN INTERN MED, V99, P608, DOI 10.7326/0003-4819-99-5-608; JUDGUTT BI, 1984, AM HEART J, V107, P505; MITTAL SR, 1992, INT J CARDIOL, V34, P222, DOI 10.1016/0167-5273(92)90162-V; MOREYRA AE, 1986, AM J MED, V81, P146, DOI 10.1016/0002-9343(86)90199-3; MOREYRA AE, 1984, ANGIOLOGY, V35, P760, DOI 10.1177/000331978403501202; NAKAHARA K, 1989, JPN HEART J, V30, P95; ROBALINO BD, 1989, AM HEART J, V118, P138, DOI 10.1016/0002-8703(89)90084-7; SETARO J F, 1992, Cardiology Clinics, V10, P69; STARLING MR, 1984, J AM COLL CARDIOL, V4, P923, DOI 10.1016/S0735-1097(84)80052-2; WEISS AT, 1984, AM HEART J, V108, P425, DOI 10.1016/0002-8703(84)90642-2	10	12	12	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					708	711		10.7326/0003-4819-118-9-199305010-00009	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460858				2022-12-28	WOS:A1993KY50200009
J	GARDNER, P; SCHAFFNER, W				GARDNER, P; SCHAFFNER, W			CURRENT CONCEPTS - IMMUNIZATION OF ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							JAPANESE ENCEPHALITIS VACCINE; HEPATITIS-B VACCINATION; UNITED-STATES; IMMUNOGENICITY; STRATEGIES; EFFICACY		VANDERBILT UNIV,MED CTR,SCH MED,DEPT PREVENT MED,NASHVILLE,TN 37232	Vanderbilt University	GARDNER, P (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,DEPT MED,OFF ACAD AFFAIRS,STONY BROOK,NY 11794, USA.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDERSEN MM, 1991, LANCET, V337, P1044, DOI 10.1016/0140-6736(91)92707-9; BEST JM, 1991, EPIDEMIOL INFECT, V107, P17, DOI 10.1017/S0950268800048640; BUFFINGTON J, 1991, J GEN INTERN MED, V6, P204, DOI 10.1007/BF02598961; DENIS F, 1984, J INFECT DIS, V149, P1019, DOI 10.1093/infdis/149.6.1019; FEDSON DS, 1990, JAMA-J AM MED ASSOC, V264, P1117; GERSHON AA, 1988, J INFECT DIS, V158, P132, DOI 10.1093/infdis/158.1.132; GERSHON AA, 1988, J INFECT DIS, V158, P1149; Hadler S C, 1992, Curr Clin Top Infect Dis, V12, P282; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; LANCASTER D, 1989, AM J INFECT CONTROL, V17, P126, DOI 10.1016/0196-6553(89)90198-3; LEVIN MJ, 1992, J INFECT DIS, V166, P253, DOI 10.1093/infdis/166.2.253; NICHOL KL, 1991, AM J MED, V91, P584, DOI 10.1016/0002-9343(91)90210-O; POLAND JD, 1990, J INFECT DIS, V161, P878, DOI 10.1093/infdis/161.5.878; RUFF TA, 1991, LANCET, V338, P881, DOI 10.1016/0140-6736(91)91531-X; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504; 1990, GUIDE ADULT IMMUNIZA; 1992, HHS CDC928280 PUBL; 1992, MMWR MORB MORTAL WKL, V41; 1991, MMWR MORB MORTAL WKL, V40	24	140	140	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1252	1258						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464436				2022-12-28	WOS:A1993KZ06100008
J	CHROUSOS, GA; KATTAH, JC; BECK, RW; CLEARY, PA				CHROUSOS, GA; KATTAH, JC; BECK, RW; CLEARY, PA			SIDE-EFFECTS OF GLUCOCORTICOID TREATMENT - EXPERIENCE OF THE OPTIC NEURITIS TREATMENT TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							INTRAVENOUS PULSE METHYLPREDNISOLONE; MULTIPLE-SCLEROSIS; ADRENOCORTICOSTEROID THERAPY; ORAL GLUCOCORTICOIDS; STEROID PSYCHOSES; PEPTIC-ULCER; TRANSPLANTATION; COMPLICATIONS; CORTICOSTEROIDS; PANCREATITIS	Objective.-To determine the incidence of side effects from short-term glucocorticoid therapy prescribed for treatment of optic neuritis in the Optic Neuritis Treatment Trial. Design.-Randomized, placebo-controlled, multicenter clinical trial. Setting.-Fifteen university- or hospital-based centers throughout the United States. Patients.-A total of 457 patients between the ages of 18 and 46 years with acute demyelinative optic neuritis were studied. Interventions.-(1) Intravenous methylprednisolone (250 mg every 6 hours) for 3 days while hospitalized followed by oral prednisone (1 mg/kg per day) for 11 days; (2) oral prednisone (1 mg/kg per day) for 14 days; and (3) oral placebo for 14 days. Each regimen was followed by a short taper. Results.-Only two patients experienced major side effects, psychotic depression in one and acute pancreatitis in the other. Both of these patients were from the intravenous methylprednisolone group and both of the side effects resolved without sequelae. Patients in both groups receiving active drugs more often reported sleep disturbances, mood change, stomach upset, and facial flushing and gained more weight during the treatment period than patients in the placebo group (P<.001 for each comparison). Conclusions.-Although minor side effects are common, short-term glucocorticoid therapy in young, healthy adults is relatively safe. Because of the infrequency of serious side effects, outpatient administration of high-dose intravenous glucocorticoids may be feasible.	UNIV S FLORIDA,COLL MED,DEPT OPHTHALMOL,12901 BRUCE B DOWNS BLVD,MDC BOX 21,TAMPA,FL 33612; GEORGETOWN UNIV,CTR SIGHT,WASHINGTON,DC 20057; GEORGETOWN UNIV,DEPT NEUROL,WASHINGTON,DC 20057; GEORGE WASHINGTON UNIV,CTR BIOSTAT,ROCKVILLE,MD	State University System of Florida; University of South Florida; Georgetown University; Georgetown University; George Washington University					NATIONAL EYE INSTITUTE [U01EY007460, U01EY007212, U10EY007461, U01EY007461, U10EY007212, U10EY007460] Funding Source: NIH RePORTER; NEI NIH HHS [EY07460, EY07212, EY07461] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALEXANDER JA, 1988, TRANSPLANTATION, V45, P1062, DOI 10.1097/00007890-198806000-00012; AZIZ S, 1985, SURGERY, V97, P653; BARNES MP, 1985, J NEUROL NEUROSUR PS, V48, P157, DOI 10.1136/jnnp.48.2.157; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; BOCANEGRA TS, 1981, ANN INTERN MED, V95, P122, DOI 10.7326/0003-4819-95-1-122_1; BORN J, 1991, AM J PHYSIOL, V260, pE183, DOI 10.1152/ajpendo.1991.260.2.E183; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CAMERON OG, 1985, INT J PSYCHIAT MED, V15, P213; CARONE FA, 1957, NEW ENGL J MED, V257, P690, DOI 10.1056/NEJM195710102571502; CARSON JL, 1991, AM J MED, V91, P223, DOI 10.1016/0002-9343(91)90119-I; COLON R, 1988, SURGERY, V103, P32; CONN HO, 1976, NEW ENGL J MED, V294, P473, DOI 10.1056/NEJM197602262940905; FUJIKAWA LS, 1983, OPHTHALMOLOGY, V90, P1239; GALLANT C, 1986, J AM ACAD DERMATOL, V14, P161, DOI 10.1016/S0190-9622(86)70018-2; GARRETT R, 1980, ARTHRITIS RHEUM, V23, P677; GOMEZ G, 1989, SURGERY, V106, P230; HALL RCW, 1979, J NERV MENT DIS, V167, P229, DOI 10.1097/00005053-197904000-00006; HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181; KAUFMANN M, 1982, J CLIN PSYCHIAT, V43, P75; KENNEDY MS, 1985, AM J MED, V78, P978, DOI 10.1016/0002-9343(85)90221-9; KIMBALL CP, 1971, ANN INTERN MED, V75, P111, DOI 10.7326/0003-4819-75-1-111; LYONS PR, 1988, J NEUROL NEUROSUR PS, V51, P285, DOI 10.1136/jnnp.51.2.285; MCCLUSKEY P, 1987, ARCH OPHTHALMOL-CHIC, V105, P793; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; MOSES RE, 1981, ANN INTERN MED, V95, P781, DOI 10.7326/0003-4819-95-6-781_3; NAKASHIMA Y, 1977, SURG GYNECOL OBSTET, V145, P105; PRYSEPHILLIPS WEM, 1984, NEUROLOGY, V34, P1119, DOI 10.1212/WNL.34.8.1119; RADIA M, 1988, J RHEUMATOL, V15, P242; Reckart M D, 1990, Int J Psychosom, V37, P57; SCHATZBERG AF, 1985, J PSYCHIAT RES, V19, P57, DOI 10.1016/0022-3956(85)90068-8; SEALE JP, 1986, MED J AUSTRALIA, V144, P139, DOI 10.5694/j.1326-5377.1986.tb112242.x; SPOOR TC, 1988, OPHTHALMOLOGY, V95, P131; SPOOR TC, 1991, OPHTHALMOLOGY S8, V98, P116; STEED DL, 1985, SURGERY, V98, P739; STUBBS SS, 1973, TRANSPLANT P, V5, P1145; SUCHMAN AL, 1983, ARTHRITIS RHEUM, V26, P117, DOI 10.1002/art.1780260123; WAKEFIELD D, 1986, ARCH OPHTHALMOL-CHIC, V104, P847; 1972, CLIN PHARMACOL THER, V13, P694; 1991, ARCH OPHTHALMOL-CHIC, V109, P1673	40	119	127	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2110	2112		10.1001/jama.269.16.2110	http://dx.doi.org/10.1001/jama.269.16.2110			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468765				2022-12-28	WOS:A1993KY36600033
J	TAFF, ML; BOGLIOLI, LR				TAFF, ML; BOGLIOLI, LR			FRATERNITY HAZING REVISITED THROUGH A DRAWING BY BELLOWS,GEORGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									LENOX HILL HOSP,DEPT MED,NEW YORK,NY 10021	Northwell Health								APPEL W, 1983, CULTS AM PROGRAMMED; BITLEY LW, 1984, G BELLOWS PERSONAL S; Carnes Mark, 1989, SECRET RITUAL MANHOO; DOEZEMA M, 1992, ANTIQUES, V141, P480; Doezema Marianne, 1992, G BELLOWS URBAN AM; KIMMELMAN M, 1992, NY TIMES        0626, pC21; KIMMELMAN M, 1992, NY TIMES        0614, pH27; KLEIN C, 1987, GRAMERCY PARK AM BLO, P213; LESLIE J, 1985, AM J FOREN MED PATH, V6, P53, DOI 10.1097/00000433-198503000-00011; MASON L, 1977, LITHOGRAPHS G BELLOW; MILROY E, 1991, PAINTERS NEW CENTURY; MORGAN CH, 1973, DRAWINGS G BELLOWS; MORGAN CH, 1979, G BELLOWS PAINTER AM; Myers J., 1988, G BELLOWS ARTIST HIS; Quick Michael, 1992, PAINTINGS G BELLOWS; Roosevelt Theodore, 1893, HARPERS WEEKLY, V37, P1236; Roosevelt Theodore, 1901, STRENUOUS LIFE; SANTAYANA C, 1913, WINDS DOCTRINE; SCHIFF B, 1992, SMITHSONIAN, V23, P58; YOUNG MS, 1973, PAINTINGS G BELLOWS; 1983, ARTISTS THEMSELVES, P134	21	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2113	2115						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468766				2022-12-28	WOS:A1993KY36600034
J	VOLAREVIC, S; NIKLINSKA, BB; BURNS, CM; JUNE, CH; WEISSMAN, AM; ASHWELL, JD				VOLAREVIC, S; NIKLINSKA, BB; BURNS, CM; JUNE, CH; WEISSMAN, AM; ASHWELL, JD			REGULATION OF TCR SIGNALING BY CD45 LACKING TRANSMEMBRANE AND EXTRACELLULAR DOMAINS	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; LEUKOCYTE-COMMON ANTIGEN; PROTEIN-TYROSINE PHOSPHATASES; INTERLEUKIN-2 PRODUCTION; T-CELLS; B-CELLS; ASSOCIATION; ACTIVATION; EXPRESSION; PHOSPHORYLATION	The CD45 protein is a transmembrane tyrosine phosphatase that is required for normal T cell receptor (TCR)-mediated signaling. A chimeric complementary DNA encoding the intracellular enzymatically active portion of murine CD45 preceded by a short amino-terminal sequence from p60c-src was transfected into CD45- T cells. Expression of this chimeric protein corrected most of the TCR signaling abnormalities observed in the absence of CD45, including TCR-mediated enhancement of tyrosine kinase activity and Ca2+ flux. Thus, the enzymatically active intracellular portion of CD45 is sufficient to allow TCR transmembrane signaling.	NCI,IMMUNE CELL BIOL LAB,BIOL RESPONSE MODIFIERS PROGRAM,BETHESDA,MD 20892; USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20889; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Volarevic, Sinisa/O-4349-2018	Volarevic, Sinisa/0000-0003-4893-389X; June, Carl/0000-0003-0241-3557				CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; IMBODEN JB, 1985, J IMMUNOL, V134, P663; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; NIKLINSKA BB, UNPUB; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RABINOVITCH PS, 1990, FLOW CYTOMETRY SORTI, P651; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; VOLAREVIC S, UNPUB	29	121	121	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					541	544		10.1126/science.8475386	http://dx.doi.org/10.1126/science.8475386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	8475386				2022-12-28	WOS:A1993KY50400034
J	DUNN, B; STEARNS, T; BOTSTEIN, D				DUNN, B; STEARNS, T; BOTSTEIN, D			SPECIFICITY DOMAINS DISTINGUISH THE RAS-RELATED GTPASES YPT1 AND SEC4	NATURE			English	Article							GENE-PRODUCT; PROTEIN GAP; YEAST; SECRETION; IDENTIFICATION; SUPERFAMILY; MECHANISM	THE essential Ras-related GTPases1,2 Ypt1 and Sec4 act at distinct stages of the secretion pathway in the yeast Saccharomyces cerevisiae: Ypt1 is required for vesicular transport from the endoplasmic reticulum to the Golgi apparatus, whereas Sec4 is required for fusion of secretory vesicles to the plasma membrane3-6. Here we use chimaeras of the two proteins to identify a 9-residue segment of Ypt1 that, when substituted for the analogous segment of Sec4, allows the chimaera to perform the minimal functions of both proteins in vivo. This segment corresponds to loop L7 of the p21ras crystal structure7. Substitution of a 24-residue Ypt1 segment, including the residues just mentioned, together with 12 residues of Ypt1 corresponding to the 'effector region' of p21ras (loop L2; refs 7, 8), transforms Sec4 into a fully functional Ypt1 protein without residual Sec4 function.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	DUNN, B (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305, USA.			Stearns, Tim/0000-0002-0671-6582; Dunn, Barbara/0000-0002-7041-0035				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AUSUBEL FM, 1987, CURR PROT MOL BIOL; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Rose MD., 1990, METHODS YEAST GENETI; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1987, MOL CELL BIOL, V7, P2367, DOI 10.1128/MCB.7.7.2367; SIGAL IS, 1988, COLD SPRING HARB SYM, V53, P863, DOI 10.1101/SQB.1988.053.01.099; SIKORSKI RS, 1989, GENETICS, V122, P19; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	27	98	98	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					563	565		10.1038/362563a0	http://dx.doi.org/10.1038/362563a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464499				2022-12-28	WOS:A1993KW45300061
J	ZEHENDER, M; KASPER, W; KAUDER, E; SCHONTHALER, M; GEIBEL, A; OLSCHEWSKI, M; JUST, H				ZEHENDER, M; KASPER, W; KAUDER, E; SCHONTHALER, M; GEIBEL, A; OLSCHEWSKI, M; JUST, H			RIGHT VENTRICULAR INFARCTION AS AN INDEPENDENT PREDICTOR OF PROGNOSIS AFTER ACUTE INFERIOR MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ST-SEGMENT DEPRESSION; CHEST LEADS V3R; PRECORDIAL ST; ELECTROCARDIOGRAPHIC ALTERATIONS; THROMBOLYTIC THERAPY; DIAGNOSTIC-ACCURACY; RANDOMIZED TRIAL; WALL INFARCTION; ELEVATION; V7R	Background. Acute inferior myocardial infarction frequently involves the right ventricle. We hypothesized that right ventricular involvement, as diagnosed by ST-segment elevation in the right precordial lead V4R, may affect the prognosis of patients with inferior myocardial infarctions. Methods. In 200 consecutive patients admitted to the hospital with acute inferior myocardial infarctions, we assessed the prevalence and diagnostic accuracy of ST-segment elevation in lead V4R (as compared with four other diagnostic procedures) to identify right ventricular involvement and its prognostic implications for in-hospital and long-term outcomes. Results. The in-hospital mortality after inferior myocardial infarction was 19 percent, and major complications occurred in 47 percent of the patients. The presence of ST-segment elevation in lead V4R in 107 patients (54 percent) was highly predictive of right ventricular infarction (sensitivity, 88 percent; specificity, 78 percent; diagnostic accuracy, 83 percent), as compared with the other diagnostic procedures. The patients with ST-segment elevation in lead V4R had a higher in-hospital mortality rate (31 percent vs. 6 percent, P<0.001) and a higher incidence of major in-hospital complications (64 percent vs. 28 percent, P<0.001) than did those without ST elevation in V4R. Multiple logistic-regression analysis showed ST elevation in V4R to be independent of and superior to all other clinical variables available on admission for the prediction of in-hospital mortality (relative risk, 7.7; 95 percent confidence interval, 2.6 to 23) and major complications (relative risk, 4.7; 95 percent confidence interval, 2.4 to 9). The post-hospital course (follow-up, at least 1 year; mean follow-up, 37 months) was similar in patients with and in those without electrocardiographic evidence of right ventricular infarction. Conclusions. Right ventricular involvement during acute inferior myocardial infarction can be accurately diagnosed by the presence of ST-segment elevation in lead V4R, a finding that is a strong, independent predictor of major complications and in-hospital mortality. Electrocardiographic assessment of right ventricular infarction should be routinely performed in all patients with acute inferior myocardial infarctions.	UNIV KLIN FREIBURG, MED BIOMETRIE & INFORMAT ABT, W-7800 FREIBURG, GERMANY	University of Freiburg	ZEHENDER, M (corresponding author), UNIV KLIN FREIBURG, KARDIOL ABT, HUGSTETTERSTR 55, W-7800 FREIBURG, GERMANY.							Altman DG, 1991, PRACTICAL STATISTICS; ANDERSEN HR, 1989, AM HEART J, V117, P82, DOI 10.1016/0002-8703(89)90659-5; ANDERSEN HR, 1989, BRIT HEART J, V61, P514; ANDERSEN HR, 1989, INT J CARDIOL, V23, P349, DOI 10.1016/0167-5273(89)90195-2; ANDERSEN HR, 1989, BRIT HEART J, V62, P328; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BAR FW, 1987, AM J CARDIOL, V59, P6, DOI 10.1016/S0002-9149(87)80060-7; BATES ER, 1990, J AM COLL CARDIOL, V16, P1538, DOI 10.1016/0735-1097(90)90297-3; BERGER PB, 1990, CIRCULATION, V81, P401, DOI 10.1161/01.CIR.81.2.401; BOUGH EW, 1986, J AM COLL CARDIOL, V7, P990, DOI 10.1016/S0735-1097(86)80216-9; BRAAT SH, 1983, BRIT HEART J, V49, P368; BRAAT SH, 1984, J AM COLL CARDIOL, V4, P940, DOI 10.1016/S0735-1097(84)80054-6; CANDELLRIERA J, 1981, AM HEART J, V101, P281, DOI 10.1016/0002-8703(81)90191-5; CHOU TC, 1981, AM J MED, V70, P1175, DOI 10.1016/0002-9343(81)90824-X; COHN JN, 1979, AM J CARDIOL, V43, P666, DOI 10.1016/0002-9149(79)90030-4; COHN JN, 1974, AM J CARDIOL, V33, P209, DOI 10.1016/0002-9149(74)90276-8; COMACANELLA I, 1986, AM HEART J, V112, P940, DOI 10.1016/0002-8703(86)90304-2; CRAGG DR, 1989, CIRCULATION S2, V80, P552; CROFT CH, 1982, AM J CARDIOL, V50, P421, DOI 10.1016/0002-9149(82)90305-8; DELLITALIA LJ, 1984, J AM COLL CARDIOL, V4, P931, DOI 10.1016/S0735-1097(84)80053-4; FORMAN MB, 1984, J AM COLL CARDIOL, V4, P640, DOI 10.1016/S0735-1097(84)80115-1; GIBSON RS, 1982, CIRCULATION, V66, P732, DOI 10.1161/01.CIR.66.4.732; GREENBERG H, 1987, AM J CARDIOL, V59, P1057, DOI 10.1016/0002-9149(87)90848-4; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; ISNER JM, 1978, AM J CARDIOL, V42, P885, DOI 10.1016/0002-9149(78)90672-0; ISNER JM, 1988, RIGHT VENTRICLE, P87; KENNEDY, 1988, CIRCULATION, V77, P1037; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KLEIN HO, 1983, CIRCULATION, V67, P558, DOI 10.1161/01.CIR.67.3.558; LEMBO NJ, 1986, CIRCULATION, V74, P56, DOI 10.1161/01.CIR.74.1.56; LOPEZSENDON J, 1981, CIRCULATION, V64, P515, DOI 10.1161/01.CIR.64.3.515; LOPEZSENDON J, 1985, J AM COLL CARDIOL, V6, P1273, DOI 10.1016/S0735-1097(85)80213-8; MORGERA T, 1984, AM HEART J, V108, P13, DOI 10.1016/0002-8703(84)90538-6; NASMITH J, 1982, ANN INTERN MED, V96, P22, DOI 10.7326/0003-4819-96-1-22; PIERARD LA, 1986, AM J CARDIOL, V57, P82, DOI 10.1016/0002-9149(86)90956-2; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RATLIFF NB, 1980, AM J CARDIOL, V45, P217, DOI 10.1016/0002-9149(80)90638-4; REDUTO LA, 1978, ANN INTERN MED, V89, P441, DOI 10.7326/0003-4819-89-4-441; ROBALINO BD, 1989, AM HEART J, V118, P138, DOI 10.1016/0002-8703(89)90084-7; RODRIGUES EA, 1986, BRIT HEART J, V56, P19; SHAH PK, 1985, J AM COLL CARDIOL, V6, P1264, DOI 10.1016/S0735-1097(85)80212-6; SHARPE DN, 1978, CIRCULATION, V57, P483, DOI 10.1161/01.CIR.57.3.483; STARLING MR, 1984, J AM COLL CARDIOL, V4, P923, DOI 10.1016/S0735-1097(84)80052-2; WACKERS FJT, 1978, AM J CARDIOL, V42, P358, DOI 10.1016/0002-9149(78)90928-1; WARTMAN WB, 1948, ANN INTERN MED, V28, P41, DOI 10.7326/0003-4819-28-1-41; WEAVER W D, 1989, Journal of the American College of Cardiology, V13, p152A; WILCOX RG, 1988, LANCET, V2, P525	48	446	473	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					981	988		10.1056/NEJM199304083281401	http://dx.doi.org/10.1056/NEJM199304083281401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	8450875				2022-12-28	WOS:A1993KW28200001
J	HAYWARD, RA; MCMAHON, LF; BERNARD, AM				HAYWARD, RA; MCMAHON, LF; BERNARD, AM			EVALUATING THE CARE OF GENERAL MEDICINE INPATIENTS - HOW GOOD IS IMPLICIT REVIEW	ANNALS OF INTERNAL MEDICINE			English	Article						QUALITY OF HEALTH CARE; INPATIENTS; HEALTH RESOURCES; MEDICAL RECORDS; PEAR REVIEW	JUDGMENTS; QUALITY; RELIABILITY	Objective: Peer review often consists of implicit evaluations by physician reviewers of the quality and appropriateness of care. This study evaluated the ability of implicit review to measure reliably various aspects of care on a general medicine inpatient service. Design: Retrospective review of patients' charts, using structured implicit review, of a stratified random sample of consecutive admissions to a general medicine ward. Setting: A university teaching hospital. Patients: Twelve internists were trained in structured implicit review and reviewed 675 patient admissions (with 20% duplicate reviews for a total of 846 reviews). Results: Although inter-rater reliabilities for assessments of overall quality of care and preventable deaths (kappa = 0.5) were adequate for aggregate comparisons (for example, comparing mean ratings on two hospital wards), they were inadequate for reliable evaluations of single patients using one or two reviewers. Reviewers' agreement about most focused quality problems (for example, timeliness of diagnostic evaluation and clinical readiness at time of discharge) and about the appropriateness of hospital ancillary resource use was poor (kappa less-than-or-equal-to 0.2). For most focused implicit measures, bias due to specific reviewers who were systematically more harsh or lenient (particularly for evaluation of resource-use appropriateness) accounted for much of the variation in reviewers' assessments, but this was not a substantial problem for the measure of overall quality. Reviewers rarely reported being unable to evaluate the quality of care because of deficiencies in documentation in the patient's chart. Conclusion: For assessment of overall quality and preventable deaths of general medicine inpatients, implicit review by peers had moderate degrees of reliability, but for most other specific aspects of care, physician reviewers could not agree. Implicit review was particularly unreliable at evaluating the appropriateness of hospital resource use and the patient's readiness for discharge, two areas where this type of review is often used.	EMORY UNIV, ATLANTA, GA 30322 USA	Emory University	HAYWARD, RA (corresponding author), UNIV MICHIGAN, MED CTR, DIV GEN MED, 3116 TAUBMAN CTR, ANN ARBOR, MI 48109 USA.							BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; BROOK RH, 1987, JAMA-J AM MED ASSOC, V258, P3138, DOI 10.1001/jama.258.21.3138; BUTLER JJ, 1958, JAMA-J AM MED ASSOC, V167, P567, DOI 10.1001/jama.1958.02990220037011; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; DANS PE, 1985, NEW ENGL J MED, V313, P1131, DOI 10.1056/NEJM198510313131806; Donabedian A., 1980, EXPLORATIONS QUALITY; Donabedian A., 1982, EXPLORATIONS QUALITY; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; GOLDMAN RL, 1992, JAMA-J AM MED ASSOC, V267, P958, DOI 10.1001/jama.267.7.958; HULKA BS, 1979, MED CARE, V17, P1; Kahn KL, 1989, STRUCTURED IMPLICIT; LAFFEL G, 1992, JAMA-J AM MED ASSOC, V268, P407, DOI 10.1001/jama.268.3.407; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; Lohr KN, 1990, MEDICARE STRATEGY QU; MCMAHON LF, 1992, MED CARE, V30, P445, DOI 10.1097/00005650-199205000-00006; Nunnally Jum C, 1967, PSYCHOMETRIC THEORY, V226; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; SPITERI MA, 1988, LANCET, V1, P873; THEODOSSI A, 1981, Liver, V1, P21	22	92	92	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					550	556		10.7326/0003-4819-118-7-199304010-00010	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442625				2022-12-28	WOS:A1993KU07900010
J	SOLLNER, T; WHITEHART, SW; BRUNNER, M; ERDJUMENTBROMAGE, H; GEROMANOS, S; TEMPST, P; ROTHMAN, JE				SOLLNER, T; WHITEHART, SW; BRUNNER, M; ERDJUMENTBROMAGE, H; GEROMANOS, S; TEMPST, P; ROTHMAN, JE			SNAP RECEPTORS IMPLICATED IN VESICLE TARGETING AND FUSION	NATURE			English	Article							CENTRAL NERVOUS-SYSTEM; VESICULAR TRANSPORT; MEMBRANE-PROTEIN; SECRETORY PATHWAY; SYNAPTIC VESICLES; GOLGI STACK; YEAST; GENES; FAMILY; PURIFICATION	The N-ethylmaleimide-sensitive fusion protein (NSF) and the soluble NSF attachment proteins (SNAPs) appear to be essential components of the intracellular membrane fusion apparatus. An affinity purification procedure based on the natural binding of these proteins to their targets was used to isolate SNAP receptors (SNAREs) from bovine brain. Remarkably, the four principal proteins isolated were all proteins associated with the synapse, with one type located in the synaptic vesicle and another in the plasma membrane, suggesting a simple mechanism for vesicle docking. The existence of numerous SNARE-related proteins, each apparently specific for a single kind of vesicle or target membrane, indicates that NSF and SNAPs may be universal components of a vesicle fusion apparatus common to both constitutive and regulated fusion (including neurotransmitter release), in which the SNAREs may help to ensure vesicle-to-target specificity.			SOLLNER, T (corresponding author), MEM SLOAN KETTERING CANC CTR,ROCKEFELLER RES LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594; Brunner, Michael/0000-0001-9798-3047; Whiteheart, Sidney/0000-0001-5577-0473				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, INPRESS P NATN ACAD; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; ERDJUMENTBROMAG.H, IN PRESS TECHNIQUES, V4; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARLOW E, 1988, ANTIBODIES LABORATOR; HESS DT, 1992, J NEUROSCI, V12, P4634; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; OYLER GA, 1989, J CELL BIOL, V109, P3030; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TAGAYA M, 1993, J BIOL CHEM, V269, P2662; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WATERS RG, 1992, J CELL BIOL, V118, P1015; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, METHOD ENZYMOL, V219, P309; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	56	2656	2728	7	319	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					318	324		10.1038/362318a0	http://dx.doi.org/10.1038/362318a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455717				2022-12-28	WOS:A1993KU17600051
J	TODD, KH; SAMAROO, N; HOFFMAN, JR				TODD, KH; SAMAROO, N; HOFFMAN, JR			ETHNICITY AS A RISK FACTOR FOR INADEQUATE EMERGENCY DEPARTMENT ANALGESIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PAIN	Objective.-To determine whether Hispanic patients with isolated long-bone fractures are less likely to receive emergency department (ED) analgesics than similar non-Hispanic white patients. Design.-Retrospective cohort study. Setting.-The UCLA Emergency Medicine Center, a level I trauma center. Participants.-All Hispanic and non-Hispanic white ED patients aged 15 to 55 years, seen between January 1, 1990, and December 31, 1991, with isolated long-bone fractures, identified by ICD-9 codes 812, 813, 821, and 823, were eligible for inclusion. Exclusion criteria included injury more than 6 hours prior to presentation, ''possible'' or chip fractures only, altered mentation, or ethanol intoxication. Main Outcome Measures.-Emergency department administration of analgesic or no analgesic. Results.-The study group consisted of 139 patients meeting inclusion criteria, of whom 31 were Hispanic and 108 non-Hispanic white. Non-Hispanic whites were significantly more likely to speak English, be insured, and suffer nonoccupational injuries, Hispanics were twice as likely as non-Hispanic whites to receive no ED pain medication (crude relative risk [RR], 2.12; 95% confidence interval [CI], 1.35 to 3.32; P=.003). The RR for ethnicity was similar and significant (P<.05) after controlling by stratification for covariates related to patient, injury, or physician characteristics. After controlling for several covariates simultaneously through multiple logistic regression, ethnicity remained the strongest predictor of ED analgesic administration (odds ratio [OR], 7.46; 95% CI, 2.22 to 25.04; P<.01). Conclusions.-Hispanics with isolated long-bone fractures are twice as likely as non-Hispanic whites to receive no pain medication in the UCLA Emergency Medicine Center. No covariate measured in this study could account for this effect. An ethnic basis for variability in analgesic practice needs to be further characterized.			TODD, KH (corresponding author), UNIV CALIF LOS ANGELES, CTR EMERGENCY MED, 924 WESTWOOD BLVD, SUITE 300, LOS ANGELES, CA 90024 USA.							Dean A. G., 1990, EPI INFO VERSION 5 W; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GREENWALD HP, 1991, PAIN, V44, P157, DOI 10.1016/0304-3959(91)90130-P; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KIRKMANLIFF B, 1991, AM J PUBLIC HEALTH, V81, P1399, DOI 10.2105/AJPH.81.11.1399; PFEFFERBAUM B, 1990, J AM ACAD CHILD PSY, V29, P642, DOI 10.1097/00004583-199007000-00020; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6; ZATZICK DF, 1990, PSYCHOSOM MED, V52, P544, DOI 10.1097/00006842-199009000-00007; 1992, STATE REFERENCE MANU	10	589	593	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1537	1539		10.1001/jama.269.12.1537	http://dx.doi.org/10.1001/jama.269.12.1537			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445817				2022-12-28	WOS:A1993KR80300027
J	PETCHEY, R				PETCHEY, R			NHS INTERNAL MARKET 1991-2 - TOWARDS A BALANCE-SHEET	BRITISH MEDICAL JOURNAL			English	Article								The first year of the internal market in the NHS has been claimed to have resulted in increased efficiency. These claims, however, are hard to substantiate because the systems for operating the market are not fully in place. Examination of data on tax relief for private health insurance premiums for over 60s, general practice fundholding, and implementation and transaction costs suggest that much of the increased efficiency is not due to the reforms but to increased funding. Furthermore, some of the changes seem to be decreasing market forces and reducing efficiency.			PETCHEY, R (corresponding author), UNIV NOTTINGHAM,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							BARTLETT W, 1991, QUASIMARKETS CONTRAC; BRINDLE D, 1992, GUARDIAN        0507, P11; DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; EVANS RG, 1986, J HEALTH POLIT POLIC, V11, P585, DOI 10.1215/03616878-11-4-585; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; HADLEY JP, 1991, HEALTH POLICY, V19, P91, DOI 10.1016/0168-8510(91)90001-E; HARRISON S, 1991, INT J HEALTH SERV, V21, P625, DOI 10.2190/BTXE-XGBW-BDFK-B5G6; HUGHES D, 1991, J SOCIAL WELFARE LAW, V5, P296; LAING W, 1992, LAINGS REV PRIVATE H; LIGHT DW, 1991, BRIT MED J, V303, P568, DOI 10.1136/bmj.303.6802.568; LIMB M, 1992, HLTH SERVICE J, V102, P6; Mellett H, 1991, Health Serv J, V101, P18; Millar B, 1991, Health Serv J, V101, P17; MOORE W, 1991, HLTH SERVICE J, V101, P3; POPE C, 1991, SOCIOL HEALTH ILL, V13, P193, DOI 10.1111/1467-9566.ep11340798; POPE C, 1992, BRIT MED J, V305, P577, DOI 10.1136/bmj.305.6853.577; PROPPER C, 1990, COMPETITION HLTH CAR, P48; QUAM L, 1991, PROVIDING HEALTH CARE : THE ECONOMICS OF ALTERNATIVE SYSTEMS OF FINANCE AND DELIVERY, P192; SHELDON T, 1992, HLTH SERVICE J, V102, P8; Williamson O.E., 1975, MARKETS HIERARCHIES; WOLLHANDLER S, 1991, NEW ENGL J MED, V324, P1253; 1992, BMJ, V305, P602; 1992, HLTH PERSONAL SOCIAL; 1992, BMA NEWS REV, V18, P28; 1992, BMJ, V304, P142; 1989, WORKING PATIENTS; 1989, 18 SECR STAT HLTH WO; 1992, BMJ, V304, P705; 1992, BMJ, V304, P400; 1991, FINANCIAL SURVEY 199; 1992, NHS REFORMS 1ST 6 MO; 1991, PUBLIC EXPENDITURE H; 1992, BMA NEW REV, V18, P12; 1992, FINANCIAL SURVEY 199; 1990, GENERAL HOUSEHOLD SU; 1992, HLTH SERVICE J, V102, P5	36	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					699	701		10.1136/bmj.306.6879.699	http://dx.doi.org/10.1136/bmj.306.6879.699			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KT216	8471927	Bronze, Green Published			2022-12-28	WOS:A1993KT21600028
J	HISATAKE, K; HASEGAWA, S; TAKADA, R; NAKATANI, Y; HORIKOSHI, M; ROEDER, RG				HISATAKE, K; HASEGAWA, S; TAKADA, R; NAKATANI, Y; HORIKOSHI, M; ROEDER, RG			THE P250 SUBUNIT OF NATIVE TATA BOX-BINDING FACTOR-TFIID IS THE CELL-CYCLE REGULATORY PROTEIN-CCG1	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; ACTIVATION DOMAIN; GENE; COACTIVATORS; INITIATION; MECHANISM; UPSTREAM	THE protein TFIID is a general transcription factor1 which initiates preinitiation complex assembly2-4 through direct interaction with the TATA promoter element5,6. It is a multisubunit complex containing a small TATA-binding polypeptide (TBP) and other TBP-associated factors (TAFs) ranging in size from about 30-250K (refs 7-10). Although native TFIID can mediate both activator-independent (basal) and activator-dependent transcription in reconstituted systems3,5,6, TBP itself can mediate only basal transcription11,12, even in cases where TBP or the general factor TFIIB are known to interact directly with transcriptional activators13-15. TFIID subunits other than TBP must therefore be essential cofactors, and thus potential targets for activators, consistent with earlier demonstrations that activators interact with TFIID (refs 3, 5, 16, 17). Here we show that the 250K subunit of TFIID is identical to a gene product previously implicated in progression through the late G1 phase of the cell cycle18,19. Part of p250 may thus serve a specific function in the activation of a subset of genes important for cell cycle progression.	NINCDS,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	HISATAKE, K (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.			Hisatake, Koji/0000-0002-5795-3115; Takada, Ritsuko/0000-0002-1615-056X				BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; Johnston Leland H., 1992, Trends in Cell Biology, V2, P353, DOI 10.1016/0962-8924(92)90041-K; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU HT, 1985, J BIOL CHEM, V260, P3269; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	30	184	186	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					179	181		10.1038/362179a0	http://dx.doi.org/10.1038/362179a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8450888				2022-12-28	WOS:A1993KR02800066
J	TASKAR, VS; BRADLEY, BB; MOUSSALI, HM; HILTON, AM				TASKAR, VS; BRADLEY, BB; MOUSSALI, HM; HILTON, AM			LESSON OF THE WEEK - FOREIGN-BODY ASPIRATION - A HAZARD OF METERED DOSE INHALERS	BRITISH MEDICAL JOURNAL			English	Article									WYTHENSHAWE HOSP,CHEST CLIN,MANCHESTER M23 9LT,LANCS,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital								[Anonymous], 1990, BMJ, V301, P651; CUCKOW PM, 1989, J ROY COLL GEN PRACT, V39, P476; HANNAN SE, 1984, AM REV RESPIR DIS, V129, P1025; MCGONAGLE M, 1984, JAMA-J AM MED ASSOC, V251, P1431, DOI 10.1001/jama.1984.03340350025016; WIESEL JM, 1981, J LARYNGOL OTOL, V95, P219, DOI 10.1017/S0022215100090629	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					575	576		10.1136/bmj.306.6877.575	http://dx.doi.org/10.1136/bmj.306.6877.575			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461778	Bronze, Green Published			2022-12-28	WOS:A1993KP88600031
J	MUTTON, DE; IDE, R; ALBERMAN, E; BOBROW, M				MUTTON, DE; IDE, R; ALBERMAN, E; BOBROW, M			ANALYSIS OF NATIONAL REGISTER OF DOWNS-SYNDROME IN ENGLAND AND WALES - TRENDS IN PRENATAL-DIAGNOSIS, 1989-91	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,LONDON EC1M 6BQ,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,PAEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND	University of London; Queen Mary University London; University of London; King's College London	MUTTON, DE (corresponding author), LONDON HOSP,COLL MED QMW,DEPT EPIDEMIOL & MED STAT,LONDON E1 4NS,ENGLAND.							BOYD PA, 1992, J MED GENET, V29, P91, DOI 10.1136/jmg.29.2.91; CULLEN S, 1992, ARCH DIS CHILD-FETAL, V67, P775, DOI 10.1136/adc.67.7_Spec_No.775; MUTTON DE, 1991, BRIT MED J, V303, P1295, DOI 10.1136/bmj.303.6813.1295; WALD N, 1992, LANCET, V340, P494, DOI 10.1016/0140-6736(92)91822-P	4	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					431	432		10.1136/bmj.306.6875.431	http://dx.doi.org/10.1136/bmj.306.6875.431			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461727	Green Published, Bronze			2022-12-28	WOS:A1993KM70000024
J	SHAPIRO, CM; FLANIGAN, MJ				SHAPIRO, CM; FLANIGAN, MJ			ABC OF SLEEP DISORDERS - FUNCTION OF SLEEP	BRITISH MEDICAL JOURNAL			English	Article											SHAPIRO, CM (corresponding author), TORONTO GEN HOSP,TORONTO M5G 1L7,ONTARIO,CANADA.							ADAM K, 1983, CLIN SCI, V65, P561, DOI 10.1042/cs0650561; BORBELY AA, 1988, BIOL RHYTHMS MENTAL; KALAT JW, 1988, BIOL PSYCHOL	3	31	32	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					383	385		10.1136/bmj.306.6874.383	http://dx.doi.org/10.1136/bmj.306.6874.383			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KL715	8461688	Green Published, Bronze			2022-12-28	WOS:A1993KL71500027
J	BERNSTEIN, SJ; MCGLYNN, EA; SIU, AL; ROTH, CP; SHERWOOD, MJ; KEESEY, JW; KOSECOFF, J; HICKS, NR; BROOK, RH				BERNSTEIN, SJ; MCGLYNN, EA; SIU, AL; ROTH, CP; SHERWOOD, MJ; KEESEY, JW; KOSECOFF, J; HICKS, NR; BROOK, RH			THE APPROPRIATENESS OF HYSTERECTOMY - A COMPARISON OF CARE IN 7 HEALTH PLANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To develop and test a method for comparing the appropriateness of hysterectomy use in different health plans. Design.-Retrospective cohort study. Setting.-Seven managed care organizations. Patients.-Random sample of all nonemergency, nononcological hysterectomies performed in the seven managed care organizations over a 1-year period. Patients who were not continuously enrolled in a plan for 2 years prior to their hysterectomy were excluded. Main Outcome Measures.-Proportion of women undergoing hysterectomy in each plan for inappropriate clinical reasons according to ratings derived from a panel of managed care physicians. Results.-Overall, about 16% of women underwent hysterectomy for reasons judged to be clinically inappropriate. Only one plan had significantly more hysterectomies rated inappropriate compared with the group mean (27%, unadjusted). Adjusting for age and race did not affect the rankings of the plans and had little effect on the numeric results. Conclusion.-The rates of inappropriate use of hysterectomies are similar to those for other procedures and vary to a small degree among health plans. This information may be useful to purchasers when they consider which health plans to offer their employees.	RAND, 1700 MAIN ST, SANTA MONICA, CA 90407 USA; UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, LOS ANGELES, CA USA; VALUE HLTH SECT, SANTA MONICA, CA USA; OXFORDSHIRE HLTH AUTHOR, DEPT PUBL HLTH MED, OXFORD, ENGLAND	RAND Corporation; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles				Hicks, Nicholas/0000-0002-7214-9678; Bernstein, Steven/0000-0003-3359-7168				BERNSTEIN SJ, 1992, HYSTERECTOMY LIT EV; DEFRIESE GH, 1989, N CAROLINA MED SOC P; DOYLE JC, 1953, JAMA-J AM MED ASSOC, V151, P360; DRANOV P, 1986, HEALTH           JUN, V6, P24; DYCK FJ, 1977, NEW ENGL J MED, V296, P1326, DOI 10.1056/NEJM197706092962306; EASTERDAY CL, 1983, OBSTET GYNECOL, V62, P203; GAMBONE JC, 1989, OBSTET GYNECOL, V73, P1045; GRAVES EJ, 1991, VITAL HLTH STAT, V113, P118; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; Jenkins V R 2nd, 1977, QRB Qual Rev Bull, V3, P7; JENKINS VR, 1977, QUAL REV B, V3, P21; KHOSLA T, 1967, BRIT J PREV SOC MED, V21, P122; MILLER NF, 1946, AM J OBSTET GYNECOL, V51, P804, DOI 10.1016/S0002-9378(16)39958-6; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; POKRAS R, 1988, AM J PUBLIC HEALTH, V78, P852, DOI 10.2105/AJPH.78.7.852; SHERWOOD MJ, 1991, RAND N3435HF PUBL; 1990, PHYSICIANS CURRENT P; 1989, INT CLASSIFICATION D; 1989, QUALITY ASSURANCE OB	19	130	131	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2398	2402		10.1001/jama.269.18.2398	http://dx.doi.org/10.1001/jama.269.18.2398			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479066				2022-12-28	WOS:A1993LA67500034
J	CASTROMAGANA, M; ANGULO, M; UY, J				CASTROMAGANA, M; ANGULO, M; UY, J			MALE HYPOGONADISM WITH GYNECOMASTIA CAUSED BY LATE-ONSET DEFICIENCY OF TESTICULAR 17-KETOSTEROID REDUCTASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							17-BETA-HYDROXYSTEROID DEHYDROGENASE-DEFICIENCY; FAMILIAL MALE PSEUDOHERMAPHRODITISM; POLYCYSTIC OVARIAN DISEASE; TESTOSTERONE; ESTRADIOL; ANDROGENS; PLASMA; DEFECT	Background. 17-Ketosteroid reductase deficiency results in male pseudohermaphroditism because conversion of the weak androgen androstenedione to the more potent androgen testosterone is impaired. If a late-onset form exists, hypogonadism and gynecomastia caused by decreased testosterone production and increased estrogen production, respectively, would be expected as the major clinical manifestations in men. Methods. We studied 48 male subjects, ranging from 14 to 26 years of age, who had idiopathic pubertal gynecomastia. Serum concentrations of gonadal and adrenal steroid hormones were measured before and after the administration of corticotropin and after the combined administration of chorionic gonadotropin and dexamethasone for three days. Results. We identified three unrelated subjects (ages, 16, 17, and 26 years) with results indicative of a partial deficiency of testicular 17-ketosteroid reductase. The three subjects had gynecomastia as well as decreased libido and impotence. Their mean (+/-SD) base-line serum androstenedione and estrone concentrations were elevated as compared with the levels in the 45 subjects without this enzyme deficiency (androstenedione, 380+/-70 vs. 110+/-70 ng er deciliter [13+/-2 vs. 4+/-2 nmol per liter]; estrone, 138+/-12 vs. 46+/-9 pg per milliliter [511+/-44 vs. 170+/-33 pmol per liter]). After the administration of chorionic gonadotropin, the mean serum androstenedione concentration in these three subjects was 910+/-48 ng per deciliter (32+/-2 nmol per liter) and the mean serum estrone concentration was 260+/-16 pg per milliliter (962+/-59 pmol per liter). The mean serum testosterone concentration at base line was 210+/-80 ng per deciliter (7.4+/-2.8 nmol per liter) in the 3 subjects, as compared with a value of 410+/-12 ng per deciliter (14.4+/-0.42 nmol per liter) in the 45 other subjects, and it did not increase in response to the administration of chorionic gonadotropin. The concentrations of androstenedione and estrone in spermatic venous serum were 19 times higher and 73 times higher, respectively, than in normal men. The serum concentrations of follicle-stimulating hormone and luteinizing hormone in these three subjects were inappropriately low, suggesting the presence of hypogonadotropic hypogonadism. Conclusions. A late-onset form of testicular 17-ketosteroid reductase deficiency can cause gynecomastia and hypogonadism in men.	WINTHROP UNIV HOSP,DIV PEDIAT ENDOCRINOL & GENET,MINEOLA,NY; SUNY STONY BROOK,HLTH SCI CTR,STONY BROOK,NY 11794	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								AKESODE FA, 1977, CLIN ENDOCRINOL, V7, P443, DOI 10.1111/j.1365-2265.1977.tb01336.x; AVRUSKIN TW, 1989, J PEDIATR ENDOCRINOL, V3, P135; BALDUCCI R, 1985, CLIN ENDOCRINOL, V23, P439, DOI 10.1111/j.1365-2265.1985.tb01102.x; CASTROMAGANA M, 1990, UROLOGY, V35, P195, DOI 10.1016/0090-4295(90)80030-Q; CASTROMAGANA M, 1988, J PEDIATR-US, V112, P397, DOI 10.1016/S0022-3476(88)80319-6; CASTROMAGANA M, 1991, FERTIL STERIL, V56, P515; ECKSTEIN B, 1989, J CLIN ENDOCR METAB, V68, P477, DOI 10.1210/jcem-68-2-477; GOEBELSMANN U, 1973, J CLIN ENDOCR METAB, V36, P867, DOI 10.1210/jcem-36-5-867; GROSS DJ, 1986, ACTA ENDOCRINOL-COP, V112, P238, DOI 10.1530/acta.0.1120238; KNORR D, 1974, KLIN WOCHENSCHR, V52, P537, DOI 10.1007/BF01468725; KOHN G, 1985, Journal of Pediatric Endocrinology, V1, P29; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; MIKHAIL G, 1970, STEROIDS, V15, P333, DOI 10.1016/S0039-128X(70)80053-8; PANG S, 1987, NEW ENGL J MED, V316, P1295, DOI 10.1056/NEJM198705213162102; PETRANGELI E, 1981, J RES LAB MED, V8, P147; ROGERS DG, 1985, STEROIDS, V45, P195, DOI 10.1016/0039-128X(85)90048-0; ROGERS DG, 1985, STEROIDS, V45, P473; ROSLER A, 1992, J CLIN ENDOCR METAB, V75, P773, DOI 10.1210/jc.75.3.773; ROSLER A, 1983, J STEROID BIOCHEM, V19, P663, DOI 10.1016/0022-4731(83)90233-9; SAEZ JM, 1971, J CLIN ENDOCR METAB, V32, P604, DOI 10.1210/jcem-32-5-604; TOSCANO V, 1990, J CLIN ENDOCR METAB, V71, P288, DOI 10.1210/jcem-71-2-288; TOSCANO V, 1981, J STEROID BIOCHEM, V14, P574, DOI 10.1016/0022-4731(81)90033-9; ULLOAAGUIRRE A, 1985, J CLIN ENDOCR METAB, V60, P639, DOI 10.1210/jcem-60-4-639; VIRDIS R, 1978, ACTA ENDOCRINOL-COP, V87, P212, DOI 10.1530/acta.0.0870212; VIRDIS R, 1984, ADRENAL DISEASES CHI, V13, P110; WEINSTEIN RL, 1974, J CLIN INVEST, V53, P1, DOI 10.1172/JCI107526	26	28	29	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1993	328	18					1297	1301		10.1056/NEJM199305063281802	http://dx.doi.org/10.1056/NEJM199305063281802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ640	8469252				2022-12-28	WOS:A1993KZ64000002
J	MORROW, K; MORRIS, CK; FROELICHER, VF; HIDEG, A; HUNTER, D; JOHNSON, E; KAWAGUCHI, T; LEHMANN, K; RIBISL, PM; THOMAS, R; UESHIMA, K; FROELICHER, E; WALLIS, J				MORROW, K; MORRIS, CK; FROELICHER, VF; HIDEG, A; HUNTER, D; JOHNSON, E; KAWAGUCHI, T; LEHMANN, K; RIBISL, PM; THOMAS, R; UESHIMA, K; FROELICHER, E; WALLIS, J			PREDICTION OF CARDIOVASCULAR DEATH IN MEN UNDERGOING NONINVASIVE EVALUATION FOR CORONARY-ARTERY DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; EXERCISE TEST; OUTCOME ASSESSMENT (HEALTH CARE); DEATH, SUDDEN, CARDIAC; HEART FAILURE, CONGESTIVE	MEDICALLY TREATED PATIENTS; PROGNOSTIC VALUE; EXERCISE TEST; STANDARDS; SURVIVAL; SCORE	Objective: To develop prediction rules from clinical and exercise test data identifying patients at high and low risk for cardiovascular events among a group of male veterans. Design: Prognostic study with prospective gathering of data and routine follow-up of consecutive patients referred for exercise testing. Patients only underwent noninvasive evaluation for coronary artery disease. No validation cohort is yet available. Setting: A 1200-bed Veterans Affairs Medical Center. Patients: Of 3609 men referred for exercise testing between 1984 and 1990, 2546 patients remained evaluable after exclusion of those who underwent subsequent cardiac catheterization, those with significant valvular heart disease, and those who had previous coronary artery bypass surgery. Measurements: Evaluation included recording of clinical data on a standardized form and a standard treadmill test followed by assessment of cardiovascular events. Results: During a mean follow-up period (+/- SD) of 2.75 (+/- 1.8) years, 119 cardiovascular deaths and 44 nonfatal myocardial infarctions occurred in 2546 patients. The Cox proportional hazards model showed the following characteristics to be statistically independent predictors of time until cardiovascular death: history of congestive heart failure or digoxin use, exercise-induced ST depression, change in systolic blood pressure during exercise, and exercise capacity. Using a simple score based on one item of clinical information (history of congestive heart failure or digoxin use) and three exercise test responses (ST depression, exercise capacity, and change in systolic blood pressure), 77% of patients were categorized as low risk (annual cardiac mortality rate, less than 2%), 18% as moderate risk (annual cardiac mortality rate, 7%), and 6% as high risk (annual cardiac mortality rate, 15%; hazard ratio, 10; 95% confidence interval, 6 to 17). This model has not yet been validated. Conclusions: Variables available from the usual noninvasive work-up of patients with known or suspected coronary artery disease can be used to predict future risk for cardiovascular death.	PALO ALTO VET AFFAIRS MED CTR, DEPT CARDIOL 111C, 3801 MIRANDA AVE, PALO ALTO, CA 94304 USA; LONG BEACH VET AFFAIRS MED CTR, LONG BEACH, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System				Froelicher, Victor/0000-0001-8831-4853				BRUNELLI C, 1989, EUR HEART J, V10, P292, DOI 10.1093/oxfordjournals.eurheartj.a059486; DANS PE, 1988, ARCH INTERN MED, V148, P2633, DOI 10.1001/archinte.148.12.2633; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; DUBACH P, 1988, CIRCULATION, V78, P1380, DOI 10.1161/01.CIR.78.6.1380; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; GOHLKE H, 1983, CIRCULATION, V68, P979, DOI 10.1161/01.CIR.68.5.979; GRABOYS TB, 1992, JAMA-J AM MED ASSOC, V268, P2537, DOI 10.1001/jama.268.18.2537; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; LACHTERMAN B, 1990, ANN INTERN MED, V112, P11, DOI 10.7326/0003-4819-112-1-11; LERMAN J, 1986, MEDICINA-BUENOS AIRE, V46, P201; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MORRIS CK, 1993, IN PRESS AM HEART J; MORRIS CK, 1993, IN PRESS J AM COLL C; OBERMAN A, 1972, B NEW YORK ACAD MED, V48, P1109; PEDUZZI P, 1986, PROG CARDIOVASC DIS, V28, P285, DOI 10.1016/0033-0620(86)90006-X; PHILBRICK JT, 1982, JAMA-J AM MED ASSOC, V248, P2467, DOI 10.1001/jama.248.19.2467; REEVES TJ, 1974, AM J CARDIOL, V33, P423, DOI 10.1016/0002-9149(74)90327-0; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; SCHLANT RC, 1986, J AM COLL CARDIOL, V8, P725; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WOLTHUIS RA, 1977, AM J CARDIOL, V39, P697, DOI 10.1016/S0002-9149(77)80131-8; WYNS W, 1985, EUR HEART J, V6, P939, DOI 10.1093/oxfordjournals.eurheartj.a061791	24	128	138	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					689	695		10.7326/0003-4819-118-9-199305010-00005	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460854				2022-12-28	WOS:A1993KY50200005
J	CLEMENS, KR; WOLF, V; MCBRYANT, SJ; ZHANG, PH; LIAO, XB; WRIGHT, PE; GOTTESFELD, JM				CLEMENS, KR; WOLF, V; MCBRYANT, SJ; ZHANG, PH; LIAO, XB; WRIGHT, PE; GOTTESFELD, JM			MOLECULAR-BASIS FOR SPECIFIC RECOGNITION OF BOTH RNA AND DNA BY A ZINC FINGER PROTEIN	SCIENCE			English	Article							TRANSCRIPTION FACTOR-IIIA; INTERNAL CONTROL REGION; 5S RNA; FACTOR TFIIIA; XENOPUS; GENE; BINDING; DOMAINS; LAEVIS; OOCYTES	Transcription factor IIIA (TFIIIA) from Xenopus oocytes binds both the internal control region of the 5S ribosomal RNA genes and the 5S RNA transcript itself. The nucleic acid binding domain of TFIIIA contains nine tandemly repeated zinc finger motifs. A series of precisely truncated forms of this protein have been constructed and assayed for 5S RNA and DNA binding. Different sets of zinc fingers were found to be responsible for high affinity interactions with RNA and with DNA. These results explain how a single protein can exhibit equal affinities for these two very different nucleic acids.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Gottesfeld, Joel/0000-0002-4643-5777; Wright, Peter/0000-0002-1368-0223	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026453, R01GM036643, R01GM047530] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47530, GM36643, GM26453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN J, 1986, J BIOL CHEM, V261, P2912; BAUDIN F, 1989, NUCLEIC ACIDS RES, V17, P10035, DOI 10.1093/nar/17.23.10035; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CHRISTIANSEN J, 1987, EMBO J, V6, P453, DOI 10.1002/j.1460-2075.1987.tb04775.x; CLEMENS KE, UNPUB; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; HAYES J, 1989, J BIOL CHEM, V264, P6009; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P2304; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HR, 1981, P NATL ACAD SCI USA, V78, P176; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; PIELER T, 1984, NUCLEIC ACIDS RES, V12, P8393, DOI 10.1093/nar/12.22.8393; ROMANIUK PJ, 1987, NUCLEIC ACIDS RES, V15, P2737, DOI 10.1093/nar/15.6.2737; ROMANIUK PJ, 1989, BIOCHEMISTRY-US, V28, P1388, DOI 10.1021/bi00429a067; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SANDS MS, 1987, MOL CELL BIOL, V7, P3985, DOI 10.1128/MCB.7.11.3985; SANDS MS, 1991, NUCLEIC ACIDS RES, V19, P1791, DOI 10.1093/nar/19.8.1791; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; TSO JY, 1986, NUCLEIC ACIDS RES, V14, P2187, DOI 10.1093/nar/14.5.2187; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	38	117	121	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					530	533		10.1126/science.8475383	http://dx.doi.org/10.1126/science.8475383			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	8475383				2022-12-28	WOS:A1993KY50400030
J	ERICE, A; MAYERS, DL; STRIKE, DG; SANNERUD, KJ; MCCUTCHAN, FE; HENRY, K; BALFOUR, HH				ERICE, A; MAYERS, DL; STRIKE, DG; SANNERUD, KJ; MCCUTCHAN, FE; HENRY, K; BALFOUR, HH			BRIEF REPORT - PRIMARY INFECTION WITH ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HIV-1 REVERSE-TRANSCRIPTASE; REDUCED SENSITIVITY; AZT; MUTATIONS; THERAPY		UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455; AIDS CLIN TRIALS UNIT,MINNEAPOLIS,MN; WALTER REED ARMY INST RES,USN,MED RES INST,WASHINGTON,DC 20307; WALTER REED ARMY INST RES,DIV RETROVIROL,WASHINGTON,DC 20307; HENRY M JACKSON FDN RES LAB,ROCKVILLE,MD; GRP HLTH INC,RIVERSIDE MED CTR,MINNEAPOLIS,MN; ST PAUL RAMSEY MED CTR,ST PAUL,MN 55101	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Naval Medical Research Center (NMRC); United States Department of Defense; United States Army; United States Navy; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Saint Paul Ramsey Medical Center					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P01AM013083] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM13083] Funding Source: Medline; NIAID NIH HHS [AI27761] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; ERICE A, 1992, J CLIN MICROBIOL, V30, P444, DOI 10.1128/JCM.30.2.444-448.1992; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; FITZGIBBON JE, 1991, AIDS RES HUM RETROV, V7, P265, DOI 10.1089/aid.1991.7.265; HEAGY W, 1991, J CLIN INVEST, V87, P1916, DOI 10.1172/JCI115217; JAPOUR AJ, 1991, P NATL ACAD SCI USA, V88, P3092, DOI 10.1073/pnas.88.8.3092; JUNG M, 1992, J ACQ IMMUN DEF SYND, V5, P359; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIM L, 1990, 6TH INT C AIDS, V3, P285; MAYERS DL, 1992, J ACQ IMMUN DEF SYND, V5, P749; RICHMAN DD, 1991, J INFECT DIS, V164, P1075, DOI 10.1093/infdis/164.6.1075; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TINDALL B, 1991, AIDS, V5, P477, DOI 10.1097/00002030-199105000-00001; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; 1990, MMWR MORB MORTAL WKL, V39, P117; 1990, MMWR MORB MORTAL WKL, V39, P110	20	224	227	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1163	1165		10.1056/NEJM199304223281605	http://dx.doi.org/10.1056/NEJM199304223281605			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY447	8455683	Bronze			2022-12-28	WOS:A1993KY44700005
J	REDMAN, JB; FENWICK, RG; FU, YH; PIZZUTI, A; CASKEY, CT				REDMAN, JB; FENWICK, RG; FU, YH; PIZZUTI, A; CASKEY, CT			RELATIONSHIP BETWEEN PARENTAL TRINUCLEOTIDE GCT REPEAT LENGTH AND SEVERITY OF MYOTONIC-DYSTROPHY IN OFFSPRING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess the relationship between the GCT repeat number in the myotonic dystrophy gene and the clinical phenotype and examine its predictive utility in prenatal testing. Design.-DNA from patients was examined for the length of the myotonic dystrophy GCT repeat region, using both Southern blot analysis and polymerase chain reaction. The results were compared with the clinical onset of disease, as well as with pregnancy outcomes. Setting.-Patient samples were referred to the Kleberg DNA Diagnostic Laboratory at the Baylor College of Medicine for DNA analysis by geneticists and genetic counselors (84%), neurologists (10%), and obstetricians and other specialists (6%). Clinical features including onset of disease and family pedigrees were determined by the referring centers. Patients.-A total of 241 patient samples from 118 families referred from primarily genetic or neurological centers for genetic linkage analysis or mutation analysis for myotonic dystrophy. This included 44 families referred for prenatal diagnosis. Main Outcome Measures.-A relationship between myotonic dystrophy disease onset and length of the GCT repeat allele, parental origin of the disease allele, and results of prenatal diagnosis predictions of disease status were measured. Results.-There is a relationship between increasing repeat length and earlier clinical onset of disease. Essentially all (>99%) myotonic mutations causing myotonic dystrophy are accounted for by GCT repeat amplification. Congenital myotonic dystrophy occurs with as few as 730 GCT repeats but only with alleles of maternal origin. Maternal GCT repeats were found as low as 75 (asymptomatic) that were amplified to result in a child with congenital myotonic dystrophy. Application of DNA diagnosis to 32 pregnancies provided an accurate method for identification of at-risk fetuses and allele enlargement. Conclusions.-The GCT repeat in myotonic dystrophy is highly mutable. The triplet repeat amplification is highly specific for mutations involving the myotonin protein kinase gene accounting for myotonic dystrophy. The quantitation of triplet repeats can be more sensitive than physical, ophthalmologic, and electromyography examinations since the mutation can be detected in patients without evidence of myotonic dystrophy clinical findings. The length of the triplet expansion is influenced by the sex of the transmitting parent and is related to the clinical onset of disease features. Prenatal measurement of the GCT triplet repeat has utility for families with myotonic dystrophy risk since mutant and normal repeats are distinguishable and the length of mutant repeat alleles is associated with clinical severity. Thus, GCT triplet measurement provides a highly accurate means of detecting the myotonic dystrophy mutation in patients and offers a new reproductive option for families at risk for myotonic dystrophy.	BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; COLLABORAT RES LABS,WALTHAM,MA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				PIZZUTI, Antonio/0000-0003-3245-1925	NHGRI NIH HHS [5P30-HG00210] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P30HG000210] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ASHIZAWA T, 1992, NEUROLOGY, V42, P1877; ASHIZAWA T, 1989, CURRENT NEUROLOGY, V11, P27; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUNNER HG, 1992, J MED GENET, V29, P780, DOI 10.1136/jmg.29.11.780; DAVIES J, 1992, J MED GENET, V29, P766, DOI 10.1136/jmg.29.11.766; EIBERG H, 1983, CLIN GENET, V24, P159; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARLEY HG, 1992, LANCET, V339, P1125, DOI 10.1016/0140-6736(92)90729-M; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1975, ARCH DIS CHILD, V50, P514, DOI 10.1136/adc.50.7.514; HARPER PS, 1990, PRINCIPLES PRACTICE, P579; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; KOCH MC, 1991, AM J HUM GENET, V48, P1084; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; OBRIEN T, 1983, ANN HUM GENET, V47, P117, DOI 10.1111/j.1469-1809.1983.tb00978.x; PENROSE LS, 1948, ANN EUGENIC, V14, P125; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021	19	168	170	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1960	1965		10.1001/jama.269.15.1960	http://dx.doi.org/10.1001/jama.269.15.1960			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464127				2022-12-28	WOS:A1993KX21500025
J	NOGUCHI, M; YI, HF; ROSENBLATT, HM; FILIPOVICH, AH; ADELSTEIN, S; MODI, WS; MCBRIDE, OW; LEONARD, WJ				NOGUCHI, M; YI, HF; ROSENBLATT, HM; FILIPOVICH, AH; ADELSTEIN, S; MODI, WS; MCBRIDE, OW; LEONARD, WJ			INTERLEUKIN-2 RECEPTOR GAMMA CHAIN MUTATION RESULTS IN X-LINKED SEVERE COMBINED IMMUNODEFICIENCY IN HUMANS	CELL			English	Article							B-CELLS; MOLECULAR-CLONING; ALPHA-CHAIN; CHROMOSOME INACTIVATION; IMMATURE THYMOCYTES; IL-2 RECEPTOR; HUMAN GENOME; LINKAGE MAP; BONE-MARROW; T-CELLS	The interleukin-2 (IL-2) receptor gamma chain (IL-2Rgamma) is a component of high and intermediate affinity IL-2 receptors that is required to achieve full ligand binding affinity and internalization. We have localized the IL-2Rgamma gene to human chromosome Xq13. Genetic linkage analysis indicates that the IL-2Rgamma gene and the locus for X-linked severe combined immunodeficiency (XSCID) appear to be at the same position. Moreover, we demonstrate that each of three unrelated patients with XSCID has a different mutation in his IL-2Rgamma gene resulting in a different premature stop codon and predicted C-terminal truncation. These data establish that XSCID is associated with mutations of the IL-2Rgamma gene product. Since XSCID is characterized by absent or markedly reduced numbers of T cells, our findings imply that IL-2Rgamma plays a vital role in thymic maturation of T cells. These results also have important implications for prenatal and postnatal diagnosis, carrier female detection, and gene therapy for XSCID.	NCI,DIV CANC BIOL & DIAG,BIOCHEM LAB,BETHESDA,MD 20892; BAYLOR COLL MED,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,HOUSTON,TX 77030; UNIV MINNESOTA HOSP & CLIN,DEPT PEDIAT,DIV IMMUNOL,MINNEAPOLIS,MN 55455; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	NOGUCHI, M (corresponding author), NHLBI,INTRAMURAL RES PROGRAM,OFF DIRECTOR,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892, USA.			Adelstein, Stephen/0000-0001-7221-6298	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00188] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHATILA T, 1990, P NATL ACAD SCI USA, V87, P10033, DOI 10.1073/pnas.87.24.10033; CONLEY ME, 1988, P NATL ACAD SCI USA, V85, P3090, DOI 10.1073/pnas.85.9.3090; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; CONLEY ME, 1990, J CLIN INVEST, V85, P1548, DOI 10.1172/JCI114603; COOPER MD, 1989, FUNDAMENTAL IMMUNOLO, P1034; CREMERS FPM, 1988, AM J HUM GENET, V43, P452; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DESAINTBASILE G, 1987, P NATL ACAD SCI USA, V84, P7576; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gelfand E W, 1983, Birth Defects Orig Artic Ser, V19, P65; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; ISHIDA N, 1985, NUCLEIC ACIDS RES, V13, P7579, DOI 10.1093/nar/13.21.7579; JENKINSON EJ, 1987, NATURE, V329, P160, DOI 10.1038/329160a0; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEONARD WJ, 1985, SCIENCE, V228, P1547, DOI 10.1126/science.3925551; LEONARD WJ, 1985, SCIENCE, V230, P633, DOI 10.1126/science.2996141; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1992, INTERLEUKIN, V2, P29; LOUGHNAN MS, 1989, NATURE, V340, P76, DOI 10.1038/340076a0; MAHTANI MM, 1991, GENOMICS, V10, P849, DOI 10.1016/0888-7543(91)90172-B; MCBRIDE OW, 1982, J EXP MED, V155, P1480, DOI 10.1084/jem.155.5.1480; MCBRIDE OW, 1982, NUCLEIC ACIDS RES, V10, P8155, DOI 10.1093/nar/10.24.8155; MICHELSON AM, 1985, J BIOL CHEM, V260, P6982; MINGARI MC, 1984, NATURE, V312, P641, DOI 10.1038/312641a0; Nezelof C, 1986, Curr Top Pathol, V75, P151; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PETRIE HT, 1990, EUR J IMMUNOL, V20, P2813, DOI 10.1002/eji.1830201243; PUCK JM, 1991, CYTOGENET CELL GENET, V58, P2082; PUCK JM, 1987, J CLIN INVEST, V79, P1395, DOI 10.1172/JCI112967; PUCK JM, 1989, AM J HUM GENET, V44, P724; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; ROSENBLATT HM, 1987, PEDIATR RES, V21, P331, DOI 10.1203/00006450-198704000-00003; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHARON M, 1988, J EXP MED, V167, P1265, DOI 10.1084/jem.167.3.1265; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SHEARER WT, 1985, NEW ENGL J MED, V312, P1151, DOI 10.1056/NEJM198505023121804; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SOUTH MA, 1977, PEDIATR RES, V11, P71, DOI 10.1203/00006450-197701000-00005; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TENTORI L, 1988, J EXP MED, V168, P1741, DOI 10.1084/jem.168.5.1741; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; Tosato G., 1991, CURRENT PROTOCOLS IM; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; VONBOEHMER H, 1985, NATURE, V314, P539, DOI 10.1038/314539a0; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	65	1111	1170	0	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					147	157		10.1016/0092-8674(93)90167-O	http://dx.doi.org/10.1016/0092-8674(93)90167-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462096				2022-12-28	WOS:A1993KW75300015
J	JANDA, M; AHLQUIST, P				JANDA, M; AHLQUIST, P			RNA-DEPENDENT REPLICATION, TRANSCRIPTION, AND PERSISTENCE OF BROME MOSAIC-VIRUS RNA REPLICONS IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; NONSTRUCTURAL PROTEINS; ESCHERICHIA-COLI; SUBGENOMIC RNA; SINDBIS VIRUS; MESSENGER-RNA; YEAST; GENE; DNA; SEQUENCES	This paper shows that yeast can be a host for the replication of a higher eukaryotic viral genome. Brome mosaic virus (BMV) is a member of the alphavirus-like superfamily of animal and plant positive strand RNA viruses. Yeast expressing BMV RNA replication genes 1a and 2a support RNA-dependent replication and transcription of BMV RNA3 derivatives. RNA3 derivatives with the coat gene replaced by a reporter gene expressed that gene in a fashion dependent on la and 2a expression in trans and on BMV RNA replication and transcription signals in cis. RNA3 derivatives carrying the yeast URA3 gene complemented ura3- yeast to prototrophy and were maintained as persistent RNA episomes. Thus, all cellular factors essential for BMV RNA replication and transcription must be present in yeast, and yeast genetics should facilitate their identification.	UNIV WISCONSIN, DEPT PLANT PATHOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	JANDA, M (corresponding author), UNIV WISCONSIN, INST MOLEC VIROL, MADISON, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035072, R37GM035072] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35072] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLQUIST P, 1984, P NATL ACAD SCI-BIOL, V81, P7066, DOI 10.1073/pnas.81.22.7066; AHLQUIST P, 1985, J VIROL, V53, P536, DOI 10.1128/JVI.53.2.536-542.1985; AHLQUIST P, 1984, PLANT MOL BIOL, V3, P37, DOI 10.1007/BF00023414; Ahlquist P, 1992, CURR OPIN GENET DEV, V2, P71, DOI 10.1016/S0959-437X(05)80325-9; ALLISON R, 1990, P NATL ACAD SCI USA, V87, P1820, DOI 10.1073/pnas.87.5.1820; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; Ausubel FM, 1988, MOL REPROD DEV; BARIC RS, 1983, J VIROL, V45, P200, DOI 10.1128/JVI.45.1.200-205.1983; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BOTSTEIN D, 1988, SCIENCE, V240, P1439, DOI 10.1126/science.3287619; DEJONG W, 1992, P NATL ACAD SCI USA, V89, P6808, DOI 10.1073/pnas.89.15.6808; DERR LK, 1991, J MOL BIOL, V67, P355; FARABAUGH PJ, 1980, NATURE, V286, P352, DOI 10.1038/286352a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRENCH R, 1986, SCIENCE, V231, P1294, DOI 10.1126/science.231.4743.1294; FRENCH R, 1988, J VIROL, V62, P2411, DOI 10.1128/JVI.62.7.2411-2420.1988; FRENCH R, 1987, J VIROL, V61, P1457, DOI 10.1128/JVI.61.5.1457-1465.1987; Goldbach R., 1991, Seminars in Virology, V2, P19; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; HASELOFF J, 1984, P NATL ACAD SCI-BIOL, V81, P4358, DOI 10.1073/pnas.81.14.4358; HAYES RJ, 1990, CELL, V63, P363, DOI 10.1016/0092-8674(90)90169-F; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ISHIKAWA M, 1991, MOL GEN GENET, V230, P33, DOI 10.1007/BF00290647; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANDA M, 1987, VIROLOGY, V158, P259, DOI 10.1016/0042-6822(87)90265-0; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JONES MD, 1989, NUCLEIC ACIDS RES, V17, P8387, DOI 10.1093/nar/17.20.8387; KAJITANI M, 1991, NUCLEIC ACIDS RES, V19, P1063, DOI 10.1093/nar/19.5.1063; KAO CC, 1992, J VIROL, V66, P7293, DOI 10.1128/JVI.66.12.7293-7302.1992; KAO CC, 1992, J VIROL, V66, P6322, DOI 10.1128/JVI.66.11.6322-6329.1992; KRONER P, 1989, J VIROL, V63, P5302, DOI 10.1128/JVI.63.12.5302-5309.1989; KRONER PA, 1990, J VIROL, V64, P6110, DOI 10.1128/JVI.64.12.6110-6120.1990; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; MARSH LE, 1988, NUCLEIC ACIDS RES, V16, P981, DOI 10.1093/nar/16.3.981; MAYER SA, 1991, MOL CELL BIOL, V11, P813, DOI 10.1128/MCB.11.2.813; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; MILLER WA, 1985, NATURE, V313, P68, DOI 10.1038/313068a0; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; PACHA RF, 1990, VIROLOGY, V174, P436, DOI 10.1016/0042-6822(90)90097-B; PARDIGON N, 1992, J VIROL, V66, P1007, DOI 10.1128/JVI.66.2.1007-1015.1992; QUADT R, 1993, P NATL ACAD SCI USA, V90, P1498, DOI 10.1073/pnas.90.4.1498; QUADT R, 1990, VIROLOGY, V178, P189, DOI 10.1016/0042-6822(90)90393-6; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RONER MR, 1990, VIROLOGY, V179, P845, DOI 10.1016/0042-6822(90)90153-I; ROSE M, 1984, MOL GEN GENET, V193, P557, DOI 10.1007/BF00382100; RUSSELL PJ, 1991, NUCLEIC ACIDS RES, V19, P4949, DOI 10.1093/nar/19.18.4949; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; TRAYNOR P, 1990, J VIROL, V64, P69, DOI 10.1128/JVI.64.1.69-77.1990; TRAYNOR P, 1991, J VIROL, V65, P2807, DOI 10.1128/JVI.65.6.2807-2815.1991; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WICKNER RB, 1989, FASEB J, V3, P2257, DOI 10.1096/fasebj.3.11.2550303; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905; WU SX, 1992, P NATL ACAD SCI USA, V89, P11136, DOI 10.1073/pnas.89.23.11136	56	170	178	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					961	970		10.1016/0092-8674(93)90584-D	http://dx.doi.org/10.1016/0092-8674(93)90584-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458084				2022-12-28	WOS:A1993KU17500016
J	WOOSLEY, RL; CHEN, YW; FREIMAN, JP; GILLIS, RA				WOOSLEY, RL; CHEN, YW; FREIMAN, JP; GILLIS, RA			MECHANISM OF THE CARDIOTOXIC ACTIONS OF TERFENADINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TORSADES-DE-POINTES; FELINE VENTRICULAR MYOCYTES; EARLY AFTERDEPOLARIZATIONS; QT-INTERVAL; BLOCK	Objectives and Methods.-To gain insight into possible mechanisms of and predisposing factors for torsades de pointes during terfenadine therapy, spontaneous reports in the US Food and Drug Administration's Spontaneous Reporting System database were examined. Based on the characteristics of the cases, in vitro cardiac electrophysiologic studies were conducted to test the hypothesis that terfenadine, and not its major metabolite, has actions similar to those of quinidine and is responsible for this form of cardiac toxicity. Design.-Spontaneous reports from the general medical community. Results.-As of April 1, 1992, 25 cases of torsades de pointes had been reported to the Food and Drug Administration's Spontaneous Reporting System. Predisposing factors in these cases indicated that the parent drug, but not its metabolite, may have actions similar to those of quinidine that are responsible for inducing arrhythmia. In vitro studies found that terfenadine is equipotent to quinidine as a blocker of the delayed rectifier potassium current in isolated feline myocytes. The metabolite, terfenadine carboxylate, did not inhibit this potassium current even at concentrations 30 times higher than the concentration of terfenadine producing a half-maximal effect. Conclusions.-Since blockade of the potassium channel did not occur with the major metabolite of terfenadine, episodes of torsades de pointes are most likely the result of a quinidinelike action of the parent drug and of factors that impair the normally rapid metabolism of terfenadine. Dosage restriction and awareness of the clinical conditions and drug interactions capable of inhibiting the metabolism of terfenadine are essential for prevention of this serious reaction.	US FDA,CTR DRUG EVALUAT & RES,DIV EPIDEMIOL & SURVEILLANCE,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)	WOOSLEY, RL (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,DIV CLIN PHARMACOL,3900 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.		Woosley, Raymond/AAE-4874-2020	Woosley, Raymond/0000-0002-2588-328X				BROWN MW, 1985, CLIN PHARMACOL THER, V37, P290, DOI 10.1038/clpt.1985.42; COUTANT JE, 1991, J CHROMATOGR-BIOMED, V570, P139, DOI 10.1016/0378-4347(91)80208-T; CRANEFIELD PF, 1991, CARDIOVASC DRUG THER, V5, P531, DOI 10.1007/BF03029780; DAVIES AJ, 1989, BRIT MED J, V298, P325, DOI 10.1136/bmj.298.6669.325; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; FOLLMER CH, 1990, CIRCULATION, V82, P11; FOLLMER CH, 1990, CIRCULATION, V82, P289, DOI 10.1161/01.CIR.82.1.289; GOLDBERG RJ, 1991, AM J CARDIOL, V67, P55, DOI 10.1016/0002-9149(91)90099-7; GUENGERICH FP, 1990, CARCINOGENESIS, V11, P2275, DOI 10.1093/carcin/11.12.2275; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; JANUARY CT, 1989, CIRC RES, V64, P977, DOI 10.1161/01.RES.64.5.977; KLEIMAN RB, 1989, AM J PHYSIOL, V256, pH1450, DOI 10.1152/ajpheart.1989.256.5.H1450; MACCONNELL TJ, 1991, BRIT MED J, V302, P1469, DOI 10.1136/bmj.302.6790.1469-b; MAY DC, 1990, CLIN PHARMACOL THER, V48, P268; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; SILVER LH, 1985, AM J PHYSIOL, V248, pH614, DOI 10.1152/ajpheart.1985.248.5.H614; SIMONSEN LL, 1992, PHARM TIMES      APR, P47; SORKIN EM, 1985, DRUGS, V29, P34, DOI 10.2165/00003495-198529010-00002; WILEY JF, 1992, J PEDIATR-US, V120, P799, DOI 10.1016/S0022-3476(05)80252-5; YUN C, IN PRESS DRUG METAB; ZEHENDER M, 1991, CARDIOVASC DRUG THER, V5, P515, DOI 10.1007/BF03029779; 1992, 1991 NATIONAL PRESCR; 1992, PHYSICIANS DESK REFE, P1349; 1990, IMPORTANT DRUG WARNI	28	498	515	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1532	1536		10.1001/jama.269.12.1532	http://dx.doi.org/10.1001/jama.269.12.1532			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445816				2022-12-28	WOS:A1993KR80300026
J	JAKOBOVITS, A; MOORE, AL; GREEN, LL; VERGARA, GJ; MAYNARDCURRIE, CE; AUSTIN, HA; KLAPHOLZ, S				JAKOBOVITS, A; MOORE, AL; GREEN, LL; VERGARA, GJ; MAYNARDCURRIE, CE; AUSTIN, HA; KLAPHOLZ, S			GERM-LINE TRANSMISSION AND EXPRESSION OF A HUMAN-DERIVED YEAST ARTIFICIAL CHROMOSOME	NATURE			English	Article							CELLS; RECOMBINATION; LIBRARIES; SEQUENCES; CLONING; GENE; CDNA; DNA	INTRODUCTION of DNA fragments, hundreds of kilobases in size, into mouse embryonic stem (ES) cells would greatly advance the ability to manipulate the mouse genome. Mice generated from such modified cells would permit investigation of the function and expression of very large or crudely mapped genes. Large DNA molecules cloned into yeast artificial chromosomes (YACs) are stable and genetically manipulable within yeast1, suggesting yeast-cell fusion as an ideal method for transferring large DNA segments into mammalian cells. Introduction of YACs into different cell types by this technique has been reported2-8; however, the incorporation of yeast DNA along with the YAC has raised doubts as to whether ES cells, modified in this way. would be able to recolonize the mouse germ line5. Here we provide, to our knowledge, the first demonstration of germ-line transmission and expression of a large human DNA fragment, introduced into ES cells by fusion with yeast spheroplasts. Proper development was not impaired by the cointegration of a large portion of the yeast genome with the YAC.			JAKOBOVITS, A (corresponding author), CELL GENESYS INC, 322 LAKESIDE DR, FOSTER CITY, CA 94404 USA.							Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BURKE DT, 1991, METHOD ENZYMOL, V194, P251; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; DAVIES NP, 1992, NUCLEIC ACIDS RES, V20, P2693, DOI 10.1093/nar/20.11.2693; GAFNER J, 1983, EMBO J, V2, P583, DOI 10.1002/j.1460-2075.1983.tb01467.x; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; IMAI T, 1990, GENOMICS, V8, P297, DOI 10.1016/0888-7543(90)90285-3; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KEIL RL, 1984, CELL, V39, P377, DOI 10.1016/0092-8674(84)90016-3; MARTIN GR, 1975, CELL, V6, P467, DOI 10.1016/0092-8674(75)90035-5; PANCHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109; PAVAN WJ, 1990, P NATL ACAD SCI USA, V87, P1300, DOI 10.1073/pnas.87.4.1300; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; PHILIPPSEN P, 1983, GENE EXPRESSION YEAS, V1, P189; RILEY JH, 1992, NUCLEIC ACIDS RES, V20, P2971, DOI 10.1093/nar/20.12.2971; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Trask B, 1990, Methods Cell Biol, V33, P383; TRAVER CN, 1989, P NATL ACAD SCI USA, V86, P5698	22	115	566	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	1993	362	6417					255	258		10.1038/362255a0	http://dx.doi.org/10.1038/362255a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8459850				2022-12-28	WOS:A1993KT02600059
J	ROBERTS, JW				ROBERTS, JW			RNA AND PROTEIN ELEMENTS OF ESCHERICHIA-COLI AND GAMMA-TRANSCRIPTION ANTITERMINATION COMPLEXES	CELL			English	Review							ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; RIBOSOMAL-RNA; ANTI-TERMINATION; GENE; POLYMERASE; RECOGNITION; SEQUENCE; SUPPRESS; SITE				ROBERTS, JW (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELLULAR BIOL SECT,ITHACA,NY 14853, USA.							ALBRECHTSEN B, 1990, J MOL BIOL, V213, P123, DOI 10.1016/S0022-2836(05)80125-1; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; DOELLING JH, 1989, NUCLEIC ACIDS RES, V17, P5565, DOI 10.1093/nar/17.14.5565; FRIEDMAN DI, 1990, GENE DEV, V4, P2210, DOI 10.1101/gad.4.12a.2210; Friedman DI., 1983, LAMBDA 2, P21; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1984, CAN J BIOCHEM CELL B, V62, P79, DOI 10.1139/o84-012; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LI J, 1992, J BIOL CHEM, V267, P6012; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; MASON SW, 1992, J BIOL CHEM, V267, P19418; MORGAN EA, 1986, J BACTERIOL, V168, P1; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SQUIRES CL, 1993, IN PRESS P NATL ACAD, V90; SULLIVAN SL, 1992, J BACTERIOL, V174, P1339, DOI 10.1128/jb.174.4.1339-1344.1992; WARD DF, 1983, J MOL BIOL, V168, P73, DOI 10.1016/S0022-2836(83)80323-4; WHALEN W, 1988, P NATL ACAD SCI USA, V85, P2494, DOI 10.1073/pnas.85.8.2494; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4515	33	59	60	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					653	655		10.1016/0092-8674(93)90394-6	http://dx.doi.org/10.1016/0092-8674(93)90394-6			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453661	Bronze			2022-12-28	WOS:A1993KR43600002
J	MARSHALL, E				MARSHALL, E			TOXICOLOGY GOES MOLECULAR	SCIENCE			English	Article																		ANDERSEN ME, IN PRESS RISK ANAL; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598	2	11	11	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1394	&		10.1126/science.8451635	http://dx.doi.org/10.1126/science.8451635			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451635				2022-12-28	WOS:A1993KP97800015
J	STEWART, PM; MAHESHWARAN, S; GRIFFITH, J; LI, J; SHEPPARD, MC; OLLIFF, J; FRANKLYN, JA				STEWART, PM; MAHESHWARAN, S; GRIFFITH, J; LI, J; SHEPPARD, MC; OLLIFF, J; FRANKLYN, JA			PITUITARY IMAGING IS ESSENTIAL FOR WOMEN WITH MODERATE HYPERPROLACTINEMIA	BRITISH MEDICAL JOURNAL			English	Article							PROLACTIN		GEN HOSP,DEPT RADIOL,BIRMINGHAM B6 4NH,ENGLAND; GEN HOSP,ENDOCRINE CLIN,BIRMINGHAM B6 4NH,ENGLAND				Griffith, James/C-3186-2011	Griffith, James/0000-0001-5206-9382				BEVAN JS, 1987, AM J MED, V82, P29, DOI 10.1016/0002-9343(87)90373-1; HARTOG M, 1988, BRIT MED J, V297, P701, DOI 10.1136/bmj.297.6650.701; NABARRO JDN, 1982, CLIN ENDOCRINOL, V17, P129, DOI 10.1111/j.1365-2265.1982.tb01573.x; ROSS RJM, 1985, CLIN ENDOCRINOL, V23, P227, DOI 10.1111/j.1365-2265.1985.tb00218.x; TEASDALE E, 1986, CLIN RADIOL, V37, P227, DOI 10.1016/S0009-9260(86)80322-1	5	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					507	508		10.1136/bmj.306.6876.507	http://dx.doi.org/10.1136/bmj.306.6876.507			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448466	Green Published, Bronze			2022-12-28	WOS:A1993KN78600026
J	HART, JT; EDWARDS, C; HART, M; JONES, J; JONES, M; HAINES, A; WATT, G				HART, JT; EDWARDS, C; HART, M; JONES, J; JONES, M; HAINES, A; WATT, G			SCREEN DETECTED HIGH BLOOD-PRESSURE UNDER 40 - A GENERAL-PRACTICE POPULATION FOLLOWED UP FOR 21 YEARS	BRITISH MEDICAL JOURNAL			English	Article							HEALTH CHECK; NON-ATTENDERS; HYPERTENSION; MANAGEMENT; INVITATION; COMMUNITY; DISEASE; COHORT; RISK; CARE	Objective-To assess hypertension detected under 40 in a general practice population. Design-Prospective case-control study. Setting and subjects-Former coal mining community in south Wales. Systematic case finding for hypertension and associated risk factors applied to a mean total population of 1945 from age 20 on a five year cycle through 21 years. Mean population aged 20-39, 227 men and 213 women. Case criteria: age < 40 and mean systolic pressure greater-than-or-equal-to 160 mm Hg or diastolic pressure greater-than-or-equal-to 100 mm Hg. Age and sex matched controls randomly sampled from the same population. Main outcome measures-Mean initial pressures and pressures at follow up in 1989 or preceding death, and all cardiovascular events. Results-25 men and 16 women met criteria. Estimated five yearly inceptions were 26/1000 for men and 18/1000 for women. Male group mean initial blood pressure was 164/110 mm Hg for cases, falling to 148/89 mm Hg at follow up. Five male cases died at mean age 47.8, compared with two controls at 49.5. Female group mean initial pressure was 172/107 mm Hg for cases, falling to 145/86 mm Hg at follow up. One female case died aged 50, no controls. 10 male cases had non-fatal cardiovascular events at mean age 40.2, compared with two controls at mean age 50.5. Four female cases had non-fatal events at mean age 47.2, compared with one control aged 58. Male differences were statistically significant. Conclusions-Hypertension under 40 is dangerous, commoner in men than women, rarely secondary to classic causes, and may be controlled in general practice on a whole community basis.	GLYNCORRWG HLTH CTR,GLYNCORRWYG SA13 3BL,W GLAM,WALES; UNIV LONDON UNIV COLL,SCH MED,LONDON WC1E 6BT,ENGLAND; UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8QQ,SCOTLAND	University of London; University College London; UCL Medical School; University of Glasgow	HART, JT (corresponding author), NORTHWICK PK & GLYNCORRWG HLTH CTR,MRC,EPIDEMIOL & MED CARE UNIT,GLYNCORRWYG SA13 3BL,W GLAM,WALES.			Haines, Andy/0000-0002-8053-4605				ARKWRIGHT PD, 1982, CIRCULATION, V66, P60, DOI 10.1161/01.CIR.66.1.60; BEEVERS DG, 1977, LANCET, V2, P111; BJORNTORP P, 1985, ANN CLIN RES, V17, P3; FOWLER G, 1990, BMJ-BRIT MED J, V300, P1318, DOI 10.1136/bmj.300.6735.1318; Hart J T, 1974, J R Coll Physicians Lond, V8, P299; Hart J T, 1970, J R Coll Gen Pract, V19, P258; HART JT, 1970, LANCET, V2, P223; HART JT, 1990, FAM PRACT, V7, P288, DOI 10.1093/fampra/7.4.288; HART JT, 1991, BMJ-BRIT MED J, V302, P1509, DOI 10.1136/bmj.302.6791.1509; HART JT, 1975, J R COLL GEN PRACT, V4, P326; HELLER RF, 1977, BRIT MED J, V1, P1442, DOI 10.1136/bmj.1.6074.1442; KURJI KH, 1984, BMJ-BRIT MED J, V288, P903, DOI 10.1136/bmj.288.6421.903; MAIN J, 1990, RCGP CONNECTION  SEP, P4; Miall W E, 1973, Clin Sci Mol Med Suppl, V45 Suppl 1, p23s; MORRELL DC, 1991, BMJ-BRIT MED J, V302, P1313, DOI 10.1136/bmj.302.6788.1313; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; PILL R, 1988, J ROY COLL GEN PRACT, V38, P57; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; THOMPSON NF, 1990, BRIT J GEN PRACT, V40, P16; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; WALLER D, 1990, BRIT MED J, V300, P1115, DOI 10.1136/bmj.300.6732.1115; WEINBERGER MH, 1983, HDB HYPERTENSION, V2, P196; WIDIMSKY J, 1980, CAS LEK CESK, V119, P1185	24	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					437	440		10.1136/bmj.306.6875.437	http://dx.doi.org/10.1136/bmj.306.6875.437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461729	Green Published, Bronze			2022-12-28	WOS:A1993KM70000026
J	LOWRY, S				LOWRY, S			MEDICAL-EDUCATION - TRENDS IN HEALTH-CARE AND THEIR EFFECTS ON MEDICAL-EDUCATION	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE											LOWRY S, 1993, BRIT MED J, V306, P127, DOI 10.1136/bmj.306.6870.127; OSWALD N, 1989, LANCET, V2, P148; OSWALD N, 1991, BRIT MED J, V303, P71, DOI 10.1136/bmj.303.6794.71; RETHANS JJE, 1987, BRIT MED J, V294, P809, DOI 10.1136/bmj.294.6575.809; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; STOCKING B, 1992, MED ADV FUTURE SHAPE; 1980, RECOMMENDATIONS BASI; 1991, 1ST REPORT EFFECTS N; 1992, 2ND REPORT EFFECTS N; 1991, UNDERGRADUATE MED ED	10	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					255	258		10.1136/bmj.306.6872.255	http://dx.doi.org/10.1136/bmj.306.6872.255			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KJ591	8443530	Bronze, Green Published			2022-12-28	WOS:A1993KJ59100027
J	SHIMMIN, LC; CHANG, BHJ; LI, WH				SHIMMIN, LC; CHANG, BHJ; LI, WH			MALE-DRIVEN EVOLUTION OF DNA-SEQUENCES	NATURE			English	Article							MOLECULAR EVOLUTION; RATES	IT is commonly believed1,2 that the mutation rate is much higher in the human male germ line than in the female germ line because the number of germ-cell divisions per generation is much larger in males than in females. But direct estimation of mutation rates is difficult, relying mainly on sex-linked genetic diseases3, so the ratio (alpha(m)) of male to female mutation rates is not clear. It has been noted4 that if alpha(m). is very large, then the rate of synonymous substitution in X-linked genes should be only 2/3 of that in autosomal genes, and comparison of human and rodent genes supported this prediction4. As the number of X-linked genes used in the study was small and the X-linked and autosomal sequences were non-homologous, and given that the synonymous rate varies among genes5, we sequenced the last intron (approximately 1 kb) of the Y-linked and X-linked zinc-finger-protein genes (ZFY and ZFX) in humans, orang-utans, baboons and squirrel monkeys. The ratio Y/X of the substitution rate in the Y-linked intron to that in the X-linked intron is approximately 2.3, which is close to that estimated from synonymous rates in the ZFY and ZFX genes6-8 and implies alpha(m) almost-equal-to 6. This estimate of alpha(m) supports the view that the evolution of DNA sequences in higher primates is male-driven. It is, however, much lower than the previous estimate4 and therefore raises a number of issues.	UNIV TEXAS,CTR DEMOG & POPULAT GENET,POB 20334,HOUSTON,TX 77225	University of Texas System; University of Texas Health Science Center Houston				Li, Wen-Hsiung/0000-0003-1086-1456				BULMER M, 1986, MOL BIOL EVOL, V3, P322; HALDANE JBS, 1947, ANN EUGENIC, V13, P262; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYASHIDA H, 1992, J MOL EVOL, V35, P181, DOI 10.1007/BF00183228; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KOHNE DE, 1970, Q REV BIOPHYS, V33, P1; KUSUKAWA N, 1990, BIOTECHNIQUES, V9, P66; LANFEAR J, 1991, J MOL EVOL, V32, P310, DOI 10.1007/BF02102189; LI WH, 1991, FUNDAMENTALS MOL EVO; MIYATA T, 1987, COLD SPRING HARB SYM, V52, P863, DOI 10.1101/SQB.1987.052.01.094; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; PAMILO P, IN PRESS MOL BIOL EV; PENROSE LS, 1955, LANCET, V2, P312; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDERGADICKE A, 1989, NATURE, V342, P708, DOI 10.1038/342708a0; TAJIMA F, 1984, MOL BIOL EVOL, V1, P269; VOGEL F, 1986, HUMAN GENETICS; WINTER RM, 1983, HUM GENET, V64, P156, DOI 10.1007/BF00327115	18	199	200	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 22	1993	362	6422					745	747		10.1038/362745a0	http://dx.doi.org/10.1038/362745a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8469284				2022-12-28	WOS:A1993KY45000054
J	GAO, WQ; HATTEN, ME				GAO, WQ; HATTEN, ME			NEURONAL DIFFERENTIATION RESCUED BY IMPLANTATION OF WEAVER GRANULE CELL PRECURSORS INTO WILD-TYPE CEREBELLAR CORTEX	SCIENCE			English	Article							TYROSINE-KINASE RECEPTOR; MUTANT MICE; MOUSE; MIGRATION; INVITRO; DROSOPHILA; DEFICIT; CULTURE; LIGAND; LOCUS	The migration of postmitotic neurons away from compact, germinal zones is a critical step in neuronal differentiation in the developing brain. To study the molecular signals necessary for cerebellar granule cell migration in situ, precursor cells from the neurological mutant mouse weaver, an animal with phenotypic defects in migration, were implanted into the external germinal layer (EGL) of wild-type cerebellar cortex. In this region, labeled weaver precursor cells of the EGL progressed through all stages of granule neuron differentiation, including the extension of parallel fibers, migration through the molecular and Purkinje cell layers, positioning in the internal granule cell layer, and extension of dendrites. Thus, the weaver gene acts nonautonomously in vivo, and local cell interactions may induce early steps in neuronal differentiation that are required for granule cell migration.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT PATHOL,NEW YORK,NY 10032	Columbia University								Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CAJAL SRY, 1966, REFLECTIONS MY LIFE, P372; CAJAL SRY, 1889, REV TRIMEST HISTOL N, V4; CAJAL SRY, 1889, REV TRIMEST HISTOL N, V3; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GOLDOWITZ D, 1989, NEURON, V2, P1565, DOI 10.1016/0896-6273(89)90045-7; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HATTEN ME, 1984, J NEUROSCI, V4, P1163; HATTEN ME, 1986, J NEUROSCI, V6, P2676; HATTEN ME, 1990, SEMIN NEUROSCI, V2, P455; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; RAKIC P, 1973, J COMP NEUROL, V152, P133, DOI 10.1002/cne.901520203; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SAUER FC, 1935, J COMP NEUROL, V63, P12; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SOTELO C, 1974, BRAIN RES, V77, P484, DOI 10.1016/0006-8993(74)90636-2; WILLINGER M, 1985, DEV BIOL, V107, P156, DOI 10.1016/0012-1606(85)90384-7; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	30	99	101	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					367	369		10.1126/science.8469990	http://dx.doi.org/10.1126/science.8469990			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8469990				2022-12-28	WOS:A1993KX80000043
J	RAVID, M; SAVIN, H; JUTRIN, I; BENTAL, T; KATZ, B; LISHNER, M				RAVID, M; SAVIN, H; JUTRIN, I; BENTAL, T; KATZ, B; LISHNER, M			LONG-TERM STABILIZING EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON PLASMA CREATININE AND ON PROTEINURIA IN NORMOTENSIVE TYPE-II DIABETIC-PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						PROTEINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES-MELLITUS, NON-INSULIN-DEPENDENT; ALBUMINURIA; KIDNEY FAILURE, CHRONIC	INSULIN-DEPENDENT DIABETICS; PROGRESSIVE RENAL-DISEASE; ANTIHYPERTENSIVE TREATMENT; KIDNEY-FUNCTION; SERUM CREATININE; URINARY ALBUMIN; NEPHROPATHY; HYPERTENSION; ENALAPRIL; MICROALBUMINURIA	Objective: To evaluate the long-term effect of angiotensin-converting enzyme inhibition on proteinuria and on the rate of decline in kidney function in patients with type II diabetes mellitus and microalbuminuria. Design: Randomized, double-blind, placebo-controlled trial. Each patient was followed for 5 years. Setting: Six clinics for diabetes mellitus coordinated by a department of medicine in a university hospital in Israel. Patients: Ninety-four normotensive, type II diabetic patients with microalbuminuria and normal renal function. Intervention: The patients were randomly assigned to receive enalapril, 10 mg per day, or placebo. Any increase in blood pressure was treated with long-acting nifedipine. Measurements: Albuminuria, blood pressure, serum creatinine, fasting blood glucose, and glycosylated hemoglobin levels, every 3 to 4 months. Results: In the patients treated with enalapril, albuminuria decreased from 143 +/- 64 (mean +/- SD) mg/24 h to 122 +/- 67 mg/24 h during the first year. Thereafter, we observed a slow increase to 140 +/- 134 mg/24 h after 5 years. In the placebo group, albuminuria increased from 123 +/- 58 mg/24 h to 310 +/- 167 mg/24 h after 5 years. (Difference in rate of change in proteinuria [P < 0.05]). Kidney function (expressed as mean reciprocal creatinine) declined by 13% in the placebo group and remained stable (-1%) in the enalapril group (P < 0.05). Control of blood glucose levels remained stable, in both groups, throughout the study. The mean blood pressure was stable in the enalapril group (initial group mean, 99 +/- 2.1 mm Hg; fifth-year mean, 100 +/- 3.2 mm Hg) and increased in the placebo group from an initial mean value of 97 +/- 3.2 mm Hg to 102 +/- 3.4 mm Hg at the end of the study period (P = 0.082). Conclusions: In normotensive patients with diabetes mellitus type II, the institution of angiotensin-converting enzyme inhibition during early stages of diabetic nephropathy results in long-term stabilization of plasma creatinine levels and of the degree of urinary loss of albumin. These effects are probably independent of the antihypertensive action of these agents.	TEL AVIV UNIV, SACKLER FAC MED, IL-69978 TEL AVIV, ISRAEL; MEIR HOSP, CLIN CHEM LAB, KEFAR SAVA, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	RAVID, M (corresponding author), MEIR HOSP, DEPT MED A, IL-44281 KEFAR SAVA, ISRAEL.							ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; APPERLOO AJ, 1991, BRIT MED J, V303, P821, DOI 10.1136/bmj.303.6806.821; BAKRIS GL, 1992, KIDNEY INT, V41, P912, DOI 10.1038/ki.1992.139; BIANCHI S, 1991, AM J NEPHROL, V11, P131, DOI 10.1159/000168289; BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Eggers P W, 1984, Health Care Financ Rev, V5, P69; FERDER LF, 1990, NEPHRON, V55, P90; FOGO A, 1988, J CLIN INVEST, V82, P322, DOI 10.1172/JCI113590; GANSEVOORT RT, 1992, ARCH INTERN MED, V152, P2137, DOI 10.1001/archinte.152.10.2137; KLEIN R, 1988, ARCH INTERN MED, V148, P181, DOI 10.1001/archinte.148.1.181; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MITCH WE, 1976, CLIN RES, V24, pA407; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; PARVING HH, 1981, DIABETOLOGIA, V20, P457; PARVING HH, 1983, LANCET, V1, P1175; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; PARVING HH, 1983, METABOLISM, V32, P943, DOI 10.1016/0026-0495(83)90210-X; RAVID M, 1992, ARCH INTERN MED, V152, P1225, DOI 10.1001/archinte.152.6.1225; Rettig BS, 1984, DIABETIC NEPHROPATHY, V3, P26; RUTHERFORD WE, 1977, KIDNEY INT, V11, P62, DOI 10.1038/ki.1977.8; SANDEMAN DD, 1992, NEW ENGL J MED, V327, P760, DOI 10.1056/NEJM199209103271103; SATHIANATHAN P, 1986, CLIN CHEM, V32, P202; SHOTT S, 1990, STAT HLTH PROFESSION, P57; UEDA Y, 1990, NEPHRON, V55, P85; VALENTINO VA, 1991, ARCH INTERN MED, V151, P2367, DOI 10.1001/archinte.151.12.2367; WEIDMANN P, 1985, HYPERTENSION, V7, P33, DOI 10.1161/01.HYP.7.6_Pt_2.II33; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; [No title captured]	33	684	692	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					577	581		10.7326/0003-4819-118-8-199304150-00001	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8452322				2022-12-28	WOS:A1993KW47000001
J	HSIAO, WC; DUNN, DL; VERRILLI, DK				HSIAO, WC; DUNN, DL; VERRILLI, DK			ASSESSING THE IMPLEMENTATION OF PHYSICIAN-PAYMENT REFORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES	Background. The Medicare program fundamentally changed its system of payment for physicians' services in 1992. Controversy over the new Medicare fee schedule has focused on three issues: the adequacy of the conversion factor used to translate resource-based relative-value units into fees; the ability of the new payment system to capture differences in work between surgeons and physicians in other specialties; and the allocation of practice expenses across services. Methods. Using a standard service in each specialty, we developed simulation methods to assess the implementation of physician-payment reform. With these methods we calculated the potential net income for each specialty, as generated by different payment scenarios, including the Medicare fee schedule. Results. We found that Medicare's current monetary-conversion factor yields an unreasonably low level of income for most specialties. Furthermore, the Medicare fee schedule misallocates practice expenses; invasive services are reimbursed for more than actual expenses, and medical services are reimbursed for less. Thus, physicians continue to be paid more generously tor invasive services. Finally, the Medicare fee schedule does recognize the wide differences in the intensity of work performed by physicians in various specialties. Conclusions. The misallocation of practice expenses in the Medicare fee schedule results in serious underpayment for medical services. We think it likely that physicians compensate by performing more lucrative services, such as diagnostic tests. Even if legislation is passed to deal with the misallocation of expenses, the current conversion factor still produces unreasonably low levels of payment overall, which could dissuade those considering a career in medicine from entering the field. Finally, the simulation method we developed can be used as a tool for fee negotiations.			HSIAO, WC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,1350 MASSACHUSETTS AVE,CAMBRIDGE,MA 02138, USA.							BLALOCK B, 1988, BIRMINGHAM NEWS 1121, V21, pA5; BURSTEIN PL, 1985, J HEALTH ECON, V4, P63, DOI 10.1016/0167-6296(85)90024-4; Crane M, 1991, Med Econ, V68, P124; HSIAO WC, 1988, NEW ENGL J MED, V319, P881, DOI 10.1056/NEJM198809293191330; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; HSIAO WC, 1992, NATIONAL STUDY RESOU; LATIMER EA, 1992, MED CARE, V30, pNS50, DOI 10.1097/00005650-199211001-00005; Owens A, 1991, Med Econ, V68, P120; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; Tolchin Martin, 1989, N Y Times Web, pA16; WALKER D, 1991, MED ECON, V68, P138; 1991, 1991 PHYS PAYM REV C; 1989, NY TIMES        1013, pA17; 1976, SURGERY US SUMMARY R; 1991, FED REGISTER, V56, P59577; 1991, FED REGISTER, V56, P59635; 1991, PHYSICIAN MARKETPLAC; 1992, CPI1992 BUR LAB STAT; 1991, SURGICAL PREVAILING; 1977, PHYSICIANS CURRENT P; 1991, FED REGISTER, V56, P25792	21	54	57	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 1	1993	328	13					928	933		10.1056/NEJM199304013281306	http://dx.doi.org/10.1056/NEJM199304013281306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU177	8446140				2022-12-28	WOS:A1993KU17700006
J	MARSHALL, CJ				MARSHALL, CJ			PROTEIN PRENYLATION - A MEDIATOR OF PROTEIN-PROTEIN INTERACTIONS	SCIENCE			English	Editorial Material							GDP DISSOCIATION INHIBITOR; GTP-BINDING-PROTEINS; C-TERMINAL REGION; REGULATORY PROTEIN; EXCHANGE PROTEIN; PLASMA-MEMBRANE; ALPHA-SUBUNIT; SMG P25A; MOTIF; CAAX				MARSHALL, CJ (corresponding author), INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BLACK SD, 1992, BIOCHEM BIOPH RES CO, V186, P1437, DOI 10.1016/S0006-291X(05)81567-0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX AD, 1992, MOL CELL BIOL, V12, P606; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HORI Y, 1991, ONCOGENE, V6, P515; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; ISOMURA M, 1991, ONCOGENE, V6, P119; ITOH T, IN PRESS J BIOL CHEM; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; OHGURO H, 1990, BIOCHEM BIOPH RES CO, V167, P1235, DOI 10.1016/0006-291X(90)90656-8; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507	24	315	318	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1865	1866		10.1126/science.8456312	http://dx.doi.org/10.1126/science.8456312			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456312				2022-12-28	WOS:A1993KU17200022
J	PARKINSON, JS; BLAIR, DF				PARKINSON, JS; BLAIR, DF			DOES ESCHERICHIA-COLI HAVE A NOSE	SCIENCE			English	Editorial Material											PARKINSON, JS (corresponding author), UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112, USA.							ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; MADDOCK JR, 1993, SCIENCE, V259, P1717; SEGALL JE, 1985, J BACTERIOL, V161, P51, DOI 10.1128/JB.161.1.51-59.1985	6	21	21	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1701	1702		10.1126/science.8456297	http://dx.doi.org/10.1126/science.8456297			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456297				2022-12-28	WOS:A1993KT81000024
J	DESTEFANO, F; ANDA, RF; KAHN, HS; WILLIAMSON, DF; RUSSELL, CM				DESTEFANO, F; ANDA, RF; KAHN, HS; WILLIAMSON, DF; RUSSELL, CM			DENTAL DISEASE AND RISK OF CORONARY HEART-DISEASE AND MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; FOLLOW-UP; HEALTH; MEN	Objective-To investigate a reported association between dental disease and risk ot coronary heart disease. Setting-National sample of American adults who participated in a health examination survey in the early 1970s. Design-Prospective cohort study in which participants underwent a standard dental examination at baseline and were followed up to 1987. Proportional hazards analysis was used to estimate relative risks adjusted for several covariates. Main outcome measures-Incidence of mortality or admission to hospital because of coronary heart disease; total mortality. Results-Among all 9760 subjects included in the analysis those with periodontitis had a 25% increased risk of coronary heart disease relative to those with minimal periodontal disease. Poor oral hygiene, determined by the extent of dental debris and calculus, was also associated with an increased incidence of coronary heart disease. In men younger than 50 years at baseline periodontal disease was a stronger risk factor for coronary heart disease; men with periodontitis had a relative risk of 1.72. Both periodontal disease and poor oral hygiene showed stronger associations with total mortality than with coronary heart disease. Conclusion-Dental disease is associated with an increased risk of coronary heart disease, particularly in young men. Whether this is a causal association is unclear. Dental health may be a more general indicator of personal hygiene and possibly health care practices.	CTR DIS CONTROL,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30333; EMORY UNIV,SCH MED,DEPT COMMUNITY & PREVENT MED,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Emory University	DESTEFANO, F (corresponding author), MARSHFIELD CLIN FDN MED RES & EDUC,DEPT EPIDEMIOL & BIOSTAT,MARSHFIELD,WI 54449, USA.		Kahn, Henry S/A-6946-2009	Kahn, Henry S/0000-0003-2533-1562				USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; DeStefano F, 1993, Ann Epidemiol, V3, P27; GILMOUR H, 1989, BRIT MED J, V298, P1579, DOI 10.1136/bmj.298.6687.1579-c; HOPKINS A, 1988, BMDP STATISTICAL SOF, P719; LOPESVIRELLA MF, 1985, CLIN IMMUNOL IMMUNOP, V37, P377, DOI 10.1016/0090-1229(85)90107-2; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P465; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; MATTILA KJ, 1989, BRIT MED J, V298, P1580, DOI 10.1136/bmj.298.6687.1580; Miyazaki H, 1991, Int Dent J, V41, P74; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; STOKES J, 1987, CIRCULATION, V75, P65; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; 1981, VIT HLTH STAT     11, V223; 1987, DHHS NIH872868 NAT I; 1987, VITAL HLTH STATIST 1, V22; 1977, VITAL HLTH STATI B 1, V10	18	705	745	0	39	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					688	691		10.1136/bmj.306.6879.688	http://dx.doi.org/10.1136/bmj.306.6879.688			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT216	8471920	Green Published, Bronze			2022-12-28	WOS:A1993KT21600020
J	WARCHOL, ME; LAMBERT, PR; GOLDSTEIN, BJ; FORGE, A; CORWIN, JT				WARCHOL, ME; LAMBERT, PR; GOLDSTEIN, BJ; FORGE, A; CORWIN, JT			REGENERATIVE PROLIFERATION IN INNER-EAR SENSORY EPITHELIA FROM ADULT GUINEA-PIGS AND HUMANS	SCIENCE			English	Article							HAIR CELL REGENERATION; ACOUSTIC TRAUMA; CHICK COCHLEA	Supporting cells in the vestibular sensory epithelia from the ears of mature guinea pigs and adult humans proliferate in vitro after treatments with aminoglycoside antibiotics that cause sensory hair cells to die. After 4 weeks in culture, the epithelia contained new cells with some characteristics of immature hair cells. These findings are in contrast to expectations based on previous studies, which had suggested that hair cell loss is irreversible in mammals. The loss of hair cells is responsible for hearing and balance deficits that affect millions of people.	UCL, INST LARYNGOL & OTOL, LONDON WC1X 8EE, ENGLAND; UNIV VIRGINIA, SCH MED, DEPT NEUROSCI, CHARLOTTESVILLE, VA 22908 USA	University of London; University College London; University of Virginia	WARCHOL, ME (corresponding author), UNIV VIRGINIA, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, CHARLOTTESVILLE, VA 22908 USA.			Goldstein, Bradley/0000-0002-9612-1696; Forge, Andrew/0000-0002-0995-0219				BALAK KJ, 1990, J NEUROSCI, V10, P2502; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; CORWIN JT, 1991, ANNU REV NEUROSCI, V14, P301, DOI 10.1146/annurev.neuro.14.1.301; CORWIN JT, 1991, CIBA F SYMP, V160, P103; CORWIN JT, 1986, BIOL CHANGE OTOLARYN, P291; COTANCHE DA, 1987, HEARING RES, V30, P181, DOI 10.1016/0378-5955(87)90135-3; CRUZ RM, 1987, ARCH OTOLARYNGOL, V113, P1058; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; GLASSCOCK ME, 1989, OTOLARYNG HEAD NECK, V100, P237, DOI 10.1177/019459988910000312; JONES JE, 1991, THESIS U VIRGINIA; LAMBERT PR, UNPUB; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; WAGNER JE, 1976, BIOL GUINEA PIG, P9; WEISLEDER P, 1992, EXP NEUROL, V115, P2, DOI 10.1016/0014-4886(92)90211-8	15	408	433	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	1993	259	5101					1619	1622		10.1126/science.8456285	http://dx.doi.org/10.1126/science.8456285			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8456285				2022-12-28	WOS:A1993KR54300042
J	REINER, SL; WANG, ZE; HATAM, F; SCOTT, P; LOCKSLEY, RM				REINER, SL; WANG, ZE; HATAM, F; SCOTT, P; LOCKSLEY, RM			T(H)1 AND T(H)2 CELL ANTIGEN RECEPTORS IN EXPERIMENTAL LEISHMANIASIS	SCIENCE			English	Article							HUMAN T-CELLS; MURINE LEISHMANIASIS; INTERFERON-GAMMA; IFN-GAMMA; HELPER; MICE; INTERLEUKIN-10; SUBSETS; LINES; EXPRESSION	The complexity and chronicity of parasitic infections have obscured the identification of biologically relevant antigens. Analysis of the T cell receptor repertoire used by mice infected with Leishmania major revealed the expansion of a restricted population of CD4+ cells. These cells expressed the V(alpha)8-J(alpha)TA72,V(beta)4 heterodimer in both progressive infection and protective immunity and across several major histocompatibility haplotypes. Thus, the same immunodominant parasite epitope drives the disparate outcomes of this infectious process, suggesting that candidate vaccine antigens selected by screening of immune individuals may be capable of exacerbating disease in genetically susceptible individuals.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV PENN,SCH VET MED,DEPT PATHOBIOL,PHILADELPHIA,PA 19104	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Pennsylvania					NIAID NIH HHS [AI30663] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030663] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS S, 1991, P NATL ACAD SCI USA, V88, P11271, DOI 10.1073/pnas.88.24.11271; BELOSEVIC M, 1989, J IMMUNOL, V143, P266; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOITEL B, 1992, J EXP MED, V175, P765, DOI 10.1084/jem.175.3.765; BOITEL B, 1991, J EXP MED, V174, P1371; CANDEIAS S, 1991, J EXP MED, V174, P989, DOI 10.1084/jem.174.5.989; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOU HS, 1986, EMBO J, V5, P2149, DOI 10.1002/j.1460-2075.1986.tb04478.x; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; HAANEN JBAG, 1991, J EXP MED, V174, P583, DOI 10.1084/jem.174.3.583; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOLADAY BJ, 1991, J IMMUNOL, V147, P1653; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; LEHN M, 1989, J IMMUNOL, V143, P3020; MALEFYT RD, 1991, J EXP MED, V174, P915; REINER SL, UNPUB; ROCKEN M, 1992, J IMMUNOL, V148, P1031; ROMANI L, 1992, J EXP MED, V176, P19, DOI 10.1084/jem.176.1.19; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SCOTT P, 1990, J IMMUNOL, V144, P1075; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; TAYLOR AH, 1990, J EXP MED, V172, P1643, DOI 10.1084/jem.172.6.1643; TITUS RG, 1985, J IMMUNOL, V135, P2108; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TOMONARI K, 1989, EUR J IMMUNOL, V19, P1131, DOI 10.1002/eji.1830190625; WHITE J, 1989, J IMMUNOL, V143, P1822; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; YSSEL H, 1991, J EXP MED, V174, P593, DOI 10.1084/jem.174.3.593	36	214	216	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1457	1460		10.1126/science.8451641	http://dx.doi.org/10.1126/science.8451641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451641				2022-12-28	WOS:A1993KP97800037
J	NEWTON, J; FRASER, M; ROBINSON, J; WAINWRIGHT, D				NEWTON, J; FRASER, M; ROBINSON, J; WAINWRIGHT, D			FUNDHOLDING IN NORTHERN REGION - THE 1ST YEAR	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE	Objective-To describe the experiences of 10 fundholding practices in the Northern region during 1991-2 and to elicit subjective assessments of the impact of their change in status on practice management and patient care. Design-Semistructured interviews were conducted with clinicians and practice managers; other staff in the practices were asked to fill in questionnaires. Questions were asked about the preparatory year, the impact of fundholding on clinical practice and practice management, perceptions of the costs and benefits of fundholding, and views about the future of the scheme. Setting-10 of the 28 first wave fundholding practices in the Northern region, March-July 1992. Results-Two interviews were conducted in nine practices and one interview in the tenth practice. Replies to the questionnaire were received from 35 general practitioners (73%) and 89 (58%) non-medical staff. Practices sought independence in applying for fundholding status and found the preparatory year challenging and time consuming. General practitioners thought that the greatest change had occurred in relationships with consultants and the least change in relationships with patients. Most respondents thought that fundholding had changed the way they worked. The perceived benefits of fundholding were mentioned more often than the perceived costs. Conclusions-The results offer some encouragement to the proponents of fundholding, but more longitudinal studies are needed to evaluate the misgivings of critics of the scheme. Fundholders are uncertain about their ability to make savings year after year, particularly in an increasingly cost contained environment.			NEWTON, J (corresponding author), UNIV NORTHUMBRIA,DEPT APPL SOCIAL SCI,NEWCASTLE TYNE NE1 8ST,ENGLAND.							Berg B.L., 1989, QUALITATIVE RES METH; BEVAN G, 1989, LANCET, V1, P947; BRAZIER JE, 1991, SCOT J POLIT ECON, V38, P96, DOI 10.1111/j.1467-9485.1991.tb00303.x; CRUMP BJ, 1991, BRIT MED J, V302, P1582, DOI 10.1136/bmj.302.6792.1582; DINGWALL R, 1991, HLTH SERVICE J, V101, P23; DRUMMOND M, 1990, BRIT MED J, V301, P1288, DOI 10.1136/bmj.301.6764.1288; FORBES JF, 1989, J ROY COLL GEN PRACT, V39, P355; GLENNERSTER H, 1992, 12 KINGS FUND I RES; Glynn J, 1992, FINANCIAL ACCOUNTABI, V8, P149; MELZER D, 1992, HLTH SERVICE J, V102, P17; Mullen P, 1990, FINANCIAL ACCOUNTABI, V6, P33; ROLAND M, 1991, BRIT MED J, V303, P171, DOI 10.1136/bmj.303.6795.171; WEINER J, 1990, 7 KINGS FUND I RES R	13	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					375	378		10.1136/bmj.306.6874.375	http://dx.doi.org/10.1136/bmj.306.6874.375			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461685	Bronze, Green Published			2022-12-28	WOS:A1993KL71500023
J	MARAN, A; LOMAS, J; ARCHIBALD, H; MACDONALD, IA; GALE, EAM; AMIEL, SA				MARAN, A; LOMAS, J; ARCHIBALD, H; MACDONALD, IA; GALE, EAM; AMIEL, SA			DOUBLE-BLIND CLINICAL AND LABORATORY STUDY OF HYPOGLYCEMIA WITH HUMAN AND PORCINE INSULIN IN DIABETIC-PATIENTS REPORTING HYPOGLYCEMIA UNAWARENESS AFTER TRANSFERRING TO HUMAN INSULIN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PURIFIED PORK INSULIN; INDUCED HYPOGLYCEMIA; RECOMBINANT DNA; COUNTER-REGULATION; AWARENESS; RESPONSES; SYMPTOMS; IDDM; COUNTERREGULATION; INFUSION	Objectives-To compare awareness of hypoglycaemia and physiological responses to hypoglycaemia with human and porcine insulin in diabetic patients who reported loss of hypoglycaemia awareness after transferring to human insulin. Design-Double blind randomised crossover study of clinical experience and physiological responses during slow fall hypoglycaemic clamping with porcine and human insulin. Setting-Clinical investigation unit of teaching hospital recruiting from diabetes clinics of five teaching hospitals and one district general hospital. Subjects-17 patients with insulin dependent diabetes mellitus of more than five years' duration who had reported altered hypoglycaemia awareness within three months of transferring to human insulin. Main outcome measures-Glycaemic control and frequency of hypoglycaemic episodes during two months' treatment with each insulin. Glucose thresholds for physiological and symptomatic responses during clamping. Results-Glycaemic control did not change with either insulin. 136 hypoglycaemic episodes (eight severe) were reported with human insulin and 149 (nine severe) with porcine insulin (95% confidence interval -4 to 2.5, p=0.63). 20 episodes of biochemical hypoglycaemia occurred with human insulin versus 18 with porcine insulin (-0.8 to 1, p=0.78). During controlled hypoglycaemia the mean adrenaline response was 138 nmol/240 min for both insulins; neurohormonal responses were triggered at 3.0 (SE 0.2) versus 3.1 (0.2) mmol/l of glucose for adrenaline and 2.5 (0.1) versus 2.5 (0.1) mmol/l for subjective awareness. Conclusions-These data suggest that human insulin per se does not affect the presentation of hypoglycaemia or the neurohumoral, symptomatic, and cognitive function responses to hypoglycaemia in insulin dependent diabetic patients with a history of hypoglycaemia unawareness.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, METAB MED UNIT, GUYS HOSP CAMPUS, LONDON SE1 9RT, ENGLAND; ST BARTHOLOMEWS HOSP, COLL MED, DEPT DIABET & METAB, LONDON EC1A 7BE, ENGLAND; UNIV NOTTINGHAM, QUEENS MED CTR, DEPT PHYSIOL & PHARMACOL, NOTTINGHAM NG7 2RD, ENGLAND	University of London; King's College London; University of London; Queen Mary University London; University of Nottingham				Macdonald, Ian/0000-0002-7540-9850; MARAN, ALBERTO/0000-0002-7266-8486				AMIEL SA, 1991, DIABETES CARE, V14, P109, DOI 10.2337/diacare.14.2.109; AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; AMIEL SA, 1988, DIABETES, V37, P901, DOI 10.2337/diabetes.37.7.901; AMIEL SA, 1987, DIABETES, V36, P518, DOI 10.2337/diabetes.36.4.518; BENDTSON I, 1991, J INTERN MED, V229, P293, DOI 10.1111/j.1365-2796.1991.tb00348.x; BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; BERGER WG, 1987, DIABETES CARE, V10, P260, DOI 10.2337/diacare.10.2.260; CLARKE WL, 1991, DIABETES, V40, P680, DOI 10.2337/diabetes.40.6.680; COLAGIURI S, 1992, LANCET, V339, P1432, DOI 10.1016/0140-6736(92)92028-E; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; EBIHARA A, 1983, DIABETES CARE, V6, P17; EGGER M, 1991, BMJ-BRIT MED J, V303, P617, DOI 10.1136/bmj.303.6803.617; EGGER M, 1992, DIABETES CARE, V15, P585, DOI 10.2337/diacare.15.4.585; EGGER M, 1991, LANCET, V338, P950, DOI 10.1016/0140-6736(91)91820-K; FERNANDEZ RP, 1985, HORM METAB RES, V17, P351, DOI 10.1055/s-2007-1013540; FISHER BM, 1988, DIABETES RES CLIN EX, V8, P1; HEINE R, 1990, LANCET, V355, P62; HEINE RJ, 1989, LANCET, V2, P946; HEPBURN DA, 1989, DIABETIC MED, V6, P586, DOI 10.1111/j.1464-5491.1989.tb01233.x; HEPBURN DA, 1991, DIABETES CARE, V14, P949, DOI 10.2337/diacare.14.11.949; Home P D, 1984, Diabet Med, V1, P93; JONES TW, 1991, DIABETES CARE, V14, P728, DOI 10.2337/diacare.14.8.728; KERN W, 1990, DIABETES, V39, P1091, DOI 10.2337/diabetes.39.9.1091; KERR D, 1991, DIABETIC MED, V8, P123, DOI 10.1111/j.1464-5491.1991.tb01557.x; LAGER I, 1986, DIABETIC MED, V3, P322, DOI 10.1111/j.1464-5491.1986.tb00772.x; LARON Z, 1988, DIABETOLOGIA, V31, P454, DOI 10.1007/BF00271593; LIU D, 1992, DIABETOLOGIA, V35, P287, DOI 10.1007/BF00400932; MULHAUSER I, 1991, DIABETES CARE, V14, P745; ORCHARD TJ, 1991, DIABETIC MED, V9, P469; OWENS DR, 1988, DIABETES RES, V8, P1; PATRICK AW, 1991, LANCET, V338, P528, DOI 10.1016/0140-6736(91)91098-F; PETERSEN KG, 1982, DIABETES CARE, V5, P90, DOI 10.2337/diacare.5.2.S90; ROSAK C, 1982, DIABETES CARE, V5, P82, DOI 10.2337/diacare.5.2.S82; RYDER REJ, 1990, BMJ-BRIT MED J, V301, P783, DOI 10.1136/bmj.301.6755.783; SCHLUTER KJ, 1982, DIABETES CARE, V5, P78, DOI 10.2337/diacare.5.2.S78; SJOBOM NC, 1989, DIABETOLOGIA, V32, P818; SJORBORN NC, 1990, DIABETIC MED, V7, P775; STEPHENSON J, 1990, LANCET, V335, P661, DOI 10.1016/0140-6736(90)90448-E; TEUSCHER A, 1987, LANCET, V2, P382	39	39	39	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	1993	306	6871					167	171		10.1136/bmj.306.6871.167	http://dx.doi.org/10.1136/bmj.306.6871.167			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443479	Green Published, Bronze			2022-12-28	WOS:A1993KH51300019
J	HENDEE, WR				HENDEE, WR			DISPOSAL OF LOW-LEVEL RADIOACTIVE-WASTE - PROBLEMS AND IMPLICATIONS FOR PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISKS				HENDEE, WR (corresponding author), MED COLL WISCONSIN,OFF RES & TECHNOL,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.							APPLE GJ, 1992, NO CALIF MED, V3, P1; CALLAGHAN JD, 1989, EFFECTIVE RISK INFOR, P137; GERSHEY EL, 1990, CRADLE GRAVE, P69; HENDEE W R, 1991, Postgraduate Radiology, V11, P164; HENDEE WR, 1991, RADIOGRAPHICS, V11, P1109, DOI 10.1148/radiographics.11.6.1749852; LAIRD FN, 1989, RISK ANAL, V9, P543, DOI 10.1111/j.1539-6924.1989.tb01265.x; MASSE FX, 1991, HEALTH PHYS, V61, P179; MCCALLUM DB, 1991, HEALTH EDUC QUART, V18, P349, DOI 10.1177/109019819101800307; Murray R., 1989, UNDERSTANDING RADIOA; WEART SR, 1988, NUCLEAR FEAR HIST IM; 1986, STATE STATE ASSESSME; 1980, J NUCL CHEM WASTE MA, V5, P123; 1989, IMPROVING RISK COMMU, P120; 1986, 398 INT AT EN AG TEC; 1989, JAMA-J AM MED ASSOC, V262, P669	15	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2403	2406		10.1001/jama.269.18.2403	http://dx.doi.org/10.1001/jama.269.18.2403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479067				2022-12-28	WOS:A1993LA67500035
J	PETERS, LL; ANDREWS, NC; EICHER, EM; DAVIDSON, MB; ORKIN, SH; LUX, SE				PETERS, LL; ANDREWS, NC; EICHER, EM; DAVIDSON, MB; ORKIN, SH; LUX, SE			MOUSE MICROCYTIC ANEMIA CAUSED BY A DEFECT IN THE GENE ENCODING THE GLOBIN ENHANCER-BINDING PROTEIN NF-E2	NATURE			English	Article							DOMINANT CONTROL REGION; MESSENGER-RNA; ALPHA-GLOBIN; CELLS; IRON	THE nuclear DNA-binding protein NF-E2 is thought to mediate the powerful erythroid enhancer activity of the alpha and beta-globin locus control regions1-4 and participates in the control of genes encoding two enzymes of haem biosynthesis (porphobilinogen deaminase and ferrochelatase)1,5 The major component of NF-E2 is a 45K polypeptide (designated p45 NF-E2) that belongs to the basic region-leucine zipper family of transcription factors6. This subunit of NF-E2 is specifically expressed in haematopoietic progenitor cells and differentiated cells of the erythroid, megakaryocyte and mast cell lineages6. The gene encoding p45 NF-E2 (murine gene Nfe2) has been mapped to mouse chromosome 15 near the mutation microcytosis (mk). Homozygous mk mice have severe hypochromic microcytic anaemia as a result of decreased globin synthesis and defects in intestinal and erythroid iron absorption. Here we investigate whether the mk mutation lies within Nfe2 by characterizing the p45 NF-E2 gene and determining its DNA sequence in wild-type and mk alleles. The mk allele carries a missense mutation that causes substitution of valine by alanine at amino acid 173 of the p45 NF-E2 protein. Expression of p45 NF-E2 messenger RNA was detected in erythroid tissues of normal mice and in the duodenum of normal and severely anaemic beta-thalassaemic (Hbb(d-th3)/Hbb(d-th3)) mice. We propose that the mk mutation results in an impaired form of NF-E2 which fails to regulate both globin production and iron metabolism properly.	CHILDRENS HOSP MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT PEDIAT, BOSTON, MA 02115 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Jackson Laboratory; Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Andrews, Nancy/0000-0003-0243-4462; Peters, Luanne/0000-0002-0784-0534				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BANNERMAN RM, 1972, BRIT J HAEMATOL, V23, P235, DOI 10.1111/j.1365-2141.1972.tb03476.x; BUCHANAN GR, 1981, J PEDIATR-US, V98, P723, DOI 10.1016/S0022-3476(81)80831-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUI DHK, 1980, BRIT J HAEMATOL, V44, P431, DOI 10.1111/j.1365-2141.1980.tb05913.x; EDWARDS JA, 1975, BLOOD, V46, P381; EDWARDS JA, 1972, P SOC EXP BIOL MED, V141, P81; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER HD, 1984, P NATL ACAD SCI-BIOL, V81, P2733, DOI 10.1073/pnas.81.9.2733; HARRISON DE, 1972, BLOOD-J HEMATOL, V40, P893, DOI 10.1182/blood.V40.6.893.893; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PETERS LL, 1992, P NATL ACAD SCI USA, V89, P5749, DOI 10.1073/pnas.89.13.5749; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; POPP RA, 1985, ANN NY ACAD SCI, V445, P432, DOI 10.1111/j.1749-6632.1985.tb17213.x; RUSSELL ES, 1970, BLOOD-J HEMATOL, V35, P838, DOI 10.1182/blood.V35.6.838.838; RUSSELL ES, 1970, TRANSPLANT P, V2, P144; Sambrook J, 1989, MOL CLONING LABORATO; TAKETANI S, 1992, EUR J BIOCHEM, V205, P217, DOI 10.1111/j.1432-1033.1992.tb16771.x; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0	23	59	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 22	1993	362	6422					768	770		10.1038/362768a0	http://dx.doi.org/10.1038/362768a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8469289				2022-12-28	WOS:A1993KY45000062
J	SRA, JS; JAZAYERI, MR; AVITALL, B; DHALA, A; DESHPANDE, S; BLANCK, Z; AKHTAR, M				SRA, JS; JAZAYERI, MR; AVITALL, B; DHALA, A; DESHPANDE, S; BLANCK, Z; AKHTAR, M			COMPARISON OF CARDIAC PACING WITH DRUG-THERAPY IN THE TREATMENT OF NEUROCARDIOGENIC (VASOVAGAL) SYNCOPE WITH BRADYCARDIA OR ASYSTOLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEAD-UP TILT; VAGAL C-FIBERS; UNEXPLAINED SYNCOPE; RECURRENT SYNCOPE; ISOPROTERENOL; DISOPYRAMIDE; HYPOTENSION	Background. The efficacy of permanent cardiac pacing in patients with neurocardiogenic (or vasovagal) syncope associated with bradycardia or asystole is not clear. We compared the efficacy of cardiac pacing with that of oral drug therapy in the prevention of hypotension and syncope during head-up tilt testing. Methods. Among 70 patients with a history of syncope in whom hypotension and syncope could be provoked during head-up tilt testing, 22 had bradycardia (a heart rate <60 beats per minute, with a decline in the rate by at least 20 beats per minute) or asystole along with hypotension during testing. There were 9 men and 13 women, with a mean (+/- SD) age of 41 +/- 17 years. Head-up tilt testing was repeated during atrioventricular sequential pacing (in 20 patients with sinus rhythm) or ventricular pacing (in 2 patients with atrial fibrillation). Regardless of the results obtained during artificial pacing, all the patients subsequently had upright-tilt testing repeated during therapy with oral metroprolol, theophylline, or disopyramide. Results. During the initial tilt test, 6 patients had asystole and 16 had bradycardia along with hypotension. Despite artificial pacing, the mean arterial pressure during head-up tilt testing still fell significantly, from 97 +/- 19 to 57+/-19 mm Hg (P < 0.001); 5 patients had syncope, and 15 had presyncope By contrast, 19 patients who later received only medical therapy (metoprolol in 10, theophylline in 3, and disopyramide in 6), 2 patients who received both metoprolol and atrioventricular sequential pacing, and 1 patient who received only atrioventricular sequential pacing had negative head-up tilt tests. After a median follow-up of 16 months, 18 of the 19 patients who were treated with drugs alone (94 percent) remained free of recurrent syncope or presyncope, whereas the patient treated only with a permanent dual-chamber pacemaker had recurrent syncope. Conclusions. Ir patients with neurocardiogenic syncope associated with bradycardia or asystole, drug therapy is often effective in preventing syncope, whereas artificial pacing is not.			SRA, JS (corresponding author), SINAI SAMARITAN MED CTR, 945 N 12TH ST, MILWAUKEE, WI 53233 USA.			Deshpande, Sanjay/0000-0002-6153-2444				ABBOUD FM, 1976, PROG CARDIOVASC DIS, V18, P371, DOI 10.1016/0033-0620(76)90003-7; ABISAMRA F, 1988, PACE, V11, P1202, DOI 10.1111/j.1540-8159.1988.tb03973.x; AKHTAR M, 1983, PACE, V6, P192, DOI 10.1111/j.1540-8159.1983.tb04346.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; DANILO P, 1976, AM HEART J, V92, P532; DERMKSIAN G, 1958, JAMA-J AM MED ASSOC, V168, P1200, DOI 10.1001/jama.1958.03000090030007; DIMARCO JP, 1981, ANN INTERN MED, V95, P542, DOI 10.7326/0003-4819-95-5-542; FITZPATRICK A, 1989, LANCET, V1, P658, DOI 10.1016/S0140-6736(89)92155-7; FUJIMURA O, 1989, NEW ENGL J MED, V321, P1703, DOI 10.1056/NEJM198912213212503; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; LERMAN BB, 1991, CIRCULATION, V83, P1499, DOI 10.1161/01.CIR.83.5.1499; Lewis T, 1932, BRIT MED J, V1932, P873, DOI 10.1136/bmj.1.3723.873; LUDBROOK J, 1989, NEWS PHYSIOL SCI, V4, P120; MILSTEIN S, 1990, AM J CARDIOL, V65, P1339, DOI 10.1016/0002-9149(90)91324-Y; NELSON SD, 1990, CIRCULATION, V82, P707; OBERG B, 1972, ACTA PHYSIOL SCAND, V85, P164, DOI 10.1111/j.1748-1716.1972.tb05247.x; SHALEV Y, 1991, J AM COLL CARDIOL, V18, P746, DOI 10.1016/0735-1097(91)90798-E; SHARPEYSCHAFER EP, 1958, BMJ-BRIT MED J, V2, P878, DOI 10.1136/bmj.2.5101.878; SRA J, 1991, J AM COLL CARDIOL, V17, pA216; SRA JS, 1992, J AM COLL CARDIOL, V19, P402, DOI 10.1016/0735-1097(92)90498-C; SRA JS, 1991, ANN INTERN MED, V114, P1013, DOI 10.7326/0003-4819-114-12-1013; THAMES MD, 1980, AM J PHYSIOL, V238, pH465, DOI 10.1152/ajpheart.1980.238.4.H465; Thoren P, 1979, Rev Physiol Biochem Pharmacol, V86, P1, DOI 10.1007/BFb0031531; WAXMAN MB, 1989, AM J CARDIOL, V63, P58, DOI 10.1016/0002-9149(89)91076-X; 1989, SAS STAT USERS GUIDE, P261	25	211	214	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1085	1090		10.1056/NEJM199304153281504	http://dx.doi.org/10.1056/NEJM199304153281504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8455666	Bronze			2022-12-28	WOS:A1993KX17800004
J	LEHMKUHLE, S; GARZIA, RP; TURNER, L; HASH, T; BARO, JA				LEHMKUHLE, S; GARZIA, RP; TURNER, L; HASH, T; BARO, JA			A DEFECTIVE VISUAL PATHWAY IN CHILDREN WITH READING-DISABILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LATERAL GENICULATE-NUCLEUS; SPECIFICALLY DISABLED READERS; DEPENDENT VISIBLE PERSISTENCE; CONTRAST SENSITIVITY; SPATIAL-FREQUENCY; X-CELL; Y-CELL; LUMINANCE; DYSLEXIA; MASKING	Background. The possibility that reading disability in children is associated with visual problems is in dispute. We sought to test the existence of this association by using electrophysiologic techniques to measure the processing of visual information in the magnicellular and parvicellular visual pathways of the brain. Methods. Visual evoked potentials were measured with scalp electrodes in children 8 to 11 years old who were normal readers and in those with reading disability. The potentials were measured for targets with low (0.5 cycle per degree of visual angle) and high (4.5 cycles per degree) spatial frequency, surrounded by either a steady background or a uniform-field flickering 12 times per second. A flickering field normally reduces the amplitude and increases the latency of a transient potential evoked by a low-spatial-frequency target, which preferentially excites the magnicellular visual pathway, but has little effect on the response to a high-spatial-frequency target. Results. With a steady background, the latencies of the early components (N1 and P1) of the visual evoked potentials were longer in the reading-disabled children than in the normal readers when the low-spatial-frequency target was used, but not when the high-spatial-frequency target was used. In normal readers, the flickering background increased the latency and reduced the amplitude of the early components, whereas in the reading-disabled children only the amplitude was affected. No differences were observed in either group with the high-spatial-frequency target. Conclusions. The pattern of results suggests that the response of the magnicellular visual pathway is slowed in reading-disabled children, who do not, however, have a general slowing of the visual response. The possibility that there is a cause-and-effect relation between these findings and reading disability will require further study.			LEHMKUHLE, S (corresponding author), UNIV MISSOURI,SCH OPTOMETRY,8001 NAT BRIDGE RD,ST LOUIS,MO 63121, USA.							BADCOCK D, 1981, J EXP PSYCHOL HUMAN, V7, P495, DOI 10.1037/0096-1523.7.3.495; BARO JA, 1988, BEHAV RES METH INSTR, V20, P515, DOI 10.3758/BF03202709; BARO JA, 1989, VISUAL NEUROSCI, V3, P563, DOI 10.1017/S0952523800009895; BARO JA, 1990, CLIN VISION SCI, V5, P265; Bassi C J, 1990, J Am Optom Assoc, V61, P98; BRANNAN JR, 1988, CLIN VISION SCI, V3, P137; BREITMEYER BG, 1976, PSYCHOL REV, V83, P1, DOI 10.1037/0033-295X.83.1.1; BREITMEYER BG, 1983, EYE MOVEMENTS READIN, P3; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; KAPLAN E, 1982, J PHYSIOL-LONDON, V330, P125, DOI 10.1113/jphysiol.1982.sp014333; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; LIVINGSTONE MS, 1991, P NATL ACAD SCI USA, V88, P7943, DOI 10.1073/pnas.88.18.7943; LOVEGROVE W, 1982, NEUROPSYCHOLOGIA, V20, P309, DOI 10.1016/0028-3932(82)90105-1; LOVEGROVE W, 1986, COGN NEUROPSYCHOL, V3, P225, DOI 10.1080/02643298608252677; Lovegrove W J, 1990, J Am Optom Assoc, V61, P137; LOVEGROVE WJ, 1980, SCIENCE, V210, P439, DOI 10.1126/science.7433985; LOVEGROVE WJ, 1980, NEUROPSYCHOLOGIA, V18, P111, DOI 10.1016/0028-3932(80)90093-7; MARTIN F, 1984, NEUROPSYCHOLOGIA, V22, P73, DOI 10.1016/0028-3932(84)90009-5; MARTIN F, 1987, PERCEPTION, V16, P215, DOI 10.1068/p160215; MARTIN F, 1988, PERCEPTION, V17, P203, DOI 10.1068/p170203; MAY JG, 1992, CLIN VISION SCI, V7, P67; MAY JG, 1988, NEUROPSYCHOLOGIA, V26, P917, DOI 10.1016/0028-3932(88)90059-0; MCCORMICK S, 1987, REMEDIAL CLIN READIN; SHAPIRO KL, 1990, J LEARN DISABIL, V23, P99, DOI 10.1177/002221949002300205; SHAPLEY R, 1981, NATURE, V292, P543, DOI 10.1038/292543a0; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SLAGHUIS WL, 1985, BRAIN COGNITION, V4, P219, DOI 10.1016/0278-2626(85)90071-5; SLAGHUIS WL, 1984, PERCEPTION, V13, P527, DOI 10.1068/p130527; STEDMAN LC, 1987, READ RES QUART, V22, P8, DOI 10.2307/747719; VELLUTINO FR, 1977, J LEARN DISABIL, V10, P375, DOI 10.1177/002221947701000614; Williams M C, 1990, J Am Optom Assoc, V61, P111; WILLIAMS MC, 1989, CLIN VISION SCI, V4, P137; WINTERS RL, 1989, J LEARN DISABIL-US, V22, P641, DOI 10.1177/002221948902201010; YULE W, 1974, BRIT J EDUC PSYCHOL, V44, P1, DOI 10.1111/j.2044-8279.1974.tb00760.x	34	110	111	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					989	996		10.1056/NEJM199304083281402	http://dx.doi.org/10.1056/NEJM199304083281402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KW282	8450876				2022-12-28	WOS:A1993KW28200002
J	SHIRASAWA, S; FURUSE, M; YOKOYAMA, N; SASAZUKI, T				SHIRASAWA, S; FURUSE, M; YOKOYAMA, N; SASAZUKI, T			ALTERED GROWTH OF HUMAN COLON CANCER CELL-LINES DISRUPTED AT ACTIVATED KI-RAS	SCIENCE			English	Article							FAMILIAL POLYPOSIS-COLI; EMBRYONIC STEM-CELLS; P53 GENE-MUTATIONS; C-MYC GENE; HOMOLOGOUS RECOMBINATION; COLORECTAL CANCERS; IDENTIFICATION; CARCINOMA; LOCUS; CHROMOSOME-5Q21	Point mutations that activate the Ki-ras proto-oncogene are present in about 50 percent of human colorectal tumors. To study the functional significance of these mutations, the activated Ki-ras genes in two human colon carcinoma cell lines, DLD-1 and HCT 116, were disrupted by homologous recombination. Compared with parental cells, cells disrupted at the activated Ki-ras gene were morphologically altered, lost the capacity for anchorage-independent growth, grew more slowly both in vitro and in nude mice, and showed reduced expression of c-myc. Thus, the activated Ki-ras gene plays a key role in colorectal tumorigenesis through altered cell differentiation and cell growth.	KYUSHU UNIV,MED INST BIOREGULAT,DEPT GENET,3-1-1 MAIDASHI,HIGASHI KU,FUKUOKA 812,JAPAN	Kyushu University								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; COLBEREGARAPIN F, 1979, P NATL ACAD SCI USA, V76, P3755, DOI 10.1073/pnas.76.8.3755; ERISMAN MD, 1989, P NATL ACAD SCI USA, V86, P4264, DOI 10.1073/pnas.86.11.4264; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HUNTER T, 1991, P NATL ACAD SCI USA, V64, P249; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEWIS SA, 1985, J MOL BIOL, V182, P11, DOI 10.1016/0022-2836(85)90023-3; MANSOUR SL, 1990, P NATL ACAD SCI USA, V87, P7688, DOI 10.1073/pnas.87.19.7688; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NIGRO JM, 1989, NATURE, V342, P795; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; SASAKI M, 1989, CANCER RES, V49, P4402; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SHIRASAWA S, UNPUB; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUGIO K, 1988, CANCER RES, V48, P4855; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VRIES MV, 1986, GENE, V50, P313; WILLSON JKV, 1987, CANCER RES, V47, P2704; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918	36	589	604	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					85	88		10.1126/science.8465203	http://dx.doi.org/10.1126/science.8465203			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8465203				2022-12-28	WOS:A1993KV42300033
J	OLSEN, B; JAENSON, TGT; NOPPA, L; BUNIKIS, J; BERGSTROM, S				OLSEN, B; JAENSON, TGT; NOPPA, L; BUNIKIS, J; BERGSTROM, S			A LYME BORRELIOSIS CYCLE IN SEABIRDS AND IXODES-URIAE TICKS	NATURE			English	Article							MONOCLONAL-ANTIBODY; BURGDORFERI	THE Lyme disease spirochaete, Borrelia burgdorferi s.l., is the only Borrelia known to infect both mammals and birds1. The main vertebrate reservoirs of B. burgdorferi are thought to be various small and intermediate size mammals2, but the importance of birds as a reservoir has not been thoroughly explored. In the Northern and Southern Hemispheres the seabird tick, Ixodes uriae, is prevalent and closely associated with many species of colony-nesting marine birds3. Here we report the presence of spirochaetes, demonstrated by immunofluorescent assay, by polymerase chain reaction and in culture. in I. uriae infesting razorbills on an island in the Baltic Sea. This island is free from mammals. The protein profile of the spirochaetes and the sequences of their flagellin and ospA genes are identical to those of the Lyme disease spirochaete, Borrelia burgdorferi s.l., previously isolated from I. ricinus on a nearby island. In biopsies from the foot web of razorbills, B. burgdorferi-specific DNA was detected after amplification by polymerase chain reaction. Our results suggest that birds play an important part in the maintenance of B. burgdorferi and that mammals may not be a prerequisite for its life cycle.	UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT INFECT DIS,S-90187 UMEA,SWEDEN; UNIV UPPSALA,DEPT ZOOL,S-75122 UPPSALA,SWEDEN	Umea University; Umea University; Uppsala University				Olsen, Bjorn/0000-0002-4646-691X; Jaenson, Thomas/0000-0003-0780-7475				ANDERSON JF, 1986, INFECT IMMUN, V51, P394, DOI 10.1128/IAI.51.2.394-396.1986; ANDERSON JF, 1989, REV INFECT DIS, V11, pS1451; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BARBOUR AG, 1986, INFECT IMMUN, V52, P549, DOI 10.1128/IAI.52.2.549-554.1986; BARBOUR AG, 1983, INFECT IMMUN, V41, P795, DOI 10.1128/IAI.41.2.795-804.1983; BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; BERGSTROM S, 1992, SCAND J INFECT DIS, V24, P181, DOI 10.3109/00365549209052610; Clifford C. M., 1979, Arctic and tropical arboviruses., P83; FILIPPOVA NA, 1977, IXODID TICKS SUBFAMI, V114; GASSMANN GS, 1989, NUCLEIC ACIDS RES, V17, P3590, DOI 10.1093/nar/17.9.3590; Kolonin G.V., 1981, WORLD DISTRIBUTION I; OLSEN B, 1992, VAR FAGELVARD, V3, P11; PICKEN RN, 1992, J CLIN MICROBIOL, V30, P99, DOI 10.1128/JCM.30.1.99-114.1992; POKKI J, 1981, ACTA ZOOL FENN, V164, P13; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Southwood TRE, 1978, ECOLOGICAL METHODS P, P170	16	168	176	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					340	342		10.1038/362340a0	http://dx.doi.org/10.1038/362340a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455718				2022-12-28	WOS:A1993KU17600059
J	WISELY, ICF				WISELY, ICF			GENERAL-PRACTITIONER FUNDHOLDING - EXPERIENCE IN GRAMPIAN	BRITISH MEDICAL JOURNAL			English	Article								Proposals for fundholding were greeted with scepticism by many general practitioners, and in Scotland the BAMA persuaded the government to allow a scheme to test the arrangements as a demonstration project operating ''shadow'' practice funds. This allowed the six selected practices to set up administrative and computer systems without the worry of dealing with real money. The shadow fundholding scheme has since been extended to small practices and to a trial of fundholding for all services except accident and emergency. The six practices in the original pilot have all become fundholders and are beginning to effect improvements in the service to their patients. However, with more practices becoming fundholders negotiating contracts with providers is becoming increasingly complicated and more time and money needs to be put into this aspect.			WISELY, ICF (corresponding author), BRIMMOND MED GRP,ABERDEEN AB2 9AT,SCOTLAND.							BEECHAM L, 1989, BMJ, V298, P1316; Howie J G, 1992, Health Bull (Edinb), V50, P316; ANN REPORT COUNCIL 1, P4	3	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					695	697		10.1136/bmj.306.6879.695	http://dx.doi.org/10.1136/bmj.306.6879.695			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT216	8471925	Green Published, Bronze			2022-12-28	WOS:A1993KT21600025
J	BRIGGS, H; ILETT, S				BRIGGS, H; ILETT, S			WEAK LINK IN VACCINE COLD CHAIN	BRITISH MEDICAL JOURNAL			English	Article							STORAGE		CTR COMMUNITY HLTH,BIRMINGHAM B12 0YA,ENGLAND; UNIV BIRMINGHAM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham								HUNTER S, 1989, BRIT MED J, V299, P661, DOI 10.1136/bmj.299.6700.661; LUGOSI L, 1990, B WORLD HEALTH ORGAN, V68, P431; MALONELEE MC, 1992, PURCHASE SUPPLY VACC; THAKKER Y, 1992, BRIT MED J, V304, P756, DOI 10.1136/bmj.304.6829.756	4	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					557	558		10.1136/bmj.306.6877.557	http://dx.doi.org/10.1136/bmj.306.6877.557			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461771	Bronze, Green Published			2022-12-28	WOS:A1993KP88600023
J	GOULD, MM; MOHAMEDALI, V; GOUBET, SA; YUDKIN, JS; HAINES, AP				GOULD, MM; MOHAMEDALI, V; GOUBET, SA; YUDKIN, JS; HAINES, AP			MICROALBUMINURIA - ASSOCIATIONS WITH HEIGHT AND SEX IN NONDIABETIC SUBJECTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEPHROPATHY; PREDICTOR; DISEASE; ALBUMIN; HEART	Objectives-To study the association(s) between microalbuminuria and cardiovascular risk factors in non-diabetic subjects. Design-Patients aged 40-75 years were randomly selected from a general practice list and invited to participate. Setting-Health centre in inner city London. Subjects-Of those invited, 1046 out of 1671 (62.6%) attended. Subjects were excluded for the following reasons: not being white (44); urinary albumin excretion rate > 200 mug/min (3); having a urinary infection (5); taking penicillamine or angiotensin converting enzyme inhibitors (7); older than 75 (2); having diabetes (25); missing data on glucose concentration (1). Main outcome measures-Glucose tolerance test results, albumin excretion rate from overnight and timed morning collections of urine; blood pressure; height. Results-Mean albumin excretion rate was significantly lower in women than men (mean ratio 0.8, 95% confidence interval (0.69 to 0.91)). Mean albumin excretion rate was significantly associated with age, blood pressure, and blood glucose concentration (fasting, 1 hour, and 2 hour) in men and inversely with height. Men who had microalbuminuria in both samples were significantly shorter (by 5 cm (1.3 to 9.3 cm)) than those who had no microalbuminuria in either sample when age was taken into account. In the case of women only systolic pressure was significantly associated with albumin excretion rate. Conclusions-Microalbuminuria and short stature in men are associated. Cardiovascular risk has been associated with both of these factors and with lower birth weight. The inverse association of microalbuminuria with height is compatible with the suggestion that factors operating in utero or early childhood are implicated in cardiovascular disease. The higher prevalence of microalbuminuria in men compared with women may indicate that sex differences in cardiovascular risk are reflected in differences in albumin excretion rate.	UNIV COLL & MIDDLESEX SCH MED, WHITTINGTON HOSP, DEPT MED, LONDON N19 5NF, ENGLAND	University of London; University College London	GOULD, MM (corresponding author), UNIV COLL & MIDDLESEX SCH MED, WHITTINGTON HOSP, DEPT PRIMARY HLTH CARE, LONDON N19 5NF, ENGLAND.		Yudkin, John S/C-1988-2008	Haines, Andy/0000-0002-8053-4605				CHESHAM J, 1986, CLIN CHEM, V32, P669; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; HAFFNER SM, 1990, ARTERIOSCLEROSIS, V10, P727, DOI 10.1161/01.ATV.10.5.727; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; MARMOT MG, 1984, LANCET, V1, P1003; MATTOCK MB, 1988, DIABETOLOGIA, V31, P82, DOI 10.1007/BF00395552; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; THOMSON A M, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P903; VIBERTI GC, 1982, LANCET, V1, P1430; WINOCOUR PH, 1992, ATHEROSCLEROSIS, V93, P71, DOI 10.1016/0021-9150(92)90201-Q; YUDKIN JS, 1988, LANCET, V2, P530	14	108	110	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	1993	306	6872					240	242		10.1136/bmj.306.6872.240	http://dx.doi.org/10.1136/bmj.306.6872.240			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443522	Green Published, Bronze			2022-12-28	WOS:A1993KJ59100018
J	BECK, PL; BRIDGES, RJ; DEMETRICK, DJ; KELLY, JK; LEE, SS				BECK, PL; BRIDGES, RJ; DEMETRICK, DJ; KELLY, JK; LEE, SS			CHRONIC ACTIVE HEPATITIS ASSOCIATED WITH TRAZODONE THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note						TRAZODONE; HEPATITIS, CHRONIC ACTIVE; HEPATITIS, TOXIC; BIOPSY		Trazodone is a widely used nontricyclic antidepressant agent that has been commercially available in North America for more than 10 year. There have been three previously reported cases of trazodone-induced hepatic injury, all of which resolved within 4 to 24 weeks after cessation of the drug. We report the first documented case of trazodone-induced chronic active hepatitis. The patient developed jaundice 8 months after beginning therapy with the drug. Her liver enzymes were markedly elevated, and mild portal hypertension was present al transjugular liver biopsy. The biopsy specimen showed a pattern consistent with chronic active hepatitis. Investigations of other possible causes of chronic active hepatitis were negative, and serum transaminase enzyme levels rapidly returned to normal after withdrawal of trazodone. We suggest that physicians be alert to the possibility of hepatic injury in patients receiving trazodone.	UNIV CALGARY, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary								CHU AG, 1983, ANN INTERN MED, V99, P128, DOI 10.7326/0003-4819-99-1-128_3; LONGSTRETH GF, 1985, J AM ACAD DERMATOL, V13, P149, DOI 10.1016/S0190-9622(85)80328-5; SHEIKH KH, 1983, ANN INTERN MED, V99, P572, DOI 10.7326/0003-4819-99-4-572_1	3	23	24	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					791	792		10.7326/0003-4819-118-10-199305150-00006	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	8470853				2022-12-28	WOS:A1993LB64900006
J	HOVIS, RR; DONOVAN, JA; MUSCI, MA; MOTTO, DG; GOLDMAN, FD; ROSS, SE; KORETZKY, GA				HOVIS, RR; DONOVAN, JA; MUSCI, MA; MOTTO, DG; GOLDMAN, FD; ROSS, SE; KORETZKY, GA			RESCUE OF SIGNALING BY A CHIMERIC PROTEIN CONTAINING THE CYTOPLASMIC DOMAIN OF CD45	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; TYROSINE PHOSPHATASE CD45; LEUKOCYTE-COMMON ANTIGEN; HUMAN LYMPHOCYTES-T; POLYMERASE CHAIN-REACTION; PHOSPHOLIPASE C-GAMMA-1; FUNCTIONAL COMPLEX; KINASE P56LCK; PHOSPHORYLATION; ACTIVATION	Surface expression of the CD45 tyrosine phosphatase is essential for the T cell antigen receptor (TCR) to couple optimally with its second messenger pathways. CD45 may be required to dephosphorylate a TCR-activated protein tyrosine kinase, which then transduces an activation signal from the TCR. A chimeric molecule that contained extracellular and transmembrane sequences from an allele of a major histocompatibility class I molecule and cytoplasmic sequences of CD45 restored TCR signaling in a CD45-deficient mutant T cell line. Thus, expression of the complex extracellular domain of CD45 is not required for the TCR to couple to its signaling machinery.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa			Koretzky, Gary/AAU-5381-2021		NCI NIH HHS [CA56050-01, CA56843-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056050, R29CA056843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JUNE CH, 1990, J IMMUNOL, V144, P1591; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KORETZKY G, UNPUB; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KORETZKY GA, IN PRESS J BIOL CHEM; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SECRIST JP, IN PRESS J BIOL CHEM; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STEIN HM, 1992, CELL, V70, P741; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; VFALIUS M, 1993, MOL CELL BIOL, V13, P133; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284	40	119	121	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					544	546		10.1126/science.8475387	http://dx.doi.org/10.1126/science.8475387			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	8475387				2022-12-28	WOS:A1993KY50400035
J	CASKEY, CT				CASKEY, CT			MOLECULAR MEDICINE - A SPIN-OFF FROM THE HELIX	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN ADENOSINE-DEAMINASE; CYSTIC-FIBROSIS GENE; DUCHENNE MUSCULAR-DYSTROPHY; SICKLE-CELL ANEMIA; INSITU HYBRIDIZATION; HUNTINGTONS-DISEASE; ENZYMATIC AMPLIFICATION; HEMOPHILUS-INFLUENZAE; RESTRICTION ENZYME; BACTERIAL PLASMIDS		BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute	CASKEY, CT (corresponding author), BAYLOR COLL MED, INST MOLEC GENET, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; [Anonymous], 1989, PEDIATRICS, V83, P449; ANSORGE W, 1987, NUCLEIC ACIDS RES, V15, P4593, DOI 10.1093/nar/15.11.4593; BALMER CM, 1991, DICP ANN PHARMAC, V25, P490, DOI 10.1177/106002809102500509; BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; BENNETT WM, 1990, SEMIN NEPHROL, V10, P552; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BILLINGS P, 1992, TRENDS GENET, V8, P198, DOI 10.1016/0168-9525(92)90098-O; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BLITZER MG, 1992, CLIN LAB MED, V12, P463, DOI 10.1016/S0272-2712(18)30500-6; BLOCH M, 1989, AM J MED GENET, V32, P217, DOI 10.1002/ajmg.1320320215; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BOWCOCK A, 1991, GENOMICS, V11, P491, DOI 10.1016/0888-7543(91)90170-J; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; BREATHNACH R, 1977, NATURE, V270, P314, DOI 10.1038/270314a0; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BROWN P, 1985, NEW ENGL J MED, V313, P728, DOI 10.1056/NEJM198509193131205; BURGHES AHM, 1987, NATURE, V328, P434, DOI 10.1038/328434a0; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; Cao A, 1991, CURR OPIN GENET DEV, V1, P48, DOI 10.1016/0959-437X(91)80040-S; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; CUTTER MAG, 1992, MAPPING SEQUENCING H; DANNA KJ, 1973, J MOL BIOL, V78, P363, DOI 10.1016/0022-2836(73)90122-8; DAUWERSE JG, 1992, HUM MOL GENET, V1, P593, DOI 10.1093/hmg/1.8.593; DAVIES KE, 1985, NUCLEIC ACIDS RES, V13, P155, DOI 10.1093/nar/13.1.155; DEMARCHI JM, 1992, AM J HUM GENET S, V51, P212; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FOX S, 1989, AM J MED GENET, V32, P211, DOI 10.1002/ajmg.1320320214; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GIESER L, 1992, GENOMICS, V13, P873, DOI 10.1016/0888-7543(92)90173-P; GILL P, 1985, NATURE, V318, P577, DOI 10.1038/318577a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HALL JM, 1992, AM J HUM GENET, V50, P1235; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HOZUMI N, 1976, P NATL ACAD SCI USA, V73, P3628, DOI 10.1073/pnas.73.10.3628; HUTCHISON DCS, 1990, LUNG, V168, P535, DOI 10.1007/BF02718176; JEFFREYS AJ, 1977, CELL, V12, P1097, DOI 10.1016/0092-8674(77)90172-6; KAN YW, 1976, NEW ENGL J MED, V295, P1165, DOI 10.1056/NEJM197611182952104; KELLY TJ, 1970, J MOL BIOL, V51, P393, DOI 10.1016/0022-2836(70)90150-6; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KHOURY G, 1973, J MOL BIOL, V78, P377, DOI 10.1016/0022-2836(73)90123-X; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KURACHI K, 1981, P NATL ACAD SCI-BIOL, V78, P6826, DOI 10.1073/pnas.78.11.6826; KUWANO A, 1991, AM J HUM GENET, V49, P707; Kuwano Akira, 1992, Human Molecular Genetics, V1, P417, DOI 10.1093/hmg/1.6.417; LANDEGREN U, 1988, SCIENCE, V242, P229, DOI 10.1126/science.3051381; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LAWRENCE JB, 1988, CELL, V52, P51; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHURAN DJ, 1990, CLIN BIOCHEM, V23, P409, DOI 10.1016/0009-9120(90)90153-L; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCBRIDE OW, 1973, P NATL ACAD SCI USA, V70, P1258, DOI 10.1073/pnas.70.4.1258; MERRIAM J, 1991, SCIENCE, V254, P221, DOI 10.1126/science.1925579; MITANI K, IN  PRESS TRENDS BIO; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MORIN JE, 1987, P NATL ACAD SCI USA, V84, P4626, DOI 10.1073/pnas.84.13.4626; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NANCE WE, 1992, AM J HUM GENET, V51, P1443; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; ORKIN SH, 1983, J BIOL CHEM, V258, P2753; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; POLYMEROPOULOS MH, 1992, GENOMICS, V12, P492, DOI 10.1016/0888-7543(92)90439-Y; QUAID KA, 1989, CLIN GENET, V36, P431; RAMIREZ F, 1975, P NATL ACAD SCI USA, V72, P1550, DOI 10.1073/pnas.72.4.1550; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBERTS HR, 1989, NEW ENGL J MED, V321, P1188, DOI 10.1056/NEJM198910263211709; ROBERTS L, 1992, SCIENCE, V258, P209, DOI 10.1126/science.1292430; ROBERTS RJ, 1978, GENE, V4, P183, DOI 10.1016/0378-1119(78)90017-3; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROWLEY JD, 1983, CANCER INVEST, V1, P267, DOI 10.3109/07357908309041365; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKOLNICK MH, 1992, CANCER, V70, P1747, DOI 10.1002/1097-0142(19920915)70:4+<1747::AID-CNCR2820701616>3.0.CO;2-E; SMITH HO, 1970, J MOL BIOL, V51, P379, DOI 10.1016/0022-2836(70)90149-X; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Tanzi R E, 1991, Curr Opin Neurobiol, V1, P455, DOI 10.1016/0959-4388(91)90069-J; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; TKACHUK DC, 1990, SCIENCE, V250, P559, DOI 10.1126/science.2237408; TRAPMAN J, 1992, PROSTATE, P159; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; Tsui L C, 1991, Adv Hum Genet, V20, P153; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; VALERIO D, 1983, GENE, V25, P231, DOI 10.1016/0378-1119(83)90227-5; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAIKAN Y, 1978, P NATL ACAD SCI USA, V75, P5631, DOI 10.1073/pnas.75.11.5631; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WIGINTON DA, 1983, P NATL ACAD SCI-BIOL, V80, P7481, DOI 10.1073/pnas.80.24.7481; WILSON JT, 1978, NUCLEIC ACIDS RES, V5, P563, DOI 10.1093/nar/5.2.563; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZHANG YH, 1992, AM J HUM GENET S, V51, P272; 1978, NIH US DHEW PHS78158; 1992, JAMA-J AM MED ASSOC, V267, P2609; 1992, DAN TECHNOLOGY FOREN; 1990, OTABA438 OFF TECHN A	121	21	23	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1986	1992		10.1001/jama.269.15.1986	http://dx.doi.org/10.1001/jama.269.15.1986			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464132				2022-12-28	WOS:A1993KX21500031
J	LATTIMER, JK				LATTIMER, JK			ADDITIONAL DATA ON THE SHOOTING OF KENNEDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											LATTIMER, JK (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,630 W 168TH ST,NEW YORK,NY 10032, USA.							BREO DL, 1992, JAMA-J AM MED ASSOC, V268, P1748, DOI 10.1001/jama.268.13.1748; BREO DL, 1992, JAMA-J AM MED ASSOC, V267, P2794, DOI 10.1001/jama.267.20.2794; DIMAIO V, 1985, GUNSHOT WOUNDS; LATTIMER JK, 1976, SURG GYNECOL OBSTET, V142, P246; LATTIMER JK, 1972, B NEW YORK ACAD MED, V48, P513; Lattimer John K., 1980, KENNEDY LINCOLN MED; LOTZ J, 1992, ANN M AM BAR ASS SAN; THORNBURN W, 1886, BRAIN, V9, P510; WILSON AJ, 1992, JAMA-J AM MED ASSOC, V268, P1681, DOI 10.1001/jama.1992.03490130069017	9	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1544	1547		10.1001/jama.269.12.1544	http://dx.doi.org/10.1001/jama.269.12.1544			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445819				2022-12-28	WOS:A1993KR80300029
J	OBEID, LM; LINARDIC, CM; KAROLAK, LA; HANNUN, YA				OBEID, LM; LINARDIC, CM; KAROLAK, LA; HANNUN, YA			PROGRAMMED CELL-DEATH INDUCED BY CERAMIDE	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN KINASE-C; DNA FRAGMENTATION; FACTOR-ALPHA; SPHINGOMYELIN TURNOVER; HL-60 CELLS; DIFFERENTIATION; ACTIVATION; INHIBITION; APOPTOSIS	Sphingomyelin hydrolysis and ceramide generation have been implicated in a signal transduction pathway that mediates the effects of tumor necrosis factor-alpha (TNF-alpha) and other agents on cell growth and differentiation. In many leukemic cells, TNF-alpha causes DNA fragmentation, which leads to programmed cell death (apoptosis). C2-ceramide (0.6 to 5 muM), a synthetic cell-permeable ceramide analog, induced internucleosomal DNA fragmentation, which was inhibited by zinc ion. Other amphiphilic lipids failed to induce apoptosis. The closely related C2-dihydroceramide was also ineffective, which suggests a critical role for the sphingolipid double bond. The effects of C2-ceramide on DNA fragmentation were- prevented by the protein kinase C activator phorbol 12-myristate 13-acetate, which suggests the existence of two opposing intracellular pathways in the regulation of apoptosis.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University				obeid, lina/0000-0002-0734-0847				ALNEMRI ES, 1990, J BIOL CHEM, V265, P17323; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; ELIAS L, 1991, LEUKEMIA, V5, P879; FLIEGER D, 1989, INT J CANCER, V44, P315, DOI 10.1002/ijc.2910440221; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KELER T, 1992, P NATL ACAD SCI USA, V89, P4830, DOI 10.1073/pnas.89.11.4830; KERR JFR, 1972, J PATHOL, V107, P41, DOI 10.1002/path.1711070107; KIM MY, 1991, J BIOL CHEM, V266, P484; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; RUBIN BY, 1988, CANCER RES, V48, P6006; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; STRAUSS WM, 1992, CURRENT PROTOCOLS MO, P1; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; TURINSKY J, 1991, AM J PHYSIOL, V261, pE620, DOI 10.1152/ajpendo.1991.261.5.E620; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	29	1632	1681	3	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1769	1771		10.1126/science.8456305	http://dx.doi.org/10.1126/science.8456305			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456305				2022-12-28	WOS:A1993KT81000042
J	JUDGE, K; BENZEVAL, M				JUDGE, K; BENZEVAL, M			HEALTH INEQUALITIES - NEW CONCERNS ABOUT THE CHILDREN OF SINGLE MOTHERS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To show that the exclusion from conventional class based analyses of child mortality of children whose parents are classified as ''unoccupied'' produces a misleading picture of health inequalities. Design-Reanalysis of data published in the childhood supplement of the registrar general's decennial supplement on occupational mortality in England and Wales, which compares numerator data for registrations of deaths in children over the age of 1 but below their 16th birthday in 1979, 1980, 1982, and 1983 with data about children aged 1-15 who were enumerated at the 1981 census. Results-Parents who are classified as ''unoccupied'' largely consist of economically inactive single mothers. Their children are estimated to represent 89% of the 614000 aged 1-15 classified as ''unoccupied'' in the childhood supplement. They have the worst mortality record of all social groups-an age specific death rate of 68.8/100000 a year, 42% worse than in social class V (48.4/100000) and worse than that of social class I (22.8) by a factor of 3. At older ages (10-15 years) these children have a relative risk of death of 4.14 relative to classes I and II; the risk is 2.58 in children 0-4 and 2.56 in those 5-9. Relative risks of child mortality in social classes I and II in comparison to classes IV and V suggests a progressive shallowing from 2.08 at ages 1-4 to 1.37 at ages 10-15. When unoccupied parents were combined with classes IV and V and compared with classes I and II, however, inequalities seemed to be pervasive throughout childhood; the relative risks were 2.21 for those aged 1-4 and 1.98 for those aged 10-15. Conclusion-Children classified as unoccupied are almost certainly living in poverty as well as experiencing relatively high risks of mortality. Class based analyses which exclude them therefore produce a misleading picture of inequalities in child health. The implications for health policy are profound. Strategies to promote the nation's health should acknowledge the importance of material and social deprivation more explicitly.			JUDGE, K (corresponding author), KINGS FUND INST,LONDON NW1 7NF,ENGLAND.		Benzeval, Michaela/J-3163-2015	Benzeval, Michaela/0000-0002-0372-2098				ALBERMAN E, 1992, 2ND HOUS COMM HLTH C, V2, pS47; [Anonymous], 1980, CLASSIFICATION OCCUP; BRADSHAW J, 1991, 6 DEP SOC SEC RES RE; DUNNELL K, 1992, 2ND HOUS COMM HLTH C, V2, pS70; HASKEY J, 1986, POPULATION TRENDS, V45, P5; HASKEY J, 1991, POPULATION TRENDS, V65, P35; WEST P, 1990, SOC SCI MED, V30, P665, DOI 10.1016/0277-9536(88)90252-3; Whitehead M, 1992, INEQUALITIES HLTH HL; 1983, CENSUS 1981 NATION 1; 1983, CENSUS 1981 NATION 2; 1984, CENSUS 1981 HOUSEHOL; 1992, DHS24 OFF POP CENS S; 1987, DEPRIVATION ILL HLTH; [No title captured]; 1988, DS8 OFF POP CENS SUR	15	69	69	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1993	306	6879					677	680		10.1136/bmj.306.6879.677	http://dx.doi.org/10.1136/bmj.306.6879.677			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT216	8471917	Green Published, Bronze			2022-12-28	WOS:A1993KT21600017
J	NGAI, J; CHESS, A; DOWLING, MM; NECLES, N; MACAGNO, ER; AXEL, R				NGAI, J; CHESS, A; DOWLING, MM; NECLES, N; MACAGNO, ER; AXEL, R			CODING OF OLFACTORY INFORMATION - TOPOGRAPHY OF ODORANT RECEPTOR EXPRESSION IN THE CATFISH OLFACTORY EPITHELIUM	CELL			English	Article							ELECTRICAL-STIMULATION; 2-DEOXYGLUCOSE METHOD; SPATIAL-DISTRIBUTION; SALMONID FISHES; RAINBOW-TROUT; BULB; RAT; PROJECTION; NEURONS; CELLS	Discrimination among the vast array of odors requires that the brain discern which of the numerous odorant receptors have been activated. If individual olfactory neurons express only a subset of the odorant receptor repertoire, then the nature of a given odorant can be discerned by identifying which cells have been activated. We performed in situ hybridization experiments demonstrating that individual olfactory neurons express different complements of odorant receptors and are therefore functionally distinct. Thus, a topographic map, defining either the positions of specific neurons in the epithelium or the positions of their projections, may be employed to determine the quality of an olfactory stimulus. Neurons expressing specific receptors appear to be randomly distributed within the olfactory epithelium. These data are consistent with a model in which randomly dispersed olfactory neurons with common receptor specificities project to common glomeruli in the olfactory bulb.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University; Howard Hughes Medical Institute; Columbia University			Dowling, Michael M./AAE-5263-2020	Dowling, Michael M./0000-0001-5058-6589; Axel, Richard/0000-0002-3141-4076	NIGMS NIH HHS [T-32 GM07367] Funding Source: Medline; PHS HHS [R01-20336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN ED, 1950, BRIT MED BULL, V6, P330, DOI 10.1093/oxfordjournals.bmb.a073625; ALLEN BA, 1990, COMPUT MED IMAG GRAP, V14, P319, DOI 10.1016/0895-6111(90)90106-L; ASTIC L, 1986, BRAIN RES BULL, V16, P445, DOI 10.1016/0361-9230(86)90172-3; ASTIC L, 1988, DEV BRAIN RES, V42, P297, DOI 10.1016/0165-3806(88)90248-9; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; BOWER JM, 1991, OLFACTION, P265; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CANCALON P, 1982, TISSUE CELL, V14, P717, DOI 10.1016/0040-8166(82)90061-1; CAPRIO J, 1978, TISSUE CELL, V10, P1, DOI 10.1016/0040-8166(78)90002-2; CLARK WEL, 1951, J NEUROL NEUROSUR PS, V14, P1, DOI 10.1136/jnnp.14.1.1; COSTANZO RM, 1976, J GEN PHYSIOL, V68, P297, DOI 10.1085/jgp.68.3.297; DEMSKI LS, 1984, BRAIN RES, V291, P241, DOI 10.1016/0006-8993(84)91256-3; DOVING KB, 1980, ACTA PHYSIOL SCAND, V108, P123, DOI 10.1111/j.1748-1716.1980.tb06509.x; DUBOISDAUPHIN M, 1980, CHEM SENSES, V5, P159, DOI 10.1093/chemse/5.2.159; DUBOISDAUPHIN M, 1981, BRAIN RES, V219, P269, DOI 10.1016/0006-8993(81)90291-2; DUNCAN HJ, 1990, J COMP NEUROL, V299, P299, DOI 10.1002/cne.902990304; FREEMAN WJ, 1991, OLFACTION, P225; FUJITA SC, 1985, BRAIN RES, V326, P192, DOI 10.1016/0006-8993(85)91403-9; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GREER CA, 1981, BRAIN RES, V217, P279, DOI 10.1016/0006-8993(81)90004-4; HARA T J, 1975, Progress in Neurobiology (Oxford), V5, P271, DOI 10.1016/0301-0082(75)90014-3; Iwamura Y, 1985, DEV ORG PROCESSING S, P239; JAKUBOWSKI M, 1979, Z MIKROSK ANAT FORSC, V93, P728; JASTREBOFF PJ, 1984, P NATL ACAD SCI-BIOL, V81, P5250, DOI 10.1073/pnas.81.16.5250; JOURDAN F, 1982, BRAIN RES, V240, P341, DOI 10.1016/0006-8993(82)90232-3; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; KAAS JH, 1979, SCIENCE, V204, P521, DOI 10.1126/science.107591; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; KAUER JS, 1991, OLFACTION, P43; KAUER JS, 1974, J PHYSIOL-LONDON, V243, P717, DOI 10.1113/jphysiol.1974.sp010773; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LAND LJ, 1973, BRAIN RES, V63, P153, DOI 10.1016/0006-8993(73)90084-X; LAND LJ, 1974, BRAIN RES, V70, P506, DOI 10.1016/0006-8993(74)90259-5; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; MACAGNO ER, 1979, ANNU REV BIOPHYS BIO, V8, P323, DOI 10.1146/annurev.bb.08.060179.001543; MACKAYSIM A, 1984, ANAT EMBRYOL, V170, P93, DOI 10.1007/BF00319463; MACKAYSIM A, 1982, J NEUROPHYSIOL, V48, P584, DOI 10.1152/jn.1982.48.2.584; MACLEOD NK, 1976, EXP BRAIN RES, V25, P267; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORI K, 1985, J COMP NEUROL, V242, P214, DOI 10.1002/cne.902420205; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; NGAI J, 1993, CELL, V72; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; PINCHING AJ, 1974, BRAIN RES, V82, P195, DOI 10.1016/0006-8993(74)90598-8; POWELL TPS, 1959, B JOHNS HOPKINS HOSP, V105, P133; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RIDDLE DR, 1991, J NEUROSCI, V11, P3752; ROWE MJ, 1985, DEV ORG PROCESSING S, P247; ROYET JP, 1987, BRAIN RES, V417, P1, DOI 10.1016/0006-8993(87)90173-9; SATOU M, 1983, J COMP PHYSIOL, V152, P319, DOI 10.1007/BF00606238; SATOU M, 1990, PROG NEUROBIOL, V34, P115, DOI 10.1016/0301-0082(90)90004-Z; SATOU M, 1979, BRAIN RES, V173, P142, DOI 10.1016/0006-8993(79)91102-8; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; Sheldon RE, 1912, J COMP NEUROL, V22, P177, DOI 10.1002/cne.900220301; SHEPHERD GM, 1991, OLFACTION, P3; STACEY NE, 1983, PHYSIOL BEHAV, V30, P621, DOI 10.1016/0031-9384(83)90231-7; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; TEICHER MH, 1980, BRAIN RES, V194, P530, DOI 10.1016/0006-8993(80)91237-8; THOMMESEN G, 1983, ACTA PHYSIOL SCAND, V117, P241, DOI 10.1111/j.1748-1716.1983.tb07203.x; THOMMESEN G, 1977, ACTA PHYSIOL SCAND, V99, P270, DOI 10.1111/j.1748-1716.1977.tb10380.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	65	214	217	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 12	1993	72	5					667	680		10.1016/0092-8674(93)90396-8	http://dx.doi.org/10.1016/0092-8674(93)90396-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453662	Bronze			2022-12-28	WOS:A1993KR43600004
J	TAKAHASHI, H; NAKADA, T; PUISIEUX, I				TAKAHASHI, H; NAKADA, T; PUISIEUX, I			INHIBITION OF HUMAN COLON CANCER GROWTH BY ANTIBODY-DIRECTED HUMAN LAK CELLS IN SCID MICE	SCIENCE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; SEVERE COMBINED IMMUNODEFICIENCY; PERIPHERAL-BLOOD LYMPHOCYTES; ACTIVATED KILLER CELLS; MONOCLONAL-ANTIBODIES; RECOMBINANT INTERLEUKIN-2; METASTATIC MELANOMA; CYTO-TOXICITY; FC-RECEPTORS; MOUSE	Advanced human colon cancer does not respond to lymphokine-activated killer (LAK) cells. In order to direct cytotoxic cells to the tumor, human LAK cells linked with antibodies to a tumor cell surface antigen were tested with established hepatic metastases in severe combined immunodeficient (SCID) mice. These cells had increased uptake into the tumor and suppression of tumor growth as compared with LAK cells alone, thereby improving the survival of tumor-bearing mice. Thus, tumor growth can be inhibited by targeted LAK cells, and SCID mice can be used to test the antitumor properties of human effector cells.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	TAKAHASHI, H (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, MOLEC HEPATOL LAB, BOSTON, MA 02129 USA.				NCI NIH HHS [CA-35711, CA-57584] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035711, R29CA057584, R01CA057584, R37CA035711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANCROFT GJ, 1991, IMMUNOL REV, V124, P5, DOI 10.1111/j.1600-065X.1991.tb00613.x; BANKERT RB, 1989, CURR TOP MICROBIOL, V152, P201; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; DEARMAN RJ, 1988, BLOOD, V72, P1985; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; FIDLER IJ, 1990, CANCER RES, V50, P6130; FISHER B, 1989, J CLIN ONCOL, V7, P250, DOI 10.1200/JCO.1989.7.2.250; FRIEDMANN T, 1991, CANCER CELL-MON REV, V3, P271; GRIFFITH KD, 1989, J NATL CANCER I, V81, P1709, DOI 10.1093/jnci/81.22.1709; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; HERLYN D, 1982, P NATL ACAD SCI-BIOL, V79, P4761, DOI 10.1073/pnas.79.15.4761; JOHNSON WJ, 1986, J IMMUNOL, V136, P4704; JONES JF, 1980, J IMMUNOL, V125, P926; KAWASE I, 1988, CANCER RES, V48, P1173; KURNICK JT, 1986, CLIN IMMUNOL IMMUNOP, V38, P367, DOI 10.1016/0090-1229(86)90247-3; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MUKHERJI B, 1988, NUCL MED BIOL, V15, P419, DOI 10.1016/0883-2897(88)90012-8; MUUL LM, 1987, J IMMUNOL, V138, P989; NELSON H, 1991, CANCER CELL-MON REV, V3, P163; NISHIHARA K, 1988, CANCER RES, V48, P4730; ORTALDO JR, 1986, J EXP MED, V164, P1193, DOI 10.1084/jem.164.4.1193; PFEFFER K, 1989, CURR TOP MICROBIOL, V152, P211; PHILLIPS JH, 1986, J EXP MED, V164, P814, DOI 10.1084/jem.164.3.814; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; ROBERTS K, 1987, CANCER RES, V47, P4366; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SCHMIDTWOLF IGH, 1991, J EXP MED, V174, P139, DOI 10.1084/jem.174.1.139; SIMPSON E, 1991, IMMUNOL REV, V124, P97, DOI 10.1111/j.1600-065X.1991.tb00618.x; STEPLEWSKI Z, 1988, P NATL ACAD SCI USA, V85, P4852, DOI 10.1073/pnas.85.13.4852; TAKAHASHI H, 1988, CANCER RES, V48, P6573; TAKAHASHI H, 1989, GASTROENTEROLOGY, V96, P1317, DOI 10.1016/S0016-5085(89)80019-8; Takahashi H., UNPUB; TONG AW, 1989, CANCER RES, V49, P4103; UNKELESS JC, 1989, J CLIN INVEST, V83, P355, DOI 10.1172/JCI113891; VIVIER E, 1991, J IMMUNOL, V146, P206; WEST WH, 1987, NEW ENGL J MED, V316, P898, DOI 10.1056/NEJM198704093161502; WILSON B, 1988, P NATL ACAD SCI USA, V85, P3140, DOI 10.1073/pnas.85.9.3140	41	89	90	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1993	259	5100					1460	1463		10.1126/science.8451642	http://dx.doi.org/10.1126/science.8451642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451642				2022-12-28	WOS:A1993KP97800038
J	PURVES, IN; EDWARDS, C				PURVES, IN; EDWARDS, C			COMPARISON OF PRESCRIBING UNIT WITH INDEX INCLUDING BOTH AGE AND SEX IN ASSESSING GENERAL-PRACTICE PRESCRIBING COSTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine and compare the prescribing unit and a new prescribing index adjusting for age and sex in assessing general practice prescribing. Design-Analysis of all prescriptions issued by two practices in one year. Use of data to derive a prescribing index adjusting for age and sex. Comparison of effect of prescribing unit and new index on relation between 80 practices' prescribing data and family health services authority average. Setting-Newcastle and Gateshead Family Health Services Authorities. Two urban practices with eight doctors and combined list size of 16300 patients. Main outcome measures-Cost and number of prescriptions issued to each age and sex group. Effect of index on relation between practice data and family health services authority average. Results-The number of items prescribed and total costs rose with age. Although total costs were greater for women than for men, individual items cost more for men aged 25-84. Comparison of data adjusted by the prescribing unit and the new index with authority averages produced no significant differences except in a few practices with skewed age-sex demography. Results with the two indexes differed by over 5% in 34% (27/80) of practices for costs and in 14% (11/80) for items prescribed. Conclusions-The age and sex profile of a practice does not explain interpractice variation in prescribing patterns. Other unidentified factors need to be considered.	CHAINBRIDGE MED PARTNERSHIP,BLAYDON ON TYNE,ENGLAND; UNIV NEWCASTLE UPON TYNE,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK								EDWARDS C, 1991, INT J PHARM PRACTICE, V1, P73; EDWARDS C, 1992, PRESCRIBER, V3, P103; GRIFFIN JP, 1990, ABPI BRIEFING; Hall M S, 1981, Practitioner, V225, P271; HARRIS JF, 1990, SOMAT CELL MOLEC GEN, V16, P39, DOI 10.1007/BF01650478; SKEGG DCG, 1977, BRIT MED J, V1, P1561, DOI 10.1136/bmj.1.6076.1561; 1988, ANN REPORT 1 APRIL 1, P12; 1990, STATISTICAL B   0422, P3; 1989, COMPENDIUM HLTH STAT, P45	9	17	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					496	498		10.1136/bmj.306.6876.496	http://dx.doi.org/10.1136/bmj.306.6876.496			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448463	Green Published, Bronze			2022-12-28	WOS:A1993KN78600022
J	COULTER, A; KLASSEN, A; MACKENZIE, IZ; MCPHERSON, K				COULTER, A; KLASSEN, A; MACKENZIE, IZ; MCPHERSON, K			DIAGNOSTIC DILATATION AND CURETTAGE - IS IT USED APPROPRIATELY	BRITISH MEDICAL JOURNAL			English	Article							HYSTEROSCOPY; WOMEN; ASPIRATION; HYSTERECTOMY; MENORRHAGIA; PIPELLE	Objective-To determine patterns of use of dilatation and curettage in Britain as compared with those in the United States; to examine variations in utilisation rates within one regional health authority. Design-Analysis of routinely collected hospital inpatient statistics. Setting-Statistics for England, Scotland, and the United States; local statistics for Oxford region. Subjects-All inpatient episodes in which dilatation and curettage was performed but excluding those related to pregnancy. Results-Dilatation and curettage rates remained stable in Britain between 1977 and 1990, whereas in the United States they declined dramatically. In 1989-90 the rate was 71.1 per 10000 women in England as compared with only 10.8 per 10000 in America. In 1989, 6936 women underwent diagnostic dilatation and curettage in the Oxford region, making it the most common elective operation. A total of 2726 (39%) of these women were under 40. There was a more than twofold variation in usage of the procedure among district health authorities within the region and even greater variation in rates in women under 40. The proportion of patients treated as day cases in the district general hospitals ranged from 22% to 82%. Conclusions-Dilatation and curettage may frequently be used inappropriately. The considerable variations in usage of dilatation and curettage internationally and nationally indicate differences in clinical perception of its appropriateness. This makes it suitable for audit. In developing guidelines it will be important to agree on the most appropriate patients and the relative merits of alternative methods of endometrial sampling. Probably this, could result in considerable cost savings at no risk and possibly some benefit to patients.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND	University of Oxford; University of London; London School of Hygiene & Tropical Medicine	COULTER, A (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019; Klassen, Anne F/AAS-3211-2021	Coulter, Angela/0000-0002-6308-8375; Klassen, Anne F/0000-0003-4720-0096				[Anonymous], 1990, TABULAR LIST CLASSIF, V4th; [Anonymous], 1978, INT CLASSIFICATION D; [Anonymous], 1990, SHORT CUT BETTER SER; BROOKS PG, 1988, AM J OBSTET GYNECOL, V158, P1354, DOI 10.1016/0002-9378(88)90367-5; COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; COULTER A, 1988, SOC SCI MED, V27, P987, DOI 10.1016/0277-9536(88)90289-4; COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x; DANERO S, 1986, European Journal of Gynaecological Oncology, V7, P162; DEJONG P, 1990, BRIT J OBSTET GYNAEC, V97, P299; EDDOWES HA, 1990, BRIT J OBSTET GYNAEC, V97, P961, DOI 10.1111/j.1471-0528.1990.tb02458.x; FINIKIOTIS G, 1989, AUST NZ J OBSTET GYN, V29, P253, DOI 10.1111/j.1479-828X.1989.tb01731.x; FRASER IS, 1990, AM J OBSTET GYNECOL, V162, P1264, DOI 10.1016/0002-9378(90)90032-3; GIMPELSON RJ, 1988, AM J OBSTET GYNECOL, V158, P489, DOI 10.1016/0002-9378(88)90011-7; GOLDRATH MH, 1985, AM J OBSTET GYNECOL, V152, P220, DOI 10.1016/S0002-9378(85)80026-0; GREGG RH, 1981, AM J OBSTET GYNECOL, V140, P179, DOI 10.1016/0002-9378(81)90106-X; GRIMES DA, 1986, OBSTET GYNECOL, V67, P760, DOI 10.1097/00006250-198606000-00002; GRIMES DA, 1982, AM J OBSTET GYNECOL, V142, P1; HAMMOND RH, 1989, BRIT J OBSTET GYNAEC, V96, P496, DOI 10.1111/j.1471-0528.1989.tb02433.x; HAYNES PJ, 1977, BRIT J OBSTET GYNAEC, V84, P763, DOI 10.1111/j.1471-0528.1977.tb12490.x; LEWIS BV, 1990, BRIT J OBSTET GYNAEC, V97, P283, DOI 10.1111/j.1471-0528.1990.tb01803.x; LOFFER FD, 1989, OBSTET GYNECOL, V73, P16; LOFGREN O, 1988, ACTA OBSTET GYN SCAN, V67, P401, DOI 10.3109/00016348809004248; LUTZ MH, 1977, SOUTHERN MED J, V70, P393, DOI 10.1097/00007611-197704000-00003; MACKENZIE IZ, 1985, BRIT J OBSTET GYNAEC, V92, P1291, DOI 10.1111/j.1471-0528.1985.tb04878.x; MACKENZIE IZ, 1978, LANCET, V2, P566; MCPHERSON K, 1981, SOC SCI MED-MED SOC, V15, P273, DOI 10.1016/0271-7123(81)90011-0; MENCAGLIA L, 1987, J REPROD MED, V32, P577; SMITH JJ, 1985, OBSTET GYNECOL, V65, P516; STOCK RJ, 1975, OBSTET GYNECOL, V45, P537; STOVALL TG, 1989, OBSTET GYNECOL, V73, P405; STOVALL TG, 1991, AM J OBSTET GYNECOL, V165, P1287; SUAREZ RA, 1983, J REPROD MED, V28, P41; VALLE RF, 1981, SURG GYNECOL OBSTET, V153, P521; VESSEY M, 1979, HLTH B, V39, P59; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x; WEBB MJ, 1976, OBSTET GYNECOL, V47, P239; 1982, NATIONAL HOSPITAL 13; 1990, SCOTTISH HLTH STATIS; 1991, HLTH US 1990; 1975, CLASSIFICATION SURGI; 1987, VITAL HLTH STATIS 13, V92; 1987, HOSPITAL INPATIE MB4	42	54	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					236	239		10.1136/bmj.306.6872.236	http://dx.doi.org/10.1136/bmj.306.6872.236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443521	Bronze, Green Published			2022-12-28	WOS:A1993KJ59100017
J	TONKS, A				TONKS, A			COUNTDOWN TO COMMUNITY CARE - MAKING PROGRESS - COMMUNITY CARE IN NORTHERN-IRELAND	BRITISH MEDICAL JOURNAL			English	Article																		1990, PEOPLE 1ST COMMUNITY	1	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					262	265		10.1136/bmj.306.6872.262	http://dx.doi.org/10.1136/bmj.306.6872.262			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443531	Green Published, Bronze			2022-12-28	WOS:A1993KJ59100030
